backgroundcas
studi
differ
monoclon
reagent
test
human
shown
equival
efficaci
donor
deriv
polyclon
addit
monoclon
result
paradox
enhanc
alloimmun
effect
also
seen
donor
deriv
case
transgen
mice
express
human
rbc
alloantigen
select
rbc
mice
becom
alloimmun
rbc
expos
either
transfus
pregnanc
latter
lead
hdfn
analog
human
polyclon
mous
serum
deriv
prevent
alloimmun
thu
mous
serv
model
antibodi
mediat
immun
regul
alloimmun
studi
designmethod
igg
subtyp
isol
independ
variabl
engin
panel
igg
subtyp
switch
variant
monoclon
monoclon
isol
murin
igg
subtyp
domain
effect
igg
subtyp
clearanc
alloimmun
transfus
rbc
test
role
fcgriib
inhibitori
fcgr
mice
human
test
use
fcgriib
ko
mice
role
activ
fcgr
afcgr
test
use
novel
condit
knockout
mous
common
gamma
chain
requir
express
murin
afcgr
delet
upon
exposur
cre
recombinas
resultsfind
signific
clearanc
rbc
observ
significantli
decreas
wherea
increas
alloimmun
studi
exampl
suppress
enhanc
antibodi
fcgriib
ko
mice
clearanc
unaffect
suppress
elimin
enhanc
alter
afcgr
delet
tissu
clearanc
observ
either
subtyp
enhanc
elimin
suppress
unaffect
tissu
specif
delet
afcgr
demonstr
afcgr
express
dendrit
cell
dc
macrophag
requir
enhanc
conclus
similar
observ
human
monoclon
antibodi
prevent
alloimmun
wherea
other
enhanc
igg
subtyp
determin
inhibit
vs
enhanc
inhibit
function
fcgriib
depend
mechan
also
lack
clearanc
mainten
suppress
mice
lack
afcgr
indic
clearanc
requir
suppress
find
consist
data
murin
human
studi
enhanc
requir
express
afcgr
dc
follow
studi
requir
see
find
translat
human
backgroundcas
studi
acut
lung
injuri
trali
remain
common
caus
death
blood
transfus
therapi
mous
model
trali
reli
administr
mhc
class
mhc
monoclon
antibodi
mab
mice
cognat
mhc
antigen
howev
critic
site
cognat
antigen
express
elucid
hypothes
endotheli
express
mhc
necessari
develop
trali
studi
designmethod
condit
mhc
knockout
mice
background
gener
cross
flox
microglobulin
mice
congen
express
mous
cre
strain
delet
mhc
myeloid
cell
endotheli
cell
platelet
trali
model
inject
mhc
mab
mice
mgkg
ip
lung
injuri
measur
use
extravascular
lung
water
lung
vascular
permeabl
albumin
measur
endotheli
express
mhc
within
lung
left
lung
remov
mhc
quantif
use
flow
cytometri
one
week
pneumonectomi
mice
challeng
trali
model
resultsfind
mice
suscept
trali
signific
differ
excess
lung
water
vs
pn
lung
vascular
permeabl
vs
pn
compar
balbc
control
x
x
mice
lack
mhc
express
platelet
fulli
suscept
trali
show
signific
differ
excess
lung
water
vs
pn
lung
vascular
permeabl
vs
pn
lung
aggreg
format
vs
pn
surviv
hour
vs
pn
test
compar
x
control
x
x
mice
reduc
mhc
express
lung
endotheli
cell
neonat
tamoxifen
administr
mfi
reduct
vs
x
control
trali
challeng
x
x
mice
express
mhc
signific
reduct
excess
lung
water
vs
lung
vascular
permeabl
vs
compar
control
high
level
mhc
express
x
x
lysmcremic
lack
mhc
express
neutrophil
experi
suscept
trali
ongo
conclus
trali
result
cognat
antibodi
recognit
endotheli
mhc
vast
endotheli
surfac
area
lung
transfus
blood
product
lung
may
explain
organ
injuri
transfus
cognat
antibodi
backgroundcas
studi
storag
shorten
circul
time
platelet
previou
experi
indic
better
hemostat
function
random
clinic
pilot
studi
perform
investig
efficaci
safeti
cold
store
platelet
treatment
bleed
patient
undergo
complex
cardiothorac
surgeri
cardiopulmonari
bypass
circul
studi
joint
effort
civilian
militari
health
care
servic
studi
designmethod
random
clinic
pilot
studi
design
evalu
leukoreduc
apheresi
platelet
pa
store
cold
degre
celciu
day
constant
agit
standard
room
temperatur
storag
rtplt
patient
enrol
prior
surgeri
aim
includ
minimum
transfus
patient
studi
arm
report
postop
bleed
total
blood
usag
laboratori
measur
coagul
blood
cell
count
within
day
surgeri
addit
thromboembol
event
hospit
stay
day
statist
analyz
perform
independ
sampl
test
spss
version
result
present
mean
sem
resultsfind
april
patient
receiv
vs
rtplt
signific
differ
age
gender
weight
bmi
cardiac
bypass
time
euroscor
ef
two
group
significantli
lower
volum
postop
bleed
observ
patient
receiv
cold
store
platelet
chest
drain
output
chest
closur
ml
vs
ml
rtplt
thromboembol
event
observ
patient
rtplt
signific
differ
observ
two
group
differ
observ
measur
coagul
prior
surgeri
immedi
heparin
revers
morn
surgeri
inr
vs
rtplt
aptt
sec
vs
rtplt
fibrinogen
gl
vs
rtplt
similarli
signific
differ
observ
platelet
count
x
vs
rtplt
hemoglobin
gdl
vs
rtplt
blood
usag
similar
two
group
platelet
vs
rtplt
red
blood
cell
vs
rtplt
sd
pool
plasma
vs
rtplt
conclus
preliminari
data
patient
indic
transfus
cold
store
leukoreduc
apheresi
platelet
pa
effect
treatment
bleed
patient
undergo
complex
cardiothorac
surgeri
cold
store
platelet
present
higher
risk
thromboembol
event
larger
studi
recommend
explor
use
cold
store
platelet
transfus
critic
bleed
backgroundcas
studi
increasingli
sensit
screen
assay
transfus
transmit
infect
develop
mandatorili
implement
develop
countri
current
technolog
exist
guarante
zero
risk
blood
product
denmark
individu
donat
id
nucleic
acid
test
nat
legisl
ad
serolog
base
screen
assay
hiv
hbv
hcv
case
transfus
transmit
hiv
infect
danish
govern
decid
chang
legisl
discontinu
fund
id
nat
screen
juli
instead
screen
ad
mandatori
serolog
screen
assay
repeat
donor
studi
designmethod
incidencewindow
model
use
estim
residu
risk
transfus
transmit
viral
infect
incid
rate
estim
blood
plasma
donat
repeat
donor
denmark
base
number
reactiv
donat
posit
test
follow
neg
donat
residu
risk
estim
incid
rate
multipli
averag
window
period
hiv
hbv
hcv
without
id
nat
test
resultsfind
million
donat
screen
averag
donat
frequenc
approx
donat
per
year
residu
risk
estim
rr
per
donat
without
id
nat
fold
reduct
rr
sinc
implement
id
nat
test
summar
tabl
addit
observ
nat
case
nat
reactiveseroneg
among
repeat
donor
includ
acut
hcv
infect
chronic
hbv
infect
without
detect
hbsag
occult
hepat
b
infect
obi
tabl
effect
futur
test
taken
account
measur
result
rr
hbv
two
valu
tabl
conclus
northern
europ
risk
transfus
transmit
viral
infect
low
current
danish
transfus
rate
rbc
popul
mio
remov
id
nat
test
result
estim
increas
risk
transfus
transmit
hiv
one
year
one
year
hbv
one
year
one
year
hcv
year
one
year
increas
risk
transfus
transmit
infect
seem
accept
major
nation
parliament
backgroundcas
studi
zika
viru
zikv
associ
sever
neurolog
consequ
fetus
adult
potenti
transfus
transmiss
tt
rna
persist
report
whole
blood
wb
long
clearanc
viremia
plasma
rais
concern
risk
tt
plasma
base
amplif
test
nat
dynam
zikv
persist
asymptomat
infect
well
understood
need
understand
natur
histori
zikv
infect
sought
character
dynam
infect
prospect
enrol
zikv
rna
blood
donor
studi
designmethod
donor
identifi
investig
zikv
nat
screen
enrol
longitudin
follow
assess
viral
serolog
persist
clinic
outcom
plasma
rbc
obtain
index
donat
blood
urin
saliva
semen
sampl
collect
prospect
week
follow
index
donat
donor
detail
symptom
questionnair
administ
studi
visit
blood
compart
bodi
fluid
test
zika
rna
real
time
plasma
sampl
test
zika
specif
igm
igg
antibodi
resultsfind
percent
zikv
rna
sampl
follow
number
sampl
test
parenthesi
sampl
type
sampl
interv
summar
tabl
plasma
viremia
declin
rapidli
index
donat
wherea
viral
rna
persist
month
peripher
blood
mononuclear
cell
pbmc
associ
viru
detect
intermitt
low
level
wane
month
urin
saliva
detect
decreas
significantli
week
undetect
month
donor
enrol
acut
stage
infect
develop
multipl
zikv
relat
symptom
week
post
index
donat
compar
donor
detect
tabl
conclus
zikv
rna
persist
cellular
blood
compart
sever
month
follow
clearanc
plasma
bodi
fluid
higher
rate
symptom
previous
report
persist
zika
rna
rbc
unknown
implic
blood
screen
current
reli
plasma
test
infect
studi
progress
wb
test
may
valu
extend
detect
acut
infect
diagnost
monitor
pregnant
women
backgroundcas
studi
blood
center
regul
unit
state
us
evalu
strategi
minim
iron
deplet
blood
donor
logist
donor
manag
might
differ
across
blood
center
optim
approach
may
also
vari
accord
biolog
behavior
differ
across
donor
studi
us
donor
conduct
predominantli
caucasian
popul
may
differ
racialethn
minor
donor
iron
metabol
capac
undergo
repeat
phlebotomi
studi
designmethod
donor
enrol
us
blood
center
ferritin
test
studi
popul
enrich
racial
minor
aa
asian
hispan
hisp
super
donor
complet
donat
two
year
without
low
hemoglobin
deferr
minor
donor
remain
white
nhw
donor
unselect
popul
specif
elig
criteria
subject
complet
questionnair
risk
factor
iron
deplet
logist
regress
use
identifi
demograph
behavior
predictor
absent
iron
store
ai
ferritin
ngml
low
ferritin
lf
ferritin
ngml
resultsfind
across
subject
ai
lf
high
degre
variabl
base
demograph
factor
donat
behavior
model
stratifi
race
expect
pattern
common
group
includ
sharp
increas
risk
increas
donat
intens
larg
decrement
risk
femal
year
old
model
includ
subject
race
independ
predictor
ai
lf
control
age
sex
bodi
weight
donat
frequenc
factor
tabl
aa
donor
show
decreas
risk
ai
compar
nhw
hisp
donor
higher
risk
daili
use
exogen
iron
reduc
risk
lf
ai
respect
estim
benefit
use
lower
protect
regular
use
antacid
associ
greater
increment
risk
report
use
hormon
supplement
show
oppos
effect
male
femal
use
oral
contracept
estrogen
femal
reduc
risk
male
report
current
use
supplement
testosteron
twice
estim
risk
ai
conclus
larg
studi
confirm
high
preval
lf
ai
us
donor
princip
risk
factor
age
sex
donat
frequenc
divers
popul
studi
questionnair
data
donor
identifi
addit
demograph
behavior
risk
factor
secondari
import
develop
iron
mitig
strategi
practic
base
age
gender
could
refin
depend
given
blood
center
oper
context
donor
popul
backgroundcas
studi
transfus
donor
antigen
consum
recipi
antigen
present
cell
process
peptid
present
recipi
mhc
class
recipi
cell
process
call
red
blood
cell
rbc
antigen
effici
transfus
howev
process
poorli
understood
rbc
antigen
link
develop
cytotox
cell
respons
capabl
bone
marrow
graft
reject
well
induct
immunolog
toler
capabl
amelior
autoimmun
subset
convent
dendrit
cell
consum
transfus
rbc
function
special
effici
use
mous
model
select
defici
determin
whether
requir
rbc
restrict
antigen
vivo
studi
designmethod
mice
genet
defici
basic
leucin
zipper
transcript
factor
select
defici
vivo
assay
rbc
transgen
hod
mice
select
rbc
express
surfac
hen
egg
lysozym
ovalbumin
duffi
antigen
transfus
antigen
sourc
cell
express
mhc
class
restrict
tcr
transgen
respond
cell
label
cell
trace
far
red
ctfr
adopt
transfer
mhc
ident
ie
wild
type
recipi
mice
hour
mice
transfus
hod
blood
day
splenic
cell
analyz
prolifer
ctfr
dye
dilut
activ
express
resultsfind
hod
blood
transfus
wild
type
mice
induc
dose
depend
prolifer
cell
compar
transfus
hod
blood
cell
prolifer
associ
cell
prolifer
respons
hod
rbc
transfus
dramat
decreas
mice
compar
wild
type
tabl
conclus
consist
report
rbc
restrict
antigen
effici
vivo
transfus
prolifer
cell
partial
acquir
effector
cell
characterist
distinctli
fail
rbc
restrict
antigen
requir
cell
thu
potenti
import
link
transfus
rbc
antigen
cellular
immun
respons
may
import
implic
understand
immun
modul
tabl
backgroundcas
studi
use
prevent
hemolyt
diseas
fetu
newborn
mechan
refer
immun
suppress
ami
none
monoclon
antibodi
develop
effect
recent
studi
demonstr
blend
monoclon
antibodi
target
differ
epitop
induc
complet
ami
present
work
perform
analysi
explor
impact
erythrocyt
sensit
erythrocyt
clearanc
antigen
modul
induct
ami
effect
studi
designmethod
mice
transfus
murin
transgen
red
blood
cell
rbc
express
hod
antigen
hen
egg
lysozym
sequenc
ovalbumin
ova
human
duffi
transmembran
protein
presenc
serial
dose
polyclon
igg
antibodi
product
evalu
elisa
evalu
erythrocyt
clearanc
antigen
modul
mice
immun
label
fluoresc
dye
follow
select
dose
igg
hour
later
percentag
remain
circul
hod
antigen
level
surviv
rbc
assess
flow
cytometri
pearson
coeffici
calcul
determin
associ
alloimmun
erythrocyt
clearanc
antigen
modul
resultsfind
ami
evid
erythrocyt
appear
satur
igg
contrast
attain
maxim
cell
level
suffici
explain
ami
activ
high
quantiti
igg
induc
signific
clearanc
well
signific
reduct
surfac
detect
hod
antigen
rbc
antigen
modul
howev
intermedi
quantiti
igg
induc
partial
clearanc
signific
hod
antigen
modul
contrast
low
dose
igg
induc
either
clearanc
antigen
modul
interestingli
abil
select
dose
antibodi
induc
ami
better
correl
antigen
modul
erythrocyt
clearanc
conclus
ami
igg
use
studi
demonstr
better
correl
antigen
modul
rbc
clearanc
level
erythrocyt
igg
satur
key
factor
predict
ami
activ
model
find
may
help
explain
superior
polyclon
antibodi
monoclon
therapeut
ami
induct
backgroundcas
studi
storag
red
blood
cell
rbc
undergo
multipl
morpholog
biochem
molecular
modif
collect
call
storag
lesion
proport
clear
rbc
correl
storag
durat
may
respons
rapid
clearanc
transfus
rbc
reduc
transfus
yield
shown
use
imag
flow
cytometri
subpopul
morpholog
alter
rbc
accumul
storag
reduc
surfac
area
small
rbc
srbc
suggest
rapid
elimin
spleen
hour
follow
transfus
hypothesi
remain
clarifi
sinc
physiolog
mechan
rbc
clearanc
remain
precis
identifi
studi
designmethod
murin
young
old
rbc
respect
storag
transfus
differ
model
includ
splenectom
mice
flow
cytometri
use
determin
kinet
clearanc
transfus
yield
quantifi
rbc
retent
organ
accumul
storag
disappear
srbc
analyz
imag
flow
cytometri
resultsfind
use
murin
model
transfus
confirm
yield
decreas
storag
durat
vs
storag
clearanc
rbc
mediat
spleen
macrophag
shown
signific
improv
yield
observ
splenectom
group
human
observ
accumul
subpopul
small
rbc
mous
small
rbc
msrbc
reduc
project
surfac
area
alter
morpholog
msrbc
disappear
rapidli
circul
control
splenectom
mice
decreas
contrast
mice
msrbc
kept
circul
msrbc
complet
disappear
model
suggest
import
elimin
presenc
compens
clearanc
mechan
control
mice
rbc
mostli
retain
spleen
also
bone
marrow
bm
retent
observ
liver
kidney
lung
mice
retent
decreas
spleen
bm
convers
elev
retent
observ
bm
splenectom
mice
associ
transient
retent
kidney
liver
conclus
storag
murin
rbc
damag
rbc
accumul
elimin
follow
transfus
via
mechan
includ
observ
human
subpopul
small
rbc
undergo
rapid
clearanc
increas
transfus
yield
absenc
spleen
macrophag
suggest
recipi
function
state
one
determin
factor
backgroundcas
studi
breakdown
toler
rbc
antigen
may
result
develop
pathogen
autoantibodi
autoab
lead
autoimmun
hemolyt
anemia
aiha
sever
sometim
fatal
diseas
aiha
human
number
known
featur
includ
increas
frequenc
age
tendenc
relaps
remit
howev
mechan
behind
observ
understood
gain
insight
toler
loss
thereof
rbc
autoantigen
util
hod
mous
express
tripl
fusion
protein
consist
hen
egg
lysosym
hel
ovalbumin
ova
duffi
hod
hod
mice
bred
transgen
mous
express
cell
receptor
specif
ova
peptid
hod
present
mhcii
otii
mice
thu
hodotii
mice
predispos
autoreact
cell
studi
designmethod
four
cohort
hodxotii
mice
micecohort
bled
monthli
month
assess
autoab
product
peripher
rbc
stain
mous
immunoglobulin
ab
spleen
weigh
splenocyt
stain
assess
presenc
rbc
progenitor
statist
analysi
hodotiiautoab
vs
vs
perform
use
test
correct
multipl
test
dunn
test
resultsfind
otii
cell
delet
thymu
hodotii
mice
rather
matur
peripheri
despit
peripher
autoreact
cell
detect
autoab
observ
hodotii
howev
age
hodotii
posit
rbc
autoab
month
thereaft
autoab
mice
stop
produc
autoab
within
two
month
onset
remain
autoab
free
throughout
studi
cohort
autoab
mice
femal
hodotiiautoab
mice
also
enlarg
spleen
compar
mice
vs
resp
p
may
due
rbc
consumpt
extramedullari
erythropoiesi
consist
increas
erythropoiesi
elev
number
rbc
progenitor
observ
spleen
hodotiiautoab
mice
vs
resp
p
moreov
autoab
deposit
found
resp
rbc
hodotiiautoab
mice
analyz
conclus
sever
featur
known
exist
human
aiha
observ
includ
autoab
product
relaps
autoimmun
onset
increas
frequenc
femal
model
may
serv
experiment
system
investig
mechan
aiha
backgroundcas
studi
red
blood
cell
rbc
alloimmun
occur
transfus
recipi
exclud
abo
rhd
underli
factor
influenc
alloimmun
poorli
understood
thu
current
reliabl
way
predict
make
alloantibodi
patient
receiv
multipl
rbc
unit
sever
separ
transfus
higher
risk
alloimmun
likewis
certain
diseas
state
higher
rate
alloimmun
myelodysplasct
syndrom
md
sickl
cell
diseas
patient
howev
despit
chronic
transfus
patient
never
develop
rbc
alloantibodi
recent
report
poli
c
inflamm
lead
enhanc
alloimmun
rate
correl
increas
splenic
neutrophil
pmn
number
addit
rbc
transfus
inflam
recipi
lead
enhanc
erythrophagocytosi
pmn
test
hypothesi
pmn
regul
rbc
alloantibodi
gener
studi
designmethod
mice
mice
treat
pb
deplet
pmn
follow
poli
c
elicit
inflamm
final
transfus
allogen
rbc
express
synthet
antigen
hod
multipl
splenic
cellular
subset
evalu
dio
fluoresc
indirect
measur
rbc
consumpt
hour
alloantibodi
gener
assess
day
flow
cytometri
human
retrospect
mean
white
blood
cell
wbc
pmn
count
collect
chronic
transfus
md
patient
va
connecticut
healthcar
alloimmun
patient
wbc
pmn
count
assess
day
exposur
alloimmun
rbc
unit
wherea
count
averag
entireti
rbc
therapi
patient
patient
match
number
rbc
transfus
resultsfind
mice
mfi
antibodi
significantli
increas
mice
compar
control
experi
p
mani
control
mice
made
alloantibodi
mice
made
detect
pmn
deplet
also
led
signific
reduct
dio
leukocyt
suggest
lack
compensatori
mechan
rbc
consumpt
absenc
pmn
also
shift
rbc
consumpt
macrophag
dendrit
cell
subset
flow
cytometr
analysi
reveal
pmn
intern
rbc
upregul
express
molecul
eg
compar
pmn
without
intern
rbc
mous
thu
pmn
may
regul
alloimmun
antigen
present
andor
inhibitori
signal
human
alloimmun
md
patient
signific
decreas
pmn
compar
p
signific
differ
detect
mean
wbc
count
two
arm
conclus
data
demonstr
murin
human
set
pmn
may
play
signific
role
regul
rbc
alloimmun
may
provid
key
insight
predict
patient
becom
alloimmun
backgroundcas
studi
human
urea
kidd
jk
blood
group
glycoprotein
function
renal
endotheli
cell
descend
vasa
recta
five
singl
case
report
link
renal
transplant
reject
includ
graft
failur
concurr
emerg
antibodi
day
yr
median
yr
transplant
sanford
kw
hla
antibodi
statu
graft
jk
type
note
case
noth
known
effect
preform
antibodi
dsa
renal
graft
studi
designmethod
rbc
antibodi
screen
perform
solid
phase
rbc
adher
immucor
norcross
ga
titer
perform
serial
salin
dilut
last
reaction
endpoint
sinc
transfus
servic
identifi
antibodi
renal
transplant
candid
recipi
current
renal
donor
type
jkab
transplant
servic
notifi
graft
patient
past
transplant
graft
jk
type
unknown
retrospect
review
case
graft
surviv
highest
hla
dsa
titer
biopsi
find
resultsfind
year
patient
renal
transplant
donor
jk
antigen
jka
jkb
patient
other
develop
earlier
transplant
donor
jk
type
unknown
tabl
transplant
case
prior
detect
current
case
hla
dsa
revers
acut
reject
amr
cmr
mo
case
hla
dsa
one
equivoc
amr
vs
glomerulonephr
gn
yr
graft
surviv
mo
median
discov
yr
transplant
underw
chronic
reject
failur
hla
dsa
titer
case
subsequ
surviv
graft
conclus
renal
transplant
patient
preform
vs
graft
jk
antigen
graft
surviv
two
patient
earli
reject
episod
also
hla
dsa
like
prior
report
found
patient
reject
graft
failur
patient
evid
reject
hla
rbc
alloimmun
associ
past
studi
found
clear
evid
reject
alon
howev
seen
graft
incompat
high
titer
hamilton
ms
reject
detect
hla
dsa
holt
backgroundcas
studi
expans
cord
blood
cb
hematopoiet
stem
progenitor
cell
hspc
investig
mean
acceler
engraft
follow
cb
transplant
small
molecul
cytokin
cocultur
sever
strategi
investig
hspc
expans
recent
discov
complementari
strategi
base
use
serum
free
medium
sfm
condit
mesenchym
stromal
cell
msc
osteoblast
osteoblast
condit
media
ocm
increas
expans
cb
cell
progenitor
vs
control
sfm
growth
factor
respons
ocm
activ
remain
identifi
herein
investig
implic
growth
factor
growth
promot
activ
ocm
studi
designmethod
bone
marrow
msc
differenti
osteoblast
osteogen
medium
sfm
condit
ocm
fraction
sampl
prepar
column
molecular
weight
kda
fraction
interest
analyz
mass
spectroscopi
assay
use
measur
express
igf
osteoblast
msc
function
contribut
igf
growth
promot
activ
ocm
cb
cell
investig
inhibit
receptor
cb
cultur
supplement
cytokin
scf
fl
tpo
resultsfind
fraction
ocm
reveal
protein
complex
greater
kda
essenti
growth
promot
activ
ocm
vs
sfm
p
sinc
signific
effect
seen
kda
preliminari
analysi
compar
fraction
medium
mcm
ocm
identifi
igf
bind
two
factor
present
prefer
ocm
reveal
larg
increas
rel
express
mrna
osteoblast
day
osteogen
differenti
compar
msc
p
express
mrna
also
significantli
greater
osteoblast
p
contrast
low
transcript
level
detect
msc
osteoblast
moreov
concentr
ocm
ngml
higher
measur
mcm
p
mitogen
activ
mediat
activ
tyrosin
kinas
receptor
inhibit
select
kinas
inhibitor
addit
reduc
manner
growth
cb
cell
ocm
cultur
p
minim
effect
sfm
cultur
moreov
increas
product
p
enrich
cell
p
cfu
progenitor
p
ocm
cultur
larg
abrog
presenc
p
contribut
signal
engraft
properti
cb
cell
immunodefici
mice
current
investig
conclus
fraction
mass
spectroscopi
identifi
potenti
promot
cell
growth
ocm
elisa
confirm
elev
level
factor
osteoblast
ocm
inhibit
sever
impair
growth
promot
activ
ocm
cell
altogeth
result
suggest
increas
expans
cell
induc
ocm
mediat
part
backgroundcas
studi
surviv
rate
patient
acut
myeloid
leukemia
aml
surviv
rate
patient
myelodysplast
syndrom
md
fail
standard
therapi
cur
therapi
aml
md
patient
allogen
hematopoiet
stem
cell
transplant
goal
studi
address
gap
treatment
option
develop
novel
cell
therapi
immun
cell
mutat
therapi
term
pactn
person
adopt
cell
therapi
target
tumor
cell
neoantigen
base
concept
cancer
caus
somat
mutat
may
gener
novel
immunogen
protein
neoantigen
evid
shown
demonstr
aml
cell
gener
pactn
method
kill
amlmd
leukem
stem
cell
mark
andor
posit
studi
designmethod
twelv
subject
aml
three
md
studi
cell
immun
process
compris
transcriptom
sequenc
amlmd
patient
andor
blast
patient
normal
blood
cell
identifi
express
dna
mutat
ii
silico
screen
peptid
span
mutat
identifi
potenti
immunogen
peptid
via
iedb
immun
epitop
databas
iii
vitro
immunogen
screen
candid
neopeptid
cell
donor
aml
md
patient
iv
select
immunogen
peptid
neoantigen
gener
cell
line
desir
neoantigen
specif
cytolyt
activ
confirm
cell
specif
immun
cell
cytotox
test
correspond
aml
cell
target
vs
control
cell
use
valid
flow
cytometri
assay
assay
run
triplic
resultsfind
least
one
driver
mutat
present
dnarna
patient
immunogen
test
select
neopeptid
express
cell
two
aml
patient
perform
allogen
autolog
cell
immun
neopeptid
capabl
kill
target
conclus
experi
demonstr
abil
aml
neopeptid
immun
allogen
autolog
cell
suffici
gener
signific
specif
kill
leukem
stem
cell
ind
approv
two
phase
clinic
trial
assess
safeti
toler
pactn
aml
md
patient
backgroundcas
studi
alloimmun
induc
hemolyt
transfus
reaction
human
mechan
respons
rbc
alloimmun
fulli
defin
cell
major
antibodi
product
alreadi
shown
respond
patient
major
cell
profil
contrast
whole
blood
patient
unexpect
express
circul
cell
phenotyp
phenotyp
usual
associ
presenc
tfh
cell
special
product
antibodi
suggest
activ
circul
tfh
could
profil
differenti
express
essenti
cell
domicili
lymph
node
encount
b
cell
major
b
cell
differenti
antibodi
product
other
chemokin
receptor
like
also
differenti
circul
tfh
subpopul
studi
interest
phenotyp
function
lymphocyt
paradox
highli
repres
patient
studi
designmethod
membran
function
phenotyp
circul
cell
compar
group
transfus
sickl
cell
patient
alloimmun
patient
analysi
also
perform
healthi
control
assay
perform
whole
blood
without
separ
procedur
known
alter
express
chemokin
receptor
resultsfind
subpopul
express
ident
transfus
group
control
express
show
differ
transfus
group
control
howev
patient
express
strong
independ
express
aim
determin
help
circul
cell
product
antibodi
cell
purifi
flow
cytometri
day
b
cell
presenc
seb
protein
level
antibodi
seb
stimul
ident
subpopul
transfus
group
control
conclus
paradox
presenc
circul
cell
transfus
patient
appear
particular
function
promot
absenc
humor
respons
howev
respond
patient
high
express
circul
cell
suggest
remark
migratori
properti
toward
secondari
lymphoid
organ
could
facilit
respons
conclus
studi
profil
express
cell
could
help
differenti
respond
patient
rbc
immun
backgroundcas
studi
red
blood
cell
rbc
alloantibodi
increas
probabl
complic
patient
becom
alloimmun
follow
transfus
howev
individu
gener
alloantibodi
appear
experi
increas
rate
addit
alloantibodi
format
follow
subsequ
transfus
howev
immun
one
rbc
alloantigen
prime
immun
complet
distinct
alloantigen
remain
unknown
though
cell
help
classic
occur
direct
recognit
peptid
resid
within
target
b
cell
antigen
individu
develop
antibodi
toward
one
rbc
alloantigen
experi
increas
rate
antibodi
format
complet
distinct
rbc
alloantigen
observ
suggest
cell
respond
one
alloantigen
may
directli
facilit
immun
complet
distinct
rbc
alloantigen
studi
designmethod
recipi
transfus
kel
rbc
presenc
absenc
poli
c
pic
follow
transfus
hod
rbc
kel
rbc
rbc
express
hod
kel
hod
x
kel
mixtur
hod
kel
rbc
hod
kel
examin
role
cell
pickel
prime
recipi
cell
deplet
prior
transfus
addit
recipi
adopt
transfer
cell
pickel
prime
donor
follow
transfus
hod
rbc
hod
x
kel
rbc
alloantibodi
format
evalu
use
indirect
immunofluoresc
stain
resultsfind
kel
rbc
transfus
presenc
pic
pickel
enhanc
antibodi
product
process
prime
event
directli
facilit
antibodi
format
follow
subsequ
hod
x
kel
rbc
transfus
p
pickel
prime
recipi
transfus
hod
kel
rbc
hod
rbc
alon
fail
impact
antibodi
format
abil
immun
kel
boost
humor
respons
hod
antigen
follow
hod
x
kel
rbc
transfus
requir
kel
prime
presenc
pic
cell
deplet
prevent
pickel
prime
recipi
boost
antibodi
respons
p
transfer
cell
pickel
prime
recipi
likewis
directli
facilit
antibodi
format
follow
hod
x
kel
rbc
transfus
p
conclus
result
demonstr
cell
prime
one
rbc
alloantigen
directli
enhanc
immun
respons
complet
distinct
rbc
alloantigen
suggest
mechan
wherebi
alloantibodi
respond
may
exhibit
increas
rate
addit
alloantibodi
format
find
also
highlight
previous
underappreci
mechan
cellular
adapt
immun
influenc
humor
immun
unrel
immunogen
backgroundcas
studi
platelet
refractori
remain
signific
clinic
problem
yet
mechan
occur
incomplet
understood
platelet
clearanc
alloantibodi
play
signific
role
patient
detect
alloantibodi
manag
transfus
platelet
still
mani
patient
refractori
even
receiv
platelet
shown
previous
cell
play
direct
role
platelet
clearanc
allogen
platelet
clear
within
hour
post
transfus
b
recipi
mice
ie
absenc
alloantibodi
deplet
cell
prevent
clearanc
sinc
minor
antigen
differ
still
exist
donor
platelet
recipi
hypothes
minor
antigen
alon
may
mediat
clearanc
otherwis
platelet
studi
designmethod
test
whether
minor
antigen
stimul
platelet
clearanc
examin
platelet
refractori
use
mova
oti
transgen
mice
leukoreduc
donor
platelet
mova
mice
express
form
chicken
ovalbumin
thu
present
ovalbumin
peptid
complex
murin
mhc
class
label
vivowith
fluoresc
dye
cfse
transfus
wildtyp
wt
mice
oti
mice
whose
cell
receptor
recogn
specif
ovalbumin
peptid
context
mhc
class
experi
oti
mice
prime
mova
wt
splenocyt
one
week
prior
mova
platelet
transfus
other
wt
mice
adopt
transfer
oti
splenocyt
hour
mova
platelet
transfus
platelet
recoveri
measur
immedi
transfus
well
hour
day
resultsfind
transfus
mova
platelet
oti
mice
result
signific
platelet
clearanc
compar
transfus
wt
platelet
clearanc
kinet
demonstr
platelet
loss
start
hour
peak
hour
similar
whether
oti
mice
previous
prime
mova
splenocyt
specif
mova
platelet
recoveri
oti
recipi
versu
wt
recipi
hour
p
wherea
transfus
wt
platelet
either
oti
wt
recipi
approxim
hour
transfus
adopt
transfer
oti
cell
wt
mice
recapitul
effect
signific
mova
platelet
clearanc
hour
compar
wt
platelet
clearanc
p
conclus
work
extend
abil
cell
mediat
platelet
clearanc
minor
antigen
provid
insight
potenti
etiolog
platelet
refractori
patient
receiv
product
studi
also
hold
implic
clinic
manag
platelet
refractori
patient
therapi
direct
toward
immunomodul
cell
respons
may
prove
benefici
backgroundcas
studi
alloimmun
major
histocompat
mhc
antigen
common
complic
transfus
neg
impact
subsequ
transfus
transplant
previous
demonstr
pathogen
reduct
riboflavin
uv
light
uvr
effect
rapidli
kill
donor
white
blood
cell
wbc
block
abil
stimul
allogen
respons
vitro
furthermor
uvr
treatment
allogen
platelet
rich
plasma
prp
prevent
alloimmun
mice
provid
partial
toler
subsequ
transfus
cell
die
differ
pathway
either
toler
inflammatori
sought
determin
cell
death
pathway
trigger
uvr
well
evalu
immunogen
prp
contain
wbc
kill
method
studi
designmethod
prp
prepar
mous
blood
treat
uvr
wbc
prepar
parallel
blood
treat
known
induc
either
apoptosi
necrosi
membran
integr
phosphatidylserin
exposur
caspas
activ
chromatin
condens
evalu
flow
cytometri
balbc
recipi
transfus
either
uvr
treat
prp
uvr
treat
prp
either
alon
ad
untreat
apoptot
necrot
wbc
gener
allogen
donor
blood
second
transfus
untreat
prp
given
week
later
allorespons
compar
mice
given
transfus
second
untreat
transfus
resultsfind
uvr
treat
wbc
pattern
phosphatidylserin
exposur
loss
membran
integr
consist
earli
apoptosi
fail
demonstr
signific
caspas
activ
clear
chromatin
condens
alloantibodi
respons
transfus
significantli
higher
mice
previous
expos
untreat
p
necrot
p
wbc
given
uvr
treat
apoptot
wbc
ex
vivo
cytokin
respons
stimul
wbc
reduc
recipi
either
uvr
apoptot
wbc
enhanc
recipi
untreat
necrot
wbc
conclus
mechan
wbc
death
follow
uvr
treatment
share
membran
characterist
earli
apoptosi
distinct
classic
apoptosi
howev
uvr
treat
apoptot
wbc
fail
trigger
allorespons
offer
protect
subsequ
alloexposur
backgroundcas
studi
red
blood
cell
rbc
oxygen
main
substrat
oxid
reaction
result
oxid
damag
consid
one
major
caus
factor
develop
rbc
storag
lesion
oxygen
satur
venou
blood
gener
assum
around
measur
central
venou
line
howev
recent
investig
level
freshli
prepar
red
cell
concentr
reveal
unexpectedli
wide
distribut
mean
yoshida
et
al
blood
transfus
present
studi
undertaken
determin
distribut
produc
blood
center
use
novel
probe
addit
quantit
metabolom
carri
examin
redox
statu
store
rbc
variou
level
studi
designmethod
unit
examin
five
consecut
day
repres
collect
unit
period
region
blood
center
unit
process
room
temperatur
within
hour
blood
collect
measur
pvc
bag
immedi
prior
refriger
employ
reson
raman
spectrometri
pendar
microvascular
oximet
pendar
technolog
cambridg
addit
process
method
rcc
volum
blood
type
gender
process
time
record
analys
separ
studi
human
volunt
store
normox
hyperox
hypox
condit
day
prior
metabolom
analys
presenc
deuter
intern
label
standard
absolut
quantit
resultsfind
measur
carri
blood
center
yield
similar
wide
distribut
previou
studi
unit
procur
sampl
invas
within
hour
blood
collect
yoshida
ibid
shape
distribut
appear
near
normal
mean
median
rang
rang
iqr
male
donor
show
higher
compar
femal
donor
p
correl
observ
level
process
time
donor
age
blood
type
metabolom
workflow
indic
lower
level
amelior
energi
oxid
metabol
lesion
lower
level
yield
higher
rate
gsh
synthesi
higher
nadph
concentr
higher
gsh
gssg
nadphnadpratio
lower
supernat
urat
consumpt
lower
purin
oxid
conclus
surprisingli
wide
distribut
start
level
observ
manufactur
blood
center
use
room
temperatur
process
consid
recent
report
show
profound
effect
oxygen
level
rbc
metabol
coupl
neg
impact
high
oxygen
satur
qualiti
store
rbc
suggest
oxygen
level
import
underappreci
sourc
unit
unit
variabl
rcc
qualiti
futur
studi
investig
whether
day
level
affect
red
blood
cell
storabl
storag
lesion
backgroundcas
studi
refriger
red
blood
cell
rbc
storag
promot
progress
accumul
biochem
lesion
affect
red
blood
cell
energi
redox
metabol
purin
catabolismoxid
gener
hypoxanthin
recent
appreci
marker
rbc
metabol
age
storag
despit
known
deleteri
effect
associ
level
circul
hypoxanthin
unclear
whether
accumul
intracellular
supernat
hypoxanthin
store
rbc
unit
clinic
relev
transfus
recipi
studi
designmethod
leukofilt
rbc
human
volunt
store
normox
hyperox
hypox
condit
day
rang
prior
metabolom
analysi
rbc
healthi
volunt
collect
sea
level
day
high
altitud
mous
rbc
incub
normox
hypox
condit
metabolom
analys
perform
human
mous
rbc
store
day
respect
correl
recoveri
studi
resultsfind
intracellular
supernat
hypoxanthin
increas
store
rbc
unit
function
oxygen
level
purin
oxid
decreas
salvag
reaction
promot
hypox
storag
glean
steadi
state
analysi
store
human
mous
rbc
concentr
metabolom
analys
rbc
healthi
human
volunt
expos
high
altitud
hypoxia
trace
experi
label
substrat
confirm
vitro
steadi
state
result
suggest
hypoxia
induc
increas
flux
salvag
reaction
use
mous
human
store
rbc
increas
hypoxanthin
neg
correl
p
recoveri
conclus
hypoxanthin
vitro
metabol
marker
rbc
storag
lesion
correl
recoveri
vivo
accumul
hypoxanthin
amelior
decreas
purin
oxid
activ
salvag
reaction
backgroundcas
studi
donor
variabl
rbc
storag
observ
human
anim
model
previous
report
rbc
mice
store
well
wherea
rbc
fvb
mice
store
poorli
determin
made
base
upon
recoveri
cross
two
strain
intermedi
storag
phenotyp
strain
mice
util
test
hypothesi
rbc
affect
storag
rbc
oppos
rbc
storag
lesion
event
intrins
individu
rbc
studi
designmethod
allow
visual
store
rbc
mice
gener
also
express
green
fluoresc
protein
rbc
rbc
store
either
fvb
rbc
control
rbc
store
rbc
green
normal
condit
amongst
group
design
rbc
fluoresc
flow
cytometri
allow
abil
assess
effect
rbc
upon
rbc
transwel
plate
consist
two
compart
separ
membran
micron
size
limit
use
test
natur
case
rbc
store
day
transfus
mice
recoveri
determin
enumer
rbc
peripher
blood
flow
cytometri
resultsfind
recoveri
rbc
significantli
increas
rbc
significantli
decreas
fvb
rbc
effect
observ
molecul
smaller
micron
allow
exchang
rbc
popul
transwel
system
antibodi
place
top
chamber
transwel
system
freeli
diffus
bottom
well
confirm
membran
allow
passag
small
molecul
conclus
find
indic
storag
rbc
one
phenotyp
impact
storag
rbc
differ
phenotyp
posit
neg
direct
molecul
smaller
micron
alon
suffici
mediat
indic
larg
molecul
andor
contact
requir
find
challeng
notion
biolog
given
rbc
entir
intrins
properti
suggest
rather
rbc
may
function
multicellular
organ
intercellular
commun
degre
find
extend
normal
rbc
physiolog
outsid
context
storag
andor
translat
human
rbc
biolog
requir
studi
backgroundcas
studi
refriger
storag
significantli
affect
metabolom
profil
rbc
unit
prior
studi
suggest
increas
storag
impair
energi
homeostasi
antioxid
capac
lead
gener
bioactiv
lipid
find
limit
lack
vivo
human
correl
evalu
relationship
rbc
metabolom
profil
vitro
hemolysi
vivo
human
transfus
recipi
studi
designmethod
healthi
adult
met
standard
allogen
blood
donat
random
transfus
one
autolog
rbc
unit
week
storag
blood
sampl
collect
defin
time
transfus
measur
marker
hemolysi
rbc
recoveri
transfus
aliquot
transfus
frozen
liquid
nitrogen
metabolom
profil
tandem
liquid
spectrometri
predict
regress
model
develop
use
sa
resultsfind
hierarch
cluster
analysi
confirm
previou
result
metabolit
correl
storag
time
discov
metabolit
predict
vivo
hemolysi
given
storag
durat
multivari
linear
regress
perform
follow
adjust
storag
time
adjust
storag
time
metabolit
significantli
p
predict
area
curv
auc
iron
eg
amount
iron
releas
recipi
circul
hour
transfus
one
autolog
rbc
unit
involv
energi
product
glutathion
homeostasi
pathway
eg
reduc
glutathion
bioactiv
lipid
eg
increas
donorrecipi
age
gender
also
correl
increas
auc
iron
adjust
similarli
adjust
storag
time
metabolit
correl
best
recoveri
involv
similar
pathway
eg
adenin
interestingli
featur
tent
assign
metabolit
tryptophan
thought
produc
bacteria
colon
predict
auc
iron
rbc
recoveri
conclus
data
confirm
oxid
stress
ie
antioxid
pathway
gener
oxid
lipid
function
import
rbc
storag
lesion
identifi
specif
metabolit
correl
outcom
vivo
interestingli
prior
mous
model
studi
suggest
specif
hete
produc
vitro
predict
rbc
recoveri
vivo
thu
report
correl
metabolom
profil
vitro
hemolysi
vivo
human
also
support
conclus
earlier
mous
studi
futur
studi
prospect
test
predict
metabolit
vivo
hemolysi
backgroundcas
studi
studi
red
blood
cell
concentr
rbcc
prepar
use
differ
manufactur
process
addit
solut
focus
chang
rbc
storag
lesion
vitro
qualiti
far
none
studi
investig
whether
rbcc
manufactur
practic
affect
bacteri
surviv
contamin
unit
previou
studi
canadian
blood
servic
cb
hq
suggest
might
differenti
effect
bacteri
growth
thu
studi
aim
compar
bacteri
growth
rbcc
prepar
four
sagm
paggsm
studi
designmethod
studi
conduct
parallel
cb
hq
three
gender
match
cpd
unit
use
prepar
three
rbcc
suspend
sagm
paggsm
respect
parallel
one
prepar
suspend
rbcc
inocul
one
four
bacteria
klebsiella
pneumonia
staphylococcu
epidermidi
yersinia
enterocolitica
propionibacterium
acn
target
load
unit
cfu
ml
day
rbcc
sampl
taken
determin
cfu
blood
agar
growth
detect
storag
day
sampl
inocul
bactalert
cultur
bottl
effect
andor
gender
bacteri
growth
statist
analyz
experiment
work
complet
hq
cb
resultsfind
result
hq
show
epidermidi
rbcc
regardless
although
k
pneumonia
growth
detect
blood
agar
posit
bactalert
cultur
obtain
day
p
acn
prolifer
surviv
rbc
storag
detect
concentr
cfuml
day
enterocolitica
grew
similarli
cfuml
cfuml
respect
increas
observ
cfuml
decreas
obtain
cfuml
preliminari
data
cb
show
similar
growth
trend
bacteria
conclus
result
confirm
differ
differenti
effect
bacteri
growth
rbcc
clinic
signific
observ
unknown
merit
investig
backgroundcas
studi
identif
base
pair
delet
receptor
gene
delta
allel
direct
correl
resist
hiv
infect
prompt
worldwid
investig
allel
frequenc
differ
popul
special
interest
cord
blood
bank
sinc
argentinean
mix
popul
well
european
ancestri
aim
studi
allel
frequenc
cord
blood
sampl
studi
designmethod
report
frequenc
allel
detect
cord
blood
donor
enrol
accord
standard
procedur
argentinean
popul
ethnic
origin
collect
survey
time
recruit
sampl
divid
group
european
ancestri
sampl
b
sampl
c
mix
ab
sampl
origin
sampl
order
character
ethnic
popul
also
studi
locu
calcul
allel
frequenc
group
b
resultsfind
overal
heterozyg
mutat
distribut
group
follow
european
ancestri
mix
ab
popul
origin
homozyg
individu
sampl
studi
regard
hla
frequenc
result
shown
tabl
tabl
conclus
frequenc
observ
delta
allel
lower
report
european
popul
consist
lack
presenc
originari
popul
also
found
allel
frequenc
group
resembl
caucasian
popul
group
b
hispan
popul
accord
optnuno
data
base
http
wwwtransplantproorgnewskidneyoptnpubliccommentproposaloffersalternatecpracalculationmethod
support
idea
mix
popul
worth
notic
sampl
select
belong
differ
region
countri
distant
collect
center
bank
studi
need
increas
number
geograph
region
well
ethnic
group
countri
backgroundcas
studi
cellular
prion
protein
prpc
cell
surfac
glycoprotein
express
mainli
brain
also
peripher
organ
includ
blood
bone
marrow
bm
lymphoid
tissu
prpc
convert
prpsc
involv
pathogenesi
neurodegen
diseas
includ
diseas
kuru
human
scrapi
bovin
spongiform
encephalopathi
anim
howev
biolog
function
prpc
yet
conclus
elucid
studi
designmethod
studi
prpc
knockout
mice
ko
util
investig
role
prpc
hematopoiet
system
control
age
prpc
transgen
mice
harbor
slightli
augment
prpcexpress
peripher
blood
examin
hematolog
analyz
establish
count
bone
marrow
thymu
spleen
lymph
node
peripher
blood
harvest
analyz
flow
cytometri
use
comprehens
panel
antibodi
specif
hematolog
cell
precursor
lineag
histolog
bone
marrow
spleen
thymu
lymph
node
evalu
light
microscopi
resultsfind
complet
blood
count
cbc
show
signific
increas
wbc
ko
mice
closer
analysi
wbc
differenti
reveal
elev
number
wbc
ko
mice
due
lymphocytosi
specif
ko
mice
increas
absolut
lymphocyt
count
ko
vs
wt
p
well
higher
lymphocyt
percentag
compar
control
ko
mice
also
trend
toward
higher
hemoglobin
rbc
hematocrit
compar
wt
mice
addit
platelet
count
ko
mice
higher
control
mice
interest
mean
platelet
volum
indic
platelet
size
significantli
increas
ko
mice
compar
control
ko
fl
vs
wt
fl
comprehens
flow
cytometr
analysi
cell
lineag
reveal
signific
differ
number
rbc
megakaryocyt
bm
lymphocyt
thymu
spleen
lymph
node
histolog
analysi
bm
thymu
spleen
lymph
node
tissu
ko
wt
anim
fail
show
morpholog
differ
two
group
conclus
absenc
prpc
result
signific
leukocytosi
specif
higher
absolut
count
percentag
lymphocyt
well
larger
platelet
peripher
blood
appear
affect
hematopoiesi
lymphopoiesi
find
indic
prpc
might
critic
surviv
traffick
lymphocyt
peripher
blood
molecular
mechan
underli
observ
chang
lymphocyt
platelet
whether
involv
function
chang
cell
subject
futur
studi
backgroundcas
studi
exosom
defin
one
type
membran
vesicl
secret
extracellular
space
type
cell
report
involv
intercellular
commun
mediat
biolog
process
human
peripheri
blood
treg
cell
report
stabl
regulatori
cell
greater
inhibit
effect
howev
deriv
exosom
function
involv
mediat
seldom
report
studi
designmethod
cell
freshli
purifi
pbmc
cultur
antibodi
packag
bead
polar
rapamycin
treg
cell
harvest
cell
bead
stimul
effector
cell
transwel
plate
supernat
deriv
treg
collect
ultrafiltr
centrifug
remain
solut
precipit
peg
harvest
precipit
resuspend
pb
exosom
analyz
sem
nta
exosom
surfac
marker
protein
express
evalu
flow
cytometri
western
blot
microrna
isol
mircut
mirna
kit
measur
qpcr
precipit
exosom
purifi
immunoaffin
captur
effector
cell
investig
function
immun
modul
resultsfind
compar
direct
contact
separ
cell
could
suppress
prolifer
effector
cell
small
declin
p
mean
factor
involv
treg
mediat
immun
modul
total
number
cell
exosom
harvest
electron
microscop
analysi
demonstr
kind
membran
vesicl
diamet
nta
express
exosom
western
blot
experi
confirm
express
exosom
surfac
marker
besid
also
express
deriv
exosom
compar
induc
effect
counterpart
deriv
exosom
contain
higher
level
p
addit
treg
cell
deriv
exosom
demonstr
inhibit
prolifer
effector
cell
conclus
cell
could
secret
extracellular
vesicl
rang
diamet
exsom
could
involv
mediat
immun
modul
backgroundcas
studi
regulatori
cell
treg
contain
subtyp
play
essenti
role
immun
regul
autoimmun
diseas
prevent
make
potenti
candid
cell
therapi
autoimmun
diseas
aid
unfortun
due
instabl
natur
cell
ntreg
inflamm
condit
includ
instabl
convers
effector
cell
unabl
modifi
establish
diseas
thu
need
investig
regulatori
cell
stabil
vitro
vivo
previou
work
found
treg
effect
therapeut
function
cia
mice
studi
aim
investig
stabil
induc
polyclon
human
cell
inflamm
transfus
studi
designmethod
human
treg
induc
rapamycin
lymphocyt
vitro
arthriti
cia
mice
induc
collagen
autoimmun
diseas
model
vitro
stabil
treg
encount
inflamm
test
express
cell
convers
inflamm
condit
vivo
treg
transfus
cia
mice
surviv
mice
express
evalu
reveal
stabil
treg
inflamm
condit
model
addit
also
investig
stabil
mainten
induc
factor
rapamycin
remov
test
express
resultsfind
ex
vivo
induc
human
treg
secret
supernat
cell
express
treg
maintain
induc
factor
rapamycin
remov
vitro
express
signific
differ
compar
control
treg
secret
encount
inflamm
condit
vivo
treg
cell
transfus
cia
mice
peak
diseas
onset
day
first
collagen
immun
inflamm
condit
vivo
test
treg
surviv
treg
found
cia
mice
foot
blood
spleen
cell
hour
transfus
remain
conclus
result
reveal
induc
expand
human
stabl
inflamm
transfus
maintain
express
induc
factor
remov
make
treg
novel
stabl
cell
potenti
cell
therapi
aid
research
provid
instruct
refer
improv
util
blood
compon
backgroundcas
studi
tolerogen
dendrit
cell
tdc
adopt
cellular
immunotherapi
cut
edg
strategi
treat
hypersensit
respons
diseas
immun
respons
direct
atop
dermat
system
lupu
erythematosu
sle
rheumatoid
arthriti
ra
et
al
howev
tradit
strategi
base
tdc
usual
unstabl
inconspicu
cytokin
induc
process
might
limit
tdc
adapt
cell
therapi
futur
clinic
use
studi
designmethod
human
tdc
deriv
fresh
purifi
monocyt
pbmnc
isol
buffi
coat
induc
mtor
inhibitor
rapamycin
temsirolimu
safe
concentr
confirm
apoptosi
assay
cell
complet
differenti
matur
marker
endocytisi
detect
flow
cytometri
product
cytokin
chemokin
measur
use
elisa
mechan
investig
analysi
pcr
western
blot
contact
hypersensit
ch
model
atop
dermat
anim
model
treat
tdc
induc
via
mtor
suppress
analyz
ear
thick
tissu
leukocyt
number
calcul
resultsfind
human
tdc
treat
mtor
inhibitor
lower
matur
marker
express
tlr
signal
activ
accompani
set
cytokin
chemokin
remark
concentr
depend
manner
lp
absent
group
moreov
mtor
suppress
extrem
reduc
capac
lp
treat
human
dc
stimul
autogen
cell
prolifer
one
import
characterist
tdc
beyond
expect
common
signal
transduct
pathway
mapk
pathway
signal
target
could
hardli
explan
tolerogen
perform
tdc
exposur
lp
stimul
howev
downstreanm
protein
especi
protein
control
protein
translat
shown
charg
tolerogen
induct
mechan
data
also
support
suggest
rare
differ
mrna
transcript
relat
function
protein
tdc
induc
mtor
inhibitor
exposur
lp
stimul
cell
although
transcript
ido
induc
mtor
inhibitor
import
edema
respons
ear
clearli
weaken
ch
model
recruit
less
leukocyt
tissu
mtor
inhibitor
tdc
induc
mtor
inhibitor
suggest
tdc
induc
mtor
suppress
abl
control
hypersensit
inflamm
respons
vivo
conclus
accordingli
tdc
induc
mtor
suppress
potent
adopt
cellular
immunotherapi
strategi
treat
hypersensit
respons
diseas
induct
mechan
might
suppress
systemat
effect
function
protein
relat
protein
translat
inhibit
backgroundcas
studi
red
blood
cell
rbc
undergo
mani
chang
store
blood
bank
condit
collect
known
storag
lesion
bioactiv
lipid
gener
rbc
storag
implic
certain
advers
outcom
recent
report
bioactiv
lipid
especi
polyunsatur
fatti
acid
pufa
oxid
product
oxylipin
accumul
rbc
storag
despit
leukoreduct
evalu
extent
membran
lipid
degrad
oxid
store
rbc
unit
among
donor
popul
differ
blood
group
quantifi
pufa
lysophospholipid
lpl
leukoreduc
rbc
unit
studi
designmethod
rbc
unit
differ
donor
acquir
process
day
one
day
past
expir
bioactiv
lipid
includ
common
fatti
acid
oxylipin
lpl
analyz
liquid
mass
spectrometri
multipl
reaction
monitor
total
fatti
acid
concentr
select
unit
also
analyz
anova
test
use
determin
signific
differ
analyt
amongst
differ
blood
group
resultsfind
observ
wide
distribut
concentr
major
pufa
store
rbc
unit
exampl
arachidon
acid
aa
rang
linol
acid
la
acid
dgla
eicosapentaeno
acid
epa
docosahexaeno
acid
dha
acid
ala
ten
oxylipin
includ
hete
hode
dihom
lpl
includ
lpc
lpss
lpe
show
larg
variat
concentr
among
donor
analyt
quantifi
show
signific
differ
concentr
among
differ
blood
type
anova
test
fdr
ab
rh
blood
group
consist
exhibit
lowest
concentr
major
pufa
blood
group
show
highest
averag
differ
concentr
rh
fold
increas
rh
among
pufa
rang
suggest
rh
blood
group
independ
abo
blood
group
correl
donor
donor
variat
lipid
metabol
conclus
wide
distribut
concentr
bioactiv
lipid
among
store
rbc
unit
suggest
lipid
degrad
highli
red
blood
cell
blood
type
rh
antigen
well
abo
blood
group
correl
may
influenc
degrad
oxid
membran
lipid
rbc
storag
backgroundcas
studi
intercept
blood
system
rbc
inactiv
pathogen
leukocyt
rbc
compon
transfus
use
amustalin
form
nucleic
acid
adduct
prevent
replic
broad
rang
contamin
pathogen
leukocyt
intercept
rbc
prepar
rbc
demonstr
recoveri
met
fda
requir
us
phase
clinic
studi
evalu
transfus
safeti
efficaci
lr
intercept
rbc
enrol
patient
studi
evalu
compat
input
lr
rbc
addit
solut
compar
studi
designmethod
whole
blood
cpd
lr
filtrat
rbc
prepar
day
follow
donat
match
pair
prepar
compos
test
rbc
process
intercept
system
store
untreat
control
c
store
respect
rbc
store
assess
throughout
day
storag
resultsfind
rbc
hb
hb
recoveri
hemolysi
similar
c
rbc
hemolysi
higher
tabl
ph
rbc
slightli
lower
c
rbc
higher
ph
c
atp
unit
significantli
higher
c
lactat
k
level
lower
c
differ
na
signific
input
rbc
rbc
slightli
higher
c
differ
glucos
concentr
reflect
glucos
level
control
c
glucos
level
higher
lower
conclus
measur
vitro
paramet
treat
rbc
similar
untreat
control
suggest
intercept
blood
system
rbc
compat
lr
rbc
input
addit
current
phase
studi
rbc
input
tabl
rbc
function
post
treatment
c
backgroundcas
studi
ensur
avail
biolog
product
hospit
blood
bank
develop
valid
multipl
storag
condit
product
maxim
shelf
life
qualiti
case
labil
product
metabol
known
remain
activ
storag
lead
storag
lesion
microrna
mirna
level
modul
damag
make
mirna
ideal
candid
potenti
biomark
qualiti
monitor
late
nanoparticl
wide
studi
use
biosens
applic
object
work
develop
biocompat
gold
nanosensor
sensit
select
direct
detect
biomark
character
assess
qualiti
blood
product
deliv
hospit
studi
designmethod
gold
nanoparticl
gnp
surround
fluoresc
silica
shell
prepar
use
wet
chemistri
method
chosen
potenti
target
sinc
strongli
express
platelet
concentr
concentr
fluctuat
accord
storag
lesion
custom
rna
dna
molecular
beacon
design
use
probe
specif
detect
target
pb
human
plasma
fluoresc
transduc
probe
conjug
surfac
fluoresc
silica
use
edcnh
reaction
hybrid
reaction
target
probe
initi
energi
transfer
mechan
record
fluoresc
resultsfind
gnp
nm
surround
thick
fluoresc
silica
shell
nm
prepar
use
nanosensor
optim
luminesc
properti
stabil
conjug
probe
onto
nanoparticl
confirm
fluoresc
spectroscopi
microscopi
well
nanoparticl
track
analysi
fluoresc
respons
molecular
beacon
studi
show
reproduc
linear
relationship
concentr
limit
detect
hybrid
assay
human
plasma
appear
demonstr
denatur
rna
probe
target
conclus
biocompat
fluoresc
gnp
prepar
use
tool
blood
product
character
conjug
molecular
beacon
surfac
nanoparticl
achiev
character
use
spectroscop
microscop
techniqu
function
probe
still
optim
fluoresc
respons
molecular
beacon
character
detect
model
mirna
target
pb
human
plasma
backgroundcas
studi
moment
matur
red
blood
cell
rbc
leav
bone
marrow
optim
adapt
perform
bind
transport
oxygen
deliveri
tissu
red
blood
cell
modul
oxygen
transport
protect
hemoglobin
damag
maintain
osmot
environ
cell
glycolysi
energet
metabol
pathway
matur
rbc
obtain
atp
energi
rbc
maintain
number
vital
cell
function
gener
current
method
use
measur
rbc
glycolysi
live
state
destruct
cell
requir
radioactivityxf
technolog
appli
differ
type
cell
red
blood
cell
suspend
cell
shape
size
differ
cell
importantli
rbc
nucleu
mitochondria
organel
applic
xf
technolog
erythrocyt
explor
assay
condit
necessari
studi
designmethod
extracellular
flux
xf
methodolog
particularli
advantag
capabl
dynam
monitor
cell
energi
metabol
glycolyt
rate
atp
concentr
determin
atp
colorimetricfluorometr
assay
kit
resultsfind
research
found
better
seed
suspend
rbc
onto
micropl
assay
improv
glucos
respons
rbc
found
incub
blood
sampl
produc
much
better
glucos
respons
vari
concentr
glucos
found
mm
glucos
optim
appli
method
measur
energi
metabol
chang
rbc
isol
storag
blood
sampl
glucos
respons
glycolysi
capac
rbc
decreas
respect
day
result
valid
atp
content
chang
conclus
standard
paramet
lay
framework
use
xf
analysi
profil
rbc
glycolysi
technolog
complement
inform
gather
extens
metabolom
platform
backgroundcas
studi
sever
studi
impact
lipem
plasma
qualiti
blood
product
indic
lipem
plasma
advers
effect
qualiti
platelet
red
blood
cell
rbc
storag
studi
possibl
relationship
donor
characterist
occurr
lipem
plasma
examin
aim
studi
expand
knowledg
donor
characterist
relat
qualiti
blood
product
studi
designmethod
whole
blood
wb
donat
lipem
plasma
rbc
concentr
sagm
produc
vitro
qualiti
cold
storag
determin
addit
donor
characterist
obtain
data
use
investig
whether
relationship
certain
donor
characterist
triglycerid
tg
level
plasma
hemolysi
storag
qualiti
control
data
normal
rbc
use
control
group
resultsfind
lipem
wb
donat
evalu
data
indic
direct
relationship
plasma
tg
level
degre
hemolysi
storag
lipem
donat
hemolysi
day
storag
control
group
hemolysi
unit
two
lipem
donat
obtain
femal
donor
donor
popul
women
regist
activ
donor
mean
age
donor
studi
year
year
mean
bmi
donor
normal
rang
bmi
donor
show
overweight
bmi
donor
obes
bmi
donat
drawn
pm
four
donat
pm
seven
donat
pm
pm
donat
pm
note
blood
bank
blood
donat
take
place
even
normal
tg
level
blood
mmoll
tg
lipem
plasma
unit
averag
mmoll
rang
mmoll
mmoll
whith
unit
show
tg
mmoll
unit
donat
pm
conclus
rbc
concentr
made
lipem
wb
hemolysi
greatli
enhanc
storag
base
limit
set
donat
evalu
tent
conclus
highest
chanc
lipem
plasma
exist
donat
men
year
bmi
donat
even
donor
characterist
donor
relat
lipem
unit
reject
product
blood
product
collect
perform
extens
data
analysi
base
investig
blood
servic
decid
use
lipem
wb
product
cellular
blood
product
donor
provid
instruct
prevent
lipem
donat
much
possibl
backgroundcas
studi
pathogen
inactiv
method
platelet
concentr
increasingli
use
blood
bank
worldwid
make
transfus
safer
vitro
studi
demonstr
effect
pathogen
inactiv
storag
lesion
littl
routin
qualiti
control
data
blood
bank
outcom
report
studi
designmethod
swirl
distribut
product
monitor
one
year
one
year
implement
intercept
pathogen
inactiv
metabol
paramet
like
ph
glucos
lactic
acid
determin
random
sampl
expir
pathogen
inactiv
product
furthermor
indic
platelet
storag
lesion
measur
apheresi
concentr
prematur
low
swirl
compar
control
normal
swirl
resultsfind
experiment
phase
limit
number
product
valid
intercept
pathogen
inactiv
method
ph
glucos
level
decreas
faster
apheresi
platelet
concentr
high
platelet
content
low
platelet
content
pool
buffi
coat
deriv
product
pathogen
inactiv
implement
routin
product
show
glucos
exhaust
often
prepar
apheresi
compar
buffi
coat
deriv
platelet
concentr
despit
plasma
carryov
former
furthermor
number
apheresi
product
prematur
low
swirl
increas
compar
previou
year
without
pathogen
inactiv
contrast
incid
prematur
low
swirl
platelet
concentr
prepar
buffi
coat
method
decreas
vs
note
apheresi
concentr
prematur
low
swirl
significantli
higher
median
platelet
count
unaffect
control
show
sign
increas
storag
lesion
compar
control
expir
day
five
without
swirl
defect
sign
includ
lower
ph
higher
lactic
acid
concentr
increas
mean
platelet
volum
phosphatidylserin
exposur
conclus
risk
increas
storag
lesion
rate
follow
intercept
pathogen
inactiv
higher
apheresi
buffi
coat
deriv
platelet
concentr
especi
platelet
content
backgroundcas
studi
blood
system
platelet
fda
approv
ex
vivo
prepar
apheresi
platelet
compon
pc
reduc
risk
tti
includ
sepsi
potenti
reduc
risk
gvhd
registr
studi
http
clinicaltrialsgov
progress
support
approv
apheresi
platform
collect
platelet
compon
pc
suspend
plasma
object
studi
evalu
vitro
function
platelet
suspend
collect
use
trima
platform
treatment
intercept
blood
system
platelet
studi
designmethod
doubl
dose
apheresi
pc
platelet
ml
collect
trima
apheresi
platform
sampl
taken
donat
prior
divid
donat
produc
intercept
treat
apheresi
pc
use
small
volum
sv
set
untreat
control
pc
c
input
volum
replic
c
dose
c
pc
store
condit
evalu
day
day
physicalmetabol
characterist
resultsfind
day
c
pc
dose
recoveri
day
lower
count
volum
dose
bicarbon
glucos
compar
c
pc
howev
paramet
predict
vivo
function
atp
morpholog
score
hsr
esc
equival
c
tabl
conclus
trima
pc
treat
intercept
blood
system
platelet
use
sv
set
store
day
retain
vitro
metabol
function
properti
consist
vivo
function
backgroundcas
studi
recent
multi
research
report
longer
red
blood
cell
rbc
unit
associ
increas
risk
clinic
advers
event
especi
critic
ill
patient
howev
studi
conclud
neg
result
whether
rbc
storag
durat
associ
increas
risk
clinic
advers
event
uncertain
becom
popular
topic
studi
advers
effect
longer
rbc
directli
aim
look
pluripot
stem
cardiomyocyt
toxic
induc
supernat
suspend
red
blood
cell
ssrbc
studi
possibl
mechan
studi
designmethod
five
dose
rbc
prepar
supernat
isol
centrifug
look
cardiotox
ssrbc
pluripot
stem
cardiomyocyt
treat
ssrbc
final
volum
simul
larg
volum
blood
transfus
use
cellular
analysi
rtca
technolog
beat
record
real
time
detail
level
k
lactic
acid
la
test
use
automat
biochem
k
la
solut
concentr
consist
ssrbc
prepar
analyz
cardiotox
k
la
solut
treat
ssrbc
k
cell
cultur
media
nuclear
shape
integr
filament
sarcomer
examin
immunofluoresc
total
rna
isol
mrna
analysi
microarray
implement
screen
toxic
effect
relat
signal
pathway
bioinformat
analysi
resultsfind
ssrbc
obviou
influenc
beat
state
treat
ssrbc
stop
beat
beat
pattern
restor
treat
ssrbc
stop
beat
beat
pattern
restor
level
k
la
ssrbc
chang
obvious
k
solut
made
stop
beat
restor
k
k
la
solut
influenc
beat
pattern
end
treatment
treat
ssrbc
show
obviou
shrinkag
end
treatment
cell
treat
k
ssrbc
show
obviou
shrinkag
shrinkag
ssrbc
group
seriou
immunofluoresc
result
show
integr
filament
sarcomer
complet
nuclear
pyknosi
detect
gene
express
array
result
show
total
gene
differenti
express
ssrbc
group
compar
naiv
group
consist
separ
within
k
naiv
group
fifteen
differ
express
gene
select
bioinformat
method
like
play
import
role
cytotox
effect
conclus
condit
simul
larg
volum
blood
transfus
ssrbc
long
rbc
toxic
effect
myocardi
cell
addit
high
potassium
induc
cardiotox
must
element
involv
toxic
effect
studi
appli
signal
pathway
ssrbc
induc
cytotox
larg
volum
transfus
long
rbc
may
risk
factor
advers
clinic
outcom
clinic
pay
attent
backgroundcas
studi
process
thaw
deglycerol
red
cell
concentr
rcc
function
close
system
allow
prolong
storag
thaw
thaw
cell
better
maintain
compar
sagm
presenc
citrat
seem
necessari
prevent
hemolysi
thaw
cell
storag
atp
level
rapidli
declin
recent
develop
addit
solut
like
shown
better
maintain
atp
level
storag
normal
unfrozen
rcc
howev
probabl
due
absenc
citrat
solut
suitabl
storag
thaw
cell
therefor
design
mannitol
replac
citrat
aim
studi
investig
vitroqu
thaw
deglycerol
rbc
storag
studi
designmethod
leukoreduc
rcc
phosphat
adenin
glucos
guanosin
glucon
citrat
store
day
rcc
glycerol
use
braintre
final
concentr
wv
frozen
store
least
two
week
thaw
deglycerol
use
rcc
resuspend
storag
stabil
hemolysi
atp
level
determin
result
compar
thaw
rcc
prefreez
storag
sagm
resuspend
sagm
resultsfind
storag
result
increas
level
day
compar
storag
sagm
resp
hb
hb
hemolysi
storag
remain
day
compar
storag
sagm
hemolysi
remain
day
first
week
storag
atp
level
increas
follow
gradual
declin
prolong
storag
whole
storag
period
rcc
show
significantli
higher
atp
level
compar
sagm
sagm
level
undetect
day
storag
level
decreas
hb
day
storag
conclus
storag
result
increas
level
compar
storag
show
compar
hemolysi
atp
level
much
better
maintain
base
maximum
allow
hemolysi
atp
content
hb
thaw
rcc
store
day
backgroundcas
studi
europ
red
cell
concentr
rcc
usual
store
sagm
storag
vitro
red
cell
qualiti
declin
includ
lower
energi
statu
increas
cell
lysi
recent
sever
addit
solut
design
diminish
declin
vitro
qualiti
storag
develop
new
solut
includ
mainli
develop
better
maintain
rbc
level
energi
statu
storag
compar
maintain
higher
level
higher
energi
statu
necessari
function
surviv
rbc
vivo
howev
recent
studi
shown
rbc
storag
neg
effect
deform
rbc
effect
seen
rbc
store
import
differ
presenc
glucon
contain
bicarbon
aim
studi
investig
effect
variou
concentr
bicarbon
vitroqu
rbc
storag
studi
designmethod
four
variant
test
mmoll
mmoll
glucon
replac
mmoll
glucon
replac
mmoll
overnight
store
whole
blood
n
leucocyt
reduc
process
plasma
pack
rbc
pack
rbc
divid
equal
volum
dilut
variant
storag
day
rcc
weekli
sampl
analyz
hematolog
metabol
rheolog
paramet
resultsfind
intern
ph
rbc
store
variant
bicarbon
remain
significantli
higher
rbc
entir
storag
period
atp
content
day
storag
show
signific
differ
variant
valu
around
hb
hemolysi
storag
compar
variant
end
storag
day
storag
level
show
signific
differ
variant
hb
day
storag
fraction
cell
measur
arca
significantli
lower
variant
reduc
glucon
concentr
rbc
reduc
variant
conclus
full
partial
replac
glucon
bicarbon
posit
effect
deform
storag
without
neg
affect
posit
effect
rbc
metabol
high
atp
level
backgroundcas
studi
platelet
plt
vital
effect
treatment
hemorrhag
cold
storag
plt
platelet
addit
solut
pa
promis
altern
convent
storag
room
temperatur
rt
due
lower
risk
bacteri
concern
preserv
plt
function
mitig
plt
activ
current
apheresi
ap
pa
system
use
us
trima
iso
terumo
amicu
intersol
int
fenwal
goal
studi
assess
adhes
function
plt
collect
appa
method
studi
designmethod
plt
collect
iso
use
trima
int
use
amicu
store
day
rt
sampl
test
day
baselin
bl
storag
assess
plt
adhes
shear
flow
bioflux
acd
vacutain
tube
collect
donor
centrifug
obtain
red
blood
cell
rbc
bioflux
run
simul
whole
blood
creat
combin
plt
label
rbc
hct
label
blood
perfus
microfluid
channel
fluxion
coat
ugml
collagen
shear
rate
imag
acquir
everi
sec
min
use
fluoresc
microscop
surfac
coverag
report
data
analyz
use
anova
posthoc
tukey
test
signific
p
resultsfind
plt
show
significantli
decreas
adhes
day
storag
compar
bl
bl
rt
p
sampl
show
differ
adhes
timepoint
compar
significantli
enhanc
adhes
compar
contrast
plt
show
signific
enhanc
surfac
coverag
compar
day
compar
day
p
conclus
work
suggest
storag
plt
collect
trima
ap
system
iso
day
offer
signific
enhanc
adhes
function
compar
plt
collect
amicu
system
int
store
result
surpris
sinc
shown
express
similar
level
phosphatidylserin
may
suggest
differ
pa
plt
intracellular
signal
expect
storag
plt
collect
either
platform
demonstr
superior
function
rt
storag
plt
product
superior
hemostat
function
longer
current
provid
potenti
shipment
product
underserv
area
may
bolster
plt
avail
trauma
care
us
backgroundcas
studi
report
storag
blood
facilit
white
blood
cell
wbc
apoptosi
therefor
releas
transform
growth
modul
red
blood
cell
rbc
alloimmun
mous
whether
storag
synerg
apoptot
effect
wbc
rare
report
earli
apoptot
cell
exclud
late
stage
apoptot
cell
stain
posit
due
passag
dye
nucleu
bind
dna
studi
designmethod
sampl
acquir
whole
blood
compon
adenin
preserv
sampl
split
two
part
one
irradi
cgi
elan
blood
irradi
best
theratron
ltd
ottawa
canada
sampl
store
c
complet
blood
count
analyz
use
sysmex
autom
hematolog
analyz
sysmex
corpor
kobe
japan
bd
ii
flow
cytomet
dna
dye
bd
bioscienc
san
jose
ca
usa
use
measur
late
apoptot
fraction
wbc
lymphocyt
irradi
unirradi
aliquot
week
storag
resultsfind
unirradi
group
storag
induc
signific
chang
wbc
count
vs
x
p
storag
wbc
count
similar
unirradi
irradi
group
percentag
apoptot
wbc
lymphocyt
significantli
higher
irradi
group
compar
unirradi
group
p
p
respect
tabl
conclus
increas
percentag
late
stage
apoptot
wbc
lymphocyt
observ
cgi
gamma
ray
irradi
whole
blood
store
week
compar
unirradi
whole
blood
store
condit
impact
apoptot
wbc
rbc
alloimmun
human
need
studi
tabl
comparison
white
blood
cell
count
percentag
apoptot
cell
whole
blood
compon
storag
unirradi
irradi
group
n
backgroundcas
studi
pathogen
inactiv
treatment
platelet
addit
solut
improv
safeti
transfus
platelet
concentr
pc
data
impact
inactiv
technolog
addit
solut
function
activ
platelet
storag
aim
studi
evalu
impact
pathogen
inactiv
technolog
addit
solut
function
activ
platelet
storag
studi
designmethod
leukoreduc
plt
unit
collect
use
autom
blood
collect
system
median
pc
collect
target
x
platelet
pc
suspend
ml
plasma
pcpl
plasma
addit
solut
ssp
pcpa
type
suspend
pc
volum
ml
separ
plastic
contain
use
control
cpcpl
cpcpa
next
day
remain
ml
pc
treat
accord
technolog
intercept
blood
system
platelet
amotosalen
ultraviolet
light
type
pathogen
reduc
pc
prpcpl
prpcpa
ml
sampl
separ
plastic
contain
control
sampl
day
pathogen
reduc
pc
storag
day
platelet
activ
investig
assess
platelet
activ
proport
spontan
activ
platelet
accord
detect
antigen
membran
surfac
percentag
specif
activ
platelet
ie
platelet
count
associ
antibodi
action
agonist
adenosin
diphosph
adp
resultsfind
storag
spontan
activ
platelet
significantli
p
increas
pc
maxim
activ
achiev
cpcpl
cpcpa
prpcpl
prpcpa
spontan
activ
platelet
day
less
pronounc
cpcpl
cpcpa
vs
p
differ
significantli
prpc
percentag
platelet
storag
day
significantli
decreas
cpcpl
cpcpa
prpcpl
prpcpa
percentag
platelet
day
storag
significantli
higher
cpcpa
cpcpl
vs
p
prpcpa
prpcpl
vs
p
conclus
inactiv
pathogen
effect
marker
platelet
activ
function
activ
platelet
influenc
suspend
medium
durat
storag
pc
backgroundcas
studi
human
platelet
antigen
hpa
proven
contributori
clinic
situat
relat
platelet
alloimmun
neonat
alloimmun
thrombocytopenia
nait
one
common
alloimmun
disord
character
matern
alloimmun
patern
fetal
platelet
antigen
studi
case
infant
sever
nait
given
birth
healthi
chines
mother
report
studi
designmethod
case
nait
involv
studi
serolog
genet
studi
blood
sampl
nait
infant
conduct
blood
sampl
ml
extract
mother
infant
detect
gene
antibodi
gene
amplifi
dna
sequenc
pcr
product
follow
antibodi
mother
blood
sampl
detect
resultsfind
among
nait
case
one
case
show
type
studi
identifi
g
mutat
nucleotid
glutam
acid
lysin
substitut
posit
exon
gpiiia
gene
sampl
infant
mutat
recent
identifi
report
mother
sampl
identifi
gg
nucleotid
posit
observ
sampl
infant
mother
identifi
homozygot
conclus
identifi
allel
one
case
among
chines
infant
sever
nait
platelet
antigen
paid
attent
nait
chines
backgroundcas
studi
autoimmun
hemolyt
anemia
aiha
due
antibodi
previous
report
associ
sudden
massiv
intravascular
hemolysi
dissemin
intravascular
coagul
fatal
outcom
case
aiha
due
antibodi
success
treat
rituximab
studi
designmethod
retrospect
case
review
male
past
medic
histori
cirrhosi
due
steatohepat
statu
post
orthotop
liver
transplant
olt
month
prior
present
present
histori
progress
anemia
scrotal
infect
right
knee
swell
pain
histori
multipl
blood
product
transfus
time
transplant
known
blood
type
rh
neg
red
blood
cell
rbc
antibodi
screen
present
hemoglobin
hb
gdl
hematocrit
hct
reticulocyt
direct
bilirubin
bili
gdl
lactat
dehydrogenas
ldh
unitl
ref
haptoglobin
mgdl
ref
treatment
includ
antibiot
septic
arthriti
confirm
arthrocentesi
cultur
blood
bank
test
reveal
autoantibodi
present
plasma
weakli
posit
direct
globulin
test
dat
igg
neg
complement
alloantibodi
major
rbc
antigen
rule
receiv
one
unit
least
incompat
blood
type
phenotyp
match
rbc
unit
cours
next
five
day
hb
hct
decreas
gdl
respect
direct
bili
increas
mgd
reticulocyt
slightli
increas
two
day
haptoglobin
decreas
less
mgdl
bone
marrow
biopsi
aspir
show
hypercellular
marrow
erythroid
hyperplasia
consist
stress
erythropoiesi
without
evid
underli
neoplast
disord
addit
perform
refer
laboratori
identifi
autoantibodi
specif
resultsfind
patient
treat
mgkg
prednison
follow
rituximab
infus
weekli
one
month
clinic
pictur
lab
includ
cbc
cmp
ldh
monitor
weekli
respond
chemotherapi
quickli
demonstr
improv
anemia
return
visit
show
hb
hct
increas
respect
conclus
unlik
prior
case
report
fatal
outcom
weekli
rituximab
infus
monitor
result
clinic
recoveri
signific
anemia
improv
male
develop
aiha
specif
backgroundcas
studi
wide
use
prevent
hemolyt
diseas
newborn
hdn
caus
rh
abo
incompat
sinc
chinabaicalin
origin
isol
scutellaria
baicalensi
georgi
major
compon
agent
good
safeti
record
clinic
could
reduc
sever
experiment
autoimmun
encephalomyel
eae
asthma
coliti
system
lupu
erythematosu
sle
immun
diseaseshowev
potenti
induc
transfus
toler
remain
exploredth
aim
studi
find
baicalin
could
inhibit
red
blood
cell
rbc
immun
elucid
possibl
mechan
prevent
hdn
studi
designmethod
use
human
red
blood
cell
adjuv
lipopolysaccharid
lp
transfus
mice
induc
antibodi
experiment
system
studi
effect
baicalin
rbc
immun
mice
divid
normal
control
group
human
rbc
transfus
posit
control
group
receiv
human
rbc
lp
intraven
weekli
five
week
control
group
receiv
dexamethason
intraperitoneali
daili
five
week
treatment
group
receiv
baicalin
intraperitoneali
daili
five
week
assess
human
rbc
immun
perform
measur
serum
immunoglobulin
g
igg
immunoglobulin
igm
human
rbc
weekli
lymphocyt
chang
spleen
also
monitor
flow
cytometri
resultsfind
found
baicalin
treatment
decreas
serum
igg
igm
product
significantli
sinc
second
week
concomit
reduct
cell
increas
regulatori
cell
spleen
mesenter
lymph
node
signific
differ
percentag
tfh
tfr
subpopul
among
groupsin
addit
baicalin
treatment
nt
decreas
size
spleen
percentag
posit
cell
spleen
baicalin
treatment
mous
dexamethason
treat
mous
conclus
result
indic
baicalin
could
inhibit
rbc
immun
especi
igg
product
without
damag
function
spleen
dexamethason
wildli
use
drug
blood
transfus
could
damag
function
spleenconsid
good
safeti
record
clinic
may
exploit
suppress
transfus
immun
event
addit
result
elucid
inhibitori
effect
antibodi
product
baicalin
may
possibl
mechan
wide
use
chines
herbal
medicin
prevent
hdn
backgroundcas
studi
alloantibodi
direct
human
platelet
membran
glycoprotein
gp
ia
iia
iib
iiia
ib
ix
iv
implic
sever
clinic
signific
disord
fetal
neonat
alloimmun
thrombocytopenia
fnait
purpura
ptp
refractori
platelet
transfus
passiv
transfer
antibodi
donor
plasma
polymorph
epitop
gp
give
rise
uniqu
human
platelet
antigen
hpa
identif
specif
platelet
alloantibodi
crucial
diagnos
treat
bleed
disord
current
fda
approv
test
permit
identif
hpa
antibodi
glycoprotein
level
immucor
recent
releas
pak
lx
research
use
ruo
assay
unit
state
abil
identifi
hpa
antibodi
singl
nucleotid
polymoph
snp
compar
perform
pak
lx
fda
approv
immucor
pakplu
studi
designmethod
compar
pakplu
pak
lx
result
plasma
serum
clinic
specimen
group
contain
singl
hpa
alloantibodi
specif
without
hla
antibodi
group
includ
specimen
hla
antibodi
alon
group
consist
patient
sampl
neg
hpa
hla
antibodi
pak
lx
util
luminex
bead
base
assay
allow
user
report
antibodi
platelet
specif
antigen
gpiv
hla
class
pakplu
use
elisa
method
result
report
glycoprotein
locat
gpiibiiia
gpiaiia
gpibix
gpiv
along
hla
class
howev
base
upon
pattern
reactiv
observ
pakplu
pak
lx
assay
possibl
determin
probabl
hpa
antibodi
specif
hpa
snp
resultsfind
conclus
analyz
hpa
antibodi
specif
concord
observ
antibodi
pakplu
assay
difficulti
discrimin
antibodi
antibodi
present
fals
posit
sampl
although
pakplu
signal
od
cutoff
od
ratio
significantli
higher
compar
sampl
discord
hla
class
antibodi
result
assay
isol
weakli
posit
antibodi
within
pakplu
adjust
ratio
pak
lx
conclud
pak
lx
easi
use
platelet
alloantibodi
screen
method
abil
differenti
hpa
antibodi
allel
level
backgroundcas
studi
blood
group
antigen
critic
transfus
practic
antibodi
rais
caus
sever
transfus
reaction
besid
blood
group
antigen
compos
sugar
chain
protein
lipid
etc
may
involv
variou
biolog
process
lewi
group
antigen
belong
abh
famili
ley
consist
carbohydr
chain
may
play
import
role
cell
recognit
adhes
well
migrat
critic
step
tumor
progress
thu
attract
wide
research
focus
relev
tumor
biolog
ley
demonstr
affect
cell
mirgrat
via
variou
mechan
howev
although
chang
cytoskeleton
organ
basi
cell
motil
littl
known
associ
cytoskeleton
ley
microtubul
construct
unit
tubulin
particip
variou
step
cell
migrat
aim
explor
role
ley
microtubul
cell
migrat
use
breast
cancer
cell
may
provid
refer
clinic
studi
group
antigen
chang
way
think
transfus
practic
studi
designmethod
first
manipul
ley
express
breast
cancer
cell
overexpress
sirna
knockdown
fucosyltransferas
block
ley
activ
cell
use
antibodi
verifi
effect
ley
cell
migrat
detect
level
chang
microtubul
acetyl
sign
stabil
establish
role
ley
cell
migrat
via
microtubul
modif
use
specif
tubacin
nonspecif
tsa
inhibitor
minim
deacetyl
test
effect
overexpress
cell
motil
resultsfind
overexpress
increas
ley
express
cell
migrat
knockdown
lead
opposit
ley
activ
blockad
antibodi
also
significantli
inhibit
cell
migrat
western
blot
immunostain
result
show
acetyl
level
neg
relat
ley
express
tubacin
tsa
treatment
increas
level
inhibit
cell
migrat
meantim
signific
overexpress
promot
cell
migrat
elimin
conclus
conclud
result
ley
promot
cell
migrat
via
regul
acetyl
wherein
ley
may
interact
deacetylas
tumor
promot
becom
target
mani
drug
demonstr
potenti
associ
ley
function
studi
mani
blood
group
antigen
also
carbohydr
chain
critic
blood
group
determin
compat
transfus
immunolog
reaction
may
also
effect
initi
develop
diseas
tumor
similar
ley
even
compon
network
import
molecul
contribut
destini
diseas
transfus
blood
product
frequent
need
tumor
patient
attent
focus
search
compat
blood
reduc
transfus
reaction
howev
may
lower
chanc
diseas
advanc
take
account
role
blood
group
antigen
per
se
need
evid
futur
theoret
clinic
research
backgroundcas
studi
one
main
risk
allogen
blood
transfus
humor
alloimmun
red
blood
cell
rbc
alloimmun
depend
immunolog
statu
patient
howev
specif
constitu
blood
product
could
involv
immun
explain
differ
alloimmun
patient
microparticl
mp
contain
blood
product
shown
exhibit
immunomodul
properti
studi
focus
mp
phenotyp
none
mp
aim
studi
determin
whether
purifi
mp
obtain
blood
product
could
modul
immun
system
accord
cellular
origin
phenotyp
studi
designmethod
mp
characterist
studi
whole
blood
wb
healthi
donor
leukoreduct
mp
phenotyp
flow
cytometri
express
marker
known
express
lymphocyt
analyz
total
mp
isol
leukoreduc
rbc
unit
sort
flow
cytometri
cytokin
content
purifi
mp
measur
luminex
assay
purifi
mp
effect
antibodi
product
studi
lymphocyt
function
purifi
mp
also
evalu
prolifer
cytokin
secret
assay
total
differenti
cell
resultsfind
blood
donor
includ
studi
measur
averag
mpsml
plasma
wb
leukoreduct
observ
higher
number
mp
mpsml
p
strike
point
high
variabl
blood
donor
mp
leukoreduct
marker
studi
present
andor
mp
among
cytokin
studi
detect
mp
independ
cellular
origin
lymphocyt
mp
induc
ig
secret
ig
titer
regardless
mp
phenotyp
cellular
origin
cultur
lymphocyt
type
mp
stimul
also
prolifer
tfh
treg
subtyp
secret
cytokin
induct
ig
product
lymphocyt
prolifer
cytokin
secret
correl
number
mp
cultur
interestingli
inhibit
immun
respons
observ
ratio
beyond
mpscell
conclus
studi
highlight
independ
cellular
origin
phenotyp
mp
abl
activ
inhibit
immun
system
depend
dose
manner
thu
allogen
blood
transfus
number
mp
transfus
repres
paramet
take
account
immun
respons
rbc
antigen
immun
reaction
importantli
studi
also
demonstr
potenti
variabl
donor
effect
recipi
immun
system
backgroundcas
studi
reduc
risk
bacteri
contamin
platelet
plt
product
great
concern
sinc
plt
storag
occur
room
temperatur
rt
pathogen
reduct
technolog
prt
develop
inactiv
pathogen
prior
transfus
howev
studi
shown
prt
may
damag
plt
cours
extend
storag
rt
result
greater
loss
function
normal
concomit
platelet
storag
lesion
storag
plt
platelet
addit
solut
pa
help
preserv
plt
function
reduc
risk
contamin
studi
establish
impact
prt
perform
plt
pa
instead
storag
plt
function
mitochondri
respir
cell
death
paramet
studi
designmethod
plt
unit
collect
pa
store
day
time
period
bag
treat
use
mirasol
prt
riboflavin
uv
sampl
obtain
test
day
collect
baselin
bl
pre
post
minut
aggregometri
adp
collagen
trap
rotem
flow
cytometri
lactadherin
ps
activ
gpib
respirometri
oroboro
imag
flow
cytometri
amni
use
analysi
data
report
pair
student
use
determin
statist
signific
p
resultsfind
day
level
significantli
higher
pre
bl
mirasol
treatment
caus
signific
increas
express
compar
pre
pre
post
remain
incub
signific
drop
collagen
trap
aggreg
observ
post
sampl
compar
pre
adp
aggreg
respons
preserv
differ
gpib
express
mitochondri
respir
observ
pre
post
sampl
sampl
display
significantli
less
function
higher
activ
level
lower
mitochondri
respir
compar
pre
post
conclus
prt
treatment
plt
unit
pa
day
storag
present
uniqu
altern
prt
treatment
plt
prior
rt
storag
addit
provid
lower
risk
bacteri
contamin
pa
plt
may
provid
better
preserv
hemostat
function
rt
plt
even
mirasol
prt
treatment
howev
show
mirasol
prt
day
pa
plt
follow
incub
minut
result
widespread
cell
damag
avoid
backgroundcas
studi
cellphir
complet
micro
dose
clinic
safeti
trial
use
lyophil
human
platelet
cellphir
also
evalu
safeti
lyophil
canin
platelet
lcp
comparison
liquid
store
canin
platelet
follow
intraven
administr
model
coronari
arteri
bypass
graft
cabg
canin
safeti
studi
support
futur
phase
ii
human
clinic
trial
cardiac
patient
studi
designmethod
three
group
eight
mix
breed
hound
underw
cabg
creat
anastomosi
administ
lcp
equal
total
circul
platelet
count
tcpc
one
group
four
anim
serv
vehicl
group
receiv
lyophil
buffer
anoth
group
four
anim
receiv
control
old
platelet
safeti
assess
collect
blood
loss
data
evalu
blood
flow
bypass
graft
evalu
develop
acut
thrombosi
mainten
patenc
graft
hr
evalu
period
full
necropsi
complet
tissu
analysi
also
perform
efficaci
signal
evalu
collect
blood
loss
data
coagul
endpoint
pt
aptt
fibrinogen
teg
resultsfind
result
demonstr
administr
test
articl
dose
tcpc
associ
unexpect
mortal
advers
chang
hematolog
coagul
paramet
develop
thrombosi
anastomosi
site
evid
advers
thrombosi
format
either
clinic
microscop
regardless
group
mortal
note
studi
consid
relat
surgic
model
result
test
articl
administr
result
also
demonstr
administr
dose
tcpc
produc
signific
decreas
blood
loss
lcp
tcpc
effect
mitig
blood
loss
old
platelet
trend
toward
effect
appreci
differ
coagul
paramet
observ
group
conclus
result
studi
demonstr
administr
lcp
tcpc
safe
canin
cabg
model
data
also
demonstr
administr
lcp
dose
tcpc
reduc
blood
loss
result
suggest
start
dose
tcpc
may
requir
achiev
effect
dose
futur
human
phase
ii
trial
cardiac
patient
although
studi
power
efficaci
data
indic
level
safeti
tcpc
similar
efficaci
signal
tcpc
observ
sever
advers
event
start
effect
dose
may
vari
depend
clinic
indic
futur
studi
requir
studi
fund
barda
contract
backgroundcas
studi
fc
base
detect
assay
develop
use
plasma
sampl
assess
storag
stabil
day
studi
ten
donor
plasma
sampl
store
test
duplic
day
storag
previous
evalu
frozen
low
high
level
posit
control
sampl
thaw
day
store
test
parallel
donor
studi
designmethod
pool
iga
coat
red
cell
rbciga
prepar
group
donor
sampl
wash
pool
tannic
acid
treat
minut
min
wash
incub
igaml
solut
human
iga
mp
biomed
santa
ana
ca
min
dilut
testcontrol
plasma
incub
rbciga
min
wash
incub
fluorescein
isothiocyan
fitc
igg
jackson
immunoresearch
lab
west
grove
pa
optim
dilut
min
sampl
wash
event
acquir
sampl
becton
dickinson
facscantm
san
jose
ca
fc
analysi
test
perform
repeat
day
resultsfind
fc
detect
fluoresc
emit
bound
plasma
bound
rbciga
report
presenc
absenc
mean
result
standard
deviat
sd
sampl
test
day
calcul
neg
low
high
control
perform
expect
test
run
day
storag
evid
fals
neg
posit
result
conclus
test
normal
donor
sampl
show
individu
variat
overal
show
stabil
day
provid
evid
allow
storag
sampl
prior
test
extend
storag
time
allow
batch
test
sampl
make
assay
cost
effect
extend
ship
time
tabl
backgroundcas
studi
platelet
glycoprotein
iv
import
characterist
platelet
antigen
implic
thrombocytopenia
chines
popul
except
common
antibodi
clinic
relev
platelet
antibodi
chines
popul
associ
high
frequenc
defici
china
gene
mutat
main
reason
lead
defici
one
mutat
caus
defici
aim
studi
develop
techniqu
genotyp
ac
mutat
individu
investig
structur
featur
gene
defici
individu
found
guangxi
popul
gene
polymorph
chines
popul
well
studi
designmethod
design
revers
primer
nucleotid
polymorph
allel
well
common
forward
primer
mutat
dna
sampl
wild
type
dna
sampl
confirm
gene
dna
sequenc
use
evalu
effect
develop
techniqu
use
develop
techniqu
structur
featur
gene
defici
individu
found
guangxi
popul
studi
gene
polymorph
gene
investig
unrel
individu
includ
han
zhuang
ethnic
group
individu
guangxi
zhuang
autonom
region
china
resultsfind
establish
techniqu
genotyp
mutat
individu
concord
genotyp
result
dna
sampl
compar
dna
sequenc
develop
genotyp
techniqu
defici
individu
found
guangxi
popul
individu
detect
includ
homozyg
individu
heterozyg
individu
allel
frequenc
han
zhuang
ethnic
group
individu
guangxi
region
china
respect
conclus
studi
success
establish
techniqu
genotyp
ac
mutat
individu
use
develop
techniqu
structur
featur
gene
defici
individu
found
guangxi
region
china
gene
polymorph
chines
popul
investig
backgroundcas
studi
safeti
rbc
preserv
addit
solut
demonstr
small
volum
transfus
pediatr
patient
yet
mani
pediatr
hospit
util
rbc
addit
solut
larg
volum
transfus
studi
examin
impact
larg
volum
transfus
lvt
use
blood
product
store
citrat
phosphat
dextros
cpd
versu
citrat
phosphat
doubl
dextros
nutricel
addit
solut
pediatr
patient
undergo
cardiac
surgeri
studi
designmethod
retrospect
review
pediatr
patient
underw
lvt
either
norwood
heart
transplant
surgeri
month
transfus
servic
lab
chang
cpd
blood
product
conduct
rbc
whole
blood
wb
unit
irradi
prior
issu
less
day
old
children
less
year
lvt
defin
wb
andor
rbc
per
kg
bodi
weight
patient
receiv
supernat
remov
rbc
heart
transplant
exclud
laboratori
valu
clinic
data
point
compar
use
statist
analys
perform
r
continu
variabl
use
wilcoxon
rank
sum
test
categor
variabl
use
fisher
exact
test
p
consid
statist
signific
resultsfind
studi
includ
patient
cpd
group
patient
group
age
weight
lvt
amount
number
intraop
rbc
platelet
cryoprecipit
unit
transfus
per
patient
two
arm
significantli
differ
mean
lvt
amount
cpd
group
ml
wb
andor
rbc
per
kg
respect
intraop
plasma
usag
higher
group
cpd
group
receiv
wb
unit
sodium
glucos
phosphor
level
significantli
higher
group
immedi
day
post
surgeri
lactat
level
significantli
higher
group
compar
cpd
group
immedi
day
mortal
total
length
stay
lo
icu
lo
significantli
differ
group
conclus
analysi
suggest
pediatr
patient
may
signific
increas
sodium
glucos
phosphor
lactat
level
immedi
lvt
product
cardiac
surgeri
increas
sodium
phosphor
attribut
use
preserv
rbc
increas
glucos
doubl
dextros
content
plasma
compon
chang
effect
mortal
lo
tabl
backgroundcas
studi
restrict
cardiac
allograft
transplant
limit
organ
avail
increas
donor
heart
avail
children
heart
transplant
aboiht
perform
similar
outcom
reject
rate
transplant
abocht
transfus
support
children
undergo
aboiht
may
contribut
success
transplant
howev
standard
guidelin
titer
test
therapeut
intervent
reduc
antibodi
titer
exist
studi
aim
survey
current
blood
bank
antibodi
reduct
practic
pediatr
aboiht
us
canada
studi
designmethod
survey
sent
us
canadian
pediatr
blood
bank
director
particip
queri
regard
blood
product
support
abo
titer
test
therapeut
intervent
antibodi
reduct
aboiht
recipi
resultsfind
respons
rate
center
perform
aboiht
consid
patient
year
old
elig
aboiht
center
protocol
respect
percent
use
titer
cutoff
aboiht
elig
variabl
titer
cutoff
either
base
age
use
intraop
techniqu
titer
cutoff
vari
implement
strategi
center
administ
therapi
regardless
titer
center
use
plasma
exchang
part
antibodi
reduct
strategi
abo
titer
test
perform
center
respect
vari
frequenc
set
center
transfus
aboc
rbc
give
ab
plasma
platelet
set
give
rbc
anoth
give
either
rbc
set
give
either
rbc
give
rbc
major
center
give
either
ab
plasma
set
respect
mani
center
wash
rbc
set
respect
intraop
center
wash
rbc
anoth
wash
rbc
remain
vari
practic
conclus
transfus
support
children
aboiht
vari
wide
among
us
canadian
blood
bank
frequenc
abo
titer
test
titer
cutoff
use
medic
intervent
point
strategi
standard
center
center
pediatr
aboiht
becom
common
sophist
understand
optim
transfus
support
therapeut
intervent
need
backgroundcas
studi
current
american
canadian
guidelin
recommend
delay
measl
mump
rubella
mmr
varicella
live
attenu
vaccin
month
follow
transfus
unwash
red
blood
cell
rbc
due
potenti
interfer
serum
antibodi
patient
chronic
transfus
rbc
commonli
suffer
delay
absenc
mmr
varicella
vaccin
pauciti
data
concern
true
effect
transfus
live
attenu
vaccin
immun
vaccin
guidelin
advisori
committe
immun
practic
also
stipul
effect
rbc
prepar
respons
mmr
vaccin
remain
unknown
last
decad
rbc
handl
blood
bank
chang
also
fewer
current
blood
donor
natur
mump
measl
rubella
infect
result
lower
antibodi
level
blood
recommend
may
thu
unfound
outdat
prevent
valuabl
vaccin
opportun
children
frequent
blood
transfus
place
alreadi
highli
vulner
pediatr
popul
risk
acquir
prevent
infect
primari
aim
project
determin
mmr
vaccin
immunogen
patient
chronic
transfus
rbc
studi
designmethod
medic
chart
review
vaccin
transfus
histori
antibodi
quantifi
pediatr
patient
receiv
dose
mmr
vaccin
month
age
chronic
rbc
transfus
program
sickl
cell
diseas
major
anemia
pyruv
kinas
defici
formal
control
group
immun
rate
literatur
mmr
compon
resultsfind
tabl
show
immunogen
vaccin
compon
delay
vaccin
serolog
test
averag
year
year
thirteen
patient
chronic
transfus
time
serolog
patient
seroconvert
least
one
vaccin
compon
tabl
immunogen
mmr
vaccin
compon
conclus
best
knowledg
first
studi
design
measur
effect
rbc
transfus
mmr
vaccin
immunogen
although
lower
rate
report
literatur
result
suggest
high
rate
immunogen
compon
mmr
vaccin
chronic
transfus
patient
immun
prior
month
weigh
risk
benefit
diseas
prevent
highli
vulner
popul
take
account
aforement
result
reevalu
immun
delay
post
rbc
transfus
call
chronic
transfus
infant
serolog
consid
backgroundcas
studi
use
uncrossmatch
cold
store
whole
blood
wb
becom
increasingli
popular
initi
resuscit
trauma
patient
without
current
abo
group
wb
advantag
convent
compon
therapi
includ
greater
platelet
factor
concentr
well
less
salin
addit
solut
compar
equival
volum
reconstitut
whole
blood
report
detail
initi
use
wb
pediatr
trauma
patient
studi
designmethod
pediatr
trauma
patient
year
old
kg
evid
hemorrhag
shock
elig
receiv
cckg
cold
store
leukoreduc
group
neg
wb
initi
resuscit
wb
unit
low
titer
reduc
likelihood
hemolysi
recipi
biochem
marker
hemolysi
measur
day
wb
transfus
follow
two
day
admiss
thromboelastogram
obtain
repeat
necessari
resuscit
receipt
maximum
quantiti
wb
convent
compon
util
resultsfind
approxim
month
trauma
patient
receiv
wb
group
group
recipi
male
median
iqr
age
blunt
trauma
mechan
patient
median
iqr
injuri
sever
score
mortal
rate
median
iqr
quantiti
wb
transfus
group
recipi
mlkg
versu
mlkg
recipi
transfus
reaction
report
mean
standard
deviat
haptoglobin
concentr
recipi
mgdl
day
mgdl
day
mgdl
day
correspond
haptoglobin
concentr
group
recipi
mgdl
mgdl
mgdl
respect
p
comparison
similarli
signific
differ
total
bilirubin
ldh
creatinin
potassium
time
point
regard
evalu
cold
platelet
function
compar
subset
patient
receiv
wb
warm
platelet
histor
group
pediatr
trauma
patient
receiv
convent
compon
includ
warm
platelet
mean
standard
deviat
platelet
volum
administ
cc
whole
blood
recipi
versu
cc
warm
platelet
recipi
teg
platelet
count
analyz
differ
median
platelet
count
teg
maximum
amplitud
cold
warm
platelet
group
conclus
use
uncrossmatch
whole
blood
resuscit
pediatr
trauma
patient
feasibl
accept
appear
safe
receipt
low
titer
group
wb
lead
detect
hemolysi
amongst
recipi
given
find
maximum
quantiti
wb
per
patient
increas
mlkg
backgroundcas
studi
human
breast
milk
contain
immunoglobulin
present
matern
serum
secret
data
mice
demonstr
potenti
kell
antibodi
absorb
enter
breast
milk
impact
surviv
transfus
kell
posit
cell
howev
method
test
titer
human
breast
milk
red
cell
antibodi
lack
two
week
old
infant
histori
hemolyt
diseas
fetu
newborn
hdfn
previous
treat
intraven
immunoglobulin
phototherapi
refer
anemia
reticulocytosi
patient
posit
posit
direct
antiglobulin
test
dat
igg
posit
antibodi
screen
gel
method
antibodi
identif
show
plasma
eluat
patient
transfus
neg
red
cell
discharg
sever
week
patient
return
twice
persist
anemia
requir
addit
transfus
eight
week
age
evalu
show
persist
dat
igg
reactiv
concern
continu
antibodi
exposur
matern
breast
milk
evalu
potenti
sourc
studi
designmethod
base
similar
properti
human
breast
milk
plasma
test
identifi
igg
antibodi
use
stantard
tube
salin
method
perform
minut
incub
follow
autom
wash
prior
addit
igg
reagent
control
breast
milk
posit
antibodi
screen
neg
mother
use
assess
interfer
milk
protein
antibodi
screen
perform
plasma
patient
patient
mother
control
concurr
use
method
antibodi
identif
titer
also
perform
indic
freshli
collect
breast
milk
store
room
temperatur
less
day
found
suitabl
techniqu
resultsfind
patient
mother
show
plasma
titer
breast
milk
show
titer
patient
consist
plasma
titer
patient
mother
chose
stop
breast
feed
week
patient
hemoglobin
improv
week
age
use
method
identifi
two
addit
case
breast
milk
induc
hemolysi
anoth
conclus
test
show
possibl
identifi
red
cell
igg
antibodi
human
breast
milk
use
standard
tube
salin
method
identifi
implic
antibodi
breast
milk
receiv
infant
persist
anemia
due
hdfn
breast
milk
titer
gener
lower
matern
serum
titer
titer
vari
depend
upon
time
frequenc
breast
feed
cessat
breast
feed
correl
improv
hemoglobin
affect
infant
backgroundcas
studi
red
blood
cell
rbc
transfus
lifesav
patient
sickl
cell
diseas
scd
commonli
complic
rbc
alloimmun
despit
transfus
protocol
serolog
match
c
e
kell
antigen
alloimmun
rh
antigen
continu
scd
patient
often
exhibit
hybrid
gene
often
character
product
partial
c
antigen
previous
document
c
scd
patient
west
indi
west
central
africa
partial
c
risk
alloimmun
c
antigen
transfus
c
rbc
studi
sought
determin
preval
within
cohort
children
scd
us
comprehens
scd
center
studi
designmethod
rbc
genotyp
result
perform
scd
patient
use
precisetyp
hea
array
immucor
norcross
ga
children
healthcar
atlanta
review
compar
serolog
type
rh
cc
ee
antigen
preval
posit
patient
serolog
determin
overal
compar
preval
partial
c
antigen
base
detect
rhce
ce
allel
absenc
rhce
gene
encod
convent
c
antigen
tran
sinc
allel
commonli
link
hybrid
rhd
gene
encod
partial
c
antigen
review
blood
bank
inform
system
perform
identifi
number
posit
transfus
exposur
frequenc
alloimmun
c
antigen
resultsfind
total
patient
genotyperh
phenotyp
data
avail
c
antigen
posit
serolog
allel
frequenc
rhce
ce
total
patient
possess
rhce
ce
absenc
convent
c
gene
tran
c
antigen
posit
patient
individu
predict
partial
c
base
four
molecular
profil
rhce
ce
rhce
rhce
ce
rh
rhce
ce
rh
ce
rhce
ce
rh
ce
partial
c
patient
alloantibodi
rh
antibodi
detect
transfus
exposur
neg
unit
mean
rang
like
placement
rbc
restrict
upon
detect
rhce
ce
allel
conclus
report
confirm
previou
data
high
preval
partial
c
antigen
scd
patient
histor
type
serolog
demonstr
benefit
rbc
genotyp
prevent
alloimmun
highli
immunogen
rh
antigen
identifi
individu
receiv
blood
patient
scd
rbc
genotyp
perform
determin
rbc
phenotyp
prefer
prior
receiv
transfus
backgroundcas
studi
zika
viru
zikv
emerg
flaviviru
primarili
transmit
infect
aed
aegypti
mosquito
recent
outbreak
reveal
transmiss
rout
includ
unpreced
sexual
transmiss
arboviru
acut
zikv
infect
mainli
asymptomat
present
diseas
also
includ
sever
congenit
defect
neurolog
disord
larg
proport
asymptomat
case
high
number
return
travel
area
sever
clinic
consequ
develop
fetus
detect
rna
asymptomat
donor
french
polynesia
epidem
suspect
case
transfus
transmiss
brazil
led
fda
releas
guidanc
document
minim
risk
zikv
transmiss
via
bloodblood
compon
studi
designmethod
investig
test
mp
use
procleix
zika
viru
assay
tma
implement
collect
five
presum
us
state
fl
ga
sc
ms
al
follow
revis
guidanc
test
extend
blood
donat
convers
individu
donat
id
implement
phase
complet
travel
histori
question
discontinu
confirmatori
test
includ
repeat
tma
addit
serolog
red
cell
rbc
tma
perform
estim
viral
load
perform
tma
plasma
rbc
resultsfind
donat
test
includ
mp
reactiv
donat
identifi
donat
initi
reactiv
ir
confirm
posit
cp
subsequ
test
cp
rate
posit
predict
valu
specif
five
cp
donat
repeat
reactiv
rr
donat
ir
igm
posit
rna
posit
rbc
cp
donor
resid
tx
ca
ny
wv
fl
local
transmiss
six
donor
travel
area
return
us
day
prior
donat
two
donor
travel
risk
report
clinic
symptom
cp
donor
remain
asymptomat
zikv
rna
detect
rbc
cp
index
donat
estim
level
vari
less
copi
c
ml
cml
time
write
longest
period
detect
rbc
day
vs
day
plasma
donor
zikv
rna
level
plasma
obtain
ir
rr
donor
rang
cml
conclus
identifi
zikv
donat
includ
infect
travel
return
area
reduc
risk
transfus
transmiss
zikv
us
backgroundcas
studi
puerto
rico
pr
began
screen
blood
donat
zika
viru
zikv
rna
investig
protocol
use
nucleic
acid
test
nat
april
result
fda
guidanc
approxim
confirm
infect
nat
donat
detect
dec
aim
analysi
categor
zikv
nat
index
donat
order
stage
accord
viral
load
vl
simul
minipool
mp
result
zikv
igm
reactiv
evalu
chang
profil
infect
donor
cours
pr
epidem
studi
designmethod
plasma
blood
donor
screen
individu
donat
presenc
zikv
rna
zika
test
sampl
repeat
duplic
test
second
nat
confirm
infect
estim
vl
igm
simul
mp
prepar
dilut
nat
plasma
test
discrimin
detect
donat
nat
yield
sampl
simul
mp
conclus
igm
result
avail
sort
categori
correspond
sequenti
stage
acut
zikv
infect
vl
vl
igmhigh
vl
igmlow
vl
resultsfind
donat
collect
april
reactiv
zikv
rna
index
donat
higher
vl
mean
x
vs
x
iuml
higher
proport
simul
result
vs
igm
donat
distribut
stage
infect
evalu
epidem
evolv
cours
epidem
rate
detect
igm
donat
increas
tabl
tabl
conclus
studi
demonstr
viral
immunolog
profil
zikv
infect
index
donat
shift
cours
pr
epidem
categor
index
sampl
stage
infect
import
blood
safeti
consider
sinc
infect
util
mp
vs
screen
like
correl
vl
serolog
stage
infect
stage
infect
also
implic
diagnost
test
understand
durat
zikv
viral
immunolog
marker
blood
persist
zikv
bodi
fluid
tissu
zika
commerci
avail
blood
screen
data
gener
zika
ind
preliminari
review
fda
project
fund
whole
part
feder
fund
biomed
advanc
research
develop
author
offic
assist
secretari
prepared
respons
offic
secretari
depart
health
human
servic
contract
backgroundcas
studi
februari
us
fda
recommend
blood
donat
area
activ
zika
viru
zikv
transmiss
test
fda
approv
nucleic
acid
test
nat
zikv
rna
treat
fda
approv
pathogen
reduct
technolog
zika
test
approv
investig
new
drug
applic
march
test
puerto
rico
donat
began
april
precautionari
measur
blood
center
us
state
also
began
nat
test
zikv
august
fda
recommend
univers
screen
blood
donat
aim
studi
describ
detect
zikv
rna
blood
donat
collect
us
state
april
februari
use
investig
zika
use
system
studi
designmethod
donat
screen
zika
individu
donat
test
initi
reactiv
ir
result
repeat
duplic
supplement
test
includ
altern
nat
altnat
assay
less
sensit
zika
serolog
test
igm
igg
reactiv
donor
invit
enrol
includ
zika
serolog
test
donor
consid
zika
confirm
posit
least
one
replic
repeat
test
zika
reactiv
index
donat
reactiv
altnat
index
donat
posit
igm
index
ir
donat
also
retest
dilut
simul
test
resultsfind
total
blood
donat
screen
use
zika
ir
donat
repeat
reactiv
rr
repeat
test
rr
donat
posit
altnat
igm
posit
altnat
neg
donor
igm
posit
one
donor
altnat
equivoc
igm
neg
rr
donor
igm
posit
index
enrol
seroconvert
donat
altnat
neg
pend
supplement
test
donor
igm
posit
index
donor
igm
neg
index
enrol
remain
igm
neg
inconclus
donat
without
repeat
test
result
met
criteria
posit
altnat
posit
igm
neg
altnat
neg
igm
posit
donat
pend
addit
test
altogeth
ir
donat
met
criteria
true
posit
index
donat
true
posit
donat
reactiv
retest
simul
minipool
igm
posit
conclus
donat
us
state
screen
zikv
rna
confirm
true
posit
coba
zika
commerci
avail
blood
screen
use
backgroundcas
studi
zika
viru
implic
larg
recent
outbreak
french
polynesia
brazil
follow
outbreak
south
america
central
america
caribbean
four
probabl
transfus
transmit
case
report
brazil
sinc
zika
case
asymptomat
actual
transfus
rate
much
higher
report
studi
use
mont
carlo
simul
risk
estim
brazilian
outbreak
studi
designmethod
data
feed
mont
carlo
simul
collect
januari
novemb
brazil
whole
countri
rio
de
janeiro
state
one
outbreak
epicent
data
came
brazilian
epidemiolog
bulletin
brazilian
blood
donat
figur
risk
assess
perform
separ
whole
blood
wb
donat
apheresi
platelet
ap
model
took
account
follow
paramet
zika
incid
brazil
rio
lognorm
distribut
symptomat
viremia
period
day
valu
lower
day
infect
donor
symptom
last
day
donationdonoryear
wb
ap
formula
transfus
risk
calcul
incid
x
infecti
period
x
averag
donat
number
per
donor
per
year
wb
xy
aph
zy
x
proport
refus
donor
x
proport
discard
donat
due
post
donat
pd
inform
resultsfind
tabl
show
result
tabl
conclus
estim
risk
transfus
transmit
zika
import
brazil
rio
de
janeiro
attain
apheresi
platelet
sever
consequ
zika
vulner
popul
pregnant
women
newborn
indic
intervent
reduc
unfavor
outcom
donor
test
pathogen
inactiv
consid
brazil
backgroundcas
studi
except
surveil
base
clinic
case
diagnosi
data
incid
zika
zikv
chikungunya
chikv
dengu
denv
arbovirus
popul
avail
brazil
object
studi
assess
contemporan
incid
agent
donor
larg
geograph
dispers
blood
center
locat
southeast
northeast
brazil
studi
designmethod
brazil
public
blood
bank
system
nat
screen
hiv
hcv
hbv
perform
minipool
mp
donat
residu
volum
mp
plasma
ml
routin
discard
begin
april
blood
center
save
mpsweek
retrospect
test
use
triplex
zikv
chikv
denv
transcript
mediat
amplif
tma
assay
develop
grifolsholog
mp
ship
usa
batch
test
grifol
first
two
week
april
combin
pool
donat
thereaft
test
without
addit
pool
estim
percent
posit
donor
denomin
adjust
account
number
donat
includ
pool
month
confid
interv
ci
calcul
use
method
develop
biggerstaff
resultsfind
triplex
assay
perform
shown
high
sensit
limit
detect
copiesml
zikvchikvdenv
accur
discrimin
arbovirus
test
first
month
sampl
complet
mp
compris
donat
collect
april
octob
total
pool
posit
detect
tabl
summar
highest
monthli
estim
percent
posit
donor
viru
citi
month
highest
percent
postiv
donor
april
may
peak
donor
belo
horizont
rio
virem
zikv
wherea
zika
evid
donor
recif
donor
citi
virem
chivk
peak
tabl
highest
monthli
estim
percent
posit
donor
arboviru
citi
period
april
septemb
conclus
latter
part
arboviru
outbreak
season
brazil
zikv
chikv
denv
transmit
mosquito
donor
asymptomat
donor
donat
indic
blood
recipi
brazil
extens
expos
virem
blood
compon
use
donor
mp
surveil
may
one
effici
approach
public
health
monitor
onset
magnitud
arboviru
infect
backgroundcas
studi
singapor
report
first
local
transmit
zika
case
august
number
rose
rapidli
case
end
septemb
eight
cluster
hotspot
case
zika
viru
zikv
share
mosquito
vector
aed
aegypti
dengu
virus
caus
microcephali
unborn
fetus
infect
pregnant
women
syndrom
hasten
singapor
blood
servic
group
bsg
look
secur
safeti
blood
suppli
zika
threat
aim
assess
assay
perform
investig
ind
procleix
zikv
nucleic
acid
technolog
nat
assay
univers
blood
donat
screen
singapor
prevent
zika
infect
studi
designmethod
blood
donat
screen
zika
procleix
zikv
nat
assay
sinc
octob
zika
nat
reactiv
sampl
test
blood
system
research
institut
bsri
zika
rna
plasma
red
cell
pcr
zika
dengu
igm
igg
antibodi
zika
confirm
case
defin
presenc
zika
rna
pcr
andor
zika
antibodi
analyt
sensit
evalu
use
blind
frozen
sampl
consist
replic
half
log
dilut
intern
standard
zikv
replic
neg
control
prepar
bsri
probit
analysi
perform
determin
limit
detect
lod
clinic
perform
procleix
zikv
assay
also
assess
local
patient
sampl
obtain
institut
infecti
diseas
epidemiolog
singapor
member
blind
zikv
refer
panel
resultsfind
total
donat
screen
octob
march
fals
posit
case
zika
confirm
donat
detect
altern
zikv
pcr
test
posit
plasma
red
cell
estim
plasma
viral
load
copiesml
zika
igm
neg
index
donat
sampl
present
follow
sampl
donor
report
clinic
symptom
analyt
sensit
procleix
zikv
assay
determin
copiesml
lod
copiesml
lod
procleix
zikv
assay
detect
rna
patient
sampl
provid
agreement
result
zikv
refer
materi
conclus
investig
procleix
zikv
assay
show
good
analyt
sensit
clinic
perform
suitabl
blood
screen
zika
infect
especi
asymptomat
donor
popul
bsg
commenc
univers
zika
nat
screen
individu
donat
test
follow
zika
outbreak
confirm
zika
donat
seroneg
interdict
translat
risk
incid
donat
singapor
backgroundcas
studi
capaabb
work
group
suggest
step
taken
phase
rhdgenotyp
patient
serolog
weak
phenotyp
weak
type
express
major
rhd
epitop
patient
manag
may
lead
reduct
unnecessari
rh
immunoglobulin
rhig
administr
conserv
rbc
studi
designmethod
rhd
genotyp
perform
patient
sampl
weaker
expect
discrep
rhd
type
result
util
commerci
avail
genotyp
kit
manufactur
immucor
rhd
beadchip
initi
test
perform
refer
lab
rhd
beadchip
valid
implement
institut
serolog
weak
phenotyp
defin
weak
reactiv
initi
gel
test
genotyp
demonstr
weak
type
intent
manag
patient
weak
type
detect
patient
consid
risk
alloimmun
treat
rhd
genotyp
result
pend
rbc
use
pregnant
patient
elig
rhig
result
gener
avail
week
resultsfind
rhdgenotyp
perform
patient
sampl
month
patient
sampl
weak
type
remain
sampl
demonstr
varieti
allel
includ
known
partial
variant
see
tabl
one
patient
identifi
weak
type
requir
multipl
transfus
studi
period
refus
rbc
remain
weak
type
patient
receiv
transfus
institut
sinc
genotyp
four
obstetr
weak
type
patient
receiv
rhig
genotyp
pend
conclus
test
manag
patient
serolog
weak
phenotyp
standard
rhd
genotyp
may
lead
consist
person
patient
care
appropri
manag
resourc
month
studi
period
serolog
weak
patient
identifi
could
manag
howev
result
withhold
dose
rhig
conserv
rbc
genotyp
result
pertain
manag
obstetr
patient
discuss
obstetrician
possibl
inform
may
impact
manag
futur
pregnanc
outcom
highlight
limit
current
genotyp
process
includ
long
result
lack
accept
new
approach
manag
serolog
weak
phenotyp
anticip
reduct
test
time
effort
educ
patient
clinician
lead
improv
resourc
util
backgroundcas
studi
rh
blood
group
highli
immunogen
clinic
signific
blood
group
secondari
abo
current
unit
state
blood
donor
type
serolog
undergo
test
identifi
weak
partial
state
rhd
express
howev
rhd
express
detect
serolog
suggest
investig
serolog
blood
donor
use
genotyp
method
accur
identifi
unit
may
lead
alloimmun
recipi
studi
designmethod
rhd
genotyp
serolog
blood
donor
present
blood
donor
center
implement
identifi
unit
alter
rhd
allel
character
repeat
donat
test
initi
serolog
test
blood
donor
perform
use
fda
approv
reagent
reactiv
reagent
neg
rhd
genotyp
perform
use
commerci
avail
genotyp
kit
manufactur
immucor
rhd
beadchip
assay
detect
rhd
variant
allel
addit
dna
sequenc
perform
select
case
maxim
effici
sampl
batch
test
test
gener
perform
month
rhd
variant
known
suspect
associ
increas
risk
alloimmun
detect
recipi
previou
donat
investig
evid
alloimmun
futur
donat
restrict
recipi
resultsfind
period
month
test
blood
donor
weak
del
donor
one
donor
sampl
novel
rhd
allel
identifi
dna
sequenc
rhd
phenotyp
associ
allel
variant
unknown
investig
previou
donat
donor
show
recipi
receiv
rbc
donor
five
recipi
underw
antibodi
screen
averag
period
month
detect
sampl
see
tabl
conclus
serolog
test
occasion
fail
identifi
donor
unit
could
place
recipi
risk
alloimmun
test
use
identifi
donor
potenti
sensit
individu
limit
studi
period
small
number
serolog
donor
whose
genotyp
indic
potenti
sensit
recipi
found
howev
review
recipi
transfus
record
indic
prior
exposur
donor
rbc
lead
detect
immun
date
futur
potenti
sensit
event
avoid
restrict
unit
recipi
backgroundcas
studi
pregnant
women
rhd
variant
may
candid
rhig
prophylaxi
molecular
analysi
reveal
genotyp
associ
possibl
format
propos
test
algorithm
advoc
molecular
character
weak
type
patient
type
action
propos
women
partial
variant
may
also
risk
format
includ
algorithm
propos
date
yet
molecular
test
may
unmask
hidden
subpopul
women
type
may
candid
rhig
prophylaxi
hospit
urban
set
deliveri
patient
initi
routin
rhdsequenc
obstetr
patient
whose
serolog
demonstr
weak
also
categor
reactiv
determin
preval
partial
patient
popul
may
risk
format
studi
designmethod
octob
march
perform
routin
type
neo
immucor
obstetr
specimen
follow
rhd
sequenc
sampl
either
serolog
weak
phenotyp
test
strength
use
least
antibodi
solid
phase
manual
test
use
seri
seri
reagent
four
addit
reagent
manufactur
grifol
dg
gel
quotient
blend
biorad
blend
ortho
bioclon
also
use
supplement
test
rhd
sequenc
perform
sanger
methodolog
use
routin
clinic
protocol
resultsfind
rhd
polymorph
variat
identifi
sampl
two
rhd
gene
common
known
intron
variant
predict
produc
refer
rhd
protein
two
heterozyg
two
appar
new
rhd
code
variat
confirm
test
four
patient
rhd
allel
known
potenti
make
rhd
rhd
weak
type
one
weak
type
uncertain
suscept
alloimmun
one
weak
type
yet
associ
interestingli
two
variabl
express
associ
appar
new
allel
pend
ongo
confirmatori
test
clone
one
patient
noncod
variat
patient
much
variabl
serolog
test
use
reagent
suggest
may
harbor
novel
unidentifi
variant
respons
reactiv
conclus
select
obstetr
patient
reactiv
least
one
reagent
readili
identifi
sever
rhd
variant
includ
possibl
unreport
process
confirm
expand
antenat
rhd
molecular
test
includ
women
serolog
reactiv
effici
method
identifi
patient
partial
weak
variant
risk
alloimmun
may
benefit
rhig
would
character
simpli
accord
standard
clinic
practic
backgroundcas
studi
weak
type
variant
rhd
protein
compris
amino
acid
substitut
locat
transmembran
segment
express
reduc
amount
antigen
variant
known
associ
missens
mutat
g
c
first
nucleotid
exon
rhd
gene
thu
could
implic
exon
skip
mutat
perform
ng
next
gener
sequenc
analysi
fulli
genotyp
known
patient
identifi
addit
variant
studi
designmethod
dna
sampl
studi
beadchip
technolog
immucorbioarray
solut
ng
use
sureselect
human
exon
agil
platform
silico
analysi
differ
bioinformat
tool
use
predict
splice
event
furthermor
function
splice
assay
perform
determin
impact
nucleotid
variat
exon
skip
rhd
gene
studi
complet
compar
model
wild
type
weak
type
rhd
protein
resultsfind
target
analysi
full
exom
sequenc
confirm
blood
group
genotyp
patient
previous
character
beadchip
technolog
interestingli
carri
intron
variat
rhd
gene
alreadi
describ
associ
del
allel
among
last
patient
one
previous
character
rhd
weak
type
carri
c
independ
sanger
sequenc
unrel
rhd
weak
type
sampl
pinpoint
linkag
disequilibrium
c
exac
maf
exac
maf
silico
analysi
mutat
locat
close
splice
acceptor
site
exon
predict
signific
reduct
strength
score
minigen
vector
harbor
rhd
wildtyp
exon
mutant
rhd
c
mutant
rhd
doubl
rhd
mutant
c
plu
show
influenc
skip
exon
due
mutat
compar
model
rhd
protein
point
addit
hydrophob
interact
rhd
weak
type
transmembran
helix
transmembran
helix
hamper
membran
insert
conclus
variat
alway
associ
ci
missens
mutat
c
allel
rhd
weak
type
found
alon
rhd
gene
neutral
polymorph
assess
two
mutat
isol
combin
lead
abnorm
rhd
transcript
result
clearli
demonstr
weak
antigen
reactiv
observ
rhd
type
red
blood
cell
due
substitut
alanin
amino
acid
posit
glycin
backgroundcas
studi
human
urea
protein
carri
kidd
blood
group
transmembran
tm
tilt
long
extracellular
connector
segment
cytoplasm
segment
end
numer
missens
variant
snmv
weaken
abolish
express
jkab
antigen
determin
map
report
snmv
onto
structur
explor
topolog
correl
jk
antigen
express
studi
designmethod
jk
jk
b
snmv
affect
jk
express
compil
dbrbc
isbt
registri
literatur
search
aabb
isbt
british
blood
transfus
societi
meet
abstract
snmv
locat
correl
human
homolog
structur
mammalian
deriv
analysi
ut
function
levin
ej
resultsfind
seven
snmv
locat
within
amino
acid
aa
exofaci
intern
end
tm
helix
mostli
weak
variant
tabl
exofaci
end
two
except
intern
end
tm
helix
bear
jkab
four
snmv
cytoplasm
segment
mostli
weak
variant
contrast
snmv
within
membran
helic
mostli
variant
three
snmv
associ
antigen
allel
weak
partial
six
variant
within
aa
jkab
none
snmv
long
extracellular
connector
region
cytoplasm
segment
variant
adjac
line
part
urea
transport
pore
conclus
rhd
rhce
protein
snmv
weak
c
c
e
e
express
mostli
within
rbc
membran
snmv
unusu
structur
similar
kidd
snmv
end
tm
helic
cytoplasm
segment
among
snmv
membran
helic
howev
whether
variant
appear
may
depend
extent
test
sequenc
may
provid
complet
correl
backgroundcas
studi
blood
group
often
inherit
recess
genet
trait
due
biallel
mutat
gene
encod
urea
transport
phenotyp
associ
transfus
risk
also
associ
abnorm
abil
concentr
urin
caus
ident
phenotyp
domin
inherit
jk
yet
defin
though
first
describ
contrast
recess
inherit
phenotyp
associ
mutat
gene
aim
studi
identifi
character
caus
gene
domin
red
blood
cell
phenotyp
injk
studi
designmethod
identifi
sever
famili
domin
inherit
phenotyp
multipl
kindr
spain
perform
linkag
analysi
exom
sequenc
express
western
analys
urea
lysi
use
patient
cell
addit
two
proband
underw
urin
concentr
test
resultsfind
use
molecular
approach
map
affect
locu
mbp
region
lod
score
use
deep
sequenc
identifi
potenti
deleteri
mutat
gene
delet
bp
result
loss
entir
zing
finger
domain
ident
mutat
present
affect
individu
absent
control
test
n
addit
two
adult
individu
homozyg
entir
haplotyp
includ
delet
within
locu
thu
complet
lack
common
allel
identifi
also
obtain
dna
unrel
injk
individu
report
japan
individu
similar
though
ident
none
potenti
genet
variant
identifi
spanish
kindr
present
dna
injk
individu
japan
consist
fact
kidd
antigen
encod
urea
transport
associ
renal
function
found
peopl
spain
inabl
concentr
urin
conclus
predict
zinc
finger
delet
preval
southern
spain
due
founder
mutat
lead
dysfunct
underli
dominantli
inherit
blood
phenotyp
phenotyp
associ
subnorm
urin
concentr
abil
backgroundcas
studi
phthalat
dehp
make
pvc
film
flexibl
use
blood
product
storag
dehp
leach
bag
film
solut
metabol
studi
rodent
suggest
exposur
dehp
may
associ
advers
health
effect
albeit
high
dosag
attempt
find
dehp
altern
blood
bag
difficult
due
rbc
effect
dehp
bi
terephthal
deht
structur
function
similar
dehp
distinct
metabol
toxicolog
standpoint
deht
undergo
complet
hydrolysi
excel
safeti
profil
classifi
carcinogen
mutagen
reproduct
toxic
endocrin
disruptor
studi
object
evalu
qualiti
fresh
frozen
plasma
ffp
store
deht
contain
versu
ffp
store
dehp
contain
day
year
studi
designmethod
wb
unit
collect
cpd
solut
leukoreduc
centrifug
separ
rbc
plasma
abo
ident
plasma
unit
pool
togeth
group
three
pool
includ
group
group
group
ab
plasma
pool
weigh
mix
sampl
divid
dehp
deht
pair
frozen
less
within
hour
collect
vitro
plasma
test
pt
aptt
factor
v
factor
viii
fibrinogen
protein
c
protein
done
day
pool
day
year
storag
dehp
deht
pair
plasma
thaw
test
time
plastic
concentr
determin
day
day
year
ffp
storag
dehp
deht
monoest
analyz
liquid
spectrometri
intern
standard
mehp
deht
meht
lower
limit
quantif
lloq
dehp
ppm
mehp
ppm
deht
ppm
meht
ppm
resultsfind
mean
standard
deviat
sd
key
clot
factor
plastic
result
summar
tabl
statist
differ
plasma
paramet
dehp
deht
bag
time
period
factor
viii
retain
greater
initi
valu
plasma
store
deht
bag
averag
plastic
content
lower
dehp
bag
conclus
deht
plastic
pvc
contain
provid
similar
ffp
perform
dehp
plastic
bag
sinc
deht
less
polar
dehp
migrat
plasma
also
reduc
base
upon
data
deht
potenti
replac
dehp
ffp
storag
bag
backgroundcas
studi
plasma
prevent
dilut
coagulopathi
trauma
victim
replac
coagul
factor
substrat
resuscit
red
blood
cell
rbc
andor
crystalloid
solut
plasma
spdp
lightweight
reconstitut
minut
make
ideal
use
combat
set
rapidli
provid
plasma
situat
impract
administ
fresh
frozen
plasma
ffp
process
preserv
coagul
protein
high
molecular
weight
multim
hmwm
von
willebrand
factor
vwf
decreas
object
studi
compar
spdp
ffp
reconstitut
whole
blood
rwb
test
hypothesi
spdp
inferior
ffp
facilit
platelet
adhes
thrombu
format
studi
designmethod
protocol
whole
blood
healthi
volunt
collect
sodium
citrat
centrifug
g
separ
rbc
plasma
prp
prp
dilut
centrifug
g
platelet
pellet
resuspend
either
spdp
ffp
recombin
pack
rbc
creat
rwb
hematocrit
addit
two
rwb
pair
reconstitut
spdp
dilut
plasma
patient
type
vw
diseas
sampl
fluoresc
label
antibodi
sampl
flow
type
microchannel
shear
rate
second
still
imag
adher
platelet
thrombi
captur
order
calcul
surfac
area
coverag
sa
along
length
channel
ratio
pair
use
compar
sa
sampl
reconstitut
spdp
vs
ffp
margin
noninferior
spdpffp
resultsfind
six
batch
spdpffp
evalu
use
subject
statist
differ
spdpffp
pair
mean
ratio
spdpffp
ci
compar
spdp
vs
differ
median
ratio
rang
sa
anova
demonstr
batch
significantli
affect
ratio
sa
spdp
vs
ffp
conclus
spdp
despit
decreas
vwf
hmwm
inferior
ffp
abil
support
platelet
adhes
thrombu
format
averag
sa
sampl
reconstitut
spdp
greater
sampl
reconstitut
ffp
lower
limit
ci
differ
less
priori
determin
margin
noninferior
even
dilut
plasma
reduct
platelet
adhes
thrombu
format
spdp
rwb
sampl
data
support
develop
studi
evalu
efficaci
safeti
spdp
prevent
revers
coagulopathi
backgroundcas
studi
restor
coagul
factor
key
acut
resuscit
traumat
hemorrhag
blood
product
frequent
unavail
emerg
respons
due
restrict
storag
need
singl
unit
spray
dri
plasma
spdp
process
develop
produc
readili
store
product
reduct
high
molecular
weight
multim
von
willebrand
factor
vwf
increas
low
molecular
weight
multim
vwf
critic
platelet
adhes
thrombu
format
follow
work
demonstr
enhanc
function
use
reconstitut
solut
spdp
studi
examin
two
differ
spdp
pretreat
condit
studi
designmethod
sampl
ffp
ffp
glycin
regular
spdp
without
pretreat
rspdp
rehydr
glycin
spdp
pretreat
spdp
pretreat
glycin
pretreat
rehydr
water
six
plasma
type
test
vwf
activ
measur
ristocetin
cofactor
assay
fibrin
polymer
kinet
analyz
turbidimetri
thrombin
gener
tg
observ
thrombogram
chemistri
evalu
residu
cell
materi
quantifi
flow
cytometri
coagul
properti
measur
thromboelastographi
teg
plasma
reconstruct
whole
blood
hct
plateletsnl
donor
platelet
adhes
collagen
shear
measur
bioflux
resultsfind
pretreat
spdp
show
enhanc
vwf
activ
rspdp
p
fibrin
polymer
densiti
slightli
diminish
rspdp
vs
ffp
vs
od
p
tg
unchang
bicarbonatebas
excess
lower
spdp
sampl
vs
ffp
p
residu
cellular
materi
especi
reduc
threefold
rspdp
vs
ffp
p
addit
twofold
pretreat
spdp
vs
rspdp
p
teg
result
unchang
sampl
reconstruct
wb
reduct
amplitud
clot
strength
spdp
sampl
vs
ffp
vs
p
platelet
adhes
equival
pretreat
spdp
ffp
rspdp
improv
vs
sampl
surfac
coverag
vs
p
conclus
spdp
longer
shelf
life
easier
storag
requir
ffp
equival
superior
ffp
vitro
assay
spdp
pretreat
glycin
solut
similar
ffp
assay
show
superior
vwf
activ
fewer
residu
cellular
materi
inferior
support
platelet
adhes
collagen
flow
compar
untreat
spdp
clinic
signific
find
unclear
overal
vitro
outcom
suggest
clinic
studi
warrant
backgroundcas
studi
red
blood
cell
rbc
transfus
associ
acut
lung
injuri
particular
patient
mechan
ventil
caus
factor
known
may
includ
residu
cell
extracellular
vesicl
ev
studi
investig
function
effect
differ
manufactur
method
rbc
product
respons
pulmonari
cell
vitro
model
mechan
ventil
studi
designmethod
group
rbc
product
whole
blood
filter
wbf
red
cell
filter
rcf
apheresi
deriv
ad
whole
blood
deriv
wbd
manufactur
donor
blood
type
b
supernat
prepar
fresh
day
storag
store
measur
thrombin
gener
ev
analysi
type
ii
alveolar
cell
seed
onto
flexibl
membran
incub
rbc
supernat
cell
subject
stretch
use
control
cell
stretch
hour
product
measur
resultsfind
fresh
store
supernat
ad
product
significantli
increas
pulmonari
cell
product
compar
incub
rbc
product
control
exacerb
cell
stretch
ad
product
also
significantli
increas
thrombin
gener
abil
compar
rbc
product
well
significantli
increas
number
ev
compar
rcf
wbd
product
p
incub
stretch
cell
store
wbf
product
result
higher
product
compar
blood
product
stretch
control
rcf
product
activ
pulmonari
cell
absenc
tg
low
level
ev
compar
product
conclus
manufactur
method
markedli
influenc
interact
rbc
product
lung
cell
ad
product
activ
lung
cell
aggrav
cell
stretch
may
part
mediat
ev
increas
thrombin
gener
potenti
effect
irrespect
storag
durat
store
wbf
product
also
show
addit
effect
induc
lung
injuri
cell
stretch
model
mechan
ventil
rcf
seem
safest
product
avoid
induct
lung
injuri
backgroundcas
studi
investig
previous
demonstr
immunosuppress
effect
rbc
supernat
monocyt
vitro
greater
effect
seen
respons
older
unit
recent
clinic
data
suggest
rbc
manufactur
method
may
influenc
immunomodulatori
potenti
directli
measur
use
vitro
model
test
hypothesi
rbc
supernat
obtain
differ
manufactur
method
differenti
effect
monocyt
function
studi
designmethod
rbc
product
manufactur
differ
method
individu
donor
whole
blood
filtrat
wbf
red
cell
filtrat
rcf
apheresi
whole
blood
deriv
wbd
rbc
product
store
sagm
wbf
rcf
preserv
solut
apheresi
wbd
supernat
obtain
day
fresh
day
expiri
monocyt
media
plu
rbc
supernat
media
control
follow
lp
stimul
experi
perform
replic
distinct
monocyt
donor
comparison
group
anova
dunnett
multipl
comparison
data
mean
sd
control
valu
resultsfind
exposur
apheresi
wbd
rbc
supernat
suppress
monocyt
product
capac
compar
control
tabl
true
fresh
unit
expiri
monocyt
expos
rbc
supernat
alon
without
lp
product
higher
exposur
fresh
wbf
control
p
wbd
expiri
control
p
conclus
manufactur
method
andor
storag
solut
significantli
alter
immunomodulatori
effect
rbc
supernat
monocyt
vitro
may
confound
analys
clinic
effect
rbc
storag
durat
particularli
within
intern
studi
tabl
product
function
manufactur
method
backgroundcas
studi
amount
hemolysi
red
blood
cell
unit
increas
product
age
shown
lower
femal
blood
donor
male
hypothes
femal
donor
possess
averag
younger
popul
red
cell
result
lower
hemolysi
observ
popul
also
hypothes
differ
donor
popul
mitig
lysi
older
cell
whole
blood
unit
undergo
process
step
produc
red
cell
concentr
rcc
unit
red
blood
cell
rbc
age
circul
undergo
characterist
chang
densiti
membran
composit
allow
separ
younger
cell
studi
designmethod
aim
studi
effect
donor
factor
method
manufactur
store
condit
averag
rbc
age
densiti
red
cell
unit
recent
develop
power
yet
simpl
inexpens
magnet
platform
allow
imag
monitor
variou
cell
popul
system
allow
densiti
profil
individu
red
blood
cell
unpreced
resolut
first
determin
effect
rcc
storag
densiti
profil
rbc
levit
densiti
profil
measur
day
addit
determin
effect
donor
age
sex
rbc
densiti
profil
blood
sampl
volunt
four
differ
age
sex
categori
male
year
male
year
femal
year
femal
year
profil
resultsfind
first
observ
levit
densiti
profil
well
morpholog
rbc
within
rcc
unit
chang
significantli
storag
addit
rbc
densiti
significantli
differ
young
gml
older
femal
donor
gml
p
moreov
rbc
young
male
gml
significantli
less
dens
compar
rbc
profil
older
femal
donor
gml
p
conclus
develop
magnet
levit
system
evalu
rbc
red
cell
concentr
rcc
qualiti
envis
result
might
inform
decis
maker
impact
donor
deferr
criteria
may
qualiti
red
cell
concentr
avail
blood
bank
optim
clinic
outcom
backgroundcas
studi
oxid
reduct
potenti
orp
redox
ratio
activ
oxid
reduc
redox
imbal
caus
higher
product
reactiv
oxygen
speci
ro
reactiv
nitrogen
speci
decreas
endogen
protect
antioxid
result
oxid
stress
os
os
caus
cellular
injuri
death
also
import
regul
healthi
immun
respons
injuri
diseas
present
studi
investig
chang
hemoglobin
free
heme
orp
red
blood
cell
rbc
age
effect
red
blood
cell
age
icu
patient
morbid
mortal
studi
designmethod
icu
patient
enrol
prospect
observ
trial
investig
effect
transfus
rbc
age
icu
patient
morbid
mortal
rbc
leukoreduc
abo
ident
citrat
blood
sampl
collect
rbc
unit
prior
issu
rbc
supernat
test
free
hemoglobinhem
orp
patient
follow
prospect
resultsfind
total
rbc
unit
transfus
patient
rbc
characterist
shown
tabl
signific
reduct
detect
orp
valu
storag
durat
p
substanti
correl
also
found
orp
free
hemoglobin
p
orp
free
heme
p
interestingli
statist
signific
differ
averag
orp
valu
transfus
rbc
patient
develop
infect
higher
orp
valu
measur
rbc
unit
given
patient
develop
infect
vs
p
signific
differ
observ
orp
patient
mortal
hospitalicu
day
thrombosi
also
correl
detect
free
hemehemoglobin
rbc
age
infect
develop
conclus
data
demonstr
older
blood
lower
orp
valu
well
increas
free
hemehemoglobin
differ
orp
valu
differ
blood
group
rbc
age
control
statist
signific
differ
patient
mortal
associ
orp
free
hemehemoglobin
rbc
age
decreas
orp
valu
observ
older
blood
like
attribut
storag
lesion
higher
transfus
rbc
orp
valu
associ
subsequ
develop
infect
younger
rbc
found
higher
orp
valu
thu
data
support
youngfresh
blood
may
predispos
subsequ
develop
infect
critic
ill
patient
studi
need
tabl
patient
rbc
characterist
backgroundcas
studi
random
trial
human
address
whether
exposur
red
blood
cell
rbc
store
long
time
associ
harm
explor
effect
mortal
transfus
rbc
store
day
compar
rbc
store
day
less
studi
designmethod
data
random
control
trial
use
exploratori
analysi
patient
hospit
adult
requir
transfus
randomli
alloc
receiv
freshest
rbc
inventori
oldest
standard
issu
rbc
provid
larg
cohort
patient
receiv
rbc
storag
durat
along
entir
rbc
storag
continuum
day
use
time
depend
variabl
patient
exposur
defin
maximum
storag
durat
rbc
receiv
use
classifi
individu
day
hospit
one
three
mutual
exclus
exposur
categori
freshest
exclus
expos
rbc
less
equal
day
storag
durat
refer
group
medium
age
least
rbc
day
storag
oldest
least
rbc
greater
day
storag
primari
outcom
mortal
cox
regress
model
death
assess
effect
exposur
rbc
categori
exclus
exposur
rbc
store
day
less
effect
fix
confound
dealt
stratif
regress
sensit
analys
conduct
weekli
partit
everi
day
b
finer
partit
use
everi
day
resultsfind
patient
receiv
rbc
includ
analysi
exposur
rbc
store
day
associ
increas
risk
death
compar
exposur
exclus
freshest
rbc
unit
store
day
less
adjust
sever
fix
potenti
confound
hr
ci
p
exposur
blood
store
day
yield
similar
hazard
ratio
hr
ci
p
sensit
analys
use
weekli
partit
exposur
rbc
store
greater
day
compar
exclus
exposur
rbc
store
day
less
signific
hr
ci
p
confid
interv
around
hazard
ratio
interv
includ
similar
find
obtain
partit
exposur
data
day
interv
exposur
rbc
store
day
associ
increas
risk
death
compar
exclus
exposur
rbc
store
day
hr
ci
p
confid
interv
around
hazard
ratio
interv
includ
conclus
individu
expos
rbc
store
day
increas
risk
death
compar
individu
expos
exclus
rbc
store
day
less
backgroundcas
studi
hemorrhag
shock
hs
sever
decreas
oxygen
deliveri
induc
cardiovascular
collaps
parallel
control
hemorrhag
clinician
respond
infus
larg
volum
red
blood
cell
rbc
restor
blood
volum
carri
capac
hemodynam
stabil
qualiti
transfus
rbc
determin
recoveri
hs
extent
clinic
sequela
prompt
hs
studi
compar
abil
recov
hs
convent
store
rbc
anaerob
satur
store
rbc
anaerobichypercapn
satur
store
rbc
studi
designmethod
pack
red
blood
cell
prbc
store
leukorfiltr
creat
donor
rat
prbc
unit
randomli
store
either
convent
anaerob
anaerobichypercapn
condit
rat
hemorrhag
blood
volum
held
hypovolemia
minut
resuscit
recov
blood
pressur
prbc
store
either
week
system
hemodynam
cardiac
function
blood
ga
paramet
monitor
shock
resuscit
vital
organ
inflamm
oxygen
function
evalu
post
resuscit
data
analyz
use
anova
follow
appropri
post
hoc
analys
resultsfind
convent
store
rbc
suscept
biochem
mechan
chang
storag
compar
anaerob
anaerobichypercapn
storag
post
transfus
recoveri
anaerob
anaerobichypercapn
store
rbc
significantli
higher
compar
convent
store
rbc
p
shock
impair
cardiac
function
oxygen
deliveri
resuscit
prbc
restor
cardiac
output
recoveri
system
vascular
resist
attain
earlier
lower
volum
either
anaerob
anaerobichypercapn
store
rbc
resuscit
either
anaerob
anaerobichypercapn
requir
significantli
lower
volum
fewer
unit
convent
storag
prbc
preserv
hemodynam
resuscit
p
convent
store
rbc
resuscit
anim
show
impair
abil
deliv
tissu
increas
lung
liver
spleen
inflammatori
marker
decreas
liver
kidney
function
compar
anim
resuscit
either
anaerob
anaerobichypercapn
prbc
conclus
studi
indic
anaerob
anaerobichypercapn
storag
rbc
improv
clinic
outcom
hemorrhag
shock
rat
model
evidenc
hemodynam
stabil
enhanc
deliveri
reduct
vital
organ
inflamm
function
backgroundcas
studi
transfus
minor
abo
incompat
platelet
pose
risk
hemolyt
reaction
differ
strategi
wash
reduct
plasma
volum
centrifug
use
reduc
risk
hemolysi
although
still
controversi
whether
safe
titer
would
result
hemolysi
mani
institut
provid
low
titer
unit
transfus
minor
abo
incompat
platelet
anoth
strategi
propos
evalu
includ
use
platelet
collect
platelet
addit
solut
pa
aim
studi
character
isoagglutinin
titer
platelet
store
pa
evalu
compar
titer
unmodifi
donor
plasma
evalu
cost
use
pa
compar
plasma
reduct
studi
designmethod
pair
plasma
donor
unmodifi
platelet
collect
sampl
obtain
local
blood
center
use
tube
method
serial
two
fold
dilut
plasma
prepar
igm
igg
antibodi
titer
interpret
reciproc
highest
dilut
yield
macroscop
reaction
resultsfind
total
pair
donorplatelet
sampl
test
includ
group
group
group
b
titer
median
rang
donor
sampl
pa
platelet
present
tabl
overal
pa
platelet
unit
isoagglutinin
titer
dilut
lower
unmodifi
plasma
donor
sampl
group
titer
distribut
pa
donor
sampl
present
tabl
group
pa
platelet
titer
cost
analysi
demonstr
plasma
reduc
platelet
platelet
volum
reduct
similar
cost
pa
platelet
unit
conclus
use
pa
effect
decreas
plasma
isoagglutinin
titer
level
consid
low
risk
hemolyt
episod
cost
effect
compar
plasma
reduct
backgroundcas
studi
daratumumab
dara
monoclon
antibodi
use
treatment
multipl
myeloma
mm
express
plasma
cell
well
red
blood
cell
rbc
interfer
serolog
test
includ
posit
type
screen
describ
patient
demonstr
serolog
interfer
anecdot
patient
may
poorer
clinic
respons
retrospect
studi
explor
relationship
serolog
interfer
clinic
respons
studi
designmethod
mm
patient
dara
identifi
clinic
team
data
period
use
identifi
patient
repeatedli
neg
neg
posit
control
po
patient
treatment
respons
evalu
eval
determin
clinic
team
review
separ
categori
short
term
assess
week
post
dara
standard
assess
week
week
post
dara
long
term
assess
week
post
dara
data
analyz
test
graphpad
version
resultsfind
dara
patient
repeat
avail
review
patient
qualifi
neg
group
see
tabl
patient
characterist
neg
patient
withdrew
treatment
compar
po
patient
neg
patient
termin
treatment
week
initi
compar
po
patient
mean
length
treatment
neg
po
group
day
day
respect
neg
patient
show
short
term
respons
patient
show
progress
diseas
neg
group
standard
eval
patient
show
respons
progress
diseas
neg
patient
long
term
respons
compar
po
patient
po
short
term
eval
patient
show
respons
patient
progress
diseas
po
group
standard
eval
patient
show
respons
patient
progress
diseas
overal
po
patient
respond
compar
neg
tabl
conclus
trend
lower
respons
rate
patient
neg
antibodi
screen
compar
posit
control
find
suggest
neutral
substanc
could
play
role
treatment
respons
altern
reduc
express
may
also
contribut
low
respons
rate
seen
group
may
result
bias
select
need
repeat
presum
repeat
transfus
may
preselect
patient
aggress
diseas
also
small
number
patient
suitabl
review
larger
prospect
studi
control
variabl
need
backgroundcas
studi
tradit
definit
massiv
transfus
eg
transfus
ten
unit
red
blood
cell
rbc
period
limit
prospect
identifi
patient
requir
massiv
transfus
exclud
patient
may
surviv
long
enough
meet
criteria
ignor
acuiti
event
address
issu
level
trauma
center
adopt
critic
administr
threshold
cat
addit
indic
activ
massiv
transfus
protocol
mtp
studi
review
blood
util
massiv
transfus
event
base
upon
whether
mtp
versu
studi
designmethod
massiv
transfus
event
januari
april
review
identifi
start
time
termin
time
number
compon
transfus
start
time
compon
transfus
transfus
three
blood
compon
hour
defin
cat
massiv
transfus
event
concern
hemorrhag
shock
either
necessit
provid
activ
mtp
blood
compon
transfus
rate
met
cat
criteria
massiv
transfus
start
time
base
either
time
provid
activ
mtp
time
first
blood
compon
transfus
whichev
came
first
unless
patient
expir
first
termin
massiv
transfus
event
determin
identifi
point
time
patient
went
three
hour
without
transfus
addit
blood
compon
inform
tabul
determin
monthli
number
mtp
mtp
averag
blood
compon
transfus
per
massiv
transfus
resultsfind
conclus
blood
util
lower
within
mtp
even
though
outnumb
mtp
howev
mode
group
suggest
massiv
transfus
requir
less
blood
compon
averag
rate
use
mode
provid
approxim
replac
blood
volum
enough
counter
earli
sign
symptom
hemorrhag
shock
though
studi
review
appropri
mtp
use
cat
indic
ensur
clinician
prepar
potenti
massiv
transfus
investig
need
determin
factor
contribut
downward
trend
averag
blood
compon
transfus
mode
would
suggest
optimist
patient
stabil
faster
resuscit
effici
case
defin
massiv
transfus
includ
rate
compon
transfus
addit
total
volum
transfus
backgroundcas
studi
drug
daratumumab
pose
problem
transfus
servic
may
caus
number
fals
posit
includ
posit
direct
antiglobulin
test
dat
indirect
antiglobulin
test
iat
panreact
eluat
result
prolong
compat
test
delay
deliveri
blood
product
patient
treat
reagent
red
cell
rrbc
dithiothreitol
dtt
remov
drug
interfer
due
daratumumab
allow
detect
underli
alloantibodi
studi
aim
investig
effect
rrbc
antigen
integr
day
period
studi
designmethod
twelv
aliquot
human
plasma
contain
antibodi
singl
known
specif
test
untreat
rrbc
immucor
panoscreen
ii
iii
dtt
acro
organ
dtt
treatment
rrbc
perform
use
methodolog
describ
aabb
technic
manual
plasma
aliquot
separ
aliquot
store
day
use
fresh
aliquot
thaw
day
avoid
unintend
antibodi
integr
degrad
polyethylen
glycol
immucor
enhanc
techniqu
use
reaction
read
iat
phase
hemolysi
present
observ
diluent
day
prior
mix
cell
suspens
given
grade
base
haemonet
color
compar
chart
serolog
antibodi
reaction
strength
observ
document
day
resultsfind
notic
hemolysi
cell
time
compar
untreat
cell
red
cell
antigen
remain
serolog
detect
cell
throughout
studi
despit
greater
degre
observ
hemolysi
minim
differ
reactiv
strength
untreat
cell
antigen
affect
dtt
instanc
cell
react
slightli
strongli
none
antibodi
produc
reactiv
strength
less
untreat
cell
studi
conclus
long
term
storag
rrbc
compromis
antigen
integr
advanc
storag
larg
aliquot
rrbc
may
serv
increas
effici
transfus
servic
tabl
hemolysi
grade
untreat
cell
base
haemonet
color
compar
chart
day
test
backgroundcas
studi
old
femal
admit
sickl
cell
crisi
symptomat
anemia
physician
order
red
blood
cell
rbc
unit
group
weak
histori
transfus
sever
year
prior
immunohematolog
refer
lab
identifi
anti
unexplain
reactiv
reagent
red
cell
test
except
molecular
test
recommend
aid
antibodi
identif
select
compat
unit
studi
designmethod
genom
dna
extract
edta
peripher
blood
rbc
genotyp
includ
precisetyp
hea
molecular
hea
rhd
rhce
beadchip
immucor
pcr
rflp
analysi
rhd
rhce
g
sanger
sequenc
pcr
product
plasmid
contain
product
perform
genewiz
sequenc
align
use
sequench
genecod
punnett
squar
analysi
perform
describ
keller
etal
transfus
antibodi
identif
studi
perform
standard
tube
method
monocyt
monolay
assay
mma
perform
describ
resultsfind
hea
panel
predict
patient
type
jk
fy
rhd
genotyp
result
support
patient
hemizyg
homozyg
rhd
famili
allel
variant
often
present
serolog
weak
rhce
genotyp
found
patient
carri
rhce
ceek
allel
novel
allel
lack
allel
provision
call
rhce
predict
rh
phenotyp
partial
partial
c
partial
e
punnett
squar
analysi
rh
genotyp
match
assign
donor
homozyg
rhce
ceek
tier
wherea
donor
homozyg
allel
rhce
cemo
rhce
cear
assign
tier
adsorb
serum
allogen
adsorpt
test
rbc
variant
rhce
allel
predict
well
r
r
cell
demonstr
patient
allo
also
mma
studi
perform
rr
cell
posit
respect
rbc
rhce
cear
rhce
cemoin
homozygos
neg
respect
conclus
individu
carri
rhce
variant
allel
predict
phenotyp
risk
known
patient
compat
rbc
carri
sever
allel
predict
test
patient
suggest
patient
rhce
ceek
allel
could
compat
donor
unit
carri
rhce
cear
rhce
cemo
sinc
rbc
neg
e
hr
rare
us
popul
studi
show
differ
allel
may
cross
compat
may
aid
effort
find
compat
blood
product
patient
backgroundcas
studi
monocyt
monolay
assay
mma
cellular
bioassay
use
evalu
hemolyt
signific
blood
group
antibodi
aid
select
rbc
alloimmun
patient
requir
fresh
autoallogen
monocyt
mma
highli
restrict
due
tediou
process
fresh
peripher
blood
pb
previou
studi
describ
process
cryopreserv
bc
deriv
fresh
mma
assay
aim
evalu
function
properti
cryopreserv
substitut
fresh
mma
evalu
previous
report
clinic
signific
rbc
alloantibodi
studi
designmethod
peripher
blood
mononuclear
cell
pbmc
isol
pool
suspend
cryopreserv
media
dmso
store
liquid
nitrogen
pbmc
membran
integr
determin
trypan
blue
exclus
pbmc
cultur
coverslip
monocyt
monolay
incub
fresh
cryopreserv
antigen
posit
rbc
sensit
either
posit
control
lipopolysaccharid
stimul
aliquot
sensit
rbc
test
opson
indirect
antiglobulin
test
iat
phagocytosi
index
pi
determin
microscop
number
fulli
phagocytos
monocyt
supernat
analyz
cytokin
use
luminex
techniqu
resultsfind
cryopreserv
pbmc
show
viabil
report
signific
differ
phagocytosi
sensit
rbc
cryopreserv
monocyt
vs
fresh
monocyt
show
signific
increas
p
gro
p
secret
cryopreserv
bc
monocyt
vs
fresh
bc
rbc
result
pi
respect
vs
sensit
rbc
pi
weak
reactiv
iat
observ
sensit
rbc
sensit
rbc
result
iat
reactiv
result
correl
previous
report
result
clinic
signific
mma
use
freshli
obtain
autolog
healthi
donor
monocyt
conclus
studi
show
cryopreserv
preserv
monocyt
viabil
phagocytosi
function
mma
previous
report
fresh
monocyt
mma
assay
two
alloantibodi
test
cryopreserv
bc
monocyt
shown
phagocyt
index
clinic
signific
pi
use
cryopreserv
abil
achiev
consist
predict
result
mma
minim
variat
backgroundcas
studi
monoclon
reagent
consid
suitabl
type
dat
posit
dat
rbc
describ
antigen
type
discrep
patient
involv
antigen
c
jka
reveal
serolog
result
differ
phenotyp
predict
dna
test
patient
posit
dat
warm
autoantibodi
identifi
plasma
investig
antigen
type
discrep
show
fals
neg
fals
posit
result
use
monoclon
reagent
studi
designmethod
standard
tube
hemagglutin
method
use
antigen
type
rbc
treat
edta
ega
use
gamma
ega
kit
genom
dna
isol
wbc
hea
precisetyp
perform
resultsfind
rbc
patient
type
initi
test
immucor
predict
c
hea
precisetyp
rbc
gave
reaction
reagent
patient
rbc
gave
variabl
reactiv
seraclon
ortho
bioclon
patient
rbc
gave
reactiv
reagent
incub
maximum
incub
time
allow
patient
rbc
jk
immucor
gammaclon
manufactur
state
suitabl
test
datrbc
predict
jk
hea
rbc
test
jk
reagent
rbc
patient
test
seraclon
predict
hea
test
immucor
gammaclon
show
rbc
patient
rbc
reagent
conclus
commerci
monoclon
reagent
valuabl
resourc
especi
phenotyp
dat
rbc
manufactur
includ
reagent
limit
regard
test
dat
rbc
describ
case
fals
neg
test
monoclon
due
antigen
block
igg
case
fals
posit
test
type
fals
posit
test
would
potenti
anticip
fals
neg
result
due
antigen
block
unexpect
extend
incub
indic
reagent
insert
may
reveal
weak
reactiv
antigen
block
involv
result
concord
dna
test
obtain
rbc
gener
accept
necessari
use
monoclon
reagent
case
caution
potenti
fals
neg
fals
posit
result
sampl
posit
dat
support
test
dissoci
igg
rbc
strongli
dat
antigen
type
addit
report
highlight
benefit
dna
test
part
routin
refer
laboratori
workup
backgroundcas
studi
human
rhesusbas
list
molecular
weak
type
type
repres
weak
type
caucasian
weak
type
caus
snp
rhd
exon
perco
colleagu
inadvert
found
origin
weak
type
sampl
explor
complementari
method
zygos
test
second
exampl
weak
type
observ
tunisia
among
sampl
neg
indirect
antiglobulin
test
also
nucleotid
sequenc
close
resembl
weak
type
addit
missens
mutat
lack
silent
mutat
none
report
document
detail
serolog
descript
rh
haplotyp
involv
present
studi
describ
serolog
weak
type
rh
haplotyp
includ
stretch
intron
studi
designmethod
sampl
tunisian
donor
origin
donor
parent
germani
collect
standard
hemagglutin
flow
cytometri
test
perform
nucleotid
sequenc
exon
well
adjac
intron
region
includ
untransl
region
utr
determin
rhd
rhce
gene
phylogenet
tree
weak
type
allel
establish
resultsfind
weak
type
allel
confirm
tunisian
donor
german
donor
molecular
analysi
german
donor
famili
show
donor
father
share
rhd
weak
type
rhce
ce
haplotyp
similar
tunisian
donor
explor
famili
german
donor
father
report
born
tunisia
antigen
densiti
donor
serolog
weak
type
phenotyp
found
antigen
per
red
blood
cell
respect
observ
agglutin
pattern
correl
well
antigen
densiti
weak
type
sampl
show
weak
neg
reactiv
panel
monoclon
compar
weak
type
weak
type
weak
type
phylogenet
analysi
show
weak
type
allel
evolv
genom
point
mutat
gene
convers
recombin
event
rhd
allel
conclus
studi
resolv
seemingli
close
relat
rhd
allel
complex
phylogen
origin
conundrum
sinc
correct
sequenc
deposit
donorw
establish
unambigu
data
rh
haplotyp
span
dna
stretch
nucleotid
short
arm
chromosom
data
appli
develop
evalu
valid
next
gener
sequenc
approach
use
target
long
rang
techniqu
backgroundcas
studi
sensit
antigen
express
transfus
cell
trigger
prematur
clearanc
diminish
therapeut
effect
transfus
may
also
lead
seriou
delay
hemolyt
transfus
reaction
accept
us
clinic
practic
provid
sensit
patient
receiv
cell
lack
offend
antigen
nevertheless
ensur
continu
alloexposur
thu
possibl
sensit
addit
antigen
therebi
complic
patient
manag
mitig
sensit
risk
especi
era
increasingli
procur
quantit
assess
immunogen
specif
antigen
desir
giblett
long
ago
introduc
rel
scale
relat
rbc
antigen
immunogen
assum
immunogen
k
http
show
absolut
estim
immunogen
may
extract
directli
observ
antibodi
count
provid
properli
normal
fraction
recipi
risk
name
lack
specif
antigen
expect
fraction
donor
express
antigen
studi
designmethod
defin
immunogen
sensit
risk
antigen
ag
interest
condit
probabl
ab
format
given
ag
ie
prob
aballoexp
prob
ab
prob
aballoexp
prob
alloexp
rewrit
prob
alloexp
prob
recipi
r
lack
ag
prob
donor
ag
estim
prob
ab
nabnr
nab
denot
number
ab
nr
recipi
obtain
nab
nr
prob
r
lack
ag
prob
ag
side
repres
observ
sensit
fraction
ie
number
observ
ab
relat
number
recipi
risk
resultsfind
valu
ag
determin
compil
http
sensit
patient
retrospect
analysi
sickl
cell
anemia
patient
transfus
studi
period
n
transfus
exclud
recipi
n
unit
predominantli
white
donor
conclus
sever
antigen
though
correspond
antibodi
may
rare
eg
jsa
e
u
nevertheless
highli
immunogen
requir
singl
exposur
averag
sensit
contrast
other
averag
requir
mani
exposur
thu
pose
rel
low
risk
conjunct
patient
genotyp
facilit
select
cell
minim
risk
prolifer
alloimmun
even
perfectli
match
cell
avail
approach
may
readili
extend
addit
rbc
antigen
antigen
system
backgroundcas
studi
aabb
fda
requir
month
deferr
donor
tattoo
appli
use
needl
reusabl
ink
review
state
regul
ascertain
tattoo
establish
licens
requir
use
steril
needl
ink
recent
ad
two
larg
state
collect
blood
accept
state
list
asl
compar
rate
donor
defer
addit
state
determin
potenti
donor
gain
chang
state
tattoo
licens
regul
studi
designmethod
analyz
allogen
interview
respons
screen
question
past
month
tattoo
ye
whether
tattoo
appli
state
regul
entiti
blood
center
state
select
analysi
state
tattoo
regul
state
comparison
period
similar
month
month
select
state
b
similar
month
month
select
frequenc
rate
respons
compar
period
among
respond
tattoo
regul
state
donat
review
presenc
infecti
diseas
marker
includ
hiv
hbv
hcv
resultsfind
higher
proport
donor
present
give
blood
admit
recent
month
tattoo
post
period
state
increas
occur
immedi
follow
addit
state
b
asl
data
shown
among
respond
ye
tattoo
state
b
respect
increas
accept
donor
tabl
absolut
number
accept
donor
tattoo
increas
state
state
b
annual
repres
potenti
gain
state
state
b
addit
donat
donor
tattoo
regul
state
asl
test
neg
hiv
hbv
hcv
conclus
counter
rise
number
inelig
donor
result
recent
ad
deferr
consid
recoveri
donor
defer
tattoo
way
enhanc
donor
base
immedi
rise
number
donor
report
tattoo
follow
addit
state
may
reflect
declin
base
recent
tattoo
demonstr
increas
potenti
number
donat
without
compromis
safeti
backgroundcas
studi
last
half
mani
us
blood
center
chang
indefinit
deferr
man
sex
anoth
man
sinc
deferr
sinc
last
sexual
contact
chang
monitor
care
assess
impact
present
donat
whether
earli
evid
chang
risk
blood
recipi
studi
designmethod
deferr
implement
blood
center
august
donor
health
questionnair
male
ask
question
msm
sexual
contact
previou
answer
question
msm
contact
sinc
rate
deferr
calendar
period
polici
chang
report
sep
mar
sep
mar
donor
request
reinstat
report
well
infecti
marker
test
result
accept
donor
resultsfind
overal
increas
number
present
period
compar
period
tabl
percent
male
donor
msm
histori
present
period
disclos
defer
period
period
follow
medic
staff
review
potenti
donor
men
report
msm
period
accept
donat
accept
rate
period
period
men
request
reinstat
return
given
success
donat
date
among
donor
report
histori
donat
two
donor
test
posit
infecti
marker
hiv
hcv
tabl
conclus
deferr
msm
behavior
decreas
adopt
reflect
remov
deferr
remot
msm
contact
initi
assess
suggest
continu
monitor
msm
deferr
rate
along
infecti
diseas
marker
track
essenti
assess
effect
donor
select
new
msm
donat
polici
backgroundcas
studi
transgend
donor
repres
small
fraction
blood
donor
determin
elig
donat
challeng
blood
center
assess
behavior
risk
donor
requir
answer
gender
specif
question
true
assess
trali
risk
donor
ask
histori
prior
pregnanc
prior
implement
fda
final
rule
blood
center
ask
donor
birth
gender
determin
elig
base
gender
donor
chang
gender
ask
answer
male
femal
question
final
rule
allow
blood
center
accept
donor
state
gender
determin
elig
base
gender
order
assess
risk
fail
ask
transgend
male
donor
birth
gender
femal
pregnanc
question
review
done
determin
number
transgend
male
activ
donat
larg
blood
center
studi
designmethod
donor
chang
gender
indentifi
comput
system
collect
staff
time
donat
track
donor
contact
resolv
descrep
donor
chang
gender
femal
male
answer
ye
prior
pregnanc
identifi
hla
antibodi
test
result
review
donor
see
test
whether
test
posit
neg
resultsfind
donor
identifi
chang
gender
birth
gender
femal
donor
chang
gender
male
male
donor
chang
gender
femal
transgend
male
donor
birth
gender
femal
answer
ye
pregnanc
question
one
donat
three
donor
apheresi
donor
test
hla
antibodi
one
test
posit
two
test
neg
hla
antibodi
four
donor
whole
blood
donor
test
hla
test
ad
donor
record
test
could
perform
next
time
present
donat
conclus
transgend
male
donor
may
prior
pregnanc
also
choos
becom
pregnant
transit
femal
male
six
percent
transgend
male
identifi
report
prior
histori
pregnanc
center
donor
request
gender
chang
femal
male
hla
test
request
next
donat
first
time
donor
qualifi
base
state
gender
transgend
donor
histori
pregnanc
identifi
unless
volunt
inform
consider
given
use
educ
materi
prompt
donor
reveal
histori
pregnanc
time
donat
hla
antibodi
test
perform
backgroundcas
studi
regul
allow
whole
blood
donat
wbd
estim
blood
volum
ebv
tradit
measuringmix
devic
set
halt
blood
flow
fix
volum
test
sampl
consist
limit
variabl
volum
scale
vv
program
vari
unit
volum
donor
ebv
maxim
transfus
rbc
plasma
recov
plasma
rp
volum
rp
wbd
small
import
sourc
deriv
blood
center
cost
recoveri
report
effect
introduc
hemoflow
vv
donor
reaction
rate
rp
volum
larg
blood
center
compar
previou
fix
set
variabl
collect
volum
expect
decreas
ebv
donor
yo
increas
other
studi
designmethod
donor
vasovag
reaction
vvr
rate
prefaint
prolongedoffsit
reaction
loss
conscious
loc
success
wbd
obtain
center
hemovigil
databas
mo
mo
phase
implement
vv
subsequ
mo
multivari
analysi
mva
period
perform
model
incorpor
donor
sex
age
ftd
vs
repeat
statu
ebv
donat
site
volum
number
unit
plasma
sent
fraction
avail
time
period
blood
center
data
warehous
resultsfind
compar
baselin
period
signific
increas
prefaint
reaction
rate
note
impl
period
continu
impl
period
return
baselin
rate
period
tabl
sever
reaction
show
increas
trend
becam
signific
period
mva
show
vv
independ
factor
contribut
increas
prefaint
sever
reaction
howev
contribut
measur
odd
ratio
consist
lower
exert
known
donor
determin
reaction
rate
young
age
low
ebv
ftd
statu
collect
site
shown
plasma
unit
volum
increas
averag
period
tempor
match
baselin
period
conclus
follow
initi
increas
mild
vvr
immedi
implement
vv
vvr
rate
fell
back
baselin
suggest
transient
staff
distract
usual
donor
care
minor
effect
increas
blood
loss
superimpos
improv
trend
subsequ
increas
prolongedoffsit
reaction
loc
prefaint
reaction
alreadi
return
baselin
suggest
staff
train
work
load
donor
complianc
mitig
strategi
determin
donor
reaction
far
greater
effect
small
addit
blood
loss
due
vv
small
signific
increment
rp
volum
improv
deriv
avail
offset
cost
vv
backgroundcas
studi
apheresi
procedur
expos
donor
variou
volum
citrat
depend
upon
type
length
procedur
type
machin
use
citrat
reaction
cr
result
variou
degre
hypocalcemia
donor
blood
volum
taken
donor
vari
accord
type
procedur
use
volum
replac
loss
blood
volum
part
respons
occurr
vasovag
reaction
vvr
analysi
conduct
estim
incid
cr
vvr
accord
variou
type
apheresi
procedur
perform
blood
center
studi
designmethod
sinc
octob
sever
donor
complic
dc
report
personnel
addit
donor
ask
dc
last
donat
electron
donor
health
questionnair
dhq
dhq
dc
match
dc
report
form
exclud
data
enter
databas
use
new
definit
classif
scheme
collect
singl
redblood
cell
rbc
doubl
rbc
singl
platelet
plt
doubl
plt
plt
plasma
pltp
plt
rbc
pltrbc
plt
rbc
plasma
pltrbcp
doubl
plt
rbc
doubl
plt
plasma
conduct
trima
system
terumobct
plasma
fraction
pf
collect
plasma
collect
system
haemonet
citrat
exposur
volum
collect
averag
rate
cr
vvr
without
loss
conscious
loc
present
per
apheresi
donat
period
januari
decemb
donat
multipl
product
one
procedur
count
one
trend
test
use
compar
rate
resultsfind
total
apheresi
procedur
perform
donor
lead
cr
rate
vvr
without
loc
rate
vvr
loc
rate
male
repres
apheresi
donor
rate
cr
higher
male
vs
p
rate
vvr
much
higher
femal
without
loc
vs
p
loc
vs
p
rate
cr
similar
age
group
vvr
steadi
linear
decreas
rate
yo
yo
rate
per
type
procedur
shown
tabl
statist
signific
increas
rate
cr
accord
citrat
exposur
p
trend
less
clear
vvr
rate
accord
volum
collect
donor
conclus
take
account
sever
dc
relat
apheresi
donat
rate
cr
vvr
quit
signific
measur
must
taken
decreas
dc
apheresi
like
ca
supplement
prophylaxi
volum
replac
salin
backgroundcas
studi
late
first
quarter
sever
case
wild
yellow
fever
viru
yfv
report
brazilian
state
rio
de
janeiro
sao
paulo
mina
gerai
santo
mainli
vector
case
mosquito
haemagogu
sabeth
gender
whose
habitat
tropic
forest
sinc
mani
brazilian
urban
area
close
rain
forest
outbreak
risk
area
infect
transmit
aed
mosquito
order
minim
risk
rio
de
janeiro
health
author
decid
promot
mass
vaccin
late
march
vaccin
produc
live
attenu
yfv
circul
least
week
vaccin
individu
vaccin
elicit
viscerotrop
effect
sometim
sever
diseas
due
brazilian
blood
regul
author
establish
week
deferr
period
yfv
vaccin
action
could
dramat
affect
avail
blood
donor
studi
show
measur
taken
rio
de
janeiro
blood
center
circumv
risk
attract
donor
studi
designmethod
strategi
consist
offer
popul
singl
place
blood
center
possibl
donat
blood
immedi
donat
get
vaccin
yfv
financi
advantag
donor
sinc
yfv
vaccin
complet
free
charg
brazilian
citizen
vaccin
administr
train
nurs
offic
close
donor
session
reason
prospect
donor
abl
donat
vaccin
also
offer
provid
contraind
blood
center
annnounc
mass
vacin
campaign
launch
would
vaccin
peopl
came
blood
center
donat
blood
reason
prospect
donor
abl
donat
vaccin
also
offer
provid
contraind
resultsfind
five
day
campaign
receiv
blood
donor
candid
accept
blood
donor
medic
interview
deferr
rate
period
year
prospect
donor
blood
donat
deferr
rate
get
vaccin
yfv
give
blood
campaign
abl
attract
five
day
period
addit
donor
compar
date
repres
increas
number
blood
donat
without
deferr
rate
increment
slight
increas
proport
donor
conclus
strategi
success
allow
blood
center
build
blood
inventori
larg
enough
avoid
risk
shortag
due
mass
vaccin
yfv
backgroundcas
studi
platelet
compon
pc
pathogen
reduc
pr
intercept
ceru
concord
ca
within
approv
criteria
volum
concentr
platelet
plt
dose
pr
result
dose
loss
must
accommod
collect
plt
donat
ensur
us
plt
dose
met
current
tripl
set
kit
pr
approv
europ
plt
loss
adjust
apheresi
target
paramet
may
impact
split
rate
sr
product
per
apheresi
procedur
inventori
suitabl
pr
without
impact
us
blood
center
sr
warrant
evalu
optim
studi
designmethod
apheresi
collect
center
differ
sr
analyz
baselin
sr
convent
pc
calcul
assum
minimum
dose
allow
product
loss
singl
doubl
tripl
convent
pc
ii
concentr
volum
requir
apheresi
devic
manufactur
use
collect
dose
volum
concentr
assess
pr
kit
compat
base
storag
medium
pa
plasma
assum
minimum
dose
allow
product
loss
pr
unit
ii
remov
small
quantiti
unit
excess
volum
dose
meet
pr
spec
iii
part
paramet
collect
could
divid
one
kit
pr
elig
part
undergo
pr
remaind
treat
convent
iv
collect
unsuit
pr
spec
would
decreas
sr
treat
would
count
convent
pc
resultsfind
conclus
blood
center
today
adopt
pr
signific
percent
current
suppli
high
without
affect
sr
compat
increas
divid
larg
donat
percent
achiev
depend
current
proport
collect
practic
chang
collect
paramet
optim
donat
count
accuraci
volum
reduct
improv
pr
compat
individu
analysi
warrant
blood
center
backgroundcas
studi
hemostat
agent
thrombosom
treat
uncontrol
hemorrhag
develop
freez
dri
platelet
thrombocytopen
rabbit
thrombosom
produc
rapid
hemostasi
ear
bleed
model
decreas
blood
loss
canin
cabg
model
safeti
thrombogen
lack
immunogen
demonstr
three
speci
new
zealand
white
rabbit
canin
nonhuman
primat
prior
studi
autolog
thrombosom
normal
subject
studi
designmethod
random
singl
blind
subject
studi
ascend
microdos
autolog
thrombosom
conduct
subject
divid
cohort
receiv
increas
dose
rang
lowest
effect
dose
found
rabbit
model
cohort
receiv
dose
cohort
receiv
two
dose
one
hour
apart
primari
end
point
safeti
toler
subject
monitor
post
infus
follow
day
advers
event
global
neurolog
assess
abbrevi
physic
exam
laboratori
test
resultsfind
seriou
advers
event
sae
subject
discontinu
due
signific
decreas
platelet
count
baselin
total
ae
treatment
emerg
teae
thrombosom
control
teae
mild
moder
sever
cohort
thrombosom
subject
treatment
relat
advers
eventson
cohort
subject
develop
upper
respiratori
infect
elev
wbc
within
hour
post
infus
resolv
hour
elev
hour
post
infus
resolv
day
subject
also
elev
prothrombin
fragment
baselin
increas
post
transfus
peak
hour
resolut
day
cohort
subject
develop
chang
hour
follow
infus
resolv
day
without
clinic
symptom
troponin
level
echo
stress
test
normal
ekg
consid
possibl
normal
variant
relat
placement
ekg
leadsanoth
cohort
subject
develop
igg
platelet
autoantibodi
day
undetect
day
chang
platelet
count
thrombosom
autoantibodi
assay
posit
baselin
day
neg
day
conclus
autolog
thrombosom
show
accept
safeti
toler
dose
expect
hemostat
effect
dose
howev
two
highest
dose
subject
experienc
relat
teae
without
clinic
consequ
continu
dose
escal
perform
bleed
patient
may
receiv
benefit
product
studi
fund
barda
contract
evalu
lyophil
hemostat
product
jame
michael
grantham
c
ashley
colbi
robbi
k
todd
michael
g
andrew
p
armi
institut
surgic
research
fort
sam
houston
san
antonio
tx
inc
rockvil
md
backgroundcas
studi
current
limit
platelet
shelf
life
day
led
increasingli
greater
demand
hemostat
agent
greater
longev
previou
work
correl
critic
link
platelet
mitochondri
function
convincingli
shown
maintain
platelet
mitochondria
shelf
life
function
platelet
extend
object
studi
evalu
function
lyophil
hemostat
product
lphp
potenti
altern
fresh
platelet
determin
mitochondri
function
play
role
hemostat
properti
product
studi
designmethod
platelet
collect
centrifug
whole
blood
healthi
donor
standard
oper
procedur
lphp
reconstitut
water
measur
includ
rotat
thromboelastometri
rotem
optic
aggregometri
flow
cytometri
thrombin
gener
potenti
evalu
calibr
autom
thrombogram
cat
mitochondri
function
assess
high
resolut
respirometri
oroboro
final
adhes
surfac
flow
assess
bioflux
resultsfind
rotem
differ
observ
maximum
clot
format
mcf
valu
intem
extem
fibtem
test
sampl
significantli
decreas
aggreg
observ
lphp
vs
platelet
agonist
mean
aggreg
rang
vs
p
agonist
flow
cytometri
measur
demonstr
signific
decreas
gpib
express
increas
phosphatidylserin
ps
express
lphp
group
compar
fresh
platelet
p
cat
assay
suggest
lphp
might
thrombogen
properti
thrombin
potenti
platelet
lphp
lagtim
shorter
min
vs
min
p
peak
thrombin
higher
vs
p
lphp
measur
mitochondri
function
use
high
resolut
respirometri
lphp
unchang
respir
media
cell
alon
bioflux
lphp
signific
adher
collagen
surfac
conclus
studi
lphp
shown
mitochondria
like
due
natur
manufactur
process
rotem
measur
reveal
lphp
impact
clot
strength
likewis
compar
platelet
lphp
display
minim
aggreg
significantli
ps
measur
activ
statu
abil
adher
collagen
surfac
flow
condit
induc
greater
thrombin
gener
suggest
could
contribut
clot
format
clinic
potenc
lphp
may
best
monitor
thrombin
gener
assay
cat
backgroundcas
studi
cryopreserv
platelet
plt
could
extend
shelf
life
day
two
year
cryopreserv
plt
cryoplt
appear
greater
vivo
hemostat
effect
plt
plt
shown
requir
protein
synthesi
capabl
certain
function
clot
signal
immun
respons
studi
design
assess
whether
reconstitut
carri
protein
synthesi
upon
thaw
short
term
storag
studi
designmethod
apheresi
plt
cryopreserv
dmso
store
thaw
unit
reconstitut
thaw
ffp
spike
either
puromycin
pm
pm
plt
store
agit
sampl
drawn
immedi
reconstitut
well
hour
assess
pm
incorpor
measur
protein
synthesi
vitro
assay
determin
platelet
activ
bind
phosphatidylserin
exposur
bind
microvesicl
count
supernat
plt
microvesicl
pmv
prepar
supernat
ultracentrifug
plt
pmv
lyse
triton
buffer
qualit
proteom
perform
sampl
follow
streptavidin
bead
resultsfind
vitro
paramet
reconstitut
subsequ
store
platelet
line
previous
publish
result
high
surfac
level
phosphatidylserin
pmv
gener
cryopreserv
count
increas
hour
storag
immunoblot
analys
plt
show
increas
pm
incorpor
hour
storag
respect
reveal
uniqu
protein
synthes
hour
storag
confirm
gtpase
protein
rhogdi
immunoblot
analys
analys
pmv
translatom
also
reveal
presenc
synthes
protein
howev
chang
throughout
storag
find
suggest
defin
panel
protein
packag
pmv
upon
freez
thaw
addit
pmv
translatom
profil
compris
smaller
subset
synthes
protein
compar
translatom
includ
protein
rhogdi
conclus
studi
demonstr
synthes
protein
upon
reconstitut
ffp
subsequ
storag
discoveri
subset
protein
pmv
suggest
encapsul
possibl
select
manner
observ
provid
novel
insight
capac
protein
synthesi
potenti
regul
protein
packag
pmv
backgroundcas
studi
room
temperatur
storag
platelet
conduc
bacteri
prolifer
contamin
unit
lead
transfus
transmit
septic
reaction
cold
temperatur
storag
could
reduc
bacteri
prolifer
cold
exposur
produc
chang
platelet
lead
rapid
clearanc
circul
chang
revers
warm
period
rewarm
cold
storag
temperatur
cycl
propos
allevi
platelet
activ
reduc
circul
studi
designmethod
conduct
clinic
trial
healthi
human
volunt
evalu
vivo
recoveri
surviv
autolog
apheresi
platelet
collect
two
differ
devic
trima
amicu
doubl
apheresi
collect
split
store
differ
condit
includ
room
temperatur
rt
cold
automat
temperatur
cycl
tc
continu
cold
cold
condit
temperatur
cycl
repeat
cycl
hour
hour
automat
control
programm
incub
end
storag
platelet
unit
radiolabel
vs
infus
autolog
donor
remain
platelet
evalu
standard
vitro
test
resultsfind
vitro
result
indic
cold
tc
platelet
reduc
metabol
storag
higher
oxygen
glucos
level
reduc
lactat
compar
rt
platelet
cold
platelet
lowest
morpholog
score
express
highest
annexin
v
bind
p
selectin
express
equival
tc
cold
higher
rt
platelet
function
respons
cold
platelet
lowest
hypoton
stress
shape
chang
aggreg
respons
tc
platelet
intermedi
result
vivo
result
differ
two
apheresi
instrument
data
present
separ
tabl
cold
store
platelet
lowest
recoveri
surviv
area
curv
temperatur
cycl
platelet
improv
recoveri
surviv
fold
greater
area
curv
compar
cold
store
platelet
howev
compar
rt
platelet
tc
platelet
lower
recoveri
surviv
fold
lower
area
curv
tabl
conclus
temperatur
cycl
cold
storag
day
produc
platelet
better
vivo
circul
kinet
continu
cold
storag
backgroundcas
studi
author
blood
bank
receiv
varianc
fda
aabb
use
cold
store
platelet
csp
shelf
life
day
group
csp
store
refriger
emerg
depart
use
support
trauma
program
use
massiv
bleed
patient
placement
csp
air
ambul
store
cooler
next
logic
step
provid
platelet
therapi
sooner
patient
studi
designmethod
eight
doubl
unit
csp
collect
use
trima
two
doubl
csp
pathogen
reduc
use
pathogen
reduct
system
half
csp
pair
subject
flat
storag
refriger
half
load
cooler
unit
ffp
unit
rbc
unit
whole
blood
three
platelet
collect
via
syring
unit
min
storag
cooler
refriger
hour
storag
function
valid
platelet
platelet
count
agonist
thrombin
receptor
agonist
peptid
trap
adenosin
diphosph
adp
collagen
stimul
platelet
aggreg
agonist
activ
platelet
surfac
express
phosphatidylserin
ps
bind
fibrinogen
receptor
bind
measur
coulter
counter
channel
aggregomet
digit
flow
cytomet
pair
wilcoxon
rank
sum
test
use
analyz
differ
degrad
rate
p
deem
signific
resultsfind
differ
slope
platelet
count
cooler
refriger
rang
platelet
aggreg
stimul
trap
adp
basal
express
platelet
surfac
ps
trap
activ
adp
activ
collagen
activ
basal
express
platelet
membran
trap
activ
adp
collagen
activ
basal
express
fibrinogen
receptor
express
trap
activ
p
conclus
platelet
includ
pathogen
reduc
store
environ
cooler
lose
function
capabl
compar
platelet
store
refriger
adequ
oxygen
hour
therefor
cold
store
platelet
transport
cooler
viabl
option
provid
timeli
platelet
intervent
sever
injur
patient
prior
hospit
arriv
backgroundcas
studi
decad
commerci
introduct
http
blood
group
genotyp
though
avail
sever
format
remain
tool
special
task
eg
profil
difficult
patient
sampl
identif
rare
antigen
combin
serolog
remain
tool
choic
routin
antigen
type
introduc
molecular
siev
altern
current
approach
manag
special
donor
unit
inventori
novel
process
dna
analysi
combin
multiplex
marker
offer
exist
genotyp
method
pool
multipl
sampl
manner
permit
step
refin
candid
set
molecular
attribut
pattern
studi
designmethod
molecular
siev
special
format
leansequenc
proprietari
process
permit
simultan
analysi
four
sampl
allel
encod
rbc
antigen
mn
rhce
lu
kel
fy
jk
di
yt
co
includ
identif
rhce
allel
molecular
siev
extend
capabl
analysi
pool
attain
larg
scale
thu
one
format
process
sampl
accommod
singl
run
follow
complet
siev
step
candid
may
directli
assign
request
may
select
enrich
subsequ
profil
step
sampl
rare
otherwis
desir
attribut
molecularsiev
use
identifi
suitabl
donor
unit
sensit
sickl
cell
anemia
sca
patient
http
exclud
le
e
variant
assum
request
per
patient
present
ab
multipl
combin
proprietari
greedi
algorithm
invok
optim
pair
candid
unit
request
resultsfind
siev
plate
hold
candid
unit
actual
black
donor
follow
profil
sampl
select
enrich
e
neg
c
neg
neg
produc
assign
request
indic
color
shown
row
assign
thu
number
assign
substanti
exceed
number
well
process
moreov
remain
pool
sampl
produc
addit
assign
second
set
request
total
assign
well
anoth
scenario
siev
full
plate
sampl
produc
assign
two
success
batch
request
sca
patient
yield
exceed
siev
alon
typic
fill
request
moder
complex
ab
conclus
molecularsiev
widen
funnel
focus
search
candid
donor
unit
attain
new
level
effici
procur
suitabl
unit
patient
hemoglobinopathi
backgroundcas
studi
provid
transfus
support
patient
sickl
cell
anemia
hemoglobinopathi
remain
challeng
logist
task
must
accommod
multipl
combin
prefer
minim
risk
continu
sensit
allel
divers
predominantli
black
patient
popul
especi
rh
locu
encod
varieti
partial
phenotyp
complic
problem
http
studi
designmethod
molecular
siev
proprietari
new
process
order
rapidli
probe
candid
donor
unit
larg
number
multipl
phenotyp
pattern
permit
analysi
pool
pool
pool
sampl
multipl
allel
includ
rhce
locu
encod
mn
rh
lu
kel
fy
jk
di
yt
co
antigen
base
siev
sampl
may
group
molecular
attribut
pattern
rang
singl
eg
specif
combin
eg
combin
allel
encod
partial
rh
phenotyp
siev
option
may
follow
profil
sampl
select
desir
attribut
pattern
genom
dna
predominantli
black
donor
independ
genotyp
one
two
commerci
method
provid
lbc
bmx
pool
prepar
prior
amplif
analyz
novel
leansequenc
method
resultsfind
pool
genotyp
consist
avail
individu
sampl
genotyp
antigen
pattern
particular
interest
includ
two
group
name
sever
pool
homozyg
certain
other
pool
heterozyg
illustr
former
pattern
type
appropri
pool
queri
reveal
siev
alon
identifi
among
sampl
also
among
sampl
also
neg
partial
phenotyp
illustr
latter
pattern
type
pool
identifi
heterozyg
het
allel
encod
antigen
high
low
preval
segreg
het
pool
subpopul
abl
select
specif
ee
pool
demonstr
subsequ
profil
contain
sampl
also
identifi
pool
het
allel
indic
possibl
presenc
rare
donor
exampl
ytab
pool
co
ab
other
conclus
molecularsiev
singl
plate
identifi
mani
desir
phenotyp
permit
select
pool
combin
pattern
includ
partial
rh
phenotyp
combin
sampl
thu
confirm
ag
neg
avail
assign
siev
also
facilit
enrich
subsequ
refin
molecular
attribut
profil
accord
pend
anticip
demand
backgroundcas
studi
sequenc
inform
gener
next
gener
sequenc
ng
often
comput
phase
use
algorithm
util
experiment
deriv
haplotyp
inform
improv
predict
routin
use
hla
type
among
blood
group
system
howev
experiment
deriv
haplotyp
known
short
gene
duffi
longer
gene
abo
kb
haplotyp
statist
deriv
recent
establish
larg
dataset
long
ermap
haplotyp
code
scianna
blood
group
system
studi
designmethod
nucleotid
sequenc
kb
use
physic
confirm
ermap
allel
previous
publish
sequenc
align
variant
site
extract
manual
bayesian
coalesc
algorithm
implement
beast
use
estim
coalesc
phylogeni
variant
allel
ancestr
state
intern
node
phylogeni
resultsfind
found
least
clade
repres
cluster
allel
clade
one
observ
allel
identifi
ancestr
allel
cluster
allel
use
allel
abl
predict
allel
high
posterior
probabl
ancestr
observ
allel
yet
observ
may
extant
conclus
explor
phylogenet
structur
evolutionari
event
underli
origin
differ
ermap
allel
predict
ancestr
allel
present
studi
show
mean
predict
allel
calcul
distinct
probabl
correct
predict
allel
probabl
instrument
defin
valu
determin
comput
predict
allel
worth
confirm
physic
evid
allel
identifi
studi
like
may
util
design
microarray
technolog
imput
genotyp
map
ng
data
backgroundcas
studi
use
dna
determin
abo
increas
sampl
collect
organ
bone
marrow
transplant
registri
often
involv
buccal
swab
blood
sampl
ashi
cap
recent
releas
guidelin
allow
genet
abo
determin
screen
tool
initi
donor
evalu
list
donor
registri
addit
next
gener
sequenc
ng
becom
widespread
bioinformat
tool
develop
attempt
translat
ng
abo
type
document
novel
allel
importantli
actual
associ
serolog
phenotyp
encod
abo
variant
critic
accur
interpret
investig
three
case
refer
determin
repres
group
subgroup
b
phenotyp
studi
designmethod
serolog
test
perform
standard
tube
agglutin
genom
dna
wbc
use
duplex
vox
sang
sequenc
analysi
perform
abo
exon
resultsfind
donor
rbc
autom
test
tube
test
react
vw
mix
field
b
lectin
plasma
b
cell
result
suggest
subgroup
indic
allel
sequenc
confirm
abo
identifi
allel
nucleotid
g
insert
exon
caus
frameshift
prematur
stop
codon
patient
pregnant
femal
whose
rbc
vw
b
incub
plasma
b
cell
suggest
subgroup
b
result
indic
abo
bb
sequenc
confirm
exon
identifi
homozyg
insert
intron
splice
site
predict
caus
defect
splice
patient
rbc
lectin
w
b
plasma
b
cell
suggest
subgroup
indic
allel
sequenc
confirm
abo
identifi
allel
chang
c
conclus
report
three
new
allel
abo
abo
c
abo
b
splice
defect
none
chang
found
dbsnp
new
allel
nucleotid
insert
would
predict
caus
complet
loss
express
correspond
antigen
bioinformat
perspect
encod
group
rather
weak
express
respect
antigen
lack
correspond
antibodi
plasma
found
confirm
repres
subgroup
b
suggest
transcript
slippag
observ
respons
low
level
antigen
express
abo
genotyp
power
serolog
molecular
result
evalu
togeth
studi
need
inform
develop
bioinformat
tool
accur
associ
abo
genotyp
phenotyp
backgroundcas
studi
evolutionarili
relat
abo
gene
encod
b
glycosyltransferas
bt
forssman
glycolipid
synthas
fs
catalyz
biosynthesi
b
forssman
oligosaccharid
antigen
respons
abo
for
blood
group
system
respect
human
bt
possess
leuglygli
metglyala
respect
codon
tripeptid
import
determin
sugar
specif
enzym
galnac
galactos
bt
function
fss
possess
glyglyala
correspond
codon
exhibit
galnac
specif
recent
shown
human
gain
weak
fs
activ
leuglygli
substitut
glyglyala
suggest
tripeptid
involv
recognitionbind
acceptor
substrat
addit
donor
substrat
studi
designmethod
search
addit
mechan
might
enabl
human
express
varieti
amino
acid
substitut
construct
human
prepar
addit
exon
delet
construct
mrna
transcript
also
prepar
dna
express
construct
transfect
cell
express
antigen
immunolog
monitor
monoclon
antibodi
resultsfind
found
substitut
also
confer
human
weak
fs
activ
also
found
delet
exon
human
transcript
bestow
weak
fs
activ
alter
rna
splice
frequent
cancer
mechan
may
explain
least
partial
appear
antigen
certain
cancer
cell
tumor
forssman
human
speci
furthermor
one
chang
togeth
glyglyala
substitut
synergist
confer
strong
fs
activ
addit
strong
bt
activ
conclus
substitut
glyglyala
tripeptid
codon
catalyt
domain
may
modifi
acceptor
specif
enzym
exon
delet
may
alter
local
enzym
mechan
function
synergi
overlap
usag
acceptor
glycosyltransferas
encod
abo
gene
reminisc
common
ancestr
origin
alpha
nac
transferas
gene
find
synthes
implic
boundari
abo
for
system
may
strict
previous
delin
due
crosstalk
backgroundcas
studi
abo
blood
group
antigen
prime
import
transfus
medicin
test
fda
licens
assay
requir
donor
hpc
cord
blood
cb
product
hand
select
base
abo
compat
patient
aborh
type
requir
fda
factaabb
ident
test
sinc
antibodi
cb
plasma
matern
origin
aborh
phenotyp
reli
red
cell
type
b
antigen
fulli
develop
birth
present
one
third
b
antigen
express
level
compar
adult
cell
result
indetermin
abo
result
cb
product
evalu
use
method
abo
type
aid
resolut
inconclus
indetermin
discrep
serolog
type
result
studi
designmethod
total
cb
unit
cbu
type
aborh
beckman
coulter
pk
system
blood
group
phenotyp
period
abo
genotyp
target
specif
snp
group
b
need
gene
sequenc
conduct
case
indetermin
result
cbu
provid
transplant
abo
discrep
found
transplant
center
resultsfind
cb
sampl
report
aborh
phenotyp
initi
test
therefor
cbu
could
use
clinic
molecular
aborh
type
resolv
one
case
heterozyg
ao
bo
ab
predict
abo
phenotyp
rh
neg
tabl
predomin
donor
race
caucasian
four
cbu
abo
discrep
also
evalu
genotyp
tabl
abo
type
perform
hospit
day
transplant
differ
report
cb
bank
fourth
identifi
abo
type
recipi
molecular
genotyp
resolv
discrep
cbu
ident
alway
verifi
confirmatori
hla
type
conclus
current
fda
approv
abo
assay
howev
abo
genotyp
use
method
sampl
antibodi
test
alon
conclus
rescu
cbu
could
use
otherwis
genotyp
help
resolv
abo
discrep
backgroundcas
studi
hepat
e
viru
hev
small
rna
viru
worldwid
distribut
recent
report
transfus
transmit
hev
outsid
us
increas
immunocompromis
transfus
recipi
ie
transplant
patient
hematolog
patient
particular
vulner
complic
tt
hev
four
major
genotyp
exist
hev
genotyp
genotyp
current
identifi
caus
autochthon
infect
us
hev
use
system
qualit
pcr
test
detect
hev
rna
human
plasma
purpos
studi
evalu
preval
hev
rna
among
us
blood
donat
collect
midwest
region
report
higher
preval
hev
infect
eastern
us
studi
designmethod
fresh
frozen
edta
plasma
sampl
american
red
cross
donor
collect
februari
screen
individu
donat
test
use
hev
use
system
research
protocol
sampl
primarili
midwestern
eastern
region
us
sampl
reactiv
hev
test
altern
hev
nat
hev
rna
quantit
hev
genotyp
hev
antibodi
resultsfind
valid
result
total
donat
reactiv
hev
confirm
posit
confirm
donat
old
male
indiana
old
male
california
old
femal
kentucki
donat
posit
pcr
altern
hev
nat
howev
kentucki
donat
high
level
hev
rna
iuml
strongli
posit
igm
igg
hev
antibodi
indiana
donat
genotyp
california
donat
genotyp
genotyp
determin
kentucki
donat
see
tabl
clinic
specif
hev
test
exact
ci
conclus
base
donat
test
hev
preval
exact
ci
detect
rate
ci
date
case
document
us
howev
base
preval
observ
immunosuppress
transfus
recipi
may
increas
risk
hev
backgroundcas
studi
monitor
epidemiolog
tti
within
donor
popul
critic
provid
ongo
assess
infect
risk
associ
fda
polici
chang
msm
deferr
criteria
ttim
program
intend
deriv
hbv
hcv
hiv
preval
incid
viral
genotyp
donor
risk
factor
greater
blood
collect
us
ttim
support
two
distinct
coordin
center
laboratori
risk
factor
lrcc
donat
databas
ddcc
report
month
preval
along
demograph
trend
ddcc
studi
designmethod
four
blood
provid
respect
test
laboratori
particip
standard
cp
monitor
definit
establish
donor
test
result
hbv
hcv
hiv
result
along
demograph
donor
donat
statu
vs
repeat
assembl
singl
data
set
rate
nucleic
acid
test
nat
yield
seroneg
concord
posit
serolog
plu
nat
posit
combin
compris
cp
comput
overal
donor
donat
demograph
geograph
tempor
characterist
appropri
rate
compar
differ
use
confid
interv
analysi
contain
data
resultsfind
among
donat
report
repeat
donor
respect
cp
result
hbv
hcv
hiv
correspond
rate
per
pht
donat
preval
among
donor
expect
higher
among
donat
repeat
donor
ratio
hbv
hcv
hiv
rate
pht
among
male
higher
among
femal
marker
hbv
vs
hcv
vs
hiv
vs
gener
higher
rate
marker
seen
among
minor
donor
age
group
also
year
hiv
southeast
south
central
hiv
hcv
southwest
hbv
trend
note
time
period
compar
conclus
data
major
us
blood
system
success
combin
baselin
monitor
purpos
demograph
trend
similar
observ
donor
studi
gener
agre
commun
trend
chang
rate
requir
analys
context
potenti
chang
demograph
structur
donor
popul
backgroundcas
studi
babesia
assay
procleix
system
qualit
vitro
nucleic
acid
test
current
develop
assay
base
amplif
tma
detect
four
clinic
relev
babesia
speci
b
microti
b
divergen
b
duncani
b
venatorum
human
whole
blood
specimen
test
intend
screen
blood
donat
individu
pool
donat
whole
blood
sampl
lyse
pool
autom
procleix
system
prior
test
procleix
panther
system
studi
evalu
preliminari
analyt
clinic
perform
procleix
babesia
assay
panther
system
studi
designmethod
analyt
sensit
determin
dilut
vitro
synthes
rna
transcript
four
babesia
speci
fresh
b
hamster
whole
blood
cryopreserv
b
hamster
whole
blood
fresh
b
human
erythrocyt
test
determin
limit
detect
lod
parasitesml
pml
probit
analysi
clinic
sensit
specif
determin
screen
unlink
whole
blood
donat
collect
august
april
northeastern
unit
state
initi
reactiv
donat
confirm
repeat
test
pcr
andor
igg
immunofluoresc
assay
ifa
reactiv
individu
donor
lysat
test
pool
resultsfind
procleix
babesia
assay
detect
four
babesia
speci
lod
rang
copiesml
preliminari
lod
parasitesml
rang
pml
b
microti
pml
b
duncani
pml
b
divergen
donat
screen
initi
reactiv
confirm
posit
donat
identifi
specif
ci
confirm
posit
specimen
reactiv
ifa
pcr
ifa
pcr
confirm
posit
sampl
reactiv
lysat
pool
donor
reactiv
donat
resid
ct
nj
nh
overal
incid
ct
conclus
procleix
babesia
assay
procleix
panther
system
demonstr
high
clinic
specif
sensit
detect
four
babesia
speci
similar
sensit
confirm
posit
donat
also
detect
pool
thu
demonstr
effect
pool
lysat
screen
backgroundcas
studi
donat
test
hiv
seroneg
nat
yield
reflect
hiv
infect
like
period
donat
rare
make
difficult
assess
statist
associ
limit
antigen
avid
lag
avid
assay
use
estim
proport
donor
seroconvert
four
month
donat
object
studi
determin
proport
donor
recent
infect
assess
demograph
factor
associ
infect
us
donor
studi
designmethod
four
larg
blood
collect
organ
provid
plasma
sampl
index
donat
confirm
nat
antibodi
posit
routin
test
sampl
test
use
sedia
bioscienc
lag
avid
assay
mean
durat
recent
infect
mdri
day
month
ci
day
base
product
insert
recommend
normal
optic
densiti
odn
sampl
odn
valu
retest
mean
odn
valu
use
associ
demograph
donat
characterist
interdon
interv
idi
repeat
donor
assess
compar
recent
hiv
infect
group
resultsfind
total
confirm
hiv
donor
plasma
sampl
test
classifi
infect
proport
donor
recent
infect
vari
across
seven
year
younger
donor
independ
repeat
donor
like
recent
infect
p
case
would
expect
repeat
donor
shorter
idi
donat
like
hiv
infect
recent
acquir
p
trend
recent
infect
younger
repeat
donor
notabl
tabl
sex
raceethn
group
significantli
associ
recent
infect
conclus
use
lag
avid
assay
show
repeat
us
blood
donor
ie
incid
hiv
infect
frequent
younger
donor
use
approach
provid
addit
monitor
tool
assess
chang
characterist
donor
whose
risk
exposur
proxim
date
donat
also
complement
tradit
incid
method
allow
deriv
incid
donor
type
backgroundcas
studi
preval
hbv
hcv
us
blood
donor
decreas
hiv
rate
remain
constant
howev
incid
recent
calcul
report
preval
incid
residu
risk
rr
hbv
hcv
hiv
larg
us
blood
system
studi
designmethod
preval
calcul
interv
incid
measur
number
posit
among
repeat
donor
divid
total
time
risk
py
rr
calcul
use
window
period
day
hbv
hcv
hiv
respect
linear
regress
calcul
p
signific
resultsfind
million
donat
donor
femal
ft
caucasian
signific
decreas
donat
preval
hbv
hcv
signific
decreas
hiv
year
see
tabl
f
valu
signific
decreas
seen
ft
donor
preval
hbv
hcv
preval
ft
donor
significantli
like
male
hbv
hcv
hiv
p
incid
agent
declin
signific
hbv
decreas
hcv
incid
signific
fewer
incid
donor
last
period
vs
hcv
incid
donor
like
male
vs
p
younger
vs
year
overal
incid
donor
like
caucasian
male
p
rr
agent
decreas
time
rr
hbv
hcv
hiv
respect
conclus
preval
incid
rr
hbv
hcv
hiv
gener
decreas
within
blood
system
time
frame
donor
screen
deferr
regul
evolv
import
monitor
risk
critic
note
even
larg
popul
small
chang
number
posit
signific
impact
preval
incid
rate
tabl
preval
incid
rate
backgroundcas
studi
mayaro
viru
mayv
member
genu
alphaviru
famili
togavirida
similar
alphavirus
chikungunya
viru
chikv
ross
river
viru
rrv
mayv
infect
result
sever
arthralgia
debilit
joint
pain
sinc
identif
viru
caus
rel
small
sporad
outbreak
across
rural
area
south
america
mayv
spread
primarili
via
forest
mosquito
aed
aegypti
aed
albopictu
mayv
outbreak
spread
larg
citi
south
america
indic
shift
rural
urban
transmiss
addit
two
travel
return
franc
netherland
evid
mayv
infect
highlight
global
concern
furthermor
mayv
isol
patient
haiti
suggest
viru
alreadi
circul
caribbean
extent
mayv
transmiss
could
underestim
due
limit
surveil
diagnost
capabl
therefor
necessari
prepar
mayv
emerg
potenti
risk
blood
suppli
case
transmit
blood
transfus
studi
designmethod
platelet
compon
pc
prepar
pa
spike
mayv
treat
amotosalen
uva
illumin
sampl
collect
illumin
infecti
titer
determin
rbc
spike
mayv
mix
glutathion
gsh
process
solut
dose
amustalin
incub
room
temperatur
sampl
collect
prior
addit
amustalin
follow
incub
determin
infecti
titer
infecti
titer
sampl
determin
plaqu
assay
cell
extent
inactiv
determin
compar
infecti
titer
plaqu
form
unit
pfu
ml
vs
sampl
resultsfind
mayv
inactiv
limit
detect
pc
rbc
platelet
pfuml
inactiv
mayv
achiev
rbc
inactiv
mayv
pfuml
conclus
studi
demonstr
robust
inactiv
mayv
amotosalenuva
treatment
pc
amustalinegsh
treatment
rbc
system
effici
inactiv
alphavirus
demonstr
potenti
includ
mayv
chikv
rrv
prt
offer
potenti
mitig
strategi
maintain
blood
compon
avail
area
multipl
alphavirus
epidem
endem
test
feasibl
data
submit
fda
review
intercept
red
blood
cell
approv
commerci
use
backgroundcas
studi
thrombot
thrombocytopen
purpura
consumpt
thrombocytopenia
microangiopath
hemolyt
anemia
caus
diffus
ischem
damag
tissu
earli
therapeut
plasma
exchang
tpe
initi
improv
surviv
absolut
immatur
platelet
count
found
aid
diagnosi
ttp
patient
chang
respons
therapi
patient
low
activ
high
inhibitor
analyz
patient
cohort
analyz
respons
therapi
five
patient
defici
high
inhibitor
larg
tertiari
academ
medic
center
studi
designmethod
patient
activ
high
inhibitor
mean
age
cohort
year
rang
four
patient
femal
one
male
patient
present
microangiopath
hemolyt
anemia
thrombocytopenia
mean
x
rang
x
low
mean
x
rang
x
patient
initi
daili
tpe
prednison
addit
immunosuppress
hospit
stay
cohort
consist
rituximab
patient
cyclophosphamid
one
patient
tpe
continu
platelet
count
reach
x
least
two
consecut
day
immatur
platelet
fraction
x
platelet
count
obtain
daili
cbc
ratio
calcul
baselin
resultsfind
patient
respond
rapidli
daili
tpe
mean
day
rang
day
achiev
increas
baselin
mean
x
rang
x
rapid
improv
platelet
count
howev
improv
platelet
count
accompani
expect
decreas
suggest
recoveri
diseas
patient
experienc
platelet
mean
x
rang
x
mean
x
rang
x
decreas
occur
concurr
receiv
daili
tpe
mean
day
rang
day
mean
platelet
count
x
rang
x
mean
x
rang
x
patient
initi
either
rituximab
cyclophosphamid
therapi
conjunct
tpe
mean
day
platelet
count
instabl
trend
level
indic
restor
neg
feedback
time
conclus
rapid
decreas
platelet
count
good
respons
ttp
patient
may
rais
suspicion
presenc
high
inhibitor
patient
high
inhibitor
similar
dynam
initi
high
product
follow
unexpect
decreas
concurr
platelet
count
recoveri
occur
neg
feedback
platelet
product
patient
high
inhibitor
may
repres
distinct
subset
ttp
suggest
respons
backgroundcas
studi
consensu
guidelin
recommend
therapeut
plasma
exchang
tpe
must
start
earli
possibl
within
hour
diagnosi
thrombot
thrombocytopen
purpura
ttp
made
howev
limit
data
document
actual
practic
sever
oper
facet
deliv
central
urgent
tpe
program
healthcar
system
includ
central
venou
cv
access
order
releas
deliveri
thaw
plasma
transport
personnel
equip
perform
procedur
studi
analyz
time
elaps
major
step
diagnosi
initi
tpe
patient
admit
ttp
studi
designmethod
retrospect
review
electron
medic
record
laboratori
inform
system
januari
novemb
conduct
identifi
ttp
patient
undergo
urgent
tpe
demograph
comorbid
pertin
laboratori
test
activ
level
complet
blood
count
biochem
marker
hemolysi
coagul
studi
review
identifi
patient
data
tpe
request
cv
access
placement
plasma
product
releas
usual
happen
cv
access
arriv
tpe
team
initi
procedur
extract
procedur
note
blood
bank
inform
system
descript
summari
statist
gener
use
stata
version
statacorp
tx
group
comparison
made
base
hospit
locat
level
care
histori
ttp
use
wilcoxon
test
resultsfind
ttp
patient
identifi
exclud
due
miss
tempor
data
import
variabl
major
patient
treat
central
academ
center
remaind
treat
peripher
site
fifteen
patient
prior
histori
ttp
sever
defici
admiss
median
time
tpe
request
initi
hour
interquartil
rang
hour
trend
shorter
time
interv
request
cv
access
request
tpe
initi
patient
admit
intens
care
unit
icu
versu
patient
tabl
treatment
start
within
window
patient
median
time
cv
access
significantli
longer
patient
vs
hour
p
two
patient
prior
histori
ttp
four
patient
sever
defici
major
time
interv
tpe
request
tpe
initi
spent
obtain
cv
access
plasma
product
signific
differ
time
interv
compar
patient
new
diagnosi
ttp
versu
patient
recurr
relaps
diseas
tabl
patient
treat
central
academ
center
versu
peripher
hospit
conclus
consensu
hour
target
window
tpe
request
initi
appear
feasibl
central
tpe
program
servic
healthcar
system
address
limit
avail
cv
access
would
like
yield
greatest
improv
timeli
urgent
tpe
backgroundcas
studi
sever
retrospect
case
seri
suggest
cytoreduct
therapi
treat
cellular
hyperviscos
prevent
thrombot
event
patient
pt
chronic
myelogen
leukemia
acceler
transform
essenti
thrombocythemia
et
may
improv
outcom
howev
random
control
trial
rct
assess
efficaci
cytapheresi
treatment
group
pt
perform
studi
designmethod
januari
januari
perform
cytapheresi
cy
treatment
tx
pt
either
et
clinic
andor
laboratori
evid
cellular
hyperviscos
pt
receiv
leukapheresi
lp
tx
pt
et
receiv
thrombocytapheresi
tc
tx
pt
present
median
wbc
x
rang
x
blast
percent
blast
count
x
median
age
year
year
male
cn
symptom
sx
leukostasi
lk
defin
headach
cognit
declin
confus
somnol
visual
abnorm
seizur
pulmonari
pulm
sx
lk
defin
dyspnea
hypoxia
bilater
chest
infiltr
pt
sx
lk
pt
sx
either
cn
pulm
lk
sx
pt
sx
cn
pulm
lk
sx
et
pt
present
median
platelet
plt
count
x
x
pt
sx
thrombosi
evid
cva
tia
mi
dvt
median
age
year
year
pt
male
resultsfind
pt
receiv
cours
cy
tx
follow
object
decreas
risk
thrombot
hemorrhag
complic
relat
hyperviscos
stabil
pt
induct
chemotherapi
ind
chemo
wbc
plt
ct
tx
goal
wbc
count
ct
x
pt
plt
ct
x
symptomat
et
pt
x
asymptomat
et
pt
pt
receiv
median
lp
tx
mean
txspt
rang
tx
et
pt
underw
median
tc
tx
mean
txspt
tx
outcom
evalu
percentag
pt
reach
wbc
plt
ct
tx
goal
receiv
ind
chemo
improv
outcom
defin
pt
reach
wbc
plt
ct
tx
goal
cy
tx
stabil
pt
achiev
reduct
wbc
plt
ct
without
reach
goal
unchang
pt
achiev
neither
cohort
pt
improv
pt
stabil
pt
worsen
et
cohort
improv
stabil
unchang
pt
median
final
wbc
ct
x
rang
x
pt
receiv
ind
chemo
et
pt
median
final
plt
ct
x
x
pt
resolut
thrombot
symptom
pt
et
pt
expir
within
day
cours
cy
tx
expir
pt
pt
blast
crisi
sx
cnspulm
lk
pt
intracrani
hemorrhag
cva
pt
hypotens
intub
unabl
toler
ind
chemo
conclus
pt
et
evid
impend
thrombosi
may
benefit
cytoreduct
therapi
limit
number
cytapheresi
treatment
median
tx
enabl
high
percentag
pt
receiv
definit
treatment
may
improv
clinic
outcom
rct
assess
efficaci
cytapheresi
treatment
versu
induct
chemotherapi
platelet
inhibitor
tx
alon
subset
pt
would
use
backgroundcas
studi
partial
normal
salin
replac
plasma
exchang
procedur
common
practic
benefit
use
normal
salin
replac
fluid
includ
reduc
procedur
cost
possibl
reduct
hypothet
effect
standard
albumin
formul
howev
use
normal
salin
may
increas
risk
undesir
potenti
costli
advers
event
hypotens
citrat
reaction
goal
studi
compar
frequenc
report
advers
outcom
patient
receiv
albumin
versu
albuminsalin
replac
fluid
plasma
exchang
institut
studi
designmethod
four
year
retrospect
chart
review
done
therapeut
apheresi
procedur
perform
apheresi
servic
use
albumin
normal
salin
replac
patient
receiv
plasma
entir
partial
replac
exclud
procedur
type
order
albumin
vs
percent
normal
salin
actual
use
procedur
age
gender
note
advers
event
procedur
record
case
repeat
procedur
model
use
gener
linear
mix
model
examin
risk
hypotens
andor
citrat
toxic
albumin
use
versu
use
covari
includ
fluid
type
age
gender
odd
ratio
confid
interv
ci
use
measur
risk
use
term
signific
resultsfind
studi
period
procedur
document
subject
femal
age
rang
year
receiv
type
fluid
use
replac
signific
effect
risk
either
hypotens
citrat
toxic
replac
albumin
significantli
lower
risk
either
event
use
ci
also
significantli
lower
risk
caus
hypotens
ci
addit
lower
risk
caus
citrat
toxic
ci
age
signific
effect
hypotens
event
ci
effect
citrat
toxic
combin
outcom
gender
effect
frequenc
event
conclus
partial
salin
use
replac
fluid
albumin
plasma
exchang
significantli
increas
risk
hypotens
citrat
toxic
procedur
age
also
increas
risk
hypotens
use
salin
replac
fluid
plasma
exchang
minim
maxim
patient
safeti
especi
older
patient
backgroundcas
studi
therapeut
apheresi
ta
complex
procedur
mostli
rare
associ
advers
event
ae
studi
publish
ae
associ
ta
lack
uniform
data
moreov
common
databas
unit
state
us
report
ae
evalu
annual
incid
rate
ae
associ
ta
larg
tertiari
academ
medic
center
year
period
compar
publish
literatur
studi
designmethod
conduct
retrospect
studi
ta
procedur
perform
ae
classifi
accord
criteria
describ
tabl
studi
period
ta
perform
use
cobe
spectra
softwar
version
sinc
spectra
optia
apheresi
system
version
literatur
search
conduct
data
publish
ae
associ
ta
four
studi
us
studi
canada
europ
japan
analyz
trend
ae
rate
also
analyz
statist
analysi
perform
use
chi
squar
spearman
rho
test
resultsfind
overal
ae
incid
procedur
year
period
frequenc
ae
associ
therapeut
plasma
exchang
tpe
significantli
higher
p
compar
ta
procedur
found
signific
correl
number
tpe
ae
spearman
rho
year
signific
trend
moder
sever
ae
spearman
rho
respect
fatal
studi
period
major
ae
grade
grade
ii
procedur
complet
due
ae
comparison
ae
european
us
studi
show
statist
signific
differ
p
conclus
overal
incid
ae
significantli
lower
current
publish
literatur
incid
ae
publish
countri
significantli
lower
rate
publish
us
differ
incid
ae
literatur
emphas
need
uniform
report
stratif
ae
develop
common
databas
report
ae
propos
grade
rational
order
standard
report
ae
tabl
tabl
backgroundcas
studi
plateletpheresi
associ
variat
biochem
marker
bone
turnov
factor
lifestyl
behavior
recogn
factor
influenc
miner
metabol
bone
health
present
studi
analyz
influenc
demograph
lifestyl
factor
observ
chang
bone
marker
larg
cohort
routin
platelet
donor
studi
designmethod
altogeth
platelet
donor
donat
activ
platelet
donat
particip
studi
detail
anamnesi
particip
underw
standard
question
ask
sever
lifestyl
factor
known
affect
bone
metabol
blood
sampl
plateletpheresi
analyz
bone
format
marker
osteocalcin
oc
bone
resorpt
marker
telopeptid
type
collagen
ctx
among
paramet
effect
calcium
supplement
bone
metabol
test
crossov
studi
involv
ten
donor
resultsfind
plateletpheresi
result
increas
serum
level
bone
resorpt
marker
ctx
bone
format
marker
oc
paramet
return
base
level
within
hour
end
collect
multipl
regress
analysi
includ
paramet
sex
age
posit
famili
histori
bone
diseas
also
individu
factor
like
hormon
contracept
smoke
regular
alcohol
consumpt
sportiv
activ
reveal
influenc
lifestyl
factor
observ
variat
ctx
oc
associ
individu
donor
career
number
previou
donat
observ
increas
bone
turnov
predict
paramet
could
identifi
amount
citrat
exposur
plateletpheresi
increas
serum
ctx
show
invers
correl
chang
serum
ioniz
calcium
continu
iv
supplement
throughout
plateletpheresi
reduc
variat
bone
marker
although
effect
pronounc
ctx
compar
oc
conclus
amount
citrat
infus
routin
plateletpheresi
predict
paramet
transient
increas
serum
marker
bone
metabol
known
risk
factor
bone
diseas
includ
sex
age
smoke
alcohol
consumpt
seem
low
impact
observ
variat
serolog
biomark
bone
turnov
backgroundcas
studi
transfus
associ
nosocomi
infect
organ
dysfunct
trauma
patient
may
mediat
solubl
bioactiv
substanc
blood
product
hypothes
remov
bioactiv
substanc
improv
host
immun
respons
reduc
organ
dysfunct
studi
designmethod
blood
product
prepar
syngen
rat
blood
accord
blood
bank
standard
solubl
mediat
remov
red
blood
cell
day
old
platelet
day
old
wash
plasma
filter
filter
rat
gram
crush
injuri
small
intestin
liver
lobe
fractur
right
femur
hemorrhag
estim
blood
volum
calcul
hemorrhag
continu
mean
arteri
pressur
reach
rat
random
resuscit
standard
blood
product
washedfilt
blood
product
sham
blood
sampl
taken
trauma
assess
biochemistri
coagul
statu
ex
vivo
whole
blood
stimul
test
lp
perform
sacrific
organ
damag
assess
histopatholog
blood
product
sampl
assess
biochem
chang
comparison
group
done
anova
dunnett
multipl
comparison
resultsfind
filter
wash
blood
product
significantli
stabil
ph
sodium
potassium
concentr
decreas
lactat
level
product
compar
standard
product
resuscit
group
receiv
averag
blood
product
ratio
howev
use
washedfilt
product
improv
organ
failur
assess
histopatholog
score
level
creatinin
asat
alat
coagul
statu
assess
thromboelastometri
derang
group
normal
transfus
show
signific
differ
washedfilt
product
standard
care
immun
respons
lp
decreas
follow
trauma
compar
healthi
control
differ
group
conclus
filter
wash
blood
product
reduc
aspect
storag
lesion
blood
product
without
affect
hemostat
capac
product
improv
organ
injuri
rat
trauma
transfus
model
improv
immunosuppress
host
respons
result
suggest
wash
filter
blood
product
may
relev
clinic
effect
rat
polytrauma
model
backgroundcas
studi
tranexam
acid
txa
antifibrinolyt
agent
wide
use
cardiovascular
surgeri
sinc
sever
studi
shown
prophylact
use
txa
effect
reduc
blood
loss
cardiovascular
surgeri
howev
concern
risk
thromboembol
event
advers
neurolog
effect
seizur
might
worsen
patient
outcom
consequ
stop
use
txa
april
enabl
us
conduct
studi
present
studi
aim
examin
associ
txa
advers
effect
seizur
thromboembol
renal
dysfunct
patient
undergo
cardiovascular
surgeri
use
propens
score
match
model
also
assess
associ
txa
clinic
outcom
reoper
bleed
transfus
volum
blood
loss
ventil
time
intens
care
unit
stay
mortal
studi
designmethod
singl
center
retrospect
cohort
studi
involv
patient
underw
cardiovascular
surgeri
cardiopulmonari
bypass
coronari
arteri
bypass
graft
januari
juli
miss
data
patient
characterist
patient
exclud
incid
advers
effect
associ
txa
clinic
outcom
evalu
januari
march
april
juli
use
propens
score
model
estim
propens
score
use
logist
regress
model
txa
use
function
baselin
variabl
gener
pair
patient
receiv
receiv
txa
also
evalu
advers
effect
txa
use
segment
regress
analysi
resultsfind
analysi
show
seizur
common
vs
p
ventil
time
longer
vs
significantli
txa
group
group
contrast
transfus
volum
blood
loss
significantli
lower
txa
group
group
vs
vs
p
respect
howev
mortal
statist
differ
group
vs
none
outcom
significantli
differ
segment
regress
analysi
yield
similar
result
conclus
even
though
txa
may
associ
increas
rate
seizur
longer
ventil
time
increas
mortal
use
txa
significantli
associ
decreas
blood
loss
transfus
volum
provid
social
benefit
reduc
need
blood
transfus
suppli
blood
compon
limit
age
japanes
societi
seem
advantag
use
txa
decreas
blood
loss
transfus
volum
associ
social
benefit
outweigh
disadvantag
increas
rate
seizur
longer
ventil
time
backgroundcas
studi
transfus
one
treatment
perform
hospit
set
choos
wise
campaign
april
http
wwwchoosingwiselyorgsocietiesamericanassociationofbloodbank
cost
risk
associ
transfus
high
may
signific
impact
patient
safeti
institut
perform
joint
replac
spine
surgeri
per
year
make
cost
high
sinc
last
formal
evalu
metric
use
post
implement
patient
blood
manag
pbm
strategi
question
regard
feasibl
continu
transfus
reduct
sustain
program
rais
administr
key
stakehold
physician
object
studi
determin
sustain
improv
blood
util
dashboard
occur
enhanc
pbm
program
determin
serv
continu
qualiti
improv
initi
organ
three
metric
evalu
transfus
rate
per
discharg
length
stay
lo
purchas
blood
product
cost
center
budget
studi
designmethod
monitor
follow
pbm
strategi
part
continu
qualiti
improv
charter
necessari
made
follow
chang
revis
maximum
surgic
blood
order
schedul
msbo
focus
reduc
primari
total
hip
arthroplasti
specif
spine
procedur
order
type
crossmatch
type
screen
revis
transfus
guidelin
base
transfus
data
collect
consensu
medic
surgic
physician
practic
present
physician
administr
stakehold
updat
blood
util
dashboard
establish
quarterli
review
effect
chang
polici
practic
transfus
rate
transfus
safeti
committe
medic
execut
committe
resultsfind
sustain
impact
pbm
strategi
monitor
measur
three
organ
wide
metric
updat
use
data
baselin
first
month
see
tabl
conclus
data
collect
show
continu
reduct
transfus
rate
blood
expenditur
length
stay
also
shown
continu
reduct
indic
pbm
strategi
implement
compromis
qualiti
outcom
continu
review
monitor
chosen
metric
evalu
chang
polici
practic
relat
transfus
medicin
commun
find
providersadministr
upon
immedi
restrospect
analysi
integr
continu
success
sustain
pbm
program
go
forward
practic
along
investig
use
addit
pbm
strategi
provid
basi
effect
continu
qualiti
improv
program
transfus
medicin
orthoped
tabl
backgroundcas
studi
prothrombin
complex
concentr
pcc
contain
factor
ii
vii
ix
x
protein
c
use
revers
vitamin
k
antagonist
acut
major
bleed
urgent
invas
procedur
occasion
use
plasma
optim
achiev
hemostasi
studi
compar
efficaci
use
pcc
correct
coagul
paramet
reduc
allogen
blood
transfus
studi
designmethod
retrospect
chart
review
perform
pcc
use
institut
margin
model
gee
method
use
account
within
patient
correl
assess
chang
lab
valu
product
transfus
logist
regress
gee
method
use
evalu
potenti
risk
factor
unsuccess
hemostasi
uh
rate
transfus
pcc
rate
pcc
thrombot
complic
resultsfind
reduct
pt
ptt
significantli
greater
use
interestingli
transfus
reduct
rbc
plasma
use
significantli
greater
use
case
uh
associ
cell
saver
acut
normovolem
hemodilut
anh
cardiopulmonari
bypass
cpb
odd
uh
time
cell
saver
anh
time
cpb
thrombos
identifi
case
associ
found
potenti
risk
factor
use
antifibrinolyt
vitamin
k
factor
viia
extracorpor
support
conclus
pcc
clinic
safe
effect
achiev
hemostasi
without
significantli
increas
thrombot
risk
pcc
rapidli
correct
coagulopathi
reduc
allogen
blood
transfus
pcc
may
less
effect
patient
recent
use
cpb
cell
saver
anh
caus
potenti
correl
need
investig
larger
studi
necessari
explor
addit
indic
pcc
backgroundcas
studi
pregnant
woman
high
risk
pregnanc
diagnos
abnorm
placent
multipl
gestat
admit
inpati
bedrest
obstetr
team
would
like
assur
abil
crossmatch
red
blood
cell
rbc
time
alway
type
screen
specimen
per
current
aabb
standard
necessit
new
sampl
everi
day
lead
excess
iatrogen
blood
loss
increas
difficulti
obtain
intraven
access
patient
point
invas
cathet
picc
line
may
place
order
mitig
issu
chose
extend
type
screen
specimen
expir
day
patient
without
rbc
alloantibodi
passiv
acquir
due
rh
immun
globulin
administr
studi
designmethod
patient
expect
antenat
hospit
least
day
high
risk
transfus
need
identifi
obstetr
servic
submit
request
transfus
servic
extens
specimen
day
transfus
servic
medic
director
review
case
give
final
approv
observ
patient
red
cell
alloantibodi
statu
baselin
new
antibodi
format
admiss
deliveri
number
patient
requir
prenat
transfus
advers
event
relat
incompat
unit
transfus
resultsfind
januari
april
request
extend
patient
approv
patient
specimen
extend
request
patient
continu
deliveri
five
patient
discharg
prior
move
anoth
state
admit
later
anoth
local
hospit
three
later
deliveri
mean
interv
approv
deliveri
day
rang
six
patient
deliv
within
day
approv
approv
mean
number
addit
specimen
per
patient
rang
patient
requir
transfus
prior
deliveri
five
patient
receiv
transfus
least
rbc
time
deliveri
none
evid
transfus
reaction
tabl
specimen
collect
approv
extend
type
screen
specimen
conclus
sinc
new
antibodi
identifi
prior
discharg
deliveri
transfus
reaction
observ
process
appear
safe
patient
deliv
within
day
approv
extend
specimen
patient
avoid
collect
least
specimen
patient
avoid
least
collect
sinc
new
antibodi
detect
least
day
immun
even
longer
extens
specimen
may
consid
although
requir
studi
believ
practic
extend
test
sampl
expir
date
day
safe
justifi
weigh
risk
excess
iatrogen
blood
loss
place
invas
line
blood
sampl
pregnant
patient
backgroundcas
studi
anemia
due
inflammatori
process
anemia
inflamm
ai
frequent
occur
critic
ill
patient
ai
hepcidin
decreas
iron
avail
process
thought
regul
erythroferron
impact
erythropoiesi
knowledg
chang
iron
metabol
cours
ai
limit
hamper
develop
strategi
counteract
ai
studi
aim
investig
dynam
paramet
iron
metabol
develop
ai
critic
ill
patient
studi
designmethod
case
control
studi
perform
tertiari
icu
netherland
compar
patient
develop
ai
icu
stay
control
group
patient
sepsi
patient
without
sepsi
patient
anemia
due
acut
blood
loss
patient
match
age
sex
linear
mix
model
use
assess
differ
paramet
iron
metabol
group
time
resultsfind
patient
ai
level
iron
transferrin
transferrin
satur
decreas
alreadi
prior
develop
anemia
lower
level
compar
control
tabl
ferritin
hepcidin
increas
ai
compar
control
cours
ai
develop
erythroferron
decreas
differ
iron
metabol
group
influenc
diseas
sever
patient
ai
differ
patient
anemia
due
acut
blood
loss
latter
character
high
iron
vs
p
transferrin
satur
vs
p
low
ferritin
vs
p
conclus
critic
ill
patient
ai
iron
metabol
alreadi
alter
prior
develop
anemia
suggest
potenti
window
opportun
therapi
iron
metabol
ai
disturb
septic
control
irrespect
diseas
sever
indic
ai
sole
determin
sever
inflamm
iron
metabol
ai
patient
differ
patient
acut
blood
loss
suggest
effort
modul
iron
metabol
anem
icu
patient
take
caus
anemia
account
tabl
mean
estim
iron
paramet
patient
per
group
time
point
ci
backgroundcas
studi
widespread
use
umbil
cord
blood
limit
process
yield
recoveri
viabl
nucleat
cell
recommend
therapeut
cell
dose
approxim
x
cell
per
kg
bodi
weight
indic
singl
cord
unit
may
insuffic
treat
larger
individu
cell
isol
method
develop
remov
erythrocyt
whilst
recov
white
cell
fraction
wcf
howev
current
method
result
signific
loss
wcf
whilst
leav
start
volum
erythrocyt
addit
almost
total
loss
potenti
import
low
abund
cellular
subset
use
cord
blood
hematopoiet
reconsititut
regen
medicin
would
widen
process
method
improv
viabl
cell
recoveri
studi
designmethod
develop
solut
consist
defin
concentr
reagent
routin
use
blood
therapi
combin
blood
solut
result
select
sediment
erythrocyt
graviti
within
minut
wcf
remain
solut
easili
separ
erythrocyt
sediment
wcf
concentr
gentl
centrifug
small
volum
contain
less
origin
erythrocyt
content
addit
dmso
cryogen
storag
control
freez
use
standard
procedur
complet
simpl
process
resultsfind
clearli
demonstr
method
allow
almost
entir
wcf
isol
andor
concentr
modest
loss
cellular
thu
far
examin
addit
improv
yield
recoveri
viabl
cell
markedli
increas
yield
approxim
fraction
post
separ
freez
thaw
tabl
possibl
import
cfu
assay
result
reproduc
yield
higher
count
bfu
coloni
tabl
strong
indic
method
improv
patient
outcom
addit
separ
method
isol
preserv
cell
earli
projenitor
cell
express
nanog
marker
vsel
two
exampl
cellular
subset
usual
lost
use
current
separ
techniqu
conclus
result
demonstr
method
achiev
routin
recoveri
wcf
level
higher
current
method
independ
volumehigh
percentag
recoveri
cell
type
test
achiev
exist
methodsmarkedli
higher
recoveri
viabl
nucleat
cell
current
methodologyalmost
complet
remov
hematocrit
result
unit
cord
blood
separ
use
new
method
contain
cell
yield
could
otherwis
achiev
pool
multipl
separ
unit
therefor
new
method
potenti
increas
demand
cord
blood
therapi
expand
larger
individu
adult
suppress
due
limit
cell
yield
deliv
exist
method
backgroundcas
studi
lymphoma
patient
receiv
lymphocyt
lymph
kg
peripher
blood
stem
cell
transplant
superior
surviv
addit
cell
target
lymph
target
also
implement
fifti
patient
alc
alc
implement
retrospect
evalu
studi
designmethod
lymph
yield
number
collect
lymph
target
reach
day
engraft
examin
mobil
g
plerixafor
gpl
consecut
alc
alc
procedur
examin
chi
squar
test
use
statist
comparison
p
consid
signific
resultsfind
alc
alc
collect
occur
among
patient
fenwal
amicu
use
alc
alc
collect
terumobct
spectra
optia
cmnc
use
remain
diagnosi
hodgkin
lymphoma
alc
hodgkin
lymphoma
alc
pre
procedur
wbc
lymph
count
significantli
higher
alc
wbc
lymph
alc
wbc
lymph
equival
whole
blood
correct
ac
process
alc
alc
alc
group
extra
collect
beyond
target
day
day
day
day
day
significantli
patient
mobil
gpl
alc
group
alc
group
collect
alc
group
mobil
discontinu
cell
target
reach
signific
differ
g
lymph
compar
gpl
mobil
collect
lymph
significantli
higher
collect
mobil
discontinu
day
wbc
engraft
alc
vs
alc
platelet
engraft
alc
vs
alc
significantli
differ
median
number
collect
alc
alc
significantli
differ
data
median
tabl
conclus
patient
achiev
lymphkg
even
lymphkg
target
implement
lymph
target
increas
patient
obtain
lymphkg
lymphkg
discontinu
mobil
cell
target
reach
significantli
reduc
lymph
yield
median
increas
one
collect
per
patient
follow
implement
less
expect
backgroundcas
studi
larg
distanc
collect
process
site
combin
staff
avail
result
long
process
delay
umbil
cord
blood
ucb
unit
current
standard
specifi
unit
store
almost
hour
room
temperatur
rt
long
unit
cryopreserv
impact
delay
hematopoiet
stem
cell
hsc
function
unclear
sinc
studi
use
transplant
assay
measur
hsc
key
properti
activ
hypothes
process
delay
reduc
engraft
activ
ucb
unit
set
measur
loss
engraft
activ
associ
preprocess
storag
studi
designmethod
ucb
unit
split
one
half
process
immedi
baselin
hour
second
hour
storag
rt
ucb
process
hetastarch
buffi
coat
maintain
cryopreserv
liquid
nitrogen
use
viabil
assess
thaw
ucb
buffi
coat
cell
transplant
nsg
mice
serial
transplant
use
test
differenti
activ
hsc
limit
dilut
ld
assay
poisson
statist
use
estim
frequenc
scid
repopul
cell
src
thaw
unit
resultsfind
storag
process
signific
impact
recoveri
viabl
cell
cell
primari
nsg
mice
transplant
ucb
cell
dose
contain
total
annexinvneg
viabl
cell
latter
done
avoid
bia
toward
one
group
anoth
short
term
platelet
vs
leucocyt
vs
p
engraft
significantli
reduc
store
mice
vs
baselin
similar
result
observ
human
bone
marrow
bm
engraft
also
reduc
primari
transplant
store
sampl
sem
vs
bm
cell
p
similarli
net
number
human
cfu
progenitor
reduc
store
recipi
multi
lineag
engraft
howev
confirm
group
bm
cell
primari
mice
transplant
secondari
recipi
human
engraft
investig
month
strikingli
frequenc
human
bm
cell
greater
baselin
vs
store
mice
p
henc
storag
rt
ucb
unit
associ
deficit
engraft
activ
like
due
loss
hsc
activ
andor
number
distinct
possibl
net
number
src
baselin
store
sampl
two
unit
calcul
ld
transplant
assay
net
number
src
measur
reduc
unit
unit
conclus
prolong
preprocess
rt
storag
significantli
impair
engraft
activ
ucb
unit
reduc
engraft
secondari
transplant
coupl
result
ld
assay
suggest
engraft
deficit
origin
loss
hsc
number
result
stress
import
rapid
ucb
process
avoid
loss
engraft
activ
backgroundcas
studi
new
cell
therapi
requir
effici
autom
method
purif
target
cell
prior
subsequ
process
apheresi
densiti
gradient
centrifug
magnet
separ
achiev
requir
method
current
avail
fulli
meet
clinic
need
close
autom
scalabl
process
continu
acoust
separ
microchannel
emerg
versatil
method
sort
separ
concentr
cell
blood
advantag
centrifug
scalabl
small
larg
quantiti
discrimin
cell
size
well
densiti
meanwhil
unlik
magnet
method
acoustophoresi
label
free
add
reagent
therapeut
cell
shown
previous
acoust
separ
separ
blood
compon
includ
purif
lymphocyt
howev
studi
use
devic
construct
silicon
glass
limit
potenti
product
dispos
cartridg
contrast
report
first
ever
demonstr
acoust
lymphocyt
enrich
along
rbc
platelet
deplet
dispos
plastic
chip
present
cartridg
concept
enabl
clinic
scale
throughput
link
microchannel
parallel
studi
designmethod
acoustophoresi
use
ultrason
wave
oscil
rectangular
microchannel
cross
section
scale
ultrason
wavelength
result
acoust
forc
across
channel
drive
cell
toward
axial
center
stream
forc
increas
cell
size
densiti
lymphocyt
experi
weaker
forc
rbc
class
wbc
thu
blood
product
flow
devic
lymphocyt
popul
enrich
side
channel
captur
branch
outlet
likewis
platelet
separ
lymphocyt
initi
output
cell
count
measur
standard
hematolog
analyz
resultsfind
acoust
system
lymphocyt
puriti
total
wbc
enrich
use
leukapheresi
product
start
materi
enrich
achiev
singl
pass
devic
resid
time
total
lymphocyt
recoveri
monocyt
concentr
reduc
furthermor
process
platelet
reduc
parallel
system
test
rbc
separ
plasma
achiev
separ
conclus
acoust
lymphocyt
enrich
along
platelet
deplet
standard
blood
product
demonstr
first
time
plastic
microchannel
dispos
devic
suitabl
scale
clinic
bioprocess
system
lymphocyt
puriti
compar
exist
method
advantag
monocyt
platelet
deplet
potenti
autom
instrument
backgroundcas
studi
use
natur
killer
nk
cell
cellular
immunotherapi
increas
past
sever
year
specif
use
patient
hematolog
malign
nk
cell
use
institut
past
year
patient
reaction
nk
cell
infus
reaction
quit
sever
retrospect
analyz
reaction
associ
nk
cell
infus
help
address
patient
sever
reaction
other
studi
designmethod
retrospect
chart
review
nk
cell
infus
perform
institut
clinic
protocol
infus
reaction
defin
symptom
time
nk
cell
infus
hour
afterward
sever
reaction
defin
symptom
grade
higher
sever
grade
common
terminolog
criteria
advers
ctcae
preliminari
data
analyz
use
r
two
major
endpoint
interest
infus
reaction
symptom
sever
infus
reaction
numer
summar
associ
continu
variabl
endpoint
median
rang
interquartil
rang
iqr
use
wilcoxon
test
perform
test
associ
continu
variabl
end
point
test
use
test
associ
categor
variabl
endpoint
interest
resultsfind
total
nk
cell
infus
patient
infus
reaction
symptom
patient
sever
reaction
infus
rate
mlmin
similar
among
reaction
sever
reaction
p
infus
rate
mlminkg
also
similar
among
reaction
sever
reaction
respect
incub
nk
cell
product
overnight
vs
similar
reaction
rate
symptom
reaction
reaction
sever
reaction
sever
reaction
sever
reaction
patient
sever
reaction
higher
calcul
monocyt
dose
monocyteskg
nk
cell
product
x
versu
without
x
conclus
preliminari
data
analysi
reveal
higher
number
monocyt
nk
cell
product
may
contribut
sever
infus
reaction
caus
patient
grade
higher
symptom
limit
studi
includ
retrospect
review
singl
institut
backgroundcas
studi
mesenchym
stem
cell
msc
investig
treatment
acut
respiratori
distress
syndrom
ard
graft
versu
host
diseas
gvhd
wound
heal
trauma
consensu
build
immunomodul
msc
key
therapeut
potenti
msc
suppress
peripher
blood
mononuclear
cell
pbmc
prolifer
vitro
suggest
correl
suppress
pbmc
inflammatori
respons
vivo
current
mix
lymphocyt
reaction
mlr
assay
gener
reli
either
direct
indirect
cultur
use
transwel
system
monitor
prolifer
isol
pbmc
presenc
mitot
inact
msc
studi
detail
msc
analyz
direct
pbmc
use
luminesc
atp
assay
studi
designmethod
blood
obtain
hous
blood
bank
pbmc
separ
centrifug
leucosep
tube
specifi
manufactur
pool
donor
pbmc
store
msc
deriv
bone
marrow
adipos
tissu
umbil
cord
respect
human
umbil
cord
endotheli
cell
huvec
serial
dilut
start
cellswel
cultur
well
plate
respect
media
day
msc
wash
resuspend
pbmc
media
incub
without
freshli
thaw
pbmcswell
presenc
absenc
phytohemagglutinin
pha
prolifer
msc
pbmc
assess
triplic
well
quantit
atp
level
use
bioluminesc
reagent
cell
promega
resultsfind
pbmc
prolifer
respons
pha
gave
robust
atp
signal
fold
increas
control
pbmc
increas
atp
respons
prolifer
seen
absenc
pha
msc
inhibit
pbmc
prolifer
depend
upon
msc
passag
sourc
msc
media
addit
varianc
triplic
sampl
variat
msc
prep
run
ident
condit
inhibit
pbmc
prolifer
grade
rang
msc
concentr
therefor
msc
cell
number
result
suppress
pbmc
could
determin
msc
prep
howev
depend
upon
pbmc
donor
pool
conclus
direct
live
msc
freshli
thaw
pbmc
give
robust
determin
immunosuppress
msc
grade
respons
determin
allow
comparison
potenc
msc
prepar
streamlin
assay
perform
within
without
irradi
cell
minim
equip
outlay
backgroundcas
studi
high
preval
iron
deplet
id
blood
donor
document
recent
studi
none
target
high
school
age
donor
consist
contribut
us
blood
suppli
differ
donor
year
old
yo
adult
baselin
iron
statu
import
understand
teenag
need
increas
iron
physiolog
growth
develop
may
suscept
harm
iron
deplet
studi
designmethod
donor
age
elig
ferritin
test
donat
high
school
hs
blood
drive
start
academ
year
two
blood
center
sampl
return
donat
remaind
school
year
also
test
preval
absent
iron
store
ai
ferritin
ngml
low
ferritin
lf
ferritin
ngml
estim
group
separ
gender
linkag
oper
databas
establish
ft
vs
repeat
rpt
donor
statu
linear
regress
analysi
test
differ
natur
log
enrol
ferritin
valu
age
multipl
logist
regress
assess
whether
young
age
independ
predict
iron
deplet
control
donat
frequenc
factor
resultsfind
total
donor
contribut
donat
donor
evenli
split
gender
ft
donor
ft
rpt
donor
averag
lower
ferritin
valu
enrol
p
greater
percentag
donor
tabl
repeat
measur
logist
regress
analysi
use
data
visit
femal
sex
greater
number
previou
donat
shorter
interv
sinc
last
donat
lower
bodi
weight
risk
factor
ai
lf
control
covari
donor
age
sharpli
higher
risk
iron
deplet
donor
odd
lf
time
greater
younger
donor
ai
higher
preliminari
statist
model
indic
donor
may
greater
risk
lf
percentag
point
control
factor
conclus
preval
iron
deplet
vari
markedli
age
sex
donat
frequenc
consider
higher
donor
adult
control
logist
regress
analysi
confirm
lower
age
independ
risk
factor
iron
deplet
blood
center
implement
measur
mitig
higher
risk
iron
deplet
potenti
advers
consequ
popul
vulner
donor
tabl
iron
statu
first
visit
sex
age
prior
donat
histori
ferritin
ngml
backgroundcas
studi
iron
defici
observ
blood
donor
meet
regulatori
hemoglobin
hb
requir
blood
donat
frequent
donat
result
neg
iron
balanc
eventu
lead
anemia
young
donor
may
risk
advers
health
consequ
cognit
dysfunct
complic
fatigu
decreas
exercis
endur
pica
even
anemia
occur
studi
designmethod
serum
ferritin
test
implement
larg
blood
collector
test
perform
success
yo
whole
blood
apheresi
donat
low
ferritin
lf
defin
valu
ngml
femal
f
ngml
male
donor
low
ferritin
notifi
deferr
red
blood
cell
rbc
donat
month
f
month
counsel
take
element
iron
daili
day
f
ferritin
ngml
indic
absent
iron
store
ai
ngml
indic
iron
defici
erythropoiesi
ide
ferritin
level
ngml
f
ngml
consid
indic
state
resultsfind
donat
test
tabl
success
donat
age
overal
rate
ai
ide
f
f
respect
deferr
rate
f
observ
proport
donor
increas
increas
hb
measur
lowest
accept
hb
level
donor
ferritin
lowest
accept
hb
level
f
donor
ferritin
test
individu
ferritin
ide
level
need
hb
observ
f
hb
valu
f
donor
rbc
donat
prior
month
lf
identifi
f
respect
data
shown
proport
donor
lf
increas
increas
number
rbc
unit
donat
prior
month
doubl
averag
rbc
per
year
f
quadrupl
conclus
ferritin
test
young
donor
identifi
individu
lf
would
benefit
risk
mitig
eg
delay
subsequ
rbc
donat
andor
take
iron
supplement
lf
common
f
donor
lf
preval
f
donor
rbc
donat
prior
month
appreci
number
donor
rbc
donat
prior
month
present
lf
data
may
use
conduct
decis
make
exercis
establish
recommend
risk
mitig
could
differ
f
eg
univers
iron
replac
teen
male
donor
may
warrant
certain
hb
valu
ferritin
blood
screen
minor
young
adult
donor
backgroundcas
studi
one
unit
whole
blood
remov
approxim
iron
iron
store
men
averag
women
averag
iron
store
studi
iron
deplet
adult
suggest
similar
effect
minor
young
adult
donor
although
yet
complet
investig
adolesc
growth
spurt
poor
nutrit
onset
mens
increas
risk
iron
deplet
young
new
studi
show
teenag
donor
give
blood
frequent
may
suscept
becom
iron
defici
older
repeat
studi
designmethod
serum
sampl
donor
age
year
analyz
ferritin
level
use
beckman
coulter
instrument
reagent
kit
reagent
suspens
polystyren
latex
particl
uniform
size
coat
polyclon
rabbit
antibodi
immun
complex
form
solut
scatter
light
proport
size
shape
concentr
decreas
light
intens
measur
resultsfind
tabl
show
sampl
test
ferritin
result
ngml
sampl
test
ferritin
result
ngml
sampl
test
ferritin
result
ngml
sampl
test
ferritin
result
ngml
level
less
ngml
femal
ngml
male
indic
donor
iron
store
low
level
less
ngml
indic
donor
iron
store
absent
conclus
approxim
donor
age
year
ferritin
level
indic
low
absent
iron
store
day
donat
although
donat
deferr
period
donor
increas
month
year
base
gender
monitor
andor
restor
iron
supplement
may
better
mitig
iron
defici
caus
frequent
donat
refer
fda
brief
document
topic
ii
blood
collect
advers
event
teenag
year
blood
donor
troy
brown
rn
blood
donor
fda
meet
iron
manag
teen
issu
medscap
beckman
coulter
instruct
use
ferritin
backgroundcas
studi
risk
cardiovascular
cv
diseas
adult
often
identifi
adolesc
year
presenc
even
borderlin
level
multipl
risk
factor
increas
likelihood
cv
event
blood
program
routin
provid
total
cholesterol
tc
blood
pressur
bp
measur
blood
donor
ad
glycat
hemoglobin
determin
perform
analys
preval
abnorm
borderlin
elev
level
multipl
risk
factor
among
adolesc
age
femal
donat
blood
studi
designmethod
abnorm
risk
factor
level
defin
sbpdbp
hg
tc
suggest
american
heart
associ
adolesc
presenc
isol
risk
factor
defin
one
singl
abnorm
risk
factor
per
individu
cluster
risk
factor
defin
presenc
abnorm
risk
factor
individu
donor
sex
record
time
donat
resultsfind
tabl
show
preval
isol
abnorm
risk
factor
preval
abnorm
risk
factor
cluster
studi
cohort
overal
adolesc
least
one
abnorm
risk
factor
male
femal
adolesc
isol
abnorm
risk
factor
adolesc
cluster
risk
factor
higher
proport
male
abnorm
bp
alon
bptc
group
higher
proport
femal
abnorm
tc
alon
alon
group
conclus
high
proport
adolesc
blood
donor
abnorm
cv
risk
profil
cluster
risk
factor
commonli
observ
higher
risk
profil
male
vs
femal
blood
donor
analyz
data
commun
blood
program
permit
identif
signific
proport
adolesc
cluster
risk
factor
screen
manner
potenti
inform
commun
prevent
effort
backgroundcas
studi
determin
hemoglobin
hb
level
candid
blood
donor
major
blood
servic
use
ensur
donor
safeti
blood
product
qualiti
howev
varieti
hb
test
strategi
use
across
blood
servic
satisfi
select
criterion
studi
aim
identifi
hb
screen
practic
vari
across
blood
donat
servic
extent
influenc
deferr
rate
low
hb
studi
designmethod
onlin
survey
perform
among
member
biomed
excel
safer
transfus
best
collabor
addit
data
literatur
use
extend
dataset
survey
involv
detail
assess
hb
screen
practic
number
donat
low
hb
deferr
male
femal
donor
separ
multivari
regress
model
built
estim
adjust
effect
minimum
donat
interv
hb
cutoff
highlow
high
defin
men
women
iron
monitor
yn
iron
supplement
yn
provid
prescrib
geograph
locat
deferr
rate
due
low
hb
resultsfind
data
includ
blood
servic
worldwid
complet
data
avail
blood
servic
deferr
percentag
low
hb
vari
among
male
donor
among
femal
donor
hb
deferr
rate
notabl
higher
asian
blood
servic
overal
iron
monitor
associ
lower
hb
deferr
rate
men
confid
interv
ci
lower
rate
women
ci
iron
supplement
associ
lower
hb
deferr
rate
among
women
ci
evid
effect
among
men
increas
minimum
donat
interv
result
lower
hb
deferr
rate
among
women
ci
among
men
level
signific
higher
hb
cutoff
appear
effect
among
men
women
conclus
variat
hb
deferr
rate
across
blood
donat
servic
particularli
femal
donor
explain
differ
hb
screen
deferr
practic
mitig
strategi
consid
variabl
respons
among
men
women
insight
help
improv
blood
servic
effici
donor
care
backgroundcas
studi
prevent
blood
donor
iron
defici
anemia
base
defer
prospect
donor
haemoglobin
hb
level
low
franc
hb
level
must
exceed
women
men
conduct
studi
determin
characterist
blood
donor
current
deferr
rate
identifi
factor
associ
hb
recoveri
consecut
wb
donat
studi
designmethod
within
individu
donor
present
donat
wb
continent
franc
donor
donat
least
select
random
donor
candid
sever
time
first
applic
kept
donor
withdrawn
volum
previou
donat
lack
data
exclud
hb
recoveri
assess
index
donat
defin
hb
reach
level
measur
prior
previou
donat
median
interv
previou
index
donat
week
women
men
respect
variabl
characterist
donor
age
sex
size
weight
region
hb
level
date
volum
donat
index
applic
previou
donat
number
previou
donat
previou
year
lifetim
data
analyz
use
logist
regress
stratifi
sex
resultsfind
candid
wb
donat
defer
continent
franc
deferr
significantli
frequent
women
men
due
anemia
defer
women
defer
men
plot
mean
hb
recoveri
time
show
mean
recoveri
time
rang
week
analysi
tabl
identifi
main
factor
associ
higher
likelihood
hb
recoveri
higher
logarithm
time
sinc
previou
donat
lower
level
hb
previou
donat
higher
number
blood
donat
previou
year
conclus
main
factor
associ
higher
likelihood
hb
recoveri
wb
donat
probabl
link
hematopoiesi
stimul
select
bia
among
donor
mean
time
requir
hb
recoveri
long
enough
requir
studi
assess
interv
franc
backgroundcas
studi
red
blood
cell
rbc
transfus
relat
event
microvesicl
rbc
product
may
support
coagul
part
may
depend
storag
time
microvesicl
procoagul
effect
vitro
amount
microvesicl
increas
storag
durat
studi
designmethod
investig
whether
transfus
rbc
contain
microvesicl
promot
coagul
human
recipi
transfus
mostli
administ
ill
patient
use
model
mild
endotoxemia
eighteen
healthi
volunt
random
receiv
either
salin
day
store
day
store
autolog
rbc
transfus
two
hour
infus
lipopolysaccharid
lp
ecoli
ngkg
blood
sampl
everi
hour
hour
lp
infus
resultsfind
lp
result
mild
increas
thrombin
gener
storag
total
number
microvesicl
increas
iqr
ml
fresh
product
iqr
p
store
product
p
mostli
rbc
deriv
vesicl
transfus
microvesicl
store
rbc
product
fresh
product
could
detect
circul
healthi
volunt
clear
within
hour
howev
infus
store
rbc
microvesicl
augment
thrombin
gener
level
complex
also
unaffect
conclus
transfus
autolog
rbc
contain
high
level
microvesicl
enhanc
coagul
human
volunt
mild
endotoxemia
backgroundcas
studi
circulatori
overload
taco
character
hydrostat
pulmonari
edema
relat
blood
transfus
sought
examin
contemporari
risk
factor
outcom
taco
period
patient
blood
manaement
led
declin
blood
util
studi
designmethod
four
academ
hospit
case
taco
detect
activ
surveil
adult
hospit
patient
receiv
blood
transfus
transfus
control
match
case
transfus
intens
taco
incid
calcul
clinic
characterist
compar
control
patient
odd
ratio
calcul
use
multivari
logist
regress
hospit
mortal
length
stay
model
use
cumul
incid
function
proport
hazard
regress
resultsfind
case
taco
match
control
enrol
transfus
patient
receiv
blood
compon
may
juli
taco
incid
case
per
patient
transfus
addit
well
describ
cardiac
renal
comorbid
multivari
analysi
identifi
follow
independ
predictor
taco
number
plasma
unit
emerg
surgeri
diuret
use
higher
hemoglobin
level
see
tabl
compar
control
taco
case
like
requir
mechan
ventil
vs
p
experienc
longer
intens
care
vs
day
hospit
length
stay
follow
transfus
vs
day
p
higher
mortal
vs
conclus
incid
taco
lower
report
prior
activ
surveil
studi
despit
declin
incid
number
blood
compon
transfus
per
case
taco
remain
complic
transfus
signific
associ
morbid
mortal
addit
risk
factor
cardiovascular
kidney
diseas
plasma
transfus
higher
hemoglobin
level
associ
taco
control
covari
model
addit
research
need
examin
util
risk
factor
develop
predict
algorithm
benefit
reduc
erythrocyt
plasma
exposur
patient
high
risk
taco
backgroundcas
studi
traine
taught
vital
sign
vital
hospit
frequent
maintain
polici
requir
transfus
discontinu
vital
sign
fall
outsid
predetermin
rang
howev
abil
vital
sign
determin
whether
advers
reaction
transfus
occur
well
establish
vital
sign
chang
associ
uncompl
transfus
well
describ
medic
literatur
almost
data
describ
vital
sign
chang
advers
event
publish
studi
designmethod
retrospect
record
review
complet
random
sampl
inpati
transfus
episod
month
month
academ
tertiari
care
hospit
total
episod
vital
sign
record
train
clinic
research
nurs
seriou
reaction
adjud
panel
transfus
medicin
expert
distribut
vital
sign
compar
use
wilcoxon
test
chang
vital
sign
transfus
period
compar
vital
sign
group
resultsfind
uncompl
transfus
includ
advers
reaction
vital
sign
fluctuat
gener
modest
transfus
result
chang
temperatur
beat
per
minut
puls
essenti
chang
respir
rate
mmhg
systol
blood
pressur
mmhg
diastol
blood
pressur
temperatur
puls
rate
bpm
higher
patient
develop
febril
reaction
compar
uncompl
transfus
bpm
respect
respiratori
rate
also
higher
patient
taco
compar
unev
transfus
analysi
statist
signific
vital
sign
chang
note
cours
transfus
expect
increas
temperatur
puls
rate
febril
reaction
conclus
studi
provid
largest
amount
vital
sign
data
date
uncompl
transfus
compon
type
divers
patient
popul
academ
medic
across
us
small
number
reaction
occur
studi
period
prevent
broad
conclus
plausibl
medic
mechan
ventil
support
may
obscur
vital
sign
chang
addit
investig
need
whether
vital
sign
may
import
yet
potenti
underutil
predictor
vital
sign
chang
transfus
backgroundcas
studi
transfus
intervent
may
associ
signific
morbid
critic
ill
patient
although
mechan
underli
transfus
relat
acut
lung
injuri
trali
well
investig
littl
known
liver
injuri
set
massiv
transfus
current
studi
design
test
hypothesi
supernat
store
red
blood
cell
rbc
induc
activ
liver
sinusoid
endotheli
cell
lsec
result
neutrophil
pmn
adhes
predisposit
liver
injuri
studi
designmethod
rbc
unit
collect
follow
leukoreduct
process
per
industri
standard
store
supernat
day
storag
appli
lsec
concentr
approxim
transfus
rbc
unit
lsec
intracellular
adhes
surfac
express
measur
fluoresc
label
monoclon
antibodi
via
flow
cytometri
pmn
adher
lsec
assess
cellular
lysat
measur
myeloperoxidas
mpo
via
spectrophotometri
resultsfind
express
increas
lsec
expos
supernat
concentr
compar
media
day
supernat
increas
express
also
observ
supernat
compar
media
control
day
supernat
supernat
rbc
significantli
increas
pmn
adher
lsec
compar
media
alon
lipoxin
natur
occur
eicosanoid
antagonist
inhibit
prbc
increas
surfac
express
p
conclus
liver
injuri
like
process
may
occur
set
massiv
transfus
first
event
insult
induc
endotheli
activ
prime
pmn
elicit
firm
adher
second
insult
may
activ
prime
adher
hyperact
pmn
lead
endotheli
damag
concentr
approxim
massiv
transfus
store
rbc
elicit
activ
lsec
could
serv
first
event
process
liver
injuri
backgroundcas
studi
photochem
treatment
process
amotosalen
uva
light
intercepttm
blood
system
develop
success
use
inactiv
pathogen
white
blood
cell
might
contamin
blood
compon
use
transfus
retrospect
cohort
studi
design
order
character
safeti
profil
platelet
intercepttm
platelet
system
compon
transfus
hospit
set
studi
designmethod
open
retrospect
cohort
hemovigil
studi
carri
hospit
set
intercepttm
platelet
compon
ipc
transfus
receiv
region
blood
center
medic
record
patient
transfus
ipc
juli
april
analyz
order
determin
safeti
data
ipc
administ
resultsfind
data
patient
ipc
administ
analyz
major
patient
popul
male
overal
cohort
mean
age
year
rang
median
patient
receiv
multipl
ipc
transfus
major
clinic
indic
ipc
transfus
hematolog
disord
follow
cardiovascular
surgeri
liver
transplant
neurosurgeri
total
transfus
patient
report
reaction
eighteen
transfus
associ
acut
advers
reaction
atar
relat
ipc
transfus
thought
advers
event
occur
patient
patient
ipc
transfus
establish
caus
ipc
atar
allerg
reaction
febril
nonhemolyt
one
acut
hemolyt
event
due
antibodi
group
ipc
given
group
patient
common
clinic
symptom
sign
transfus
reaction
urticari
lesion
chill
fever
dyspnea
nausea
hypotens
episod
ipc
acut
lung
injuri
detect
surgic
patient
receiv
ipc
indic
record
unexpect
coagulopathi
excess
bleed
associ
transfus
conclus
studi
percent
transfus
reveal
reaction
attribut
intercept
platelet
transfus
thu
intercept
platelet
demonstr
low
rate
acut
advers
transfus
reaction
reveal
safeti
profil
similar
convent
platelet
compon
backgroundcas
studi
residu
risk
bacteri
contamin
apheresi
platelet
ap
recent
address
march
fda
draft
guidanc
enhanc
safeti
platelet
transfus
document
also
describ
exist
pathway
ap
outdat
extens
day
use
fda
clear
rapid
test
rt
hospit
base
transfus
servic
use
rt
enhanc
safeti
ap
transfus
sinc
juli
routin
extend
ap
outdat
day
sinc
februari
studi
report
month
experi
secondari
screen
ap
use
rt
studi
designmethod
ap
obtain
donor
center
one
four
extern
supplier
ap
screen
cultur
base
method
prior
entri
inventori
juli
ap
underw
rt
day
day
unit
transfus
physician
approv
deem
medic
necessari
unit
remain
inventori
day
second
rt
perform
februari
ap
underw
rt
day
routin
outdat
extens
day
perform
second
rt
day
third
rt
day
per
manufactur
instruct
posit
rt
repeat
triplic
repeat
rt
posit
unit
quarantin
cultur
identifi
true
posit
fals
posit
fp
defin
repeat
rt
neg
type
repeat
rt
posit
neg
confirmatori
cultur
type
rt
result
review
studi
period
ap
transfus
outdat
rate
also
summar
resultsfind
sinc
juli
ap
enter
inventori
transfus
prior
rt
test
remain
underw
rt
day
day
rt
posit
type
fp
return
inventori
type
fp
discard
leav
total
avail
inventori
unit
test
rt
origin
inventori
transfus
end
day
remain
origin
inventori
reach
day
outdat
total
origin
inventori
transfus
day
day
underw
second
rt
day
rt
posit
fp
type
one
fp
type
underw
third
rt
day
posit
result
total
origin
inventori
outdat
day
underw
second
rt
day
posit
result
conclus
date
perform
rt
ap
hospit
true
posit
identifi
use
rt
studi
period
decreas
outdat
rate
predict
total
ap
test
twice
rt
day
day
posit
result
deem
fp
repeat
test
cultur
total
unit
test
time
day
day
day
addit
posit
identifi
yet
identifi
unit
initi
neg
rt
result
subsequ
convert
true
posit
low
fp
rate
also
expect
perform
repeat
test
unit
data
suggest
yield
repeat
rt
everi
hour
current
specifi
manufactur
instruct
quit
low
addit
studi
need
clarifi
rt
optim
use
enhanc
detect
ap
bacteri
contamin
backgroundcas
studi
trypanosoma
cruzi
agent
chaga
diseas
associ
million
infect
worldwid
mostli
latin
america
despit
extens
immigr
endem
area
case
tt
cruzi
report
us
blood
donor
screen
implement
contribut
factor
low
number
tt
case
possibl
associ
parasit
lineag
tt
high
number
unreport
case
platelet
almost
exclus
involv
cruzi
tt
case
howev
prepar
compon
larg
fraction
parasit
found
red
blood
cell
rbc
investig
blood
compon
prepar
storag
time
affect
surviv
parasit
thu
play
role
tt
cruzi
studi
designmethod
whole
blood
wb
unit
spike
cruzi
trypomastigot
final
concentr
parasitesml
parasit
concentr
wb
test
aliquot
contamin
wb
use
prepar
hemocultur
detect
live
parasit
prepar
compon
rbc
separ
half
compon
leukoreduc
lr
filtrat
platelet
plasma
separ
along
one
aliquot
plasma
collect
lr
rbc
store
day
platelet
store
rt
agit
day
plasma
frozen
aliquot
cultur
remov
weekli
rbc
daili
platelet
day
frozen
plasma
sampl
cultur
liver
infus
tryptos
lit
media
detect
live
parasit
week
resultsfind
hemocultur
posit
concentr
parasit
lr
rbc
cultur
storag
posit
concentr
storag
rbc
unit
spike
parasitesml
posit
day
time
yield
neg
result
lower
concentr
rbc
spike
parasitesml
posit
day
plasma
sampl
cultur
freez
posit
highest
concentr
one
sampl
other
neg
platelet
obtain
wb
spike
parasitesml
posit
day
rt
parasit
observ
plasma
platelet
prior
storag
lower
concentr
molecular
analysi
determin
presenc
parasit
dna
compon
conclus
platelet
storag
condit
offer
suitabl
environ
cruzi
surviv
howev
high
concentr
parasit
also
surviv
rbc
week
leukoreduct
offer
partial
protect
freez
condit
appear
unsuit
cruzi
surviv
backgroundcas
studi
amotosalenultraviolet
uva
light
blood
system
ceru
corpor
pathogen
reduct
pr
delay
larg
volum
bacteri
cultur
system
dlvbc
biomerieux
inc
repres
respect
system
reduc
risk
str
associ
platelet
concentr
pc
implement
hemovilig
hv
program
continu
receiv
report
suspect
str
low
imput
caus
like
insuffici
inform
avail
imput
system
failur
studi
designmethod
unit
kingdom
french
swiss
belgium
hv
report
ceru
corpor
advers
event
record
review
assess
residu
risk
imput
str
pc
resultsfind
approxim
million
issu
day
outdat
releas
inventori
day
collect
million
pc
releas
inventori
day
day
septic
fatal
report
either
technolog
french
belgium
swiss
hv
program
monitor
million
convent
pc
record
str
fatal
concurr
zero
definit
possibl
str
report
pc
significantli
fewer
convent
pc
tabl
str
per
million
vs
per
million
p
one
definit
possibl
undeterminedindetermin
str
contamin
near
miss
pc
report
million
pc
reduc
rate
compar
prior
five
year
str
per
million
vs
per
million
p
hv
program
highlight
major
weak
report
str
stringent
criteria
use
determin
definit
imput
includ
evid
patient
infect
pc
contamin
irrefut
evid
donor
sourc
confirm
strain
ident
report
incomplet
investig
consid
undetermin
indetermin
possibl
sepsi
case
almost
certainli
due
bacteri
contamin
pc
suggest
actual
rate
sepsi
consider
higher
report
hv
program
conclus
pathogen
reduct
bacteri
cultur
system
reduc
str
risk
although
underreport
inadequ
clinic
data
may
result
underestim
true
rate
pathogen
reduct
platelet
intercept
blood
system
least
effect
dlvbc
allow
earlier
releas
fresh
platelet
inventori
tabl
hemovigl
report
high
imput
septic
transfus
reaction
backgroundcas
studi
despit
extant
mitig
measur
eg
divers
pouch
primari
platelet
cultur
collect
facil
bacteri
contamin
platelet
associ
septic
transfus
reaction
remain
lead
caus
fatal
unit
state
us
consequ
us
food
drug
administr
recommend
adopt
addit
measur
point
releas
test
port
andor
pathogen
reduct
safeguard
sepsi
howev
port
pose
logist
challeng
particularli
institut
platelet
util
pathogen
reduct
high
cost
intervent
evalu
second
bacteri
cultur
contend
residu
risk
studi
designmethod
phase
implement
secondari
bacteri
cultur
test
bactalert
biomerieux
inc
durham
nc
initi
octob
platelet
receiv
institut
time
receipt
blood
bank
day
post
collect
product
sampl
use
steril
connect
devic
terumo
elkton
md
sampl
kit
sampl
kit
itl
biomed
malaysia
five
ml
product
transfer
asept
bactalert
bpa
aerob
cultur
bottl
use
sampl
devic
inocul
cultur
bottl
load
bactalert
incub
modul
incub
three
day
resultsfind
total
platelet
product
success
cultur
octob
march
respect
period
two
true
posit
cultur
obtain
incid
platelet
product
cultur
grew
acinetobact
speci
case
coagulas
neg
staphylococcu
speci
case
b
posit
result
obtain
four
day
follow
collect
repeat
test
case
b
grew
organ
identifi
initi
cultur
inventori
case
neg
initi
repeat
cultur
none
product
releas
transfus
initi
product
cultur
remain
neg
collect
facil
time
period
fals
posit
detect
implement
requir
hire
one
addit
dedic
fte
total
cost
technologist
time
equip
relat
suppli
calcul
per
product
test
cost
per
avert
case
conclus
demonstr
feasibl
implement
secondari
bacteri
cultur
test
apheresi
platelet
interdict
bacteri
contamin
unit
prevent
septic
transfus
reaction
present
strategi
compar
pathogen
reduct
mitig
risk
septic
transfus
reaction
importantli
offer
viabl
altern
port
high
volum
institut
logist
eg
time
personnel
constraint
imped
practic
adopt
port
backgroundcas
studi
accord
unit
state
food
drug
administr
fda
bacteri
contamin
associ
septic
transfus
reaction
account
transfus
associ
fatal
increas
case
blood
cultur
posit
transfus
reaction
bcptr
note
hospit
bcptr
defin
bacteri
cultur
posit
transfus
recipi
andor
associ
transfus
blood
product
investig
transfus
reaction
sought
character
risk
clinic
present
bcptr
institut
studi
designmethod
analysi
conduct
report
transfus
reaction
john
hopkin
hospit
jhh
januari
decemb
data
extract
hemovigil
record
evalu
determin
incid
bcptr
sever
symptom
evalu
concord
recipi
data
includ
patient
diagnosi
medic
clinic
manifest
reaction
bacteri
cultur
result
evalu
patient
associ
blood
product
ie
partial
transfus
residu
product
blood
bag
resultsfind
studi
period
total
transfus
reaction
report
bcptr
transfus
reaction
bcptr
associ
apheresi
platelet
red
blood
cell
plasma
recipi
diagnos
span
hematologiconcolog
renal
cardiac
autoimmun
obstetr
organ
identifi
blood
product
recipi
case
case
organ
grown
blood
product
recipi
case
organ
isol
recipi
due
inabl
cultur
product
transfus
recipi
case
isol
organ
recipi
antibiot
time
transfus
symptom
bcptr
includ
fever
chill
nausea
vomit
pain
dyspnea
blood
pressur
bp
decreas
increas
report
bcptr
chang
bp
conclus
sign
symptom
bcptr
specif
overlap
underli
diseas
well
type
advers
transfus
associ
event
thu
contribut
delay
diagnosi
furthermor
high
rate
antibiot
use
transfus
recipi
mask
symptom
true
septic
transfus
reaction
hospit
consid
expand
clinic
indic
cultur
blood
compon
implic
transfus
reaction
furthermor
excess
stringent
criteria
cdcnhsn
blood
safeti
surveil
infect
may
contribut
misclassif
septic
event
recipi
particularli
antibiot
backgroundcas
studi
four
differ
subclass
human
igg
differ
effector
function
essenti
exist
data
effect
igg
subclass
hemolyt
transfus
reaction
hdfn
gener
use
ahg
specif
igg
subclass
recent
decad
becom
appreci
least
natur
human
variant
igg
studi
reactiv
igg
specif
ahg
test
known
variant
studi
designmethod
heavi
light
chain
variabl
region
monoclon
antibodi
sequenc
clone
express
plasmid
fuse
variabl
region
frame
known
igg
variant
plasmid
express
cho
cell
result
panel
antibodi
rbc
subject
test
current
avail
igg
subtyp
specif
ahg
monoclon
ahg
southern
biotech
sanquin
polyclon
ahg
sanquin
bindingsit
test
carri
flow
cytometri
resultsfind
polyclon
reagent
variant
found
igg
subclass
specif
amino
acid
respons
identifi
site
direct
mutagenesi
tabl
titrat
ahg
identifi
dilut
lost
authent
target
still
detect
howev
could
neutral
ahg
igg
form
third
parti
antigen
remain
reactiv
recogn
intend
igg
subtyp
without
detect
detect
polyclon
monoclon
ahg
test
monoclon
blindspot
due
shorter
hing
region
blindspot
detect
monoclon
polyclon
ahg
conclus
rel
quantit
differ
igg
subtyp
studi
multipl
immun
set
play
import
role
diagnosi
research
human
diseas
includ
immunohematolog
herein
demonstr
reagent
use
gener
bodi
knowledg
suffer
problem
blindspot
exist
data
regard
igg
subtyp
biolog
may
inaccuraci
result
defect
igg
specif
ahg
backgroundcas
studi
among
differ
treatment
modal
avail
sickl
cell
diseas
scd
blood
transfus
frequent
use
howev
alloimmunis
remain
signific
problem
even
prophylact
antigen
match
perform
c
e
kell
antigen
partli
explain
differ
antigen
frequenc
among
caucasian
blood
donor
recipi
variant
rh
blood
group
peopl
blood
group
genotyp
propos
potenti
way
allevi
problem
scd
cohort
pediatr
academ
hospit
genotyp
rhd
rhce
fy
gene
primari
object
studi
evalu
whether
compat
genotyp
blood
donor
present
similar
rh
variant
could
identifi
studi
designmethod
sinc
local
blood
provid
intensifi
recruit
blood
donor
donor
phenotyp
genotyp
clinic
relev
antigen
differ
mean
genomelab
snp
stream
assay
idcorext
scd
children
genotyp
sequenc
rhd
rhce
fy
cdna
obtain
inform
consent
extend
red
blood
cell
phenotyp
done
diagnosi
hospit
patient
genotyp
compar
donor
databas
attribut
blood
donor
specif
patient
resultsfind
diagnosi
septemb
patient
transfus
antibodi
known
blood
group
antigen
specif
seventeen
patient
either
partial
rhce
result
show
patient
express
normal
c
antigen
express
partial
c
e
antigen
normal
antigen
bore
partial
antigen
weakli
express
fy
phenotyp
found
patient
total
genotyp
blood
donor
avail
tabl
indic
compat
donor
conclus
studi
show
sever
patient
rhce
variant
difficult
match
even
avail
genotyp
blood
donor
commun
although
measur
probabl
benefici
decreas
alloimmunis
larger
donor
pool
still
need
fulfil
patient
need
continu
effort
put
toward
recruit
phenogenotyp
improv
situat
backgroundcas
studi
rbc
alloimmun
associ
sever
factor
individu
characterist
patient
recent
found
cytokin
polymorph
rhag
allel
may
predict
good
respond
phenotyp
sippert
etal
transfus
rhag
allel
close
link
rh
alloimmun
base
consid
challeng
fulfil
transfus
need
patient
rh
variant
use
genet
marker
select
respond
scd
patient
transfus
rh
haplotyp
match
rbc
unit
evalu
risk
alloimmun
studi
designmethod
studi
includ
patient
scd
homozyg
hb
receiv
rang
rbc
unit
rbc
antigen
phenotyp
patient
histori
rbc
antibodi
obtain
medic
record
transfus
servic
computer
databas
rbc
genotyp
perform
use
whea
wrhd
wrhce
beadchip
array
bioarray
solut
immucor
accord
manufactur
instruct
cytokin
gene
polymorph
rhag
gene
polymorph
analys
taqman
assay
hla
class
ii
genotyp
perform
use
resultsfind
among
patient
homozyg
compound
heterozyg
rh
variant
allel
rhag
andor
allel
least
one
cytokin
polymorph
associ
risk
alloimmun
transfus
extend
rh
haplotyp
match
rbc
unit
patient
risk
factor
associ
rbc
alloimmun
consid
transfus
extend
rh
match
unit
patient
follow
one
year
develop
rbc
antibodi
conclus
find
contribut
develop
transfus
strategi
scd
patient
type
polymorph
could
potenti
help
classif
respond
scd
patient
allow
blood
high
level
compat
transfus
respond
order
avoid
product
rbc
antibodi
neg
consequ
alloimmun
backgroundcas
studi
transfus
remain
cornerston
therapi
manag
sickl
cell
diseas
scd
high
degre
rbc
antigen
variat
pose
inher
risk
alloimmun
mitig
rbc
alloimmun
genotyp
assay
increasingli
employ
success
depend
abil
detect
specif
allel
variant
comparison
show
high
concord
rate
genotyp
serolog
lead
expert
suggest
genotyp
without
serolog
confirm
consid
studi
designmethod
perform
commonli
use
genotyp
platform
compar
accuraci
interrog
blood
group
allel
variant
cohort
scd
patient
decemb
june
dna
extract
hbss
patient
test
human
erythrocyt
antigen
hea
beadchip
dna
array
bioarrayimmucor
time
extract
subsequ
id
core
xt
progenika
biopharmagrifol
result
compar
concord
rate
calcul
discrep
resolv
sanger
sequenc
test
done
protocol
resultsfind
total
snp
call
repres
separ
rbc
antigen
compar
concord
rate
demonstr
five
discrep
sampl
requir
sequenc
id
core
xt
identifi
three
rhce
cear
sampl
encod
partial
c
partial
e
predict
phenotyp
vweak
confirm
sequenc
third
sampl
found
rhce
rhce
cebi
sequenc
predict
phenotyp
v
vs
sampl
type
v
ce
vs
es
hea
addit
id
core
xt
accur
identifi
rhce
ce
sampl
snp
link
variou
allel
variant
affect
c
e
antigen
express
sampl
predict
c
hea
tabl
discrep
resolut
summari
conclus
blood
group
genotyp
platform
vari
depend
specif
snp
includ
assay
variat
may
clinic
signific
genotyp
use
tool
provid
match
blood
discrep
lead
differ
predict
phenotyp
could
affect
unit
select
despit
discrep
method
high
concord
rate
limit
serolog
warrant
reconsider
need
serolog
confirm
extend
phenotyp
backgroundcas
studi
three
decad
ago
two
independ
group
publish
work
suggest
novel
categor
warm
autoimmun
hemolyt
anemia
waiha
basi
dat
score
rbc
type
waiha
compris
patient
show
increas
bind
autoantibodi
age
rbc
wherea
type
ii
waiha
autoantibodi
patient
bound
young
old
rbc
appar
prejudic
ubiquit
express
rbc
transmembran
protein
play
vital
role
mainten
rbc
structur
integr
cellular
hemostasi
regul
senesc
suggest
target
autoantibodi
patient
waiha
regul
phosphoryl
key
residu
hyperphosphoryl
hallmark
normal
rbc
senesc
caus
disengag
cytoskeleton
increas
later
diffus
therebi
permit
format
aggreg
form
new
epitop
recogn
natur
igg
autoantibodi
caus
phagocytosi
destruct
senesc
rbc
type
waiha
postul
caus
exacerb
normal
rbc
senesc
studi
designmethod
effort
confirm
character
two
waiha
subtyp
whole
blood
sampl
patient
waiha
discontinu
gradient
look
differ
dat
result
less
young
rbc
dens
age
rbc
fraction
fraction
pattern
tyrosin
phosphoryl
resultsfind
confirm
two
distinct
type
waiha
identifi
base
autoantibodi
reactiv
youngest
oldest
autolog
rbc
compar
type
type
ii
patient
found
type
character
fraction
similar
healthi
control
increas
tyrosin
phosphoryl
compar
healthi
control
phosphoryl
occur
younger
stage
rbc
develop
type
ii
patient
character
fraction
lack
fraction
contain
oldest
rbc
show
complet
lack
dramat
decreas
tyrosin
phosphoryl
compar
healthi
control
conclus
result
confirm
two
distinct
type
waiha
type
waiha
increas
bind
autoantibodi
older
rbc
coupl
increas
tyrosin
phosphoryl
suggest
rbc
type
patient
age
faster
rbc
normal
healthi
control
may
repres
acceler
pathogen
form
normal
rbc
senesc
contrast
type
ii
waiha
autoantibodi
bind
strongli
either
young
old
rbc
coupl
lack
fraction
band
repres
oldest
rbc
dramat
diminut
tyrosin
phosphoryl
band
suggest
faster
destruct
rbc
consist
earli
publish
data
metabol
chang
could
affect
rbc
function
backgroundcas
studi
known
specif
group
patient
immunolog
respond
readili
other
rbc
antigen
rbc
antigen
differ
donor
recipi
requir
humor
immun
respons
variabl
also
involv
studi
shown
signific
primari
sequenc
ident
common
rbc
antigen
microb
possibl
antigen
experiment
model
hypothes
respond
popul
may
immunolog
prime
form
rbc
alloantibodi
via
environment
exposur
microbi
antigen
correl
may
link
observ
blood
group
antigen
immunogen
studi
designmethod
perform
peptid
homolog
search
immunogen
rbc
antigen
base
previous
publish
antigen
find
thirteen
amino
acid
peptid
contain
polymorph
residu
k
jka
lua
e
c
c
fya
antigen
queri
ident
microbi
peptid
use
blast
databas
blastp
algorithm
e
word
size
gap
cost
search
result
restrict
bacteria
fungi
select
threshold
ident
set
inclus
criteria
corrobor
observ
patient
data
also
examin
preced
cultur
alloimmun
patient
explor
agreement
specif
pathogen
rbc
alloantibodi
resultsfind
signific
peptid
ident
found
rbc
antigen
pathogen
organ
includ
b
fragili
p
aeruginosa
candida
spp
among
other
linear
regress
analysi
number
genus
microbi
kingdom
meet
inclus
criteria
show
statist
signific
invers
trend
predict
degre
immunogen
fya
outlier
remov
r
lower
immunogen
antigen
associ
larger
number
kingdom
cluster
analysi
compar
immunogen
kingdom
show
antigen
cluster
low
c
moder
e
c
high
k
jka
lua
fya
immunogen
group
suggest
antibodi
respons
invers
associ
environment
antigen
preval
alloimmun
patient
review
group
patient
group
patient
agreement
remain
antibodi
agreement
rang
overal
patient
demonstr
agreement
interestingli
observ
particularli
strong
agreement
infect
klebsiella
speci
despit
lack
sequenc
ident
patient
review
posit
cultur
klebsiella
speci
patient
demonstr
conclus
studi
highlight
potenti
connect
microbi
infect
rbc
alloimmun
base
share
epitop
specul
antigen
exposur
highli
preval
microbi
antigen
commens
may
promot
immunotoler
provid
model
invers
relationship
rbc
antigen
immunogen
preval
microorgan
longitudin
studi
microbi
carriag
acut
microbi
infect
rbc
alloimmun
respons
larger
patient
cohort
may
inform
backgroundcas
studi
thromboelastogram
teg
incorpor
mani
hospit
armori
manag
transfus
cardiovascular
cv
surgeri
institut
use
protocol
teg
util
differ
stage
surgeri
baselin
rewarm
hand
institut
teg
util
driven
mainli
clinic
judgment
teg
order
base
clinic
judgment
clinic
bleed
case
patient
receiv
blood
transfus
teg
perform
publish
literatur
transfus
impact
teg
result
guid
transfus
requir
cv
surgeri
studi
tri
address
issu
studi
designmethod
retrospect
review
teg
perform
patient
undergo
cv
surgeri
institut
jan
dec
specif
teg
protocol
use
direct
transfus
plasma
platelet
cryoprecipit
period
first
teg
perform
surgeri
includ
analysi
exclud
patient
receiv
red
blood
cell
rbc
transfus
surgeri
rbc
transfus
usual
base
teg
result
teg
analyz
teg
result
divid
three
categori
normal
reaction
time
r
kinet
k
angl
maximum
amplitud
lysi
minut
min
within
refer
rang
hypocoagul
r
min
k
min
degre
hypercoagul
r
min
k
min
degre
fisher
exact
test
two
popul
proport
use
identifi
statist
signific
differ
teg
result
blood
product
util
resultsfind
teg
analyz
patient
receiv
transfus
found
significantli
fewer
hypocoagul
teg
result
transfus
patient
nontransfus
patient
vs
data
also
reflect
trend
suggest
may
normal
teg
result
transfus
patient
compar
nontransfus
vs
statist
signific
differ
transfus
obtain
teg
result
group
howev
trend
suggest
hypocoagul
state
like
correct
transfus
patient
alreadi
transfus
compar
nontransfus
versu
conclus
transfus
impact
teg
result
transfus
correctnorm
coagulopathi
significantli
impact
blood
product
util
cv
surgeri
decreas
threshold
transfus
correct
hypocoagul
state
patient
alreadi
receiv
transfus
may
due
clinic
signific
bleed
patient
begin
backgroundcas
studi
orthotop
liver
transplant
olt
associ
signific
blood
loss
due
complex
procedur
extens
liver
vascular
demand
blood
transfus
set
cell
salvag
autotransfus
cs
use
altern
decreas
allogen
red
blood
cell
transfus
howev
long
studi
shown
cs
olt
decreas
allogen
blood
transfus
other
report
cs
present
littl
benefit
might
associ
increas
blood
loss
fibrinolysi
studi
evalu
cs
efficaci
reduc
allogen
blood
transfus
intraop
period
studi
designmethod
retrospect
evalu
data
liver
transplant
perform
patient
divid
two
group
one
cell
salvag
cs
anoth
without
cs
nc
studi
endpoint
includ
requir
allogen
blood
compon
transfus
intraop
period
group
cs
use
liver
transplant
recipi
patient
malign
sepsi
blood
transfus
indic
base
clinic
hemodynam
criteria
clinic
data
includ
age
gender
diagnosi
bodi
weight
height
warm
cold
ischem
time
model
liver
diseas
meld
score
statist
analys
perform
use
test
mann
whitney
test
resultsfind
studi
period
olt
perform
total
patient
submit
cs
median
age
year
rang
yo
cirrhosi
caus
chronic
hepat
c
viru
infect
main
etiolog
liver
diseas
hepatocellular
carcinoma
hcc
found
patient
averag
meld
score
slightli
higher
cs
group
vs
p
statist
signific
differ
variabl
bodi
weight
height
cold
ischem
time
mean
salvag
blood
volum
mean
reinfus
blood
volum
allogen
blood
transfus
requir
patient
cs
group
compar
patient
nc
group
howev
averag
red
blood
cell
rbc
fresh
frozen
plasma
ffp
unit
transfus
lower
cs
group
threshold
rbc
transfus
significantli
lower
cs
group
unit
vs
unit
p
find
similar
ffp
transfus
unit
vs
p
signific
differ
transfus
cryoprecipit
platelet
unit
group
conclus
autolog
cs
decreas
allogen
blood
transfus
requir
liver
transplant
less
rbc
ffp
unit
transfus
intraop
backgroundcas
studi
hemorrhag
lead
caus
mortal
trauma
patient
morbid
patientsaddin
encitedata
massiv
transfus
protocol
mtp
reduc
mortal
trauma
set
howev
may
cost
blood
product
wastageaddin
encitedata
blood
product
wastag
benchmark
loos
establish
data
wastag
associ
mtp
especi
spars
redesign
mtp
obstetr
massiv
transfus
protocol
obp
differ
blood
product
prepar
schedul
assess
wastag
deliveri
method
product
util
identifi
differ
wastag
protocol
studi
designmethod
follow
institut
review
board
approv
retrospect
studi
blood
product
wastag
associ
mtp
obp
juli
perform
data
number
product
dispens
wast
manual
collect
transfus
servic
paper
electron
record
autom
data
report
electron
medic
record
resultsfind
mtp
result
higher
total
number
wast
product
obp
product
respect
howev
obp
wastag
occur
frequent
month
period
reflect
automat
thaw
cryoprecipit
first
round
deploy
product
opb
activ
contribut
higher
wastag
activ
versu
product
skew
one
month
product
wast
due
expir
product
floor
issu
product
dwell
long
control
environ
common
reason
report
wastag
overal
product
wastag
rate
mtp
trauma
mtp
obp
respect
total
exsanguin
protocol
wast
rate
differ
overal
proport
wast
mtp
obp
protocol
insignific
conclus
wastag
associ
protocol
low
statist
differ
mtp
versu
obp
wastag
issu
account
product
wastag
allow
target
wast
reduct
strategi
includ
educ
outreach
improv
product
deliveri
method
better
document
wast
event
identifi
wastag
trend
product
util
optim
protocol
backgroundcas
studi
year
old
femal
multipl
gun
shot
admit
level
one
trauma
center
receiv
uncrossmatch
group
rh
neg
red
blood
cell
rbc
rapid
infus
resuscit
transfus
uncrossmatch
product
sampl
collect
lead
error
confus
blood
type
venipunctur
site
use
collect
patient
blood
sampl
current
fda
guidanc
aabb
standard
two
sampl
determin
blood
type
prevent
case
wrong
blood
tube
wbit
electron
identif
system
alway
catch
clarifi
error
studi
designmethod
patient
test
manual
tube
method
two
differ
technologist
use
two
differ
reagent
rack
perform
initi
test
match
result
resultsfind
two
sampl
collect
resuscit
patient
type
patient
transfus
unit
rbc
stabil
two
day
later
anoth
sampl
collect
type
rh
posit
mix
field
seen
weak
test
perform
see
neg
result
could
strengthen
incub
origin
sampl
still
result
tabl
consult
patient
care
team
discov
sampl
collect
iv
site
one
unit
complet
second
unit
transfus
also
discov
clinic
laboratori
sampl
reject
due
possibl
line
contamin
result
sodium
potassium
glucos
appear
inaccur
transfus
servic
laboratori
differ
area
hospit
unawar
sampl
reject
conclus
initi
sampl
collect
iv
site
contamin
blood
product
rapidli
transfus
resuscit
sampl
collect
initi
trauma
respons
reject
request
made
sampl
drawn
iv
site
sampl
collect
unit
transfus
contamin
use
handheld
barcod
system
would
caught
error
patient
correctli
identifi
futur
prevent
anomali
would
educ
transfus
test
staff
recogn
abnorm
high
hematocrit
secondli
remind
staff
collect
sampl
awar
proper
collect
procedur
laboratori
test
would
includ
type
screen
facil
also
strive
perform
collect
confirmatori
sampl
complet
differ
venipunctur
site
tabl
backgroundcas
studi
institut
perform
averag
solid
organ
transplant
sot
yearli
transfus
support
transplant
tremend
account
larg
percentag
red
blood
cell
rbc
transfus
annual
even
best
practic
allogen
transfus
without
risk
transmiss
pathogen
possibl
even
strictest
screen
method
transfus
increas
risk
alloimmun
advent
intraop
blood
recoveri
reduc
need
allogen
donor
rbc
surgeri
expect
bleed
heavili
cell
braintre
patient
blood
shed
surgeri
collect
wash
concentr
lessen
need
transfus
support
studi
sought
examin
amount
allogen
donor
rbc
unit
save
sot
use
cell
saver
intraop
blood
recoveri
studi
designmethod
data
collect
sot
util
cell
saver
includ
liver
liverkidney
combin
lung
heart
transplant
data
point
includ
type
transplant
volum
shed
blood
collect
volum
concentr
rbc
wash
averag
donor
rbc
unit
volum
use
determin
equival
number
donor
unit
data
collect
period
fourteen
month
resultsfind
total
sot
document
util
cell
saver
total
shed
blood
collect
concentr
rbc
wash
tabl
use
averag
donor
rbc
unit
volum
volum
concentr
shed
blood
patient
equival
allogen
donor
rbc
unit
unit
per
transplant
accord
publish
literatur
averag
cost
per
rbc
unit
reduc
need
allogen
rbc
unit
solid
organ
transplant
equat
averag
save
per
transplant
conclus
given
high
volum
sot
perform
institut
intraop
blood
recoveri
cell
saver
proven
greatli
reduc
need
allogen
donor
rbc
transplant
result
reduc
risk
allogen
blood
exposur
signific
cost
save
tabl
cell
saver
usag
solid
organ
transplant
backgroundcas
studi
turnaround
time
tat
emerg
blood
compon
order
deliveri
level
trauma
center
minut
proppr
trial
rapid
tat
led
posit
feedback
satisfi
clinician
way
improv
speed
effici
transfus
servic
ts
continu
evalu
trauma
respons
protocol
includ
full
trauma
team
activ
ftta
sever
trauma
modifi
tta
base
mechan
injuri
age
hemodynam
stabil
previous
ftta
requir
ts
staff
respond
remain
present
rbc
plasma
platelet
univers
product
longer
need
impact
ed
blood
refriger
oper
effici
blood
util
evalu
studi
designmethod
februari
monitor
blood
storag
refriger
activ
use
ed
rbc
rbc
ab
low
titer
plasma
ed
staff
train
given
code
access
activ
alarm
ts
use
process
chang
ftta
requir
physic
presenc
ts
staff
member
request
pertin
metric
collect
year
prior
year
post
implement
resultsfind
prior
use
ed
refriger
half
ts
staff
time
ftta
essenti
unnecessari
uncrossmatch
blood
given
ed
refriger
idl
tsl
staff
time
tta
reduc
hour
ed
refriger
consist
use
month
due
ed
stakehold
ffp
use
gener
result
mtp
ratio
rbc
overal
slight
increas
number
tta
uncrossmatch
rbc
use
number
ftta
injuri
sever
score
iss
remain
stabl
conclus
level
trauma
center
highli
effici
ts
implement
ed
refriger
enhanc
oper
effici
like
improv
alreadi
rapid
tat
blood
compon
backgroundcas
studi
emerg
red
blood
cell
rbc
transfus
trauma
patient
often
initi
blood
type
determin
avail
univers
blood
type
neg
unit
support
trauma
patient
need
emerg
transfus
thu
unit
reserv
trauma
femal
age
institut
femal
year
old
yo
transfus
rbc
wherea
femal
yo
male
age
receiv
posit
trauma
resuscit
uncrossmatch
type
rbc
maintain
refriger
kiosk
trauma
depart
emerg
transfus
appropri
rbc
either
select
kiosk
yo
femal
admit
trauma
depart
motor
vehicl
collis
mvc
transfus
rbc
unit
kiosk
blood
type
determin
neg
rbc
antibodi
screen
transfus
unit
rbc
two
month
later
repeat
identifi
two
new
rbc
alloantibodi
format
result
rbc
transfus
kiosk
sourc
undetermin
sinc
e
antigen
express
rh
individu
trauma
depart
staff
notifi
delay
serolog
transfus
reaction
ask
investig
sinc
yo
femal
patient
receiv
rbc
studi
designmethod
investig
plan
develop
trauma
staff
involv
patient
censu
review
chart
kiosk
inventori
obtain
feedback
clinic
provid
review
inform
provid
emerg
servic
em
resultsfind
trauma
unit
busi
admiss
hour
preced
patient
arriv
chart
review
found
follow
physic
attribut
patient
overweight
obviou
facial
deform
mvc
compromis
age
assess
determin
kiosk
fulli
stock
rbc
unit
one
clinic
provid
recal
patient
identif
id
might
unknown
review
em
commun
state
patient
yo
femal
conclus
use
visual
examin
determin
age
signific
select
rbc
patient
trauma
staff
propos
implement
chang
polici
prevent
futur
incid
femal
patient
arriv
without
id
written
confirm
age
transfus
uncrossmatch
rbc
blood
type
determin
notifi
incid
trauma
staff
took
lead
investig
provid
process
improv
resolut
credit
excel
collabor
relationship
transfus
servic
trauma
depart
ensur
patient
safeti
emerg
uncrossmatch
rbc
transfus
backgroundcas
studi
approxim
surgeri
urinari
incontin
pelvic
organ
prolaps
pop
perform
annual
abdomin
pelvic
floor
disord
pfd
surgeri
transfus
rate
histor
rang
wherea
transfus
rate
vagin
robot
pfd
surgeri
rang
respect
sinc
implement
colleg
american
pathologist
cap
requir
aborh
confirm
approxim
patient
receiv
transfus
hospit
requir
second
aborh
specimen
drawn
howev
limit
data
avail
regard
impact
new
requir
patient
prepar
undergo
outpati
surgeri
current
requir
preoper
type
screen
primari
object
studi
assess
rate
aborh
confirm
women
underw
outpati
pop
surgeri
studi
designmethod
plan
secondari
analysi
retrospect
cohort
studi
consecut
patient
undergo
pop
surgic
repair
may
may
academ
tertiari
care
institut
among
sampl
patient
exclud
first
drawn
institut
implement
aborh
confirm
requir
fisher
exact
test
use
statist
signific
defin
p
resultsfind
identifi
patient
analysi
preoper
order
two
patient
posit
antibodi
screen
one
patient
one
autoantibodi
patient
requir
second
aborh
specimen
per
hospit
protocol
actual
second
specimen
drawn
patient
aborh
confirm
indic
differ
aborh
confirm
compar
age
bodi
mass
index
bmi
hemoglobin
hgb
surgic
approach
tabl
aborh
discrep
identifi
one
patient
receiv
unit
red
cell
abdomin
pop
surgeri
conclus
rate
requir
aborh
confirm
pop
surgeri
markedli
higher
seen
patient
receiv
transfus
institut
vs
respect
vast
major
women
undergo
vagin
robot
pop
surgeri
transfus
periop
hospit
transfus
servic
consid
elimin
routin
popul
maximum
surgic
blood
order
schedul
avoid
unneed
test
subsequ
aborh
confirm
backgroundcas
studi
one
attribut
older
blood
increas
supernat
potassium
level
contribut
transient
hyperkalemia
problem
exacerb
condit
massiv
transfus
patient
renal
failur
wash
rbc
effect
remov
free
potassium
time
consum
often
perform
one
unit
time
estim
amount
potassium
remov
volum
reduct
red
cell
unit
also
examin
whether
techniqu
would
feasibl
set
massiv
transfus
patient
hyperkalemia
studi
designmethod
expir
temperatur
unit
remov
inventori
util
studi
unit
weigh
volum
reduct
procedur
perform
supernat
weigh
potassium
supernat
measur
use
routin
laboratori
assay
formula
weight
convert
volum
use
specif
graviti
hematocrit
hct
volum
reduc
rbc
measur
use
sysmex
instrument
percentag
supernat
remov
calcul
divid
residu
supernat
volum
reduc
unit
rbc
hct
x
rbc
volum
total
supernat
prior
procedur
residu
supernat
remov
supernat
remain
free
potassium
meq
calcul
concentr
potassium
supernat
mmoll
x
estim
red
blood
cell
residu
supernat
volum
simul
process
would
occur
set
massiv
transfus
protocol
mtp
unit
subject
volum
reduct
record
time
need
process
unit
perform
twice
total
unit
process
manner
resultsfind
volum
reduct
procedur
reduc
supernat
volum
averag
rang
unit
day
estim
mean
residu
k
meq
rang
two
mock
mtp
trial
time
complet
procedur
approxim
minut
estim
addit
minut
would
requir
modifi
issu
unit
lisemr
conclus
manual
volum
reduct
protocol
red
cell
unit
significantli
reduc
amount
potassium
administ
unit
red
cell
procedur
may
use
older
red
cell
unit
avail
patient
risk
hyperkalemia
procedur
perform
less
one
hour
may
use
condit
massiv
transfus
backgroundcas
studi
mesenchym
stem
cell
msc
cell
capabl
differenti
multipl
lineag
msc
possess
tremend
therapeut
potenti
limit
sourc
quantiti
although
msc
identifi
expand
umbil
cord
tissu
uct
current
practic
uct
bank
standard
goal
develop
valid
method
cryopreserv
uct
gener
viabl
consist
msc
gmp
facil
meet
product
biolog
licens
requir
futur
therapeut
applic
cfr
biolog
fda
studi
designmethod
donat
human
uct
wash
section
store
freez
media
contain
dmso
cryostor
vapor
phase
liquid
nitrogen
tank
freshli
process
uct
sampl
week
expand
msc
growth
media
consecut
passag
rna
analysi
perform
aliquot
tissu
expand
cell
msc
marker
qpcr
msc
identityphenotyp
confirm
flow
cytometri
use
stemflow
facscalibur
bd
detect
presenc
absenc
surfac
express
replic
tissu
sampl
subject
steril
test
accredit
servic
laboratori
encompass
aerob
anaerob
yeast
fungal
id
supplement
speciationsensit
test
perform
posit
sampl
resultsfind
find
demonstr
mrna
express
detect
fresh
uct
variat
rel
level
among
donor
week
cryostorag
recoveri
marker
signal
averag
significantli
chang
indic
minim
deterior
frozen
uct
similar
mrna
express
also
detect
expand
msc
cultur
fresh
tissu
adher
msc
cultur
fresh
uct
sampl
passag
show
posit
marker
neg
characterist
mesenchym
origin
expand
msc
cultur
includ
group
show
viabl
particular
msc
cultur
cryostorag
show
similar
cell
viabil
stabil
seen
fresh
group
steril
test
show
overal
contamin
rate
privat
bank
uct
sampl
conclus
develop
comprehens
procedur
privat
uct
bank
msc
expans
complementari
test
employ
valid
isol
cryopreserv
expans
msc
may
lead
approv
use
regen
medicin
backgroundcas
studi
umbil
cord
uc
tissu
grow
import
mesenchym
stem
cell
msc
isol
wharton
jelli
uc
studi
grow
number
research
indic
futur
regen
medicin
approach
may
requir
autolog
msc
remot
collect
preserv
uc
tissu
referr
site
remain
challeng
requir
practic
method
transport
process
cryopreserv
hospit
collect
preliminari
studi
three
ship
condit
collect
test
use
steril
contain
steril
normal
salin
ns
alon
ns
plu
antibioticantimycot
abam
dri
contain
prolong
exposur
abam
solut
retard
outgrowth
msc
control
microbi
growth
cultur
tissu
sampl
need
find
use
construct
valid
studi
studi
designmethod
valid
studi
design
test
procedur
collect
transport
process
store
umbil
cord
tissu
measur
outgrowth
collect
uc
tissu
consent
mother
transport
distant
lab
valid
ship
contain
dri
steril
cup
vagin
caesarian
birth
uc
collect
divid
segment
test
condit
segment
explant
place
grid
tissu
cultur
plate
explant
per
plate
enrich
medium
specifi
msc
outgrowth
contain
antibiot
endpoint
day
growth
score
number
squar
explant
exhibit
outgrowth
compar
total
plant
explant
one
segment
fresh
control
dissect
plant
without
process
remain
tissu
segment
soak
abam
salin
solut
hr
hr
respect
tissu
segment
frozen
cryo
bag
proprietari
dmsolarg
molecular
weight
sugar
solut
tissu
store
vapor
phase
minimum
hr
resultsfind
sampl
receiv
lab
hour
collect
condit
show
growth
report
percent
squar
dissect
tissu
fragment
show
outgrowth
outgrowth
plate
exhibit
expect
msc
cd
marker
fresh
short
exposur
abam
sampl
fare
similarli
longer
abam
exposur
outgrowth
yield
lower
fifteen
cultur
plate
evalu
growth
plate
exhibit
contamin
conclus
fresh
tissu
sampl
exhibit
similar
level
growth
ship
uc
tissu
dri
steril
cup
effici
preserv
outgrowth
potenti
prolong
exposur
abam
retard
tissu
outgrowth
averag
number
coloni
equal
fresh
short
abam
incub
extend
incub
abam
solut
gave
poorer
outgrowth
result
storag
cryopreserv
medium
preserv
tissu
outgrowth
potenti
method
success
provid
collect
cord
blood
tissu
commun
set
capabl
msc
outgrowth
thaw
backgroundcas
studi
practic
institut
process
time
total
blood
volum
bv
patient
maximum
liter
l
per
procedur
obtain
peripher
blood
stem
cell
consequ
patient
often
would
need
spend
hour
machin
would
desir
abl
specifi
exact
volum
blood
process
achiev
desir
cell
yield
thu
minim
patient
time
machin
nurs
time
perform
procedur
number
bag
submit
cryopreserv
storag
studi
designmethod
institut
recent
implement
new
spectra
optia
cmnc
collect
protocol
continu
flow
continu
collect
procedur
use
autom
interfac
manag
aim
system
precis
manag
separ
interfac
analysi
collect
data
suggest
highli
reliabl
collect
process
predict
algorithm
pa
base
linear
regress
patient
yield
normal
per
liter
blood
process
deriv
util
patient
patient
weight
kilogram
kg
target
dosekg
pa
calcul
exact
volum
whole
blood
process
achiev
request
dose
peripher
stem
cell
initi
equat
modifi
add
addit
predict
volum
account
natur
variabl
process
pa
test
prospect
clinic
set
resultsfind
patient
repres
allogen
autolog
donor
averag
blood
volum
process
rang
l
target
dose
achiev
patient
previou
practic
patient
would
requir
assum
standard
bv
procedur
process
averag
per
patient
rang
quantifi
well
new
pa
work
decid
evalu
ratio
actual
predict
volum
vs
ratio
actual
expect
yield
result
high
correl
two
ratio
indic
algorithm
produc
consist
result
conclus
predict
collect
process
time
period
analyz
robust
confirm
find
first
data
analysi
blood
volum
process
patient
time
machin
decreas
substanti
patient
need
hour
less
achiev
target
dose
nurs
lab
medic
technologist
seen
dramat
chang
workflow
number
bag
process
drop
lab
consequ
freezer
space
save
shorter
collect
time
allow
lab
medic
technologist
finish
work
earlier
day
implement
pa
produc
huge
increas
patient
provid
satisfact
import
factor
like
contribut
success
protocol
includ
precis
consist
aim
system
apheresi
devic
well
small
number
nurs
perform
procedur
result
less
variabl
econom
impact
pa
quantifi
might
interest
area
futur
studi
backgroundcas
studi
biosimilar
granulocyt
factor
recent
introduc
clinic
practic
use
stimul
certain
debat
regard
possibl
less
efficaci
secur
mobil
aim
studi
evalu
differ
good
bad
mobil
assess
need
plerixafor
biosimilar
use
studi
designmethod
retrospect
evalu
autolog
mobil
process
perform
june
march
patient
evalu
diagnos
malign
lymphoma
multipl
myeloma
primari
amyloidosi
mobil
accord
standard
protocol
collect
cellular
target
establish
two
group
good
bad
mobil
determin
predictor
unsuccess
mobil
defin
year
old
previou
fludarabin
lenalidomid
bendamustin
treatment
previou
regimen
present
peripher
cytopenia
activ
diseas
previou
mobil
failur
u
test
use
compar
mean
comparison
median
perform
median
test
count
perform
accord
ishag
protocol
advers
event
ae
analys
accord
ctcae
resultsfind
media
rang
gener
collect
paramet
day
blood
volum
process
exchang
volemia
seventeen
patient
consid
bad
mobil
need
plerixafor
undergon
collect
procedur
twice
statist
signific
differ
group
mobil
characterist
product
cellular
mean
sd
day
versu
cnkg
versu
versu
trend
toward
statist
signific
term
cmnkg
versu
gmkg
versu
signific
differ
mobil
characterist
product
cellular
group
five
mobil
ae
observ
muscl
pain
fever
flu
syndrom
grade
two
patient
could
undergo
hematopoiet
stem
cell
transplant
due
low
cellular
conclus
differ
product
collect
good
mobil
rich
gm
versu
poor
mobil
plerixafor
rich
cn
cmn
mobil
could
smaller
expect
sinc
signific
differ
compar
good
mobil
versu
bad
mobil
although
number
case
studi
limit
backgroundcas
studi
mesenchym
stem
cell
msc
wide
studi
shown
benefici
effect
tissu
regener
immunomodul
improv
multipl
organ
failur
caus
infect
sepsi
trauma
howev
msc
express
tissu
factor
may
risk
factor
thrombosi
especi
administr
system
follow
trauma
coagulopathi
common
appli
msc
preclin
anim
model
sought
determin
procoagul
properti
rat
msc
vitro
studi
designmethod
bone
marrow
adipos
deriv
msc
bmsc
amsc
isol
bone
femur
tibia
viscer
fat
tissu
normal
young
spragu
dawley
rat
respect
bmsc
amsc
cultur
passag
use
dmem
medium
fetal
bovin
serum
bmsc
amsc
passag
use
studi
tissu
factor
express
msc
determin
immunohistochemistri
citrat
whole
blood
collect
normal
rat
treat
rat
bmsc
amsc
low
medium
high
dose
respect
prothrombin
time
pt
coagul
properti
platelet
aggreg
respons
adp
collagen
measur
hemostasi
analyz
rotat
thromboelastometri
rotem
imped
aggregometri
multipl
respect
within
incub
resultsfind
tissu
factor
significantli
express
among
bmsc
amsc
passag
vitro
bmsc
amsc
dose
time
treatment
neither
shorten
elong
pt
whole
blood
howev
bmsc
amsc
significantli
shorten
clot
time
ct
none
second
versu
low
medium
high
dose
amsc
second
bmsc
second
p
clot
format
time
cft
p
increas
alpha
angl
p
natem
measur
significantli
affect
ct
cft
alpha
angl
extem
maximum
clot
firm
mcf
fibrinolyt
index
affect
msc
signific
impact
bmsc
amsc
platelet
aggreg
simul
adp
collagen
signific
differ
hemostat
platelet
function
found
treatment
bmsc
amsc
conclus
consist
report
human
deriv
msc
rat
bmsc
amsc
significantli
express
tissu
factor
earli
late
passag
led
signific
decreas
clot
time
variou
dose
time
treatment
howev
msc
direct
impact
platelet
aggreg
vitro
consid
procoagul
capabl
msc
futur
studi
necessari
determin
optim
dose
safeti
use
msc
system
applic
vivo
backgroundcas
studi
terumo
bct
recent
offer
new
method
peripher
blood
stem
cell
pbsc
collect
use
spectra
optia
apheresi
instrument
new
protocol
continu
mononuclear
cell
collect
cmnc
collect
cell
continu
oppos
older
protocol
mononuclear
cell
collect
mnc
protocol
batch
collect
dual
stage
collect
involv
addit
step
platelet
separ
mnc
within
cell
separ
chamber
institut
use
protocol
purpos
studi
compar
pbsc
product
characterist
run
time
cmnc
mnc
protocol
studi
designmethod
retrospect
review
comparison
paramet
collect
procedur
use
mnc
protocol
collect
procedur
use
cmnc
protocol
done
use
data
patientsdonor
includ
allogen
donor
well
procedur
detail
includ
run
time
flow
cytometri
marker
stem
cell
throughput
collect
effici
ce
platelet
loss
per
total
blood
volum
process
plt
losstbv
collect
product
characterist
includ
analysi
resultsfind
numer
result
summar
tabl
mnc
cmnc
donor
group
includ
allogen
donor
respect
donor
weight
significantli
differ
two
group
wbc
valu
also
similar
two
group
run
time
found
significantli
shorter
use
cmnc
protocol
compar
mnc
protocol
product
volum
also
significantli
lower
cmnc
group
compar
mnc
group
although
volum
lower
cmnc
product
significantli
higher
percentag
mononuclear
cell
mono
lymphocyt
lymph
collect
compar
mnc
product
throughput
significantli
higher
cmnc
group
mnc
group
ce
found
slightli
increas
cmnc
group
though
significantli
platelet
loss
significantli
differ
protocol
normal
total
blood
volum
product
hematocrit
hct
significantli
higher
use
cmnc
protocol
howev
red
blood
cell
volum
never
exceed
due
lower
product
volum
cmnc
protocol
conclus
cmnc
protocol
collect
smaller
volum
purer
product
compar
mnc
protocol
compar
platelet
red
blood
cell
loss
staff
member
perform
apheresi
procedur
pleas
shorter
run
time
backgroundcas
studi
hematopoiet
stem
cell
hsc
donor
recipi
need
match
blood
type
eventu
hsc
recipi
becom
blood
type
hsc
donor
scenario
becom
quit
conundrum
hsc
recipi
becom
patient
need
organ
transplant
order
patient
receiv
donor
organ
patient
donor
blood
type
hla
type
must
compat
studi
designmethod
blood
type
determin
use
gel
test
card
hla
type
determin
use
oligonucleotid
sso
primer
ssp
sequenc
base
type
sbt
technolog
hsc
sourc
bone
marrow
umbil
cord
blood
resultsfind
patient
origin
type
bone
marrow
donor
cord
blood
transplant
one
cord
blood
transplant
success
engraft
engraft
unit
type
donor
patient
type
type
patient
origin
type
receiv
bone
marrow
transplant
type
b
donor
patient
b
ab
sinc
patient
abo
front
match
note
must
made
confirm
abo
crossmatch
abo
match
patient
hla
abo
ident
kidney
match
father
type
b
previous
patient
father
abo
incompat
conclus
abo
hla
result
patient
patient
indic
hsc
transplant
engraft
result
also
indic
abo
hla
match
donor
differ
recipi
origin
abo
hla
type
due
variou
reason
exampl
side
effect
immunosuppress
patient
need
kidney
transplant
patient
enter
unet
system
accord
new
abo
hla
type
uno
regul
requir
patient
list
per
result
two
separ
abo
type
test
patient
antibodi
monitor
per
lab
polici
commun
transplant
center
blood
bank
crucial
backgroundcas
studi
mesenchym
stem
cell
msc
benefici
tissu
regener
immunomodul
improv
multipl
organ
failur
caus
infect
sepsi
trauma
msc
express
tissu
factor
tf
activ
clot
cascad
interfer
hemostasi
hypoxia
condit
occur
trauma
global
shock
site
injuri
known
chang
influenc
phenotyp
cell
includ
msc
studi
want
determin
hypoxia
chang
express
tissu
factor
properti
rat
msc
vitro
studi
designmethod
bone
marrow
adipos
deriv
msc
bmsc
amsc
isol
bone
femur
tibia
viscer
fat
tissu
normal
young
spragu
dawley
rat
respect
bmsc
amsc
cultur
use
dmem
medium
fetal
bovin
serum
either
normoxia
hypoxia
msc
growth
curv
measur
cell
counter
tf
express
determin
immunohistochemistri
measur
posit
neg
marker
msc
respect
flow
cytometri
citrat
rat
whole
blood
treat
msc
either
normoxia
hypoxia
coagul
properti
measur
hemostasi
analyz
rotat
thromboelastometri
rotem
resultsfind
hypoxia
potenti
growth
bmsc
depress
growth
amsc
day
comparison
normoxia
bmsc
amsc
equal
express
cultur
condit
tissu
factor
significantli
express
among
bmsc
amsc
normoxia
hypoxia
whole
blood
treat
bmsc
amsc
normoxia
significantli
shorten
clot
time
ct
control
versu
bmsc
amsc
second
natem
hypoxia
also
significantli
shorten
ct
bmsc
amsc
second
p
compar
control
chang
ct
significantli
differ
bmsc
amsc
maximum
clot
firm
mcf
fibrinolyt
index
chang
treatment
bmsc
amsc
regardless
normoxia
hypoxia
condit
conclus
tissu
factor
constitut
express
rat
bmsc
amsc
adjust
msc
cultur
condit
hypoxia
affect
tissu
factor
express
procoagul
properti
msc
bmsc
amsc
studi
also
suggest
procoagul
properti
affect
msc
recruit
injur
tissu
hypox
environ
futur
studi
necessari
determin
optim
dose
msc
whether
safe
use
msc
system
applic
trauma
backgroundcas
studi
current
clinic
gene
therapi
trial
use
freshli
collect
cryopreserv
cell
start
fraction
prior
gene
manipul
follow
cultur
end
product
infus
fresh
recipi
wider
applic
gene
therapi
manufactur
protocol
would
benefit
cryopreserv
dec
cell
manufactur
ie
immedi
modif
dec
help
delink
patient
prepar
condit
phase
cell
manufactur
eas
logist
cell
transport
ensur
fulfil
regulatori
product
releas
criteria
infus
object
studi
effect
dec
gene
transduc
mobil
peripher
blood
mpb
cell
studi
designmethod
cryopreserv
cell
healthi
adult
donor
thaw
transduc
tr
retronectin
coat
tissu
cultur
bag
lentiviru
concentr
media
human
serum
albumin
hsa
ngml
cytokin
scf
tpo
day
untransduc
utr
cell
cultur
control
tr
utr
fraction
standard
dmso
pentastarch
hsa
use
cryopreserv
viabil
hematopoiet
stem
cell
hsc
cell
phenotyp
cfu
assay
done
follow
first
thaw
ptxn
second
resultsfind
tnc
recoveri
decreas
gradual
donor
sampl
step
transduct
effici
cfu
similar
hsc
rang
cell
arm
compar
rang
cell
viabil
cfu
lower
tr
compar
utr
arm
differ
alter
tabl
conclus
dec
mpb
human
cell
decreas
tnc
recoveri
minim
effect
cell
phenotyp
transduct
effici
cell
function
hsc
number
within
accept
rang
lower
viabil
tr
arm
compar
utr
arm
like
due
vector
toxic
unaffect
addit
studi
assess
dec
mediat
chang
cell
earli
apoptot
marker
telomer
length
gene
express
engraft
potenti
nodscid
mice
inform
clinic
trial
backgroundcas
studi
autolog
peripher
blood
stem
cell
pbsc
transplant
use
power
resourc
treatment
hematolog
malign
cryopreserv
cell
routin
perform
allow
patient
adequ
condit
chemotherapi
case
pbsc
harvest
backup
option
remain
store
sever
year
although
effect
storag
lesion
product
still
controversi
work
present
retrospect
data
pbsc
infus
storag
studi
designmethod
product
harvest
patient
mobil
apheresi
cobe
flow
cytometri
analysi
cell
perform
prior
cryopreserv
cryoprotect
solut
freshli
prepar
addit
hydroxyethyl
starch
human
serum
albumin
dmso
final
concentr
pbsc
cryopreserv
direct
immers
mechan
freezer
dump
freez
store
transplant
viabil
determin
store
cryotub
sampl
trypan
blue
exclus
minut
prior
infus
cell
thaw
infus
bedsid
engraft
defin
first
day
consecut
day
neutrophil
count
platelet
count
day
resultsfind
multipl
myeloma
lymphoma
relaps
first
pbsc
transplant
median
patient
age
rang
median
storag
time
year
content
harvest
median
infus
content
x
cell
kg
cell
viabil
prior
cryopreserv
median
loss
engraft
median
neutrophil
recoveri
day
platelet
recov
day
compar
data
pbsc
infus
year
storag
neutrophil
platelet
recoveri
day
lower
valu
publish
aabb
pearson
correl
index
show
moder
neg
correl
r
storag
time
viabil
loss
infus
reaction
mild
nausea
cough
microbiolog
posit
sampl
report
prior
cryopreserv
conclus
cell
integr
cryopreserv
product
depend
differ
regard
mani
factor
affect
qualiti
pbsc
cool
rate
freez
curv
cryoprotect
solut
data
demonstr
even
wide
recommend
dump
freez
combin
constant
temperatur
storag
could
gener
good
result
cell
viabil
engraft
time
also
reason
consid
longer
storag
time
autolog
pbsc
second
chanc
therapeut
hematolog
malign
relaps
backgroundcas
studi
increas
number
patient
ongo
bone
marrow
transplant
requir
better
understand
hematopoiet
progenitor
cell
hpc
harvest
apheresi
obtain
enough
cell
transplant
without
submit
patient
donor
excess
procedur
object
evalu
whether
accur
predict
yield
hpc
harvest
apheresi
patient
healthi
donor
target
valu
tailor
tvt
apheresi
studi
designmethod
perform
retrospect
analysi
hpc
collect
use
cobe
spectra
devic
patient
healthi
donor
decemb
present
date
healthi
donor
mobil
four
day
patient
five
day
use
mozobil
x
cellsl
fourth
day
hpc
collect
perform
fourth
day
mobil
healthi
donor
fifth
day
patient
procedur
realiz
base
predict
algorithm
use
day
collect
estim
wbc
liter
process
obtain
suffici
stem
cell
transplant
algorithm
design
use
linear
regress
peripher
blood
day
collect
versu
collect
per
liter
blood
process
distinct
patient
donor
effici
coeffici
use
collect
materi
sent
analysi
total
calcul
final
laboratori
count
per
kilogram
compar
number
predict
algorithm
spearman
correl
evalu
whether
formula
effect
calcul
made
use
ibm
spss
softwar
resultsfind
among
patient
collect
hpc
autolog
transplant
need
one
day
hpc
harvest
need
two
day
need
three
day
collect
effici
ce
standard
error
mean
sem
compar
predict
valu
collect
final
product
found
strong
correl
p
patient
strong
correl
healthi
donor
p
conclus
use
mathemat
model
predict
algorithm
safe
low
cost
provid
good
tool
estim
wb
liter
process
avoid
unnecessari
procedur
patient
healthi
donor
backgroundcas
studi
mesenchym
stem
cell
msc
pois
invalu
part
regen
medicin
come
year
increasingli
common
cryopreserv
umbil
cord
deriv
msc
public
famili
bank
report
vari
techniqu
cryopreserv
abil
success
obtain
viabl
cultur
upon
thaw
studi
evalu
phenotyp
characterist
deriv
fresh
cryopreserv
cord
tissu
ct
describ
isct
posit
paper
minim
characterist
mesenchym
stem
cell
plastic
adher
studi
designmethod
umbil
cord
tissu
wash
blood
vessel
remov
cut
piec
wash
twice
salin
fresh
tissu
immers
salin
day
cultur
frozen
tissu
cryopreserv
least
hour
prior
cultur
coloni
form
unit
cfu
test
tissu
plate
directli
tissu
cultur
flask
follow
wash
pb
antibioticantimycot
tissu
allow
adher
minut
prior
addit
cell
cultur
media
media
chang
sever
time
week
cell
pass
robust
coloni
growth
observ
subsequ
cultur
confluenc
cell
test
msc
flow
panel
passag
prior
confluenc
resultsfind
fresh
cryopreserv
tissu
show
excel
coloni
form
capabl
averag
time
cellular
emerg
day
fresh
frozen
day
total
msc
reach
passag
fresh
frozen
cell
readi
flow
analysi
approxim
week
time
statist
differ
fresh
frozen
tissu
coloni
emerg
p
growth
rate
p
flow
cytometri
show
averag
posit
marker
neg
marker
statist
differ
fresh
frozen
flow
result
p
conclus
show
excel
adher
plastic
fresh
frozen
explant
cultur
consist
morpholog
flow
cytometri
analysi
show
strong
msc
phenotyp
fresh
frozen
sampl
data
show
cryogen
process
appear
detriment
effect
abil
obtain
msc
coloni
backgroundcas
studi
hematopoiet
stem
cell
transplant
hsct
therapeut
strategi
use
treat
patient
diseas
umbil
cord
blood
ucb
proven
graft
sourc
hsct
studi
shown
hsct
improv
surviv
surviv
rate
compar
convent
chemotherapi
treatment
increas
number
hsct
last
year
demand
qualiti
safeti
improv
cell
process
cryopreserv
servic
cell
recoveri
viabil
crucial
paramet
assess
ucb
qualiti
viabl
hsct
graft
sourc
studi
designmethod
ucb
unit
cryopreserv
period
year
analyz
unit
underw
red
cell
plasma
deplet
subject
control
rate
freez
subsequ
cryopreserv
use
dmso
dimethylsulfoxid
cryoprotect
concentr
inform
consent
unit
discard
term
unit
obtain
unit
thaw
c
water
bath
aliquot
dilut
proport
human
albumin
solut
plasmin
prepar
enabl
dmso
stabil
concentr
reduct
follow
analysi
perform
nucleat
cell
count
tnc
autom
hematolog
counter
cell
viabil
use
flow
citometri
cell
viabil
test
use
trypan
blue
exclus
dye
cell
viabil
assess
use
marker
flow
cytometr
analysi
resultsfind
ucb
storag
period
year
mean
cell
recoveri
mean
statist
signific
correl
storag
period
cell
recoveri
p
cell
viabil
mean
show
statist
signific
correl
unit
storag
period
p
post
thaw
cell
viabil
result
within
paramet
defin
studi
conclus
result
indic
correl
ucb
storag
time
period
cell
recoveri
well
cell
viabil
backgroundcas
studi
umbil
cord
uc
tissu
rich
sourc
mesenchym
stem
cell
msc
collect
noninvas
birth
store
potenti
futur
use
grow
number
stem
cell
bank
establish
uc
storag
program
base
mount
preclin
evid
therapeut
potenti
howev
littl
report
abil
isol
cell
uc
tissu
extend
period
cryopreserv
work
describ
character
isol
msc
uc
tissu
cryopreserv
composit
materi
famili
stem
cell
bank
year
studi
designmethod
donat
uc
unit
consent
mother
evalu
unit
cryopreserv
composit
tissu
piec
vapor
cryoprotect
unit
rapidli
thaw
rins
dpb
piec
excis
use
biopsi
punch
piec
unit
explant
grid
pattern
medium
incub
day
tissu
discard
media
exchang
cell
isol
day
count
subcultur
two
passag
end
passag
cell
collect
count
popul
doubl
time
calcul
isol
cell
unit
also
evalu
msc
immunomark
resultsfind
small
prolif
cell
fibroblast
morpholog
obtain
explant
yield
success
rate
cell
posit
msc
marker
respect
neg
hematopoiet
marker
passag
passag
doubl
time
day
day
respect
line
valu
report
msc
isol
fresh
uc
tissu
conclus
due
immatur
statu
eas
collect
potenti
therapeut
valu
uc
msc
appeal
candid
futur
clinic
research
treatment
present
work
demonstr
cryopreserv
uc
tissu
disrupt
abil
isol
function
msc
tissu
later
date
importantli
growth
characterist
isol
msc
appear
compar
report
msc
fresh
uc
tissu
base
consist
isol
lack
appar
impact
prolifer
kinet
reason
expect
cell
yield
rang
anticip
therapeut
requir
suffici
move
clinic
grade
bioreactor
expans
result
support
feasibl
storag
uc
composit
materi
futur
potenti
cell
isol
expans
clinic
relev
dose
backgroundcas
studi
larg
volum
leukapheresi
lvl
shown
enhanc
yield
collect
studi
evalu
perform
safeti
spectra
optia
cmnc
protocol
version
adult
pediatr
lvl
predict
algorithm
yield
also
test
studi
designmethod
evalu
retrospect
lvl
perform
adult
patient
lvl
pediatr
patient
treat
uhc
zagreb
march
till
septemb
mobil
regimen
combin
chemotherapi
filgrastim
poor
mobil
receiv
plerixafor
addit
combin
heparin
use
anticoagul
whole
blood
ratio
patient
rbc
prime
perform
lymphocyt
ly
monocyt
mo
collect
effici
ce
calcul
custom
predict
algorithm
determin
linear
regress
count
collect
blood
volum
process
predict
accuraci
evalu
compar
predict
valu
real
yield
result
present
median
iqr
resultsfind
group
ly
mo
ce
high
target
dose
success
reach
procedur
adult
children
procedur
well
toler
advers
reaction
restrict
mild
citrat
toxic
symptom
adult
pediatr
apheresi
went
unev
bleed
episod
occur
transfus
need
product
procedur
characterist
high
correl
collectedblood
volum
observ
group
adult
children
respect
p
suggest
yield
could
predict
base
blood
volum
process
linear
regress
equat
serv
predict
algorithm
high
correl
predict
yield
observ
yield
adult
children
respect
p
show
accuraci
algorithm
implement
algorithm
could
allow
spare
median
l
blood
adult
procedur
l
pediatr
procedur
conclus
lvl
perform
use
spectra
optia
cmnc
protocol
safe
effici
adult
low
bodi
weight
children
high
ly
mo
observ
group
implement
predict
algorithm
reliabl
minim
blood
volum
process
shorten
procedur
durat
reduc
anticoagul
volum
infus
improv
patient
comfort
backgroundcas
studi
steroid
refractori
acut
diseas
gvhd
seriou
complic
allogen
hematopoiet
stem
cell
transplant
hsct
experi
accumul
immunomodulatori
effect
mesenchym
stem
cell
msc
infus
numer
immunopatholog
disord
gvhd
signal
msc
natur
studi
designmethod
evalu
efficaci
msc
transfus
case
acut
gvhd
refractori
convent
immunosuppress
treatment
patient
gvhd
receiv
msc
deriv
wharton
jelli
bone
marrow
time
per
case
weekli
dose
million
cellskg
clinic
respons
assess
day
administ
first
dose
complet
remiss
defin
complet
disappear
symptom
partial
remiss
assess
signific
relief
symptomsand
gener
improv
patient
condit
resultsfind
patient
receiv
cycl
dose
per
cycl
median
age
year
old
malefemal
ratio
distribut
origin
malign
n
acut
myeloid
leukemia
acut
lymphoblast
leukemia
myelofibrosi
myelodysplast
syndrom
multipl
myeloma
lymphoma
nine
patient
undergon
allogen
hsct
match
unrel
donor
three
stem
cell
deriv
rel
first
episod
gvhd
hsct
start
median
day
involv
organ
skin
gut
skin
gut
combin
even
lung
case
median
time
msc
first
infus
day
stem
cell
transplant
hsct
day
first
episod
gvhd
cycl
led
complet
remiss
result
inparti
remiss
conclus
evalu
effect
treatment
gvhd
major
observ
case
overal
cumul
respons
rate
applic
msc
offer
promis
altern
therapi
gvhd
complic
hsct
research
need
determin
optim
start
treatment
along
issu
safeti
backgroundcas
studi
stem
cell
collect
leukapheresi
transplant
signific
endeavor
patient
clinic
team
whether
collect
allogen
autolog
patient
undergo
collect
physician
care
patient
alway
concern
whether
abl
harvest
enough
cell
transplant
engraft
typic
goal
adult
procedur
million
cellskg
patient
reach
goal
day
procedur
like
return
follow
day
undergo
second
procedur
reach
desir
goal
given
logist
challeng
plan
transplant
reason
attempt
optim
number
cell
collect
minim
number
collect
measur
patient
peripher
blood
leukapheresi
procedur
use
predict
collect
success
reach
million
cellskg
goal
ideal
minimum
lead
success
harvest
conclus
identifi
studi
designmethod
analyz
collect
data
patient
evalu
predict
valu
level
data
collect
month
everi
patient
underw
stem
cell
collect
four
patient
allogen
donor
autolog
donor
patient
weight
diagnosi
level
collect
run
time
amount
volum
process
absolut
viabl
cell
collect
record
collect
effici
cellskg
calcul
patient
resultsfind
data
show
strong
linear
correl
cellskg
patient
count
greater
collect
least
million
cellskg
patient
count
less
collect
less
million
cellskg
patient
count
variabl
result
control
age
clinic
diagnosi
demonstr
differ
younger
versu
older
patient
variou
diseas
state
likelihood
collect
target
yield
cell
conclus
level
peripher
blood
strong
predict
valu
cellskg
level
confid
know
patient
abl
produc
desir
million
cellskg
count
least
obtain
patient
count
counsel
collect
like
take
least
second
day
second
procedur
studi
includ
potenti
lengthen
run
time
volum
process
evalu
handl
patient
fall
conduct
backgroundcas
studi
critic
aspect
hematopoiet
progenitor
cell
process
cryopreserv
method
program
use
dump
freez
method
consist
product
placement
directli
liquid
nitrogen
vapour
addit
cryopreserv
solut
contain
dmso
final
concentr
he
hydroxyethyl
starch
pentastarch
he
sourc
critic
compon
cryoprotect
formul
discontinu
commerci
vendor
requir
altern
cryoprotect
formul
valid
minim
risk
patient
safeti
without
compromis
engraft
qualiti
studi
designmethod
valid
studi
consist
phase
first
evalu
efficaci
four
differ
cryoprotect
formul
second
evalu
full
scale
product
crypreserv
third
concurr
valid
clinic
transplant
phase
sampl
four
differ
cryoprotect
formul
test
tnc
viabil
cfu
three
point
manufactur
fresh
post
process
post
thaw
phase
ii
mock
hpc
apheresi
unit
use
comparison
freez
curv
control
replac
formul
phase
iii
five
clinic
transplant
perform
hpc
apheresi
product
cryopreserv
use
recommend
replac
hetastarch
resultsfind
phase
indic
aliquot
cryopreserv
dmso
he
hetastarch
behav
significantli
differ
cell
cryopreserv
control
term
cell
recoveri
viabil
cell
prolifer
assay
cfu
phase
ii
major
freez
profil
display
typic
expect
bulk
freez
profil
formul
phase
iii
transplant
perform
result
mean
engraft
time
day
advers
patient
reaction
observ
engraft
time
use
new
hetastarch
formula
compar
previou
engraft
time
signific
differ
conclus
chang
formul
cryoprotect
solut
repres
major
chang
could
signific
impact
qualiti
addit
maintain
current
dmso
final
concentr
critic
post
thaw
wash
perform
clinic
site
histori
demonstr
low
toxic
rate
exist
formul
studi
demonstr
accept
hetastarch
formul
use
dmso
hetastarch
replac
pentastarch
cryoprotect
formul
use
cryopreserv
hpc
apheresi
product
backgroundcas
studi
autolog
stem
cell
transplant
usual
perform
mobil
peripher
blood
stem
cell
pbsc
tradit
mobil
regimen
includ
granulocyt
coloni
stimul
factor
without
chemotherapi
failur
rate
rang
plerixafor
adjunct
agent
use
improv
mobil
mani
clinic
set
howev
high
cost
signific
concern
dose
therefor
patient
weigh
would
requir
second
vial
thu
doubl
drug
cost
implement
polici
cap
plerixafor
patient
weigh
retrospect
studi
compar
mobil
patient
receiv
cap
dose
histor
control
patient
receiv
full
uncap
dose
studi
designmethod
patient
weigh
crcl
receiv
cap
full
dose
plerixafor
identifi
pharmaci
databas
electron
medic
record
use
collect
baselin
characterist
cell
collect
data
resultsfind
total
consecut
patient
includ
cap
full
dose
group
respect
show
compar
baselin
distribut
age
weight
gender
diagnos
plerixafor
given
upfront
rescu
agent
due
suboptim
mobil
group
cap
dose
group
fewer
patient
receiv
plerixafor
upfront
compar
histor
control
use
half
number
vial
plerixafor
collect
similar
number
kg
achiev
compar
collect
success
rate
tabl
comparis
patient
receiv
cap
vs
full
dose
plerixafor
median
rang
percentag
report
conclus
strategi
dose
cap
plerixafor
patient
achiev
compar
mobil
outcom
decreas
drug
cost
half
backgroundcas
studi
peripher
blood
stem
cell
pbsc
collect
apheresi
relat
unrel
donor
continu
import
allogen
transplant
sourc
report
sever
thousand
pbsc
transplant
everi
year
pbsc
product
cell
dose
utmost
import
engraft
cellskg
recipi
weight
consid
minimum
requir
higher
dose
requir
condit
haploident
transplant
studi
evalu
effect
ethnic
success
pbsc
mobil
vasu
report
white
donor
lowest
cell
count
mobil
compar
black
asianpacif
hispan
donor
popul
donor
richa
report
race
influenc
mobil
cohort
donor
much
smaller
larg
cohort
donor
hsu
report
african
american
much
higher
level
mobil
compar
white
data
need
elucid
area
ensur
optim
donor
select
transplant
center
studi
designmethod
pbsc
donor
collect
januari
decemb
retrospect
evalu
repres
uniqu
donor
one
donor
requir
emerg
central
line
exclud
analysi
data
collect
remain
donor
includ
age
year
time
donat
gender
ethnic
hispan
vs
hispan
donor
peripher
race
group
includ
south
asian
korean
african
american
northern
european
white
north
american
indian
western
european
mix
north
american
resultsfind
tabl
show
data
donor
stratifi
age
group
mean
rang
peripher
blood
calcul
data
show
group
youngest
donor
higher
level
group
reach
statist
signific
compar
youngest
group
yr
oldest
group
yr
hispan
donor
show
statist
similar
level
age
group
moreov
hispan
older
age
group
statist
higher
level
older
age
group
conclus
analysi
sequenti
unrel
pbsc
donor
hispan
donor
maintain
similar
level
even
donor
age
donor
show
decreas
level
age
proven
data
would
suggest
genet
factor
modul
person
abil
mobil
stem
cell
age
genet
factor
differ
ethnic
group
small
data
set
would
suggest
peopl
hispan
ethnic
maintain
robust
quickli
respons
stem
cell
pool
even
age
studi
larger
cohort
need
valid
observ
proven
far
reach
implic
within
stem
cell
research
therapi
arena
backgroundcas
studi
updat
hpc
apheresi
collect
softwar
led
higher
collect
volum
organ
human
progenitor
cell
hpc
product
without
correspond
increas
total
cellular
count
incorpor
volum
reduct
step
therefor
warrant
larger
product
volum
requir
addit
time
transfus
lead
larger
dmso
load
recipi
often
result
need
transfus
sever
day
object
studi
develop
suitabl
mock
hpc
mhpc
product
evalu
effect
biosaf
pericel
volum
reduct
technolog
white
blood
cell
wbc
recoveri
viabil
studi
designmethod
hpc
product
readili
avail
develop
mhpc
creat
whole
blood
buffi
coat
bc
fresh
abo
compat
bc
pool
concentr
use
centrifug
manual
extract
supernat
red
cell
mhpc
product
dilut
plasma
produc
appropri
concentr
volum
hpc
collect
data
last
year
analyz
determin
percentil
median
percentil
valu
hpc
volum
wbc
concentr
six
mhpc
product
test
three
high
wbc
x
cell
ml
three
low
wbc
x
cell
ml
concentr
high
low
median
volum
unit
process
sequenti
high
median
low
volum
henc
highest
mhpc
volum
process
volum
reduct
first
sepax
pericel
protocol
kit
analyz
reconstitut
volum
adjust
next
volum
target
volum
reduc
forth
one
addit
mock
product
prepar
reproduc
studi
volum
reduc
three
time
wbc
concentr
viabil
determin
volum
reduct
control
sampl
remov
product
prior
process
sat
bench
top
end
protocol
assess
chang
cell
concentr
viabil
time
resultsfind
mock
hpc
product
mean
start
viabil
rang
hematocrit
well
maximum
allow
limit
pericel
signific
differ
wbc
recoveri
chang
viabil
seen
mhpc
product
aggreg
data
show
mean
wbc
recoveri
volum
reduct
process
chang
viabil
recoveri
protocol
use
salvag
product
volum
reduct
gave
recoveri
chang
viabil
input
product
method
found
cv
chang
wbc
concentr
wbc
viabil
test
product
significantli
differ
unprocess
control
sampl
conclus
mock
bc
product
suitabl
altern
hpc
product
avail
develop
good
use
product
otherwis
direct
reject
dispos
volum
reduct
protocol
evalu
minim
impact
wbc
concentr
wbc
viabil
mock
product
found
highli
reproduc
give
confid
valuabl
process
step
hpc
facilit
transfus
hpc
product
recipi
protocol
use
patient
hpc
product
engraft
kinet
track
studi
backgroundcas
studi
mani
center
use
bedsid
thaw
infus
maintain
function
viabl
stem
cell
fundament
transplant
success
reduc
potenti
damag
cell
due
dmso
exposur
product
must
administ
promptli
like
transplant
center
previous
infus
product
graviti
high
flow
rate
central
venou
line
exist
peripher
line
central
cathet
picc
sometim
use
picc
line
infus
result
prolong
infus
time
caus
aggreg
acceler
cell
death
infus
time
decreas
transfer
product
syring
use
manual
push
may
increas
contamin
risk
infus
pump
routin
use
blood
product
commonli
use
administr
peripher
blood
stem
cell
product
pbsc
use
pump
provid
consist
control
infus
practic
studi
analyz
safeti
infus
pump
use
thaw
autolog
pbsc
studi
designmethod
safeti
analysi
sigma
spectrum
infus
pump
baxter
perform
phase
vitro
simul
vivo
clinic
assess
first
phase
cryopreserv
pbsc
product
test
two
aliquot
thaw
simultan
product
one
pass
infus
pump
second
control
aliquot
drain
graviti
aliquot
test
baselin
total
nucleat
cell
tnc
count
viabil
final
tnc
recoveri
trypan
blue
tb
viabil
viabil
potenc
cfu
effect
exposur
dmso
assess
visual
inspect
product
aggreg
measur
viabil
hour
post
thaw
second
vivo
phase
includ
use
infus
pump
consecut
autolog
patient
comparison
infus
transplant
outcom
previou
infus
graviti
drip
comparison
variabl
includ
infus
rate
advers
event
ae
engraft
time
resultsfind
signific
differ
observ
infus
pump
drip
product
test
vitro
includ
tnc
recoveri
cell
viabil
potenc
method
tnc
tb
viabil
decreas
within
hour
cell
viabil
remain
stabl
hour
post
thaw
small
aggreg
appear
hour
method
increas
similar
rate
time
comparison
infus
transplant
outcom
drip
infus
pump
patient
show
signific
differ
measur
variabl
engraft
time
similar
group
anc
day
engraft
pump
drip
respect
platelet
day
engraft
pump
drip
respect
infus
rate
slightli
higher
pump
group
control
patient
requir
transfer
product
syring
due
slow
infus
rate
other
experienc
allerg
hypotens
infus
advers
event
conclus
signific
vitro
clinic
differ
observ
thaw
pbsc
infus
graviti
infus
pump
result
demonstr
use
pump
pbsc
infus
safe
provid
consist
infus
rate
elimin
need
transfer
product
syring
result
compar
engraft
time
backgroundcas
studi
zika
viru
zikv
link
central
nervou
system
malform
fetus
due
theoret
risk
zikv
transmiss
hctp
document
transplacent
transmiss
first
trimest
pregnanc
deliveri
fda
identifi
zikv
relev
communic
diseas
amend
donor
elig
guidelin
fda
donor
screen
recommend
reduc
risk
transmiss
zika
viru
human
cell
tissu
cellular
product
march
donor
potenti
exposur
zikv
shall
declar
inelig
one
blood
test
avail
investig
blood
donor
purpos
studi
determin
impact
matern
potenti
exposur
zikv
donor
elig
cb
bank
donor
studi
designmethod
cord
blood
unit
cbu
collect
five
collect
site
qualifi
clinic
grade
assess
elig
determin
matern
medic
histori
risk
factor
inform
test
result
complet
donor
declar
inelig
zikv
reason
indic
tabl
resultsfind
elig
assign
clinic
cbu
collect
cbu
declar
inelig
cbu
clinic
cbu
inelig
cbu
least
onezikv
risk
factor
sinc
aim
studi
analysi
zikv
impact
donor
elig
rank
zikv
primari
reason
cbu
addit
risk
factor
donor
racial
distribut
among
zikv
inelig
cbu
caucasian
asian
blackaa
racial
distribut
clinic
cbu
donor
caucasian
asian
blackaa
suggest
race
correl
risk
factor
driven
cultur
habit
famili
travel
case
onlyth
sexual
partner
potenti
exposur
determin
donor
inelig
conclus
studi
indic
current
lead
risk
factor
inelig
cb
donor
potenti
exposur
zikv
inelig
cbu
bank
cbu
studi
period
anticip
number
case
decreas
follow
matern
educ
travel
warn
recogn
import
zikv
public
health
potenti
transmiss
via
hctp
product
fda
approv
screen
test
hctp
donor
becom
time
necess
acknowledg
fund
zimmer
biomet
zimmer
biomet
compani
ibgrl
red
cell
refer
nhsbt
reagent
backgroundcas
studi
storag
red
blood
cell
rbc
becom
less
deform
deplet
adenosin
triphosph
atp
releas
phospholipid
accumul
molecul
free
iron
haemoglobin
increas
potenti
adhes
recipi
vascular
endothelium
longer
rbc
storag
may
impair
transfus
outcom
due
impair
oxygen
deliveri
promot
oxid
stress
increas
state
coagul
steril
rejuven
solut
contain
pyruv
inosin
phosphat
adenin
citra
lab
llc
braintre
approv
us
food
drug
administr
rejuven
store
rbc
solut
act
restor
atp
store
rbc
level
equival
circul
aim
studi
investig
effect
treatment
rejuven
solut
crossmatch
reaction
profil
phenotyp
state
store
rbc
studi
designmethod
aliquot
remov
aborh
group
leucocyt
deplet
rbc
unit
n
store
sagm
day
act
untreat
control
remaind
unit
underw
treatment
rejuven
solut
follow
cell
wash
twice
sagm
manual
process
repres
current
transfus
laboratori
practic
unit
crossmatch
plasma
random
donor
use
diam
gel
column
glass
tube
techniqu
phenotyp
investig
commerci
antisera
perform
identifi
effect
rejuven
solut
treatment
exert
rbc
surfac
antigen
b
c
c
e
e
k
n
lua
k
kpa
kpb
lea
leb
fya
fyb
jka
jkb
includ
whether
expos
crypt
antigen
tn
tk
th
tx
cad
crossmatch
phenotyp
agglutin
score
observ
untreat
treat
rbc
compar
resultsfind
crossmatch
find
defin
compat
suitabl
incompat
studi
identifi
differ
crossmatch
reaction
profil
untreat
treat
rbc
furthermor
differ
observ
phenotyp
state
untreat
treat
rbc
conclus
treatment
day
old
store
rbc
rejuven
solut
effect
crossmatch
reaction
profil
phenotyp
state
compar
match
untreat
sampl
backgroundcas
studi
aim
studi
evalu
platelet
function
relationship
abo
phenotyp
regular
apheresi
platelet
donor
blood
bank
locat
intermedi
altitud
studi
designmethod
blood
sampl
collect
apheresi
platelet
donor
accept
platelet
function
determin
dynam
flow
siemensdad
behr
collagenadp
closur
time
refer
rang
rr
second
collagenepinephrin
rr
second
data
analyz
unpair
test
chi
squar
resultsfind
sixti
percent
particip
blood
group
women
men
women
men
b
woman
men
ab
men
associ
donor
age
collagenadp
collagenepinephrin
closur
time
men
women
differ
found
averag
median
gender
platelet
count
closur
time
collagenadp
collagenepinephrin
howev
men
women
show
prolong
collagenepinephrin
closur
time
respect
refer
rang
p
likewis
men
women
collagenadp
closur
time
refer
valu
p
donor
present
increas
collagenepinephrin
time
vs
donor
p
similarli
donor
prolong
collagenadp
vs
donor
p
overal
donor
particip
prolong
platelet
function
time
p
found
donor
collagenepinephrin
time
baselin
vs
donor
p
addit
observ
decreas
collagenadp
time
donor
vs
donor
time
reduct
two
test
evalu
donor
vs
donor
p
suggest
relationship
alter
abo
phenotyp
conclus
contrast
previou
report
gener
popul
apheresi
platelet
donor
phenotyp
like
alter
platelet
function
test
depend
collagen
epinephrin
adp
condit
associ
higher
hbhct
sea
level
could
eventu
reflect
variabl
clinic
effect
transfus
product
backgroundcas
studi
cryopreserv
platelet
product
burgeon
worldwid
current
autom
platelet
cryopreserv
method
contrast
red
blood
cell
cryopreserv
use
acp
haemonet
corp
baintre
autom
process
within
close
system
increas
labour
product
provid
high
qualiti
blood
compon
purpos
autom
platelet
cryopreserv
procedur
studi
designmethod
apheresi
platelet
concentr
pc
collect
trima
accel
system
platelet
count
perform
use
abx
micro
pc
centrifug
sorval
centrifug
sorval
usa
min
combin
cryoprotect
dmsodextran
cryosur
germani
use
pc
cryopreserv
cryopreserv
pc
cpc
frozen
store
kelvin
chest
freezer
cpc
thaw
degre
c
barkey
plasmatherm
min
cpc
osmol
measur
osmomat
osmomet
resultsfind
stage
platelet
cryopreserv
technolog
develop
platelet
cryopreserv
close
system
patent
ru
first
stage
cpc
spun
separ
plasma
prp
fraction
plasma
ppp
second
step
resuspend
prp
ad
combin
dmsodextran
cryosur
cryoprotect
obtain
final
concentr
dmso
platelet
suspens
injectomat
mc
agilia
npbi
compomix
instrument
autom
phase
pc
frozen
osmol
less
mosml
prp
ppp
frozen
cool
rate
store
chest
freezer
month
defrost
platelet
also
process
close
system
patent
ru
transfer
set
made
possibl
autom
platelet
resuspens
plasma
agenc
prp
resuspend
plasma
lower
osmol
mosml
recoveri
platelet
origin
popul
defrost
pc
store
continu
gentl
stir
helmer
platelet
agit
longer
hour
transfus
took
min
cryopreserv
pc
process
thaw
platelet
autom
process
account
bulk
time
min
conclus
autom
techniqu
develop
reduc
workload
offer
reproduc
procedur
high
cpc
qualiti
use
close
system
rule
bacteri
contamin
employ
infus
pump
platelet
stirrer
precis
flow
regul
enabl
adequ
osmol
monitor
backgroundcas
studi
recent
publish
fda
draft
guidanc
describ
bacteri
test
enhanc
safeti
avail
platelet
outlin
step
blood
collect
establish
transfus
servic
extend
apheresi
platelet
date
day
evalu
compar
cultur
base
rapid
base
test
method
detect
bacteri
contamin
apheresi
platelet
studi
designmethod
larg
commun
blood
center
transfus
servic
collect
leukoreduc
apheresi
platelet
lrap
use
amicu
separ
system
fenwal
lake
zurich
il
trima
accel
system
terumo
bct
lakewood
co
lrap
unit
sampl
day
secondari
cultur
use
bactalert
biomerieux
durham
nc
rapid
bacteri
test
use
bactx
immunet
boston
pgd
verax
marlborough
lrap
unit
still
avail
also
sampl
test
rapid
test
day
total
lrap
unit
test
period
cultur
rapid
test
day
rapid
test
day
rapid
test
method
also
evalu
base
cost
eas
use
incub
time
indic
use
resultsfind
lrap
unit
evalu
studi
true
neg
tn
fals
posit
fp
day
test
bactalert
tn
day
bactx
test
result
show
tn
day
tn
day
test
use
pgd
kit
show
tn
day
tn
fp
day
fp
result
confirm
perform
secondari
cultur
found
neg
bactx
requir
specif
analyz
minut
requir
result
interpret
instrument
requir
pgd
reaction
read
within
minut
conclus
result
evalu
make
pgd
best
fit
blood
center
base
transfus
servic
pgd
offer
shorter
time
read
result
need
initi
invest
analyz
indic
lrap
plasma
lrap
pasplasma
eas
use
allow
test
lrap
day
day
night
shift
accomplish
without
addit
staf
allow
extend
outdat
storag
lrap
backgroundcas
studi
growth
factor
thought
among
activ
compon
serum
use
treatment
syndrom
stabil
growth
factor
frozen
storag
mini
contain
unknown
product
store
feasibl
store
product
household
freezer
make
product
avail
patient
need
serum
eye
drop
purpos
studi
demonstr
stabil
growth
factor
content
human
serum
longtim
storag
pack
new
micro
dose
devic
singl
use
eye
drop
studi
designmethod
serum
produc
whole
blood
donat
healthi
donor
quickli
frozen
frozen
storag
month
control
thaw
six
differ
sera
use
fill
larg
number
mini
contain
refrozen
store
either
storag
month
interv
sampl
test
sever
growth
factor
use
luminex
multiplex
assay
compar
control
sampl
store
growth
factor
test
abbb
vegf
egf
studi
studi
without
preset
accept
criteria
resultsfind
abund
growth
factor
averag
resp
ngml
also
detect
rel
high
concentr
human
serum
averag
ngml
egf
vegf
detect
rel
low
valu
resp
ngml
ngml
ngml
averag
level
close
detect
limit
ngml
control
store
show
growth
factor
close
initi
valu
sampl
moment
fill
mini
contain
serum
store
month
factor
show
less
decreas
except
show
resp
lower
valu
serum
store
valu
egf
vegf
stabl
wherea
show
decreas
resp
conclus
human
serum
eye
drop
store
new
micro
dose
devic
household
freezer
profession
freezer
least
one
year
prepar
without
larg
decreas
growth
factor
content
maximum
decreas
found
serum
store
yet
unknown
test
compon
add
vivo
effect
serum
eye
drop
minim
concentr
ensur
vivo
effect
stabil
test
combin
vitro
vivo
applic
requir
extend
beyond
year
backgroundcas
studi
differ
blood
manufactur
method
influenc
residu
cell
number
membran
vesicul
may
affect
qualiti
safeti
blood
compon
aim
identifi
quantifi
character
residu
cell
extracellular
vesicl
ev
store
rbc
product
produc
differ
blood
manufactur
method
studi
designmethod
rbc
unit
produc
use
whole
blood
filtrat
wbf
red
cell
filtrat
rcf
apheresi
whole
blood
deriv
wbd
method
examin
per
method
residu
platelet
white
blood
cell
wbc
measur
day
use
flow
cytomet
fc
storag
day
number
cell
originsurfac
marker
ev
assess
fc
concentr
ev
examin
use
tunabl
resist
plu
sens
trp
resultsfind
day
apheresi
wbd
unit
significantli
greater
residu
platelet
comparison
rcf
vs
apheresi
p
wbd
p
wbf
vs
apheresi
p
wbd
p
method
rcf
unit
yield
lowest
count
day
highest
number
apheresi
day
wbd
day
similarli
signific
differ
among
method
number
rcf
contain
smallest
concentr
moreov
trp
fc
show
increas
total
number
ev
day
vs
day
process
method
noteworthi
trp
show
number
small
evsexosom
greater
larg
ev
product
day
highest
level
ev
apheresi
unit
trp
result
also
show
signific
differ
ev
amongst
rbc
product
p
conclus
studi
show
method
manufactur
significantli
affect
rbc
ev
characterist
throughout
storag
potenti
impact
qualiti
safeti
rbc
product
differ
ev
concentr
observ
manufactur
method
warrant
examin
potenti
immunomodulatori
effect
clinic
consequ
backgroundcas
studi
whole
blood
demonstr
retain
hemostat
activ
includ
platelet
aggreg
function
least
week
storag
without
agit
may
possibl
extend
preserv
platelet
function
agit
wb
order
fulli
character
qualiti
wb
store
without
agit
evalu
complement
activ
marker
inflammatori
potenti
studi
designmethod
subject
donat
one
unit
wb
collect
citrat
phosphat
dextros
anticoagul
adenin
wb
leukoreduc
separ
compon
unit
store
refriger
condit
day
collect
unit
store
day
without
agit
unit
store
day
agit
storag
model
hybrid
incub
set
end
end
rotat
rpm
appropri
time
point
platelet
free
plasma
obtain
wb
sampl
store
frozen
plasma
analyz
elisa
assay
determin
complex
tat
marker
coagul
solubl
measur
platelet
activ
granul
releas
plasmin
complex
pap
marker
fibrinolysi
plasminogen
activ
inhibitor
anoth
fibrinolyt
measur
complement
activ
marker
data
analyz
one
way
repeat
measur
anova
resultsfind
platelet
recov
unit
store
day
without
agit
level
meet
fda
requir
x
platelet
per
wb
unit
subsequ
wb
agit
platelet
recoveri
differ
seen
elisa
analysi
agit
sampl
chang
seen
tat
pap
level
day
collect
measur
signific
elev
indic
activ
platelet
inhibit
fibrinolysi
p
activ
complement
peptid
elev
time
p
howev
level
normal
refer
rang
time
maximum
refer
respect
conclus
whole
blood
agit
appear
necessari
recov
platelet
fda
requir
whole
blood
store
day
show
activ
complement
protein
contrast
studi
store
red
blood
cell
elev
report
wb
show
elev
complement
gradual
modestli
activ
level
remain
within
refer
rang
whole
blood
shelf
life
backgroundcas
studi
blood
system
platelet
ceru
concord
ca
use
pathogen
reduct
pr
platelet
collect
replac
irradi
cmv
test
bacteri
cultur
point
issu
bacteri
test
better
understand
pr
compat
impact
split
rate
data
analyz
blood
center
roughli
platelet
collect
per
year
split
rate
prior
intercept
adopt
exclud
tripl
post
adopt
intercept
high
hospit
demand
catalyz
center
object
treat
mani
collect
possibl
goal
pathogen
reduc
singl
doubl
dose
platelet
collect
platelet
collect
must
meet
specif
volum
concentr
dose
rang
qualifi
intercept
pr
chang
made
apheresi
devic
includ
ad
follow
collect
target
studi
designmethod
four
month
collect
retrospect
analyz
platelet
collect
evalu
determin
elig
pr
treatment
product
meet
pr
process
specif
unless
intend
hla
match
recipi
hospit
abl
accept
pr
product
underw
pr
treatment
regardless
potenti
impact
split
rate
minimum
dose
requir
classifi
collect
singl
doubl
respect
volumedos
mitig
remov
volum
increas
number
product
elig
pr
util
studi
thu
unit
treat
convent
volum
dose
andor
concentr
meet
pr
specif
without
manipul
resultsfind
singl
doubl
collect
elig
underw
pr
treatment
split
rate
singl
doubl
collect
tabl
percent
collect
elig
pr
treatment
conclus
possibl
treat
singl
doubl
platelet
donat
intercept
pr
blood
center
current
state
slight
impact
split
rate
center
will
make
alter
target
practic
platelet
collect
fall
outsid
specif
pr
process
distribut
convent
product
strategi
increas
elig
toward
minim
impact
split
rate
investig
includ
incorpor
new
collect
set
split
tripl
volumedos
mitig
evalu
need
determin
addit
quantiti
pr
elig
product
result
chang
backgroundcas
studi
platelet
plt
store
room
temperatur
rt
support
bacteri
prolifer
contamin
unit
therefor
septic
transfus
reaction
may
occur
store
plt
cold
temperatur
ct
limit
bacteri
growth
result
rapid
clearanc
upon
transfus
develop
altern
storag
condit
usual
involv
costli
radiolabel
human
studi
success
studi
difficult
predict
base
vitro
studi
thu
anim
model
plt
circul
could
predict
perform
human
plt
human
volunt
would
posit
impact
develop
altern
storag
condit
studi
designmethod
design
immunodefici
scid
mous
model
evalu
recoveri
human
plt
compar
side
side
radiolabel
studi
human
volunt
conduct
evalu
new
plt
storag
condit
thermocycl
plt
hr
ct
hr
tc
autolog
apheresi
plt
store
rt
tc
ct
radiolabel
infus
healthi
human
volunt
plt
also
infus
mice
blood
sampl
human
mice
collect
time
gener
surviv
clearanc
curv
plt
circul
flow
cytometri
use
detect
analyz
human
plt
mous
sampl
gener
curv
count
consid
background
resultsfind
mean
recoveri
infus
plt
rt
tc
ct
human
mice
mean
recoveri
plt
rt
ct
ct
compar
perform
plt
human
mice
express
recoveri
percentag
rt
recoveri
human
tc
ct
rt
mice
tc
ct
rt
area
surviv
curv
auc
calcul
individu
mous
studi
human
trial
data
set
result
auc
normal
rt
plt
human
tc
plt
auc
ct
plt
auc
compar
rt
plt
human
comparison
tc
plt
auc
ct
plt
auc
rt
auc
mice
calcul
ratio
auc
tc
plt
ct
plt
human
data
set
mous
model
data
set
respect
conclus
scid
mous
model
differenti
rt
plt
ct
plt
similar
human
base
auc
plt
recoveri
data
howev
mous
model
differenti
ct
plt
tc
plt
occur
human
even
though
mous
model
differenti
ct
plt
tc
plt
may
still
use
tool
screen
novel
storag
condit
human
plt
backgroundcas
studi
initi
focus
improv
donor
collect
process
drove
us
investig
opportun
compon
manufactur
process
goal
maintain
blood
qualiti
streamlin
manufactur
autom
document
compomat
evalu
use
approach
includ
compon
manufactur
staff
equip
manag
qa
regulatori
affair
studi
designmethod
comprehens
evalu
team
decid
purchas
compomat
compomast
net
softwar
data
manag
implement
plan
novemb
central
process
new
work
counter
instal
freseniu
kabi
instal
compomat
compomast
june
train
valid
success
complet
full
launch
occur
devic
sop
train
perform
train
qualif
checklist
complet
technician
requir
number
success
unit
process
complet
decemb
valid
complet
sign
march
manufactur
data
collect
use
compomast
net
data
manag
system
qualiti
control
softwar
platelet
plt
paramet
includ
plt
count
plt
weight
plt
yield
implement
bi
implement
ai
compomat
system
data
point
collect
unit
bi
unit
ai
resultsfind
upon
initi
implement
staff
train
use
compomat
found
easi
plt
weight
spread
reduc
averag
averag
gm
actual
plt
weight
reduc
averag
result
averag
increas
recov
plasma
per
unit
plt
count
averag
increas
count
neglig
chang
plt
yield
conclus
plt
weight
spread
reduc
implement
compomat
plt
concentr
increas
averag
abl
consist
produc
smaller
volum
plt
averag
gm
gave
us
plasma
per
unit
recov
plasma
team
intend
review
dryer
cryo
next
step
potenti
addit
plasma
yield
recov
plasma
backgroundcas
studi
upon
implement
close
system
cell
processor
glycerol
deglycerol
red
cell
concentr
rcc
mani
rare
rcc
frozen
use
current
manual
open
system
glycerol
method
remain
organ
frozen
inventori
studi
undertaken
assess
feasibl
deglycerol
exist
inventori
close
cell
processor
evalu
chang
may
impact
red
blood
cell
rbc
vitro
qualiti
close
cell
processor
use
fix
centrifug
bowl
deglycerol
rbc
larg
small
unit
assess
determin
impact
cellular
loss
variabl
hematocrit
product
studi
designmethod
aborh
match
lr
sagm
rcc
pool
split
produc
larg
small
rcc
rcc
store
glycerol
manual
mix
glycerol
rcc
freez
bag
unit
frozen
remov
frozen
storag
thaw
water
bath
larg
rcc
small
rcc
deglycerol
use
organ
current
procedur
cobe
cell
processor
prior
salin
dextros
remain
rcc
transfer
bag
spun
allow
remov
excess
glycerol
manual
extract
achiev
hematocrit
deglycerol
centrifug
bowl
rbc
qualiti
test
resultsfind
larg
rcc
significantli
higher
hemoglobin
per
unit
cobe
lower
cell
recoveri
cobe
p
smaller
rcc
cell
processor
larg
rcc
deglycerol
cobe
higher
hemolysi
p
supernat
potassium
small
volum
rcc
larg
cobe
rcc
higher
hematocrit
hemoglobin
recoveri
larg
rcc
howev
cobe
rcc
higher
p
hemolysi
level
rcc
cobe
rcc
fail
meet
regulatori
hemolysi
standard
conclus
addit
bolu
dose
glycerol
rcc
differ
volum
result
differ
concentr
glycerol
frozen
rcc
product
may
lead
differ
frozen
rcc
qualiti
addit
size
rcc
impact
qualiti
rcc
process
close
cell
processor
due
centrifug
bowl
volum
limit
result
lower
recoveri
hemoglobin
hematocrit
use
close
cell
processor
storag
met
vitro
qualiti
standard
recoveri
hemoglobin
hematocrit
drastic
reduc
hemolysi
level
rcc
glycerol
manual
cell
processor
therefor
use
deglycerol
rcc
glycerol
use
manual
open
system
glycerol
method
backgroundcas
studi
wash
platelet
may
indic
thrombocytopen
patient
experi
sever
allergicanaphylact
febril
reaction
convent
platelet
transfus
platelet
wash
process
may
delay
transfus
studi
conduct
evalu
manual
platelet
wash
method
mm
use
salin
centrifug
wash
method
sam
use
cobe
cell
processor
studi
designmethod
studi
unit
singl
donor
platelet
evalu
wash
use
mm
wash
use
sam
collect
data
includ
product
weight
platelet
count
total
plasma
protein
presenceabs
platelet
clump
calcul
protein
remov
calcul
platelet
recoveri
rate
platelet
count
measur
sysmex
exn
total
plasma
protein
sampl
measur
roch
coba
resultsfind
tabl
show
averag
platelet
recoveri
sam
significantli
higher
compar
mm
mm
slightli
higher
averag
protein
remov
compar
sam
platelet
clump
observ
either
mm
sam
observ
time
mm
took
minut
longer
sam
tabl
comparison
manual
wash
method
mm
vs
method
sam
prepar
wash
platelet
plt
conclus
sam
util
cobe
blood
cell
processor
yield
wash
platelet
significantli
higher
platelet
recoveri
less
time
compar
mm
method
yield
compar
protein
remov
sam
feasibl
altern
manual
techniqu
prepar
wash
platelet
backgroundcas
studi
blood
system
platelet
current
licens
pathogen
reduct
pr
amicu
platelet
intersol
input
platelet
dose
platelet
plasma
pa
new
platelet
process
set
design
three
storag
contain
ts
process
apheresi
platelet
compon
contain
dose
platelet
volum
studi
designmethod
apheresi
pc
collect
plasma
one
studi
perform
nomin
dose
platelet
volum
plasma
use
singl
donor
apheresi
collect
two
studi
perform
evalu
high
dose
high
volum
condit
x
platelet
use
either
singl
pool
donat
input
pc
treat
intercept
ts
set
end
day
post
collect
incub
time
compound
adsorpt
devic
cad
contain
rang
hour
intercept
treat
pc
store
contain
day
pc
evalu
use
panel
vitro
platelet
function
assay
resultsfind
vitro
function
data
apheresi
pc
treat
intercept
ts
set
demonstr
accept
vitro
function
tabl
intercept
treat
pc
ph
platelet
dose
volum
recoveri
rang
respect
conclus
pathogen
reduc
platelet
compon
process
use
intercept
ts
set
either
singl
pool
apheresi
donat
maintain
accept
vitro
qualiti
day
storag
intercept
blood
system
platelet
ts
set
current
approv
use
us
backgroundcas
studi
possibl
transmit
infecti
organ
via
blood
product
plasma
deriv
major
public
health
concern
current
screen
measur
consider
improv
transfus
safeti
reduc
risk
associ
known
pathogen
protect
emerg
infecti
threat
pathogen
reduct
technolog
prt
repres
proactiv
strategi
reduc
infecti
risk
howev
scientif
commun
broadli
agre
fact
prt
neg
impact
product
qualiti
marker
studi
aim
evalu
impact
mirasol
prt
platelet
plt
qualiti
plt
process
studi
designmethod
two
platelet
concentr
pc
contain
plasma
obtain
either
apheresi
sagm
whole
blood
wb
process
pair
pool
split
two
equal
unit
one
unit
use
control
ctrl
riboflavin
ad
pc
unit
expos
uv
light
accord
manufactur
instruct
mirasol
prt
terumobct
test
numer
qualiti
marker
plt
concentr
atp
ph
glucos
lactat
sodium
potassium
measur
pc
day
apheresi
pc
day
pc
two
flow
cytometri
assay
use
evalu
express
without
thrombin
activ
measur
percent
annexin
plt
resultsfind
platelet
recoveri
apheresi
pc
respect
pc
show
higher
level
annexin
cell
test
vs
ctl
day
higher
rate
express
control
pc
unit
test
vs
ctl
day
mirasol
treatment
gener
chang
ph
glucos
lactat
pc
storag
conclus
mirasol
treatment
induc
loss
net
number
pltsunit
elev
platelet
activ
chang
ph
glucos
lactat
suggest
prt
affect
plt
metabol
final
prt
numer
impact
logist
storag
process
time
constraint
blood
bank
oper
nevertheless
mirasol
prt
routin
use
europ
accept
clinic
outcom
backgroundcas
studi
bacteri
contamin
platelet
plt
lead
infecti
risk
platelet
transfus
therapi
signific
infecti
caus
morbid
mortal
therefor
detect
variou
potenti
bacteri
contamin
platelet
time
manner
critic
bactx
assay
rapid
colorimetr
assay
detect
peptidoglycan
cell
wall
compon
neg
bacteria
report
analysi
bactx
assay
hospit
studi
designmethod
aim
determin
sensit
specif
bactx
assay
intact
leukoreduc
apheresi
plt
lrap
unit
test
bactx
storag
day
control
intact
lrap
also
cultur
autom
bacteri
detect
system
bact
cultur
storag
day
result
bactx
test
compar
result
bact
cultur
system
resultsfind
total
lrap
test
lrap
initi
test
neg
bactx
lrap
initi
test
posit
bactx
initi
posit
bactx
test
neg
subject
repeat
test
contrast
lrap
test
neg
bact
cultur
system
specif
bactx
test
true
posit
test
result
therefor
sensit
bactx
could
determin
conclus
small
studi
platelet
unit
expect
rate
bacteri
contamin
platelet
less
per
unit
initi
posit
rate
therefor
higher
expect
given
small
sampl
size
clear
studi
need
rigor
assess
true
sensit
specif
bactx
assay
backgroundcas
studi
addit
rejuven
solut
store
red
blood
cell
rbc
shown
increas
intracellular
atp
fresh
level
object
demonstr
vitro
qualiti
measur
maintain
rbc
store
hour
treatment
fda
approv
rejuven
solut
studi
designmethod
whole
blood
collect
process
site
rbc
total
rejuven
solut
citra
lab
ad
rbc
day
incub
minut
agit
water
bath
helmer
wash
haemonet
store
oc
day
vitro
recoveri
calcul
hemolysi
atp
determin
day
rejuven
wash
postrjv
unit
cultur
postrjv
concentr
centrifug
resultsfind
vitro
rbc
recoveri
respect
bacteri
growth
observ
hemolysi
maintain
unit
unit
unit
hemolysi
follow
concentr
centrifug
morpholog
score
reduc
restor
rejuven
respect
maintain
atp
restor
maintain
fresh
level
rejuven
restor
fresh
level
maintain
fresh
level
valu
significantli
differ
compar
except
note
p
pair
tabl
conclus
rejuven
store
rbc
restor
atp
fresh
valu
morpholog
near
fresh
level
maintain
improv
vitro
rbc
qualiti
measur
compar
rbc
studi
fund
zimmer
biomet
storag
hour
fda
approv
use
time
public
backgroundcas
studi
liposom
shown
minim
rbc
membran
damag
occur
hypotherm
storag
hs
rejuven
solut
shown
restor
rbc
metabol
maintain
atp
level
studi
aim
evalu
effect
combin
liposom
rejuven
qualiti
store
rbc
studi
designmethod
five
leukoreduc
pack
rbc
unit
obtain
pool
split
unit
produc
segreg
four
experiment
group
sham
control
l
r
liposom
lr
prbc
incub
sham
liposom
dopc
chol
mol
lipid
rejuvesol
liposom
plu
rejuvesol
vitro
qualiti
access
hemolysi
deform
aggreg
atp
day
hs
resultsfind
hemolysi
significantli
decreas
treatment
compar
sham
control
l
r
lr
ektacytometri
analysi
show
increas
maximum
elong
eimax
r
lr
treatment
compar
l
rbc
rigid
kei
increas
treatment
compar
sham
l
r
rl
aggreg
amplitud
significantli
increas
r
treatment
au
vs
au
atp
level
significantli
higher
treatment
compar
sham
hb
l
hb
r
hb
lr
hb
level
longer
detect
l
treatment
day
combin
treatment
compar
r
hb
vs
hb
conclus
rejuven
liposom
treatment
improv
qualiti
store
rbc
compar
sham
control
combin
treatment
lr
greater
impact
improv
vitro
qualiti
store
rbc
compar
rejuven
alon
backgroundcas
studi
hq
face
major
logist
challeng
transport
distribut
blood
compon
larg
geograph
area
collabor
institut
de
technologi
de
emballag
et
du
geni
alimentair
appli
research
group
work
develop
optim
transport
packag
whole
blood
leukotrap
rc
system
haemonet
corp
object
design
packag
system
rapid
cool
one
six
whole
blood
unit
wbu
within
collect
moreov
insul
thermoregul
system
must
maintain
intern
temperatur
wbu
extrem
extern
condit
includ
initi
blood
cool
period
studi
designmethod
propos
packag
design
base
extern
coroplast
box
contain
six
vacuum
insul
panel
vip
increas
insul
effici
preserv
initi
cool
period
extend
thermoregul
properti
ensur
assembl
precondit
phase
chang
materi
pcm
number
pcm
posit
condit
optim
test
order
meet
expect
perform
criteria
precondit
pcm
store
vip
box
test
mimic
scenario
remot
blood
drive
experiment
test
wb
bag
fill
salin
mimic
freshli
collect
wb
probe
posit
insid
bag
monitor
temperatur
profil
wbu
extrem
winter
summer
condit
ship
box
fill
either
one
six
bag
n
resultsfind
result
show
thermoregul
box
prototyp
abl
cool
wbu
bag
maintain
intern
temperatur
final
valu
rang
extrem
summer
scenario
similar
result
obtain
extrem
winter
scenario
unit
reach
threshold
valu
bag
intern
temperatur
within
accept
rang
conclus
insul
thermoregul
system
met
hq
perform
criteria
preliminari
result
show
pcm
could
condit
temperatur
higher
without
signific
impact
system
perform
hq
current
valid
ship
box
prototyp
perform
addit
work
reduc
pcm
condit
time
optim
logist
oper
packag
mani
advantag
term
durabl
price
conveni
hq
intend
evalu
system
packag
transport
line
blood
product
backgroundcas
studi
platelet
collect
store
platelet
addit
solut
pa
reduc
recipi
exposur
donor
plasma
compon
better
defin
effect
pa
platelet
supernat
composit
compar
total
protein
isohemagglutinin
titer
hla
antibodi
vitro
neutrophil
pmn
prime
activ
supernat
platelet
plasma
platelet
studi
designmethod
apheresi
platelet
group
blood
donor
collect
either
donor
plasma
donor
plasma
within
hour
collect
sampl
product
supernat
frozen
assay
total
protein
concentr
titer
pmn
prime
activ
within
total
lipid
extract
fraction
sampl
screen
hla
antibodi
sampl
test
use
luminex
singl
bead
assay
antibodi
strength
specif
solubl
ligand
measur
use
elisa
resultsfind
supernat
platelet
significantli
lower
total
protein
concentr
titer
compar
plasma
platelet
signific
differ
number
screen
posit
product
compar
plasma
platelet
product
howev
supernat
platelet
fewer
hla
specif
specif
compar
plasma
platelet
specif
pmn
prime
activ
significantli
increas
supernat
platelet
lipid
extract
fraction
affect
howev
level
increas
supernat
compar
plasma
platelet
tabl
conclus
decreas
plasma
protein
like
underli
lower
rate
allerg
febril
transfus
reaction
seen
use
platelet
decreas
titer
may
prevent
hemolysi
minor
abo
mismatch
lower
specif
may
mitig
transfus
relat
acut
lung
injuri
trali
increas
pmn
prime
platelet
like
due
platelet
membran
releas
bioactiv
lipid
although
associ
trali
pmn
prime
lipid
cytokin
agent
causal
link
trali
mechan
clinic
impact
increas
platelet
remain
elucid
perform
workflow
effici
bd
facsvia
nanoentek
assess
residu
wbc
leukoreduc
blood
product
maryam
nouroozian
brian
read
william
davey
rob
tressler
san
diego
blood
bank
san
diego
ca
usa
backgroundcas
studi
current
guidelin
requir
reduct
residu
white
blood
cell
rwbc
wbc
us
wbc
europ
per
unit
establish
refer
method
test
rwbc
platelet
plt
red
blood
cell
rbc
product
flow
cytometri
altern
technolog
develop
includ
hemocytometri
microfluorometri
studi
designmethod
studi
compar
perform
workflow
effici
facsvia
flow
cytomet
simplifi
workflow
autom
loader
adam
automat
microscop
cell
counter
base
imag
technolog
nonfilt
whole
blood
wb
sampl
apheresi
platelet
unit
leukoreduc
lr
rbc
unit
use
gener
spike
sampl
apheresi
platelet
lr
rbc
filter
deplet
wbc
use
diluent
nonfilt
wb
sampl
sourc
wbc
prepar
sampl
wbcul
spike
sampl
wbcul
prepar
sourc
sampl
wbcul
filter
platelet
rbc
unit
evalu
linear
wbc
concentr
wbcul
measur
use
adam
facsvia
sampl
stain
run
triplic
analyz
data
analyz
use
linear
regress
result
proport
wbc
concentr
spike
sampl
reproduc
two
system
measur
run
spike
sampl
wbcul
tube
sampl
stain
run
per
system
cv
diff
calcul
batch
sampl
plt
rbc
run
analyz
repeat
day
workflow
effici
assess
observ
measur
time
task
perform
task
record
instrument
qc
assay
control
sampl
test
analysi
resultsfind
wbc
concentr
result
plt
rbc
sampl
facsvia
correl
well
adam
wbcul
respect
wbcul
respect
averag
total
test
time
similar
instrument
min
facsvia
min
adam
total
test
time
adam
requir
continu
time
facsvia
demonstr
min
time
conclus
instrument
show
compar
precis
linear
accuraci
averag
total
test
time
similar
instrument
facsvia
offer
signific
workflow
effici
advantag
user
save
averag
time
minut
could
use
task
backgroundcas
studi
autolog
plasma
aprp
poorli
regul
blood
compon
often
produc
patient
bedsid
use
indic
chronic
acut
orthoped
injuri
wound
rheumatolog
diseas
prp
isol
done
apheresi
yield
consist
fraction
howev
aprp
made
use
small
centrifug
cartridg
deliv
uneven
platelet
enrich
thu
consist
qualiti
aprp
question
lower
yield
prp
may
decreas
efficaci
studi
designmethod
survey
design
assess
aprp
manufactur
usag
qualiti
control
qc
measur
taken
prior
use
survey
develop
input
content
expert
survey
sent
member
best
isbt
survey
respond
encourag
forward
survey
colleagu
thu
true
denomin
unknown
total
complet
partial
complet
survey
receiv
resultsfind
respons
came
countri
major
respons
came
unit
state
us
respond
report
aprp
use
hospit
aprp
use
predominantli
outpati
though
hospit
also
use
aprp
set
hospit
aprp
use
md
howev
hospit
md
use
aprp
aprp
use
orthoped
woundincis
repair
rheumatolog
indic
us
aprp
manufactur
outsid
blood
bank
outsid
us
aprp
isol
blood
bank
personnel
nearli
aprp
manufactur
done
qualiti
control
qc
measur
howev
respond
assess
final
product
prior
releas
qc
measur
includ
platelet
count
measur
enrich
platelet
fraction
cultur
product
infecti
serolog
test
case
aprp
fail
qc
could
still
use
pend
md
approv
hospit
conduct
qc
final
aprp
test
done
blood
bank
subset
respond
african
nation
also
use
allogen
prp
allprp
contrast
pattern
use
aprp
allprp
use
primarili
indic
includ
orthoped
woundincis
repair
allprp
manufactur
blood
bank
donor
center
qc
regular
check
centrifug
use
isol
prp
fraction
conclus
prp
use
hospit
throughout
world
wide
varieti
indic
blood
bank
involv
manufactur
countri
us
aprp
made
outsid
blood
bank
qualiti
control
aprp
product
final
product
done
hospit
improv
consist
efficaci
prp
stringent
qc
measur
need
place
backgroundcas
studi
morpholog
donat
red
blood
cell
rbc
chang
storag
along
loss
deform
increas
surfac
exposur
phosphatidylserin
ps
decreas
intracellular
atp
chang
associ
increas
rbc
clearanc
within
hour
transfus
analysi
morpholog
alter
store
rbc
imag
flow
cytometri
ifc
identifi
subpopul
small
rbc
accumul
upon
storag
rbc
subpopul
reduc
project
surfac
area
undergo
spherocyt
shift
expect
induc
retent
spleen
roussel
dussiot
etal
storag
alter
revers
rbc
metabol
reestablish
treatment
rejuven
solut
citra
lab
transfus
expect
restor
rbc
properti
thu
potenti
increas
capac
stay
circul
oper
effect
tissu
oxygen
follow
transfus
studi
designmethod
analysi
rbc
alter
perform
evalu
effect
rejuven
rbc
store
sagm
blood
bank
condit
day
day
rejuven
r
rejuven
wash
rw
morpholog
alter
store
rbc
evalu
ifc
imagestream
x
mark
ii
resultsfind
rejuven
increas
level
intracellular
atp
confirm
metabol
effect
process
popul
distribut
per
rbc
project
surfac
area
measur
ifc
depict
subpopul
small
rbc
increas
storag
rejuven
markedli
reduc
spherocyt
shift
partial
restor
rbc
morpholog
effect
confirm
differenti
interfer
contrast
microscopi
restor
effect
rejuven
process
correct
loss
rbc
elong
associ
decreas
ps
exposur
tabl
conclus
analysi
show
alter
therefor
correct
metabol
rejuven
impact
effect
gener
posit
cellular
scale
requir
analysi
specif
clinic
studi
assess
transfus
yield
tissu
oxygen
tabl
rbc
analysi
backgroundcas
studi
blood
servic
use
toptop
whole
blood
filtrat
wbf
topbottom
red
cell
filtrat
rcf
method
prepar
cpdsagm
lr
red
cell
concentr
rcc
mean
volum
ml
higher
wbf
unit
rcf
unit
similar
hematocrit
close
system
cell
processor
current
implement
cryopreserv
rcc
addit
solut
perform
defin
total
end
volum
dictat
centrifug
bowl
size
impact
result
variat
hematocrit
vitrorbc
qualiti
evalu
ensur
regulatori
standard
still
met
rcc
extrem
edg
input
volum
rang
studi
designmethod
small
rcf
larg
wbf
rcc
store
glycerol
frozen
larg
rcc
whose
red
cell
mass
exceed
capac
deglycerol
centrifug
bowl
volum
reduc
prior
glycerol
rcc
thaw
water
bath
deglycerol
rcc
store
test
vitrorbc
qualiti
resultsfind
small
rcf
rcc
lower
p
hematocrit
specif
graviti
hemoglobin
per
unit
supernat
k
na
concentr
deform
eimax
higher
p
recoveri
larg
wbf
unit
signific
differ
hemolysi
atp
rbc
indic
rbc
morpholog
residu
glycerol
seen
group
major
unit
met
accept
criteria
tabl
howev
larg
wbf
unit
rbc
recoveri
due
volum
reduct
small
rcf
unit
hemoglobin
valu
per
unit
recoveri
hemoglobin
failur
rate
analyz
organ
rcc
product
volum
distribut
mean
recoveri
project
well
hemoglobin
failur
rate
would
unit
test
compliant
regulatori
standard
conclus
differ
group
cryopreserv
rcc
physic
characterist
expect
due
method
differ
input
product
red
cell
mass
lack
signific
metabol
differ
group
indic
differ
hematocrit
advers
affect
product
qualiti
tabl
rbc
qualiti
rcc
cryopreserv
use
close
system
cell
processor
expiri
backgroundcas
studi
red
blood
cell
rbc
metabol
chang
liquid
storag
shown
increas
affin
hemoglobin
hb
oxygen
thu
transfus
store
rbc
suggest
ineffici
impair
deliveri
tissu
compar
fresh
circul
rbc
hasan
object
determin
effect
rbc
rejuven
rbc
oxygen
releas
capac
orc
estim
oxygen
consumpt
simul
singl
unit
transfus
either
standard
rejuven
rbc
store
day
studi
designmethod
oxygen
dissoci
curv
odc
hemox
analyz
tc
scientif
gener
rbc
unit
day
day
rejuven
wash
pw
odc
sampl
use
determin
orc
ml
hb
total
releas
oxygen
tro
unit
ml
orc
determin
assess
chang
satur
hg
eg
lung
hg
eg
venou
blood
multipli
hb
li
simul
baselin
estim
use
day
orc
assum
transfus
trigger
cardiac
output
blood
volum
pair
student
test
use
compar
statist
analys
resultsfind
rbc
rejuven
day
restor
orc
tro
level
greater
day
tabl
orc
rejuven
unit
time
time
greater
rbc
day
day
respect
p
increas
simul
singl
unit
transfus
rbc
day
day
pw
pre
transfus
respect
p
conclus
result
suggest
transfus
rejuven
rbc
potenti
releas
time
volum
compar
standard
untreat
rbc
store
day
inferior
oxygen
deliveri
tissu
observ
exercis
healthi
human
volunt
transfus
two
autolog
rbc
unit
store
day
vs
day
seem
depend
genet
variabl
storag
time
therefor
transfus
practic
correct
anemia
may
less
effect
intend
due
variabl
orc
standard
store
rbc
unit
transfus
strategi
consid
whether
use
rbc
increas
orc
may
physiolog
advantag
disclosur
studi
fund
zimmer
biomet
tabl
chang
hb
satur
orc
total
hb
tro
day
day
rejuven
rbc
avg
sd
backgroundcas
studi
deleteri
chang
develop
storag
pack
red
blood
cell
rbc
collect
call
storag
lesion
includ
alter
membran
composit
decreas
deform
increas
hemolysi
loss
atp
vasodilatori
capac
cell
surfac
ps
express
deplet
loss
increas
oxygen
affin
hemoglobin
result
lower
partial
pressur
oxygen
hemoglobin
satur
decreas
may
neg
impact
abil
transfus
rbc
releas
oxygen
peripher
tissu
rejuven
solut
citra
lab
restor
normal
level
atp
normal
membran
function
oxygen
affin
respect
process
requir
incub
hour
impract
step
situat
follow
wash
rbc
test
hypothesi
rejuven
without
incub
step
cold
rejuven
could
prevent
revers
chang
oxygen
affin
deform
suscept
hemolysi
rbc
studi
designmethod
eight
unit
group
leukoreduc
prbc
store
obtain
local
blood
center
day
storag
unit
divid
separ
aliquot
control
ctl
wash
w
standard
rejuven
sr
cold
rejuven
cr
rejuven
solut
ad
cr
group
group
store
anoth
day
day
storag
sr
group
incub
hour
rejuven
solut
w
sr
cr
group
separ
wash
freseniu
kabi
use
high
qualiti
wash
set
hemoglobin
measur
tonometri
use
hemox
analyz
tc
scientif
deform
elong
index
ei
measur
ektacytometri
lorrca
mechatron
supernat
plasma
free
hemoglobin
pfhb
measur
use
spectrophotometri
cell
surfac
ps
express
ps
measur
annexin
v
flow
cytometri
group
result
compar
use
nonparametr
wilcoxon
test
resultsfind
signific
differ
notic
group
tabl
ei
ps
pfhb
differ
group
conclus
cold
rejuven
prevent
increas
oxygen
affin
lower
seen
day
rbc
storag
without
advers
effect
deform
hemolysi
offer
altern
incub
rejuven
provid
clinician
readi
access
rbc
highnorm
may
better
releas
oxygen
tissu
tabl
compil
result
normal
backgroundcas
studi
extracellular
potassium
concentr
k
red
blood
cell
rbc
unit
increas
dramat
cold
storag
reach
meql
unit
near
end
storag
life
caus
transient
potenti
fatal
cardiac
arrhythmia
upon
transfus
particularli
infant
patient
compromis
renal
function
reactiv
antibodi
inflammatori
agent
rbc
also
elicit
reaction
potenti
caus
high
fever
acut
lung
injuri
trali
anaphylaxi
even
death
studi
multifunct
filter
evalu
remov
k
along
free
hemoglobin
hb
prbc
contamin
contribut
transfus
relat
advers
event
studi
designmethod
ten
prbc
unit
store
obtain
region
blood
donor
center
expir
day
pass
graviti
contain
multifunct
polym
bead
flow
rate
supernat
analyz
k
remov
well
free
hb
antibodi
cytokin
biorad
rbc
analyz
viabil
integr
via
flow
cytometri
osmot
fragil
assay
respect
resultsfind
filtrat
age
prbc
unit
sorbent
devic
reduc
k
meql
equival
reduct
free
hb
reduc
antibodi
specif
igg
iga
igm
decreas
respect
inflammatori
cytokin
significantli
reduc
specif
pgml
pgml
pdgf
pgml
filtrat
signific
impact
cell
surfac
marker
rbc
viabil
decreas
sensit
osmot
chang
valu
list
repres
mean
sem
p
analyt
test
pair
use
assess
signific
conclus
sorbent
filter
highli
effect
reduc
level
extracellular
k
well
free
hb
antibodi
cytokin
prbc
without
impact
rbc
viabil
integr
studi
demonstr
viabil
multifunct
sorbent
filter
remov
k
along
detriment
compon
store
prbc
readili
incorpor
transfus
practic
minim
advers
effect
backgroundcas
studi
platelet
carri
rh
antigen
residu
red
blood
cell
rbc
platelet
product
immun
neg
recipi
donor
posit
current
recommend
give
rh
immunoglobulin
rhig
rh
neg
patient
receiv
rh
posit
platelet
unit
avoid
potenti
alloimmun
antigen
recent
studi
shown
low
frequenc
alloimmun
rh
mismatch
platelet
transfus
restrict
neg
patient
receiv
neg
platelet
could
creat
shortag
caus
inventori
challeng
higher
yield
platelet
minimum
none
residu
rbc
obtain
new
gener
apheresi
machin
consequ
need
prophylact
rh
immunoglobulin
rhig
may
unnecessari
use
apheresi
deriv
platelet
accur
determin
residu
rbc
platelet
unit
import
patient
safeti
prevent
rh
alloimmun
hemocytomet
consid
gold
standard
cell
count
howev
rapid
conveni
offer
autom
method
result
widespread
use
autom
hematolog
analyz
current
standard
andor
guidelin
advis
system
use
rbc
quantif
platelet
product
studi
designmethod
design
studi
quantifi
residu
rbc
apheresi
platelet
whole
blood
deriv
platelet
compar
hemocytomet
autom
method
measur
amount
red
blood
cell
per
microlit
apheresi
whole
blood
deriv
platelet
unit
use
hemocytomet
two
differ
autom
hematolog
analyz
name
sysmex
sysmex
america
lincolnshir
il
advia
siemen
healthcar
diagnost
tarrytown
ny
whole
blood
deriv
platelet
unit
produc
use
acrodosetm
system
technolog
conduct
permut
test
base
permut
compar
sysmex
advia
apheresi
whole
blood
deriv
group
resultsfind
residu
rbc
detect
apheresi
unit
hemocytomet
found
autom
instrument
acrodos
unit
statist
signific
higher
amount
residu
rbc
hemocytomet
p
valu
see
tabl
conclus
manual
residu
rbc
measur
give
statist
signific
differ
result
rbc
quantif
autom
method
autom
method
overestim
residu
rbc
apheresi
acrodos
minim
number
rbc
quantifi
conclud
autom
counter
accur
compar
hemocytomet
larger
studi
need
establish
clinic
signific
differ
accur
measur
residu
rbc
platelet
product
tabl
residu
rbc
concentr
platelet
product
backgroundcas
studi
addit
rejuven
solut
store
red
blood
cell
rbc
shown
increas
atp
profil
fresh
level
object
compar
satur
morpholog
profil
fresh
day
collect
rbc
rbc
store
day
treatment
fda
approv
rejuven
solut
studi
designmethod
addit
rejuven
solut
store
red
blood
cell
rbc
shown
increas
atp
profil
fresh
level
object
compar
satur
morpholog
profil
fresh
day
collect
rbc
rbc
store
day
treatment
fda
approv
rejuven
solut
resultsfind
vitro
rbc
recoveri
overal
hemolysi
similar
day
incub
rejuven
solut
vs
percent
hemolysi
decreas
wash
maintain
unit
storag
averag
atp
restor
averag
fresh
valu
morpholog
score
decreas
day
restor
near
fresh
valu
follow
rejuven
wash
storag
respect
rbc
oxygen
affin
assess
restor
fresh
valu
valu
significantli
differ
compar
day
p
pair
tabl
conclus
rbc
morpholog
restor
near
fresh
averag
atp
restor
fresh
valu
incub
rejuven
solut
use
incub
process
rbc
morpholog
atp
maintain
storag
rejuven
refriger
rbc
may
offer
avenu
improv
rbc
qualiti
prior
transfus
tabl
atp
morpholog
score
valu
fresh
day
rbc
storag
day
rejuven
wash
pw
storag
hour
backgroundcas
studi
blood
donor
screen
donor
histori
questionnair
includ
question
regard
behavior
risk
factor
none
specif
screen
use
marijuana
therefor
theoret
possibl
transfer
activ
cannabi
metabolit
transfus
donor
plasma
collect
urban
blood
donor
center
examin
presenc
activ
cannabi
metabolit
thc
studi
designmethod
donor
plasma
segment
sequest
store
frozen
time
test
test
thc
perform
liquid
mass
spectrometri
base
method
modifi
lacroix
saussereau
summari
method
use
dabsyl
chlorid
derivat
thc
produc
sampl
analysi
lc
use
column
detect
msm
use
posit
ion
electrospray
ion
pair
mz
intern
standard
mz
thc
mz
quantit
result
thc
obtain
standard
curv
ratio
analyt
integr
integr
intern
standard
rang
ngml
thc
limit
quantit
defin
standard
deviat
background
ngml
thc
ngml
resultsfind
total
donor
plasma
sampl
test
thc
sampl
test
posit
either
thc
theoret
calcul
accord
statist
poisson
distribut
indic
would
probabl
one
posit
preval
posit
sampl
probabl
one
posit
preval
posit
sampl
result
thu
indic
boundari
preval
presenc
activ
plasma
sampl
less
among
donor
popul
standard
pharmacokinet
cannabi
metabol
previou
studi
indic
like
time
window
less
hour
detect
thc
andor
plasma
conclus
test
donor
plasma
sampl
activ
metabolit
cannabi
one
urban
blood
donor
center
produc
statist
result
indic
preval
posit
greater
zero
less
probabl
occurr
cannabi
metabolit
blood
donor
sampl
like
highli
variabl
across
donor
center
larg
depend
blood
donor
demograph
backgroundcas
studi
controversi
around
qualiti
clinic
impact
age
red
blood
cell
concentr
rcc
ongo
current
studi
limit
lack
qualiti
measur
suitabl
routin
screen
rcc
base
evid
fragment
call
microparticl
mp
extracellular
vesicl
marker
cellular
activ
degrad
studi
investig
util
mp
screen
character
effect
rcc
product
method
storag
studi
designmethod
red
blood
cell
concentr
prepar
whole
blood
filtrat
wbf
toptop
red
cell
filtrat
rcf
topbottom
method
centrifug
prepar
supernat
test
mp
content
measur
dynam
light
scatter
tunabl
resist
puls
sens
techniqu
hemolysi
atp
red
cell
deform
day
storag
one
rcf
rcc
test
day
six
aliquot
store
parallel
test
day
sampl
test
mp
content
compar
qualiti
indic
resultsfind
mp
content
show
linear
increas
storag
time
statist
signific
differ
day
p
correl
supernat
hemoglobin
invers
atp
rbc
elast
mp
test
method
agre
respect
total
mp
content
start
level
qualiti
indic
vari
donat
prepar
method
wbf
rcc
contain
much
higher
level
mp
storag
time
mp
content
aliquot
consist
time
point
statist
higher
origin
rcc
day
storag
conclus
mp
content
correl
measur
hemolysi
rbc
qualiti
indic
could
implement
routin
screen
tool
differ
mp
content
donor
process
age
could
monitor
use
inform
compon
product
decis
measur
mp
content
would
allow
screen
rcc
product
studi
pragmat
qc
initi
need
settl
controversi
clinic
effect
rcc
age
backgroundcas
studi
frozen
plasma
integr
hemostasi
manag
mani
situat
logist
cumbersom
frozen
storag
long
thaw
time
plasma
odp
demand
plasma
potenti
superior
may
store
refriger
near
patient
reconstitut
minut
object
studi
determin
odp
consist
manufactur
blood
center
key
protein
coagul
function
compar
ffp
studi
designmethod
unit
never
frozen
plasma
collect
blood
center
process
fix
volum
odp
use
velico
spray
dryer
odp
n
pair
ffp
aliquot
store
day
respect
reconstitut
fix
volum
rehydr
fluid
steril
water
inject
extens
character
respect
level
hemostat
protein
coagul
complement
activ
marker
clot
perform
volum
process
plasma
rehydr
fluid
ensur
similar
total
protein
concentr
reconstitut
odp
ffp
direct
comparison
resultsfind
compar
ffp
odp
level
function
clot
factor
fibrinogen
factor
ii
v
vii
viii
ix
x
xi
xii
plasminogen
proteas
inhibitor
antithrombin
iii
protein
c
protein
plasmin
esteras
alpha
inhibitor
level
factor
xiii
odp
slightli
lower
ffp
activ
antigen
assay
odp
ident
ffp
level
albumin
immunoglobulin
iga
igg
igm
lipoprotein
calcium
citrat
coagul
protein
evalu
antigen
assay
except
factor
xiii
level
marker
coagul
prothrombin
fragment
iii
complement
activ
odp
remain
similar
ffp
odp
equival
ffp
assess
aptt
pt
thrombelastographi
fragment
substanti
number
high
molecular
weight
von
willebrand
factor
vwf
multim
smaller
one
lead
net
increas
vwf
multim
odp
size
reduc
vwf
ristocetin
cofactor
activ
vwf
rco
odp
rel
ffp
impact
vwf
antigen
factor
viii
function
stabil
vwf
studi
shown
odp
retain
hemostat
function
support
platelet
adhes
aggreg
see
abstract
meledeo
etalu
armi
institut
surgic
research
bercovitz
etalblood
center
wisconsin
conclus
odp
manufactur
blood
center
qualiti
compar
ffp
futur
studi
determin
product
bioequival
ffp
compar
safeti
efficaci
backgroundcas
studi
collect
time
whole
blood
accord
european
guidelin
limit
minut
addit
donat
collect
time
minut
use
prepar
platelet
plt
concentr
pc
chanc
much
activ
plt
seem
justifi
qualiti
plt
donat
new
gener
collect
system
mixer
introduc
includ
effici
needl
aim
studi
investig
vitro
qualiti
pc
prepar
minut
buffi
coat
bc
aim
prevent
unnecessari
discard
bc
simplifi
total
blood
bank
process
studi
designmethod
pc
spc
prepar
one
minut
bc
autolog
plasma
contain
refer
spc
donat
collect
time
minut
prepar
addit
pc
prepar
bc
least
bc
minut
donat
pool
bc
ad
standard
pool
set
storag
contain
use
storag
pc
pc
store
day
sampl
regular
interv
determin
vitro
qualiti
aggreg
test
perform
chronolog
adp
collagen
multipl
arachidon
acid
aggregomet
thromboelastographi
teg
use
kaolin
activ
appli
assess
overal
clot
capac
valu
express
u
test
appli
statist
analys
normal
distribut
data
respect
resultsfind
volum
vs
platelet
content
vs
similar
group
end
storag
group
show
compar
vitro
qualiti
day
ph
vs
data
shown
differ
aggreg
respons
stimul
arachidon
acid
adp
collagen
measur
teg
paramet
group
also
compar
pc
fulfil
requir
european
guidelin
asid
occurr
small
aggreg
day
andor
pc
possibl
sometim
incompat
accept
day
plt
show
low
express
phosphatidylserin
exposur
annexin
v
bind
hypoton
shock
respons
platelet
compar
histor
data
conclus
plasma
well
pc
prepar
minut
whole
blood
donat
normal
composit
show
good
vitro
qualiti
day
storag
substanti
exclus
minut
donat
pc
prepar
could
stop
studi
perform
backgroundcas
studi
use
pneumat
tube
system
pt
becom
commonplac
mani
healthcar
facil
throughout
world
purpos
system
transport
product
specimen
result
reduc
turnaround
time
laboratori
test
aid
time
deliveri
patient
care
downfal
ptss
potenti
play
role
increas
hemolysi
sever
studi
publish
effect
ptss
blood
specimen
address
effect
blood
product
specif
red
blood
cell
rbc
object
studi
twofold
determin
pt
use
facil
contribut
increas
hemolysi
rbc
unit
evalu
pt
system
affect
red
cell
microparticl
rmp
level
studi
designmethod
unit
rbc
irradi
select
studi
unit
vari
age
rang
day
old
specimen
obtain
unit
prior
transport
pt
run
underground
span
length
mile
half
specimen
spun
plasma
supernat
remov
specimen
evalu
plasma
hemoglobin
hgb
potassium
k
hemolysi
index
hi
rmp
wilcoxon
test
p
valu
use
compar
pre
post
valu
addit
statist
analysi
perform
compar
valu
adjust
age
irradi
resultsfind
send
rbc
unit
pt
hgb
hi
rmp
statist
p
higher
adjust
irradi
analyt
remain
statist
higher
howev
adjust
age
signific
hgb
hi
k
valu
significantli
chang
rmp
significantli
increas
unit
irradi
tabl
conclus
use
pt
provid
effect
mean
transport
blood
product
howev
contribut
biolog
chang
within
rbc
unit
uncertain
time
chang
affect
outcom
patient
receiv
product
pt
system
differ
specif
valid
prior
use
transport
blood
product
backgroundcas
studi
plasma
transfus
indic
patient
coagul
factor
defici
activ
bleed
undergo
invas
procedur
fresh
frozen
plasma
ffp
place
freezer
within
hour
process
store
colder
order
preserv
coagul
factor
thaw
ffp
expir
period
hour
henc
reduc
wastag
studi
aim
investig
factor
viii
fviii
activ
thaw
plasma
store
day
kept
fviii
chosen
import
coagul
factor
correct
coagulopathi
arbitrari
fviii
level
accept
limit
set
less
iudl
studi
designmethod
randomli
select
unit
ffp
measur
fviii
concentr
base
clot
assay
viii
diagnostica
stago
fviii
level
measur
five
time
point
hour
ffp
thaw
use
helmer
plasma
thawer
helmer
scientif
minut
aliquot
thaw
ffp
unit
remov
measur
fviii
refriger
hour
thaw
plasma
tp
unit
kept
refriger
day
subsequ
test
resultsfind
result
obtain
list
tabl
unit
test
fviii
post
hour
due
oper
issu
overal
fviii
concentr
decreas
averag
post
thaw
hour
storag
tp
post
hour
hour
residu
fviii
level
remain
iudl
except
unit
lower
initi
fviii
concentr
post
hour
unit
test
residu
fviii
activ
within
standard
iudl
averag
declin
respect
observ
trend
blood
group
higher
lower
fviii
like
due
small
sampl
size
conclus
decreas
coagul
factor
fviii
ffp
expect
due
diminish
stabil
nevertheless
data
show
major
tp
retain
least
iudl
fviii
typic
patient
factor
level
iudl
may
start
show
abnorm
coagul
profil
tp
use
specif
factor
replac
therapi
may
indic
patient
gener
coagulopathi
activ
bleed
studi
extend
measur
labil
factor
fv
may
add
valu
valid
studi
tabl
fviii
analysi
thaw
ffp
store
backgroundcas
studi
grow
number
infecti
tti
risk
includ
emerg
endem
pathogen
constant
challeng
blood
center
saudi
arabia
limit
number
pathogen
tti
risk
reduc
use
blood
screen
assay
altern
solut
anticip
pathogen
reduct
pr
technolog
identifi
potenti
solut
valid
amotosalenuva
photochem
treatment
blood
center
perform
compar
platelet
compon
pc
qualiti
standard
control
plasma
day
storag
period
new
test
pool
pool
prp
pc
plasma
day
storag
period
efficaci
bacteri
inactiv
also
assess
set
studi
designmethod
qualiti
paramet
leucoreduc
test
pc
assess
day
storag
compar
leucoreduc
control
pc
day
storag
test
pc
intercept
blood
system
ceru
corpor
concord
usa
day
process
complet
day
sampl
taken
daili
qualiti
analysi
test
control
pc
day
day
respect
bacteri
spike
addit
pc
spike
receiv
mcfarland
cfu
aureu
epidermidi
e
coli
p
aeruginosa
viridan
respect
challeng
pr
efficaci
resultsfind
averag
platelet
loss
test
pc
post
pr
treatment
total
averag
platelet
loss
day
averag
platelet
loss
control
unit
day
averag
ph
test
unit
day
rang
control
pc
ph
glucos
concentr
test
pc
day
mmoll
lower
day
control
unit
mmoll
lactat
level
increas
cours
storag
lactat
level
day
outsid
rang
assay
mmoll
cultur
inocul
pathogen
reduc
bacteri
spike
unit
neg
day
incub
contrast
inocul
reduc
sampl
control
unit
posit
bacteri
growth
conclus
qualiti
paramet
pathogen
reduc
test
pc
within
specif
compar
convent
control
pc
high
efficaci
bacteri
inactiv
togeth
compar
qualiti
paramet
valu
suggest
use
amotosalenuva
pathogen
reduct
safe
effici
enhanc
pc
transfus
safeti
backgroundcas
studi
coagul
cascad
reli
complex
interact
protein
known
clot
factor
cryoprecipit
cryo
blood
product
contain
sever
protein
central
clot
cascad
typic
use
fibrinogen
replac
bleed
patient
howev
cryo
content
tend
variabl
littl
quantit
evid
exist
regard
exact
therapeut
effect
cryo
coagul
studi
aim
better
character
cryo
consist
across
within
sourc
term
function
effect
vitroclot
format
studi
designmethod
duke
proteom
core
conduct
liquid
spectrometrymass
spectrometri
analysi
deplet
undeplet
sampl
cryo
plasma
character
protein
content
evalu
function
procoagul
effect
cryo
vitro
analyz
unit
cryo
across
three
differ
sourc
group
cryoprecipit
american
red
crossarc
singl
pool
unit
australian
red
crossaurc
singl
unit
use
novel
modif
rotat
thromboelastometri
rotem
techniqu
develop
vitromodel
coagulopath
patient
use
serial
dilut
pool
normal
plasma
salin
ad
equival
one
two
three
cryoprecipit
dose
tissu
test
delta
hemostasi
analyz
extem
perform
condit
sourc
curv
clot
time
ct
alpha
angl
maximum
clot
format
mcf
gener
use
linear
regress
model
unit
variabl
determin
anova
tukey
hsd
analysi
rstudio
inc
resultsfind
identifi
protein
cryo
abund
fibrinogen
relev
coagul
notabl
american
red
cross
arc
singl
donor
sourc
steepest
slope
mcf
indic
greater
per
dose
potenc
sourc
arc
singl
donor
sourc
highest
mean
mcf
across
dose
level
also
highest
standard
deviat
respons
variabl
arc
singl
donor
sourc
significantli
potent
australian
sourc
conclus
pair
estim
regard
variabl
clot
format
respons
cryo
quantit
curv
provid
studi
ct
mcf
alpha
angl
provid
physician
inform
regard
cryo
dose
futur
studi
evalu
therapeut
effect
cryoprecipit
versu
fresh
frozen
plasma
fibrinogen
concentr
would
clinic
import
give
us
insight
rel
util
dose
requir
cryo
correct
dilut
coagulopathi
backgroundcas
studi
solventdeterg
sd
process
use
plasma
safe
inactiv
virus
method
prove
effect
process
coagul
factor
concentr
disrupt
membran
virus
cell
protozoa
leav
labil
coagul
factor
intact
studi
done
assess
viral
inactiv
factor
viii
factor
xiii
fibrinogen
von
willebrand
factor
vwf
multim
enrich
capac
vip
plasma
viru
inactiv
treatment
system
studi
designmethod
vip
plasma
viru
inactiv
treatment
system
compris
interconnect
bag
system
sd
reagent
remov
filtrat
final
product
subject
bacteri
filtrat
cryoprecipit
subject
sd
viral
inactiv
follow
one
oil
extract
filtrat
sd
phthalat
di
phthalat
dehp
adsorpt
devic
filter
initi
final
product
compar
visual
appear
blood
cell
count
factor
viii
factor
xiii
fibrinogen
von
willebrand
factor
vwf
multim
initi
final
product
also
check
hiv
hbv
hcv
dengu
malaria
bacteri
contamin
resultsfind
analysi
show
treat
cryoprecipit
clear
neg
blood
count
protein
content
factor
viii
factor
xiii
fibrinogen
von
willebrand
factor
vwf
multim
well
conserv
tabl
kit
ensur
bacteri
steril
tabl
importantli
final
product
free
hbv
hcv
hiv
tabl
conclus
first
time
vip
plasma
viru
inactiv
treatment
system
use
south
asia
product
enrich
viral
inactiv
result
show
effect
product
enrich
viral
inactiv
condit
investig
need
character
function
activ
enrich
compon
irrespect
process
may
offer
one
addit
option
blood
establish
product
viral
inactiv
plasma
compon
especi
low
incom
countri
backgroundcas
studi
buffi
coat
bc
donor
use
pain
medic
like
aspirin
ibuprofen
day
prior
donat
discard
known
side
effect
drug
nsaid
inhibit
platelet
plt
aggreg
nsaid
inhibit
enzym
therebi
block
synthesi
thromboxan
arachidon
acid
howev
qualiti
platelet
concentr
pc
prepar
bc
known
aim
studi
investig
vitro
qualiti
pc
prepar
autolog
plasma
storag
studi
designmethod
pc
spc
prepar
autolog
plasma
inform
type
pain
medic
extract
anamnes
form
spc
store
day
sampl
regular
interv
aggreg
test
perform
chronolog
adp
collagen
multipl
arachidon
acid
aggregomet
thromboelastographi
teg
kaolin
appli
assess
overal
clot
capac
spc
plasma
normal
control
investig
refer
valu
express
median
iqr
u
test
appli
statist
analys
normal
distribut
data
respect
resultsfind
volum
vs
plt
content
vs
similar
group
day
group
show
compar
ph
chang
plt
content
data
shown
phosphatidylserin
exposur
day
signific
higher
subset
donor
use
ibuprofen
aggreg
test
arachidon
acid
reveal
gener
low
absent
respons
spc
aspirin
p
diclofenac
naproxen
p
compar
normal
control
differ
detect
aggreg
adp
collagen
teg
slightli
longer
initi
phase
measur
day
spc
aspirin
diclofenac
naproxen
compar
normal
control
signific
naproxen
differ
disappear
storag
conclus
storag
properti
spc
prepar
compar
spc
normal
control
main
differ
observ
aggreg
coagul
properti
donor
use
aspirin
diclofenac
naproxen
plt
donor
use
ibuprofen
show
littl
deviat
like
caus
fast
hour
disappear
ibuprofen
blood
circul
revers
bind
plt
use
bc
donor
use
ibuprofen
investig
worst
case
pc
plasma
best
case
pc
addit
solut
scenario
effect
ibuprofen
aggreg
coagul
properti
investig
studi
design
ad
differ
level
ibuprofen
plt
backgroundcas
studi
previous
shown
donor
could
classifi
platelet
plt
good
averag
poor
storag
properti
bonteko
transfus
main
differ
good
poor
storag
properti
involv
metabol
activ
result
faster
declin
ph
storag
poor
plt
concentr
pc
might
caus
differ
function
plt
mitochondria
indic
donor
histori
poor
pc
like
health
issu
point
toward
metabol
syndrom
type
diabet
strong
rise
peopl
dutch
popul
aim
studi
character
plt
whole
blood
donor
diagnos
accept
donor
studi
designmethod
twelv
whole
blood
donor
use
insulin
select
buffi
coat
bc
plasma
overnight
hold
use
prepar
pc
spc
equival
number
spc
prepar
age
sex
match
control
donor
deriv
collect
session
spc
store
day
sampl
day
diabet
marker
determin
red
cell
cholesterol
triglycerid
level
plasma
group
good
poor
store
spc
select
analys
detail
resultsfind
donor
age
year
primarili
men
donor
higher
mean
bmi
higher
control
spc
group
volum
vs
plt
content
vs
day
glucos
concentr
higher
diabet
group
vs
p
day
averag
vitro
qualiti
compar
group
data
shown
combin
select
good
poor
store
plt
group
larg
differ
lactat
product
observ
vs
poor
plt
show
faster
declin
mitochondri
membran
potenti
measur
storag
good
plt
remark
differ
triglycerid
level
detect
day
poor
vs
good
p
conclus
bc
donor
use
insulin
fulfil
donor
criteria
compar
bc
age
sex
match
control
seem
suitabl
prepar
pc
select
good
poor
store
plt
combin
group
result
previou
studi
confirm
signific
differ
glycolysi
rate
function
mitochondria
metabol
syndrom
still
suspect
health
issu
involv
poor
storag
plt
donor
high
mean
age
observ
differ
triglycerid
level
good
poor
store
pc
backgroundcas
studi
hospit
base
blood
donor
program
use
blood
collect
system
leukoreduc
unit
room
temperatur
prior
centrifug
manufactur
recommend
minimum
wait
time
minut
prior
filtrat
anecdot
vendor
state
wait
hour
improv
leukoreduct
experienc
leukoreduct
failur
januari
februari
detect
routin
qc
initi
investig
caus
unexpect
failur
studi
designmethod
leukoreduct
failur
follow
factor
analyz
collect
time
length
filtrat
length
wait
time
prior
filtrat
platelet
count
staff
perform
process
lot
number
collect
system
bag
whether
unit
collect
donor
fail
leukoreduct
past
hemoglobin
determin
sought
repeat
donor
failur
note
donor
popul
would
suggest
minim
number
donor
would
found
hemoglobin
posit
resultsfind
relationship
establish
length
time
product
rest
wait
prior
filtrat
leukoreduct
failur
found
shorter
wait
time
increas
percentag
leukoreduct
failur
see
tabl
unit
fail
wait
time
less
one
hour
similar
trend
notic
previou
year
investig
show
relationship
length
collect
time
length
filtrat
time
leukoreduct
failur
staff
perform
filtrat
rule
possibl
caus
failur
spread
among
numer
personnel
observ
techniqu
display
sampl
collect
issu
platelet
count
donor
involv
avail
none
outsid
normal
rang
variou
lot
number
collect
set
involv
donor
repeat
failur
conclus
small
studi
found
follow
manufactur
recommend
rest
wait
time
prior
filtrat
insuffici
avoid
excess
leukoreduct
failur
extend
minimum
wait
time
minut
base
data
experienc
leukoreduct
failur
chang
backgroundcas
studi
prior
studi
highlight
util
absolut
immatur
platelet
count
ratio
therapeut
plasma
exchang
tpe
initi
differenti
thrombot
thrombocytopen
purpura
ttp
thrombot
microangiopathi
help
determin
may
benefit
prompt
initi
tpe
test
readili
avail
report
young
pediatr
patient
present
diarrhea
set
laboratori
result
suggest
microangiopath
thrombocytopenia
suspici
ttp
measur
clinic
use
studi
designmethod
previous
healthi
month
old
unvaccin
girl
present
histori
diarrhea
day
bloodi
onset
accompani
fever
dehydr
laboratori
result
show
white
blood
cell
count
x
platelet
x
bun
creatinin
lactat
dehydrogenas
ul
hospit
cours
complic
seizur
episod
stop
acut
kidney
injuri
requir
hemodialysi
peripher
blood
smear
reveal
schistocyt
third
day
hospit
platelet
count
decreas
x
sampl
sent
tpe
initi
clinic
suspicion
ttp
versu
hemolyt
urem
syndrom
atyp
versu
mediat
immatur
platelet
fraction
calcul
x
platelet
count
obtain
daili
cbc
ratio
calcul
baselin
resultsfind
platelet
count
began
increas
prior
tpe
initi
x
x
two
consecut
tpe
complet
result
platelet
count
decreas
x
x
ratio
ratio
report
ttp
patient
similarli
count
x
threshold
report
set
ttp
sever
defici
time
stool
cultur
obtain
prior
start
tpe
came
back
posit
e
coli
toxin
test
factor
h
factor
h
autoantibodi
factor
factor
b
normal
activ
patient
treat
infect
platelet
count
improv
within
day
x
resolut
renal
failur
bun
creatinin
addit
seizur
observ
conclus
measur
use
aid
clinic
decis
pediatr
patient
suspect
ttp
especi
test
etiolog
still
pend
tpe
seem
signific
effect
decreas
platelet
count
patient
rapid
obtain
provid
help
inform
set
potenti
overlap
etiolog
set
test
longer
turnaround
time
backgroundcas
studi
thrombot
thrombocytopen
purpura
ttp
thrombot
microangiopathi
character
low
activ
mani
patient
sever
defici
initi
diseas
present
may
suffer
one
recurr
episod
follow
month
year
unclear
diseas
cours
characterist
recurrentrelaps
ttp
may
differ
seen
initi
present
sinc
absolut
immatur
platelet
count
shown
use
diagnosi
follow
respons
therapi
ttp
patient
proceed
evalu
pattern
differ
relaps
vers
initi
present
studi
designmethod
studi
cohort
consist
three
patient
two
femal
one
male
acquir
ttp
activ
underw
daili
therapeut
plasma
exchang
tpe
clinic
cours
laboratori
valu
review
platelet
count
plt
immatur
platelet
fraction
x
platelet
count
analyz
treatment
cours
valu
present
peak
peak
time
day
plt
count
recoveri
time
day
compar
initi
onset
relaps
episod
patient
percent
chang
relaps
episod
compar
initi
present
calcul
resultsfind
patient
increas
decreas
plt
count
present
initi
recurr
episod
tpe
treatment
initi
rapidli
increas
reach
peak
valu
day
prior
plt
count
recoveri
consist
previous
describ
ttp
patient
howev
compar
first
onset
recurr
episod
featur
lower
present
result
shown
percent
decreas
column
increas
peak
valu
result
shown
percent
increas
column
delay
peak
delay
plt
recoveri
tabl
moreov
recurr
episod
requir
procedur
compar
initi
present
tabl
conclus
recurrentrelaps
ttp
demonstr
lower
present
delay
increas
peak
valu
respons
tpe
compar
initi
present
longer
treatment
cours
observ
recurr
patient
futur
studi
relaps
ttp
patient
need
tabl
pattern
initi
vers
relaps
ttp
backgroundcas
studi
frequent
plateletpheresi
donor
asset
blood
bank
donor
matter
concern
studi
intend
analyz
effect
plateletpheresi
hematolog
paramet
donor
assess
prior
subsequ
procedur
also
tri
compar
effect
cell
separ
use
plateletpheresi
post
donat
hematolog
paramet
studi
designmethod
studi
conduct
februari
march
repeat
plateletpheresi
donor
come
depart
transfus
medicin
time
within
month
first
plateletpheresi
valu
hematolog
paramet
includ
red
cell
platelet
indic
test
prior
plateletpheresi
enter
excel
sheet
gap
donat
calcul
plateletpheresi
done
either
hemonet
mc
separ
hemonet
corpor
braintre
massachusett
usa
fresiniu
separ
comtec
dn
fresiniu
hemocar
gmbh
bad
homburg
vdh
germani
gambro
trima
accel
softwar
version
take
consent
donor
target
collect
procedur
dose
x
platelet
plasma
compar
effect
cell
separ
hematolog
paramet
due
plateletpheresi
paramet
consecut
donat
within
day
consid
data
analyz
stata
within
chang
continu
variabl
assess
pair
test
two
group
comparison
done
independ
wilcoxon
rank
sum
test
comparison
among
cell
separ
done
test
one
way
anova
resultsfind
donor
repeat
plateletpheresi
within
week
group
underw
plateletpheresi
within
day
group
ii
signific
alter
found
red
cell
platelet
indic
within
either
group
signific
differ
variat
platelet
count
group
though
elig
platelet
count
lower
baselin
group
donor
wherea
higher
plateletpheresi
group
ii
donor
donor
present
us
time
plateletpheresi
mean
gap
plateletpheresi
day
signific
differ
paramet
assess
prior
plateletpheresi
found
except
platelet
distribut
width
plateletpheresi
cell
separ
similar
effect
hematolog
paramet
conclus
signific
chang
hematolog
paramet
plateletpheresi
donor
underw
frequent
plateletpheresi
post
donat
hematolog
paramet
affect
cell
separ
use
plateletpheresi
backgroundcas
studi
kidney
transplant
recipi
develop
antibodi
mediat
reject
amr
without
detect
hla
donor
specif
antibodi
dsa
sera
recent
year
angiotensin
ii
receptor
antibodi
report
caus
amr
especi
refractori
amr
possibl
contract
renal
arteri
institut
therapeut
plasma
exchang
tpe
follow
ivig
everi
day
appli
reduc
kidney
transplant
recipi
report
efficaci
tpe
treatment
two
case
studi
designmethod
two
kidney
transplant
recipi
receiv
tpe
treatment
follow
ivig
decreas
ab
review
resultsfind
case
patient
current
femal
focal
segment
glomerulosclerosi
receiv
first
kidney
transplant
live
relat
donor
age
second
deceas
donor
transplant
due
reject
transplant
kidney
age
three
year
creatinin
cr
start
rise
biopsi
show
banff
criteria
grade
amr
grade
mediat
reject
tcmr
grade
interstiti
fibrosi
tubular
atrophi
hla
dsa
neg
serum
high
level
identifi
uml
high
uml
intermedi
uml
neg
uml
receiv
tpe
treatment
everi
day
start
losartan
cours
tpe
decreas
uml
histolog
show
improv
amr
tcmr
howev
cr
kept
increas
slowli
one
month
increas
uml
therefor
receiv
tpe
treatment
decreas
uml
although
level
increas
slightli
uml
month
cr
stabl
case
patient
femal
malign
hypertens
receiv
deceas
donor
kidney
transplant
age
cr
start
rise
week
without
detect
hla
dsa
although
biopsi
show
amr
tcmr
focal
sever
arteriopathi
found
high
level
uml
receiv
tpe
procedur
everi
day
decreas
uml
decreas
cr
improv
arteriopathi
histolog
level
slightli
increas
uml
next
week
start
weekli
tpe
treatment
weekli
tpe
tpe
treatment
stop
level
remain
rel
unchang
cr
stabl
around
date
conclus
present
kidney
transplant
recipi
receiv
tpe
treatment
high
level
cours
tpe
procedur
follow
ivig
everi
day
effect
decreas
level
howev
weekli
tpe
effect
reduc
tpe
treatment
may
also
benefici
improv
histolog
amr
clinic
kidney
function
backgroundcas
studi
thyroid
storm
ts
extrem
manifest
thyrotoxicosi
seriou
complic
occur
primarili
patient
grave
diseas
clinic
may
present
wide
rang
hypermetabol
symptom
may
fatal
manag
appropri
report
two
case
ts
sever
cardiac
complic
manag
plasmapheresi
plex
excel
effect
studi
designmethod
year
old
man
patient
medic
histori
hyperthyroid
present
ts
complic
cardiogen
shock
eject
fraction
ef
renal
hepat
dysfunct
well
coagulopathi
patient
persist
tachycard
intub
sedat
requir
tandem
heart
support
year
old
man
patient
b
medic
histori
hypothyroid
synthroid
year
end
stage
renal
diseas
cardiomyopathi
ef
present
evalu
dual
transplant
subsequ
develop
ts
multiorgan
failur
standard
steroid
medic
treatment
show
littl
respons
resultsfind
patient
underw
urgent
plex
along
standard
medic
administr
soon
clinic
suspicion
thyroid
storm
rais
plasma
volum
procedur
use
fresh
frozen
plasma
replac
perform
intens
care
unit
procedur
associ
hemodynam
impact
could
easili
manag
patient
show
signific
clinic
improv
within
hour
procedur
complet
total
free
level
trend
normal
near
normal
rang
within
hour
tabl
addit
plex
effect
hormon
associ
antibodi
remov
seem
remain
rebound
phenomenon
observ
case
make
repeat
plex
unnecessari
patient
total
thyroidectomi
week
event
great
clinic
outcom
conclus
case
demonstr
plex
safe
effect
treatment
option
manag
ts
patient
sever
cardiac
dysfunct
procedur
lead
rapid
decreas
thyroid
hormon
associ
antibodi
level
also
lessen
sever
tissu
injuri
moder
inflammatori
process
correct
complic
backgroundcas
studi
extracorpor
photopheresi
ecp
immunomodulatori
therapi
wide
use
sinc
year
cutan
cell
lymphoma
sever
autoimmun
diseas
organ
transplant
reject
last
year
also
use
graft
versu
host
diseas
treatment
use
ecp
cutan
cell
lymphoma
ctcl
mycosi
fungoid
mf
syndrom
ss
erytroderm
form
recent
categor
american
societi
pheresi
asfa
first
line
treatment
alon
combin
therapi
strong
recommend
grade
ib
categori
sinc
mf
ss
incur
diseas
current
therapi
focu
control
skin
symptom
minim
immunosuppress
object
observ
studi
assess
outcom
patient
diagnos
ss
compar
first
evalu
procedur
perform
studi
designmethod
ecp
therapi
ex
vivo
exposit
photosensit
drug
uva
light
subsequ
reinfus
treat
cell
induc
apoptosi
volum
treat
vari
total
bodi
volum
tbv
schedul
ss
diseas
one
cycl
two
daili
ecp
procedur
twice
per
month
venou
access
peripher
case
except
central
cathet
need
procedur
perform
optia
amicu
devic
aphaeresi
extern
uva
irradi
system
patient
onlin
system
therako
main
paramet
evalu
cutan
respons
rate
number
cell
previou
treatment
durat
respons
possibl
complic
ecp
treatment
resultsfind
global
respons
rate
partial
remiss
complet
remiss
maintain
respons
sever
side
effect
relat
procedur
found
patient
outcom
analyz
similar
result
publish
literatur
conclus
case
treat
hospit
confirm
efficaci
ecp
ss
treatment
good
safeti
profil
anoth
great
advantag
ecp
rel
lack
immun
suppress
mani
question
remain
still
unansw
ecp
schedul
suitabl
one
must
continu
stop
partial
complet
remiss
achiev
number
leukocyt
treat
techniqu
also
get
good
result
question
make
prospect
studi
necessari
perform
backgroundcas
studi
thrombot
thrombocytopen
purpura
ttp
time
difficult
differenti
thrombot
microangiopathi
ttp
requir
immedi
initi
therapeut
plasma
exchang
tpe
platelet
count
normal
achiev
microangiopathi
may
respons
tpe
test
modal
promptli
increas
level
suspicion
ttp
desir
sinc
test
often
perform
refer
laboratori
absolut
immatur
platelet
count
shown
aid
diagnost
ttp
present
present
pediatr
case
clinic
suspicion
ttp
use
guid
therapi
studi
designmethod
previous
healthi
unimmun
year
old
male
present
diarrhea
vomit
eleven
day
famili
histori
signific
immun
thrombocytopen
purpura
itp
sibl
initi
laboratori
result
show
sever
hemolyt
anemia
hemoglobin
hgb
lactat
dehydrogenas
ldh
ul
requir
transfus
mild
thrombocytopenia
x
acut
kidney
injuri
bun
creatinin
third
hospit
day
hgb
improv
howev
worsen
thrombocytopenia
x
led
clinic
concern
ttp
peripher
smear
show
mani
red
cell
fragment
patient
transfus
platelet
day
prior
first
tpe
immatur
platelet
fraction
x
platelet
count
obtain
daili
cbc
ratio
calcul
baselin
resultsfind
four
tpe
five
day
perform
hospit
day
platelet
count
improv
x
x
respect
prior
first
tpe
respons
four
tpe
led
decreas
platelet
count
x
x
dynam
resembl
describ
ttp
patient
defici
obtain
prior
tpe
initi
result
time
caus
organ
toxin
identifi
urin
blood
stool
examin
cultur
base
result
tpe
discontinu
led
immedi
increas
x
preced
platelet
count
increas
x
three
day
later
patient
discharg
laboratori
valu
time
ldh
ul
hgb
set
recoveri
renal
function
conclus
time
diagnosi
ttp
essenti
start
tpe
dynam
differ
ttp
compar
thrombot
microangiopathi
patient
fail
improv
despit
tpe
improv
procedur
discontinu
follow
increas
platelet
count
three
day
later
ttp
caus
etiolog
help
adjust
therapi
lead
clinic
improv
research
need
character
immatur
platelet
dynam
microangiopathi
backgroundcas
studi
ttp
life
threaten
diseas
defin
microangiopath
hemolyt
anemia
thrombocytopenia
sever
defici
sinc
introduct
therapeut
plasma
exchang
tpe
treatment
modal
ttp
prognosi
improv
dramat
nonetheless
patient
may
develop
relaps
refractori
potenti
fatal
outcom
despit
notabl
progress
made
studi
emphas
pivot
role
epidemiolog
ttp
remain
uncertain
previou
studi
suggest
mani
factor
appear
influenc
pathogenesi
studi
point
toward
infect
possibl
trigger
may
contribut
develop
ultim
influenc
clinic
cours
one
theori
explain
associ
possibl
cross
reactiv
antibodi
target
infecti
pathogen
direct
aim
studi
prospect
examin
potenti
associ
infect
clinic
outcom
cohort
patient
idiopath
ttp
studi
designmethod
patient
idiopath
ttp
underw
tpe
januari
march
studi
session
perform
daili
platelet
reticulocyt
normal
session
gradual
taper
includ
patient
activ
less
data
infect
occur
within
week
prior
develop
ttp
analyz
resultsfind
patient
categor
idiopath
ttp
sever
defici
eight
patient
associ
suspect
bacteri
infect
four
patient
show
acut
relaps
coincid
bacteri
infect
central
line
associ
staphylococcu
aureu
infect
occur
three
patient
acinetobact
urinari
tract
infect
report
one
patient
one
patient
symptom
respiratori
infect
develop
ttp
initi
well
relaps
episod
refractori
treatment
demonstr
patient
associ
dental
abscess
one
patient
two
associ
mycoplasma
pneumonia
tpe
session
continu
refractori
patient
death
conclus
patient
idiopath
ttp
refractori
convent
treatment
seriou
consider
given
caus
particularli
presenc
remot
sourc
infect
addit
trigger
factor
initi
recurr
episod
backgroundcas
studi
therapeut
leukapheresi
tl
becom
ordinari
procedur
low
bodi
weight
children
cancer
use
time
replac
exchang
transfus
leukodeplet
preced
chemotherapi
help
prevent
leukostasi
hiperviscos
aim
reduc
metabol
renal
complic
associ
cell
lysi
object
studi
evalu
efficaci
safeti
leukapheresi
procedur
pediatr
patient
less
kilogram
use
singl
apheresi
procedur
studi
designmethod
octob
june
two
children
possibl
leukemia
submit
tl
procedur
month
old
weight
kilogram
french
central
venou
cathet
place
apheresi
perform
use
continu
flow
apheresi
system
devic
prime
abo
rh
kell
compat
irradi
hematocrit
pack
rbc
anticoagul
use
plu
heparin
unit
heparin
blood
anticoagul
ratio
complet
blood
count
determin
apheresi
room
heat
avoid
hypothermia
ioniz
calcium
measur
everi
minut
prevent
hypocalcemia
collect
chang
blood
pressur
oxygen
satur
heart
rate
observ
net
fluid
balanc
calcul
sum
volum
anticoagul
cation
nondivert
apheresi
prime
solut
minu
product
volum
procedur
complet
blood
fill
apheresi
tube
discard
patient
intens
care
unit
icu
supervis
pediatr
physician
icu
nurs
awar
potenti
advers
event
procedur
perform
two
hematolog
physician
nurs
practition
resultsfind
white
blood
cell
wbc
blood
count
immedi
apheresi
subject
formula
collect
pump
flow
x
inlet
flow
x
wbc
count
use
goal
remov
x
singl
leukapheresi
procedur
perform
total
blood
volum
process
per
patient
immedi
procedur
wbc
count
post
tl
wbc
count
respect
net
fluid
balanc
zero
procedur
patient
requir
transfus
conclus
tl
safe
effici
experi
leukodeplet
infant
limit
procedur
children
weigh
less
need
forethought
multidisciplinari
effort
henc
oper
need
custom
procedur
safe
collect
howev
despit
potenti
complic
may
occur
placement
adequ
vascular
access
manag
low
extracorpor
blood
volum
toxic
metabol
hematolog
issu
remain
excel
sourc
leukoreduct
hematolog
malign
diseas
backgroundcas
studi
nationwid
apheresi
registri
give
us
inform
current
statu
trend
regard
apheresi
procedur
data
compar
region
find
understand
differ
perspect
indic
technolog
clinic
practic
korean
societi
apheresi
ksfa
launch
onlin
web
base
registri
system
apheresi
procedur
sinc
report
data
year
studi
designmethod
registri
consist
two
one
address
overal
aspect
apheresi
procedur
perform
institut
focus
therapeut
plasmapheresi
procedur
data
regist
voluntarili
particip
hospit
korea
resultsfind
total
apheresi
procedur
perform
hospit
therapeut
plasmapheresi
frequent
procedur
follow
autolog
peripher
blood
stem
cell
pbsc
collect
allogen
pbsc
collect
donor
leukapheresi
therapeut
leukapheresi
cobe
spectra
amicu
wide
distribut
instrument
centrifug
domin
techniqu
therapeut
plasmapheresi
detail
inform
given
therapeut
plasmapheresi
procedur
perform
patient
item
complet
fill
spectra
optia
cobe
spectra
frequent
use
instrument
therapeut
plasmapheresi
fresh
frozen
plasma
ffp
use
frequent
replac
fluid
follow
albumin
albumin
albumin
ffp
procedur
perform
plasma
volum
acd
heparin
use
anticoagul
central
venou
cathet
domin
type
vascular
access
major
clinic
indic
desensit
abo
incompat
renal
transplant
antibodi
mediat
reject
renal
transplant
thrombot
microangiopathi
desensit
abo
compat
renal
transplant
neuromyel
optica
spectrum
disord
hyperviscos
monoclon
gammopathi
advers
reaction
observ
procedur
allerg
reaction
hypocalcem
symptom
hypotens
frequent
report
therapeut
effect
achiev
patient
conclus
apheresi
registri
well
run
year
recent
data
reflect
increas
abo
incompat
transplant
korea
revis
updat
registri
plan
year
help
us
achiev
better
understand
apheresi
statu
region
backgroundcas
studi
hypertriglyceridem
pancreat
hp
character
sever
hypertriglyceridemia
shtg
triglycerid
acut
pancreat
ap
absenc
caus
hp
potenti
fatal
complic
acut
pancreat
incid
casesyear
complic
shtg
includ
abdomin
pain
nauseavomit
acut
pancreat
hepatosplenomegali
erupt
xanthoma
lipemia
retinali
memori
loss
dementia
peripher
neuropathi
report
effect
use
plasma
exchang
pe
treat
patient
pt
hp
refractori
convent
medic
therapi
diet
plu
pharmaceut
intervent
studi
designmethod
review
medic
record
pt
diagnos
hp
januari
januari
refer
immunotherapi
evalu
pt
receiv
convent
therapi
ct
pe
pe
group
pt
receiv
ct
alon
ct
group
mean
age
year
rang
femal
baselin
mean
triglycerid
level
normal
pe
group
versu
ct
group
baselin
mean
lipas
level
normal
ul
pe
group
ul
versu
ul
ct
group
resultsfind
pt
treat
dietari
restrict
diet
noth
mouth
aggress
lipid
lower
protocol
involv
medic
pe
group
ct
group
receiv
insulin
therapi
manag
symptom
sx
hyperglycemia
andor
diabet
ketoacidosi
pe
group
ct
group
receiv
heparin
therapi
stimul
lipoprotein
lipas
releas
pe
group
underw
averag
pe
treatment
tx
median
rang
daili
tx
use
albumin
requir
ffp
treat
dilut
coagulopathi
case
perform
pe
tx
baselin
triglycerid
level
lipas
ul
x
upper
limit
normal
mean
triglycerid
level
pe
tx
pe
group
mean
decreas
mean
triglycerid
level
addit
hour
ongo
ct
ct
group
mean
decreas
pe
group
achiev
greater
mean
decreas
triglycerid
level
pe
tx
compar
ct
group
hour
ct
group
experienc
mark
improv
clinic
sx
pancreat
hyperglycemia
p
limit
retrospect
cohort
studi
includ
lack
conclus
small
studi
add
literatur
demonstr
plasma
exchang
effect
rapidli
lower
triglycerid
level
pt
acut
pancreat
hypertriglyceridemia
suggest
may
threshold
rang
triglycerid
lipas
level
convent
therapi
may
nearli
effect
achiev
clinic
resolut
symptom
random
control
trial
would
elucid
appropri
use
adjunct
plasma
exchang
set
hypertriglyceridem
pancreat
backgroundcas
studi
apheresi
servic
perform
chronic
therapeut
plasma
exchang
tpe
man
chronic
histori
hypertriglyceridemia
diabet
mellitu
type
ii
chronic
abdomin
pain
abdomin
pain
sever
persist
overt
evid
chronic
pancreat
imag
fecal
elastas
test
target
sequenc
reveal
pathogen
mutat
explain
patient
hypertriglyceridemia
hypertriglyceridem
pancreat
categori
iii
indic
tpe
asfa
guidelin
patient
unrespons
optim
medic
manag
asfa
guidelin
disord
state
use
plasma
contain
lipoprotein
lipas
could
enhanc
triglycerid
tg
remov
direct
comparison
replac
fluid
report
three
apheresi
physician
servic
use
partial
plasma
replac
variabl
undertook
retrospect
studi
efficaci
partial
plasma
replac
patient
studi
designmethod
perform
tpe
patient
perform
chart
review
captur
replac
fluid
use
level
drawn
tpe
perform
use
spectra
optia
terumo
lakewood
co
exchang
approxim
one
plasma
volum
use
entir
albumin
exchang
fluid
albumin
procedur
partial
plasma
replac
unit
thaw
plasma
tpe
tg
valu
avail
determin
percent
tg
reduct
achiev
tpe
also
determin
daili
rate
tg
increas
next
tpe
appoint
assess
effect
plasma
prevent
tg
rebound
signific
assess
student
heteroscedast
resultsfind
twelv
tpe
perform
partial
plasma
replac
perform
albumin
replac
tabl
show
partial
plasma
replac
associ
significantli
greater
tg
reduct
rate
subsequ
daili
tg
increas
also
lower
partial
plasma
replac
meet
signific
one
mild
allerg
reaction
occur
partial
plasma
replac
respond
quickli
addit
iv
diphenhydramin
conclus
perform
ad
hoc
studi
efficaci
partial
plasma
replac
tpe
hypertriglyceridemia
patient
without
lipoprotein
lipas
mutat
plasma
significantli
associ
improv
tg
reduct
prevent
tg
rebound
backgroundcas
studi
therapeut
plasma
exchang
tpe
albumin
replac
use
treat
varieti
diseas
howev
rise
cost
suppli
shortag
import
albumin
countri
solv
problem
nation
blood
centr
establish
plasma
fraction
plant
manufactur
plasma
deriv
includ
albumin
object
studi
evalu
safeti
efficaci
local
albumin
replac
tpe
studi
designmethod
tpe
use
local
albumin
replac
two
tertiari
care
hospit
perform
june
februari
includ
complet
blood
count
serum
calcium
test
tpe
serum
albumin
test
tpe
local
albumin
avail
solut
use
dilut
albumin
concentr
normal
salin
patient
hospit
receiv
oral
calcium
tpe
prevent
hypocalcemia
advers
effect
record
resultsfind
total
tpe
patient
includ
shown
tabl
neurolog
disord
common
indic
tpe
follow
autoimmun
diseas
median
total
plasma
volum
rang
ml
although
correct
calcium
level
low
procedur
clinic
manifest
hypocalcemia
detect
advers
effect
observ
tpe
procedur
patient
first
patient
event
mild
symptomat
hypotens
previous
took
angiotensin
convert
enzym
inhibitor
second
patient
complain
nausea
finish
tpe
reaction
mild
incid
advers
effect
incid
tpe
advers
effect
commerci
albumin
use
differ
statist
differ
p
median
serum
albumin
level
gdl
increas
serum
albumin
tpe
statist
signific
p
percent
serum
albumin
level
lower
explain
rise
albumin
procedur
conclus
demonstr
local
albumin
safe
effect
maintain
albumin
level
patient
undergo
tpe
tabl
patient
characterist
backgroundcas
studi
within
eu
collect
mononuclear
cell
mnc
start
sourc
manufactur
autolog
cell
therapi
mainli
perform
hospit
apheresi
center
report
challeng
perform
leukapheresi
procedur
la
privat
held
medic
practic
specif
emphas
safeti
cell
collect
effici
studi
designmethod
review
record
altogeth
outpati
underw
total
la
procedur
privat
held
medic
practic
certifi
cell
collect
facil
locat
vienna
austria
patient
particip
variou
clinic
p
trial
studi
sponsor
respons
manufactur
activ
cell
product
diseas
entiti
mainli
prostat
cancer
ovarian
cancer
base
differ
studi
protocol
la
perform
either
interv
least
week
repeat
collect
resultsfind
patient
success
complet
apheresi
cours
poor
venou
access
patient
requir
femor
cathet
insert
seriou
side
effect
patient
requir
femor
cathet
patient
repeat
la
procedur
side
effect
la
procedur
mainli
consist
mild
symptom
patient
survey
one
week
complet
la
reveal
infecti
complic
patient
requir
hospit
median
cell
yield
collect
per
singl
apheresi
wbc
consist
mnc
mnc
cell
yield
remain
stabl
even
repeat
la
collect
cell
product
success
transform
activ
cellular
product
analysi
cost
structur
show
total
cost
care
lower
set
privat
collect
center
compar
apheresi
center
conclus
leukapheresi
perform
privat
medic
practic
certifi
cell
collect
facil
safe
effect
low
rate
complic
high
level
patient
satisfact
servic
model
help
reduc
cost
manufactur
good
product
innov
cellular
product
backgroundcas
studi
hyperviscos
syndrom
hv
refer
clinic
manifest
increas
blood
viscos
gener
character
mucos
bleed
visual
chang
neurolog
symptom
although
typic
associ
monoclon
gammopathi
eg
waldenstrom
macroglobulinemia
multipl
myeloma
hv
rare
report
patient
disord
immun
system
rheumatoid
diseas
sjogren
syndrom
hiv
diseas
therapeut
plasma
exchang
tpe
indic
hv
due
monoclon
gammopathi
asfa
categori
indic
howev
limit
data
util
tpe
hv
due
polyclon
gammopathi
studi
designmethod
year
old
femal
patient
medic
histori
signific
seroposit
eros
rheumatoid
arthriti
hypertens
diabet
mellitu
cutan
lupu
diffus
parenchym
lung
diseas
present
institut
complaint
progress
fatigu
muscl
weak
poor
appetit
headach
epistaxi
month
fundoscop
examin
show
dilat
tortuou
vasculatur
well
bilater
retin
hemorrhag
mix
pattern
pertin
laboratori
find
includ
posit
antibodi
screen
antibodi
antibodi
serum
rheumatoid
factor
markedli
elev
iuml
ref
rang
citrullin
peptid
antibodi
elev
unit
ref
rang
serum
protein
electrophoresi
immunofix
demonstr
polyclon
hypergammaglobulinemia
protein
precipit
note
point
applic
suggest
circul
immun
complex
serum
igg
igm
iga
respect
cryoglobulin
screen
neg
serum
free
kappa
lambda
ratio
peripher
blood
flow
cytometri
identifi
monoclon
popul
plasma
viscos
note
centipois
cp
admiss
ref
rang
imag
neg
patient
treat
high
dose
steroid
singl
tpe
procedur
perform
use
follow
paramet
volum
treat
total
plasma
volum
replac
fluid
albumin
normal
salin
ratio
replac
fluid
volum
total
volum
process
procedur
toler
without
complic
resultsfind
immedi
plasma
viscos
level
drop
cp
serum
igg
igm
iga
level
decreas
respect
rf
decreas
iuml
patient
report
subject
improv
strength
subsequ
receiv
two
infus
rituximab
separ
two
week
plasma
viscos
remain
less
cp
sinc
tpe
conclus
polycolon
gammomathi
eg
secondari
ra
rare
caus
hv
tpe
provid
transient
relief
symptom
unusu
case
hv
may
facilit
therapi
prevent
recurr
hv
episod
backgroundcas
studi
neuromyel
optica
spectrum
disord
nmosd
idiopath
inflammatori
demyelin
disord
central
nervou
system
preferenti
involv
optic
nerv
upper
segment
spinal
cord
lead
optic
neuriti
myeliti
tpe
indic
acut
phase
mainten
therapi
treat
prevent
relaps
chronic
phase
studi
designmethod
assess
efficaci
plasma
exchang
patient
nmosd
respond
high
dose
intraven
steroid
retrospect
review
tpe
record
patient
nmosd
period
three
year
jan
dec
tpe
done
use
cobe
spectra
terumo
bct
lakewood
co
usa
replac
one
one
half
patient
plasma
volum
human
serum
albumin
fresh
frozen
plasma
altern
day
improv
clinic
sign
symptom
record
tpe
procedur
end
therapi
advers
reaction
also
record
resultsfind
eleven
patient
nmosd
year
age
f
underw
tpe
procedur
averag
per
patient
patient
high
dose
immunosuppress
therapi
without
much
clinic
improv
three
patient
visual
symptom
visual
well
muscular
symptom
wherea
patient
muscular
symptom
three
seven
test
posit
patient
show
signific
improv
visual
symptom
post
exchang
visionlight
percept
finger
count
two
patient
recoveri
colour
vision
diplopia
six
patient
post
exchang
recoveri
muscl
power
observ
patient
patient
seven
advers
event
observ
procedur
allerg
reaction
replac
fluid
common
event
follow
hypotens
follow
avail
patient
well
immunosuppress
therapi
one
patient
die
due
respiratori
failur
month
anoth
relaps
underw
second
tpe
cycl
continu
well
conclus
tpe
safe
effect
adjunct
therapi
high
dose
immunosuppress
nmosd
backgroundcas
studi
terumobct
releas
trima
accel
softwar
version
enhanc
allow
collect
platelet
plt
platelet
addit
solut
pa
provid
addit
improv
increas
overal
reliabl
addit
manufactur
identifi
slower
centrifug
speed
low
draw
flow
rate
softwar
expect
function
similarli
version
object
retrospect
studi
identifi
varianc
softwar
upgrad
influenc
plt
product
collect
process
product
collect
studi
designmethod
prior
plt
collect
perform
nine
trima
accel
machin
oper
version
upgrad
valid
nine
machin
version
occur
trima
program
plt
configur
softwar
updat
platelet
collect
data
version
compar
version
incomplet
collect
run
identifi
possibl
leukocyt
contamin
durat
collect
plt
split
rate
evalu
time
period
gener
estim
equat
gee
use
assess
differ
plt
collect
version
adjust
multipl
visit
per
donor
signific
defin
resultsfind
follow
upgrad
version
staff
observ
number
chang
includ
increas
centrifug
recoveri
time
donor
low
flow
notabl
increas
possibl
leukocyt
contamin
product
version
trima
accel
show
statist
signific
increas
possibl
leukocyt
contamin
collect
compar
version
durat
collect
plt
split
rate
remain
constant
even
centrifug
speed
adjust
version
conclus
due
fda
limit
allow
implement
trima
accel
pa
plt
current
avail
pathogen
reduct
system
institut
decid
implement
pathogen
reduct
system
time
subsequ
version
softwar
longer
requir
note
slight
increas
possibl
leukocyt
contamin
well
lack
enhanc
plt
collect
upgrad
version
current
provid
ad
valu
version
plt
collect
backgroundcas
studi
patient
hematolog
malign
present
high
leukocyt
count
hyperleucocytosi
may
lead
pulmonari
neurolog
symptom
due
leukostasi
therapeut
leukocytaphersi
tl
use
adjuv
therapeut
modal
patient
symptom
suggest
leukostasi
tl
procedur
perform
use
cell
separ
anticoagul
blood
subject
centrifug
forc
result
separ
layer
cell
plasma
depend
densiti
two
program
cell
separ
mononuclear
mnc
program
greater
centrifug
speed
effici
collect
mnc
polymorphonuclear
pmn
cell
program
lower
centrifug
speed
collect
pmn
hydroxyethyl
starch
he
prefer
collect
granulocyt
transfus
healthi
donor
use
he
facilit
sediment
granulocyt
layer
increas
effici
collect
though
use
he
tl
associ
advers
event
use
volum
expand
pagano
use
tl
vari
report
avail
effici
leukodeplet
use
he
tl
studi
designmethod
receiv
request
leukoreduct
ladi
chronic
myelogen
leukemia
cml
good
respons
imatinib
week
pregnant
increas
wbc
count
due
discontinu
imatinib
perform
tl
cobe
spectra
use
replac
fluid
albumin
wbc
count
monitor
pre
post
tl
patient
collect
product
modifi
collect
base
result
use
mnc
program
pmn
program
leukodepet
adequ
program
elect
use
he
discuss
patient
physician
tl
perform
use
he
citrat
pmn
program
wbc
pre
procedur
immedi
post
procedur
product
obtain
effici
leukodeplet
differ
program
calcul
resultsfind
effici
wbc
deplet
calcul
product
wbc
patient
wbc
base
blood
volum
also
pre
post
wbc
patient
toler
procedur
well
advers
reaction
patient
fetal
monitor
procedur
conclus
therapeut
leukocytapheresi
cml
patient
safe
effect
reduc
wbc
count
use
hydroxyethyl
starch
anticoagul
post
procedur
patient
wbc
count
sometim
may
provid
data
effici
leucodeplet
pagano
etal
transfus
thank
due
clinic
apheresi
staff
backgroundcas
studi
earli
recognit
hypertriglyceridemia
htg
set
acut
pancreat
ap
critic
initi
effect
therapi
role
plasmapheresi
earlyadjuv
approach
acut
pancreat
controversi
current
consensu
guidelin
optim
therapi
asfa
categori
iii
report
case
tg
level
well
clinic
symptom
improv
one
therapeut
plasma
exchang
tpe
studi
designmethod
year
old
male
histori
hypertens
htg
diabet
mellitu
dm
present
emerg
depart
excruci
abdomin
pain
patient
diagnos
htg
year
old
treat
initi
diet
lifestyl
modif
howev
clinic
cours
compromis
develop
pancreat
acut
episod
requir
prolong
hospit
admiss
approxim
month
success
treat
medic
howev
recurr
episod
result
chronic
pancreat
complic
pancreat
pseudocyst
pancreat
insuffici
sinc
first
episod
pancreat
medic
manag
fenofibr
lovaza
lisinopril
levemir
novolog
evalu
current
admiss
found
tg
level
lipas
ul
glucos
bicarbon
mmoll
anion
gap
ct
find
consist
ap
without
evid
necrosi
stabl
pancreat
pseudocyst
medic
therapi
start
omega
fatti
acid
fibrat
statin
hydrat
well
pain
control
statin
therapi
suspend
day
hospit
note
elev
liver
function
test
lft
tpe
request
start
day
admiss
resultsfind
patient
tg
decreas
medic
therapi
follow
addit
one
volum
tpe
symptom
significantli
improv
discharg
medic
treatment
day
admiss
compar
previou
episod
hospit
stay
significantli
decreas
tg
level
remain
day
follow
discharg
conclus
earli
tpe
may
valu
treat
patient
elev
tg
associ
recurr
pancreat
plasmapheresi
might
effect
earli
adjuv
therapi
mitig
length
hospit
stay
improv
patient
safeti
tabl
chronolog
triglycerid
level
backgroundcas
studi
nation
blood
donor
center
southeast
asia
conduct
program
monitor
ferritin
level
platelet
blood
donor
aim
studi
explor
trend
chang
ferritin
studi
designmethod
studi
collect
case
whose
ferritin
level
monitor
twice
interv
detect
day
collect
plasma
sampl
test
ferritin
chemiluminesc
use
commerci
assay
inclus
criteria
includ
apheresi
platelet
blood
donor
two
result
ferritin
first
time
ferritin
test
result
upper
limit
set
male
femal
describ
manufactur
insert
impact
ferritin
gender
age
blood
donat
frequenc
examin
anova
test
blood
donat
frequenc
categor
five
group
time
time
time
time
time
high
frequenc
time
group
blood
donor
analyz
ferritin
chang
longitudin
data
resultsfind
donor
includ
studi
male
femal
mean
ferritin
male
ci
femal
ci
result
anova
indic
group
highest
frequenc
time
signific
lowest
ferritin
level
p
averag
chang
ferritin
donat
time
would
younger
elder
yo
male
femal
high
frequenc
half
year
time
group
blood
donor
longitudin
analysi
found
sustain
high
frequenc
blood
donat
caus
signific
declin
ferritin
averag
chang
ferritin
high
frequenc
donor
time
day
reduc
first
period
third
period
day
along
period
declin
ferritin
decreas
conclus
analysi
reveal
frequent
apheresi
platelet
donat
would
decreas
ferritin
donor
high
frequenc
platelet
blood
donor
continu
donat
year
declin
ferritin
slow
backgroundcas
studi
report
case
whole
blood
wb
donat
precipit
transient
agit
delirium
first
time
male
donor
present
local
blood
center
complet
donor
health
questionnair
exam
hemoglobin
check
deem
elig
blood
donat
approxim
minut
uncompl
wb
donat
donor
observ
brief
loss
conscious
area
fall
injuri
seen
shortli
regain
conscious
donor
becam
agit
confus
orient
month
year
unabl
rememb
name
friend
famili
member
unabl
read
analog
clock
difficulti
word
find
donor
transport
local
univers
hospit
note
comb
deliri
alter
mental
statu
forcibl
restrain
ultim
sedat
intub
transfer
intens
care
unit
studi
designmethod
extens
laboratori
investig
perform
includ
standard
hematolog
chemistri
panel
serolog
studi
multipl
organ
includ
west
nile
herp
hiv
varicella
zoster
syphili
aerob
anaerob
blood
cultur
urin
drug
screen
multipl
drug
abus
radiograph
imag
perform
includ
chest
ct
mri
head
spine
addit
eeg
perform
inpati
neurolog
psychiatri
servic
consult
patient
resultsfind
sedat
discontinu
patient
success
extub
rapidli
improv
complet
return
baselin
within
hour
onset
event
laboratori
investig
reveal
sign
infecti
organ
evid
drug
abus
radiograph
imag
eeg
studi
show
abnorm
addit
infecti
diseas
marker
test
perform
blood
center
laboratori
neg
investig
reveal
donor
experienc
high
level
stress
school
avers
sight
blood
coerc
donat
girlfriend
peer
week
follow
hospit
discharg
blood
center
medic
director
contact
donor
phone
donor
resum
normal
routin
attend
graduat
level
class
conclus
knowledg
first
report
blood
donat
precipit
transient
acut
delirium
time
donat
health
statu
potenti
blood
donor
assess
help
ensur
safeti
donor
recipi
health
questionnair
physic
exam
vital
sign
hemoglobin
level
infecti
diseas
test
help
identifi
overt
sign
medic
ill
may
disqualifi
donor
howev
routin
donor
screen
explicitli
evalu
mental
health
issu
diagnos
undiagnos
although
exceedingli
rare
case
highlight
limit
donor
screen
identifi
donor
may
risk
mental
health
advers
reaction
donat
blood
backgroundcas
studi
continu
need
blood
product
requir
frequent
transfus
individu
sickl
cell
diseas
could
benefit
product
collect
african
american
donor
warrant
need
target
intervent
increas
blood
donat
underrepres
popul
one
popul
particular
african
american
account
blood
donor
unit
state
literatur
indic
numer
reason
popul
underrepres
amongst
donor
includ
fear
lack
knowledg
blood
donat
specif
popul
lack
trust
medic
commun
studi
designmethod
african
american
richmond
norfolk
virginia
recruit
church
local
univers
studi
aim
develop
implement
assess
target
educ
approach
incorpor
theori
plan
behavior
variou
teach
method
develop
implement
survey
evalu
particip
feel
attitud
intent
donat
motiv
african
american
attempt
donat
blood
particip
attend
educ
session
educ
import
red
blood
cell
donat
african
american
particip
complet
three
survey
session
one
directli
session
one
two
month
session
use
compar
known
proport
african
american
present
donat
studi
area
present
donat
studi
regress
analysi
use
estim
relationship
among
survey
variabl
resultsfind
total
subject
includ
data
analysi
sixteen
percent
studi
particip
present
donat
result
attend
educ
session
result
statist
significantli
higher
proport
african
american
present
donat
current
proport
area
state
studi
conduct
result
first
two
survey
indic
subject
norm
attitud
signific
predictor
one
intent
donat
blood
perceiv
behavior
control
factor
educ
session
increas
survey
score
relat
intent
donat
comparison
score
obtain
prior
session
conclus
studi
show
target
educ
program
chang
attitud
toward
blood
donat
african
american
result
increas
new
blood
donor
addit
studi
need
see
behavior
continu
whether
african
american
influenc
commun
increas
awar
motiv
blood
donat
backgroundcas
studi
implement
adjust
male
hemoglobin
standard
armi
blood
donor
center
note
signific
increas
hemoglobin
deferr
scrutini
increas
hemoglobin
deferr
determin
major
deferr
observ
two
differ
servic
compon
basic
train
site
southeast
popul
basic
train
site
largest
activ
initi
entri
station
armi
train
new
recruit
enlist
women
armi
demograph
basic
train
site
b
much
differ
roughli
marin
recruit
women
studi
designmethod
basic
train
site
armi
basic
train
site
basic
train
site
b
marin
basic
train
site
recruit
basic
train
site
present
asbp
blood
drive
day
train
cycl
blood
drive
basic
train
site
b
schedul
day
day
train
cycl
therefor
group
traine
present
roughli
time
separ
train
schedul
amount
time
initi
entri
asbp
blood
drive
schedul
monthli
hemoglobin
deferr
percentag
basic
train
site
b
obtain
calcul
compar
use
test
resultsfind
hemoglobin
deferr
obtain
compar
obtain
basic
train
site
b
demonstr
signific
increas
hemoglobin
deferr
basic
train
site
increas
p
basic
train
site
b
increas
p
hemoglobin
deferr
demograph
basic
train
site
stratifi
demonstr
femal
basic
traine
hemoglobin
deferr
demograph
stratif
basic
train
site
b
reveal
femal
basic
traine
conclus
signific
increas
hemoglobin
deferr
basic
train
site
could
result
chang
blood
drive
time
train
schedul
locat
basic
traine
site
schedul
day
januari
blood
drive
date
chang
day
extra
three
day
basic
train
atmospher
associ
diet
chang
increas
physic
activ
may
effect
hemoglobin
level
popul
basic
train
site
b
signific
increas
hemoglobin
deferr
attribut
larger
male
popul
present
site
basic
train
addit
percentag
femal
recruit
donat
blood
drive
decreas
observ
support
hypothesi
increas
hemoglobin
deferr
result
implement
male
hemoglobin
standard
chang
basic
train
site
b
plan
blood
drive
basic
train
site
b
screen
addit
recruit
must
consid
perform
blood
drive
order
meet
collect
goal
set
prior
implement
chang
male
hemoglobin
standard
backgroundcas
studi
donat
blood
compon
bc
donor
spinal
cord
injuri
sci
poorli
studi
paralysi
state
diseas
reason
time
sinc
acquisit
peopl
differenti
rest
popul
term
bc
donat
literatur
review
blood
donat
suitabl
criteria
among
peopl
scarc
veget
labil
may
present
depend
type
sci
obviou
daili
practic
potenti
donor
often
reject
donat
specif
criteria
relat
sci
object
studi
establish
select
criteria
bc
donat
peopl
sci
base
medic
criteria
evalu
rate
advers
donat
blood
reaction
donor
donor
control
group
without
sci
studi
designmethod
organ
regularli
organ
donat
campaign
rehabilit
center
patient
sci
campaign
donor
sci
donor
without
profession
center
rel
etc
donat
blood
januari
decemb
analyz
number
donor
came
give
blood
number
reason
exclus
could
make
donat
whether
sci
number
typolog
advers
reaction
donat
detect
group
donor
sci
higher
due
high
risk
autonom
dysreflexia
exclud
donat
donor
sci
less
one
year
evolut
set
temporari
exclus
criteria
presenc
neurogen
bladder
consid
reason
exclus
resultsfind
analyz
period
donor
came
give
blood
exclud
donat
variou
reason
two
donor
exclud
suffer
sci
higher
exclud
due
high
risk
dysreflexia
anoth
one
donor
exclud
suffer
sci
lower
hemoglobin
level
lower
select
criteria
donor
select
donat
sci
lower
advers
reaction
donat
record
haemovigil
program
none
donor
sci
conclus
accord
experi
donor
sci
lower
type
advers
reaction
blood
donat
select
exclus
criteria
base
donor
paralyt
condit
vagal
syndrom
could
appear
complic
donat
sci
donor
approach
differ
usual
protocol
use
backgroundcas
studi
blood
pressur
bp
import
determin
health
suitabl
blood
donor
manual
method
read
bp
result
variabl
due
minor
varianc
way
staff
perform
manual
procedur
autom
bp
devic
abl
reduc
variabl
bp
determin
decemb
autom
bp
devic
valid
replac
manual
bp
method
blood
donor
center
object
retrospect
studi
determin
chang
manual
autom
bp
process
impact
averag
systol
diastol
pressur
addit
differ
deferr
reaction
rate
observ
studi
designmethod
data
manual
bp
process
accumul
month
period
januari
novemb
inform
assembl
autom
bp
process
month
period
januari
novemb
autom
bp
process
implement
decemb
data
exclud
studi
bp
bp
deferr
reaction
donor
weight
demograph
evalu
time
period
donor
may
includ
multipl
time
year
could
set
data
gener
estim
equat
use
assess
differ
autom
manual
bp
signific
defin
p
resultsfind
significantli
peopl
defer
use
autom
bp
compar
manual
bp
read
systol
diastol
bp
measur
significantli
higher
autom
bp
method
manual
method
although
donor
autom
bp
group
experienc
fewer
reaction
manual
bp
group
reduct
larg
enough
reach
statist
signific
even
adjust
gender
weight
age
donat
bp
deferr
systol
diastol
bp
remain
significantli
higher
p
autom
bp
reaction
remain
lower
p
conclus
autom
bp
devic
improv
conveni
staff
donor
statist
signific
increas
deferr
margin
decreas
reaction
use
autom
bp
devic
may
play
minor
role
safeti
blood
donor
backgroundcas
studi
blood
donor
center
plagu
hemoglobin
hgb
deferr
accur
hgb
valu
import
mitig
unnecessari
deferr
june
institut
valu
analysi
team
made
decis
implement
differ
finger
stick
lancet
reduc
cost
newli
acquir
lancet
b
retain
depth
origin
lancet
focal
differ
lancet
b
smaller
gaug
needl
versu
previou
gaug
needl
lancet
object
studi
determin
lancet
convers
impact
number
finger
stick
requir
obtain
free
flow
sampl
blood
addit
differ
donor
hgb
valu
subsequ
deferr
observ
studi
designmethod
lancet
b
usag
hgb
valu
inform
accumul
month
period
start
june
inform
assembl
lancet
month
period
start
june
donor
may
includ
multipl
time
year
could
year
data
hemoglobin
assess
donor
gender
proport
first
time
donor
number
visit
per
donor
across
two
year
evalu
may
minimum
hemoglobin
deferr
men
increas
purpos
studi
hemoglobin
valu
compar
surrog
deferr
adjust
multipl
visit
per
donor
gener
estim
equat
use
assess
signific
lancet
lancet
b
use
appropri
distribut
data
type
defin
statist
signific
resultsfind
averag
hgb
slightli
lower
lancet
b
larger
chang
number
donor
statist
visit
hgb
less
use
lancet
b
lancet
addit
fewer
first
time
donor
seen
lancet
b
time
lancet
time
adjust
effect
gender
donat
use
logist
regress
risk
hgb
higher
lancet
b
lancet
conclus
donor
hgb
slightli
lower
lancet
b
lancet
clinic
differ
slightli
lancet
bs
use
per
visit
lancet
addit
hgb
deferr
obtain
use
lancet
b
lancet
even
adjust
effect
gender
repeat
donor
saw
potenti
deferr
lancet
b
lancet
slight
differ
gaug
lancet
may
associ
amount
blood
may
affect
hgb
level
prior
implement
materi
lower
cost
evalu
downstream
consequ
would
recommend
backgroundcas
studi
surg
demand
blood
due
age
popul
hospit
built
becom
increasingli
import
abl
ensur
donor
return
regular
basi
improv
blood
suppli
blood
stock
manag
dislik
oblig
impos
appoint
singaporean
donor
gener
prefer
oppos
appoint
book
blood
servic
group
bsg
singapor
made
move
chang
donor
mindset
introduc
automat
appoint
schedul
paper
aim
studi
donor
level
accept
toward
initi
studi
designmethod
determin
donor
accept
rate
data
collect
januari
march
complet
donat
donor
automat
given
next
earliest
elig
date
next
donat
wish
accept
recommend
appoint
either
declin
arrang
log
blood
bank
donor
appoint
book
system
make
chang
appoint
offer
remind
sent
phone
via
sm
andor
email
account
three
day
appoint
date
data
collect
use
measur
number
appoint
made
declin
three
month
period
donor
declin
appoint
schedul
verbal
interview
reason
resultsfind
total
donor
donat
blood
blood
bank
main
branch
use
baselin
studi
donor
accept
automat
appoint
book
wherea
donor
comfort
declin
still
prefer
base
time
schedul
rest
decid
variabl
situat
donat
frequenc
choic
prefer
donat
locat
reason
declin
automat
appoint
book
prior
implement
appoint
book
blood
bank
branch
show
donor
book
appoint
comparison
made
found
studi
shown
signific
increas
accept
rate
conclus
gener
result
posit
automat
appoint
book
system
enabl
bsg
predict
donor
attend
ensur
better
manpow
manag
reduc
donor
turnaround
time
thu
hope
improv
donor
retent
bsg
still
monitor
automat
appoint
system
futur
studi
still
requir
determin
effect
automat
appoint
book
donor
return
retent
rate
current
bsg
collect
center
manag
appoint
system
eventu
aim
abl
central
appoint
book
system
wherebi
donor
book
appoint
still
abl
donat
collect
site
backgroundcas
studi
normal
sourc
plasma
import
sourc
therapeut
protein
includ
clot
factor
factor
viii
ix
immun
globulin
albumin
other
howev
littl
inform
avail
regard
demograph
characterist
donor
analysi
demograph
physiolog
characterist
group
normal
sourc
plasma
donor
unit
state
studi
designmethod
evalu
screen
demograph
physiolog
data
group
healthi
return
normal
sourc
plasma
donor
donor
center
unit
state
donor
particip
studi
assess
possibl
effect
plasma
donat
cholesterol
level
result
compar
refer
usa
popul
health
unit
state
cdc
anthropometr
refer
data
resultsfind
donor
male
white
hispan
averag
year
old
donor
similar
p
refer
popul
term
gender
race
ethnic
age
group
howev
donor
younger
p
donor
refer
popul
respect
year
old
donor
mean
weight
overal
donor
male
femal
weigh
mean
male
donor
weight
similar
p
refer
group
except
year
group
donor
heavier
p
mean
femal
donor
weight
significantli
p
higher
except
year
group
weight
similar
mean
donor
cholesterol
level
similar
male
femal
overal
mean
cholesterol
level
lower
p
younger
yr
donor
male
donor
refer
femal
donor
refer
incid
elev
cholesterol
similar
p
donor
refer
popul
except
younger
yr
male
donor
p
donor
refer
mean
donor
sbp
dbp
puls
mmhg
mmhg
bpm
respect
screen
blood
pressur
level
consist
hypertens
male
femal
year
donor
group
significantli
p
higher
refer
popul
male
femal
differ
observ
year
group
conclus
normal
sourc
donor
demograph
physiolog
characterist
often
parallel
refer
usa
popul
howev
differ
includ
lower
cholesterol
level
higher
rate
high
blood
pressur
younger
donor
higher
weight
year
old
femal
backgroundcas
studi
donor
must
suffici
inform
make
decis
time
consid
option
make
decis
opportun
make
choic
whether
proceed
declin
donat
donor
educ
de
materi
must
address
mandat
set
forth
regulatori
agenc
materi
must
access
understand
gener
popul
goal
qualit
design
studi
evalu
knowledg
acquir
standard
de
materi
studi
irb
approv
exempt
protocol
studi
designmethod
develop
de
document
written
comprehens
level
conveni
sampl
volunt
identifi
studi
focu
group
fg
incorpor
knowledg
acquisit
read
de
document
quiz
follow
group
discuss
feedback
contain
multipl
choic
question
singl
best
answer
includ
option
answer
nt
know
de
document
revis
base
upon
fg
feedback
quiz
result
revis
page
de
document
test
use
individu
interview
ii
resultsfind
demograph
quiz
result
summar
tabl
result
fg
ii
reveal
lack
knowledg
four
area
donor
might
ask
donat
time
donat
process
need
photo
identif
donat
iron
help
increas
low
red
blood
cell
level
donat
sole
purpos
obtain
hiv
test
ii
group
reveal
improv
knowledg
acquisit
four
area
feedback
group
reiter
document
long
tabl
demograph
quiz
result
conclus
develop
de
materi
requir
complic
balanc
provid
critic
inform
concis
appropri
comprehens
level
grade
test
de
materi
essenti
step
develop
process
ensur
intend
knowledg
acquir
end
user
popul
next
step
group
pilot
revis
de
document
donat
site
backgroundcas
studi
rh
blood
suppli
program
develop
purpos
prompt
stabl
blood
suppli
base
computer
system
program
oper
emerg
contactcommun
program
major
function
request
emerg
blood
recruit
manag
rh
blood
donor
emerg
blood
donat
blood
suppli
statu
monitor
program
statist
program
aim
research
valid
effect
rh
blood
suppli
program
oper
respons
emerg
blood
suppli
rh
blood
suppli
program
studi
designmethod
research
investig
databas
rh
blood
suppli
program
develop
investig
analyz
compar
recruit
blood
donat
rh
blood
donor
emerg
blood
donat
secur
blood
suppli
upon
request
resultsfind
data
show
number
voluntari
blood
donor
pledg
give
blood
emerg
blood
donat
increas
respect
also
actual
particip
rate
rh
blood
donat
among
group
pledg
give
blood
emerg
blood
donat
increas
moreov
data
indic
blood
suppli
fulli
met
demand
emerg
blood
request
conclus
result
show
rh
blood
suppli
program
effect
recruitmentmanag
rh
blood
donor
emerg
blood
donat
system
contribut
recruit
manag
rh
blood
donor
pledg
donat
blood
secur
rh
blood
emerg
situat
institut
need
meet
demand
rare
blood
type
could
possibl
use
rh
blood
suppli
program
lead
secur
special
type
blood
tabl
number
rh
blood
donor
pledg
donat
blood
emerg
blood
donat
blood
suppli
statu
backgroundcas
studi
china
volunt
blood
donor
donat
platelet
apheresi
ap
time
per
year
howev
awar
knowledg
ap
donat
much
lower
whole
blood
donat
among
chines
popul
approxim
million
dose
ap
transfus
within
billion
peopl
year
china
one
challeng
recruit
new
ap
donor
retent
frequenc
ap
donor
china
studi
designmethod
one
stratifi
recruit
retent
strategi
establish
applic
wuhan
blood
center
sinc
firstli
telephon
model
whole
blood
donor
instead
donat
platelet
secondli
group
messag
perman
ap
donor
donat
interv
day
low
inventori
thirdli
specif
recruit
telephon
ap
donor
donat
ap
time
donat
day
less
time
interv
day
last
donat
last
one
prepar
one
letter
thank
ap
donor
gave
time
annual
advis
voluntarili
come
blood
center
ap
donat
avail
resultsfind
past
decad
overal
donat
time
ap
donor
increas
time
dose
ap
increas
time
within
year
ap
collect
fulfil
clinic
need
accord
donat
frequenc
ap
donor
divid
group
donat
ap
donat
time
time
time
donat
time
respect
found
number
perman
ap
donor
donat
ap
time
denot
total
dose
ap
conclus
ap
increas
rapid
steadi
pace
wuhan
blood
center
met
clinic
need
also
suppli
region
outsid
wuhan
addit
perman
ap
donor
gain
attent
donat
greatest
percentag
platelet
conclus
stratifi
recruit
one
effect
approach
meet
clinic
need
platelet
worth
popular
region
backgroundcas
studi
zinc
protoporphyrin
zpp
point
care
test
could
show
iron
store
surrog
ferritin
fer
test
blood
donor
studi
designmethod
f
whole
blood
doubl
red
blood
cell
donor
repeat
age
year
evalu
site
consecut
donat
finger
stick
fs
hemoglobin
hb
per
site
polici
venou
ven
capillari
cap
zpp
ven
ferritin
fer
perform
per
manufactur
direct
donor
assess
subclin
iron
defici
use
rang
fer
ngml
zpp
level
umolmol
heme
hb
level
particip
complet
onlin
survey
donat
collect
data
symptom
anemia
univari
linear
regress
analysi
use
determin
relationship
test
resultsfind
subclin
iron
defici
present
among
repeat
blood
donor
hb
level
gender
age
group
tabl
highli
signific
correl
fs
zpp
ven
zpp
first
second
donat
first
donat
compar
fs
hb
variat
could
explain
variat
fs
zpp
ven
zpp
ven
fer
second
donat
compar
fs
hb
variat
could
explain
variat
fs
zpp
ven
zpp
ven
fer
donat
variat
among
test
fs
hb
ven
fer
ven
zpp
fs
zpp
signific
p
suggest
strong
evid
correl
respond
survey
report
feel
well
donat
note
note
femal
studi
particip
report
feel
unwel
first
donat
ferritin
level
zpp
level
less
umolmol
heme
male
particip
report
feel
well
none
ferritin
level
ngml
ven
fs
zpp
level
umolmol
heme
conclus
subclin
iron
defici
present
hemoglobin
level
insuffici
correl
fs
hb
ven
fer
support
use
fs
ven
zpp
analysi
measur
iron
store
blood
donor
symptom
report
studi
particip
consist
laboratori
result
backgroundcas
studi
pattern
drug
use
evolv
greatli
recent
year
data
drug
use
among
blood
donor
necessari
guid
develop
relev
donor
select
criteria
studi
perform
estim
preval
illicit
drug
use
associ
factor
among
blood
donor
estim
donor
select
criteria
regard
drug
associ
factor
studi
designmethod
anonym
onlin
survey
carri
among
individu
gave
blood
email
address
avail
particip
complet
questionnair
assess
characterist
b
use
illicit
drug
previou
month
c
cocain
snort
previou
month
drug
inject
previou
month
lifetim
preval
rate
calcul
accord
age
sex
region
resid
donor
statu
overal
preval
rate
weight
accord
sourc
popul
distribut
gender
age
donor
statu
studi
period
logist
regress
analys
carri
studi
correl
drug
use
resultsfind
donor
contact
complet
survey
particip
rate
exclud
incomplet
answer
particip
femal
vs
sourc
popul
p
donor
vs
p
year
old
vs
p
overal
rate
drug
use
weight
rate
cannabi
frequent
use
follow
ecstasi
hallucinogen
cocain
amphetamin
drug
lifetim
past
year
drug
inject
di
report
respect
donor
lifetim
di
past
cocain
snort
criteria
multivari
analys
present
tabl
factor
significantli
associ
drug
use
male
gender
young
age
live
larg
urban
area
wherea
male
gender
young
age
associ
conclus
preval
drug
use
among
blood
donor
neglig
impact
drug
use
blood
safeti
unknown
despit
deferr
criteria
lifetim
drug
inject
past
cocain
snort
report
donor
howev
like
donor
select
process
effect
exclud
high
risk
drug
user
given
low
rate
transmiss
diseas
marker
backgroundcas
studi
ask
prospect
blood
donor
fear
first
step
help
cope
unfortun
blood
collect
staff
typic
retic
make
inquiri
due
belief
caus
donor
distress
increas
risk
faint
present
studi
test
hypothesi
fear
relat
risk
faint
independ
assess
studi
designmethod
anonym
onlin
survey
conduct
among
individu
report
donat
blood
within
previou
day
femal
mean
prior
donat
sd
donor
respond
answer
seri
question
recent
donat
includ
fear
blood
drawn
faint
reaction
use
logist
linear
regress
analys
fear
relat
faint
reaction
control
donat
experi
resultsfind
rel
rate
fear
afraid
fear
donor
higher
odd
report
faint
somewhat
afraid
ci
moder
afraid
ci
afraid
ci
extrem
afraid
ci
similarli
fear
rate
posit
relat
report
intens
reaction
beta
p
conclus
although
caution
need
interpret
retrospect
data
due
possibl
report
bia
present
find
suggest
routin
fear
assess
may
help
identifi
donor
increas
risk
syncop
reaction
backgroundcas
studi
may
final
rule
fda
amend
cfr
part
becam
effect
chang
minimum
hemoglobin
hb
level
male
vital
sign
vs
extrem
requir
qualifi
donor
minimum
male
hb
rais
gmdl
fda
impos
specif
vs
rang
accept
puls
p
blood
pressur
bp
remov
discret
survey
member
america
blood
center
abc
perform
assess
impact
donor
deferr
result
chang
studi
designmethod
onlin
survey
softwar
surveygizmo
boulder
co
use
solicit
collect
deferr
inform
blood
center
two
interv
ie
implement
deadlin
final
rule
respect
inform
deferr
present
whole
blood
wb
donat
apheresi
platelet
ap
donat
request
hb
threshold
vs
inform
stratifi
gender
malem
femalef
abo
type
statist
analysi
includ
numer
categor
data
minitab
chicago
il
p
consid
signific
resultsfind
data
provid
center
invit
repres
wb
donat
ap
donat
aggreg
two
interv
respect
gender
abo
distribut
appear
repres
us
donor
base
among
wb
donor
rate
deferr
rose
two
interv
among
aggreg
donat
attempt
p
ap
p
mean
center
deferr
rate
tabl
similar
signific
p
mean
center
hb
deferr
rate
among
f
donat
two
interv
wb
ap
respect
absent
chang
accept
hb
threshold
data
vs
deferr
much
sparser
p
deferr
center
could
provid
specif
high
vs
low
vs
irregular
puls
deferr
provid
summari
ie
total
puls
deferr
could
provid
none
bp
provid
detail
high
vs
low
summari
none
p
deferr
increas
success
interv
among
f
wb
donor
center
mean
wb
donor
detail
avail
high
irregular
puls
respons
chang
gender
bp
deferr
significantli
increas
among
wb
donor
regardless
gender
data
set
deferr
rate
vs
ap
donor
quit
small
possibl
reflect
cull
prior
donat
experi
conclus
substanti
addit
donor
deferr
attend
increas
hb
threshold
final
rule
wb
ap
chang
modest
among
femal
donor
consist
absenc
chang
allow
hb
level
modest
signific
chang
attend
stringent
requir
vs
though
data
limit
restrict
aspect
analysi
tabl
mean
center
percent
present
donor
defer
backgroundcas
studi
diabet
mellitu
reach
potenti
epidem
proport
india
given
diseas
highli
visibl
across
section
societi
within
india
demand
screen
diabet
urgent
research
intervent
region
nation
level
tri
mitig
potenti
catastroph
increas
diabet
predict
upcom
year
due
eas
use
sever
studi
found
test
identifi
patient
commun
might
otherwis
go
undiagnos
took
initi
find
incid
diabet
random
blood
sugar
rb
measur
among
indian
blood
donor
measur
level
among
rb
studi
designmethod
prospect
studi
done
depart
transfus
medicin
depart
biochemistri
march
march
total
blood
donor
test
rb
rb
test
gold
standard
hplc
method
use
variant
ii
biorad
blood
donor
rb
advis
consult
physician
evalu
resultsfind
donor
test
donor
show
rb
forti
two
male
femal
mean
age
year
year
known
case
diabet
mellitu
dm
oral
medic
exclud
remain
famili
histori
dm
donor
donor
give
consent
test
among
donor
test
level
donor
counsel
refer
physician
manag
overal
incid
donor
dm
popul
donor
conclus
screen
blood
glucos
level
target
blood
donor
go
long
way
curb
diabet
burden
societi
backgroundcas
studi
iron
defici
known
complic
regular
blood
donat
order
protect
donor
health
prevent
iron
defici
aabb
increas
minimum
accept
hemoglobin
level
male
whole
blood
apheresi
donor
last
may
current
minimum
accept
hemoglobin
male
donor
singapor
aim
studi
determin
incid
low
ferritin
level
regular
whole
blood
apheresi
male
blood
donor
accept
borderlin
hemoglobin
level
donor
hemoglobin
studi
designmethod
month
period
serum
ferritin
test
perform
regular
male
whole
blood
regular
male
apheresi
donor
made
least
donat
last
two
year
accept
hemoglobin
level
donor
divid
group
accord
donat
type
hemoglobin
rang
group
whole
blood
hemoglobin
group
b
whole
blood
hemoglobin
group
c
apheresi
hemoglobin
group
apheresi
hemoglobin
serum
ferritin
level
four
donor
group
compar
analyz
ferritin
level
ugl
consid
low
level
ugl
consid
absent
iron
store
resultsfind
donor
studi
ferritin
level
ugl
donor
low
ferritin
group
compar
group
b
respect
p
apheresi
donor
low
ferritin
rate
higher
group
c
donor
compar
group
respect
ferritin
result
group
seen
tabl
tabl
ferritin
level
result
conclus
half
donor
studi
low
ferritin
donor
low
ferritin
half
absent
iron
store
donor
low
ferritin
immedi
inform
result
given
iron
supplement
advis
come
back
donat
month
sinc
donor
health
safeti
paramount
import
measur
limit
prevent
iron
defici
blood
donor
must
implement
due
high
incid
low
ferritin
level
whole
blood
apheresi
donor
hemoglobin
recommend
minimum
hemoglobin
level
cut
male
blood
donor
singapor
increas
measur
implement
includ
better
donor
educ
risk
iron
defici
need
iron
supplement
use
websit
social
media
backgroundcas
studi
safe
blood
crucial
irreplac
compon
medic
manag
mani
diseas
voluntari
blood
donat
ideal
sourc
qualiti
blood
form
less
demand
blood
pakistan
motiv
among
youth
particularli
student
essenti
make
voluntari
blood
movement
success
assess
knowledg
attitud
practic
regard
voluntari
blood
donat
among
young
student
popul
karachi
effect
approach
made
regard
motiv
enrol
voluntari
non
remuner
blood
donor
futur
pakistan
studi
designmethod
cross
section
prospect
studi
conduct
among
student
differ
univers
colleg
karachi
questionnair
english
use
access
knowledg
attitud
practic
voluntari
blood
donat
score
mechan
use
understand
overal
knowledg
level
obtain
data
analyz
resultsfind
sampl
popul
consist
male
femal
student
age
group
year
student
heard
voluntari
blood
donat
student
given
blood
lifetim
among
blood
donor
moment
particip
believ
specif
reason
nt
donat
blood
believ
risk
involv
donor
donat
blood
student
want
promot
voluntari
blood
donat
fear
lack
awar
blood
donat
reason
donat
blood
student
gather
inform
voluntari
blood
donat
sever
sourc
mostli
school
colleg
famili
friend
conclus
studi
show
increas
awar
market
differ
way
boost
cultur
voluntari
blood
donat
societi
despit
good
knowledg
voluntari
blood
donat
student
donat
blood
blood
donat
educ
begin
school
level
cours
includ
blood
donat
drive
student
popul
motiv
particip
differ
way
dire
need
mobil
electron
media
educ
youth
voluntari
blood
donat
due
access
mass
backgroundcas
studi
previous
donor
elig
assess
facil
test
capillari
blood
donor
candid
hemocu
hb
system
hc
donor
candid
hemoglobin
valu
greater
equal
elig
donat
valid
new
hematocrit
measur
devic
ultracrit
uc
separ
technolog
inc
sti
implement
test
method
record
juli
nine
month
deferr
rate
data
uc
base
hematocrit
valu
greater
equal
use
comparison
prior
method
record
studi
designmethod
uc
ultrasound
base
system
subject
instrument
valid
protocol
approv
qualiti
assur
depart
nine
month
deferr
data
method
base
singl
determin
capillari
blood
sampl
applic
state
valu
resultsfind
uc
hematocrit
measur
system
met
manufactur
specif
valid
process
instal
oper
perform
qualif
precis
accuraci
test
yield
result
support
decis
implement
uc
method
record
blood
bank
juli
hc
method
record
test
octob
june
time
donor
candid
test
result
deferr
rate
total
test
mobil
unit
deferr
rate
popul
data
uc
test
nine
month
post
implement
juli
yield
deferr
rate
defer
test
deferr
rate
mobil
unit
use
uc
total
test
annual
basi
decreas
deferr
rate
translat
collect
addit
unit
per
year
conclus
comparison
deferr
rate
nine
month
period
sinc
ultracrit
implement
nine
month
prior
implement
demonstr
signific
decreas
deferr
rate
base
hemoglobin
hematocrit
test
result
decreas
deferr
rate
observ
mobil
unit
collect
fix
facil
collect
decreas
deferr
rate
nine
month
contribut
signific
increas
unit
collect
backgroundcas
studi
doubl
red
blood
cell
donat
drbcd
lead
deplet
iron
store
especi
frequent
donor
iron
supplement
shown
prevent
iron
deplet
secondari
blood
donat
pilot
studi
iron
supplement
carri
one
donor
site
order
evalu
feasibl
program
follow
paramet
measur
accept
toler
complianc
supplement
effect
ferritin
level
rate
drbcd
studi
designmethod
studi
design
open
trial
donor
made
least
one
success
drbcd
solicit
inform
consent
obtain
donor
given
tablet
ferrou
sulfat
element
iron
visit
drbcd
instruct
take
one
tablet
per
day
inform
side
effect
precaut
take
supplement
given
visit
ferritin
level
measur
sinc
routin
ferritin
monitor
place
donor
site
questionnair
complianc
supplement
side
effect
fill
resultsfind
donor
chose
particip
least
ferritin
measur
constitut
particip
donor
refus
particip
serv
control
group
one
donor
male
age
distribut
number
previou
rbc
donat
particip
control
similar
howev
particip
gave
rbc
donat
per
year
control
studi
donor
vs
control
gave
rbcyear
complianc
defin
take
tablet
vari
first
cours
close
took
cours
questionnair
fill
cours
supplement
cours
advers
effect
note
frequent
side
effect
report
constip
dyspepsia
diarrhea
nausea
black
stool
miscellan
effect
report
cours
side
effect
led
interrupt
supplement
instanc
ferritin
level
entri
program
last
visit
particip
vs
control
posit
impact
iron
supplement
ferritin
level
observ
took
tablet
ferritin
level
found
particip
control
deferr
low
hemoglobin
group
conclus
iron
supplement
program
drbcd
program
feasiblehowev
take
account
accept
particip
complianc
supplement
donor
obtain
full
benefit
program
use
iron
prepar
better
toler
may
increas
complianc
backgroundcas
studi
knowledg
sourc
plasma
sp
donor
demograph
shed
light
plasma
collect
industri
mani
mispercept
abound
pertain
plasma
donat
know
basic
donor
age
weight
donat
frequenc
help
understand
donat
thu
plasma
industri
donat
data
analyz
provid
donor
profil
inform
sp
donat
volum
frequenc
previous
avail
studi
designmethod
collect
donor
demograph
data
approxim
million
donor
million
donat
particip
compani
analyz
data
includ
age
weight
gender
donor
often
donat
donat
volum
limit
set
fda
memorandum
weight
depend
collect
volum
plasma
anticoagul
donor
lb
gi
lb
gii
lb
giii
donat
distribut
statist
present
resultsfind
overal
sp
donor
male
thirti
percent
total
donat
given
donor
age
donor
year
old
overal
donat
rate
highest
year
old
weigh
lb
femal
lb
femal
male
percentag
approxim
equal
lb
greater
percentag
male
eg
male
lb
overal
highest
percentag
femal
donor
weigh
lb
male
highest
percentag
donor
weigh
lb
donat
frequenc
increas
increas
weight
donat
lightest
donor
vs
lb
highest
donat
rate
femal
male
weigh
though
compris
small
percent
donor
percent
donor
fell
giii
gii
gi
percent
donat
made
giii
donor
gii
gi
total
volum
collect
donat
giii
donor
gii
gi
male
donor
lb
us
male
popul
lb
lb
femal
donor
lb
us
femal
popul
lb
lb
averag
number
donat
per
donor
month
last
donat
number
increas
donor
made
donat
made
made
conclus
contrast
blood
donor
major
plasma
donor
male
young
donor
year
old
provid
fewer
donat
older
donor
make
major
donat
heavier
donor
donat
frequent
frequent
donor
essenti
achiev
critic
plasma
suppli
manufactur
essenti
lifesav
protein
therapi
backgroundcas
studi
hereditari
hemochromatosi
hh
patient
permit
donat
blood
allogen
blood
suppli
long
elig
donat
collect
therapeut
phlebotomi
blood
collect
establish
need
except
altern
make
collect
provis
requir
set
forth
met
object
describ
current
hh
donor
contribut
donor
center
hospit
blood
suppli
studi
designmethod
irb
protocol
approv
enrol
therapeut
phlebotomi
hh
patientssubject
requir
file
fda
varianc
permit
hh
donor
blood
use
allogen
suppli
without
diseas
label
frequenc
therapeut
bleed
guid
routin
clinic
assess
mcvhemoglobin
serum
ferritin
transferrin
satur
monitor
serum
ferritin
level
ngml
target
mainten
phlebotomi
oper
custom
computer
databas
applic
employ
eas
phlebotomi
manag
resultsfind
sinc
incept
cumul
number
hh
subject
enrol
hemochromatosi
protocol
reach
homozygot
without
activ
recruit
accrual
rate
per
quarter
subject
qualifi
allogen
donor
mean
current
age
year
male
caucasian
major
hh
donor
activ
cohort
mainten
phase
therapi
averag
donationsyear
deferr
rate
last
year
hh
donor
contribut
approxim
hospit
allogen
blood
suppli
averag
whole
blood
unit
transfus
per
year
moreov
hh
donor
whole
blood
wb
donat
provid
blood
vitro
research
institut
averag
wb
research
donationsyear
hh
infect
year
sinc
increas
male
hgb
deferr
threshold
hh
male
deferr
blood
donat
conclus
simpl
safe
system
donor
evalu
phlebotomi
manag
transfus
blood
drawn
hh
subject
establish
blood
donat
hh
donor
remain
import
resourc
hospit
hh
donor
benefit
care
medic
iron
statu
mutual
benefici
relationship
feasibl
sustain
backgroundcas
studi
object
studi
assess
accuraci
hemoglobin
hb
level
measur
orsens
occlus
spectroscopi
devic
compar
hb
level
measur
venou
sampl
laboratori
hematolog
analyz
addit
studi
examin
oper
eas
use
donor
satisfact
finger
method
studi
designmethod
studi
procedur
protocol
includ
accept
criteria
defin
conjunct
devic
manufactur
determin
standard
deviat
sd
differ
sampl
result
sysmex
hematolog
analyz
venou
sampl
result
staff
provid
train
use
occlus
spectroscopi
devic
span
day
elig
blood
donor
male
femal
first
screen
occlus
spectroscopi
devic
follow
perform
test
util
capillari
blood
screen
method
venou
sampl
collect
blood
donor
perform
hb
measur
sysmex
hematolog
analyz
within
hour
collect
venou
sampl
resultsfind
sd
differ
sampl
result
sysmex
hematolog
analyz
venou
sampl
result
exceed
hb
measur
obtain
sysmex
hematolog
analyz
analyz
use
statist
softwar
minitab
sd
differ
report
precis
yield
variat
standard
deviat
conclus
oper
found
easi
instal
maintain
oper
minim
train
occlus
spectroscopi
technolog
show
accur
perform
compar
venou
sampl
result
compar
capillari
finger
stick
method
deem
suitabl
screen
donor
donor
satisfi
process
appreci
safe
painless
methodolog
backgroundcas
studi
maintain
adequ
blood
suppli
south
african
blood
center
need
collect
blood
major
black
african
popul
success
recruit
black
blood
donor
temper
lower
suboptim
return
rate
studi
designmethod
perform
prospect
cohort
studi
black
blood
donor
donat
period
follow
one
year
within
day
post
donat
questionnair
includ
question
blood
donat
motiv
deterr
administ
telephon
question
use
likert
scale
assess
agreement
statement
relat
domain
altruism
collectiv
market
deriv
local
focu
group
muthivhi
etal
link
questionnair
blood
donat
databas
allow
logist
regress
analysi
predict
return
second
donat
within
one
year
resultsfind
includ
black
donor
median
age
femal
predomin
within
one
year
donor
attempt
least
one
addit
donat
likert
scale
analyz
ordin
variabl
strongli
agre
strongli
disagre
donor
return
associ
follow
motiv
blood
donat
easi
way
make
differ
odd
ratio
likert
increment
ci
donat
respons
advertscampaign
radio
tv
newspap
ci
respons
statement
associ
return
among
deterr
donor
less
like
donat
agre
statement
afraid
sight
blood
ci
nt
treat
well
blood
center
staff
ci
surprisingli
donor
like
return
agre
statement
afraid
find
hiv
statu
ci
secondari
analysi
treat
likert
scale
categor
variabl
reveal
gener
similar
result
addit
find
donor
disagre
statement
give
blood
blood
avail
need
nt
know
nearest
blood
collect
point
like
return
conclus
novel
design
allow
us
studi
link
donat
motiv
deterr
actual
rather
intend
return
donat
interest
market
predict
return
better
altruism
fear
poor
custom
experi
recogn
deterr
could
address
plan
use
data
construct
black
donor
recruit
intervent
may
test
use
random
trial
design
backgroundcas
studi
year
donat
rate
fall
summer
month
strain
blood
bank
capac
meet
local
demand
hope
identifi
factor
increas
summer
donat
studi
investig
donor
report
barrier
influenc
summer
donat
habit
studi
designmethod
anonym
question
survey
investig
variou
donat
factor
administ
across
multipl
blood
donor
center
region
question
address
donor
demograph
frequenc
blood
donat
prefer
appoint
make
modal
includ
smartphon
app
use
summer
travel
habit
willing
donat
vacat
factor
deter
donor
donat
vacat
resultsfind
total
survey
receiv
survey
respond
across
multipl
demograph
group
cite
similar
barrier
summer
donat
name
busi
travel
time
relax
respond
travel
summer
report
donat
travel
summer
donat
rate
summertim
travel
essenti
equival
prefer
method
schedul
appoint
via
region
blood
donor
center
websit
phone
willing
use
region
blood
donat
smartphon
app
highest
among
respond
age
lowest
among
age
older
respond
prior
knowledg
summer
season
shortag
indic
newfound
motiv
donat
conclus
regardless
travel
increas
awar
summer
shortag
may
increas
summer
donat
use
donor
websit
smartphon
app
may
instrument
part
recruit
effort
backgroundcas
studi
viral
infect
adenoviru
ebv
cmv
bk
rsv
etc
implic
major
contributor
morbid
mortal
hematopoiet
stem
cell
transplant
hsct
unrel
donor
investig
shown
expand
viru
specif
cytotox
lymphocyt
ctl
gener
donor
specif
one
virus
safe
effect
treat
viral
infect
hsct
set
recent
clinic
trial
present
clinic
trial
shown
ctl
rapidli
produc
singl
stimul
donor
peripher
blood
mononuclear
cell
pbmc
span
target
antigen
presenc
potent
prosurviv
cytokin
other
use
bank
third
parti
epstein
barr
viru
ebv
ctl
gener
third
parti
blood
donor
encourag
result
studi
designmethod
elig
consent
blood
donor
test
cmv
antibodi
serolog
whole
blood
wb
unit
underw
buffi
coat
process
reduc
wb
unit
collect
fenwal
tripl
underw
hard
spin
minut
separ
spin
plasma
buffi
coat
separ
red
cell
first
spin
second
spin
lead
separ
buffi
coat
plasma
buffi
coat
submit
gmp
stem
cell
lab
process
ctl
hla
type
high
resolut
loci
obtain
donor
resultsfind
forti
five
elig
healthi
blood
volunt
f
median
age
year
rang
donat
unit
blood
buffi
coat
averag
volum
process
buffi
coat
process
previous
valid
wb
unit
mononuclear
cell
lymphocyt
monocyt
recov
buffi
coat
list
figur
buffi
coat
receiv
gmp
stem
cell
lab
adequ
cell
number
process
conclus
process
buffi
coat
whole
blood
viabl
option
concentr
pbmc
specif
product
viral
specif
ctl
third
parti
shelf
product
well
use
research
project
requir
pbmc
healthi
adult
figur
averag
number
cellsul
whole
blood
figur
percent
recoveri
wbc
platelet
refer
gerdemann
u
keirnan
jm
katari
ul
etal
rapidli
gener
cytotox
lymphocyt
prophylaxi
treatment
viral
infect
mol
ther
haqu
wilki
gm
jone
mm
etal
allogen
cytotox
therapi
ebv
posit
posttransplant
lymphoprolif
diseas
result
phase
multicent
clinic
trial
blood
wilki
g
taylor
c
jone
etal
establish
character
bank
ctl
immunotherapi
diseas
j
immunoth
dey
etal
transfus
supplement
abstract
backgroundcas
studi
goal
present
describ
journey
challeng
toward
tjc
patient
blood
manag
pbm
certif
health
risk
increas
econom
pressur
driven
hospit
recogn
blood
manag
import
strategi
provid
holi
cross
medic
center
phcmc
provid
california
region
alpha
site
embark
journey
goal
pbm
certif
reduct
number
unnecessari
transfus
within
month
program
launch
improv
patient
outcom
paper
discuss
journey
toward
certif
variou
hurdl
overcom
studi
designmethod
tjc
aabb
societi
advanc
blood
manag
serv
primari
resourc
identifi
current
transfus
practic
manag
method
need
identifi
organiz
gap
data
gather
analysi
could
determin
baselin
perform
set
improv
target
intern
assess
learn
start
scratch
easili
access
data
metric
gap
educ
staff
took
follow
step
develop
pbm
program
form
interdisciplinari
pbm
team
consist
physician
nurs
blood
bank
staff
data
analystsconstruct
report
rbc
transfus
help
identifi
outlier
opportunitiesad
best
practic
alert
rbc
transfusionsupd
peer
review
trigger
transfus
committeetransfus
decis
consid
patient
condit
addit
labstransfus
singl
rbc
unit
often
sufficienthgb
patient
undergo
procedur
associ
major
predict
blood
losshgb
patient
cardiovascular
diseas
patient
follow
cardiovascular
orthoped
surgeri
critic
ill
patientshgb
hemodynam
stabl
patient
includ
critic
ill
patient
develop
educ
plan
cme
lectur
blood
mgmtbloodless
medicinepresent
provid
ca
regionsystem
leadership
provid
system
blood
administr
track
teamrevis
educ
letterssnf
collaborativecr
two
modul
transfus
safeti
new
blood
product
administr
modulephysician
educ
acknowledg
letterpbm
index
card
appropri
guidelin
resultsfind
data
rbc
transfus
criteria
complianc
rate
increas
rbc
transfus
volum
decreas
unitsmonth
unitsmonth
reduct
rbc
transfus
per
patient
day
decreas
conclus
region
leadership
local
ministri
leadership
support
provid
foundat
success
phcmc
pbm
team
program
continu
collabor
busi
leader
throughout
organ
identifi
priorit
optim
transfus
care
provid
reinforc
educ
increas
rbc
transfus
complianc
rate
decreas
rbc
transfus
volum
averag
unit
per
month
reduc
number
rbc
transfus
per
patient
day
pt
day
demonstr
invest
educ
best
interest
organ
patient
backgroundcas
studi
maximum
surgic
blood
order
schedul
msbo
list
surgic
procedur
perform
hospit
along
recommend
test
rbc
alloc
surgeri
extent
hospit
msbo
design
explor
survey
studi
designmethod
survey
design
pilot
refin
member
best
collabor
invit
colleagu
encod
onlin
survey
softwar
link
distribut
best
member
colleagu
encourag
respond
distribut
survey
open
day
resultsfind
complet
respons
indic
hospit
msbo
major
hospit
without
msbo
academ
center
oceania
europ
bed
major
hospit
transfus
rbc
per
year
go
implement
msbo
msbo
major
north
america
major
academ
hospit
bed
transfus
rbc
unit
per
year
offer
wide
rang
surgic
servic
averag
procedur
list
msbo
msbo
recommend
test
mean
procedur
list
type
screen
crossmatch
rbc
unit
procedur
differ
recommend
made
msbo
creat
combin
obtain
consensu
surgic
servic
blood
bank
use
transfus
data
msbo
creat
sole
use
data
use
data
make
test
recommend
msbo
updat
less
frequent
annual
hospit
transfus
committe
often
involv
updat
msbo
gener
avail
electron
oper
room
blood
bank
opinion
major
respond
msbo
use
regularli
limit
number
surgeon
anesthesiologist
respond
felt
regularli
use
surgeon
anesthesiologist
felt
use
hospit
respond
conclus
msbo
avail
half
respond
hospit
minor
case
felt
regularli
use
howev
hospit
current
without
one
indic
would
implement
suggest
hospit
perceiv
valu
one
place
implement
follow
msbo
import
step
patient
blood
manag
streamlin
oper
blood
bank
test
backgroundcas
studi
system
pioneer
aco
referr
center
dedic
serv
patient
across
new
york
citi
area
beyond
compris
four
hospit
see
hospit
admiss
nearli
emerg
depart
visit
annual
activ
program
high
risk
ob
stem
cell
transplant
solid
organ
transplant
heart
liver
kidney
ct
surgeri
ecmo
oncolog
critic
care
transfus
medicin
play
key
role
support
servic
blood
product
spend
approxim
nov
interdisciplinari
committe
creat
effort
improv
patient
care
reduc
blood
product
exposur
reduc
blood
product
expenditur
vice
multidisciplinari
committe
compos
repres
surgeri
anesthesia
blood
bank
pediatr
perfus
cardiothorac
surgeri
critic
care
medicin
emerg
depart
studi
designmethod
first
import
step
know
number
although
committe
multipl
sourc
data
one
report
could
display
pertin
inform
baselin
number
imper
committe
abil
effect
chang
home
grown
one
time
report
reveal
servic
clinician
highest
volum
user
initi
plan
target
use
educ
initi
goal
set
reduc
expenditur
journey
continu
regular
bimonthli
meetingsto
brainstorm
strategi
monitor
util
util
analyz
use
home
grown
crystal
report
transfus
patient
locat
report
compar
util
pattern
dollar
spent
total
unit
per
patient
project
manag
use
excel
key
initi
develop
committe
develop
evid
base
transfus
triggerseduc
evid
base
transfus
trigger
across
multipl
campus
specialti
resid
programsclin
inform
system
ci
soft
stop
order
blood
product
outsid
guidelin
rbc
order
set
default
unit
instead
unitsupd
guidelin
post
easi
find
intern
intranet
spot
resultsfind
despit
higher
patient
volum
complic
patient
mix
still
abl
reduc
blood
product
expenditur
compar
conclus
spite
limit
resourc
committe
abl
effect
chang
capit
current
stakehold
fulli
support
leadership
project
manag
backgroundcas
studi
anemia
due
iatrogen
blood
loss
preterm
low
birth
weight
infant
major
contributori
factor
lead
red
blood
cell
transfus
patient
popul
method
reduc
phlebotomi
laboratori
test
reduc
iatrogen
anemia
teach
hospit
pathway
collect
cord
blood
sampl
newborn
deliveri
establish
cord
blood
sampl
use
initi
blood
bank
laboratori
test
newborn
patient
transfer
neonat
intens
care
unit
nicu
prevent
need
addit
blood
draw
blood
tube
save
week
cost
per
deliveri
tray
steril
tube
initi
neg
antibodi
screen
cord
blood
sampl
addit
phlebotomi
requir
blood
product
select
compat
test
popul
four
month
age
studi
designmethod
labor
deliveri
data
facil
analyz
gestat
age
birth
weight
infant
transfer
nicu
collect
data
abl
calcul
total
blood
volum
infant
use
medcalc
system
use
blood
volum
valu
assign
valu
minimum
amount
blood
would
drawn
perform
antibodi
screen
calcul
percent
infant
blood
would
drawn
cord
blood
pathway
establish
resultsfind
total
infant
deliv
facil
deliveri
infant
transfer
nicu
infant
receiv
least
one
red
blood
cell
transfus
receiv
least
one
platelet
transfus
infant
transfer
nicu
percentag
blood
volum
would
drawn
blood
bank
test
greater
equal
consid
signific
cord
blood
pathway
effect
percentag
blood
volum
preserv
infant
rang
way
infant
birth
weight
rang
gram
gestat
age
rang
week
week
day
conclus
establish
cord
blood
pathway
proven
rel
method
prevent
iatrogen
blood
loss
secondari
blood
bank
test
popul
nicu
infant
suscept
iatrogen
anemia
infant
like
benefit
polici
prematur
infant
low
birth
weight
less
gram
backgroundcas
studi
manag
massiv
transfus
protocol
mtp
oper
room
rel
frequent
occurr
team
member
well
train
specif
role
howev
event
mtp
activ
outsid
suffici
andor
appropri
train
individu
may
present
lead
scene
confus
chao
potenti
patient
harm
studi
designmethod
failur
mode
effect
analysi
perform
develop
standard
process
manag
mtp
outsid
set
particip
anesthesia
surgeri
transfus
medicin
patient
safeti
qualiti
nurs
everi
step
hospit
mtp
analyz
potenti
error
result
use
creat
code
hemorrhag
team
train
respond
massiv
hemorrhag
patient
resultsfind
code
hemorrhag
repres
team
critic
event
requir
coordin
differ
primari
resuscit
surgicalintervent
transfus
servic
blood
prepar
equip
manag
medic
manag
lab
requisitionmonitor
code
hemorrhag
protocol
util
critic
care
train
nurs
hospit
rapid
respons
team
play
two
key
new
coordin
role
hemorrhag
coordin
electron
medic
record
emr
coordin
combin
role
serv
reduc
cognit
load
variou
team
prevent
duplic
resourceseffort
mtp
enabl
enhanc
close
loop
task
perform
hemorrhag
coordin
establish
reliabl
commun
primari
resuscit
team
transfus
servic
aid
coordin
emr
coordin
enter
order
emr
sendscommun
laboratori
result
ensur
blood
product
avail
resuscit
team
primari
resuscit
team
includ
team
leader
medic
decis
make
cardiac
manag
proceduralist
establish
venou
andor
arteri
access
event
document
document
action
medic
event
etc
medic
manag
regist
nurs
prepar
administ
medic
equip
technologist
manag
rapid
blood
product
infus
devic
addit
secondari
role
also
assign
blood
product
checker
verifi
blood
product
prior
transfus
blood
bank
runner
courier
sent
retriev
blood
product
shipment
conclus
code
hemorrhag
protocol
design
ensur
time
effici
deliveri
blood
product
massiv
bleed
patient
outsid
set
futur
work
assess
overal
effect
compar
blood
product
utilizationwastag
patient
outcom
implement
backgroundcas
studi
preoper
anemia
affect
surgic
patient
increas
risk
red
blood
cell
rbc
transfus
preoper
anemia
periop
rbc
transfus
associ
increas
risk
advers
outcom
follow
surgeri
preoper
treatment
anemia
includ
oral
intraven
iv
iron
erythroid
stimul
agent
esa
erythropoietin
epo
howev
optim
treatment
strategi
preoper
anemia
remain
establish
object
evalu
efficaci
safeti
esa
iron
therapi
base
effect
preval
rbc
transfus
advers
thrombot
event
studi
designmethod
search
cochran
central
regist
control
trial
medlin
embas
incept
juli
refer
list
publish
guidelin
review
associ
paper
well
confer
proceed
languag
restrict
appli
includ
random
control
trial
adult
patient
undergo
surgeri
receiv
either
esa
andor
iron
surgeri
versu
iron
intervent
three
author
independ
review
studi
extract
data
includ
trial
risk
bia
assess
includ
studi
applic
pool
risk
ratio
dichotom
outcom
mean
differ
continu
outcom
across
trial
use
model
primari
outcom
number
patient
transfus
red
blood
cell
secondari
outcom
includ
risk
mortal
thrombovascular
event
stroke
myocardi
infarct
deep
vein
thrombosi
pulmonari
embol
resultsfind
total
random
control
trial
particip
includ
patient
receiv
esa
addit
oral
iv
iron
reduct
risk
transfus
risk
ratio
rr
ci
rel
receiv
oral
iv
iron
intervent
treatment
iv
iron
alon
rel
oral
iron
treatment
also
reduc
risk
rbc
transfus
rr
ci
clear
increas
risk
advers
event
observ
epo
use
mortal
rr
ci
myocardi
infarct
rr
ci
deep
vein
thrombosi
rr
ci
stroke
rr
ci
pulmonari
embol
rr
ci
conclus
amongst
patient
undergo
surgeri
administr
esa
addit
oral
iv
iron
associ
reduct
patient
requir
rbc
transfus
intraven
iron
less
effect
reduc
rbc
transfus
neither
treatment
associ
clear
increas
risk
advers
thrombot
event
addit
larg
prospect
random
control
trial
requir
determin
optim
manag
strategi
patient
undergo
surgeri
iron
restrict
anemia
backgroundcas
studi
million
unit
pack
red
blood
cell
prbc
transfus
annual
unit
state
clinic
basi
mani
half
transfus
random
prospect
trial
ever
demonstr
clinic
benefit
transfus
mild
moder
anem
patient
yet
larg
bodi
evid
shown
due
varieti
reason
includ
immunomodulatori
effect
storag
lesion
blood
transfus
caus
consider
harm
includ
higher
risk
hospit
acquir
bacteri
infect
transfus
relat
acut
lung
injuryacut
pulmonari
edema
acut
myocardi
infarct
higher
recurr
rebleed
higher
cancer
recurr
studi
designmethod
system
wide
goal
launch
across
hospit
decreas
number
prbc
transfus
given
clinic
stabl
patient
hemoglobin
hgb
level
numer
consist
prbc
unit
transfus
patient
hgb
greater
prior
transfus
denomin
consist
prbc
unit
transfus
exclus
includ
cardiac
surgeri
nurseri
nicu
pregnanc
hemorrhag
massiv
transfus
protocol
transfus
prbc
unit
transfus
one
episod
data
extract
directli
electron
medic
record
hospit
receiv
patient
level
detail
everi
month
prbc
unit
transfus
patient
hgb
higher
prior
transfus
extens
educ
campaign
transfus
practic
launch
physician
nurs
includ
develop
blood
therapeut
toolkit
develop
standard
digniti
health
blood
therapeut
guidelin
one
day
blood
therapeut
advanc
train
symposium
visit
hospit
includ
cme
present
onlin
physician
nurs
educ
video
commun
tool
includ
infograph
new
button
develop
patient
educ
resourc
webinar
variou
educ
topic
speaker
addit
ehr
powerplan
revis
ensur
avail
select
transfus
indic
requir
field
align
evid
base
guidelin
facilti
encourag
develop
blood
therapeut
committe
review
transfus
given
patient
hgb
routin
basi
provid
feedback
provid
whose
transfus
deem
accord
current
guidelin
resultsfind
reduct
prbc
unit
transfus
patient
hgb
start
baselin
repres
annual
save
baselin
unit
per
patient
day
averag
unit
approxim
fewer
unit
transfus
per
month
conclus
blood
transfus
life
save
regard
organ
transplant
carri
consider
risk
transfus
stabl
patient
hgb
level
accord
guidelin
avoid
due
associ
potenti
harm
furthermor
potenti
harm
dose
depend
decis
transfus
made
one
unit
prbc
transfus
rather
two
backgroundcas
studi
background
red
blood
cell
rbc
common
blood
compon
transfus
approxim
unit
transfus
annual
us
rbc
transfus
associ
increas
morbid
mortal
rbc
transfus
decreas
remain
one
five
overus
procedur
hospit
data
order
transfus
patient
identifi
unit
request
hemoglobin
hb
trigger
captur
laboratori
lab
system
electron
record
includ
data
impact
intervent
eg
anemia
manag
restrict
transfus
rt
antifibrinolyt
rbc
transfus
frequenc
practic
recommend
help
lab
work
effect
order
physician
reduc
rbc
transfus
studi
designmethod
method
systemat
review
method
use
search
studi
effect
rbc
transfus
reduct
pubm
embas
cinahl
unpublish
data
request
clinic
site
popul
adult
patient
rbc
transfus
intervent
rt
computer
physician
order
entryclin
decis
support
system
cpoecd
auditfeedback
af
antifibrinolyt
control
standard
practic
outcom
percentag
patient
number
rbc
unit
transfus
exclus
pediatr
obstetr
trauma
genet
diseas
resultsfind
result
one
hundr
sixteen
studi
met
criteria
quantit
synthesi
nine
publish
one
unpublish
studi
show
reduc
number
patient
rbc
unit
transfus
standard
differ
mean
sdm
nine
studi
three
lab
reduc
rbc
unit
sdm
percentag
patient
transfus
hb
alert
cpoecd
studi
favor
rt
percentag
patient
rbc
unit
transfus
sdm
three
af
studi
reduc
rbc
unit
two
studi
decreas
percentag
patient
transfus
studi
show
intraven
tranexam
acid
reduc
percentag
patient
rbc
unit
transfus
translat
recommend
expert
panel
approv
lmbp
workgroup
reduc
rbc
transfus
recommend
earli
assess
effect
rt
hb
alert
cpoecd
reduct
blood
loss
af
assess
percentag
patient
rbc
unit
transfus
across
case
physician
servic
area
discret
period
time
feedback
physician
continu
qualiti
improv
conclus
conclus
lmbp
method
led
recommend
reduc
transfus
critic
laboratori
support
need
achiev
continu
qualiti
patient
safeti
backgroundcas
studi
reduc
inappropri
use
blood
product
via
implement
evid
base
guidelin
main
tenet
patient
blood
manag
use
electron
decis
support
tool
best
practic
alert
bpa
enforc
red
blood
cell
rbc
transfus
threshold
shown
reduc
use
inform
order
provid
transfus
tool
use
date
provid
dose
rbc
transfus
fact
provid
continu
base
number
unit
rbc
given
therapeut
hemoglobinhematocrit
hgbhct
target
approach
rbc
indicationsord
allow
calcul
dose
rbc
achiev
desir
target
could
reduc
use
rbc
unit
group
develop
comput
algorithm
calcul
rbc
dose
base
patient
specif
data
drawn
electron
medic
record
emr
use
select
patient
popul
prospect
appli
hospit
wide
clinic
practic
studi
describ
initi
experi
use
algorithm
rbc
transfus
studi
designmethod
blood
util
calcul
buc
mathemat
formula
draw
patient
specif
inform
includ
index
hgbhct
calcul
dose
number
unit
rbc
transfus
order
achiev
select
target
hgbhct
hgbhct
target
base
indic
rbc
transfus
design
use
basi
rbc
order
set
eth
buc
embed
within
emr
rbc
order
set
provid
recommend
transfus
dose
number
unit
rbc
indic
select
target
hgbhct
indic
number
rbc
unit
order
transfus
track
prospect
order
indic
comparison
unit
transfus
per
month
buc
implement
perform
use
student
resultsfind
histor
three
rbc
indic
repres
approxim
total
rbc
transfus
prior
buc
mean
number
rbc
unit
transfus
unitsmonth
first
month
buc
activ
mean
number
unit
unitsmonth
reduct
unitsmonth
blood
use
rbc
use
repres
approxim
total
rbc
use
hospit
wide
reduct
chang
repres
signific
cost
save
rbc
time
conclus
use
target
base
transfus
indic
electron
decis
support
algorithm
calcul
recommend
transfus
dose
significantli
reduc
rbc
transfus
rate
provid
enhanc
patient
blood
manag
potenti
cost
save
backgroundcas
studi
collabor
blood
center
bc
consult
three
hospit
bed
healthcar
system
hc
implement
patient
blood
manag
pbm
program
undertaken
review
first
month
studi
designmethod
year
one
pbm
work
group
establish
achiev
includ
physician
engag
program
creation
transfus
committe
provid
nurs
educ
audit
process
implement
nonconform
letter
sent
physician
nurs
complianc
inform
consent
transfus
tag
threshold
discharg
instruct
achiev
year
two
creat
best
practic
alert
bpa
order
meet
transfus
threshold
criteria
bpa
show
first
line
associ
procedur
link
full
procedur
three
recent
lab
result
eg
hemoglobin
hematocrit
red
blood
cell
rbc
allow
order
physician
cancel
order
review
blood
administr
video
creat
mandatori
physician
grant
privileg
complet
within
six
month
low
vital
sign
complianc
requir
action
includ
reduc
requir
five
three
transfus
format
work
group
wg
address
knowledg
practic
gap
year
three
histor
hc
jehovah
wit
patient
jwp
present
pbm
wg
involv
implement
bloodless
medicin
program
step
care
address
includ
identifi
jwp
registr
creat
special
arm
band
form
bloodless
medicin
physician
group
implement
nurs
bpa
electron
medic
record
creat
advanc
direct
market
public
resultsfind
follow
monitor
complianc
vs
present
complet
consent
vs
present
complet
nurs
flow
sheet
vs
transfus
threshold
support
vs
discharg
instruct
provid
vs
vital
sign
complianc
jwp
increas
cost
save
realiz
decreas
util
implement
bpa
tabl
conclus
pbm
implement
hc
continu
multiyear
process
even
robust
program
challeng
vital
sign
complianc
remain
backgroundcas
studi
emerg
medicin
golden
hour
refer
critic
time
period
follow
traumat
injuri
patient
higher
likelihood
surviv
nearli
half
trauma
relat
death
occur
first
hour
injuri
half
death
result
major
hemorrhag
rapid
administr
blood
product
vital
surviv
patient
implement
bloodtrack
emerg
haemonet
braintre
trauma
emerg
depart
ed
part
qualiti
improv
initi
effici
provid
group
rbc
thawedliquid
plasma
incom
trauma
patient
support
transfus
ensur
proper
handl
traceabl
regul
resourc
studi
designmethod
treat
approxim
trauma
patient
monthli
assess
current
blood
suppli
chain
reveal
manual
process
took
minut
prepar
physic
transport
cooler
blood
bank
ed
cooler
blood
provid
incom
trauma
patient
whether
end
need
transfus
practic
work
ensur
avail
blood
suppli
critic
moment
result
ineffici
unnecessari
inventori
percent
cooler
fulli
use
also
consum
valuabl
staff
time
technologist
typic
made
trip
per
month
blood
bank
ed
plu
effect
way
maintain
traceabl
control
access
cooler
monitor
usag
resultsfind
sinc
novemb
implement
bloodtrack
emerg
freed
technologist
perform
import
task
tighten
traceabl
inventori
control
procedur
contribut
medic
citi
plano
verif
level
trauma
center
rather
prepar
cooler
blood
case
may
need
emerg
situat
bloodtrack
emerg
provid
ed
staff
readi
access
emerg
unit
whenev
actual
need
free
estim
hour
tech
time
per
month
perform
task
audio
visual
alert
notifi
blood
bank
emerg
unit
remov
allow
quick
respons
plu
stock
emerg
blood
suppli
ed
blood
bank
nt
unnecessarili
tie
group
rbc
unit
today
blood
bank
stock
maintain
unit
group
rhd
neg
unit
rhd
posit
unit
group
thaw
plasmaliquid
plasma
bloodtrack
emerg
conclus
implement
bloodtrack
emerg
enabl
us
effect
provid
blood
product
incom
trauma
patient
support
transfus
improv
staff
effici
proactiv
respond
emerg
situat
backgroundcas
studi
platelet
limit
resourc
benefit
transfus
must
weigh
risk
aabb
publish
platelet
transfus
guidelin
assist
provid
academ
medic
center
comput
provid
order
entri
cpoe
system
combin
institut
transfus
guidelin
patient
recent
lab
result
guid
transfus
decis
discord
inform
activ
overrid
system
provid
prompt
select
prefix
indic
transfus
eg
count
prophylaxi
option
add
comment
order
place
data
store
later
review
studi
designmethod
overrid
platelet
order
place
june
review
use
follow
data
prefix
indic
recent
platelet
count
comment
order
servicedepart
one
five
code
assign
order
indic
base
institutionalaabb
guidelin
inform
eg
liver
transplant
comment
eg
reserv
comment
categor
assign
one
keyword
order
determin
common
reason
overrid
resultsfind
period
cpoe
overrid
platelet
order
occur
percentag
code
assign
month
provid
tabl
overal
assign
indic
ni
tabl
code
assign
month
top
keyword
assign
comment
platelet
count
less
activ
bleed
platelet
count
downtrend
mani
specifi
platelet
count
goal
certain
platelet
count
goal
reason
transfus
eg
downtrend
anticip
drop
per
servic
includ
institut
aabb
guidelin
note
overrid
place
provid
conclus
major
overrid
platelet
order
determin
indic
base
institut
aabb
guidelin
concern
keyword
downtrend
anticip
drop
indic
transfus
expos
patient
unnecessari
transfus
unclear
whether
traine
progress
throughout
year
effect
order
practic
associ
overrid
pattern
review
suggest
potenti
benefit
provid
educ
initi
level
experi
particular
emphasi
order
improv
blood
product
util
practic
backgroundcas
studi
earli
diagnosi
iron
defici
anemia
ida
clinic
laboratori
cl
effect
prevent
treatment
primari
care
may
impact
pack
red
blood
cell
prbc
transfus
well
intraven
iron
therapi
importantli
appli
lower
transfus
trigger
help
avoid
essenti
transfus
also
promot
health
wellb
improv
iron
statu
popul
result
describ
implement
process
prevent
ida
earli
detect
treatment
year
studi
designmethod
perform
measur
educ
organiz
intervent
set
public
integr
healthcar
system
locat
north
africa
border
morocco
isol
sea
distanc
nearest
continent
spain
airport
gener
hospit
blood
transfus
servic
establish
blood
donat
compon
product
cl
involv
anemia
detect
diagnosi
receiv
four
primari
care
center
hospit
base
sampl
share
common
leadership
blood
establish
process
guidelin
first
step
cl
diagnosi
ida
call
attent
primari
oral
iron
prevent
treatment
first
level
care
earli
intraven
iron
complex
inpati
sucros
outpati
carboxymaltos
transfus
avoid
stabl
ida
patient
without
activ
bleed
coronari
heart
diseas
safeti
hemoglobin
hb
threshold
sever
anem
patient
close
follow
ass
hb
increas
refer
etiolog
studi
hb
outcom
measur
prbc
transfus
iron
formul
prescript
year
hospit
discharg
prbc
use
analyz
quarter
year
iron
formul
prescript
varianc
analyz
yearli
packag
spss
use
univari
analysi
linear
regress
resultsfind
mean
quarter
prbc
unit
transfus
year
wherea
quarter
discharg
respect
p
mean
net
reduct
prbc
use
studi
period
compar
year
averag
chang
tendenc
place
estim
monthli
regress
line
year
mean
prescript
oral
iron
increas
studi
year
vs
p
iron
sucros
vs
carboxymaltos
vs
p
without
major
advers
event
conclus
ida
manag
target
avoid
prbc
transfus
intervent
level
care
success
strategi
improv
awar
health
problem
sustain
blood
resourc
backgroundcas
studi
bedsid
nurs
critic
safeguard
deliveri
appropri
patient
care
recent
nurs
also
begun
play
import
role
patient
blood
manag
pbm
program
administr
level
although
knowledg
littl
publish
influenc
nurs
may
transfus
practic
bedsid
goal
studi
evalu
impact
nurs
patient
expect
physician
order
practic
studi
designmethod
short
electron
survey
question
prepar
assess
often
bedsid
nurs
discuss
transfus
necess
person
patient
physician
discuss
well
discuss
felt
appropri
lab
threshold
transfus
survey
distribut
regist
nurs
via
email
floor
leader
respons
also
solicit
hospit
volunt
lab
staff
electron
tablet
includ
coverag
night
shift
resultsfind
total
complet
respons
nurs
rang
experi
less
one
year
forti
year
nineti
percent
state
discuss
transfus
necess
patient
physician
report
proactiv
order
place
percent
said
would
discuss
transfus
suggest
patient
requir
blood
product
respond
would
suggest
product
need
nurs
percept
accept
transfus
threshold
wider
distribut
commonli
report
valu
hemoglobin
platelet
count
inr
greater
conclus
studi
demonstr
nurs
will
discuss
transfus
patient
provid
although
appear
comfort
set
perceiv
transfus
necess
limit
number
survey
respons
suggest
discomfort
level
educ
transfus
practic
along
distribut
perceiv
threshold
reluct
recommend
transfus
present
opportun
educ
empow
nurs
provid
appropri
patient
care
within
guidelin
pbm
program
backgroundcas
studi
use
red
blood
cell
per
inhabit
may
vari
fold
european
countri
reveal
may
substanti
room
blood
optim
strategi
patient
blood
manag
pbm
multidisciplinari
approach
aim
preserv
optimis
patient
blood
order
improv
clinic
outcom
object
studi
assess
effect
nationwid
pbm
program
public
health
portug
studi
designmethod
first
phase
research
project
involv
group
key
opinion
leader
kol
state
prefer
inquiri
assess
rel
valu
specif
pbm
strategi
group
pbm
pillar
highlight
need
strategi
priorit
implement
nationwid
pbm
polici
adapt
conjoint
analysi
techniqu
use
elicit
kol
prefer
second
phase
decis
analysi
model
use
estim
impact
pbm
implement
follow
therapeut
area
surgeri
orthopaed
cardiac
urolog
cardiolog
oncolog
gastrointestin
bleed
abnorm
uterin
bleed
haemodialysi
inflammatori
bowel
diseas
pregnanc
model
input
includ
effect
data
regard
transfus
util
health
resourc
consumpt
mortal
obtain
portugues
nation
health
databas
literatur
review
public
health
valu
pbm
implement
portug
deriv
comparison
two
scenario
current
clinic
practic
pbm
implement
resultsfind
kol
elicit
iron
administr
follow
restrict
transfus
red
blood
cell
prefer
pbm
strategi
remain
strategi
weight
vari
estim
patient
would
elig
pbm
strategi
one
year
time
horizon
result
prematur
death
avoid
reduct
correspond
gain
approxim
life
year
reduct
disabl
adjust
life
year
dali
rel
current
clinic
practic
decreas
day
expect
mainli
due
reduct
hospit
length
stay
reduct
readmiss
rate
popul
overal
transfus
rate
could
decreas
current
reduct
impli
blood
transfus
avoid
red
blood
cell
unit
spare
conclus
anticip
implement
nationwid
patient
blood
manag
program
repres
paramount
improv
clinic
outcom
term
morbid
mortal
may
substanti
public
health
impact
contribut
effici
use
health
resourc
backgroundcas
studi
maximum
surgic
blood
order
schedul
msbo
guid
clinician
order
appropri
number
crossmatch
prbc
unit
elect
surgic
patient
base
local
transfus
rate
procedur
type
implement
msbo
import
compon
patient
blood
manag
program
contribut
accur
effici
util
prbc
studi
designmethod
base
measur
transfus
rate
procedur
type
msbo
creat
implement
elect
orthopaed
surgic
procedur
total
transfus
total
preoper
crossmatch
measur
month
prior
month
msbo
implement
resultsfind
total
elect
orthopaed
surgic
procedur
perform
month
studi
period
implement
msbo
preoper
crossmatch
order
decreas
case
case
p
transfus
rate
also
significantli
decreas
case
case
p
crossmatch
transfus
ratio
c
decreas
exceed
best
practic
standard
c
less
conclus
implement
maximum
surgic
blood
order
schedul
reduc
unnecessari
crossmatch
well
transfus
rate
elect
orthopaed
surgic
patient
import
compon
effect
patient
blood
manag
program
backgroundcas
studi
transfus
algorithm
commonli
employ
augment
restrict
transfus
practic
gener
reli
test
coagul
platelet
indic
fibrinolysi
take
account
clinic
factor
beyond
blood
loss
clinician
reli
laboratori
result
broad
rang
physiolog
paramet
drive
decis
transfus
develop
algorithm
alon
concert
algorithm
may
allow
optim
transfus
therapi
machin
learn
artifici
intellig
methodolog
may
provid
develop
algorithm
facilit
transfus
blood
blood
product
address
critic
clinic
gap
studi
designmethod
sought
transform
current
empir
method
decis
make
transfus
one
use
advanc
analyt
machin
learn
techniqu
irb
approv
deploy
data
extract
method
applic
program
interfac
api
collect
pertin
clinic
inform
consecut
patient
undergo
cardiac
surgeri
cardiopulmonari
bypass
data
pars
translat
variou
format
employ
mongodb
mssql
oracl
sql
nosql
redi
couchdb
mysql
tool
seri
machin
learn
artifici
intellig
experi
conduct
use
train
subset
data
result
train
experi
run
valid
set
final
test
set
resultsfind
machin
learn
artifici
intellig
method
reveal
predict
relationship
numer
clinic
paramet
blood
transfus
addit
tradit
laboratori
result
bodi
weight
euroscor
fibrinogen
chest
tube
output
low
molecular
weight
heparin
age
hemoglobin
bodi
surfac
area
gender
hematocrit
nadir
artifici
ventil
hemoglobin
multipl
platelet
function
vital
sign
trajectori
identifi
signific
predictor
transfus
conclus
develop
predictor
thu
algorithm
clinic
laboratori
transfus
further
object
standard
transfus
practic
empow
provid
relev
patient
inform
refin
current
clinic
guidelin
thu
reduc
inappropri
util
advanc
care
backgroundcas
studi
blood
util
liver
transplant
vari
end
stage
liver
diseas
alter
hemostasi
due
factor
defici
portal
hypertens
hyperfibrinolysi
platelet
sequestr
newli
transplant
liver
contribut
signific
hemorrhag
sought
develop
predict
model
intraop
rbc
usag
liver
transplant
studi
designmethod
retrospect
studi
primari
liver
transplant
singl
institut
januari
decemb
multivari
analysi
preoper
factor
use
develop
model
predict
intraop
rbc
use
resultsfind
adult
liver
transplant
perform
evalu
period
preoper
hemoglobin
creatinin
meld
score
spontan
bacteri
periton
sbp
preoper
hemodialysi
gender
portal
vein
thrombosi
pvt
gave
strongest
model
predict
rbc
usag
model
predict
rbc
case
transfus
captur
time
use
rbc
predict
transfus
use
time
predict
usag
time
exceed
conclus
model
use
specif
preoper
factor
use
predict
intraop
rbc
usag
patient
risk
rbc
transfus
identifi
reason
accuraci
use
model
institut
use
model
might
help
improv
prepar
util
blood
bank
backgroundcas
studi
blood
common
result
wast
blood
bank
resourc
blood
unit
withdrawn
pool
lead
constraint
alloc
limit
blood
resourc
meet
need
patient
transfus
ct
ratio
often
use
benchmark
effici
blood
util
within
hospit
blood
transfus
servic
accord
american
associ
blood
bank
aabb
ct
ratio
less
favor
anyth
indic
blood
achiev
necessari
review
blood
order
practic
matern
hospit
studi
designmethod
data
elect
surgeri
requir
blood
standbi
collect
retrospect
month
period
jan
mar
detail
total
blood
issu
transfus
return
analyz
along
ct
ratio
resultsfind
month
period
patient
undergo
obstetr
gynecolog
procedur
requir
blood
standbi
total
unit
blood
request
unit
unit
sent
oper
theatr
ot
blood
issu
ot
transfus
rest
unutil
observ
ct
ratio
conclus
although
total
blood
request
ct
ratio
remain
recommend
guidelin
almost
blood
unutil
need
improv
standard
blood
order
practic
achiev
reduc
unnecessari
workload
establish
adher
maximum
surgic
blood
order
schedul
msbo
could
help
conserv
blood
prevent
blood
backgroundcas
studi
total
knee
arthroplasti
tka
major
orthopaed
procedur
increas
periop
blood
loss
periop
blood
loss
could
signific
patient
undergo
bilater
tka
singl
stage
increas
blood
loss
bilater
tka
often
requir
blood
transfus
result
high
morbid
studi
designmethod
retrospect
studi
patient
receiv
tranexam
acid
txa
studi
group
patient
receiv
txa
surgeri
control
evalu
blood
loss
transfus
requir
studi
group
receiv
singl
bolu
dose
txa
iv
tourniquet
deflat
first
side
knee
statist
analys
perform
use
statist
softwar
instat
version
level
signific
set
p
valu
less
resultsfind
group
compar
term
age
sex
bodi
mass
index
mean
preoper
hb
hct
valu
found
similar
group
mean
hb
hct
level
studi
control
group
gmdl
gmdl
respect
tabl
signific
differ
chang
hb
level
gmdl
vs
gmdl
p
hct
vs
p
observ
txa
group
control
group
tabl
although
mean
total
measur
blood
loss
intraop
blood
loss
drain
lower
studi
group
vs
p
statist
signific
differ
observ
tabl
differ
blood
transfus
requir
observ
studi
group
control
group
unit
group
interquartil
iqr
rang
unit
p
conclus
singl
intraop
dose
txa
adequ
reduct
blood
loss
transfus
requir
patient
undergo
bilater
tka
compar
multicentr
prospect
studi
singl
dose
vs
multipl
dose
fix
dose
vs
weight
dose
txa
need
perform
concurr
bilater
tka
establish
benefit
tabl
baselin
demograph
clinic
data
tabl
comparison
outcom
paramet
backgroundcas
studi
coagulopathi
common
issu
patient
end
stage
liver
diseas
usual
requir
liver
transplant
lt
profound
chang
imbal
procoagul
anticoagul
system
lt
lead
diffus
bleed
result
massiv
usag
blood
transfus
therefor
monitor
hemostasi
patient
critic
coagul
manag
lt
periop
period
thromboelastographi
teg
differ
convent
coagul
test
includ
pt
aptt
fibrinogen
level
perform
point
care
test
multipl
arm
coagul
cascad
current
teg
gener
use
liver
transplant
monitor
level
fibrinogen
platelet
count
hyperfibrinolysi
assess
patient
haemostat
statu
guid
coagul
manag
blood
product
factor
concentr
antifibrinolyt
studi
designmethod
retrospect
analysi
conduct
affili
hospit
qingdao
univers
exist
record
lt
patient
review
januari
decemb
transfus
blood
data
patient
undergo
orthotrop
liver
transplant
analyz
patient
divid
two
group
teg
group
patient
monitor
lt
periop
period
use
point
care
teg
analysi
control
group
patient
monitor
use
convent
coagul
test
resultsfind
data
show
need
blood
transfus
teg
group
patient
significantli
decreas
compar
control
group
patient
usag
red
blood
cell
vs
unit
p
platelet
vs
therapeut
dose
p
fresh
frozen
plasma
vs
ml
p
cryoprecipit
vs
unit
p
teg
group
control
group
respect
also
signific
differ
intraop
blood
loss
two
group
vs
ml
p
conclus
teg
provid
overal
effici
evalu
coagul
lt
construct
impact
reduc
avoid
transfus
allogen
blood
product
teg
valuabl
tool
guid
transfus
algorithm
base
teg
hemostasi
monitor
lt
reduc
usag
blood
product
backgroundcas
studi
blood
product
util
increas
concern
hospit
system
attempt
reduc
risk
one
strategi
optim
util
employ
clinic
decis
support
form
alert
clinician
order
blood
product
investig
whether
alert
target
patient
transfus
indic
could
alter
provid
order
behavior
studi
designmethod
retrospect
observ
studi
cours
seven
month
includ
inpati
adult
medicin
floor
intens
care
unit
larg
academ
hospit
time
crossmatch
pack
red
blood
cell
prbc
order
via
hospit
electron
order
system
indic
eg
hemodynam
stabl
hemoglobin
must
select
indic
select
contain
threshold
hemoglobin
concentr
patient
recent
hemoglobin
record
greater
threshold
interrupt
alert
display
patient
hemoglobin
activ
order
provid
given
three
option
cancel
order
select
appropri
indic
list
provid
explan
via
free
text
transfus
request
outsid
approv
indic
alert
encount
defin
activ
patient
within
six
hour
period
without
interven
transfus
resultsfind
seven
month
uniqu
alert
encount
led
crossmatch
order
led
order
cancel
provid
like
cancel
transfus
respons
alert
hemodynam
stabl
patient
lower
hemoglobin
threshold
complic
patient
bleed
cardiovascular
diseas
preoper
higher
hemoglobin
threshold
cancel
rate
hemodynam
stabl
patient
compar
complic
patient
p
fisher
exact
test
furthermor
hemoglobin
higher
cancel
order
order
hemodynam
stabl
patient
median
vs
p
u
test
provid
evid
effect
transfus
alert
popul
conclus
evid
suggest
target
alert
prevent
unnecessari
transfus
patient
hemodynam
stabl
provid
recept
transfus
alert
result
higher
crossmatch
cancel
rate
despit
lower
hemoglobin
threshold
backgroundcas
studi
maximum
surgic
blood
order
schedul
msbo
list
surgic
procedur
perform
along
recommend
extent
test
complet
surgeri
begin
improv
patient
data
manag
system
possibl
creat
msbo
base
actual
red
blood
cell
rbc
util
data
basi
studi
investig
transfus
pattern
academ
hospit
msbo
studi
designmethod
hospit
group
one
share
msbo
group
three
hospit
larg
academ
center
one
children
hospit
center
msbo
recommend
test
patient
transfus
specif
procedur
previou
year
type
screen
patient
transfus
crossmatch
median
number
rbc
transfus
patient
transfus
data
collect
center
month
period
januari
march
includ
maximum
case
per
hospit
one
month
ensur
equal
represent
center
resultsfind
center
total
case
analyz
frequent
perform
surgeri
includ
orthoped
case
gener
surgeri
cardiac
surgeri
order
case
posit
antibodi
day
surgeri
order
order
accord
msbo
recommend
order
msbo
recommend
one
order
msbo
recommend
one
remaind
order
procedur
list
msbo
rbc
crossmatch
perform
case
unit
crossmatch
patient
rbc
issu
involv
rbc
unit
transfus
crossmatch
transfus
c
ratio
crossmatch
issu
c
ratio
major
crossmatch
order
msbo
recommend
perform
one
crossmatch
rbc
issu
patient
msbo
recommend
crossmatch
rbc
issu
msbo
recommend
crossmatch
rbc
issu
msbo
recommend
crossmatch
unit
transfus
return
blood
bank
wast
c
ratio
convers
msbo
recommend
crossmatch
unit
issu
rbc
transfus
return
blood
bank
wast
c
ratio
conclus
adher
msbo
center
especi
order
rbc
crossmatch
rel
low
nonetheless
msbo
follow
lower
c
ratio
less
wastag
compar
rbc
order
outsid
msbo
effort
rais
awar
msbo
well
rapid
avail
crossmatch
rbc
use
electron
crossmatch
made
institut
improv
complianc
good
transfus
practic
backgroundcas
studi
peripartum
blood
transfus
common
south
africa
usa
recent
studi
demonstr
antenat
anemia
strong
risk
factor
transfus
odd
ratio
prenat
hemoglobin
hgb
therefor
analyz
etiolog
characterist
antenat
anemia
accord
hiv
statu
larg
hospit
hiv
preval
among
obstetr
patient
studi
designmethod
studi
sampl
anem
hgb
pregnant
women
refer
antenat
anemia
clinic
larg
hospit
south
africa
clinic
inform
abstract
blood
sent
laboratori
studi
use
compar
continu
variabl
group
resultsfind
total
women
enrol
median
age
interquartil
rang
year
median
gravida
para
median
gestat
age
week
mean
hgb
referr
alreadi
take
oral
iron
therapi
total
women
hiv
posit
mean
lymphocyt
count
cellsul
hiv
posit
subject
therapi
art
prior
pregnanc
art
current
pregnanc
iron
defici
anemia
overwhelmingli
preval
diagnosi
present
women
concurr
chronic
diseas
infect
vitamin
defici
antenat
hemorrhag
otherunknownmiss
caus
anemia
pregnanc
relat
complic
hiv
posit
women
higher
level
protein
slightli
lower
level
transferrin
solubl
transferrin
receptor
rbc
folat
hiv
neg
women
tabl
tabl
laboratori
valu
first
clinic
visit
conclus
iron
defici
overwhelm
caus
antenat
anemia
among
south
african
pregnant
women
compar
women
women
evid
increas
inflamm
rel
littl
differ
iron
studi
earli
treatment
iron
lower
red
cell
folat
high
proport
hiv
posit
women
receiv
art
consist
nation
guidelin
futur
studi
examin
respons
iron
therapi
assess
potenti
decreas
incid
peripartum
blood
transfus
backgroundcas
studi
red
blood
cell
rbc
transfus
guidelin
deriv
mainli
studi
inpati
popul
repres
hematologyoncolog
hemonc
patient
studi
aim
identifi
variat
rbc
transfus
practic
hemonc
patient
determin
preval
guidelin
transfus
studi
designmethod
survey
address
institut
rbc
transfus
guidelin
individu
practic
distribut
hemonc
clinician
survey
distribut
five
state
oncolog
associ
blood
center
physician
hemonc
colleagu
onlin
survey
administ
surveymonkey
platform
respons
receiv
resultsfind
thirti
complet
survey
receiv
repres
state
institut
institut
guidelin
clinician
report
institut
guidelin
rbc
transfus
stabl
adult
patient
hospit
set
common
transfus
threshold
gmdl
hemoglobin
other
report
gmdl
eight
clinician
report
inclus
specif
except
guidelin
outpati
receiv
myelosuppress
therapi
institut
rbc
guidelin
audit
eleven
clinician
notifi
transfus
order
fall
outsid
institut
guidelin
six
prospect
hemonc
clinician
institut
guidelin
ask
routin
given
exempt
rbc
transfus
guidelin
audit
enforc
inpati
set
respons
ye
similarli
outpati
set
respons
ye
clinic
practic
sixteen
clinician
guidelin
rbc
transfus
past
three
month
approxim
number
instanc
rang
one
repres
total
transfus
order
mean
median
follow
frequent
select
reason
except
specif
request
patient
seek
improv
daili
qualiti
life
less
fatigu
etc
medic
judgment
specif
clinic
set
extend
interv
visit
due
travel
distanc
difficulti
conclus
institut
vari
rbc
transfus
threshold
exceptionsexempt
made
hemonc
patient
two
third
clinician
report
guidelin
transfus
base
medic
judgment
consider
patient
qualiti
life
guidelin
specif
patient
popul
need
specif
prospect
random
trial
includ
object
clinic
outcom
well
qualiti
life
measur
backgroundcas
studi
abo
incompat
mother
babi
common
caus
hemolyt
diseas
newborn
hdn
direct
antiglobulin
test
dat
neonat
blood
may
posit
phototherapi
may
requir
hyperbilirubinemia
rare
hdn
due
abo
incompat
requir
neonat
exchang
transfus
studi
designmethod
case
report
abo
hdn
meet
criteria
exchang
transfus
brief
review
literatur
resultsfind
femal
blood
type
rhd
posit
prior
histori
intrauterin
fetal
demis
week
underw
spontan
vagin
deliveri
week
femal
infant
mother
antibodi
screen
neg
cord
blood
test
show
neonat
blood
type
b
rhd
posit
posit
dat
elut
posit
b
reagent
cell
total
serum
bilirubin
level
rose
rapidli
day
deliveri
hour
despit
intens
phototherapi
partial
dose
ivig
test
defici
hereditari
spherocytosi
neg
patient
underw
doubl
volum
exchang
transfus
reconstitut
whole
blood
hematocrit
even
adequ
respons
matern
igg
titer
elev
consist
case
report
literatur
requir
invas
therapi
abo
hdn
typic
mild
scatter
sever
case
report
literatur
requir
exchang
transfus
report
suggest
bo
incompat
individu
african
descent
may
risk
factor
sever
abo
hdn
case
meet
criteria
exchang
transfus
bo
ao
incompat
conclus
report
case
abo
hdn
meet
american
academi
pediatr
criteria
neonat
exchang
transfus
due
bo
incompat
mother
african
descent
exchang
transfus
improv
hyperbilirubinemia
avoid
sever
hyperbilirubinemia
result
favor
outcom
abo
hdn
alway
mild
close
coordin
transfus
servic
neonatologist
key
prompt
manag
whether
bo
incompat
african
descent
risk
factor
need
exchang
transfus
requir
character
refer
bakkeheim
e
etal
matern
igg
titr
predict
outcom
neonat
acta
paediatr
christensen
r
etal
caus
hemolysi
neonat
extrem
hyperbilirubinemia
j
perinatol
goraya
j
etal
unusu
sever
abo
hemolyt
diseas
newborn
indian
j
pediatr
mcdonnel
etal
hydrop
fetali
due
abo
incompat
arch
di
child
fetal
neonat
ed
backgroundcas
studi
month
old
boy
present
institut
month
hospit
japan
admit
sever
week
unremark
term
birth
ab
rh
posit
woman
lethargi
failur
thrive
bloodi
mucoid
stool
eosinophilia
elev
serum
white
count
found
anem
thrombocytopen
requir
multipl
transfus
also
diffus
scale
erythemat
rash
inner
thigh
studi
designmethod
initi
workup
suspic
allergicnecrot
enterocol
patient
elev
ldh
potassium
concern
rais
leukemia
possibl
tumor
lysi
syndrom
sampl
sent
blood
bank
show
posit
dat
igg
complement
posit
e
e
c
antigen
concern
antibodi
rais
possibl
red
cell
antigen
passiv
transfus
blood
product
administ
japanes
hospit
possibl
exclud
workup
reveal
infect
hematolog
prolifer
biopsi
rash
show
spongiot
dermat
clinic
cours
deterior
develop
hepatomegali
jaundic
concern
syndrom
rais
workup
show
normal
immunoglobulin
level
elev
ige
kul
rr
antibodi
identifi
three
day
admiss
test
sent
genet
alter
physician
institut
read
prior
flow
cytometri
studi
show
defici
lymphocyt
resultsfind
mutat
implic
syndrom
call
ipex
immun
dysregul
polyendocrinopathi
enteropathi
protein
transcript
factor
regulatori
protein
constitut
express
regulatori
cell
treg
master
regul
treg
develop
function
mutat
gene
locat
result
decreas
toler
self
antigen
result
autoimmun
diseas
patient
male
present
prenat
within
month
birth
often
profus
wateri
bloodi
diarrhea
develop
varieti
autoimmun
condit
dmi
dermat
thyroid
diseas
renal
failur
cytopenia
patient
mutat
locat
within
protein
domain
associ
high
mortal
report
case
mutat
result
loss
protein
loss
inhibitori
action
treg
b
cell
lead
autoantibodi
prolifer
effector
cell
lead
prolifer
overexpress
eosinophilia
addit
overexpress
produc
patient
mutat
similar
clinic
cours
suggest
genet
interact
epigenet
divers
environment
cofactor
diseas
progress
standard
care
includ
immunosuppress
sct
conclus
rare
present
neonat
patient
posit
antibodi
screen
dat
neg
matern
workup
caus
consid
possibl
autoimmun
process
includ
ipex
backgroundcas
studi
per
abbb
circular
inform
indic
plasma
transfus
revers
warfarin
bleed
manag
coagulopath
patient
exchang
ttp
patient
major
indic
seen
adult
report
plasma
wastag
fortun
pediatr
incid
indic
low
despit
heterogen
patient
popul
util
review
process
primari
pediatr
institut
note
mean
wastag
last
year
recent
chang
clinic
practic
liver
transplant
increas
trauma
recent
evid
faster
plasma
improv
massiv
transfus
protocol
mtp
outcom
facil
decid
implement
use
thaw
plasma
benchmark
mtp
plasma
wastag
studi
designmethod
blood
util
review
reveal
increas
overal
percentag
plasma
wastag
peak
rang
singl
caus
could
readili
identifi
prompt
us
queri
children
hospit
associ
cha
initi
extern
pediatr
benchmark
determin
wastag
compar
children
hospit
addit
review
time
plasma
avail
mtp
resultsfind
mtp
activ
time
case
patient
receiv
blood
product
case
plasma
alreadi
avail
time
rbc
allocationissu
left
case
evalu
median
time
plasma
avail
minut
rang
minut
minut
mean
plasma
wastag
mtp
activ
rang
cha
repli
use
thaw
plasma
wastag
conclus
increas
clinic
evid
support
prompt
transfus
plasma
set
mtp
decreas
morbid
mortal
brief
review
suggest
implement
thaw
plasma
allow
potenti
decreas
plasma
avail
minut
implement
began
thaw
singl
unit
plasma
level
neuro
trauma
alert
keep
singl
unit
ab
plasma
thaw
time
plasma
avail
time
rbc
thu
provid
effect
balanc
blood
product
support
reduc
wastag
preliminari
estim
level
consist
extern
benchmark
prospect
evalu
practic
ongo
institut
includ
collabor
clinic
assess
trauma
team
ultim
prospect
studi
pediatr
institut
necessari
defin
best
clinic
practic
effect
benchmark
blood
bank
practic
backgroundcas
studi
dat
test
neg
autoimmun
hemolyt
anemia
aiha
primari
explan
aiha
includ
low
quantiti
igg
low
affin
igg
iga
igm
mediat
hemolysi
cell
mediat
hemolysi
suspicion
aiha
remain
high
despit
neg
dat
clinician
consid
serolog
test
variou
serolog
aid
exist
perform
special
laboratori
describ
pediatr
case
aiha
identifi
special
test
studi
designmethod
perform
retrospect
chart
review
patient
undergo
investig
autoimmun
hemolyt
anemia
lucil
packard
children
hospit
stanford
januari
august
eleven
pediatr
case
warrant
special
laboratori
test
upon
present
gener
hematolog
clinic
serolog
test
perform
immunohematolog
research
laboratori
irl
american
red
cross
blood
servic
southern
california
region
pomona
ca
test
includ
retain
autoantibodi
use
cold
low
ionic
strength
salin
liss
detect
igg
direct
polybren
test
case
posit
test
confirm
diagnosi
aiha
resultsfind
eleven
case
present
tabl
tabl
characterist
children
dat
neg
aiha
conclus
special
test
irl
led
definit
diagnosi
eleven
case
correct
treatment
larg
academ
referr
hematolog
clinic
refer
worlledg
sm
blajchman
autoimmun
haemolyt
anaemia
br
j
haematol
chaplin
h
jr
clinic
use
specif
antiglobulin
reagent
autoimmun
hemolyt
anemia
progr
hematol
petz
ld
garratti
g
acquir
immun
hemolyt
anemia
new
york
ny
churchil
livingston
garratti
g
immun
hemolyt
anemia
associ
neg
routin
serolog
semin
hematol
backgroundcas
studi
bacteri
fungal
infect
remain
signific
caus
morbid
mortal
sever
neutropen
patient
hematolog
diseas
receiv
chemotherapi
hematopoiet
stem
cell
transplant
hsct
granulocyt
transfus
gtx
use
year
although
effect
indic
patient
donor
safeti
remain
debat
particularli
children
contribut
discuss
demonstr
case
gtx
pediatr
patient
age
month
year
old
neutropen
sever
infect
resist
antibiot
andor
antifung
therapi
undergo
hsct
chemotherapi
studi
designmethod
donor
data
concern
total
granulocyt
donat
collect
health
donor
male
femal
donor
match
blood
type
serolog
statu
cytomegaloviru
patient
neg
granulocyt
mobil
singl
dose
filgrastim
subcutan
donor
maximum
oral
dexamethason
prior
apheresi
apheresi
perform
use
cobe
spectra
citrat
anticoagul
product
irradi
resultsfind
granulocyt
number
increas
time
basal
level
median
cell
collect
rang
gener
donor
report
signific
advers
reaction
donat
report
light
paresthesia
procedur
patient
patient
medic
prior
transfus
diphenhydramin
acetaminophen
product
transfus
within
hour
collect
effort
transfus
soon
possibl
detail
transfus
describ
tabl
advers
reaction
patient
minor
frequent
gtx
includ
vomit
hypotens
headach
resolv
without
seriou
last
complic
assum
gtx
well
toler
conclus
studi
provid
evid
gtx
transfus
safe
perform
pediatr
patient
tabl
granulocyt
transfus
profil
backgroundcas
studi
infect
caus
major
mortal
among
person
prolong
neutropenia
relat
hsct
chemotherapi
among
patient
granulocyt
disord
granulocyt
transfus
therapi
logic
approach
treat
patient
infect
refractori
antibiot
want
demonstr
granulocyt
transfus
experi
children
neutropenia
defect
immun
system
sever
infect
studi
designmethod
analyz
retrospect
data
period
donor
underw
granulocyt
mobil
dose
sc
hr
prior
donat
granulocyt
collect
cobe
spectra
caridianbct
analysi
perform
microsoft
excel
nonparametr
spearman
test
resultsfind
perform
granulocyt
collect
donor
f
age
mean
increment
wbc
stimul
age
group
year
year
mean
increment
wbc
respect
mean
volum
treat
blood
mean
volum
product
mean
number
total
wbc
product
three
donor
advers
effect
analysi
includ
granulocyt
transfus
case
infecti
complic
patient
mean
number
transfus
patient
receiv
transfus
mean
donor
granulocyt
transfus
start
mean
day
infect
mean
dose
wbc
transfus
wbc
increment
abl
estim
transfus
wbc
increment
record
transfus
mean
increment
efficaci
determin
number
patient
surviv
infect
episod
amount
case
sever
sepsi
efficaci
transfus
frequenc
reaction
n
febril
nonhemolyt
reaction
n
pulmonari
complic
n
antibodi
format
n
conclus
signific
differ
mobil
granulocyt
product
volum
men
women
age
group
find
signific
relationship
baselin
wbc
increment
stimul
mean
total
wbc
collect
product
mean
volum
treat
blood
men
women
significantli
differ
perhap
reason
lower
cell
product
women
treat
smaller
blood
volum
lack
increment
wbc
transfus
equival
lack
efficaci
found
signific
associ
transfus
dose
increment
wbc
deliber
estim
data
treatment
patient
sepsi
sever
infect
patient
receiv
receiv
granulocyt
transfus
need
transfus
granulocyt
indic
sever
patient
infect
neutropenia
dysfunct
immun
system
refractori
antibiot
backgroundcas
studi
rare
antibodi
high
incid
red
blood
cell
rbc
antigen
ag
present
peopl
common
rh
phenotyp
ag
miss
individu
rh
null
rh
delet
phenotyp
includ
individu
strongli
express
lack
c
c
e
e
ag
clinic
relev
primarili
report
pregnant
women
caus
mild
fatal
hemolyt
diseas
newborn
hdn
present
rare
case
hdn
due
alloimmun
pregnanc
mother
studi
designmethod
full
term
infant
born
mother
neg
trimest
antibodi
screen
prior
transfus
two
prior
pregnanc
first
result
normal
term
singleton
second
result
spontan
miscarriag
trimest
father
blood
type
unknown
presum
rh
antigen
infant
transfer
institut
hour
life
found
anemia
hemoglobin
sever
hyperbilirubinemia
total
bilirubin
bili
reticulocytosi
posit
direct
antiglobulin
test
igg
admit
neonat
intens
care
unit
potenti
need
exchang
transfus
given
concern
hdn
treat
intraven
immunoglobulin
tripl
phototherapi
day
admiss
temporarili
blunt
hemolysi
bili
rose
maximum
day
life
phototherapi
bili
subsequ
stabil
discharg
home
follow
clinic
meanwhil
mother
donat
blood
given
compat
red
blood
cell
avail
unit
state
via
rare
donor
queri
nine
day
discharg
readmit
worsen
anemia
hemoglobin
given
steroid
wash
matern
red
blood
cell
discharg
follow
clinic
sever
month
ultim
resolut
anemia
hyperbilirubinemia
resultsfind
deliveri
mother
antibodi
screen
posit
identifi
alloantibodi
detect
antibodi
identif
perform
use
polyethylen
glycol
low
ionic
strength
solut
ficin
enhanc
matern
serum
pan
reactiv
panel
cell
cell
sera
react
matern
rbc
phenotyp
mother
reveal
molecular
test
confirm
genotyp
molecular
beadchip
test
yield
type
due
low
signal
e
e
v
vs
ag
genotyp
rh
variant
target
genom
rhce
test
fail
detect
sever
rhce
exon
father
unavail
test
conclus
report
rare
case
hdn
due
antibodi
mother
hope
obtain
laboratori
studi
matern
rel
given
rariti
phenotyp
gener
popul
studi
import
implic
genet
counsel
mother
sister
backgroundcas
studi
manag
sever
autoimmun
hemolyt
anemia
aiha
present
anemia
challeng
particularli
pediatr
popul
mortal
rate
aiha
typic
low
howev
children
rate
may
high
although
corticosteroid
immunomodulatori
therapi
first
line
modal
sever
case
report
describ
use
manual
whole
blood
exchang
wbex
success
treat
aiha
older
children
adult
refractori
first
line
treatment
knowledg
first
case
report
infant
sever
aiha
success
treat
manual
wbex
acut
care
set
studi
designmethod
case
report
format
resultsfind
previous
healthi
femal
patient
present
emerg
depart
hemodynam
instabl
nadir
hemoglobin
hb
hematocrit
hct
wbc
count
x
l
mildli
elev
platelet
count
x
l
within
normal
limit
histori
notabl
upper
respiratori
tract
infect
day
prior
onset
anemia
laboratori
studi
admiss
show
hyperbilirubinemia
total
direct
normal
ldh
ul
undetect
haptoglobin
indic
ongo
hemolysi
clinic
symptom
includ
diffus
jaundic
hemoglobinuria
lethargi
emesi
admit
pediatr
intens
care
unit
manag
includ
right
intern
jugular
central
venou
cathet
placement
due
poor
peripher
vascular
access
patient
blood
group
rh
posit
antibodi
screen
panel
demonstr
strong
panagglutinin
reactiv
posit
autocontrol
dat
posit
neg
despit
posit
cold
antibodi
screen
patient
weigh
estim
total
blood
volum
initi
receiv
simpl
transfus
total
least
incompat
group
rh
rbc
increment
respons
manual
wbex
perform
reconstitut
whole
blood
consist
rh
rbc
ab
fresh
frozen
plasma
ffp
hct
util
central
venou
cathet
advers
event
took
place
cours
hour
exchang
one
hour
hb
subsequ
antibodi
screen
demonstr
reduc
intens
panagglutinin
initi
steroid
therapi
methylprednisolon
continu
improv
clinic
one
week
later
patient
discharg
home
hb
one
month
later
experienc
recurr
hemolysi
requir
time
normal
igm
iga
level
markedli
elev
igg
level
subsequ
visit
month
initi
present
anemia
resolv
complet
wean
steroid
conclus
demonstr
case
sever
neonat
aiha
success
treat
manual
wbex
main
advantag
wbex
includ
remov
autolog
rbc
plasma
well
infus
allogen
rbc
case
manual
exchang
transfus
avoid
need
autom
apheresi
procedur
requir
citrat
anticoagul
summari
manual
wbex
potenti
safe
procedur
may
perform
young
children
sever
aiha
backgroundcas
studi
recent
four
similar
transfus
reaction
involv
infant
report
institut
transfus
oper
room
experienc
urin
laboratori
evid
hemolysi
acut
kidney
injuri
cleric
serolog
investig
reveal
caus
hemolysi
mechan
hemolysi
transfus
rate
cathet
gaug
recent
introduc
valv
consid
studi
designmethod
vitro
simul
transfus
perform
via
syring
measur
includ
hematocrit
hct
free
hemoglobin
visual
hemolysi
index
wash
unwash
red
blood
cell
rbc
test
without
valv
use
gaug
g
intraven
iv
cathet
valv
use
test
three
ident
sampl
constant
pressur
appli
manual
rapidli
mechan
syring
pump
slowli
subset
manual
transfus
time
control
sampl
baselin
measur
collect
graviti
drip
without
pass
valv
cathet
resultsfind
valv
increas
hemolysi
markedli
rapid
transfus
use
cathet
well
wash
unwash
rbc
see
tabl
cathet
mean
chang
hct
valv
without
p
compar
valv
test
differ
hemolysi
observ
chang
hct
p
rapid
manual
transfus
cathet
unwash
rbc
hemolysi
greater
sampl
took
longer
transfus
use
valv
chang
hct
versu
time
p
compar
significantli
differ
slight
increas
hemolysi
sampl
took
less
time
transfus
use
valv
chang
hct
versu
time
correl
time
hemolysi
similar
insignific
use
wash
rbc
iv
cathet
conclus
mechan
hemolysi
consid
investig
possibl
hemolyt
transfus
reaction
especi
high
rate
transfus
use
valv
rapid
manual
transfus
valv
greater
resist
associ
increas
hemolysi
tabl
backgroundcas
studi
gerbich
ge
antigen
express
glycophorin
c
present
popul
ge
antibodi
caus
delay
hemolyt
transfus
reaction
hemolyt
diseas
fetu
newborn
hdfn
ge
antibodi
also
suppress
erythropoiesi
result
anemia
report
case
hdfn
due
studi
designmethod
woman
paraguayan
origin
prior
termin
pregnanc
present
week
gestat
passiv
titer
ge
antigen
type
obstetrician
schedul
matern
blood
collect
near
due
date
possibl
neonat
transfus
woman
went
labor
week
cord
blood
dat
posit
igg
eluat
confirm
birth
hemoglobin
hgb
reticulocyt
retic
bilirubin
bili
infant
discharg
day
life
infant
refer
pediatr
hematolog
lethargi
poor
feed
hgb
retic
bili
blood
avail
blood
center
rare
donor
registri
mother
b
babi
b
rh
obstetr
author
matern
blood
donat
due
hgb
matern
blood
collect
rbc
wash
expedit
infant
receiv
matern
rbc
within
hour
time
hgb
hgb
one
week
later
infant
symptomat
hgb
retic
bili
aliquot
wash
matern
cell
transfus
two
week
thereaft
infant
hgb
retic
titer
need
anoth
transfus
matern
blood
store
week
hemolyz
necessit
matern
donat
babi
transfus
week
infant
titer
hgb
retic
transfus
necessari
week
life
hgb
retic
babi
thrive
resultsfind
serolog
studi
hospit
refer
blood
center
confirm
antibodi
risk
hdfn
molecular
analysi
reveal
mother
homozyg
ge
father
homozyg
wild
type
ge
infant
heterozyg
ge
conclus
infant
hdfn
due
antibodi
high
preval
antigen
continu
need
transfus
consist
hemolysi
suppress
erythrocyt
product
caus
hemolysi
store
matern
blood
consist
absenc
glycophorin
c
case
demonstr
cooper
multidisciplinari
care
among
blood
bank
donor
center
obstetr
hematolog
rare
case
hdfn
result
success
neonat
outcom
backgroundcas
studi
patient
blood
manag
collabor
approach
optim
transfus
therapi
improv
patient
outcom
pediatr
blood
manag
one
size
fit
given
pauciti
clinic
trial
guid
practic
addit
pediatr
care
encompass
heterogen
patient
popul
appli
one
set
guidelin
difficult
standard
clinic
best
practic
regard
blood
product
usag
children
unnecessari
variat
occur
institut
design
robust
analyt
process
studi
baselin
clinic
practic
examin
blood
product
usag
plan
target
three
pediatr
highest
usag
establish
standard
order
decreas
variationunnecessari
transfus
studi
designmethod
data
base
encompass
admiss
outpati
visit
larg
tertiari
care
academ
children
women
hospit
establish
includ
relev
patient
demograph
diagnost
procedur
code
attend
physician
specialti
visitadmiss
relev
hematologycoagul
laboratori
result
blood
product
order
focus
rbc
order
given
tripicu
random
clinic
trial
result
support
hemoglobin
trigger
stabl
critic
ill
children
ffp
sinc
anecdot
note
mani
children
receiv
product
minim
elev
intern
normal
ratio
inr
valu
without
bleed
resultsfind
rbc
order
occur
top
three
patient
group
congenit
heart
diseas
patient
hematologyoncolog
patient
neonat
neonat
intens
care
unit
nicu
averag
hemoglobin
everi
patient
measur
hour
prior
rbc
order
placement
ffp
order
occur
top
three
patient
group
neonat
nicu
congenit
heart
diseas
patient
pediatr
intens
care
patient
averag
inr
everi
patient
measur
hour
prior
ffp
order
placement
conclus
design
robust
data
base
continu
updat
children
larg
tertiari
care
academ
children
hospit
serv
import
benchmark
pediatr
blood
util
plan
leverag
usag
pattern
make
relev
practic
chang
care
children
heterogen
set
ill
lacroix
j
hubert
pc
hutchison
js
etal
transfus
strategi
patient
pediatr
intens
care
unit
nejm
backgroundcas
studi
bacteri
contamin
plt
remain
ongo
threat
transfus
recipi
recent
pr
technolog
reduc
replic
potenti
pathogen
store
plt
fda
approv
describ
approach
phase
inventori
includ
preliminari
result
ongo
qa
studi
neonat
pediatr
ped
recipi
studi
designmethod
arriv
undertook
educ
campaign
hospit
administr
staff
laboratori
staff
clericalclin
aid
nurs
physician
also
contact
risk
manag
hospit
ethic
committe
phototherapi
devic
use
hospit
confirm
compat
product
shortli
follow
arriv
introduc
day
bacteri
safeti
measur
test
convent
suppli
ped
qa
studi
monitor
plt
util
advers
transfus
event
report
relat
transfus
studi
evalu
neonat
month
age
infant
month
age
children
year
age
receiv
least
one
transfus
resultsfind
risk
manag
ethic
committe
agre
bacteria
test
would
hospit
standard
care
phase
transfus
patient
base
abo
compat
expir
date
per
routin
without
regard
patient
age
medic
condit
month
repres
platelet
inventori
averag
daili
plt
inventori
unit
encount
complic
pr
platelet
either
clinic
informat
logist
perspect
due
dual
inventori
mani
ped
patient
age
group
transfus
tabl
two
potenti
transfus
reaction
tr
report
studi
period
teenag
recipi
one
associ
case
symptom
ultim
attribut
underli
medic
condit
rash
observ
among
transfus
neonat
receiv
phototherapi
conclus
adequ
coordin
integr
larg
blood
bank
without
clinic
administr
complic
unexpect
advers
event
rash
tr
attribut
detect
neonatalpediatr
popul
studi
tabl
backgroundcas
studi
hyperkalemia
known
complic
red
blood
cell
rbc
transfus
result
arrhythmia
cardiac
arrest
episod
common
rapid
transfus
rbc
neonat
infant
small
circul
plasma
volum
unabl
accommod
rapid
potassium
bolu
method
decreas
magnitud
hyperkalemia
instanc
includ
use
fresh
rbc
avoid
manipul
rbc
ie
product
slow
rate
transfus
invas
procedur
trauma
larg
volum
hemorrhag
slow
rate
transfus
may
feasibl
although
massiv
transfus
adult
often
accomplish
use
rapid
transfus
system
pediatr
patient
rapid
transfus
gener
achiev
use
syring
push
blood
product
increas
pressur
due
forc
deliveri
blood
via
small
calib
cathet
may
result
erythrocyt
damag
potassium
leak
higher
deliv
potassium
concentr
studi
designmethod
assess
chang
potassium
concentr
deliveri
rbc
iv
cathet
high
pressur
potassium
concentr
measur
plasma
old
adsol
rbc
unit
infus
via
belmont
rapid
infus
system
belmont
instrument
co
flow
rate
set
manufactur
stipul
maxim
rate
specif
cathet
pressur
approxim
mmhg
flow
blood
inject
gaug
g
peripher
intraven
cathet
french
fr
central
venou
cathet
inject
blood
collect
immedi
separ
via
centrifug
potassium
concentr
supernat
determin
dimens
rxl
integr
chemistri
system
siemen
use
indirect
electrod
resultsfind
consist
previou
studi
baselin
supernat
potassium
concentr
old
adsol
rbc
unit
elev
meql
howev
despit
achiev
pressur
hg
inject
statist
signific
differ
potassium
concentr
observ
among
cathet
flow
rate
anova
potassium
valu
remain
meql
condit
assay
conclus
high
rate
administr
rbc
via
small
calib
intraven
cathet
use
rapid
infus
system
result
appreci
increas
potassium
concentr
suggest
minim
increas
hyperkalemia
risk
pressur
relat
erythrocyt
damag
rapid
infus
high
potassium
concentr
note
old
rbc
unit
suggest
fresh
rbc
unit
use
rapid
transfus
infant
neonat
reduc
hyperkalem
risk
backgroundcas
studi
autoimmun
hemolyt
anemia
aiha
occur
solid
organ
transplant
common
entiti
howev
case
report
patient
calcineurin
inhibitor
calcineurin
cell
suppress
dysregul
b
cell
prolifer
implic
pathogenesi
hemolyt
anemia
sever
treatment
modal
avail
counter
hemolysi
limit
inform
avail
regard
transfus
guidanc
outcom
patient
immunohematolog
workup
case
complex
transfus
support
may
requir
incompat
rbc
studi
designmethod
two
pediatr
case
calcineurin
inhibitor
relat
hemolyt
anemia
follow
liver
transplant
duke
univers
medic
center
investig
resultsfind
patient
present
aiha
hgb
pure
red
cell
aplasia
thrombocytopenia
approxim
year
liver
transplant
antibodi
screen
identifi
high
titer
alloantibodi
react
room
temperatur
globulin
ahg
phase
patient
present
hemolyt
anemia
hgb
approxim
month
liver
transplant
direct
antiglobulin
test
posit
eluat
show
react
cell
test
ahg
patient
treat
intraven
immunoglobulin
ivig
rituximab
steroid
tacrolimu
discontinu
multipl
blood
transfus
requir
phenotyp
match
pack
rbc
prbc
least
incompat
transfus
patient
respond
appropri
transfus
precaut
minim
risk
transfus
reaction
includ
divis
prbc
product
aliquot
infus
slow
rate
febril
reaction
fnhtr
report
tabl
summar
salient
featur
case
tabl
conclus
cessat
implic
calcineurin
inhibitor
crucial
manag
relat
autoimmun
hemolyt
anemia
mani
requir
extend
transfus
support
serolog
compat
blood
transfus
may
possibl
use
phenotyp
match
rbc
divis
prbc
product
aliquot
slow
rate
infus
associ
seriou
reaction
transfus
report
case
backgroundcas
studi
pack
red
blood
cell
prbc
transfus
believ
improv
oxygen
deliveri
particularli
vulner
patient
neonat
children
howev
evid
show
hemoglobin
hgb
prbc
increas
oxygen
affin
thu
reduc
oxygen
deliveri
tissu
due
decreas
dpg
level
standard
prbc
transfus
practic
popul
scientif
evid
current
practic
base
limit
addit
due
small
transfus
volum
infant
may
expos
multipl
blood
donor
increas
potenti
advers
event
studi
designmethod
medic
record
pediatr
patient
receiv
prbc
transfus
month
period
retrospect
review
total
patient
identifi
receiv
allogen
prbc
transfus
patient
receiv
autolog
blood
cell
salvag
exclud
patient
characterist
length
stay
prbc
transfus
volum
hgb
advers
event
collect
resultsfind
averag
hgb
hgb
rise
mean
prbc
volum
transfus
use
dose
patient
complic
note
volum
overload
thrombosi
feverinfect
hemolysi
necrot
enterocol
nec
death
tabl
conclus
evid
base
transfus
guidelin
lack
neonat
infant
typic
dose
patient
instanc
would
translat
full
prbc
unit
averag
size
adult
current
standard
dose
yield
high
increas
hgb
may
put
patient
risk
advers
outcom
especi
thrombosi
due
increas
blood
viscos
addit
mani
patient
receiv
volum
reduc
product
deliv
higher
hgb
concentr
per
transfus
dose
base
goal
hgb
patient
condit
rather
weight
base
though
hematocrit
level
benefit
outweigh
risk
remain
unclear
tabl
backgroundcas
studi
mycoplasma
pneumonia
associ
igm
cold
agglutinin
diseas
cad
children
young
adult
pneumonia
rare
associ
warm
autoimmun
hemolyt
anemia
case
report
suggest
associ
howev
case
confound
find
addit
mycoplasma
infect
describ
uniqu
case
pediatr
patient
clear
evid
sever
hemolysi
strongli
reactiv
warm
autoantibodi
clinic
laboratori
evid
mycoplasma
infect
without
detect
cold
agglutinin
studi
designmethod
patient
previous
healthi
femal
infant
present
hospit
histori
fever
fatigu
decreas
appetit
pallor
treat
acetaminophen
also
develop
clear
rhinorrhea
day
hospit
admiss
time
admiss
laboratori
test
outsid
hospit
reveal
hemoglobin
hematocrit
respect
platelet
reticulocyt
count
element
complet
blood
count
within
normal
refer
rang
age
complet
metabol
panel
reveal
abnorm
except
total
bilirubin
direct
fraction
filmarray
respiratori
panel
biofir
diagnost
salt
lake
citi
ut
detect
mycoplasma
pneumonia
pathogen
total
patient
start
cours
azithromycin
zithromax
resultsfind
prior
rbc
transfus
blood
bank
evalu
reveal
patient
antibodi
screen
test
demonstr
antibodi
reactiv
reagent
red
blood
cell
dat
strongli
reactiv
igg
weakli
reactiv
eluat
reactiv
reagent
red
cell
test
final
cold
agglutinin
studi
neg
undilut
serum
addit
start
azithromycin
patient
given
iv
methylprednisolon
hospit
cours
patient
receiv
rbc
transfus
day
admiss
sever
rbc
transfus
thereaft
see
tabl
despit
transfus
hemolyt
process
persist
infus
dose
iv
immunoglobulin
hospit
day
hemoglobin
rose
hospit
day
increas
hospit
day
time
patient
discharg
hospit
instruct
wean
oral
steroid
dose
next
week
follow
close
hematolog
clinic
found
stabl
hemoglobin
day
hospit
admiss
recurr
hemolyt
process
conclus
pneumonia
infect
typic
caus
cad
rare
associ
warm
autoimmun
hemolyt
anemia
case
demonstr
clear
evid
sever
warm
autoimmun
hemolysi
previous
healthi
infant
increas
use
multiplex
respiratori
viral
bacteri
pathogen
detect
system
rare
phenomenon
pneumonia
infect
associ
warm
autoimmun
hemolyt
anemia
may
becom
recogn
entiti
tabl
laboratori
valu
therapeut
intervent
backgroundcas
studi
bed
suburban
hospit
level
nicu
perform
cord
blood
test
rh
neg
mother
posit
mother
mother
previous
identifi
clinic
signific
transfus
servic
ts
staff
decid
investig
whether
cord
blood
direct
antiglobulin
test
dat
result
correl
hyperbilirubinemia
diagnosi
neonat
studi
designmethod
neonat
posit
dat
period
track
initi
newborn
admiss
diagnosi
code
hyperbilirubinemia
princip
secondari
diagnosi
mother
blood
type
presenc
clinic
signific
antibodi
also
track
resultsfind
data
dat
test
neonat
group
mother
hyperbilirubinemia
diagnosi
list
tabl
neonat
born
posit
mother
clinic
signific
diagnosi
hyperbilirubinemia
made
elimin
cord
blood
test
neonat
born
posit
mother
would
result
save
approxim
per
year
addit
strength
dat
posit
correl
percentag
neonat
diagnos
hyperbilirubinemia
hyper
conclus
hospit
elimin
cord
blood
test
neonat
born
posit
mother
clinic
signific
cord
blood
dat
consist
correl
diagnosi
hyperbilirubinemia
addit
test
depart
hematolog
chemistri
need
support
diagnosi
evalu
point
care
test
measur
total
bilirubin
directli
neonat
avail
transcutan
bilirubinomet
may
serv
reliabl
reflect
neonat
risk
hyperbilirubinemia
difficulti
elimin
cord
blood
test
neonatologist
relianc
use
abo
incompat
part
neonat
risk
assess
rather
use
point
care
bilirubin
test
current
ts
requir
posit
dat
test
commun
nurs
staff
immedi
given
dat
strength
posit
correl
percentag
neonat
diagnos
hyperbilirubinemia
ts
staff
may
also
consid
notifi
nurs
staff
patient
whose
dat
backgroundcas
studi
hematopoiet
stem
cell
transplant
hsct
match
unrel
donor
increasingli
use
world
common
protocol
hsct
unrel
donor
prefer
includ
patient
donor
match
possibl
allel
hla
loci
current
commonli
taken
consider
donor
select
impact
mismatch
unrel
hematopoiet
stem
cell
transplant
hsct
remain
controversi
studi
designmethod
individu
pair
unrel
underw
unrel
allogen
hsct
hla
allel
match
donor
sep
apr
zhejiang
provinc
includ
retrospect
analysi
genotyp
sampl
perform
method
accord
previou
report
resultsfind
among
individu
pair
unrel
differ
allotyp
detect
frequenc
allel
frequenc
gene
frequenc
distribut
donor
recipi
list
tabl
pair
pair
complet
match
pair
partial
match
pair
complet
mismatch
match
rate
studi
conclus
match
rate
hla
match
unrel
hematopoiet
stem
cell
transplant
low
gene
frequenc
unrel
hematopoiet
stem
cell
transplant
obtain
help
studi
relationship
unrel
hematopoiet
stem
cell
transplant
work
sponsor
nation
scienc
foundat
china
zhejiang
provinci
program
cultiv
innov
health
talent
scienc
research
foundat
zhejiang
provinc
tabl
distribut
allel
unrel
zhejiang
provinc
backgroundcas
studi
thrombot
thrombocytopen
purpura
ttp
caus
sever
reduc
activ
von
willebrand
proteas
therapeut
plasma
exchang
tpe
well
immunosuppress
minim
morbid
potenti
mortal
present
absolut
immatur
platelet
count
shown
help
diagnos
follow
ttp
patient
respons
therapi
report
case
man
relaps
ttp
low
high
inhibitor
treat
mycophenol
mofetil
unexpect
respons
therapi
studi
designmethod
year
old
male
histori
ttp
present
statu
epilepticu
complic
acut
respiratori
failur
admit
suspicion
relaps
ttp
patient
treat
prior
admiss
tpe
prednisolon
rituximab
cyclophosphamid
clinic
improv
mycophenol
mofetil
mainten
therapi
last
receiv
prior
day
admiss
due
consist
low
platelet
count
inhibitor
day
admiss
platelet
count
x
decreas
within
five
day
x
lead
initi
daili
tpe
along
mycophenol
mofetil
discontinu
prior
tpe
start
immatur
platelet
fraction
calcul
x
platelet
count
obtain
daili
cbc
ratio
calcul
baselin
resultsfind
platelet
count
x
x
respect
count
improv
rapidli
initi
one
tpe
tripl
x
achiev
ratio
previous
shown
diagnost
ttp
day
platelet
count
improv
x
x
respect
absenc
antibodi
rule
thrombocytopenia
time
day
unexpect
decreas
platelet
count
x
x
respect
worsen
day
x
x
respect
despit
daili
tpe
patient
receiv
addit
tpe
fail
improv
platelet
day
x
x
respect
remain
level
day
suggest
observ
decreas
irrevers
activ
remain
low
high
inhibitor
patient
clinic
condit
continu
deterior
famili
place
patient
comfort
care
conclus
ttp
patient
low
plt
count
present
former
improv
first
initi
despit
appropri
therapi
lead
earli
improv
platelet
count
patient
count
declin
rapidli
lead
suspicion
platelet
product
suppress
indic
sustain
low
set
ttp
relaps
ttp
use
immunosuppress
close
follow
may
aid
establish
earli
therapi
affect
platelet
product
backgroundcas
studi
detect
antibodi
human
platelet
antigen
hpa
crucial
patient
refractori
platelet
transfus
therapi
text
luminex
bead
coupl
monoclon
antibodi
impli
detect
antibodi
sensit
luminex
bead
technolog
compar
monoclon
antibodi
immobil
platelet
antigen
maipa
assay
studi
designmethod
monoclon
antibodi
specif
platelet
glycoprotein
gpiibiiia
gpiaiia
separ
coupl
luminex
xmap
bead
four
standard
sera
contain
respect
bought
nibsc
three
neg
sera
without
hpa
antibodi
prepar
ab
type
blood
donor
platelet
contain
collect
react
standard
sera
respect
reaction
complex
lyse
lysat
incub
luminex
bead
specif
captur
complex
via
epitop
platelet
glycoprotein
complex
subject
flow
cytometr
analysi
serum
dilut
serial
dilut
neat
test
sensit
maipa
luminex
bead
assay
two
method
use
test
five
blind
sampl
collect
fmait
patient
resultsfind
luminex
bead
technolog
show
mfi
valu
standard
sera
sampl
react
coupl
bead
significantli
higher
neg
control
vs
vs
vs
valu
vs
vs
vs
impli
luminex
bead
technolog
could
specif
identifi
neg
posit
sera
furthermor
platelet
serum
react
coupl
bead
mfi
compar
neg
control
vs
sera
maipa
result
compar
luminex
bead
technolog
illustr
detect
hpa
antibodi
luminex
bead
technolog
success
sensit
luminex
bead
assay
maipa
detect
respect
observ
sampl
contain
hla
abo
platelet
antibodi
result
five
blind
sampl
test
luminex
assay
show
four
sera
posit
gpiibiiia
antibodi
consist
maipa
result
conclus
luminex
bead
coupl
gpiibiiia
gpiaiia
monoclon
antibodi
could
success
use
detect
antibodi
via
epitop
platelet
glycoprotein
sensit
luminex
technolog
higher
maipa
technolog
work
sponsor
nation
natur
scienc
foundat
china
scienc
research
foundat
zhejiang
healthi
bureau
use
test
five
blind
sampl
collect
fmait
patient
backgroundcas
studi
atyp
hemolyt
urem
syndrom
ahu
thrombot
microangiopathi
tma
character
triad
microangiopath
hemolyt
anemia
thrombocytopenia
renal
failur
absenc
infecti
toxin
literatur
suggest
presenc
pathogen
mutat
complement
protein
case
ahu
lack
recommend
regard
test
genet
ahu
complement
pathway
mutat
analysi
expens
test
appropri
util
crucial
prevent
undu
health
care
cost
review
indic
genet
test
understand
physician
order
practic
determin
frequenc
pathogen
mutat
popul
studi
designmethod
perform
retrospect
review
case
refer
complement
pathway
mutat
analysi
nation
refer
laboratori
januari
decemb
clinic
histori
solicit
genet
counselor
case
classifi
author
primari
ahu
tma
renal
failur
without
identifi
caus
secondari
tma
tma
renal
failur
identifi
caus
previous
associ
tma
test
panel
identifi
variant
complement
protein
cfh
cfi
mcp
factor
b
thbd
dgke
classifi
vu
varianc
uncertain
signific
pathogen
benign
american
colleg
medic
genet
chi
squar
analysisfish
exact
test
use
determin
differ
proport
patient
pathogen
mutat
primari
ahu
versu
secondari
tma
independ
sampl
use
compar
differ
continu
variabl
primari
ahu
secondari
tma
resultsfind
patient
test
pathogen
mutat
detect
vu
patient
fulfil
criteria
tma
pathogen
mutat
found
group
vu
patient
primari
ahu
pathogen
mutat
vu
patient
secondari
tma
pathogen
mutat
vu
patient
pathogen
mutat
children
posit
famili
histori
ahu
recurr
diseas
patient
primari
ahu
significantli
lower
age
present
vs
yr
higher
proport
pathogen
mutat
vs
compar
patient
secondari
tma
gender
distribut
hemoglobin
nadir
serum
creatinin
level
similar
two
group
conclus
found
lower
frequenc
patient
pathogen
mutat
compar
report
literatur
data
suggest
patient
secondari
tma
care
evalu
prior
order
genet
test
without
tma
undergo
test
backgroundcas
studi
hematolog
analyz
made
count
whole
blood
sampl
often
use
qualiti
control
blood
compon
platelet
plt
concentr
pc
flow
cytometr
method
count
plt
pc
develop
valid
tool
van
der
meer
etal
transfus
therefor
pertin
evalu
plt
count
bc
hematolog
analyz
valid
method
flow
cytomet
studi
designmethod
sampl
ten
apheresi
pc
buffi
pc
subject
plt
count
hematolog
analyz
horiba
abx
montpeli
franc
sysmex
toa
kobe
japan
imped
score
addit
dilut
stain
fitc
truecount
tube
bd
bioscienc
intern
bead
standard
measur
gallio
flow
cytomet
beckman
coulter
indianapoli
usa
result
analyz
pair
sampl
test
shown
plot
resultsfind
mean
plt
valu
sd
count
sysmex
toa
gallio
flow
cytomet
respect
sysmex
count
lowest
less
flow
cytometri
plt
count
significantli
differ
p
although
least
pentra
flow
cytometri
conclus
valid
flow
cytometr
method
seem
suitabl
routin
qualiti
control
pc
small
differ
lower
count
compar
flow
cytometr
method
cumbersom
routin
set
much
lower
plt
count
sysmex
may
reflect
optim
plt
count
whole
blood
rather
pc
backgroundcas
studi
interact
glycoprotein
extracellular
matrix
play
signific
role
hemostasi
human
platelet
antigen
hpa
found
within
glycoprotein
stimul
product
antibodi
recipi
transfus
platelet
fetu
mother
incompat
hpa
thu
platelet
incompat
associ
variou
form
thrombocytopenia
purpura
blood
disord
new
zealand
blood
servic
perform
hpa
type
pool
platelet
donor
provid
compat
transfus
need
aris
molecular
basi
hpa
character
gener
caus
polymorph
snp
hpa
type
typic
perform
use
method
util
post
pcr
analysi
step
aim
studi
evalu
use
techniqu
transfus
laboratori
set
studi
designmethod
evalu
commerci
avail
solut
consist
reaction
identifi
variant
relev
snp
locat
within
hpa
gene
hpa
genom
dna
purifi
blood
sampl
previous
genotyp
hous
method
use
studi
valid
sampl
resultsfind
result
valid
sampl
concord
type
obtain
pcr
approach
overcom
major
challeng
hpa
molecular
type
provid
autom
solut
result
increas
laboratori
product
decreas
time
analysi
facilit
softwar
gener
result
less
minut
oper
intervent
reagent
complet
molecular
genotyp
result
provid
approxim
minut
sinc
amplifi
product
never
handl
risk
laboratori
contamin
significantli
reduc
pcr
approach
autom
analysi
implement
new
zealand
blood
servic
tissu
type
laboratori
late
date
test
dna
sampl
blood
donor
donor
test
duplic
concord
sampl
replic
occas
assay
repeat
give
repeat
rate
occasion
reaction
peak
insuffici
trigger
softwar
automat
allel
call
manual
interpret
requir
occur
commonli
assay
conclus
pcr
autom
analysi
provid
effect
robust
accur
method
molecular
hpa
genotyp
minim
time
workflow
also
easi
implement
offer
cost
effect
altern
classic
method
use
transfus
laboratori
set
backgroundcas
studi
implic
platelet
refractori
neonat
alloimmun
thrombocytopenia
posttransfus
purpura
especi
defici
vari
wide
among
differ
ethnic
popul
frequenc
asian
african
american
respect
howev
littl
inform
molecular
basi
individu
defici
jiangsu
chines
han
popul
studi
designmethod
investig
platelet
express
level
determin
molecular
basi
defici
platelet
surfac
han
popul
jiangsu
region
express
level
platelet
detect
flow
cytometri
among
blood
donor
jiangsu
region
donor
without
antigen
express
platelet
surfac
determin
express
antigen
peripher
blood
monocyt
cell
code
exon
gene
adjac
intron
amplifi
sequenc
defici
individu
resultsfind
among
blood
donor
individu
respect
frequenc
type
type
ii
defici
among
studi
popul
respect
among
individu
platelet
express
accord
mean
fluoresc
intens
mfi
valu
individu
show
low
moder
high
express
level
respect
mfi
p
respect
type
defici
individu
heterozyg
g
g
respect
among
type
ii
defici
individu
two
harbor
insert
posit
exon
caus
frameshift
codon
one
c
exchang
posit
exon
result
tryptophan
arginin
substitut
codon
one
insert
bp
start
codon
atg
promot
region
one
heterozyg
c
g
respect
conclus
platelet
surfac
express
level
diversifi
jiangsu
chines
han
popul
frequenc
type
ii
defici
higher
type
studi
find
indic
frequenc
defici
chines
popul
slightli
lower
asian
countri
backgroundcas
studi
phenotyp
immun
pregnanc
transfus
involv
neonat
alloimmun
thrombocytopenia
platelet
transfus
refractori
disord
frequenc
platelet
individu
wide
vari
among
ethnic
group
japanes
african
african
american
caucasian
although
studi
defici
focus
asian
popul
rel
littl
inform
report
chines
popul
investig
express
platelet
larg
sampl
eastern
chines
donor
studi
designmethod
peripher
blood
sampl
collect
unrel
donor
eastern
china
express
antigen
platelet
determin
flow
cytometri
use
fluorescein
conjug
monoclon
antibodi
isotyp
control
igg
also
analyz
calcul
refer
rang
phenotyp
donor
platelet
antigen
express
monocyt
analyz
distinguish
type
type
ii
defici
flow
cytometr
paramet
statist
analyz
test
work
support
nation
natur
scienc
foundat
china
zhejiang
innov
health
talent
resultsfind
mfi
mean
fluoresc
intens
platelet
sampl
show
continu
distribut
profil
obviou
could
util
distinguish
neg
posit
phenotyp
account
limit
classifi
phenotyp
use
mean
background
mfi
observ
isotyp
control
sampl
detect
defici
platelet
one
sampl
neg
platelet
monocyt
frequenc
type
type
ii
defici
eastern
chines
donor
respect
averag
mfi
defici
sampl
significantli
lower
posit
sampl
vs
p
conclus
frequenc
platelet
defici
eastern
chines
donor
close
japanes
african
american
mean
possibl
antibodi
occur
pregnanc
transfus
popul
exist
use
find
regist
donor
screen
potenti
immun
thrombocytopenia
patient
antibodi
backgroundcas
studi
gpiv
chromosom
kda
glycoprotein
express
multipl
cell
type
includ
platelet
plt
monocyt
mono
erythroblast
although
rare
among
white
defici
observ
african
classifi
either
type
plt
mono
type
ii
plt
mono
acquir
type
ii
phenotyp
also
observ
set
myelodysplast
syndrom
md
type
individu
develop
alloantibodi
plt
refractori
neonat
alloimmun
thrombocytopenia
report
case
profound
plt
refractori
caus
patient
newli
diagnos
md
studi
designmethod
hla
antibodi
test
perform
commerci
fluoresc
assay
phenotyp
plt
mono
patient
famili
member
perform
flow
cytometri
fc
stain
bone
marrow
perform
immunohistochemistri
plt
crossmatch
perform
american
red
cross
alloantibodi
test
dna
sequenc
perform
commerci
refer
laboratori
resultsfind
patient
group
male
present
blurri
vision
lightheaded
complet
blood
count
find
signific
hemoglobin
plt
count
bone
marrow
biopsi
cytogenet
analysi
reveal
multilineag
dysplasia
blast
complex
karyotyp
del
consist
md
plt
refractori
initi
repeat
plt
transfus
failur
correct
count
increment
cci
hla
antibodi
test
neg
class
panel
reactiv
antibodi
pra
patient
donor
trial
group
plt
unsuccess
cci
subsequ
test
alloantibodi
identifi
show
patient
mono
plt
consist
type
preliminari
dna
result
show
patient
heterozyg
apheresi
plt
unavail
blood
supplier
patient
children
grandson
screen
possibl
donor
show
normal
express
plt
trial
eltrombopag
romiplostim
attempt
improv
plt
count
repeat
hla
antibodi
test
day
demonstr
new
class
alloantibodi
pra
respons
transfus
apheresi
plt
rbc
given
plt
refractori
poor
prognosi
patient
opt
hospic
conclus
describ
patient
sever
plt
refractori
set
new
md
chromosom
abnorm
absenc
plt
mono
support
congenit
type
although
contribut
patient
underli
md
exclud
backgroundcas
studi
prophylact
platelet
transfus
standard
care
manag
thrombocytopenia
emerg
paradigm
person
medicin
select
cellular
product
accord
patient
immunomolecular
signatur
potenti
reduc
rate
platelet
clearanc
thu
improv
treatment
efficaci
benefit
custom
transfus
therapi
long
recogn
http
routin
select
platelet
immunogenet
profil
remain
impract
current
method
dna
analysi
address
issu
evalu
process
platelet
donor
classif
use
buccal
swab
sampl
apheresi
platelet
donor
determin
combin
hla
class
hpa
signatur
without
dna
purif
use
novel
leansequenc
process
studi
designmethod
studi
protocol
inform
consent
evalu
process
collect
classifi
buccal
swab
sampl
adult
donor
made
donat
previou
month
sampl
label
studi
barcod
ship
weekli
biomolecular
analyt
bmx
prepar
crude
extract
leansequenc
novel
process
combin
proprietari
sampl
pool
strategi
protocol
elimin
mani
tradit
sampl
step
briefli
prepar
crude
extract
sampl
amplifi
pool
analyz
separ
run
hla
class
b
c
latter
use
proprietari
design
limit
analysi
inform
allel
hla
sequenc
design
permit
direct
allel
haplotyp
reconstruct
use
softwar
subset
crude
extract
purifi
analyz
side
side
posit
neg
control
resultsfind
crude
extract
buccal
swab
produc
viabl
profil
hpa
well
hla
class
signific
save
illustr
tabl
report
allel
frequenc
hpa
consist
predominantli
caucasian
hispan
platelet
donor
popul
http
hw
equilibrium
similarli
haplotyp
frequenc
determin
conclus
leansequenc
lend
rapid
determin
hpa
signatur
platelet
process
streamlin
lean
protocol
achiev
addit
time
cost
save
accommod
crude
extract
produc
buccal
swab
sampl
collect
handl
accord
process
valid
project
process
could
readili
implement
anoth
site
use
element
process
develop
pool
plex
process
earli
donor
recruit
enabl
economi
scale
match
donor
procur
backgroundcas
studi
hla
allel
document
accord
imgt
hla
sequenc
databas
identifi
last
year
besid
sequenc
mani
novel
hla
allel
analyz
serolog
reactiv
allel
fist
detect
laboratori
hla
type
china
bone
marrow
donor
program
cmdp
studi
serolog
characterist
heritag
investig
perform
studi
designmethod
routin
hla
tie
potenti
donor
cmdp
perform
type
method
use
commerci
kit
rose
europ
gmbh
frankfurt
germani
case
full
match
hla
type
result
group
specif
sbt
type
kit
texa
biogen
inc
taipei
taiwan
employ
identifi
nucleotid
sequenc
novel
allel
fresh
blood
sampl
collect
proband
famili
member
consent
order
nanalysi
serolog
reactiv
possibl
haplotyp
associ
novel
allel
hla
serolog
specif
indic
one
lambda
hla
kit
resultsfind
full
match
result
obtain
locu
hla
type
donor
suggest
possibl
exist
novel
allel
latter
nanalysi
indic
proband
nucleotid
sequenc
locu
new
sequenc
close
nucleotid
substitut
exon
nt
result
one
aminoacid
substitut
asn
novel
allel
offici
name
nomenclatur
committe
factor
hla
system
novemb
hla
type
result
propand
daughter
assign
b
b
respect
haplotyp
associ
could
b
serolog
reactiv
pattern
novel
allel
show
characterist
conclus
novel
allel
identifi
associ
haplotyp
b
serolog
specif
backgroundcas
studi
multipl
transfus
platelet
concentr
pc
hematolog
patient
risk
factor
alloimmun
refractori
pc
transfus
caus
allosensit
recipi
donor
blood
cell
hlahpa
immun
patient
advis
conduct
pc
transfus
individu
select
use
test
case
multipl
alloimmun
individu
select
may
difficult
imposs
method
choic
appli
plasmapheresi
procedur
pp
elimin
circul
alloantibodi
circul
immun
complex
studi
assess
efficaci
pp
combin
transfus
individu
select
pc
patient
refractori
platelet
transfus
studi
designmethod
octob
till
januari
patient
refractori
pc
transfus
treat
center
clinic
among
patient
aplast
anemia
patient
acut
myeloid
leukemia
aml
patient
underw
pc
transfus
individu
select
consid
ineffici
individu
select
becam
necessari
patient
receiv
addit
pp
use
blood
separ
haemonet
patient
receiv
individu
select
pc
transfus
day
pp
efficaci
pp
individu
select
pc
transfus
assess
absolut
platelet
increment
api
correct
count
increment
cci
level
circul
alloantibodi
probabl
match
antibodi
activ
rel
unit
ru
assess
immucor
analyz
resultsfind
patient
receiv
pp
treatment
combin
individu
select
pc
transfus
show
increas
apicci
decreas
circul
alloantibodi
activ
aml
median
ru
median
ru
increas
probabl
match
former
transfus
without
addit
pp
treatment
one
patient
aa
ineffici
therapi
pp
treatment
plu
individu
cross
match
select
note
case
probabl
autoimmun
cytolysi
platelet
well
increas
intak
syndrom
rule
due
sever
infect
conclus
case
ineffici
individu
pc
select
patient
refractori
platelet
transfus
pp
significantli
improv
transfus
efficaci
perform
pp
combin
individu
select
pc
transfus
decreas
circul
alloantibodi
activ
increas
probabl
match
increas
api
cci
significantli
improv
clinic
efficaci
immunolog
safeti
pc
transfus
backgroundcas
studi
frequent
caus
hemolyt
diseas
fetu
newborn
hdfn
rule
immun
occur
neg
pregnant
women
occasion
also
observ
carrier
variant
current
matern
plasma
analysi
determin
fetal
rhd
statu
becam
excit
new
tool
manag
pregnant
women
one
challeng
non
invas
fetal
rhdgenotyp
presenc
variant
pregnant
women
present
case
pregnant
woman
type
ab
deliv
babi
affect
sever
hdfn
newborn
type
b
present
posit
direct
antiglobulin
test
dat
identifi
eluat
babi
treat
exchang
transfus
mother
sampl
investig
studi
designmethod
serolog
test
done
hemagglutin
gel
card
genom
dna
extract
whole
blood
spin
column
rhd
exon
sequenc
sanger
sequenc
method
resultsfind
mother
rbc
react
four
monoclon
use
igm
clone
rum
blend
clone
type
identifi
serum
molecular
analysi
show
c
exon
snp
c
chang
exon
g
nucleotid
chang
exon
set
snp
found
similar
molecular
background
except
c
chang
conclus
novel
set
snp
found
mother
relat
novel
rhd
allel
lead
partial
antigen
involv
product
caus
sever
hdfn
find
show
need
elucid
clinic
signific
differ
rhd
genotyp
variou
ethnic
background
backgroundcas
studi
autom
test
studi
designmethod
eflexi
bloodtyp
instrument
evalu
resultsfind
result
match
requir
conclus
new
erytra
analyz
evalu
routin
use
french
medic
analysi
laboratori
togeth
dg
system
jl
souchet
pichard
j
bendahan
laboratoir
danalys
xlab
cholet
franc
background
erytra
grifol
new
fulli
autom
analyz
perform
immunohematolog
test
use
dg
aim
studi
perform
usabl
adapt
differ
workflow
laboratori
routin
erytra
evalu
laboratoir
danalys
xlab
cholet
french
medic
analysi
laboratori
method
comparison
throughput
studi
erytra
routin
refer
platform
perform
total
immuno
hematolog
test
abod
group
includ
newborn
sampl
extend
erythrocyt
phenotyp
antibodi
screen
antibodi
identif
dat
crossmatch
perform
patient
whole
blood
sampl
erytra
perform
evalu
accord
protocol
design
simul
routin
workload
use
system
two
differ
configur
concord
system
assess
discrep
analyz
follow
perform
metric
assess
time
first
result
ttfr
time
tat
total
workload
first
result
last
result
throughput
resultsh
manual
time
requir
well
time
consid
two
differ
configur
system
eas
use
evalu
differ
usabl
featur
rank
number
step
time
follow
activ
track
sampl
sort
load
routin
test
procedur
consum
use
space
requir
threshold
vitrodetect
gamma
globulin
also
determin
result
concord
result
erytra
analyz
refer
method
obtain
abod
test
antibodi
screen
test
antibodi
identif
test
dat
test
discrep
abod
patient
antibodi
screen
antibodi
identif
case
erytra
conclud
wherea
erytra
could
due
poor
reaction
use
stat
mode
incub
reserv
urgent
test
prove
use
test
sever
sampl
time
save
min
detect
threshold
antibodi
assess
ngml
uiml
wherea
french
recommend
ngml
possibl
interchang
tray
reagentssampl
make
also
possibl
optim
analyz
oper
impress
technic
staff
posit
regard
esthet
function
design
intuit
easi
use
well
flexibl
summari
conclus
erytra
result
demonstr
veloc
sensit
well
abil
easili
perform
routin
workload
medic
analysi
laboratori
erytra
requir
french
regulatori
immunohematolog
iso
accredit
backgroundcas
studi
kell
system
antibodi
inhibit
erythropoiesi
caus
sever
anemia
hemolyt
diseas
fetu
newborn
hdfn
report
case
hdfn
secondari
result
multipl
intrauterin
transfus
kp
donor
cell
hemolyt
anemia
upon
birth
case
year
old
present
fifth
pregnanc
initi
titer
measur
histori
develop
third
pregnanc
end
spontan
abort
antibodi
titer
could
initi
patient
antibodi
titer
peak
fourth
pregnanc
result
healthi
male
without
anemia
jaundic
latest
pregnanc
ultrasound
initi
elev
middl
cerebr
arteri
doppler
exam
mom
peak
week
result
three
intrauterin
transfus
due
potenti
labor
find
revers
diastol
flow
middl
cerebr
arteri
doppler
studi
find
associ
impend
intrauterin
fetal
demis
caesarean
deliveri
perform
week
gestat
babi
boy
requir
phototherapi
hyperbilirubinemia
indirect
bilirubin
birth
hemoglobin
babi
type
posit
kp
b
micro
posit
dat
antibodi
workup
reveal
continu
hemolysi
requir
one
transfus
week
age
posit
dat
passiv
acquir
longer
detect
week
age
hemoglobin
recov
indirect
bilirubin
week
age
clinic
sign
hemolyt
anemia
resolv
studi
designmethod
serolog
test
includ
peg
iat
tube
method
acid
elut
perform
use
immucor
gamma
ii
molecular
test
perform
use
immucor
hea
platform
resultsfind
antibodi
identif
mother
perform
well
alloadsorpt
studi
rule
underli
alloantibodi
new
weakli
react
detect
day
deliveri
babi
type
posit
howev
detect
eluat
prepar
babi
red
cell
intrauterin
transfus
unit
neg
conclus
knowledg
five
case
report
describ
result
moder
sever
hdfn
pregnant
mother
detect
monitor
close
backgroundcas
studi
clinic
case
dat
may
insensit
detect
low
signific
level
may
inconclus
due
spontan
red
cell
rbc
aggreg
dat
well
suit
quantifi
number
immunoprotein
molecul
rbc
sinc
reaction
correspond
moleculescel
number
flow
cytometr
method
detect
publish
howev
mainli
design
quantifi
fraction
rbc
aim
studi
present
flow
cytometr
method
quantif
level
studi
designmethod
ten
microlit
ul
document
experiment
amount
ensur
maximum
bind
mous
monoclon
abcam
clone
ad
ul
rbc
suspens
incub
minut
sampl
wash
ul
dilut
ab
dako
ad
incub
sampl
wash
resuspend
acquir
flow
cytomet
becton
dickinson
facscanto
ii
enabl
calibr
fluoresc
signal
antibodi
bind
capac
abc
calibr
standard
dako
qifikit
stain
run
parallel
experi
background
fluoresc
abc
subtract
yield
net
abc
valu
correspond
specif
stain
assay
parallel
routin
dat
gel
card
biorad
appli
seri
rbc
stain
level
dilut
serum
high
titer
estim
normal
rang
sampl
healthi
donor
test
final
assay
appli
sampl
patient
clinic
aiha
inconclus
dat
due
unspecif
dat
polyreact
resultsfind
correl
net
level
valu
rang
abc
level
dilut
use
sensit
rbc
prove
highli
linear
logarithm
vs
logarithm
plot
p
compar
sensit
flow
cytometr
assay
superior
detect
sensit
least
dilut
step
median
normal
level
abc
rang
abc
assay
enabl
demonstr
specif
patient
level
sampl
significantli
elev
abc
conclus
present
flow
cytometr
assay
capabl
quantifi
level
high
degre
linear
analyt
sensit
capabl
quantifi
level
dat
polyreact
sampl
backgroundcas
studi
abo
blood
group
system
red
blood
cell
rbc
consist
b
oligosaccharid
antigen
antibodi
antigen
present
sera
individu
express
antigen
landstein
law
express
antigen
epitheli
endotheli
cell
bodi
abo
match
critic
blood
transfus
also
celltissueorgan
transplant
spite
fact
antigen
antibodi
involv
genet
trait
specifi
singl
genet
locu
abo
forssman
for
system
anoth
rbc
blood
group
system
consist
glycosyl
polymorph
specifi
gene
human
abo
genet
loci
locat
chromosom
function
allel
encod
b
glycosyltransferas
bt
forssman
glycolipid
synthas
fs
catalyz
last
biosynthet
step
b
forssman
oligosaccharid
antigen
molecular
genet
base
allel
two
system
human
abo
gene
also
present
speci
addit
human
howev
presenceabs
molecular
mechanismsforc
creat
speci
diverg
includ
human
polymorph
unknown
studi
designmethod
util
genom
inform
avail
genbank
ensembl
databas
gene
map
chromosom
region
surround
abo
gene
construct
vertebr
speci
resultsfind
extens
similar
observ
kind
number
order
gene
well
chromosom
locat
howev
numer
differ
also
identifi
includ
chromosom
rearrang
well
insert
amplif
specif
gene
interestingli
abo
gene
found
locat
boundari
chromosom
fragment
seem
undergon
frequent
inversionstransloc
speci
evolut
conclus
genet
alter
delet
duplic
known
preval
end
rearrang
chromosom
fragment
therefor
diverg
polymorph
within
speci
clinic
import
glycosyltransferas
gene
may
result
least
partial
unstabl
chromosom
structur
neighbor
gene
backgroundcas
studi
red
blood
cell
transfus
play
import
role
treatment
patient
sickl
cell
diseas
sickl
cell
patient
significantli
increas
risk
alloimmun
compar
gener
popul
standard
care
provid
phenotyp
match
unit
least
c
e
antigen
reduc
risk
unfortun
genotyp
true
alloimmun
risk
may
alway
accur
repres
red
blood
cell
phenotyp
particularli
patient
complex
partial
rhce
variant
studi
designmethod
year
old
femal
histori
sickl
cell
diseas
stroke
iron
overload
present
routin
exchang
transfus
patient
blood
type
posit
red
cell
previous
phenotyp
c
e
antibodi
screen
posit
antibodi
c
e
antigen
identifi
plasma
patient
receiv
phenotyp
match
unit
neg
c
e
antigen
previou
transfus
institut
base
known
red
blood
cell
phenotyp
blood
sampl
sent
refer
laboratori
molecular
test
look
partial
rhce
variant
might
explain
antibodi
develop
resultsfind
molecular
test
perform
reveal
presenc
two
differ
partial
rhce
allel
result
predict
phenotyp
partial
c
partial
e
probabl
rhce
genotyp
rhce
cejalrhc
result
partial
express
c
e
antigen
addit
known
risk
alloimmun
absent
c
e
antigen
result
indic
patient
also
capabl
form
alloantibodi
absent
portion
c
e
antigen
base
result
patient
determin
alloantibodi
autoantibodi
conclus
although
phenotyp
match
unit
standard
care
patient
sickl
cell
diseas
red
blood
cell
phenotyp
may
accur
repres
alloimmun
risk
patient
complex
partial
rhce
genotyp
case
molecular
test
confirm
patient
risk
develop
alloantibodi
c
c
e
e
antigen
patient
alreadi
made
alloantibodi
c
e
antigen
determin
would
requir
unit
molecularli
match
rhce
variant
futur
transfus
case
demonstr
phenotyp
match
sickl
cell
diseas
patient
may
adequ
prevent
alloimmun
individu
partial
rhce
variant
backgroundcas
studi
rhd
weak
type
variant
commonli
found
caucasian
associ
weak
phenotyp
previous
report
vege
etal
transfus
c
chang
character
rhd
weak
type
allel
splice
variant
induc
skip
whole
rhd
exon
report
alter
splice
rhd
weak
type
allel
associ
skip
exon
pregnant
women
newborn
weak
express
studi
designmethod
antigen
express
evalu
commerci
avail
monoclon
reagent
blend
igmigg
clone
igm
clone
igg
tube
gel
card
c
c
e
e
phenotyp
perform
gel
rhd
genotyp
perform
rhd
beadchip
platform
immucor
direct
autom
sequenc
rhd
exon
flank
intron
region
perform
sanger
dideoxi
method
resultsfind
pregnant
women
newborn
sampl
phenotyp
sampl
show
weak
hemagglutin
reaction
clone
use
rhd
beadchip
result
show
ls
signal
indic
possibl
delet
exon
dna
sampl
sequenc
show
c
chang
intron
c
substitut
associ
rhd
weak
type
allel
conclus
result
show
c
associ
c
variat
probabl
function
impact
splice
induc
exclus
exon
dna
mother
newborn
find
import
develop
assay
interpret
genotyp
result
current
guidelin
recommend
igg
prophylaxi
women
weak
type
backgroundcas
studi
rbc
consid
devoid
hla
antigen
howev
donor
detect
class
antigen
rbc
flow
cytometri
especi
certain
hla
type
bga
bgb
bgc
rare
hla
antibodi
hlab
associ
shorten
rbc
surviv
hemolyt
transfus
reaction
htr
report
case
htr
attribut
hlab
transfus
txn
patient
studi
designmethod
abo
type
antibodi
screen
ab
identif
gel
method
dat
tube
method
rbc
acid
eluat
prepar
per
manufactur
instruct
test
rbc
tube
peg
hlab
test
perform
fluoresc
assay
rbc
sampl
group
renal
transplant
patient
obtain
hematolog
resultsfind
patient
woman
chronic
anemia
thrombocytopenia
rbc
alloimmun
e
cw
cryptogen
cirrhosi
diabet
chronic
kidney
diseas
occult
gi
bleed
treat
iv
iron
folat
darbopoietin
episod
rbc
txn
follow
increas
rbc
requir
reach
rbc
twice
weekli
routin
rbc
txn
develop
rigor
headach
fatigu
nausea
hypertens
laboratori
workup
show
cleric
error
type
ab
show
visual
hemolysi
check
weakli
posit
specimen
lab
drawn
hour
show
increas
hemoglobin
iul
dat
weakli
posit
polyspecif
igg
specimen
rbc
eluat
neg
donor
rbc
panel
cell
donor
rbc
xm
specimen
tube
gel
addit
plasma
test
show
weak
reactiv
hla
panel
cell
tube
peg
sensit
chloroquin
hlab
test
show
patient
highli
alloimmun
hlab
class
class
ii
antigen
addit
weak
class
hlab
mfi
class
ii
hlab
identifi
rbc
eluat
includ
hlab
patient
plasma
weakli
reactiv
donor
rbc
rbc
group
renal
patient
posit
least
antigen
crossreact
subsequ
rbc
transfus
gel
attempt
obtain
rbc
unsuccess
patient
place
amicar
weekli
ivig
slight
improv
rbc
surviv
haptoglobin
due
ongo
medic
issu
patient
transit
hospic
care
conclus
present
anoth
case
htr
poor
rbc
surviv
like
due
high
titer
hlab
backgroundcas
studi
sickl
cell
diseas
scd
patient
requir
red
blood
cell
rbc
transfus
minim
symptomatolog
previou
studi
shown
children
scd
receiv
least
one
rbc
transfus
lifetim
simpl
transfus
erythrocytapheresi
associ
increas
risk
rbc
alloimmun
publish
literatur
lack
frequenc
alloimmun
geograph
associ
pediatr
popul
made
difficult
compar
due
lack
standard
categor
repres
pediatr
patient
popul
across
studi
therefor
look
alloimmun
rate
pediatr
patient
scd
unit
state
us
countri
studi
designmethod
literatur
search
perform
studi
publish
alloimmun
rate
scd
pediatr
patient
includ
hbss
sickl
hbsc
evalu
overal
alloimmun
rate
number
alloantibodi
per
transfus
patient
alloantibodi
per
transfus
unit
across
world
literatur
compar
use
analysi
resultsfind
fourteen
studi
report
data
deriv
alloimmun
rate
pediatr
scd
patient
found
includ
eleven
us
studi
patient
studi
region
brazil
egypt
franc
patient
major
patient
includ
studi
hbss
diseas
patient
receiv
either
episod
chronic
simpl
transfus
erythrocytapheresi
age
rang
us
studi
year
countri
year
avail
data
us
studi
includ
total
alloantibodi
frequent
antibodi
c
e
kell
kidd
antigen
respect
alloimmun
rate
calcul
antibodi
per
patient
studi
antibodi
per
transfus
unit
studi
evalu
rate
use
approach
per
avail
data
us
alloimmun
rate
ci
vs
studi
ci
alloantibodi
per
transfus
patient
vs
similarli
number
alloantibodi
per
transfus
unit
us
evalu
five
studi
higher
compar
larg
french
patient
cohort
vs
averag
number
rbc
unit
transfus
per
patient
us
also
higher
compar
data
franc
vs
conclus
despit
limit
studi
avail
compar
alloimmun
rate
pediatr
scd
patient
us
countri
overal
rate
higher
us
though
definit
reason
could
conclud
avail
data
limit
number
rbc
exposur
ie
unit
transfus
condit
could
lead
lower
alloimmun
rate
backgroundcas
studi
year
old
african
american
femal
admit
hospit
diagnosi
atrial
fibril
anemia
facil
report
known
antibodi
histori
recent
transfus
antibodi
detect
test
posit
use
gel
techniqu
sampl
refer
immunohematolog
refer
laboratori
irl
antibodi
identif
crossmatch
irl
record
indic
patient
histori
antibodi
identif
reveal
new
auto
control
direct
antiglobulin
test
dat
neg
crossmatch
compat
unit
provid
transfus
next
day
hospit
report
transfus
reaction
patient
temperatur
blood
pressur
respir
increas
hemoglobinuria
also
report
studi
designmethod
antibodi
identif
perform
use
tube
techniqu
gamma
immucor
inc
norcross
ga
reaction
read
rt
minut
indirect
antiglobulin
test
iat
use
globulin
ahg
tube
test
use
gamma
immucor
inc
norcross
ga
perform
minut
read
ahg
gamma
ii
immucor
inc
norcross
ga
reagent
antisera
use
investig
monocyt
monolay
assay
mma
perform
predict
clinic
signific
identifi
antibodi
transfus
reaction
trxn
investig
includ
cleric
check
visual
inspect
hemolysi
dat
repeat
aborh
sampl
addit
test
need
resultsfind
sampl
refer
irl
trxn
investig
cleric
error
howev
hemolysi
present
transfus
plasmaserum
aborh
crossmatch
use
repeat
sampl
discrep
dat
posit
neg
eluat
hospit
request
anoth
unit
investig
complet
antibodi
identif
post
transfus
sampl
neg
suspect
weak
antibodi
addit
investig
use
pegtm
sampl
reveal
addit
clinic
signific
alloantibodi
detect
sampl
use
conclus
patient
experienc
acut
hemolyt
transfus
reaction
due
anamnest
interact
patient
plasmaserum
c
antigen
transfus
cell
detect
routin
antibodi
identif
techniqu
mma
confirm
clinic
signific
backgroundcas
studi
ena
antigen
high
preval
antigen
mn
blood
group
system
antigen
mn
system
carri
glycophorin
gpa
glycophorin
b
gpb
rare
immun
igmigg
antibodi
made
individu
lack
part
gpa
protein
implic
fatal
htr
hdfn
en
phenotyp
result
either
rare
delet
gpa
protein
even
rarer
mk
phenotyp
individu
mkphenotyp
lack
gpa
gpb
protein
red
blood
cell
type
en
wr
reduc
sialic
acid
studi
designmethod
year
old
white
mennonit
femal
present
midwif
prenat
care
intent
home
deliveri
posit
antibodi
screen
solid
phase
hospit
transfus
servic
antibodi
identif
panel
done
gel
test
antibodi
select
cell
uvar
tube
peg
enhanc
phenotyp
done
base
mn
phenotyp
suspect
specimen
refer
immunohematolog
refer
laboratori
irl
test
includ
phenotyp
unlicens
antisera
ficin
treat
panel
tube
techniqu
allogen
adsorpt
antibodi
exclus
identif
antibodi
titrat
follow
identif
irl
midwif
advis
refer
patient
matern
fetal
medicin
specialist
academ
center
close
patient
home
midwif
also
advis
consid
autolog
blood
donat
test
sibl
resultsfind
test
hospit
blood
bank
demonstr
posit
reactiv
antibodi
screen
gel
antibodi
panel
ahg
phase
result
panagglutin
neg
autocontrol
suggest
high
preval
antibodi
phenotyp
perform
determin
u
outdat
u
variant
reagent
cell
react
peg
igg
phase
rule
suspect
sampl
refer
irl
allogen
adsorpt
perform
rule
antibodi
common
red
cell
antigen
lack
reactiv
ficin
panel
elimin
presenc
phenotyp
unlicens
neg
unlicens
glycin
soja
demonstr
reactiv
suggest
patient
en
patient
phenotyp
consist
mk
phenotyp
base
lack
reactiv
ficin
panel
antibodi
identifi
sinc
extrem
rare
specif
could
confirm
due
lack
en
cell
appropri
antisera
baselin
antibodi
titer
igg
phase
without
enhanc
conclus
case
studi
describ
workup
rare
antibodi
prenat
patient
tertiari
care
hospit
studi
perform
patient
transfer
closer
home
confirm
fs
genotyp
perform
three
titer
perform
remaind
pregnanc
held
although
implic
hdfn
healthi
infant
deliv
without
complic
patient
monitor
close
futur
pregnanc
autolog
donat
andor
sibl
test
consid
order
provid
compat
blood
intrauterin
transfus
transfus
deliveri
backgroundcas
studi
year
old
caucasian
male
diagnos
hemolyt
anemia
previou
transfus
refer
immunohematolog
refer
laboratori
irl
antibodi
identif
rbc
genotyp
initi
serolog
test
refer
facil
irl
demonstr
andor
specif
posit
auto
control
igg
dat
specif
frequent
found
rr
individu
expos
r
r
cell
g
antigen
present
rbc
express
either
rhd
andor
c
rare
rgr
cell
rhce
c
rhd
gene
encod
determin
g
express
rare
rhd
variant
antigen
lack
studi
designmethod
serolog
evalu
includ
tube
test
use
gamma
immucor
inc
norcross
ga
enhanc
elut
studi
gamma
ii
immucor
inc
edta
glycin
acid
treatment
gamma
egatmkit
immucor
inc
allogen
adsorpt
papain
treat
intact
rbc
reagent
rbc
antisera
molecular
test
perform
bioarray
precis
type
ivd
hea
assay
immucor
inc
resultsfind
molecular
test
reveal
rhce
ce
genotyp
predict
phenotyp
otherwis
unremark
rbc
type
report
serolog
antibodi
i
demonstr
specif
serum
eluat
use
ror
r
r
rgr
rr
cell
patient
predict
dcedc
therefor
possibl
allogen
except
unlik
allogen
adsorpt
use
papain
treat
ror
r
r
cell
exclud
leav
explan
initi
find
reactiv
patient
ega
treat
dat
neg
cell
neat
serum
eluat
antisera
confirm
auto
conclus
warm
autoantibodi
common
find
often
rh
specif
howev
antibodi
usual
demonstr
broad
weaker
specif
eluat
serum
enhanc
use
reactiv
cell
differenti
gener
academ
transfus
recommend
provid
unit
relev
clinic
import
determin
presenc
absenc
rhd
neg
women
childbear
age
present
specif
exclud
women
receiv
rhig
part
prenat
care
case
differenti
auto
necessari
provid
transfus
recommend
provid
unit
give
serolog
compat
rbc
could
result
format
allogen
backgroundcas
studi
acid
eluat
elu
kit
ii
immucor
norcross
ga
test
via
tube
iat
method
parallel
recov
last
wash
per
manufactur
packag
insert
finck
etal
immunohematolog
demonstr
acid
eluat
may
test
platform
manual
gel
microcolumn
assay
card
ortho
clinic
diagnost
raritan
nj
autom
red
cell
adher
system
echo
immucor
norcross
ga
studi
look
compar
use
autom
gel
microcolumn
analyz
vision
ortho
clinic
diagnost
raritan
nj
red
cell
adher
analyz
echo
immucor
norcross
ga
test
acid
eluat
region
midwestern
transfus
servic
studi
designmethod
twenti
patient
sampl
less
day
collect
drawn
edta
use
prepar
acid
eluat
ii
immucor
norcross
ga
retain
last
wash
test
parallel
two
sampl
dat
posit
weakli
dat
posit
dat
neg
prepar
eluat
observ
color
ph
document
prepar
eluat
whatman
whatman
intern
maidston
england
prepar
eluat
last
wash
test
vision
echo
antibodi
screen
antibodi
screen
posit
sampl
test
antibodi
panel
determin
prior
eluat
test
autom
platform
spun
minut
twice
remov
rbc
debri
could
caus
fals
posit
reaction
resultsfind
eluat
prepar
rang
color
bb
bg
bp
ph
eluat
rang
highest
percentag
eluat
ph
sixteen
eluat
test
yield
result
autom
platform
concord
four
eluat
differ
result
summar
tabl
conclus
studi
demonstr
analyz
may
use
eluat
investig
method
yield
appar
fals
posit
result
sampl
initi
dat
neg
echo
sensit
yield
fals
posit
result
vision
neg
vision
fals
posit
one
eluat
echo
neg
appar
associ
eluat
result
relat
color
eluat
age
sampl
eluat
prepar
ph
eluat
larger
studi
may
abl
better
elucid
appar
fals
posit
result
note
studi
echo
vision
eluat
studi
tabl
eluat
result
backgroundcas
studi
blood
agglutin
observ
landstein
led
discoveri
human
blood
group
abo
system
allel
describ
glycosyltransferas
encod
result
weaken
express
b
null
group
phenotyp
test
method
reagent
improv
donor
may
appear
chang
abo
type
describ
frequent
group
blood
donor
unit
year
actual
aw
studi
designmethod
donat
test
instrument
beckman
coulter
inc
routin
forward
revers
abo
test
use
investig
discrep
molecular
studi
perform
dna
sequenc
abo
intron
exon
specif
primer
locat
flank
intron
region
blood
group
gene
use
amplifi
relev
exon
pcr
templat
use
genom
dna
extract
whole
blood
collect
edta
exon
subject
bidirect
dna
sequenc
analysi
use
standard
sanger
dideoxi
chemistri
seqscap
softwar
abi
use
analyz
sequenc
data
compar
obtain
sequenc
refer
sequenc
ncbi
resultsfind
serolog
result
shown
tabl
test
b
neg
cell
revers
test
result
dna
sequenc
abo
intronsexon
shown
tabl
signific
chang
found
exon
exon
nucleotid
nt
delet
result
shorten
transcript
due
stop
codon
anoth
nt
substitut
lead
amino
acid
chang
mutat
exon
includ
nt
substitut
caus
chang
nt
delet
result
shorten
transcript
tabl
serolog
test
tabl
molecular
analysi
conclus
serolog
test
donor
plasma
cell
reveal
abo
discrep
molecular
test
confirm
donor
genotyp
heterozygot
ao
abo
predict
aw
phenotyp
normal
donor
rbc
test
revers
type
confirm
test
b
cell
abo
discrep
caus
presenc
plasma
caus
forward
revers
type
interpret
group
accord
fda
guidelin
donor
technic
group
donat
need
label
group
donor
contact
instruct
ceas
donat
blood
transfus
donat
continu
unit
label
group
would
like
test
group
transfus
facil
result
fda
report
error
numer
report
literatur
rel
insuscept
cell
destruct
howev
one
hemolyt
transfus
reaction
ax
blood
transfus
patient
potent
titer
schmidt
nacarrow
etal
review
transfus
recipi
donor
report
reveal
untoward
reaction
transfus
backgroundcas
studi
edta
blood
tube
use
sourc
genom
dna
gdna
red
blood
cell
rbc
genotyp
patient
donor
rbc
genotyp
blood
donor
perform
batch
start
extract
gdna
whole
blood
pilot
tube
deriv
unit
dna
extract
whole
blood
perform
blood
tube
use
biorobot
univers
system
qiagen
inform
maximum
accept
age
blood
purpos
either
vendor
literatur
set
assess
blood
day
post
collect
yield
suitabl
gdna
downstream
rbc
genotyp
studi
designmethod
edta
blood
tube
collect
random
blood
donor
use
extract
dna
microlit
whole
blood
day
day
post
collect
blood
sampl
store
extract
tube
brought
room
temperatur
rock
load
biorobot
extract
perform
use
mdx
blood
minikit
qiagen
result
dna
sampl
assess
gdna
yield
absorb
use
nanodrop
thermo
scientif
extract
gdna
test
use
precisetyp
hea
molecular
beadchip
hea
immucor
failur
rate
biorobot
hea
assess
resultsfind
three
extract
success
invalid
biorobot
univers
report
evid
visibl
clot
splatter
extract
note
technologist
sampl
sampl
chosen
random
concentr
measur
use
nanodrop
extract
plate
dna
concentr
rang
ngul
read
except
concentr
interestingli
one
day
yield
day
post
collect
next
month
set
sampl
extract
test
hea
fail
extract
fail
hea
none
sampl
fail
extract
day
post
collect
none
fail
hea
day
post
collect
day
post
collect
conclus
base
result
conclud
edta
blood
tube
day
post
collect
use
sourc
gdna
rbc
genotyp
without
neg
effect
concentr
result
dna
sampl
valid
result
genotyp
backgroundcas
studi
daratumumab
monoclon
antibodi
therapi
receiv
fda
approv
treatment
multipl
myeloma
commun
suggest
patient
receiv
therapi
would
posit
antibodi
screen
common
antigen
express
red
blood
cell
current
patient
treat
daratumumab
larg
academ
medic
center
wide
variat
reactiv
observ
includ
patient
found
consist
neg
antibodi
screen
sever
potenti
caus
neutral
antibodi
could
easili
test
appli
establish
techniqu
use
neutral
antibodi
reactiv
studi
designmethod
sampl
receiv
drawn
standard
care
indirect
antiglobulin
test
perform
use
solid
phase
red
cell
adher
gel
neutral
perform
ad
equal
volum
neg
daratumumab
treat
patient
plasma
posit
daratumumab
treat
patient
plasma
dilut
control
made
ad
salin
posit
patient
plasma
sampl
incub
hour
room
temperatur
antibodi
screen
repeat
serial
dilut
also
test
determin
neutral
could
titer
test
repeat
use
variou
posit
patient
sampl
determin
negativeposit
combin
result
differ
reactiv
resultsfind
control
sampl
remain
posit
positiveneg
sampl
neg
solid
phase
test
across
patient
combin
dilut
variabl
reactiv
observ
gel
serial
dilut
show
neutral
neg
patient
observ
dilut
conclus
result
suggest
patient
plasma
may
substanc
neutral
antibodi
possibl
correl
patient
persist
neg
antibodi
screen
patient
respons
daratumumab
addit
studi
necessari
uncov
correl
patient
outcom
studi
use
standard
sampl
conduct
backgroundcas
studi
mn
blood
group
red
cell
antigen
system
locat
glycophorin
gypa
glycophorin
b
gypb
individu
lack
gypa
gypa
gypb
red
blood
cell
may
develop
rare
antibodi
en
antigen
en
antigen
antigen
locat
gypa
present
case
rare
red
cell
phenotyp
alloimmun
en
antigen
yo
approxim
week
gestat
discov
antibodi
plasma
prenat
type
screen
worrisom
mother
fetu
en
antibodi
igg
isotyp
implic
acut
delay
hemolyt
transfus
reaction
hemolyt
diseas
fetu
newborn
hdfn
test
red
cell
antisera
reveal
patient
lack
n
u
antigen
multiplex
pcr
platform
commonli
use
detect
presenc
absenc
red
cell
gene
sequenc
fail
amplifi
gene
specif
n
u
antigen
find
consist
null
phenotyp
gypa
gypb
antigen
ie
k
k
phenotyp
patient
husband
father
unborn
babi
demonstr
phenotyp
serolog
molecular
mean
given
exceedingli
rare
incid
en
individu
posit
frequenc
clinic
encount
alloantibodi
antigen
limit
experi
literatur
howev
exist
data
give
credenc
associ
transfus
reaction
hemolyt
diseas
fetu
newborn
hdfn
consensu
case
work
pregnanc
frequent
intens
monitor
involv
frequent
monitor
antibodi
titer
transfus
requir
mother
fetu
option
either
search
rare
unit
lack
en
antigen
via
rare
blood
donor
registri
direct
donat
famili
member
match
patient
phenotyp
term
patient
underw
induct
labor
success
deliv
health
babi
boy
vagin
rout
deliveri
without
event
transfus
necessari
antepartum
postpartum
studi
designmethod
na
resultsfind
na
conclus
rare
antibodi
limit
data
potenti
clinic
sequela
concern
pregnant
woman
provid
patient
rare
en
neg
red
cell
via
nation
intern
blood
donor
registri
would
arduou
task
need
patient
mani
compat
famili
member
avail
will
donat
blood
k
null
allel
within
famili
like
due
genet
recombin
among
gypa
gype
gene
rather
mutat
gypa
gypb
gene
result
absenc
glycophorin
b
constitut
antigen
mn
blood
group
system
patient
expos
en
present
glycophorin
unborn
babi
red
cell
inherit
father
utero
subsequ
alloimmun
conclus
case
report
demonstr
clinic
approach
identifi
rare
antibodi
prenat
sampl
clinic
find
rare
antibodi
limit
data
requir
leverag
everi
resourc
avail
order
predict
behavior
provid
safe
blood
product
patient
may
requir
backgroundcas
studi
transfus
essenti
patient
scd
thalassemia
maintain
growth
develop
childhood
sustain
good
qualiti
life
adulthood
howev
develop
red
blood
cell
rbc
alloantibodi
autoantibodi
complic
transfus
therapi
patient
routin
phenotyp
blood
recipi
use
blood
unit
transfus
use
lower
occurr
red
cell
alloantibodi
chronic
transfus
patient
thalassemia
scd
nevertheless
extens
phenotyp
expens
labori
perform
certain
situat
molecular
understand
blood
group
enabl
design
assay
use
better
guid
match
red
blood
cell
transfus
maintain
inventori
unit
dna
type
base
aim
evalu
clinic
outcom
molecular
match
perform
differ
level
year
patient
scd
thalassemia
studi
designmethod
blood
group
genotyp
determin
dna
sampl
chronic
transfus
patient
scd
patient
thalassemia
dna
sampl
blood
donor
laboratori
develop
test
ldt
hea
beadchiptm
rhd
beadchiptm
rhce
beadchiptm
sequenc
use
determin
genotyp
among
patient
donor
molecular
match
perform
level
rh
k
match
extend
match
extend
match
includ
rh
variant
consid
total
red
blood
cell
unit
request
patient
number
donat
per
year
compat
donor
resultsfind
accord
patient
need
perform
molecular
match
thalassem
scd
patient
level
scd
patient
patient
thalassemia
level
patient
scd
patient
thalassemia
level
patient
transfus
median
rbc
unit
three
year
molecular
match
observ
transfus
strategi
avoid
new
alloantibodi
develop
hemolyt
transfus
reaction
studi
patient
conclus
molecular
match
shown
clinic
benefit
patient
scd
thalassemia
contribut
significantli
reduc
rate
alloimmun
c
e
k
match
extend
match
improv
clinic
outcom
patient
also
observ
shown
increas
hb
level
reduct
hb
scd
patient
better
vivo
rbc
surviv
diminish
frequenc
transfus
backgroundcas
studi
ideal
manual
backup
method
autom
antibodi
detect
system
import
choic
current
backup
method
salin
tube
drop
plasma
minut
incub
chang
either
low
ionic
strength
solut
liss
polyethylen
glycol
peg
method
would
reduc
incub
time
minut
specimen
volum
drop
import
laboratori
consider
object
studi
compar
rel
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
peg
liss
determin
appropri
manual
backup
method
exist
autom
solid
phase
system
studi
designmethod
total
specimen
compar
util
autom
solid
phase
red
cell
adher
assay
sprca
manual
tube
peg
liss
sampl
suffici
quantiti
test
liss
identif
panel
use
determin
clinic
signific
antibodi
warm
autoantibodi
nonspecif
reaction
calcul
base
upon
comparison
sprca
resultsfind
total
clinic
signific
antibodi
detect
use
sprca
techniqu
well
warm
autoantibodi
nonspecif
reaction
peg
demonstr
highest
sensit
lowest
specif
liss
least
sensit
specif
clinic
signific
antibodi
warm
autoantibodi
liss
sensit
peg
specif
reduc
detect
nonspecif
reaction
peg
nonspecif
reaction
versu
identifi
clinic
signific
antibodi
liss
tabl
conclus
ultim
decis
choos
manual
backup
method
must
base
upon
highest
sensit
clinic
signific
antibodi
minim
failur
detect
one
peg
select
backup
manual
method
even
though
peg
higher
sensit
nonspecif
reaction
studi
clearli
demonstr
interplay
tradeoff
method
import
understand
consid
make
method
choic
decis
tabl
comparison
studi
peg
liss
antibodi
identif
test
backgroundcas
studi
monoclon
eg
daratumumab
dara
use
treat
patient
multipl
myeloma
caus
posit
indirect
antiglobulin
test
iat
due
express
red
blood
cell
rbc
serolog
reactiv
remov
adsorpt
method
develop
detectidentifi
underli
alloantibodi
one
popular
method
denatur
antigen
treatment
rbc
thiol
reagent
eg
dithiothreitol
dtt
bromid
aet
chapuy
etal
describ
valid
method
use
dtt
ph
phosphat
buffer
salin
pb
anani
etal
describ
use
aet
branch
etal
previous
report
dtt
ph
pb
final
ph
adjust
denatur
kell
yta
antigen
advani
etal
previous
show
aet
ph
inactiv
kell
antigen
dtt
ph
pb
aet
ph
requir
special
prepar
process
branch
etal
also
show
zzap
papain
dtt
ph
destroy
kell
antigen
shulman
etal
show
dtt
normal
salin
destroy
reactiv
commerci
compani
market
dtt
ph
given
safeti
data
sheet
list
two
ingredi
dtt
nacl
blood
banker
use
dtt
ph
inactiv
igm
antibodi
plasma
rbc
studi
designmethod
rbc
five
donor
treat
day
commerci
dtt
dtt
nacl
prepar
dtt
ph
pb
dtt
pb
ph
aet
ph
per
aabb
technic
manual
ed
treat
untreat
rbc
store
alsev
test
day
two
method
polyethylen
glycol
peg
iat
use
plasma
two
myeloma
patient
receiv
dara
plasma
total
dara
patient
test
reactiv
flow
cytometri
use
phycoerythrin
pe
rbc
also
test
day
serum
contain
peg
iat
resultsfind
dtt
ph
pb
final
ph
ph
commerci
dtt
result
tabl
flow
cytometri
result
day
data
shown
similar
day
rbc
treat
dtt
sourc
aet
nonreact
plasma
dara
patient
gave
low
result
posit
event
pe
flow
cytometri
day
treatment
rbc
treat
dtt
react
similarli
untreat
rbc
dara
plasma
show
weaken
reactiv
pe
tabl
conclus
rbc
treat
minut
dtt
ph
pb
final
ph
commerci
dtt
ph
minut
aet
ph
gave
equival
result
plasma
dara
patient
pe
day
dtt
use
concentr
minut
incub
inadequ
denatur
k
use
ph
pb
prepar
dtt
may
critic
denatur
backgroundcas
studi
clinic
signific
hemolyt
diseas
fetu
newborn
hdn
often
caus
rhd
incompat
discoveri
fetal
dna
ccfdna
matern
plasma
becam
possibl
determin
rhd
genotyp
fetu
use
techniqu
howev
reliabl
prenat
rhd
test
nip
rhd
depend
suffici
amount
cffdna
matern
plasma
sampl
recent
studi
show
fraction
ccfdna
matern
plasma
vari
significantli
pregnant
women
invers
relat
matern
bodi
mass
index
bmi
thu
high
matern
bmi
may
impair
valid
nip
rhd
aim
studi
examin
effect
matern
bmi
correct
nip
rhd
correl
matern
bmi
fraction
ccfdna
total
free
dna
sampl
studi
designmethod
measur
bodi
height
weight
pregnant
rhd
neg
women
gestat
week
obtain
patient
record
use
calcul
matern
bmi
data
bmi
combin
result
nip
rhd
pcr
target
rhd
exon
sampl
fraction
ccfdna
measur
threshold
cycl
ct
valu
rhd
total
free
dna
measur
ct
gestat
week
correct
nip
rhd
determin
correl
postnat
serolog
rhd
determin
resultsfind
total
pregnant
women
includ
nip
rhd
posit
neg
inconclus
compar
postnat
rhd
type
nip
rhd
result
fals
posit
fp
fals
neg
inconclus
nip
rhd
postnat
rhd
type
posit
mean
bmi
gestat
week
differ
mean
bmi
individu
test
inconclus
fals
neg
nip
rhd
compar
remaind
fraction
ccfdna
calcul
randomli
select
nip
rhd
true
posit
case
median
ccfdna
ratio
distribut
highli
posit
skew
statist
correl
bmi
fraction
ccfdna
total
free
dna
conclus
neither
correct
nip
rhd
test
result
fraction
cffdna
total
free
dna
appear
correl
matern
bmi
regard
matern
plasma
sampl
drawn
gestat
week
backgroundcas
studi
lan
antigen
sole
member
lan
blood
group
system
rare
igg
antibodi
conflict
inform
regard
clinic
signific
potenti
hemolysi
report
case
delay
hemolysi
patient
antibodi
studi
designmethod
patient
medic
record
avail
literatur
review
resultsfind
year
old
man
histori
heart
diseas
bladder
cancer
admit
radic
cystectomi
antibodi
screen
panel
panreact
multipl
test
method
gel
liss
peg
neg
autocontrol
dat
salin
antibodi
titer
suggest
antibodi
antigen
antibodi
identifi
refer
laboratori
donor
two
frozen
rbc
unit
local
avail
transfus
patient
sibl
test
one
sibl
identifi
nine
month
later
patient
admit
surgic
manag
metastas
time
antibodi
screen
weakli
reactiv
cell
new
antibodi
rule
blood
conserv
measur
institut
includ
limit
blood
draw
cell
salvag
surgeri
due
bleed
surgeri
rbc
unit
transfus
day
includ
rare
donor
unit
unit
sibl
donor
anoth
surgic
procedur
perform
day
patient
symptomat
anemia
hemoglobin
hb
serial
increas
troponin
rbc
unit
avail
four
rbc
unit
untest
lan
transfus
without
advers
event
unit
presum
lan
crossmatch
compat
phenotyp
match
patient
antigen
hb
maintain
day
antibodi
screen
neg
day
strongli
panreact
day
posit
dat
igg
antibodi
identifi
plasma
eluat
also
evid
hemolysi
includ
progress
decreas
hb
day
day
bleed
identifi
increas
total
bilirubin
ldh
peak
ul
day
normal
haptoglobin
patient
febril
leukocytosi
neg
cultur
evid
infect
rbc
unit
transfus
day
good
respons
hb
patient
remain
stabl
discharg
skill
nurs
facil
day
later
conclus
transfus
lan
rbc
caus
resurg
antibodi
delay
hemolyt
transfus
reaction
day
transfus
rariti
unit
may
requir
patient
transfus
lan
unit
close
monitor
delay
hemolysi
necessari
even
antibodi
demonstr
time
transfus
backgroundcas
studi
first
describ
rosenfield
cowork
serum
hemophiliac
multipli
transfus
f
antigen
compris
c
e
antigen
allign
ci
chromosom
antigen
assign
rh
blood
group
system
isbt
capabl
caus
signific
transfus
reaction
mild
hdfn
report
case
year
old
caucasian
male
admit
evalu
suspect
lymphoma
appear
delay
serolog
transfus
reaction
dstr
due
auto
studi
designmethod
antibodi
screen
compat
test
perform
autom
solid
phase
echo
neo
lmmucor
inc
red
cell
phenotyp
done
standard
tube
test
commerci
reagent
follow
manufactur
instruct
molecular
genotyp
perform
use
bloodchip
assay
grifol
san
marco
tx
elut
studi
perform
use
kit
ii
lmmucor
inc
resultsfind
initi
antibodi
screen
neg
patient
transfus
unit
rbc
two
week
later
patient
receiv
addit
rbc
within
day
hgb
decreas
direct
antiglobulin
test
dat
posit
unit
incompat
identifi
patient
plasma
eluat
three
addit
unit
request
transfus
due
rariti
rbc
patient
transfus
dcedc
rbc
report
complic
patient
discharg
follow
clinic
molecular
genotyp
show
patient
rhd
delet
rho
del
normal
rhce
rhce
cerhc
ce
gene
predict
phenotyp
rh
phenotyp
repeat
sampl
collect
day
later
c
type
micro
posit
mix
field
minut
incub
rh
antigen
mix
file
non
reactiv
howev
dat
weakli
posit
elut
studi
perform
conclus
expect
post
hour
hgb
increment
receipt
standard
unit
blood
near
hct
throughout
patient
hospit
increment
fulli
achiev
expect
first
transfuion
result
increas
second
unit
last
transfus
unit
increas
less
three
week
later
rhc
antigen
type
microscopicmix
field
extend
incub
indic
remov
unit
nearli
complet
case
ohto
kariyon
transf
report
studi
f
rbc
patient
show
initit
surviv
f
cell
fairli
normal
howev
day
sudden
increas
red
cell
destruct
day
f
cell
clear
circul
unusu
find
mani
report
howev
unusu
find
caus
clearanc
three
unit
blood
patient
monitor
see
autoantibodi
recur
determin
still
specif
backgroundcas
studi
use
dithiothreitol
dtt
treat
reagent
red
cell
rrbc
increas
blood
bank
effect
way
negat
interf
panreact
caus
daratumumab
drug
treatment
multipl
myeloma
daili
prepar
rrbc
test
individu
patient
burdensom
laboratori
may
delay
patient
care
evalu
effect
rrbc
store
day
treatment
antibodi
detect
test
studi
designmethod
rrbc
ortho
clinic
diagnost
raritan
nj
select
base
phenotyp
match
antisera
test
rrbc
treat
dtt
st
loui
mo
store
reagent
red
cell
diluent
rrbc
test
commerci
antisera
ortho
clinic
diagnost
raritan
nj
immucor
norcross
ga
per
manufactur
instruct
specif
rh
duffi
kidd
mn
blood
group
see
tabl
patient
sourc
antibodi
also
test
test
perform
dtt
treatment
day
dtt
treatment
day
follow
dtt
treatment
rrbc
reaction
grade
use
standard
serolog
grade
neg
posit
reaction
strength
store
rrbc
also
observ
hemolysi
storag
period
resultsfind
see
tabl
summari
result
commerci
monoclon
human
sourc
antisera
patient
sourc
antibodi
reactiv
rrbc
throughout
storag
period
reactiv
decreas
less
one
reaction
grade
antisera
patient
sourc
antibodi
test
mild
moder
hemolysi
note
rrbc
storag
period
conclus
rrbc
show
adequ
reactiv
variou
red
cell
antisera
storag
day
suggest
reagent
red
cell
store
least
day
use
detect
alloantibodi
minim
effect
detect
abil
batch
prepar
storag
rrbc
increas
test
effici
decreas
perform
test
patient
receiv
therapi
tabl
reactiv
evalu
hemolysi
dtt
treatment
backgroundcas
studi
daratumumab
dara
agent
known
interfer
routin
blood
bank
antibodi
screen
test
dara
igg
monoclon
antibodi
bind
present
red
cell
surfac
univers
chicago
blood
bank
seen
mani
patient
treat
dara
show
interf
reactiv
well
describ
molecul
immun
epitop
disrupt
reduc
agent
dtt
perform
valid
reagent
rbc
abrog
dara
interfer
studi
designmethod
valid
done
prove
dtt
treat
red
cell
could
use
screen
patient
receiv
dara
still
detect
clinic
signific
screen
cell
panel
cell
select
dtt
treatment
rbc
homozyg
clinic
signific
antigen
therefor
allow
clinic
signific
antibodi
patient
plasma
sever
patient
receiv
dara
drug
protocol
select
test
well
mani
patient
antibodi
dara
treatment
reagent
screen
cell
panel
cell
treat
dtt
prepar
use
sop
judd
method
immunohematolog
aabb
technic
manual
treat
cell
preserv
test
episod
use
alsev
solut
store
observ
hemolysi
none
seen
day
immunohematolog
test
use
cell
perform
use
gel
methodolog
untreat
dtt
treat
cell
test
anti
k
patient
test
done
untreat
cell
react
anti
k
treat
cell
neg
control
run
test
time
dtt
treatment
done
thirti
eight
patient
sampl
includ
six
dara
patient
sampl
test
resultsfind
six
patient
dara
interfer
untreat
antibodi
screen
sampl
neg
reaction
dtt
treat
cell
except
one
patient
weak
reaction
one
cell
specimen
repeat
three
time
repeat
weak
posit
reaction
cell
sampl
sent
arc
refer
lab
dtt
treatment
clinic
signific
antibodi
rule
patient
present
plasma
react
dtt
treat
cell
would
expect
base
underli
alloantibodi
except
newli
form
antibodi
patient
plasma
four
patient
nascent
anti
show
reactiv
dtt
treat
cell
plasma
fourteen
patient
long
histori
greater
month
react
dtt
treat
cell
conclus
dtt
treatment
elimin
dara
interfer
previous
describ
also
unexpectedli
lessen
abil
treat
cell
react
nascent
neg
test
e
antibodi
patient
ucm
given
kell
e
neg
blood
immunohematolog
test
perform
use
dtt
reagent
cell
backgroundcas
studi
benign
ethnic
neutropenia
ben
seen
approxim
person
african
descent
character
neutrophil
count
obviou
caus
increas
suscept
infect
advers
effect
present
laboratori
assay
use
identifi
condit
gener
diagnos
clinic
basi
studi
investig
whether
duffi
fy
blood
group
phenotyp
would
potenti
use
modal
help
identifi
patient
ben
test
could
potenti
use
surrog
test
prevent
unnecessari
work
includ
bone
marrow
biopsi
correct
ethnic
clinic
set
studi
designmethod
case
includ
patient
clinic
diagnos
ben
control
chosen
randomli
pool
patient
cbc
type
screen
check
reason
case
control
test
rbc
antigen
fya
fyb
phenotyp
use
serolog
method
fy
phenotyp
absolut
neutrophil
count
anc
white
blood
cell
wbc
hemoglobin
level
platelet
count
medic
diagnos
extract
medic
record
appropri
data
compar
statist
use
u
test
signific
set
p
resultsfind
subject
clinic
identifi
probabl
ben
includ
patient
mean
age
male
control
includ
patient
mean
age
african
american
male
case
diagnos
ben
fy
phenotyp
mean
anc
wbc
count
significantli
lower
case
ben
fy
phenotyp
respect
compar
control
mean
anc
mean
wbc
count
signific
differ
mean
platelet
count
vs
mean
hemoglobin
level
vs
two
group
none
patient
ben
accompani
hematolog
disord
base
record
review
howev
subject
control
group
accompani
condit
potenti
includ
hepatocellular
carcinoma
acut
myeloid
leukemia
myelodysplast
syndrom
conclus
test
fy
phenotyp
could
potenti
use
surrog
test
patient
chronic
neutropenia
correct
ethnic
clinic
set
diagnosi
ben
studi
regard
fy
phenotyp
compar
control
neutropenia
reason
ben
popul
progress
better
determin
posit
predict
valu
facil
carson
taho
region
medic
center
carson
citi
nv
laboratori
inc
hercul
ca
backgroundcas
studi
purpos
studi
evalu
perform
autom
blood
group
analyz
laboratori
inc
transfus
servic
analyz
compar
exist
platform
ortho
clinic
diagnost
facil
object
continu
util
gel
technolog
differ
manufactur
higher
throughput
better
effici
hospit
facil
perform
approxim
type
screen
per
year
studi
designmethod
edta
sampl
test
gel
card
aborh
forward
revers
antibodi
screen
ab
aborh
unit
confirm
crossmatch
compat
igg
antibodi
identif
abid
weak
direct
antiglobulin
test
dat
perform
edta
sampl
edta
cord
blood
sampl
test
compar
provu
concord
addit
sampl
test
correl
tube
test
dat
antigen
type
c
c
e
e
k
resultsfind
concord
blood
group
assay
ahg
assay
detect
warm
antibodi
antibodi
high
incid
antigen
warm
antibodi
miss
provu
identifi
one
addit
identifi
provu
discrep
also
note
dat
result
five
sampl
posit
vs
tube
test
reflect
increas
sensit
gel
methodolog
tube
tabl
summar
result
conclus
studi
demonstr
analyz
associ
gel
card
equival
ortho
provu
random
access
capabl
minim
oper
touchpoint
broad
test
menu
excel
assay
perform
ideal
immunohematolog
system
hospit
transfus
servic
environ
backgroundcas
studi
erytra
grifol
new
fulli
autom
analyz
perform
compat
test
use
dg
technolog
erytra
analyz
perform
usabl
adapt
differ
workflow
evalu
routin
environ
larg
uk
acut
hospit
transfus
laboratori
studi
designmethod
comparison
studi
perform
erytra
erytra
routin
system
provid
refer
platform
total
test
perform
adult
patient
sampl
donor
red
cell
unit
eflexi
perform
evalu
accord
seri
scenario
design
simul
routin
workload
use
system
differ
configur
concord
system
assess
discrep
analyz
time
first
result
ttfr
overal
time
tat
total
workload
first
result
last
result
throughput
resultsh
manual
time
time
record
eas
use
evalu
rank
usabl
featur
number
step
time
activ
includ
sampl
sort
load
routin
test
procedur
consum
use
space
requir
fault
recognit
messag
assess
simul
failur
eg
reagent
absenc
resultsfind
blood
group
antibodi
screen
antibodi
identif
use
panel
direct
antiglobulin
test
red
cell
phenotyp
serolog
crossmatch
success
test
concord
result
erytra
analyz
refer
method
obtain
sampl
test
discrep
antibodi
screen
fals
posit
failur
detect
weak
prophylact
anti
posit
reaction
detect
erytra
panel
system
suggest
genuin
anti
cw
ttfr
tat
depend
significantli
number
factor
includ
number
varieti
test
request
whether
stat
function
activ
analys
seem
prioritis
antibodi
screen
priorit
group
especi
stat
sampl
consid
prefer
laboratori
team
found
softwar
easi
use
improv
exist
ertyra
softwar
physic
design
analys
consid
good
easi
access
almost
area
probe
chang
quick
simpl
analys
success
flag
error
scenario
messag
consid
mislead
could
better
phrase
conclus
result
show
erytra
offer
robust
autom
solut
routin
transfus
test
devic
could
comfort
deal
medium
laboratori
process
group
screen
per
day
flexibl
abl
deliv
group
antibodi
screen
identif
dat
phenotyp
serolog
crossmatch
compens
singl
probe
wash
station
clever
use
incub
centrifug
design
featur
allow
compact
design
maximum
flexibl
without
compromis
turnaround
time
backgroundcas
studi
monoclon
antibodi
use
reagent
autom
manual
phenotyp
fals
neg
phenotyp
implic
variant
antigen
eg
alter
c
antigen
mistyp
blood
unit
stimul
recipi
develop
new
reagent
includ
evalu
antigen
variant
confirm
fidel
evalu
two
monoclon
reagent
compar
reagent
use
larg
panel
molecular
confirm
rh
e
variant
studi
designmethod
two
monoclon
clone
licens
compar
diagast
loo
franc
evalu
rbc
sampl
either
recov
frozen
storag
n
edta
blood
donor
n
test
use
manual
tube
method
autom
platform
score
greater
deem
accept
manual
tube
posit
call
autom
test
result
tabul
complex
rhce
ce
allel
tabl
resultsfind
specif
monoclon
confirm
use
common
rhce
haplotyp
r
r
differ
rhce
ce
allel
includ
extens
panel
rhce
ce
tran
rhce
ce
variou
rhce
ce
plu
rhce
compound
heterozygot
rhce
ce
rhce
ce
homozygot
variou
rhce
ce
rhce
ce
compound
heterozygot
compar
reagent
neg
unaccept
weak
rhce
ce
allel
tran
rhce
ce
rhce
cear
rhce
cemo
rhce
cejal
rhce
cehar
rhce
cearrhc
compound
heterozygot
rhce
cecf
homozygot
rhce
cear
rhce
cemo
rhce
cejal
rhce
cecf
homozygot
detect
use
compar
reagent
fail
e
variant
respect
tabl
failur
detect
e
variant
observ
use
manual
tube
autom
method
compar
clone
none
reagent
detect
e
antigen
variant
express
exampl
rhce
ceharrhc
ce
conclus
react
e
variant
compar
reagent
e
antigen
encod
rhce
jal
rhce
ar
alway
detect
tran
rhce
ce
howev
express
detect
suggest
monoclon
reagent
bind
weakli
respect
alter
e
antigen
epitop
e
antigen
encod
rhce
cehar
continu
challeng
detect
tabl
summari
monoclon
reagent
passfail
acceptableunaccept
result
backgroundcas
studi
extend
molecular
type
larg
number
blood
donor
increas
likelihood
identifi
donor
red
blood
cell
rbc
match
recipi
especi
import
manag
patient
patient
rbc
alloantibodi
sever
multiplex
blood
group
molecular
type
platform
develop
determin
blood
group
antigen
phenotyp
target
sequenc
ng
provid
comprehens
sequenc
inform
focus
specifi
genom
region
allow
simultan
detect
genet
variant
multipl
gene
larg
number
sampl
develop
evalu
target
ng
assay
use
two
differ
target
enrich
platform
extend
blood
group
genotyp
studi
designmethod
two
custom
design
platform
sureselect
haloplex
use
independ
prepar
probe
target
entir
gene
blood
group
gene
associ
express
blood
group
antigen
blood
group
system
use
illumina
hiseq
system
perform
next
gener
sequenc
first
gene
dna
refer
sampl
averag
target
design
coverag
gene
dna
refer
sampl
averag
target
design
coverag
twelv
sampl
enrich
sequenc
method
allow
direct
comparison
refer
sampl
previous
character
blood
group
genet
variant
gene
use
taqman
snp
assay
sanger
sequenc
assay
serolog
data
also
avail
sampl
ng
data
analyz
clc
genom
workbench
sequenc
variant
detect
annot
use
dbsnp
databas
blood
group
genotyp
call
two
target
ng
method
compar
refer
result
resultsfind
two
target
ng
method
evalu
compar
target
enrich
effici
enrich
qualiti
ng
sequenc
coverag
genotyp
concord
higher
percentag
haloplex
read
map
target
region
rel
sureselect
read
mean
sequenc
coverag
depth
target
base
around
sureselect
method
haloplex
method
exon
rhd
exon
rhce
exon
ermap
exon
exon
gene
exon
gypb
exon
consist
cover
less
coverag
sureselect
haloplex
target
ng
method
method
detect
rhd
gene
delet
repres
sampl
genotyp
call
concord
blood
group
genet
variant
assess
compar
ng
result
taqman
genotyp
sanger
sequenc
result
concord
obtain
target
ng
method
incorrect
call
restrict
four
complex
blood
group
gene
mn
rhd
rhce
abo
involv
mainli
heterozyg
variant
indel
conclus
use
two
target
ng
method
correctli
detect
blood
group
genet
variant
select
gene
backgroundcas
studi
rhce
gene
mani
variant
form
yet
mani
phenotyp
encod
variant
allel
unknown
incomplet
new
inform
elucid
two
alter
allel
haplotyp
express
individu
subsequ
alloantibodi
format
rhce
cehar
allel
first
describ
phenotyp
partial
antigen
express
describ
new
inform
regard
rh
haplotyp
includ
rhce
cehar
allel
appar
rh
express
studi
designmethod
rbc
type
perform
standard
tube
method
polyclon
monoclon
antisera
antibodi
identif
studi
perform
standard
tube
hemagglutin
method
publish
techniqu
molecular
immunohematolog
test
perform
genom
dna
extract
whole
blood
includ
hea
rhd
rhce
beadchip
immucor
analysi
rhce
g
rhd
resultsfind
sampl
african
american
femal
histori
evalu
unexpect
antibodi
red
cell
serolog
rh
phenotyp
untransfus
sampl
plasma
contain
antibodi
react
strongli
random
reagent
red
cell
except
unidentifi
reactiv
persist
follow
ficin
dtt
pretreat
reagent
red
cell
red
cell
initi
test
differenti
adsorpt
studi
exclud
antibodi
common
antigen
hrb
except
e
k
subsequ
exampl
red
cell
homozyg
rhd
rhce
haplotyp
ie
r
sr
rhd
diiia
rhce
rhd
rhce
ie
bastiaan
genotyp
found
patient
plasma
antibodi
specif
determin
patient
red
cell
antigen
genotyp
identifi
follow
probabl
rh
haplotyp
rhd
rhce
cehar
rhd
rhce
addit
antigen
type
patient
red
cell
unlicens
antisera
indic
hr
sourc
sourc
phenotyp
conclus
rhd
rhce
haplotyp
one
rh
haplotyp
express
origin
individu
bastiaan
hrb
antigen
statu
red
cell
individu
rhce
cehar
allel
describ
report
individu
probabl
rhd
rhce
cehar
rhd
rhce
rh
haplotyp
product
specif
alloantibodi
produc
red
cell
hrb
serolog
antigen
type
support
conclus
variant
allel
rhce
cehar
encod
hrb
antigen
backgroundcas
studi
antibodi
htla
group
clinic
insignific
antibodi
ab
direct
red
cell
antigen
interfer
exclus
clinic
signific
red
cell
ab
crossmatch
test
lead
long
potenti
transfus
delay
often
use
autom
solid
phase
red
cell
adher
assay
antibodi
panel
sp
htla
interfer
seen
method
undertook
studi
determin
efficaci
studi
designmethod
search
laboratori
inform
system
databas
conduct
patient
htla
patient
sampl
avail
record
full
serolog
investig
review
test
method
result
specif
attent
valu
given
test
method
permit
exclus
clinic
signific
ab
rule
resultsfind
approxim
year
patient
htla
establish
least
titrat
studi
serolog
investig
total
sampl
use
combin
gel
sp
peg
liss
tube
method
occasion
dtt
ficin
panel
found
htla
interfer
note
frequent
gel
primari
method
inde
less
often
seen
sp
howev
proport
case
achiev
rule
sp
greater
peg
test
tabl
sampl
rule
could
perform
combin
method
patient
assign
transfus
test
refer
refer
laboratori
refer
test
sampl
success
rule
case
addit
patient
sampl
neg
antibodi
screen
htla
identifi
upon
incompat
crossmatch
conclus
sp
use
avoid
interfer
htla
conclus
limit
sp
perform
sampl
inabl
use
select
cell
panel
sp
made
difficult
complet
rule
sampl
contain
multipl
ab
peg
test
avail
sampl
least
effect
manual
test
allow
flexibl
select
test
cell
ab
present
sp
peg
test
may
use
alon
combin
avoid
interfer
due
htla
potenti
decreas
number
patient
requir
unit
due
incomplet
serolog
evalu
tabl
sampl
rule
despit
htla
interfer
backgroundcas
studi
dau
famili
rhd
allel
character
allel
harbor
chang
associ
depress
alter
antigen
express
ancestr
allel
dau
allel
purport
evolv
srivastava
etal
transfus
recent
summar
serolog
characterist
associ
alloimmun
dau
famili
allel
investig
two
sampl
chang
refer
weak
antigen
express
studi
designmethod
serolog
test
perform
standard
tube
method
use
licens
reagent
albaclon
partial
rhd
type
kit
genom
dna
isol
wbc
use
manual
array
assay
amplif
sequenc
rhd
resultsfind
sampl
yo
multiraci
femal
rbc
react
immedi
spin
iat
immucor
seri
mi
iat
ortho
bioclon
rbc
react
lhm
partial
type
kit
pattern
match
defin
partial
epitop
pattern
rhd
beadchip
found
chang
rflp
detect
characterist
dau
rhd
sequenc
confirm
identifi
two
adjac
chang
exon
encod
sampl
rbc
react
w
iat
ortho
bioclon
quotient
albaclon
delta
immucor
seri
quotient
albaclon
blend
alpha
papain
treat
rbc
iat
ortho
bioclon
result
suggest
del
like
phenotyp
rhd
beadchip
found
chang
rflp
detect
sequenc
confirm
found
new
chang
exon
report
encod
stop
codon
japanes
vox
sang
conclus
report
two
new
allel
rhd
rhd
also
carri
characterist
african
dau
cluster
antigen
associ
partial
antigen
novel
epitop
pattern
chang
associ
phenotyp
first
observ
knowledg
dau
allel
antigen
rbc
detect
iat
commerci
rhd
nucleotid
chang
report
dbsnp
databas
studi
bring
dau
famili
allel
number
divers
allel
dau
cluster
support
chang
major
ancestr
african
background
allel
wagner
etal
blood
backgroundcas
studi
case
alloimmun
caus
transfus
serolog
neg
blood
compon
analysi
genotyp
blood
compon
confirm
asian
type
del
reason
applic
genet
analysi
blood
donor
requir
addit
serolog
assay
establish
algorithm
genet
analysi
rhdin
blood
donor
studi
would
introduc
experi
applic
algorithm
result
preliminari
test
studi
designmethod
septemb
present
day
got
sampl
repeat
blood
donor
known
neg
c
posit
andor
e
neg
blood
center
obtain
consent
test
donor
provid
sampl
genet
analysi
accomplish
polymeras
chain
reaction
primer
region
promot
exon
exon
exon
rhd
gene
base
result
discrimin
result
total
rhd
delet
hybrid
rhd
variant
result
discrimin
rhd
variant
addit
analyz
sequenc
exon
confirm
exist
variat
sampl
indetermin
result
perform
sequenc
full
region
exon
result
confirm
rhd
delet
hybrid
blood
compon
regard
rhd
neg
result
confirm
rhdvariant
blood
compon
regard
rhd
posit
blood
compon
suppli
final
result
obtain
resultsfind
sampl
identifi
case
total
rhd
delet
case
hybrid
case
rhd
variant
rhd
variant
determin
asian
type
del
variat
case
rhdvariant
regard
unknown
variat
conclus
frequenc
rhd
variant
studi
higher
gener
neg
donor
consid
rhce
phenotyp
previou
studi
reason
consid
genet
analysi
rhd
target
donor
neg
c
posit
andor
e
neg
effici
approach
identifi
rhd
variant
better
way
improv
blood
safeti
transfus
medicin
relat
rhd
neg
blood
donor
backgroundcas
studi
certain
abo
subgroup
physiolog
condit
may
lead
agglutin
abo
type
among
blood
donor
phenotyp
found
common
subgroup
taiwanes
howev
hard
distinguish
phenotyp
b
subtyp
also
agglutin
use
routin
serolog
without
genotyp
studi
aim
evalu
flow
cytometr
method
could
altern
differenti
differ
b
subtyp
agglutin
rather
use
molecular
genotyp
studi
designmethod
blood
sampl
taiwanes
blood
donor
exhibit
known
common
abo
phenotyp
includ
establish
normal
flow
cytometr
pattern
genotyp
blood
sampl
b
subtyp
donor
agglutin
routin
serolog
tube
method
gel
card
analyz
flow
cytometri
genotyp
flow
cytometr
method
perform
facscalibur
flow
cytometri
use
genotyp
exon
exon
abo
gene
amplifi
sequenc
abo
allel
confirm
analysi
resultsfind
among
subject
phenotyp
genotyp
abo
abo
group
perform
similar
characterist
flow
cytometr
pattern
profil
reproduc
time
pattern
show
main
popul
cell
express
b
antigen
percentag
rbc
exhibit
b
antigen
level
diminish
increas
fluoresc
subject
subject
genotyp
abo
abo
abo
abo
abo
display
flow
pattern
differ
abo
group
abo
abo
abo
subject
also
show
main
popul
cell
express
b
antigen
howev
less
percentag
rbc
exhibit
b
antigen
level
abo
abo
subject
abo
subject
abo
abo
display
pattern
conclus
flow
cytometr
method
detect
b
antigen
rbc
might
use
discrimin
b
subtyp
agglutin
especi
abo
genotyp
approach
could
assist
serolog
abo
subgroup
clinic
refer
laboratori
backgroundcas
studi
effort
autom
test
platform
autom
red
blood
cell
adher
vs
autom
gel
column
agglutin
recent
initi
due
percept
excess
equivoc
reaction
result
unnecessari
workup
one
site
hospit
system
data
avail
parallel
test
gel
peg
perform
anoth
cite
hospit
system
collect
evalu
determin
frequenc
specif
detect
erythrocyt
antibodi
see
antibodi
workup
necessari
patient
care
studi
designmethod
throughout
transfus
servic
use
autom
red
blood
cell
rbc
adher
primari
method
antibodi
screen
identif
antibodi
screen
posit
sampl
use
gel
column
agglutin
peg
method
manual
order
determin
method
use
antiglobulin
phase
crossmatch
rbc
product
antibodi
screen
result
three
method
final
antibodi
identif
result
transcrib
spread
sheet
analyz
resultsfind
total
patient
posit
antibodi
screen
gel
peg
antibodi
screen
patient
antibodi
reactiv
observ
solid
phase
concurr
gel
peg
test
complet
neg
clinic
signific
rbc
alloantibodi
warm
autoantibodi
clinic
insignific
antibodi
identifi
case
respect
rbc
alloantibodi
identifi
includ
see
tabl
conclus
rbc
antibodi
clinic
import
signific
portion
case
roughli
case
workup
antibodi
unnecessari
workload
transfus
correspond
antigen
neg
rbc
patient
prevent
possibl
hemolyt
transfus
reaction
tabl
frequenc
specif
detect
erythrocyt
antibodi
backgroundcas
studi
human
gene
previous
known
darc
compris
two
exon
singl
intron
encod
glycoprotein
express
duffi
blood
group
antigen
fy
duffi
protein
act
chemokin
receptor
variou
cytokin
malaria
parasit
plasmodium
vivax
p
knowlesi
studi
fy
variant
low
altitud
tropic
gambela
region
import
malaria
endem
endogen
popul
live
region
long
time
present
studi
determin
full
length
nucleotid
sequenc
gene
encod
fy
antigen
donor
ethiopia
southwestern
gambela
region
studi
designmethod
whole
blood
collect
studi
volunt
gambela
region
whole
gene
amplifi
one
reaction
cover
base
pair
bp
primari
amplicon
use
nest
primer
cover
nucleotid
nucleotid
sequenc
obtain
sequenc
reaction
manual
annot
use
ncbi
refseq
sequenc
cover
bp
exon
bp
intron
bp
region
bp
bp
utr
bp
region
encompass
variat
present
dbsnp
nhlbi
esp
databas
resultsfind
among
sampl
total
snp
includ
one
novel
snp
observ
snp
occur
exon
region
intron
individu
carri
snp
indic
common
phenotyp
individu
homozyg
heterozyg
gata
box
mutat
splice
site
mutat
detect
individu
observ
homozyg
heterozyg
snp
could
unambigu
assign
distinct
allel
remain
individu
heterozyg
snp
allel
specif
pcr
requir
identifi
allel
conclus
sequenc
kb
gene
identifi
least
differ
allel
present
studi
found
vast
major
allel
gambela
popul
defin
snp
similar
clinic
relev
fy
allel
turn
defin
snp
posit
c
remain
allel
similar
fy
fy
b
phenotyp
similar
fy
fyx
phenotyp
high
frequenc
fy
studi
similar
studi
conduct
western
central
region
gambia
mozambiqu
detail
analysi
includ
region
ethiopia
use
support
transfus
care
us
major
may
mix
ethiopian
ethnic
background
backgroundcas
studi
homolog
proxim
invert
orient
rhd
rhce
chromosom
favor
gene
convers
event
region
rhd
transfer
rhce
convers
result
hybrid
allel
encod
novel
absenc
high
preval
antigen
rhd
common
hybrid
found
african
black
aros
convers
exon
rhce
ce
rhd
diiia
longer
encod
antigen
rather
somewhat
confusingli
encod
partial
c
antigen
rhd
locu
hybrid
allel
ci
rhce
ce
togeth
known
r
haplotyp
investig
atyp
rh
genotyp
result
three
sampl
two
associ
weak
type
one
patient
sickl
cell
diseas
scd
studi
designmethod
serolog
test
standard
method
genom
dna
isol
wbc
sampl
investig
hea
precisetyp
rhd
rhce
beadchip
rflp
sequenc
sequenc
use
establish
linkagephas
resultsfind
sampl
male
sampl
multiraci
femal
presum
present
weaker
expect
type
iat
rhd
beadchip
identifi
common
african
rhd
hybrid
encod
partial
c
antigen
appar
convent
rhd
tran
result
provid
explan
weak
antigen
hea
indic
rhce
ce
ce
concord
rh
phenotyp
g
heterozyg
also
detect
rhce
ce
report
analysi
done
transcript
rhce
locu
includ
one
convent
rhce
ce
tran
rhce
ce
exon
replac
rhd
diiia
rhd
locu
one
convent
rhd
hybrid
rhd
found
sampl
sampl
scd
male
rh
beadchip
one
convent
rhd
rhd
diii
type
rhce
rhd
diiia
type
never
found
either
rhce
allel
analysi
perform
transcript
repres
uniqu
convers
event
rhd
locu
specif
rhce
ce
exon
replac
exon
common
hybrid
rhd
express
partial
c
antigen
lost
uniqu
hybrid
allel
deposit
genbank
conclus
report
two
differ
novel
complex
rh
rearrang
two
sampl
thought
uniqu
rhce
locu
repres
gene
convers
rhce
ce
design
rhce
kind
sampl
genotyp
diii
type
rather
novel
rhd
locu
repres
gene
convers
common
hybrid
design
rhd
repres
novel
event
r
haplotyp
confound
rh
genotyp
interpret
interestingli
sampl
weaker
expect
antigen
type
despit
presenc
convent
rhd
rhce
ce
haplotyp
dce
import
investig
sampl
unconvent
result
interpret
rh
genotyp
backgroundcas
studi
caucasian
femal
refer
immunohematolog
refer
laboratori
irl
serolog
investig
diagnos
anemia
renal
failur
cardiac
histori
hemoglobin
level
record
pregnanc
histori
provid
receiv
unit
pack
red
blood
cell
rbc
past
includ
unit
within
last
month
none
transfus
unit
refer
hospit
obtain
panreact
gel
rbc
rbc
neg
direct
antiglobulin
test
dat
autocontrol
studi
designmethod
aborh
dat
antibodi
identif
perform
irl
accord
approv
techniqu
addit
rbc
rbc
reagent
rbc
dithiothreitol
dtt
test
alloadsorpt
done
use
allogen
rbc
rr
id
core
xt
platform
progenika
biopharm
grifol
vizcaya
spain
use
analys
polymorph
determin
antigen
includ
carthright
lutheran
blood
group
sequenc
specif
primer
restrict
fragment
length
polymorph
also
perform
verifi
absenc
high
frequenc
antigen
yta
lub
sibl
sampl
also
request
conduct
famili
studi
resultsfind
initi
serolog
test
show
strongli
reactiv
panel
gel
liss
suspend
rbc
rbc
well
rbc
rbc
neg
media
lead
probabl
antibodi
direct
antigen
alloadsorpt
procedur
allow
identif
select
panel
high
frequenc
antigen
absent
caucasian
popul
test
patient
sera
react
weakli
one
jk
lu
reagent
cell
meantim
genotyp
result
confirm
probabl
phenotyp
patient
jk
lu
yt
addit
test
gel
use
trypsin
dtt
differenti
effect
antigen
lu
b
yt
perform
confirm
antibodi
specif
rbc
unit
jk
lu
yt
avail
transfus
select
unit
jk
lu
known
caus
none
moder
transfus
reaction
daughter
sampl
type
yt
lu
b
conclus
serolog
studi
show
presenc
addit
two
antibodi
direct
high
preval
antigen
name
associ
variou
select
serolog
procedur
combin
ethnic
clue
genotyp
result
serv
solv
uncommon
antibodi
combin
backgroundcas
studi
kel
blood
group
system
consist
antigen
encod
kel
gene
organ
exon
approxim
kel
allel
associ
kell
null
phenotyp
kell
antigen
express
allel
associ
kell
mod
phenotyp
kmod
individu
kmod
phenotyp
express
weak
amount
antigen
surfac
rbc
express
level
vari
base
allel
present
describ
molecular
serolog
test
perform
case
hispan
male
blood
donor
whose
rbc
phenotyp
js
kp
studi
designmethod
blood
donor
phenotyp
k
k
kpb
jsb
antigen
use
standard
tube
agglutin
method
adsorpt
elut
studi
donor
red
cell
perform
use
commerci
antisera
american
nation
red
cross
genom
dna
gdna
isol
edta
blood
tube
use
standard
techniqu
dna
genotyp
human
erythrocyt
antigen
use
precisetypetm
hea
molecular
beadchip
immucor
exon
flank
intron
sequenc
amplifi
sequenc
total
rna
extract
use
rneasi
lipid
tissu
mini
kit
qiagen
kel
cdna
amplifi
result
pcr
product
subject
sanger
sequenc
analysi
align
use
sequench
genecod
resultsfind
precisetypetm
hea
molecular
beadchip
test
predict
sampl
k
kp
js
sequenc
analysi
perform
detect
singl
transcript
speci
miss
sequenc
correspond
exon
amplif
exon
gdna
identifi
nucleotid
chang
compar
refer
sequenc
splice
site
intact
cdna
analysi
repeat
aberr
transcript
detect
adsorpt
elut
studi
k
antigen
demonstr
weak
reactiv
incub
phase
conclus
describ
donor
homozyg
novel
kel
allel
donor
presum
phenotyp
base
serolog
molecular
test
reclassifi
kmod
phenotyp
extrem
weak
express
k
discoveri
aberr
transcript
led
adsorpt
elut
studi
confirm
presenc
weakli
express
k
antigen
red
cell
variant
allel
report
date
http
wwwisbtweborgworkingpartiesredcellimmunogeneticsandbloodgroupterminolog
associ
missens
mutat
contrast
allel
report
associ
aberr
mrna
transcript
propos
allel
name
kel
backgroundcas
studi
b
subgroup
uncommon
observ
infrequ
especi
compar
subgroup
allel
associ
weak
b
express
character
variat
exon
b
transferas
gene
report
case
possibl
novel
b
subgroup
observ
pregnant
black
femal
patient
specimen
refer
refer
laboratori
investig
possibl
abo
discrep
refer
facil
report
patient
red
blood
cell
nonreact
reagent
patient
plasma
reactiv
cell
nonreact
b
cell
use
autom
gel
methodolog
studi
designmethod
serolog
test
patient
red
blood
cell
perform
use
routin
enhanc
method
molecular
test
perform
determin
patient
genet
abo
type
predict
abo
phenotyp
resultsfind
serolog
test
patient
red
blood
cell
summar
tabl
similar
result
obtain
multipl
sourc
antisera
enzym
treatment
fail
enhanc
reactiv
patient
sera
strongli
agglutin
cell
fail
agglutin
multipl
sourc
b
cell
phase
test
tabl
molecular
test
result
uncommon
band
pattern
indic
presenc
delet
g
characterist
allel
characterist
uncommon
allel
characterist
b
allel
genom
sequenc
exon
confirm
presenc
allel
abo
g
presenc
b
allel
reveal
chang
associ
previous
report
weak
subgroup
b
conclus
serolog
abnorm
pregnanc
report
due
decreas
antigen
express
unusu
weak
reaction
observ
test
patient
unlik
due
pregnanc
alon
addit
abo
gene
sequenc
requir
determin
specif
allel
mutat
respons
weaken
antigen
express
backgroundcas
studi
elucid
molecular
basi
vel
molecular
tool
use
explain
reduc
express
vel
antigen
differ
popul
neg
weak
reaction
gener
relat
delet
homozyg
heterozyg
statu
howev
nucleotid
chang
describ
reduc
vel
express
exampl
major
allel
snp
locat
second
intron
gene
regulatori
region
erythroblast
studi
aim
character
genet
chang
relat
atyp
vel
express
brazilian
popul
studi
designmethod
total
blood
donor
sampl
southeast
region
brazil
type
vel
serum
inventori
sampl
type
analyz
molecular
studi
perform
sampl
neg
result
sampl
react
sampl
reactiv
dna
isol
peripher
blood
sequenc
resultsfind
donor
sampl
studi
serolog
vel
neg
posit
present
reaction
remain
sampl
show
reactiv
genotyp
result
show
sampl
neg
result
sampl
present
reaction
heterozyg
bp
delet
present
allel
homozyg
statu
remain
sampl
reactiv
allel
allel
contrast
sampl
stronger
reaction
found
allel
sampl
allel
sampl
conclus
molecular
chang
locat
intron
distanc
nucleotid
studi
reinforc
associ
allel
reduct
vel
express
suggest
involv
new
chang
vel
express
conclus
sever
pattern
vel
express
found
differ
popul
influenc
differ
molecular
chang
backgroundcas
studi
antigen
immunogen
antigen
abo
consequ
misclassif
patient
donor
sever
person
inherit
mutat
result
quantit
reduct
antigen
cell
surfac
weak
inherit
rh
haplotyp
result
biochem
effect
reduc
avail
antigen
reagent
ceppellini
effect
other
inherit
gene
qualit
differ
wild
type
latter
individu
often
identifi
form
hypothes
person
risk
form
might
uncov
weak
andor
dispar
type
result
reagent
recogn
differ
epitop
antigen
studi
designmethod
test
perform
use
direct
agglutin
galileoneo
galileoecho
immucor
norcross
ga
specimen
react
rh
neg
neo
echo
rh
posit
seri
seri
antisera
includ
patient
discrep
histor
type
also
evalu
specimen
meet
inclus
criteria
test
neo
echo
salin
tube
method
use
seri
seri
antisera
genotyp
perform
whole
blood
sampl
sent
immucor
genotyp
laboratori
warren
nj
use
algorithm
rhd
beadchip
rhdxp
prototyp
assay
rhd
zygos
rhce
beadchip
resultsfind
patient
met
inclus
criteria
molecular
test
antigen
weak
rhd
variant
identifi
sampl
ceppellini
effect
ie
c
tran
rhd
result
weak
reactiv
seen
sampl
sampl
result
weak
discrep
reactiv
type
genet
caus
resolv
use
algorithm
test
sampl
result
indic
weakvari
protein
potenti
caus
alloimmun
antigen
remain
sampl
identifi
genet
caus
weak
andor
discrep
test
result
presumpt
classifi
wild
type
conclus
transfus
servic
use
galileoneo
galileoecho
perform
rh
type
consid
molecular
test
patient
whose
rh
type
result
discrep
posit
galileoneo
posit
galileoecho
half
patient
develop
particularli
relev
femal
potenti
avoid
transfus
administr
rhig
pregnanc
prudent
type
confirm
molecular
test
backgroundcas
studi
rhd
rhce
major
protein
constitu
red
blood
cell
membran
compos
complex
togeth
rhag
mani
variant
rh
protein
describ
affect
integr
rh
protein
membran
antigen
express
affect
sever
molecular
chang
also
rhcehaplotyp
present
studi
investig
score
reactiv
sampl
present
strong
reduct
express
studi
designmethod
total
sampl
includ
studi
previous
genotyp
rhd
rhd
rhd
sampl
phenotyp
immucor
cc
ee
antigen
direct
agglutinationin
micropl
result
obtain
express
score
correspond
reaction
intens
zygos
assay
perform
multiplex
quantit
pcr
use
set
primer
rhd
exon
rhce
genotyp
perform
presenc
identifi
amultiplex
pcr
sequenc
identif
rhce
variant
also
perform
necessari
resultsfind
zygos
result
show
sampl
rhd
gene
phenotyp
genotyp
rhce
cerhcec
rhd
rhce
genotyp
sampl
show
presenc
gene
rhce
variant
investig
sampl
show
rhce
cearc
genotyp
sampl
rhce
genotyp
sampl
rhce
cesc
genotyp
tabl
describ
differ
found
reactiv
among
sampl
carri
c
ce
allel
sampl
homozyg
rhce
ce
tabl
score
agglutin
variant
rhd
allel
associ
differ
rhceallel
conclus
result
show
presenc
rhce
c
ce
significantli
reduc
express
antigen
probabl
due
express
partial
c
partial
antigen
tran
rhd
addit
sampl
reduct
express
carri
rhce
variant
alel
phenotyp
use
provid
compat
blood
patient
rarerh
variant
allel
backgroundcas
studi
del
rbc
express
weak
antigen
detect
adsorpt
elut
molecular
method
consequ
del
rbc
type
routin
serolog
method
transfus
routin
recipi
despit
low
preval
phenotyp
among
east
asian
mani
east
asian
estim
del
phenotyp
associ
rhd
allel
del
case
report
east
asia
describ
rhd
alloimmun
del
rbc
transfus
recipi
given
number
east
asian
resid
unit
state
import
know
transfus
unit
del
rbc
pose
risk
rhd
alloimmun
recipi
us
studi
designmethod
literatur
review
perform
estim
number
unit
rbc
transfus
us
percent
east
asian
donor
preval
del
phenotyp
among
east
asian
calcul
perform
estim
minim
maxim
number
del
rbc
unit
transfus
annual
recipi
us
resultsfind
preval
phenotyp
east
asian
popul
vari
preval
del
rhd
allel
base
popul
survey
differ
east
asian
popul
averag
number
unit
rbc
transfus
us
percent
east
asian
donor
urban
red
cross
blood
center
use
formula
tabl
estim
number
del
rbc
unit
transfus
annual
unit
state
rang
minimum
maximum
case
rhd
alloimmun
attribut
transfus
del
rbc
report
us
conclus
like
explan
absenc
report
case
rhd
alloimmun
lack
activ
hemovigil
one
initi
step
address
potenti
risk
transfus
del
rbc
would
activ
hemovigil
rhd
alloimmun
commun
signific
popul
east
asian
option
alreadi
implement
limit
donor
program
includ
screen
c
e
antigen
base
statist
associ
test
pool
donor
sampl
del
allel
pcr
usd
one
european
center
tabl
estim
number
rbc
unit
del
transfus
per
year
us
backgroundcas
studi
drug
known
interfer
routin
blood
bank
test
novel
monoclon
human
antibodi
bind
human
enter
clinic
trial
patient
acut
myeloid
leukemia
lymphoma
solid
tumor
describ
two
case
patient
treat
abo
discrep
revers
type
panaggutinin
plasma
studi
designmethod
retrospect
review
two
case
immunohematolog
show
abo
discrep
plasma
panagglutinin
first
case
year
old
femal
progress
follicular
lymphoma
enrol
phase
trial
combin
rituximab
design
patient
relapsedrefractori
b
cell
nhl
prior
transfus
histori
histor
blood
type
known
two
rbc
unit
request
anticip
surgic
procedur
second
case
year
old
male
refractori
diffus
larg
b
cell
lymphoma
enrol
clinic
trial
histor
blood
type
rh
posit
neg
antibodi
screen
receiv
three
rbc
unit
within
past
month
prior
test
receiv
therapi
resultsfind
abo
type
first
case
show
discrep
forward
type
revers
type
cell
b
cell
rhd
type
posit
extend
reagent
rbc
panel
test
patient
serum
react
cell
test
immedi
spin
phase
ahg
plasma
reactiv
persist
dtt
ficin
treat
red
cell
remov
cold
autoadsorpt
cold
alloadsorpt
rest
adsorpt
repeat
test
avoid
read
antihuman
globulin
ahg
phase
use
liss
peg
enhanc
rule
clinic
signific
alloantibodi
direct
toward
common
red
blood
cell
antigen
direct
antiglobulin
test
dat
autocontrol
neg
rbc
unit
issu
patient
crossmatch
compat
ahg
phase
abo
type
second
case
perform
administr
show
discrep
forward
revers
b
cell
rhd
type
posit
antibodi
screen
perform
solid
phase
technolog
posit
reagent
red
cell
plasma
react
reagent
red
cell
liss
polyspecif
ahg
dat
autocontrol
neg
genotyp
determin
full
rbc
phenotyp
dna
analysi
obtain
repeat
test
avoid
phase
show
reactiv
exclud
alloantibodi
direct
toward
common
red
blood
cell
antigen
conclus
therapi
interfer
blood
bank
test
caus
abo
discrep
panagglutinin
reactiv
plasma
liss
ahg
phase
use
unlik
interfer
knowledg
patient
blood
type
phenotyp
start
therapi
critic
provid
safe
blood
backgroundcas
studi
male
discrep
abo
type
result
investig
initi
forward
type
group
seen
revers
type
unexpect
reaction
note
b
reagent
genotyp
surprisingli
show
abo
consist
group
initi
test
refer
center
sampl
sent
extend
analysi
studi
designmethod
standard
serolog
method
flow
cytometri
use
panel
abo
reagent
lectin
test
nativ
red
blood
cell
rbc
lewi
phenotyp
perform
genet
test
abo
patient
rbc
use
screen
donor
plasma
two
reactiv
plasma
treatment
specif
convert
b
antigen
h
j
biol
chem
plasma
enzym
activ
assay
hult
etal
transfu
med
epub
apr
perform
resultsfind
posit
reaction
obtain
polyclon
b
monoclon
clone
test
patient
rbc
panel
lectin
gave
neg
result
genet
test
confirm
predict
group
rule
presenc
antigen
patient
le
thu
secretor
posit
crossmatch
seen
group
plasma
reactiv
obtain
b
plasma
dtt
treatment
plasma
indic
antibodi
mainli
igg
type
confirm
posit
flow
cytometri
cross
match
use
igg
secondari
antibodi
reactiv
remain
treatment
thu
exclud
normal
type
b
antigen
underli
reason
inhibit
lewi
substanc
significantli
decreas
reactiv
enzym
activ
assay
show
patient
plasma
contain
fulli
function
b
glycosyltransferas
suspicion
patient
cell
produc
type
chain
sampl
hematopoiet
stem
cell
transplant
hsct
patient
group
b
secretor
receiv
group
donor
cell
includ
control
gave
type
reaction
conclus
medic
histori
patient
queri
inde
undergon
hsct
year
earlier
reaction
like
due
uptak
bleb
type
antigen
isbt
domin
lewi
antigen
recipi
origin
blood
group
b
le
interestingli
affect
bleb
simpli
plu
insepar
rare
report
specif
appear
common
among
group
donor
phenomenon
report
unknown
clinic
implic
highlight
complex
carbohydr
blood
group
backgroundcas
studi
ortho
scientif
raritan
new
jersey
autom
analyz
use
card
technolog
perform
immunohematolog
test
benefit
autom
test
includ
improv
effici
enhanc
reliabl
eight
year
use
transfus
medicin
servic
switch
ortho
analyz
januari
shortli
implement
technologist
report
increas
time
spent
perform
manual
resolut
indetermin
design
result
addit
test
column
note
visual
neg
call
posit
analyz
object
studi
investig
caus
appar
fals
posit
result
antibodi
screen
studi
designmethod
assist
ortho
diagnost
analyz
archiv
queri
identifi
number
gel
card
column
use
screen
number
column
result
gel
card
lot
number
use
test
reactiv
determin
fals
posit
base
supervisori
review
digit
imag
antibodi
panel
result
investig
also
includ
review
daili
qc
record
instrument
mainten
instrument
diagnost
camera
calibr
resultsfind
column
run
part
antibodi
screen
column
gener
result
assum
second
technologist
time
per
estim
hour
need
resolv
updat
result
among
potenti
caus
investig
gel
card
lot
number
associ
number
gener
tabl
case
three
column
visual
neg
analyz
report
reactiv
cell
case
antibodi
identif
panel
perform
also
ficin
panel
yield
panel
perform
two
routin
panel
weak
reactiv
hla
cell
four
ficin
panel
weak
reactiv
appar
specif
fourteen
patient
coincident
subsequ
type
screen
neg
one
patient
newli
demonstr
fifti
percent
visual
neg
analyz
posit
sampl
test
gel
card
lot
number
lot
lot
conclus
incid
visual
neg
analyz
posit
result
depend
specif
lot
card
use
differ
lot
investig
ortho
diagnost
remain
explain
avoid
unnecessari
wast
technologist
time
resourc
assist
ortho
diagnost
implement
surveil
program
assess
incid
everi
chang
gel
card
lot
unsatisfactori
lot
replac
visual
neg
analyz
posit
screen
repeat
manual
neg
test
perform
backgroundcas
studi
daratumumab
dara
human
monoclon
antibodi
licens
use
multipl
myeloma
dara
bind
red
cell
vitro
caus
indirect
antiglobulin
test
iat
mask
underli
red
cell
alloantibodi
dara
releas
compassion
use
march
republ
ireland
test
patient
receiv
dara
ireland
current
perform
irish
blood
transfus
servic
ibt
studi
designmethod
ibt
red
cell
immunohaematolog
laboratori
evalu
variou
method
detect
known
alloantibodi
presenc
dara
prior
releas
cord
cell
antibodi
screen
dtt
treat
reagent
red
cell
dtt
method
evalu
direct
tube
iat
techniqu
low
ionic
strength
salin
liss
tube
iat
techniqu
gel
column
gc
iat
techniqu
retrospect
analysi
perform
sampl
refer
ibt
may
march
inclus
follow
introduct
dtt
method
perform
monitor
perform
period
dtt
liss
tube
dtt
gc
iat
techniqu
observ
describ
resultsfind
method
evalu
dtt
method
prove
use
mitig
dara
interfer
cord
cell
effect
limit
suppli
alloadsorpt
ineffect
three
differ
dtt
method
evalu
tube
method
initi
fail
led
addit
liss
pass
gc
method
sensit
method
follow
releas
dara
sampl
patient
sampl
unit
issu
test
use
liss
tube
gc
iat
method
despit
dtt
treatment
gc
method
remain
posit
iat
patient
test
perform
eight
test
presenc
antibodi
confirm
rouleaux
format
observ
patient
reactiv
detect
transfus
reaction
report
date
alloantibodi
format
observ
date
conclus
previous
report
dtt
method
use
mitig
dara
interfer
observ
interfer
seem
due
rouleaux
andor
cold
reactiv
antibodi
seen
least
liss
tube
iat
may
due
wash
phase
techniqu
dissip
rouleaux
format
reactiv
due
cold
reactiv
antibodi
elimin
perform
strict
practic
use
dtt
iat
method
initi
patient
referr
residu
reactiv
gc
observ
use
liss
tube
prefer
thereaft
patient
observ
investig
could
includ
use
cord
cell
confirmexclud
dara
use
suspect
backgroundcas
studi
incid
posit
direct
antiglobulin
test
blood
donor
report
semin
hematol
low
level
iga
igg
igm
report
immunosorb
assay
studi
blood
donor
immunohematolog
laboratori
test
random
allogen
blood
donor
autolog
donor
intend
repres
hospit
patient
popul
determin
mean
rang
normal
level
year
retrospect
studi
perform
assess
level
igg
iga
igm
normal
donor
studi
designmethod
residu
aliquot
random
allogen
autolog
blood
donor
sequest
test
per
institut
review
board
approv
protocol
sampl
test
fc
fluorescein
isothiocyan
fitc
igg
iga
jackson
immunoresearch
lab
west
grove
pa
igm
life
technolog
carlsbad
ca
optim
dilut
dulbecco
pb
contain
bsa
becton
dickinson
facscaliburtm
facscantm
san
jose
ca
fc
analyz
rbc
sampl
sampl
ig
coat
control
rbc
test
determin
fc
set
control
valid
control
react
expect
resultsfind
fc
method
detect
ig
report
percent
rbc
character
amount
bound
ig
allogen
donor
sampl
yield
elev
level
iga
donor
test
igg
donor
test
igm
donor
test
autolog
donor
yield
sampl
elev
level
igg
see
tabl
data
conclus
unexpectedli
autolog
donor
gave
lower
mean
valu
compar
allogen
donor
igg
iga
igm
bound
ig
less
autolog
donor
test
mean
age
donor
could
older
allogen
donor
mean
age
allogen
donor
captur
despit
rel
small
number
sampl
test
higher
expect
instanc
allogen
donor
elev
iga
igg
igm
level
emphas
need
includ
test
normal
donor
popul
establish
expect
reactiv
thu
normal
abnorm
rang
flow
cytometr
test
backgroundcas
studi
recombin
event
gener
mani
gypa
gypb
hybrid
give
rise
glycophorin
gp
variant
express
antigen
eg
mia
mini
mur
rare
individu
homozyg
allel
associ
lack
antigen
eg
enkt
eneh
enav
complex
hybrid
recombin
event
make
challeng
elucid
specif
allel
present
sampl
particularli
heterozygot
investig
sampl
pregnant
asian
hmong
woman
antibodi
unidentifi
mn
antigen
sampl
sister
studi
designmethod
standard
method
use
rbc
type
licens
unlicens
reagent
antibodi
identif
dna
isol
wbc
hea
precisetyp
amplif
sequenc
gypb
exon
long
rang
sequenc
exon
amplicon
perform
primer
use
associ
chang
phase
specif
allel
resultsfind
rbc
pregnant
proband
type
gammaclon
plasma
reactiv
consist
antibodi
high
preval
antigen
suggest
specif
mn
system
howev
hea
genotyp
gypb
ss
ortho
quotient
seraclon
react
rbc
rbc
mi
hilmini
wr
plasma
compat
en
rbc
rbc
peopl
homozyg
gyp
hil
sampl
sister
react
similar
variabl
gypb
ss
genotyp
surprisingli
rbc
compat
proband
molecular
investig
gypb
exon
fail
amplifi
proband
long
rang
amplif
sequenc
reveal
gypb
exon
replac
gypa
consist
gyp
hybrid
specif
homozyg
gyp
hilhil
gypb
sequenc
sister
found
gyp
hybrid
exon
portion
exon
nucleotid
heterozyg
gyp
exon
gypa
linkagephas
primer
indic
sister
compound
heterozygot
hybrid
gyp
gyp
bun
tran
hybrid
gyp
gyp
hil
conclus
case
illustr
long
rang
pcr
superior
standard
sequenc
investig
complex
glycophorin
hybrid
scarciti
relev
antibodi
mn
low
preval
antigen
incompat
gyp
hilhil
proband
sister
difficult
explain
reveal
sister
gyp
hilbun
show
gyp
hil
gyp
bun
associ
partial
antigen
express
detect
gammaclon
antibodi
compat
en
rbc
ie
molecular
result
indic
also
risk
proband
two
previou
pregnanc
transfus
hemorrhag
three
autolog
rbc
unit
collect
mother
frozen
fetal
neonat
complic
report
pregnanc
went
term
backgroundcas
studi
u
antigen
belong
mn
blood
group
system
lack
african
american
individu
lack
u
develop
exposur
u
red
blood
cell
rbc
result
transfus
reaction
decreas
red
cell
surviv
rbc
type
serolog
may
actual
express
one
two
known
uvar
antigen
weak
antigen
express
miss
serolog
test
st
unless
use
peg
enhanc
reid
etal
immunohematolog
molecular
test
mt
rbc
genotyp
distinguish
uvar
type
survey
sent
immunohematolog
refer
lab
irl
gather
inform
use
rbc
genotyp
patient
donor
serolog
johnson
n
etal
transfus
sinc
mt
made
requir
submiss
donor
american
rare
donor
program
ardp
resurvey
facil
assess
chang
practic
studi
designmethod
survey
question
sent
irl
email
surveymonkey
tabul
result
examin
assess
differ
practic
amongst
laboratori
detect
chang
practic
prior
current
survey
respons
resultsfind
irl
respond
respond
report
use
mt
determin
uuvar
statu
blood
donor
furthermor
respond
report
nearli
donor
test
mt
respond
estim
less
donor
test
mt
respond
use
mt
primari
method
determin
uuvar
statu
patient
wherea
use
st
use
st
first
follow
mt
patient
test
st
respond
report
request
unit
ardp
report
routin
request
unit
confirm
mt
respond
report
suppli
unit
ardp
report
suppli
unit
confirm
mt
wherea
respond
survey
report
use
mt
donor
first
donat
other
subsequ
donat
increas
respond
irl
requir
mt
confirm
donor
unit
rose
irl
suppli
donor
unit
ardp
confirm
statu
mt
rose
particip
queri
transfus
reaction
patient
receiv
blood
particip
report
case
involv
mt
report
case
mt
conclus
donor
center
increasingli
adopt
use
mt
identifi
andor
confirm
statu
donor
trend
result
lower
risk
patient
need
rbc
transfus
backgroundcas
studi
rhd
antigen
clinic
signific
immunogen
therefor
individu
develop
risk
haemolyt
transfus
reaction
rhd
polymorph
show
substanti
ethnic
variabl
least
rhd
variant
associ
weak
allel
report
studi
report
two
new
rhd
allel
brazilian
blood
donor
associ
weak
antigen
express
studi
designmethod
statu
evalu
commerci
avail
monoclon
reagent
blend
igmigg
clone
igm
clone
igg
tube
gel
card
c
c
e
e
phenotyp
perform
gel
common
weak
partial
allel
investig
allel
specif
pcr
rhd
beadchip
platform
immucor
direct
autom
sequenc
rhd
exon
flank
intron
region
perform
sanger
dideoxi
method
order
determin
rhd
allel
combin
also
perform
clone
sequenc
resultsfind
donor
sampl
phenotyp
sampl
show
weak
hemagglutin
reaction
clone
neg
igm
clone
clone
sequenc
reveal
two
variant
allel
combin
previous
describ
one
donor
found
weak
type
rhd
ci
hybrid
exon
rhd
tran
rhd
exon
donor
present
new
g
base
chang
rhd
exon
encod
transmembran
segment
rhd
protein
also
ci
hybrid
exon
rhd
tran
rhd
conclus
identifi
two
novel
allel
carri
mutat
associ
dv
type
one
addit
point
mutat
tran
rhd
donor
herein
character
region
intens
process
admixtur
descend
european
african
gene
brazilian
blood
donor
contribut
rhd
gene
variabl
backgroundcas
studi
donor
neg
multipl
common
antigen
lack
high
preval
antigen
effici
identifi
use
red
blood
cell
rbc
genotyp
panel
serolog
use
confirm
antigen
neg
statu
discrep
identifi
albeit
rare
investig
discrep
often
lead
identif
variant
antigen
known
set
gyp
variant
associ
express
sta
antigen
also
associ
n
type
discrep
individu
meyer
etal
br
j
haematol
sta
allel
also
describ
gyp
hybrid
crossov
intron
sought
investig
five
n
type
discrep
altern
genotyp
methodolog
perform
found
concord
initi
panel
studi
designmethod
sampl
set
compris
five
african
american
donor
sampl
predict
precisetyp
hea
molecular
beadchip
immucor
warren
nj
genom
sequenc
analysi
found
n
serolog
oligonucleotid
primer
synthes
pcr
reaction
condit
detect
gyp
hybrid
encod
sta
base
meyer
etal
pcr
amplif
genom
dna
perform
analyz
agaros
gel
electrophoresi
pcr
product
subject
sanger
sequenc
use
primer
sequenc
perform
genewiz
plainfield
nj
sequenc
align
gypa
gypb
consensu
sequenc
use
sequench
genecod
ann
arbor
mi
resultsfind
three
sampl
yield
base
pair
pcr
product
sta
primer
control
sampl
whose
genotyp
phenotyp
known
concord
yield
product
sequenc
sampl
match
known
mn
hybrid
gyp
type
b
gyp
type
f
sequenc
previous
report
novel
gyp
hybrid
sequenc
reveal
gypb
exon
gypa
exon
breakpoint
intron
rather
breakpoint
intron
observ
previous
report
staallel
conclus
n
type
discrep
genotyp
predict
sampl
type
serolog
find
sampl
type
n
may
caus
presenc
hybrid
gyp
allel
encod
sta
implic
n
type
donor
unit
transfus
patient
unknown
would
reason
disqualifi
phenotyp
case
backgroundcas
studi
sampl
year
old
pregnant
african
american
femal
sent
blood
bank
aborh
antibodi
screen
sampl
analyz
use
provu
analyz
ortho
diagnost
patient
type
po
revers
type
discrep
retyp
sampl
perform
use
tube
method
biorad
reagent
per
hospit
polici
due
previou
aborh
histori
file
retyp
show
patient
subgroup
antibodi
present
plasma
sampl
refer
genotyp
suspicion
like
phenotyp
genet
test
support
serolog
find
subgroup
new
abo
allel
abo
never
report
correl
subgroup
detect
studi
designmethod
patient
rbc
type
immucor
b
biorad
grifol
dg
gel
antibodi
work
perform
use
three
differ
lot
cell
three
lot
well
type
screen
cell
auto
control
tube
read
also
incub
rt
patient
initi
antibodi
screen
use
ortho
gel
neg
dna
sequenc
perform
sanger
dideoxi
method
genom
dna
extract
edta
whole
blood
sequenc
region
includ
abo
exon
flank
intron
region
well
intron
enhanc
ci
vs
tran
arrang
polymorph
abo
polymorph
determin
amplif
genom
dna
segment
includ
aboexon
ligat
topo
ta
clone
vector
life
technolog
clone
sequenc
resultsfind
patient
type
neg
b
biorad
b
dg
gel
grifol
work
reveal
igm
antibodi
react
rt
gel
liss
antibodi
screen
neg
genet
test
show
polymorph
encod
aspart
acid
histidin
chang
posit
found
otherwis
common
abo
background
genom
dna
clone
sequenc
show
patient
genotyp
consist
allel
abo
unreport
abo
conclus
patient
deliv
healthi
babi
boy
week
gestat
babi
cord
sent
laboratori
babi
serolog
type
show
phenotyp
refer
genet
test
babi
rbc
show
abo
found
mother
previous
report
abo
allel
encod
aspart
acid
asparagin
chang
posit
consist
aweak
phenotyp
also
least
five
allel
encod
phenoytp
consist
polymorph
posit
give
special
characterist
new
unreport
abo
allel
data
collect
conclud
phenotyp
encod
variant
allel
abo
highlight
clinic
relev
confirm
serolog
abo
subgroup
molecular
method
backgroundcas
studi
elucid
molecular
basi
blood
group
express
led
develop
high
throughput
molecular
method
predict
blood
group
antigen
commonli
use
singl
nucleotid
polymorph
snp
array
requir
nucleic
acid
isol
typic
achiev
extract
genom
dna
whole
blood
method
requir
venipunctur
may
ideal
approach
sever
anem
patient
potenti
donor
unabl
provid
sampl
whole
blood
due
remot
locat
dna
extract
buccal
swab
sampl
offer
noninvas
altern
venipunctur
may
provid
safe
effici
mean
transport
sampl
remot
locat
refer
laboratori
extend
blood
type
predict
canadian
blood
servic
cb
perform
larg
scale
dna
extract
hla
genotyp
onematch
stem
cell
marrow
registri
use
buccal
swab
sinc
buccal
swab
also
use
unrel
donor
stem
cell
registri
us
nmpd
sought
assess
accuraci
reliabl
use
dna
extract
buccal
swab
predict
blood
group
antigen
express
studi
designmethod
perform
parallel
red
cell
genotyp
autom
type
platform
progenikagrifol
idcorext
assay
progenika
bizkaia
spain
use
dna
extract
blood
buccal
tissu
volunt
antigen
system
avail
serolog
reagent
also
compar
result
serolog
type
evalu
three
differ
method
dna
extract
perform
test
regardless
dna
yield
puriti
two
buccal
swab
puritan
medic
product
guilford
main
use
test
swab
store
room
temperatur
dna
extract
perform
within
six
day
collect
initi
phase
studi
buccal
swab
sampl
n
process
autom
biorobot
robot
use
magattract
dna
mini
extract
method
qiagen
venlo
netherland
extract
dna
mean
concentr
puriti
respect
second
phase
studi
n
dna
extract
buccal
swab
perform
use
method
avail
nation
red
cell
immunohematolog
refer
laboratori
qiaamp
dna
mini
kit
use
either
manual
autom
qiacub
robot
workstat
qiagen
venlo
netherland
resultsfind
manufactur
recommend
analyt
rang
dna
concentr
recommend
puriti
absorb
ratio
use
id
corext
platform
dna
extract
buccal
swab
sampl
meet
specif
sever
case
howev
case
lower
concentr
dna
adequ
predict
phenotyp
dombrock
system
suscept
failur
interpret
sampl
low
dna
concentr
call
result
report
concord
genotyp
result
sourc
dna
extract
whole
blood
buccal
tissu
also
concord
predict
phenotyp
serolog
test
result
conclus
studi
support
use
genom
dna
extract
buccal
tissu
id
corext
predict
rbc
phenotyp
high
accuraci
extract
method
may
requir
optim
achiev
dna
yield
within
recommend
analyt
rang
assay
backgroundcas
studi
well
establish
weak
phenotyp
risk
form
wherea
weak
partial
neg
phenotyp
routin
serolog
type
distinguish
among
consequ
rhd
genotyp
recommend
especi
patient
id
rhd
xt
progenika
grifol
qualit
xmap
genotyp
test
identif
follow
rhd
gene
allel
variant
rhd
weak
type
rhd
weak
type
rhd
weak
type
rhd
delet
rhd
pseudogen
rhd
gene
genom
dna
extract
whole
blood
specimen
studi
perform
id
rhd
xt
genotyp
assay
evalu
term
whole
system
failur
rate
call
rate
accuraci
rh
blood
group
type
studi
designmethod
cohort
previous
serotyp
sampl
antigen
obtain
three
european
blood
center
analyz
id
rhd
xt
progenika
sampl
distribut
recommend
annex
common
technic
specif
ivd
product
list
clinic
sampl
neonat
specimen
weak
donor
intend
use
product
weak
serotyp
donor
enrich
commerci
serolog
test
antigen
predict
phenotyp
bd
weak
type
confirm
predict
phenotyp
use
comparison
resultsfind
system
failur
call
rate
inconclus
result
obtain
discrep
found
antigen
serolog
id
rhd
xt
predict
phenotyp
result
although
concord
obtain
analyz
bd
consid
id
rhd
xt
result
correct
concord
id
rhd
xt
bd
result
weak
type
follow
id
rhd
xt
predict
phenotyp
result
obtain
neg
amplif
variant
weak
type
weak
type
heterozyg
weak
type
weak
type
heterozyg
weak
type
weak
type
heterozyg
weak
type
detect
regard
blood
group
predict
phenotyp
result
obtain
id
rhd
xt
concord
bd
result
posit
neg
posit
neg
conclus
id
rhd
xt
genotyp
assay
perform
reliabl
accur
method
predict
genotyp
phenotyp
high
preval
rhd
neg
weak
type
specif
sensit
antigen
antigen
make
use
tool
implement
rhdgenotyp
recommend
patient
blood
transfus
prophylaxi
backgroundcas
studi
scd
patient
form
red
blood
cell
rbc
antibodi
higher
rate
transfus
popul
multipl
predictor
alloimmun
report
well
replic
larg
scd
cohort
investig
clinic
laboratori
genet
predictor
alloimmun
studi
designmethod
larg
scd
cohort
establish
brazil
investig
diseas
outcom
particip
site
patient
current
transfus
abodcceekel
match
rbc
prophylact
extend
phenotyp
match
rbc
first
antibodi
form
polici
match
evolv
increas
level
match
exposur
period
includ
studi
transfus
subject
rbc
alloantibodi
defin
specif
within
cohort
compar
transfus
antibodi
neg
subject
use
chi
squar
compar
categor
variabl
wilcoxon
test
appropri
compar
continu
variabl
backward
elimin
multivari
logist
model
use
gener
odd
ratio
identifi
independ
predictor
alloimmun
use
result
univari
analys
subject
peripher
blood
whole
genom
snp
type
perform
use
affymetrix
array
includ
enhanc
content
blood
relat
snp
genom
wide
associ
gwa
analys
conduct
use
logist
model
identifi
addit
genet
effect
associ
alloimmun
p
valu
clinic
analysi
gwa
consid
statist
signific
resultsfind
cohort
patient
transfus
subject
includ
alloimmun
children
year
alloimmun
adult
multivari
logist
regress
model
age
age
compar
gender
femal
compar
male
transfus
histori
p
transfus
compar
site
hemolysi
log
transform
lactat
dehydrogenas
presenc
autoimmun
disord
p
independ
predictor
alloimmun
gwa
identifi
singl
snp
unclear
biolog
signific
associ
alloimmun
eefsec
gene
respons
incorpor
selenocystein
protein
conclus
rbc
alloimmun
primarili
driven
transfus
burden
scd
cohort
hemolysi
remain
significantli
associ
alloimmun
control
transfus
presenc
autoimmun
diseas
also
associ
rbc
alloimmun
indic
system
immun
dysregul
may
present
scd
patient
develop
rbc
alloantibodi
howev
gwa
identifi
snp
immunoregulatori
gene
significantli
associ
rbc
antibodi
format
studi
popul
backgroundcas
studi
physiolog
anemia
sever
preterm
infant
worsen
blood
loss
requir
laboratori
test
reduc
iatrogen
anemia
placent
blood
otherwis
would
discard
use
laboratori
test
mother
infant
blood
mix
placenta
deliveri
test
result
potenti
alter
due
hemorrhag
publish
studi
show
test
result
placent
blood
give
result
heel
stick
sampl
standard
practic
studi
designmethod
transfus
servic
test
sampl
pair
newborn
less
gr
birth
weight
one
sampl
collect
newborn
heel
stick
sampl
placenta
follow
test
perform
sampl
pair
abo
rh
antibodi
screen
direct
antiglobulin
test
igg
dat
resultsfind
abo
rh
dat
test
perform
sampl
pair
dat
test
neg
sampl
pair
two
posit
concord
abo
rh
dat
test
perform
sampl
pair
antibodi
screen
perform
placent
blood
sampl
heel
stick
sampl
twenti
eight
sampl
pair
neg
antibodi
screen
test
one
posit
heel
stick
sampl
also
posit
use
placent
sampl
one
heel
stick
sampl
neg
presenc
antibodi
found
posit
placent
blood
sampl
antibodi
detect
placent
sampl
passiv
mother
receiv
pregnanc
discrep
result
indic
placent
blood
sampl
sensit
detect
weak
antibodi
conclus
studi
show
placent
blood
sampl
inferior
heel
stick
sampl
regard
abo
rh
dat
test
base
comparison
studi
placent
blood
use
test
birth
weight
newborn
backgroundcas
studi
well
known
frequenc
red
blood
cell
rbc
phenotyp
vari
popul
differ
ethnic
background
exist
data
describ
frequenc
western
black
popul
preval
omani
unknown
research
aim
studi
preval
differ
rbc
phenotyp
among
omani
blood
donor
studi
designmethod
studi
approv
local
reserach
ethic
board
blood
group
rbc
phenotyp
enrol
omani
blood
donor
serolog
test
follow
blood
group
system
assess
rh
c
c
e
e
kell
k
k
kpa
kpb
kidd
jka
jkb
duffi
fya
fyb
lewi
lea
leb
lutheran
lua
lub
mn
n
antigen
frequenc
differ
phenotyp
analyz
use
r
softwar
version
resultsfind
total
omani
blood
donor
test
common
blood
group
follow
b
ab
among
test
donor
posit
common
rh
phenotyp
kell
blood
group
system
donor
k
posit
k
antigen
found
common
phenotyp
duffi
blood
group
system
fy
fy
ab
found
higher
frequenc
compar
report
black
popul
tabl
commonest
phenotyp
kidd
mn
blood
group
system
jk
ab
respect
lea
leb
allel
seen
donor
respect
phenotyp
found
donor
frequenc
rare
phenotyp
jk
le
ab
lu
respect
phenotyp
found
frequenc
antigen
found
similar
report
caucasian
conclus
first
studi
examin
frequenc
rbc
blood
group
phenotyp
among
omani
blood
donor
result
show
higher
frequenc
rare
null
phenotyp
fy
jk
lu
compar
report
caucasian
frequenc
duffi
blood
group
system
resembl
report
black
popul
data
help
understand
influenc
arab
ethnic
background
rbc
blood
group
system
warrant
larg
studi
region
backgroundcas
studi
rh
antibodi
develop
individu
expos
antigen
scenario
commonli
observ
alloimmun
antenat
volunt
immun
patient
quantit
serum
import
clinic
set
predict
risk
hemolyt
diseas
newborn
quantit
also
perform
qualiti
control
oper
organ
procur
organ
plasma
fraction
common
practic
report
strength
serum
antibodi
titer
valu
qualiti
control
oper
requir
quantit
valu
develop
screen
assay
use
flow
cytometri
quantit
serum
studi
designmethod
develop
method
quantit
serum
use
flow
cytometri
modifi
protocol
christensson
etal
hilden
etal
red
blood
cell
blood
sampl
wash
three
time
salin
pb
ph
supernat
discharg
dilut
buffer
contain
human
serum
albumin
vv
phosphat
buffer
salin
prepar
serum
sampl
standard
suspend
dilut
buffer
mix
wash
red
cell
cell
suspens
incub
min
follow
incub
dilut
buffer
ad
mixtur
incub
addit
min
sampl
analyz
flow
cytometri
use
gate
typic
red
cell
base
forward
signal
green
fluoresc
collect
use
filter
set
event
record
frequenc
cell
resultsfind
multipl
dilut
refer
standard
test
red
blood
cell
five
differ
donor
reproduc
assay
determin
measur
chang
coeffici
varianc
due
dilut
procedur
machin
variat
sampl
storag
condit
optim
factor
linear
regress
calcul
establish
standard
curv
fluoresc
intens
emit
probe
demonstr
linear
correl
concentr
rh
antigen
refer
standard
serum
thirti
rh
volunt
analyz
concentr
result
benchmark
antibodi
titer
valu
conclus
base
studi
conclud
quantit
rh
antigen
flow
cytometri
use
reliabl
assay
measur
concentr
antibodi
serum
method
reproduc
advantag
report
antibodi
titer
valu
oper
platform
translat
base
flow
cytometri
backgroundcas
studi
use
emerg
issu
group
plasma
uncrossmatch
group
whole
blood
wb
patient
without
valid
abo
group
becom
increasingli
common
usa
unclear
low
titer
product
provid
situat
inde
univers
agre
upon
threshold
would
qualifi
low
titer
establish
studi
design
determin
rate
high
titer
donor
use
titer
threshold
studi
designmethod
three
academ
hospit
routin
issu
group
plasma
unit
emerg
issu
particip
studi
issu
plasma
patient
dilut
donor
plasma
salin
produc
ad
group
b
reagent
red
blood
cell
rbc
degre
macroscop
agglutin
immedi
spin
observ
unit
consid
high
titer
would
issu
group
recipi
three
center
temperatur
plasma
volum
time
enhanc
perform
titer
procedur
globulin
ad
one
center
sampl
taken
plasma
group
wb
unit
procedur
follow
use
b
reagent
rbc
least
one
antibodi
demonstr
macroscop
agglutin
immedi
spin
wb
unit
consid
high
titer
centrifug
rbc
unit
transfus
plasma
platelet
compon
discard
two
center
provid
plasma
test
data
period
respect
one
center
provid
plasma
wb
test
data
period
resultsfind
total
group
plasma
unit
test
high
titer
rang
high
titer
group
plasma
unit
three
center
wb
unit
test
unit
high
titer
unit
high
titer
high
titer
high
titer
conclus
even
rel
low
titer
threshold
signific
proport
donor
high
titer
antibodi
addit
immedi
spin
titer
method
like
sensit
igm
compon
whether
igg
compon
also
consid
determin
suitabl
unit
potenti
minor
incompat
transfus
especi
group
wb
requir
studi
backgroundcas
studi
dithiothreiol
dtt
sulfhydryl
reagent
denatur
select
blood
group
antigen
reagent
red
blood
cell
rbc
treat
dtt
use
tool
identifi
antibodi
high
frequenc
antigen
recent
dtt
becom
wide
use
destroy
reagent
rbc
render
free
plasma
drug
interfer
procedur
prepar
dtt
publish
advoc
use
buffer
salin
differ
ph
level
studi
effect
ph
dtt
treatment
time
investig
studi
designmethod
salin
nb
thermo
fischer
scientif
inc
middletown
va
use
prepar
dtt
adjust
ph
ph
use
sodium
phosphat
dibasi
sigma
aldrich
saint
loui
mo
reagent
rbc
immucor
norcross
ga
treat
dtt
solut
parallel
mix
ratio
pack
rbc
dtt
solut
follow
incub
minut
treatment
express
k
antigen
measur
everi
minut
tube
method
use
differ
sourc
assur
uniform
reaction
grade
investig
reaction
grade
rbc
antiserum
convert
semiquantit
score
averag
score
calcul
everi
minut
ph
level
reduct
averag
score
differ
ph
also
calcul
everi
minut
measur
impact
dtt
reagent
ph
rate
k
antigen
destruct
resultsfind
express
k
antigen
measur
agglutin
grade
two
differ
k
antisera
significantli
weaken
minut
dtt
treatment
ph
minut
minut
complet
loss
k
express
seen
minut
dtt
treatment
minut
minut
ph
reactiv
pattern
k
antigen
test
sourc
correl
reduct
averag
score
seen
minut
rang
dtt
treatment
time
ph
rais
rang
rais
minut
rang
rais
conclus
use
higher
ph
buffer
salin
may
shorten
treatment
time
take
weaken
destroy
k
antigen
base
comparison
reaction
score
differ
ph
level
ph
level
impact
dtt
treatment
minut
andor
beyond
minut
incub
ph
dtt
reagent
rel
treatment
time
factor
consid
valid
process
qualif
dtt
reagent
laboratori
tabl
averag
score
reduct
averag
score
everi
minut
backgroundcas
studi
data
characterist
frequenc
clinic
signific
red
cell
antibodi
within
prenat
popul
well
establish
unit
state
aim
studi
determin
frequenc
red
cell
antibodi
differ
geograph
distinct
region
within
continent
unit
state
studi
designmethod
aim
retrospect
studi
evalu
cohort
prenat
patient
n
drawn
juli
june
patient
divid
unit
state
censu
bureau
region
division
categori
accord
place
resid
prenat
blood
work
collect
includ
abo
rh
screen
unexpect
alloantibodi
sampl
found
posit
red
cell
antibodi
sent
one
nine
region
laboratori
identif
resultsfind
total
patient
found
possess
clinic
signific
red
cell
antibodi
overal
incid
percent
three
commonli
encount
antibodi
n
n
n
frequenc
total
prenat
women
found
possess
two
antibodi
gener
combin
prove
common
instanc
follow
multipl
antibodi
identifi
includ
least
one
antibodi
rh
blood
group
south
region
largest
number
antibodi
identifi
total
west
midwest
northeast
conting
tabl
use
fisher
exact
test
perform
compar
northeast
south
midwest
west
region
p
valu
calcul
determin
nonrandom
associ
valu
deem
signific
perspect
regard
pacif
divis
compris
california
oregon
washington
alaska
p
valu
threshold
compar
seven
eight
divis
west
south
central
divis
texa
oklahoma
arkansa
louisiana
show
statist
signific
result
compar
pacif
divis
p
conclus
depend
upon
antibodi
statist
signific
variat
geograph
region
divis
within
unit
state
observ
relationship
antibodi
local
requir
investig
may
attribut
presenc
absenc
red
cell
antigen
among
differ
racial
ethic
popul
backgroundcas
studi
institut
current
use
immucor
neo
immucor
inc
norcross
georgia
perform
aborh
antibodi
screen
absc
test
util
solid
phase
technolog
result
unabl
obtain
immucor
neo
test
repeat
manual
test
bench
use
tube
agglutin
repeat
test
lead
signific
expens
includ
reagent
suppli
technologist
time
decid
leadership
laboratori
would
benefici
observ
methodolog
perform
regard
evalu
perform
immucor
neo
ortho
vision
ortho
clinic
diagnost
rochest
ny
determin
signific
differ
amount
repeat
manual
tube
test
need
perform
evalu
look
aborh
absc
test
test
current
autom
laboratori
studi
designmethod
thirti
specimen
process
immucor
neo
result
type
determin
ntd
aborh
test
select
test
ortho
vision
specimen
process
immucor
neo
produc
posit
result
absc
test
select
test
ortho
vision
specimen
edta
tube
collect
within
previou
day
timefram
specimen
test
immucor
neo
ortho
vision
day
resultsfind
ntd
specimen
immucor
neo
result
valid
aborh
type
ortho
vision
three
result
flag
indic
possibl
extra
reactiv
upon
perform
visual
review
result
determin
reactiv
valid
result
present
sampl
requir
manual
tube
test
interpret
aborh
due
mix
field
weak
isoagglutinin
unexplain
extra
reactiv
hemolysi
absc
specimen
result
posit
immucor
neo
specimen
produc
neg
result
ortho
vision
confirm
neg
manual
tube
test
use
peg
enhanc
media
one
specimen
flag
fibrin
upon
perform
visual
review
determin
neg
nine
specimen
posit
immucor
neo
also
posit
ortho
vision
one
specimen
prove
seen
gel
tube
one
specimen
display
unexplain
reactiv
gel
neg
tube
clinic
signific
antibodi
rule
conclus
evalu
demonstr
use
ortho
vision
aborh
absc
test
would
result
estim
reduct
repeat
aborh
test
reduct
antibodi
detect
workup
addit
reduct
test
would
result
annual
cost
save
approxim
reagent
suppli
technologist
time
backgroundcas
studi
abo
genotyp
donor
patient
routin
practic
howev
help
resolv
case
abo
discrep
characterist
abo
blood
subgroup
crucial
elucid
mechan
variant
phenotyp
molecular
basi
one
individu
abw
variant
studi
studi
designmethod
abo
antigen
serum
antibodi
proband
detect
serolog
method
whole
code
region
flank
intron
abo
gene
amplifi
polymeras
chain
reaction
pcr
pcr
product
sequenc
bidirect
haplotyp
proband
analyz
clone
sequenc
three
dimension
model
mutant
protein
built
analysi
resultsfind
proband
express
weak
b
antigen
red
blood
cell
monoclon
antibodi
abo
antibodi
serum
detect
standard
b
cell
identifi
abw
variant
phenotyp
heterozyg
site
exon
ag
code
region
abo
gene
identifi
directli
sequenc
analysi
haplotyp
analysi
show
proband
carri
allel
novel
b
allel
sequenc
novel
b
allel
ident
except
c
nucleotid
posit
nomin
dbrbc
ncbi
c
b
allel
result
amino
acid
chang
leu
pro
posit
structur
show
gt
enzym
structur
chang
conclus
novel
b
allel
identifi
c
glycosyltransferas
b
gene
may
decreas
enzymat
activ
result
abw
variant
presenc
antibodi
serum
work
support
scienc
research
foundat
zhejiang
provinc
medic
scienc
research
foundat
zhejiang
provinc
backgroundcas
studi
locr
antigen
character
coghlan
al
transfus
rhce
allel
rhce
rhce
celocr
later
describ
encod
locr
coghlan
al
transfus
substitut
also
report
caus
loss
antigen
faa
al
transfus
locr
consequ
consid
antithet
antigen
rh
phenotyp
partial
c
initi
describ
donor
made
patient
huesti
al
transfus
describ
novel
rhce
allel
rhce
sever
peopl
western
european
ancestri
refer
weak
c
express
allel
show
close
molecular
background
rhce
prompt
us
studi
locr
express
studi
designmethod
unrel
blood
donor
sampl
refer
weak
c
reactiv
male
femal
obstetr
histori
without
unknown
ce
express
studi
polyclon
monoclon
reagent
rhce
analyz
genom
dna
cdna
sequenc
resultsfind
sampl
dcece
show
discrep
result
monoclon
reagent
similar
pattern
reactiv
reaction
sampl
test
polyclon
show
reactiv
dcece
case
test
polyclon
monoclon
show
weaken
reactiv
rhce
sequenc
genom
dna
cdna
show
mutat
exon
predict
encod
substitut
appar
donor
type
allow
predict
rhce
ce
genotyp
altogeth
result
consist
presenc
like
rhce
allel
c
e
ci
sampl
dcece
individu
reactiv
origin
sourc
slightli
weaker
compar
rhce
ce
rbc
sampl
avail
cryobank
conclus
result
confirm
mutat
alter
conform
properti
rhce
protein
either
ce
ce
background
encod
locr
antigen
locr
reactiv
appear
rather
similar
code
rhce
rhce
allel
quit
unexpect
find
sinc
substitut
close
critic
cc
express
none
case
made
andor
subject
potenti
alloimmun
background
howev
rhce
report
code
partial
c
rh
consid
rhce
like
encod
partial
c
e
also
support
predict
local
chang
second
loop
rhce
protein
h
g
bloodwork
nw
univers
washington
depart
laboratori
medicin
backgroundcas
studi
weak
genotyp
recommend
transfus
recipi
pregnant
women
newborn
rhd
type
discrep
serolog
weak
phenotyp
determin
carri
weak
genotyp
purpos
studi
analyz
underli
rhd
genotyp
patient
sampl
receiv
weak
genotyp
sinc
publish
recommend
particular
found
carri
weak
genotyp
studi
designmethod
sampl
receiv
weak
genotyp
test
perform
use
target
sequenc
variant
rhd
gene
previous
defin
sampl
weak
type
genotyp
evid
rhd
genet
sequenc
exon
andor
intron
preliminari
test
evalu
sanger
sequenc
rhd
rhce
exon
determin
underli
rh
genotyp
provid
patient
ethnic
presenc
record
resultsfind
major
sampl
obstetr
patient
follow
transfus
patient
clinic
indic
provid
sampl
found
weak
type
sampl
respect
sampl
appear
genet
rhd
neg
genet
sequenc
perform
sampl
rhd
genet
variant
weak
type
tabl
variant
rhd
sampl
also
show
variat
rhce
gene
two
sampl
wild
type
rhd
allel
evalu
ongo
conclus
sampl
test
weak
genotyp
found
weak
type
sampl
evid
rhd
gene
carri
known
weak
type
polymorph
found
rhd
variant
underli
genet
variat
detect
rhd
gene
major
non
weak
type
variant
dar
allel
often
associ
product
backgroundcas
studi
rhd
genotyp
recommend
guid
transfus
rbc
administr
rh
immunoglobulin
patient
discord
weaker
expect
type
particularli
femal
ob
patient
sandler
etal
transfus
recommend
base
observ
evid
primarili
europ
flegel
curr
opin
individu
weak
type
risk
clinic
signific
implic
util
approach
divers
us
popul
yet
clear
report
month
experi
rhd
genotyp
sampl
refer
discrep
weak
type
investig
januari
april
studi
designmethod
serolog
test
perform
standard
tube
agglutin
licens
reagent
dna
isol
wbc
use
manual
rflp
rhd
beadchip
assay
rhd
sequenc
ethnic
known
sampl
caucasian
african
americanafrican
multiraci
hispan
asian
resultsfind
rhd
genotyp
identifi
weak
type
allel
known
encod
partial
phenotyp
tabl
uncommon
rare
weak
allel
includ
type
found
partial
allel
found
divers
largest
number
includ
partial
rhd
dar
famili
other
order
preval
includ
dol
dvii
dfv
dfr
dfw
dvi
dlo
compound
heterozygot
dhmi
dma
dmb
nine
sampl
rhd
gene
neg
rhce
variant
express
epitop
seven
new
rhd
allel
found
dau
rhd
c
rhd
c
rhd
g
rhd
conclus
multiraci
cohort
individu
weaker
expect
type
due
weak
type
would
consid
risk
clinic
signific
potenti
unknown
risk
studi
import
gain
insight
preval
specif
allel
us
multiethn
popul
continu
evalu
refin
rhd
genotyp
clinic
practic
backgroundcas
studi
human
rh
blood
group
system
c
c
e
e
antigen
express
two
highli
homolog
gene
rhce
rhd
c
immunogen
rh
antigen
differ
c
c
caus
snp
posit
rhce
gene
rhd
allel
also
known
rhd
cat
vii
type
carri
snp
c
rhd
gene
addit
snp
c
rhd
allel
describ
partial
express
rhc
polypeptid
faa
transfus
aim
genotyp
perform
clarifi
caus
weak
c
express
serolog
patient
sampl
male
indic
partial
c
phenotyp
cde
studi
designmethod
rhd
rhce
phenotyp
done
accredit
routin
protocol
monoclon
ab
id
card
diaclon
rh
subgroup
seraclon
genotyp
perform
taqman
probe
assay
veryfi
diagnostik
gmbh
sso
inc
hila
rode
commerci
gene
cde
diagnostik
gmbh
sanger
sequenc
rhd
gene
perform
use
method
diagnostik
gmbh
resultsfind
discrep
genotyp
result
gener
differ
test
system
taqman
probe
base
assay
show
repetit
ccee
genotyp
sso
system
predict
repetit
ccee
phenotyp
sampl
show
weak
c
band
method
band
visibl
commerci
test
kit
parallel
analysi
rhd
gene
gene
cde
test
system
reveal
variant
cat
vii
rhd
allel
sequenc
dna
sampl
identifi
two
snp
one
rhd
allel
c
c
confirm
rhd
one
rhd
allel
conclus
usual
genotyp
provid
clear
answer
conspicu
serolog
howev
case
pcr
offer
conform
result
eg
mutat
primer
bind
site
prevent
amplif
describ
must
differ
primer
andor
probe
design
case
rhce
c
detect
differ
test
system
caus
either
correct
erron
genotyp
result
exampl
high
homolog
rhd
rhce
gene
combin
presenc
cat
vii
snp
c
lead
fals
posit
rhce
c
snp
sso
ssp
genotyp
result
therefor
suggest
genotyp
rhce
rhd
resolv
true
natur
weak
rhce
serolog
backgroundcas
studi
serolog
test
rbc
year
old
hispan
femal
prepar
surgeri
result
variabl
reactiv
weakli
posit
reaction
use
agglutin
versu
tube
test
determin
whether
antigen
express
repres
weak
variant
could
resolv
serolog
test
alon
report
character
novel
rhd
gene
mutat
identifi
rhd
gene
sequenc
studi
designmethod
serolog
type
initi
perform
agglutin
autom
analyz
platform
galileo
neo
galileo
echo
immucor
norcross
ga
standard
tube
test
use
immucor
seri
reagent
immunohematolog
evalu
perform
standard
tube
test
immedi
spin
indirect
antiglobulin
iat
use
orthobioclon
immucor
gammaclon
immucor
seri
seri
albaclon
reagent
dna
isol
wbc
use
manual
rflp
rhd
beadchip
assay
immucor
bioarray
rhd
sequenc
resultsfind
rbc
reactiv
summar
tabl
dna
test
detect
hybrid
rhesu
box
associ
rhd
gene
delet
indic
patient
hemizyg
rhd
rflp
assay
rhd
beadchip
identifi
chang
rhd
gene
sequenc
identifi
new
g
chang
exon
encod
amino
acid
chang
predict
locat
chang
within
fourth
transmembran
segment
rhd
protein
conclus
identifi
novel
rhd
allel
g
chang
exon
sever
snp
delet
insert
report
chang
exon
phenotyp
genet
variat
result
rh
neg
weak
type
variant
sinc
chang
previous
identifi
unabl
determin
confer
risk
alloimmun
rhd
g
snp
result
serolog
weak
phenotyp
express
antigen
test
agglutin
neoecho
platform
case
combin
agglutin
dna
sequenc
help
identifi
new
allel
would
miss
standard
tube
serolog
test
current
commerci
avail
array
assay
backgroundcas
studi
joa
antigen
one
three
high
incid
antigen
dombrock
system
preval
antigen
popul
greater
black
popul
joa
antigen
resist
enhanc
enzym
treatment
ficinpapain
typic
variabl
dithiothreitol
dtt
immucor
zzap
treatment
igg
antibodi
demonstr
ahg
phase
hemolyt
transfus
reaction
joa
antigen
vari
none
moderatesever
hemolyt
diseas
fetu
newborn
hdfn
observ
antibodi
associ
dombrock
system
two
common
phenotyp
present
black
popul
hy
negativejoa
neg
hy
weakli
expressedjoaneg
studi
designmethod
antibodi
identif
red
blood
cell
rbc
unit
request
posit
year
old
femal
histori
sickl
cell
diseas
histori
pregnanc
patient
recent
transfus
howev
histori
chronic
transfus
last
report
transfus
three
year
prior
current
specimen
known
rbc
antibodi
time
request
facil
report
patient
hemoglobin
gdl
hematocrit
hgbhct
appear
sickl
cell
crisi
request
phenotyp
match
unit
per
hospit
polici
c
e
k
receiv
immunohematolog
refer
laboratori
irl
resultsfind
detect
patient
plasma
react
liss
peg
tube
method
manual
antibodi
resist
test
dtt
treat
red
cell
frozen
reagent
rbc
neg
joa
antigen
posit
hy
use
serolog
prove
presenc
antibodi
high
incid
antigen
allogen
peg
adsorpt
perform
rule
common
clinic
signific
antibodi
identifi
use
adsorb
plasma
test
molecular
genotyp
grifol
idcorext
confirm
patient
genotyp
antigen
neg
joa
kpa
posit
hy
conclus
molecular
test
frequent
perform
patient
retain
donor
sampl
local
commun
donor
pool
throughout
florida
georgia
alabama
staff
abl
search
databas
combin
antigen
neg
phenotyp
use
intern
k
blood
establish
comput
softwar
bec
integr
blood
bank
inform
system
ibbi
enabl
us
locat
one
refriger
three
cryogen
preserv
joa
neg
rbc
unit
found
elig
blood
donor
could
recruit
via
automat
gener
call
list
request
rbc
cancel
patient
clinic
symptom
improv
without
transfus
repeat
hgbhct
increas
patient
sibl
histor
neg
joa
antigen
futur
transfus
requir
recommend
direct
donat
made
patient
behalf
order
continu
blood
compon
avail
meetal
patient
need
irl
staff
consist
screen
search
inventori
blood
compon
neg
rare
antigen
retain
patient
need
antigen
neg
unit
time
fashion
backgroundcas
studi
avail
rhd
genotyp
contribut
recognit
allel
howev
adequ
blood
sampl
alway
avail
serolog
character
antigen
express
encod
new
allel
report
interpret
rbc
two
femal
whose
sampl
refer
rhd
genotyp
previous
report
allel
serolog
reactiv
never
investig
studi
designmethod
serolog
test
perform
autom
analyz
galileo
echo
neo
immucor
norcross
ga
standard
tube
test
licens
reagent
albaclon
advanc
partial
rhd
type
kit
genom
dna
isol
wbc
use
immucor
rhd
beadchip
assay
rhd
sequenc
resultsfind
patient
yo
femal
whose
rbc
react
echo
neo
test
tube
gave
initi
spin
respect
indirect
antiglobulin
test
iat
rbc
ortho
bioclon
biorad
seraclon
w
immucor
gammaclon
iat
rbc
react
two
lhm
alba
partial
kit
pattern
match
partial
identifi
clone
rhd
beadchip
detect
inact
rhd
pseudogen
tran
rhd
gene
sequenc
confirm
presenc
pseudogen
rhd
chang
encod
patient
yo
pregnant
femal
whose
rbc
w
iat
immucor
seri
gammaclon
moder
reactiv
iat
alba
alpha
alba
blend
delta
rbc
react
two
lhm
partial
kit
known
partial
pattern
dna
test
predict
rhd
hemizyg
rhd
beadchip
detect
marker
rhd
dar
exon
gave
low
signal
ls
sequenc
found
hybrid
dar
nucleotid
exon
encod
amino
acid
chang
conclus
found
two
previous
report
rare
allel
rhd
previous
found
franc
lefloch
etal
genbank
rhd
dar
part
exon
replac
rhce
report
africa
granier
etal
transfus
design
rhd
dar
allel
frequenc
blood
sampl
avail
test
alter
express
either
allel
provid
serolog
evid
allel
found
two
femal
evalu
rhd
genotyp
inform
transfus
rh
immun
globulin
prophylaxi
encod
partial
phenotyp
novel
epitop
express
pattern
mean
patient
risk
form
allo
backgroundcas
studi
human
monoclon
antibodi
recogn
clinic
trial
treat
hematolog
solid
malign
transmembran
glycoprotein
bind
protein
macrophag
function
regul
phagocytosi
block
thought
enhanc
phagocytosi
promot
respons
also
highli
express
rbc
purpos
studi
evalu
drug
interfer
blood
bank
test
studi
designmethod
serolog
test
perform
standard
method
serial
sampl
patient
test
cours
month
treatment
plasma
test
immedi
spin
iat
rr
rhmod
rhnullrbc
express
level
vari
depend
rh
phenotyp
dtt
enzym
treat
rbc
also
test
immucor
detect
ortho
bioclon
total
igg
use
titrat
plasma
dilut
pb
perform
papain
treat
rr
rbc
eluat
made
use
gamma
ii
resultsfind
observ
plasma
soon
hour
post
infus
plasma
react
panel
cell
peg
iat
use
ortho
rhmod
rhnull
rbc
weaker
peg
iat
ortho
reagent
reactiv
panel
cell
ortho
igg
gel
card
contrast
iat
reactiv
use
w
reactiv
confirm
agglutin
rhmod
rhnull
peg
iat
use
titer
peg
iat
ortho
plasma
react
dtt
trypsin
papain
warm
treat
rbc
somewhat
unexpect
autocontrol
neg
dat
microscop
acid
eluat
reactiv
ortho
plasma
reactiv
remov
papain
treat
rr
cell
sampl
low
level
reactiv
remain
peg
adsorpt
invalid
due
precipitationcomplex
antibodi
robust
plasma
reactiv
interf
abo
revers
type
observ
weak
spontan
agglutin
rbc
abo
forward
rh
type
conclus
therapi
interfer
routin
test
antibodi
screen
crossmatch
abo
rh
type
high
level
express
rbc
result
plasma
agglutin
mimick
reactiv
observ
igm
antibodi
although
reactiv
observ
phase
test
method
cleav
rbc
dtt
trypsin
papainficin
dtt
ficin
warm
treatment
rbc
mitig
interfer
numer
adsorpt
papain
treat
rr
rbc
requir
remov
reactiv
plasma
use
immucor
detect
mitig
interfer
iat
although
carryov
reactiv
may
observ
due
block
patient
rbc
dat
autocontrol
weak
howev
eluat
prepar
dat
rbc
strong
use
ortho
backgroundcas
studi
caucasian
woman
histori
caesarean
section
rbc
tx
august
admit
hospit
trauma
surgeri
ab
screen
neg
two
unit
transfus
without
transfus
reaction
five
day
later
refer
tertiari
care
trauma
center
due
sever
postop
infect
need
reoper
ab
screen
posit
antibodi
react
panel
cell
detect
urgent
need
rbc
tx
two
weakli
posit
rhk
match
unit
transfus
warn
possibl
alloantibodi
patient
got
acut
hemolysi
studi
designmethod
gel
techniqu
use
hospit
transfus
laboratori
addit
variou
antibodi
identif
panel
special
serolog
genotyp
method
use
refer
laboratori
kel
sequenc
done
intern
immunohematolog
center
resultsfind
hospit
transfus
laboratori
result
rhd
neg
dat
neg
ab
identif
untreat
cell
weakli
posit
autocontrol
sampl
submit
refer
laboratori
addit
investig
dat
weakli
posit
ab
identif
result
similar
hospit
result
differ
genotyp
method
use
addit
sever
identif
panel
exclud
rare
blood
group
pk
vel
neg
jk
etc
exclud
reveal
total
silenc
mutat
known
kel
gene
genotyp
kit
use
recogn
antibodi
react
cell
apart
presenc
confirm
treat
panel
cell
may
caus
immedi
delay
hemolyt
transfus
reaction
sampl
taken
patient
two
sibl
daughter
kel
sequenc
reveal
kel
encod
report
individu
austria
two
known
countri
homozyg
daughter
heterozygot
sibl
variant
new
oper
necessari
avail
countri
help
isbt
rare
donor
work
parti
rhd
neg
donor
found
japan
one
unit
deliv
us
use
next
oper
conclus
alloantibodi
alway
suspect
autocontrol
weaker
panel
cell
reaction
even
direct
coomb
posit
combin
serolog
genotyp
approach
offer
best
solut
problemat
antibodi
case
compat
blood
alway
avail
rare
blood
group
case
intern
may
help
find
suitabl
donor
backgroundcas
studi
antigen
variant
studi
molecularli
mani
arab
popul
includ
gaza
tunisia
egypt
libya
sinc
tunisian
popul
largest
known
preval
weak
type
allel
occur
rh
haplotyp
compar
less
europ
systemat
studi
miss
sampl
serolog
weak
phenotyp
routin
found
blood
donor
patient
test
tunisia
studi
design
obtain
data
weak
type
popul
known
harbor
greatest
preval
allel
worldwid
studi
designmethod
total
random
blood
donor
serolog
screen
antigen
use
routin
techniqu
sampl
weak
reactiv
test
panel
monoclon
partial
set
identifi
partial
phenotyp
rhd
gene
sequenc
sampl
serolog
weak
phenotyp
rhce
gene
also
test
molecularli
either
direct
sequenc
use
rhce
beadchip
kit
ascertain
rhce
allel
link
rhd
allel
resultsfind
total
discrep
sampl
observ
express
serolog
weak
phenotyp
among
carri
allel
weak
type
cluster
sampl
show
weak
type
allel
sampl
found
weak
type
dvii
sampl
show
consensu
rhd
sequenc
mutat
rhd
exon
detect
anoth
sampl
molecular
analysi
rhce
gene
show
sampl
serolog
weak
phenotyp
variant
rhce
allel
common
associ
weak
type
link
rhce
weak
type
cear
weak
type
rhce
rhd
allel
link
one
common
rhce
allel
conclus
almost
weak
phenotyp
tunisia
caus
allel
weak
type
cluster
repres
weak
type
allel
base
establish
rh
haplotyp
variant
rhd
rhce
allel
lack
advers
clinic
report
tunisia
recommend
posit
transfus
patient
rhig
administr
pregnant
women
weak
type
tunisia
propos
strategi
pragmat
clinic
decis
even
eventu
rare
immun
would
occur
tunisia
associ
weak
type
phenotyp
possibl
rhce
allel
typic
associ
tunisian
individu
may
protect
immunizaton
rhce
allel
rhce
ce
often
associ
individu
ethnic
group
may
howev
conclud
conjectur
much
evid
support
time
would
need
corrobor
experiment
clinic
data
use
guid
clinic
recommend
backgroundcas
studi
plasma
transfus
year
old
white
femal
post
liver
transplant
rbc
aplasia
react
rt
peg
iat
rbc
sampl
test
except
studi
designmethod
standard
hemagglutin
method
use
antibodi
id
antigen
type
acid
eluat
prepar
use
gamma
ii
immucor
genom
dna
isol
wbc
use
hea
precisetyp
array
kel
sc
gene
sequenc
sampl
proband
mother
test
applic
resultsfind
patient
dat
neg
plasma
react
rbc
avail
rbc
sampl
lack
antigen
phenotyp
similar
rbc
sampl
fy
reactiv
detect
titer
remov
prewarm
techniqu
peg
alloadsorpt
adsorb
plasma
react
rbc
extens
rbc
phenotyp
result
unremark
except
follow
js
kp
sc
plasma
react
ko
mcleod
sc
rbc
sampl
sc
rbc
rt
peg
iat
dilut
plasma
pretransfus
eluat
show
rel
kpb
specif
patient
transfus
aliquot
crossmatch
incompat
kp
rbc
dat
eluat
react
rbc
sampl
except
kp
sampl
toler
addit
aliquot
phenotyp
similar
rbc
untest
kell
scianna
antigen
hea
precisetyp
predict
k
kp
js
discord
rbc
phenotyp
kel
gene
sequenc
identifi
homozyg
chang
kel
encod
low
preval
antigen
ula
chang
associ
lack
kell
system
antigen
howev
rbc
type
ul
sc
sequenc
found
heterozygos
chang
preval
convent
sc
predict
kel
sc
result
mother
kel
heterozyg
sc
chang
rbc
type
kp
ula
consist
dna
predict
plasma
collect
month
later
nonreact
rt
peg
iat
rbc
type
k
kp
ul
concord
predict
kell
sc
phenotyp
conclus
report
exampl
kell
scianna
antigen
suppress
block
presenc
autoantibodi
alloantibodi
kel
system
knowledg
first
report
ula
kel
homozygot
rbc
may
lack
antigen
antithet
ula
without
dna
test
gene
sequenc
patient
would
presum
kell
null
sc
null
phenotyp
search
ko
andor
sc
rbc
unit
would
perform
would
prompt
rbc
dat
neg
backgroundcas
studi
common
antibodi
identifi
blood
bank
provid
phenotyp
character
red
cell
lack
antigen
import
avoid
acut
delay
hemolyt
transfus
reaction
nearli
case
antibodi
identifi
context
phenotyp
homozyg
jkb
patient
jk
scenario
quit
rare
present
two
case
phenotyp
observ
studi
designmethod
patient
multipar
femal
known
transfus
histori
blood
type
posit
posit
antibodi
screen
neg
dat
clearli
identifi
plasma
patient
phenotyp
jk
genotyp
reveal
presenc
jk
b
allel
jk
allel
complet
sequenc
jk
gene
show
intron
polymorph
homozygos
specif
patient
show
jk
b
genotyp
associ
jkb
null
phenotyp
anti
identifi
conclus
jk
null
patient
patient
receiv
transfus
patient
b
multipli
transfus
old
femal
blood
type
posit
posit
dat
antibodi
screen
plasma
eluat
reveal
despit
recent
transfus
patient
phenotyp
jk
jk
b
genotyp
show
presenc
jk
jk
ballel
whole
gene
sequenc
perform
hematolog
biochem
evid
hemolysi
patient
consid
jka
neg
cell
use
transfus
resultsfind
patient
b
develop
uncommon
phenotypesgenotyp
conclus
common
jk
null
patient
develop
howev
specul
express
kidd
glycoprotein
jkb
epitop
threshold
serolog
detect
enough
prevent
format
usual
report
context
activ
hemolyt
process
patient
b
illustr
without
hemolysi
commonli
observ
autoantibodi
exhibit
specif
rh
epitop
rare
case
requir
phenotyp
genet
analysi
jkb
epitop
jk
b
allel
respect
complex
case
whole
gene
sequenc
backgroundcas
studi
donor
genotyp
red
blood
cell
antigen
becom
common
practic
mani
blood
bank
laboratori
packag
insert
commerci
assay
indic
fals
neg
result
may
gener
unexpect
rare
mutat
affect
primer
probe
bind
caus
allel
dropout
fail
amplif
outcom
may
go
unrecogn
unless
serolog
result
avail
comparison
studi
designmethod
routin
blood
donor
african
american
select
red
blood
cell
genotyp
dna
extract
genotyp
perform
use
two
commerci
platform
precisetyp
bioarray
warren
nj
idcorext
grifol
emeryvil
ca
genotyp
result
compar
histor
serolog
result
discrep
resolv
sanger
sequenc
grifol
ih
san
marco
tx
resultsfind
genotyp
result
show
variant
duffi
fy
kell
kel
blood
group
system
donor
genotyp
concord
platform
fy
afi
bgata
kp
akp
predict
phenotyp
fy
kp
genotyp
result
compar
histor
serolog
note
donor
previous
type
fy
separ
donat
previou
kpa
kpb
serotyp
avail
sequenc
fy
exon
reveal
mutat
known
silenc
fya
sequenc
kel
exon
expos
silent
polymorph
exon
c
polymorph
caus
dropout
artifact
yield
fals
neg
kpb
interpret
conclus
discrep
fy
result
well
unlik
kp
type
prompt
request
sequenc
rare
mutat
report
peopl
caucasian
descent
first
exampl
fy
mutat
identifi
region
popul
kpb
antigen
present
nearli
popul
howev
kp
frequent
seen
peopl
caucasian
descent
date
african
american
donor
genotyp
kp
akp
b
blood
center
given
divers
region
heterogen
feasibl
identifi
kp
donor
african
american
red
blood
cell
genotyp
offer
abund
inform
replac
serolog
sole
mean
red
cell
antigen
character
donor
ethnic
continu
play
key
role
select
genotyp
search
rare
unusu
red
cell
type
case
donor
select
genotyp
base
ethnic
initi
thought
genet
variant
previous
report
african
descent
proven
present
case
act
remind
genotyp
limit
must
consid
even
use
licens
methodolog
backgroundcas
studi
natur
occur
typic
develop
month
age
healthi
individu
antibodi
usual
produc
strong
agglutin
revers
type
weak
absent
seen
immunodefici
elderli
patient
newborn
case
report
present
two
group
pediatr
patient
enter
feed
absentweak
becam
strong
time
patient
studi
designmethod
patient
male
born
prematur
short
gut
syndrom
underw
small
bowel
liver
transplant
year
age
chang
undetectableweak
strong
age
year
patient
femal
metabol
urea
cycl
disord
underw
liver
transplant
patient
total
parenter
nutrit
tpn
sinc
birth
strong
normal
immunoglobulin
test
abo
type
enhanc
techniqu
present
tabl
resultsfind
patient
type
group
forward
type
strong
patient
vari
strength
patient
reaction
year
age
thereaft
abo
type
show
mainli
strong
patient
conclus
intestin
bacteria
stimul
product
unexpect
chang
caus
abo
discrep
report
children
tpn
patient
absentweak
sinc
birth
year
age
develop
strong
chang
feed
regiment
medic
patient
consist
strong
absentweak
find
support
notion
normal
colon
gut
import
develop
suggest
microflora
gut
patient
prolong
tpn
differ
lead
delay
format
antibodi
compar
individu
normal
enter
diet
differ
strength
could
due
stronger
b
antigen
express
gut
bacteria
tabl
summari
abo
type
result
backgroundcas
studi
use
antigen
type
cord
cell
panel
lieu
dithiothreitol
treatment
reagent
red
cell
determin
presenc
underli
alloantibodi
panagglutin
benefici
studi
designmethod
daratumumab
monoclon
antibodi
use
treat
multipl
myeloma
patient
medic
interfer
serolog
test
demonstr
panagglutin
cord
cell
demonstr
low
amount
use
antibodi
screen
underli
alloantibodi
daratumumab
treat
patient
antigen
neg
cord
cell
dithiothreitol
treatment
evalu
use
clinic
set
reagent
suppli
cost
technologist
labor
skill
level
eas
use
product
factor
decis
cord
panel
option
determin
conduc
clinic
set
cord
cell
antigen
type
develop
cord
panel
rule
rh
kell
kidd
duffi
mnss
blood
group
system
doubl
dose
express
six
eight
cord
cell
compos
final
cord
panel
select
panel
cell
subsequ
suspend
red
cell
storag
solut
remain
viabl
day
antigen
type
initi
cord
cell
take
four
eight
hour
complet
addit
treatment
cell
requir
antigen
neg
unit
antigen
rule
doubl
dose
express
genotyp
select
crossmatch
order
resultsfind
daratumumab
protocol
establish
incorpor
use
cord
panel
multipl
myeloma
patient
select
candid
daratumumab
treatment
baselin
test
blood
type
antibodi
screen
dat
genotyp
daratumumab
infus
two
unit
crossmatch
order
precaut
event
patient
develop
reaction
medic
repeat
antibodi
screen
demonstr
panagglutin
serv
posit
control
medic
cord
panel
rule
underli
alloantibodi
select
red
cell
unit
crossmatch
immedi
spin
phase
avoid
expect
indirect
antiglobulin
reactiv
conclus
cord
panel
use
time
five
month
period
rule
underli
alloantibodi
test
daratumumab
protocol
consist
rout
antibodi
screen
follow
cord
panel
resolut
daratumumab
protocol
significantli
reduc
test
time
allow
provis
compat
blood
product
effici
cost
effect
manner
backgroundcas
studi
purpos
perform
antibodi
screen
detect
clinic
signific
unexpect
antibodi
decreas
probabl
detect
clinic
insignific
antibodi
sever
antibodi
detect
method
polyethylen
glycol
peg
liss
albumin
routin
use
small
transfus
servic
util
peg
enhanc
sensit
detect
clinic
signific
antibodi
indirect
antiglobulin
procedur
code
feder
regul
titl
cfr
part
state
manufactur
instruct
follow
test
unexpect
antibodi
packag
insert
gamma
immucor
inc
norcross
ga
state
neg
reaction
may
examin
optic
aid
base
direct
institut
polici
confirm
neg
reaction
use
microscop
studi
designmethod
retrospect
document
review
perform
patient
sampl
posit
antibodi
screen
absc
trigger
antibodi
identif
abid
perform
total
sampl
evalu
abid
subcategor
new
antibodi
facil
patient
share
electron
health
record
within
healthcar
system
whether
microscop
absc
result
trigger
abid
also
patient
known
antibodi
group
accord
microscop
absc
result
comparison
new
patient
previous
known
antibodi
patient
microscop
result
review
determin
antibodi
clinic
signific
resultsfind
total
abid
perform
new
patient
sampl
new
abid
sampl
microscop
absc
result
previous
known
antibodi
patient
account
total
abid
perform
review
total
abid
workup
total
absc
microscop
result
result
abid
perform
antibodi
identifi
new
antibodi
sampl
conclus
total
new
antibodi
identifi
base
microscop
absc
clinic
insignific
manufactur
direct
follow
state
optic
aid
requir
confirm
neg
result
due
result
studi
decis
made
discontinu
use
microscop
switch
peg
manufactur
whose
direct
indic
observ
macroscop
agglutin
defin
use
agglutin
viewer
optic
aid
decreas
number
abid
save
time
money
provid
potenti
rbc
transfus
time
effici
manner
backgroundcas
studi
anwj
antigen
isbt
number
anton
preval
greater
popul
hereditari
absenc
anwj
describ
singl
famili
howev
red
cell
express
anwj
may
markedli
decreas
near
undetect
level
blood
donor
lu
domin
lutheran
inhibitor
phenotyp
similarli
antibodi
format
rare
case
report
literatur
antibodi
develop
context
hereditari
absenc
anwj
ie
true
alloantibodi
one
case
nine
case
antibodi
occur
context
autoimmun
lymphoprolif
diseas
context
believ
develop
secondari
transient
anwj
antigen
suppress
report
case
lack
clinic
laboratori
evid
hemolysi
howev
recent
report
case
involv
woman
aplast
anemia
antibodi
associ
acut
hemolyt
reaction
rbc
transfus
necessit
transfus
support
lu
rbc
case
also
uniqu
result
direct
antiglobulin
test
dat
posit
complement
rather
igg
like
previou
case
dat
perform
posit
studi
designmethod
woman
sever
aplast
anemia
experienc
acut
hemolyt
transfus
reaction
ahtr
develop
panagglutinin
indirect
antiglobulin
test
iat
screen
prior
identifi
specif
panreact
antibodi
patient
receiv
rbc
transfus
show
sign
hemolysi
six
first
three
transfus
prior
posit
iat
electron
crossmatch
next
seven
transfus
incompat
globulin
ahg
phase
crossmatch
extend
phenomatch
clinic
signific
antigen
patient
ahtr
sign
symptom
includ
fever
rigor
nausea
vomit
dark
urin
flank
pain
impend
doom
anxieti
laboratori
find
includ
hemoglobin
decreas
level
increas
total
bilirubin
ldh
dat
initi
neg
immedi
workup
transfus
reaction
eventu
becam
posit
igg
neg
reagent
antibodi
show
peak
iat
titer
resultsfind
antibodi
identifi
anwj
specif
patient
sampl
show
weak
anwj
express
w
altogeth
suggest
monocyt
monolay
assay
test
use
patient
plasma
rbc
unit
yield
monocyt
indic
rang
consist
clinic
hemolysi
observ
given
patient
group
rh
neg
blood
type
continu
transfus
depend
order
avoid
ahtr
intern
collabor
necessari
order
procur
provis
group
rh
neg
rbc
also
serolog
neg
anwj
patient
success
transfus
three
unit
without
incid
conclus
second
document
case
patient
aplast
anemia
overal
third
case
associ
ahtr
case
also
underscor
import
intern
collabor
backgroundcas
studi
follow
recommend
colleg
american
pathologist
cap
transfus
medicin
resourc
committe
tmrc
aabb
sandler
etal
start
offer
weak
genotyp
servic
june
everi
hospit
provinc
quebec
obtain
unusu
weak
serolog
result
women
weak
genotyp
particular
interest
pregnanc
may
allow
prevent
unnecessari
inject
rh
immun
globulin
rhig
well
prevent
transfus
scarc
neg
red
blood
cell
rbc
posit
rbc
could
safe
use
studi
designmethod
primer
ssp
restrict
fragment
length
polymorph
rflp
assay
use
allow
analysi
weak
type
type
safe
consid
posit
weak
type
also
analys
statist
reason
preval
popul
etal
resultsfind
three
hundr
nineti
weak
genotyp
determin
day
frequenc
type
type
type
type
investig
conduct
determin
molecular
ident
other
sampl
confirm
legitim
serolog
weak
partial
mainli
delet
exon
exon
surpris
amount
sampl
discov
normal
rhd
conclus
along
sandler
etal
data
find
highlight
difficulti
hospit
face
interpret
serolog
weak
trend
analysi
conduct
regard
reagent
technolog
use
hospit
origin
request
ethnic
concern
patient
signific
correl
could
identifi
point
altogeth
find
allow
share
frequenc
weak
type
obtain
serolog
weak
year
old
quebec
women
also
highlight
need
investig
standard
practic
amongst
hospit
regard
manag
interpret
atyp
type
backgroundcas
studi
japanes
main
hemovigil
system
oper
japanes
red
cross
societi
jrc
sinc
rel
sever
advers
event
tend
record
report
system
voluntari
basi
reduc
bia
establish
altern
onlin
report
system
collect
data
everi
two
month
regularli
transfus
bag
reaction
recipi
approxim
japanes
hospit
sinc
studi
designmethod
start
perform
pilot
studi
septemb
develop
hemovigil
system
cover
entir
transfus
chain
collect
blood
compon
recipi
connect
donor
data
jrc
exist
recipi
data
enrol
japanes
hospit
jrc
submit
transfus
bag
data
accord
instruct
studi
resultsfind
hospit
report
data
transfus
bag
rbc
pc
ffp
link
bag
data
donor
inform
provid
jrc
analyz
data
bag
data
link
mainli
human
error
due
manual
input
hospit
bag
dispos
hospit
incid
advers
event
bag
bag
rbc
bag
pc
bag
ffp
respect
evalu
advers
event
classifi
gender
donor
recipi
donor
blood
type
recipi
age
period
blood
collect
transfus
found
ffp
caus
frequent
advers
event
femal
recipi
male
recipi
storag
period
signific
influenc
advers
event
recipi
analysi
conclus
studi
japanes
labil
blood
product
thoroughli
traceabl
donat
usag
upgrad
instruct
reduc
input
error
collect
precis
inform
would
import
improv
hemovigil
system
backgroundcas
studi
acut
transfus
reaction
defin
clinic
sign
symptom
appear
within
hour
transfus
rang
mild
sever
common
reaction
febril
transfus
reaction
fnhtr
allerg
reaction
circulatori
overload
taco
acut
lung
injuri
trali
urticaria
fnhtr
common
reaction
occur
respect
transfus
taco
classifi
rel
common
reaction
occur
less
transfus
trali
unfrequ
happen
less
transfus
object
evalu
result
transfus
reaction
occur
patient
refer
oncolog
hospit
studi
designmethod
patient
receiv
transfus
month
evalu
nurs
evalu
clinic
sign
symptom
could
relat
transfus
data
record
specif
form
form
review
hematolog
physician
reaction
could
relat
transfus
exclud
resultsfind
analyz
transfus
reaction
occur
erythrocyt
random
platelet
apheresi
fresh
frozen
plasma
classifi
allerg
moder
sever
reaction
classifi
fnhtr
taco
incid
trali
happen
period
prophylaxi
use
patient
conclus
fnhtr
describ
common
advers
event
relat
transfus
data
show
higher
incid
allerg
reaction
fnhtr
occur
time
less
allerg
reaction
might
explain
univers
leukoreduct
univers
prophylaxi
adopt
institut
studi
necessari
evalu
benefit
approach
backgroundcas
studi
red
cell
rbc
transfus
import
often
treatment
modern
medicin
unfortun
sometim
caus
advers
event
ae
although
recent
random
control
clinic
trial
conclud
signific
differ
mortal
fresh
older
rbc
impact
storag
durat
well
modif
mild
yet
common
complic
fulli
investig
studi
designmethod
retrospect
studi
elig
unit
total
rbc
transfus
patient
age
rang
year
old
median
male
femal
ratio
juli
march
rbc
leukoreduc
prior
storag
wash
deglycerol
autolog
direct
rbc
rbc
transfus
massiv
transfus
protocol
exclud
attribut
rbc
product
includ
apheresi
vs
whole
blood
deriv
cmv
serolog
statu
irradi
analyz
along
recipi
age
gender
total
rbc
relat
ae
report
blood
bank
independ
review
pathologist
studi
exclud
ae
associ
specif
rbc
unit
deem
unrel
transfus
rbc
transfus
ae
analyz
test
logist
regress
use
compar
ae
incid
among
transfus
group
resultsfind
univari
multivari
logist
analys
show
irradi
rbc
associ
significantli
increas
incid
ae
p
signific
differ
febril
transfus
reaction
fnhtr
vs
p
ae
type
inflamm
etiolog
vs
p
includ
acut
lung
injuri
dyspnea
circulatori
overload
infect
hemolyt
transfus
reaction
irradi
rbc
rbc
contrast
incid
allerg
ae
vs
p
similar
two
group
incid
inflamm
ae
transfus
irradi
rbc
store
week
respect
p
logist
regress
signific
differ
incid
inflamm
ae
caus
irradi
rbc
store
week
longer
week
p
conclus
irradi
rbc
associ
higher
incid
transfus
inflamm
ae
compar
rbc
risk
increas
rbc
store
longer
week
irradi
like
patient
popul
factor
ae
caus
irradi
rbc
also
possibl
rbc
radiat
damag
shown
previou
studi
contribut
increas
ae
incid
backgroundcas
studi
anecdot
transfus
medicin
specialist
agre
transfus
reaction
particularli
suspect
transfus
relat
acut
lung
injuri
trali
case
goal
studi
obtain
object
data
trali
studi
designmethod
inform
technolog
depart
search
electron
medic
record
emr
patient
diagnos
trali
possibl
trali
via
code
list
patient
one
code
gener
emr
search
find
clinic
scenario
trali
mention
patient
record
search
within
laboratori
inform
system
copath
determin
transfus
reaction
report
transfus
medicin
servic
resultsfind
search
electron
medic
record
found
patient
trali
mention
chart
diagnosi
possiblelik
diagnosi
one
patient
exclud
studi
trali
mention
past
medic
histori
outsid
hospit
patient
trali
list
diagnosi
possibl
diagnosi
includ
studi
patient
clinic
scenario
transfus
blood
product
occur
follow
variou
form
respiratori
distress
clinic
team
care
patient
either
give
diagnosi
trali
consid
trali
possibl
diagnosi
case
report
transfus
medicin
servic
transfus
reaction
report
case
one
determin
trali
one
consist
taco
eight
case
never
report
conclus
trali
lead
caus
transfus
relat
death
trali
transfus
medicin
servic
creat
risk
caus
trali
addit
patient
receiv
product
donor
case
trali
prevent
implic
donor
identifi
remov
donor
pool
via
indefinit
deferr
role
transfus
medicin
servic
investig
everi
possibl
trali
case
determin
diagnosi
warrant
investig
donor
blood
caus
antibodi
found
test
reactiv
recipi
wbc
may
arduou
process
identifi
indefinit
defer
donor
implic
case
trali
critic
first
step
clinic
team
report
reaction
studi
conclud
trali
transfus
medicin
servic
institut
result
show
possibl
trali
case
report
transfus
medicin
servic
suspect
institut
would
show
similar
result
backgroundcas
studi
norwegian
hemovigil
system
implement
voluntari
report
system
becom
mandatori
transfus
reaction
donor
complic
advers
event
report
use
definit
haemovigil
andor
intern
haemovigil
network
possibl
definit
pulmonari
edema
use
period
definit
trali
transfus
relat
acut
lung
injuri
current
use
definit
taco
transfus
associ
circulatori
overload
trali
implement
sinc
implement
norwegian
hemovigil
system
eight
transfus
relat
death
report
includ
four
case
trali
two
case
taco
two
case
acut
hemolyt
reaction
caus
transfus
red
blood
cell
incid
trali
norway
low
gener
use
octapla
sinc
studi
designmethod
studi
focus
age
gender
clinic
outcom
involv
blood
compon
patient
pulmonari
transfus
complic
trali
taco
transfus
relat
dyspnea
tad
resultsfind
total
pulmonari
complic
report
report
trali
taco
pulmonari
edema
case
tad
six
case
four
trali
two
taco
patient
die
consequ
complic
case
seven
trali
taco
reaction
signific
differ
incid
trali
taco
tad
male
femal
data
may
indic
incid
taco
higher
elderli
one
case
taco
two
case
tad
report
children
eleven
trali
case
report
red
blood
cell
transfus
eleven
case
platelet
transfus
trali
never
report
octapla
transfus
taco
tad
report
conclus
pulmonari
transfus
complic
lead
caus
transfus
relat
mortal
norway
reduc
incid
trali
screen
femal
male
donor
inclus
male
platelet
donor
could
attempt
taco
potenti
prevent
risk
factor
well
defin
measur
reduc
taco
taken
patient
risk
backgroundcas
studi
despit
dilig
effort
transfus
safest
product
avail
patient
undetect
alloantibodi
may
caus
delay
hemolyt
transfus
reaction
dhtr
transfus
reaction
seen
mani
transfus
product
therapeut
plasma
exchang
tpe
may
employ
mitig
ongo
immun
mediat
hemolysi
report
literatur
describ
tpe
clinic
manag
profound
hemolysi
studi
designmethod
case
review
patient
perform
diagnosi
treatment
sever
dhtr
resultsfind
man
histori
gastrointestin
bleed
present
emerg
room
short
breath
hematuria
known
histori
transfus
two
unit
crossmatch
compat
rbc
seven
day
prior
previou
admiss
readmiss
hemoglobin
hb
declin
next
day
antibodi
screen
consist
direct
antiglobulin
test
dat
neg
receiv
three
unit
crossmatch
compat
rbc
day
poor
respons
day
routin
lab
could
report
due
mark
hemolysi
worsen
hematuria
creatinin
rose
refer
lactat
dehydrogenas
report
linear
ul
refer
ul
test
reveal
addit
dat
plasma
free
hb
refer
hemoglobinuria
four
five
transfus
rbc
unit
jk
b
one
also
e
one
volum
tpe
perform
remov
free
hb
day
use
fresh
frozen
plasma
replac
fluid
haptoglobin
supplement
creatinin
peak
day
decreas
discharg
day
return
outpati
follow
remain
dialysi
independ
conclus
case
highlight
import
clinic
recognit
delay
hemolyt
transfus
reaction
critic
role
laboratori
staff
may
first
identifi
tpe
prevent
perman
renal
failur
current
recommend
american
societi
apheresi
use
tpe
treatment
acut
sever
hemolysi
case
report
one
contribut
exist
literatur
rais
awar
potenti
benefit
tpe
manag
profound
hemolysi
backgroundcas
studi
compar
data
analysi
benchmark
import
healthcar
qualiti
improv
recipi
hemovigil
system
provid
member
hospit
platform
report
data
blood
transfus
bt
incid
transfus
associ
advers
reaction
taar
benchmark
purpos
report
result
analysi
taar
bt
data
submit
particip
hospit
us
recipi
hemovigil
program
studi
designmethod
monthli
bt
taar
data
report
particip
hospit
examin
taar
categor
reaction
type
case
definit
sever
imput
use
us
nation
hemovigil
network
report
protocol
taar
rate
calcul
number
transfus
compon
inclus
criteria
taar
report
month
denomin
report
complet
taar
meet
case
definit
criteria
definit
probabl
imput
statu
definit
probabl
possibl
relat
transfus
resultsfind
total
blood
compon
transfus
particip
hospit
studi
period
total
taar
report
reaction
meet
inclus
criteria
overal
taar
rate
transfus
compon
allerg
reaction
ar
commonli
report
type
taar
rate
transfus
compon
among
taar
pulmonari
manifest
circulatori
overload
taco
frequent
report
reaction
type
reaction
rate
transfus
compon
sever
life
threaten
taar
categor
either
sever
life
threaten
fatal
transfus
compon
among
specif
compon
platelet
transfus
pt
associ
highest
reaction
rate
pt
follow
red
cell
transfus
rbc
twice
mani
apheresi
platelet
ap
report
transfus
whole
blood
deriv
wbd
platelet
reaction
rate
ap
higher
wbd
platelet
case
vs
pt
frequent
report
reaction
pt
allerg
febril
transfus
reaction
conclus
taar
rate
report
hemovigil
qualiti
benchmark
program
consist
report
previous
us
ar
frequent
report
taar
ap
transfus
associ
highest
reaction
rate
compon
comparison
hospit
hemovigil
data
allow
benchmark
effort
transfus
reaction
definit
standard
identifi
area
qualiti
improv
particip
backgroundcas
studi
transfus
associ
chest
pain
trach
rare
report
clinic
symptom
potenti
link
chest
patholog
without
correspond
cdc
hemovigil
definit
object
studi
character
clinic
present
suspect
transfus
reaction
chest
pain
report
studi
designmethod
retrospect
chart
review
patient
develop
chest
pain
transfus
singl
larg
academ
institut
resultsfind
twenti
three
case
identifi
medic
record
avail
analysi
ten
patient
male
mean
age
year
rang
year
underli
hematolog
malign
bone
marrow
disord
histori
coronari
arteri
diseas
cad
implic
unit
includ
red
blood
cell
platelet
patient
receiv
singl
unit
receiv
two
within
previou
hour
mean
volum
transfus
rang
mean
time
onset
chest
pain
minut
sd
minut
patient
present
within
hour
within
hour
start
transfus
chest
pain
present
symptom
case
case
accompani
symptom
includ
dyspnea
fever
back
pain
hypertens
chest
perform
case
show
evid
pulmonari
edema
suggest
possibl
volum
overloadtransfus
associ
circulatori
overload
taco
electrocardiogram
perform
case
show
find
suggest
acut
ischemia
three
patient
minim
increas
troponin
level
although
histori
chronic
elev
troponin
due
stress
cardiomyopathi
fourteen
patient
receiv
form
treatment
includ
increas
oxygen
supplement
metoprolol
acetaminophen
morphin
oral
calcium
carbon
pain
resolv
minut
major
patient
case
result
new
admiss
icu
procedur
cancel
conclus
chest
pain
associ
transfus
infrequ
sever
case
identifi
review
period
symptom
diagnost
criterion
hemovigil
categori
merit
character
determin
whether
blood
product
transfus
could
caus
chest
pain
larger
observ
studi
power
clinic
character
could
help
inform
hypothes
regard
mechan
could
interrog
translat
research
studi
backgroundcas
studi
massiv
transfus
volum
ratio
administ
plasma
pl
vol
rbc
rbc
vol
appear
associ
reduc
blood
util
improv
surviv
aim
studi
evalu
optim
transfus
threshold
decreas
blood
util
set
liver
transplant
studi
designmethod
retrospect
studi
liver
transplant
perform
singl
institut
januari
decemb
patient
receiv
least
red
blood
cell
includ
analysi
two
model
use
calcul
ratio
pl
volrbc
vol
b
pl
plt
platelet
volrbc
vol
patient
transfus
ratio
low
ratio
compar
patient
transfus
ratio
high
ratio
consid
refer
group
multivari
analysi
factor
perform
identifi
factor
associ
intraop
rbc
use
gener
linear
regress
normal
distribut
ridg
estim
method
valid
method
use
analysi
resultsfind
total
patient
identifi
factor
associ
increas
blood
loss
includ
male
gender
moder
ascit
spontan
bacteri
periton
hemodialysi
meld
score
bilirubin
hemoglobin
intern
normal
ratio
inr
compar
rbc
volum
transfus
use
model
low
plasma
ratio
demonstr
excess
rbc
transfus
p
p
univari
multivari
analysi
respect
compar
rbc
volum
transfus
use
model
b
low
plasma
ratio
demonstr
excess
rbc
transfus
univari
multivari
analysi
respect
conclus
patient
undergo
liver
transplant
transfus
plasma
rbc
ratio
decreas
need
rbc
transfus
benefit
signific
plasma
contain
platelet
unit
includ
equat
find
confirm
prospect
studi
tabl
univari
multivari
analysi
backgroundcas
studi
thrombot
microangiopathi
tma
children
commonli
seen
form
hemolyt
urem
syndrom
hu
howev
tma
may
seen
presenc
streptococcu
pneumonia
spn
action
bacteri
neuraminidas
spn
result
exposur
normal
hidden
antigen
found
erythrocyt
tissu
ultim
may
lead
spn
induc
hemolyt
urem
syndrom
phu
subsequ
hemolysi
end
organ
damag
natur
occur
antibodi
expos
antigen
specif
lectin
confirm
exposur
antigen
phu
altern
phu
identifi
minor
crossmatch
incompat
result
agglutin
expos
antigen
recipi
erythrocyt
antibodi
plasma
portion
blood
product
present
case
suspect
phu
result
compat
minor
crossmatch
lead
concern
eventu
diagnosi
atyp
hu
ahu
studi
designmethod
month
old
boy
present
respiratori
failur
found
blood
cultur
posit
spn
well
hemolyt
anemia
thrombocytopenia
acut
renal
failur
shiga
toxin
neg
normal
level
adamt
base
find
clinic
team
concern
phu
therefor
receiv
wash
erythrocyt
thrombocytopenia
institut
routin
provid
wash
platelet
due
decreas
qualiti
platelet
product
result
minor
crossmatch
suggest
perform
determin
activ
present
resultsfind
minor
crossmatch
perform
patient
erythrocyt
plasma
platelet
transfus
agglutin
seen
immedi
spin
degre
globulin
phase
check
cell
found
find
convey
clinic
team
platelet
issu
without
wash
due
lack
identif
activ
minor
crossmatch
poor
clinic
respons
despit
appropri
antibiot
treatment
addit
studi
perform
primari
team
complement
mutat
found
consist
ahu
patient
treat
eculizumab
clinic
laboratori
improv
conclus
present
case
clinic
consist
phu
confirm
diagnosi
done
lectin
readili
avail
altern
mean
identifi
phu
minor
crossmatch
incompat
demonstr
minor
crossmatch
compat
elucid
definit
diagnosi
ahu
appropri
manag
backgroundcas
studi
femal
infant
biliari
atresia
underw
success
live
donor
liver
transplant
father
patient
donor
blood
group
b
respect
baselin
hemoglobin
hb
receiv
total
b
red
blood
cell
rbc
transfus
intraop
immunosuppress
treatment
tacrolimu
prednisolon
postop
day
pod
patient
recoveri
complic
elizabethkingia
meningoseptica
septicemia
follow
acinetobactor
baumanii
tip
central
line
patient
develop
respiratori
failur
requir
intub
shown
tabl
rbc
transfus
given
pod
appropri
respons
hb
drop
without
bleed
b
rbc
given
pod
without
proper
increment
hb
level
rbc
transfus
request
pod
crossmatch
result
incompat
b
rbc
studi
designmethod
abo
group
antibodi
screen
repeat
tube
method
direct
antiglobulin
test
dat
elut
test
perform
resultsfind
serolog
test
pod
reveal
patient
plasma
antibodi
screen
neg
tube
test
posit
dat
igg
detect
use
gel
agglutin
techniqu
elut
demonstr
patient
red
cell
sensit
donor
titer
eluat
indirect
antiglobulin
test
iat
neg
room
temperatur
diagnosi
passeng
lymphocyt
syndrom
pl
made
one
dose
rbc
given
patient
sampl
pod
retest
dat
dat
posit
igg
complement
elut
rbc
undetect
plasma
due
subtherapeut
level
tacrolimu
cyclosporin
use
instead
pod
patient
subsequ
transfus
dose
rbc
pod
acut
graft
reject
suspect
pod
immunosuppress
drug
adjust
two
month
transplant
hb
evid
ongo
hemolysi
conclus
rare
immun
hemolysi
igg
pediatr
liver
transplant
report
condit
improv
treatment
transfus
pl
consid
unexplain
anemia
follow
solid
organ
transplant
dat
elut
test
perform
case
earlier
diagnosi
prompt
manag
tabl
hb
backgroundcas
studi
orthotop
liver
transplant
olt
complex
technic
challeng
procedur
complic
sever
intraop
bleed
report
case
massiv
transfus
olt
patient
necessit
abo
blood
group
switch
sustain
transfus
support
minimum
group
rbc
inventori
studi
designmethod
type
screen
ts
gel
titer
tube
perform
use
routin
method
chart
review
perform
pertin
medic
laboratori
find
resultsfind
patient
man
cirrhosi
secondari
nonalcohol
steatohepat
antitrypsin
defici
present
olt
donor
olt
patient
endur
substanti
bleed
retroperiton
collater
vessel
complic
coagulopathi
requir
rapid
high
volum
rbc
plasma
support
strain
hospit
inventori
receiv
unit
rbc
unit
plasma
ongo
sever
hemorrhag
switch
group
product
ten
unit
plasma
transfus
wash
antibodi
prior
transfus
rbc
due
difficulti
control
bleed
biliari
reconstruct
fascial
closur
delay
hour
patient
total
estim
blood
loss
receiv
total
unit
rbc
includ
unit
plasma
includ
unit
cryoprecipit
unit
platelet
toward
end
second
procedur
patient
hemorrhag
stabil
final
two
rbc
unit
receiv
postop
day
pod
ts
show
predominantli
rbc
trace
rbc
well
low
igm
igg
titer
tabl
receiv
two
addit
rbc
unit
pod
pod
increas
rbc
ts
rise
titer
blood
type
unequivoc
pod
patient
show
recoveri
liver
synthet
function
pod
factor
activ
complic
cholestasi
tabl
conclus
studi
show
success
switch
group
patient
group
set
rapid
hemorrhag
massiv
transfus
pod
patient
revert
recoveri
titer
month
patient
aliv
sign
improv
biliari
graft
function
backgroundcas
studi
new
transfus
safeti
system
tss
base
process
technolog
especi
identif
radio
frequenc
rfid
current
implement
two
hospit
gener
one
oncolog
center
tss
fulli
effect
protect
incid
specif
offer
mechan
detect
near
miss
nm
use
procedur
physic
barrier
assur
pretransfusion
sampl
extract
pse
blood
compon
administr
bca
take
place
bed
side
use
locat
control
interact
clinic
transfus
inform
system
ti
tss
allow
analyz
transfusion
activ
inform
real
time
project
organiz
chang
transfus
servic
hospit
unit
creat
new
classif
nm
studi
designmethod
retrospect
analysi
transfus
activ
show
pse
bca
respect
sinc
tss
deploy
retrospect
analysi
classif
secur
event
done
resultsfind
activ
result
hospit
shown
tabl
tabl
result
safeti
event
classifi
pretransfus
sampl
extract
pse
blood
compon
assign
bca
transfus
servic
blood
compon
administr
bca
near
miss
nm
nm
relat
pse
account
mistak
concord
patient
identif
prescript
order
frequent
nm
detect
bca
mostli
occur
patient
inform
ti
match
one
regist
tss
nm
detect
bca
mostli
system
detect
assign
bracelet
nm
relat
pse
account
error
concord
transfus
secur
number
bracelet
pretransfus
sampl
frequent
nm
detect
bca
account
occur
patient
inform
ti
match
one
regist
tss
nm
detect
bca
blood
compon
assign
anoth
patient
conclus
analysi
transfus
activ
inform
real
time
allow
implement
organiz
chang
adjust
work
load
use
time
locat
inform
regist
tss
allow
defin
new
nm
relat
correct
transfus
prescript
correct
match
patient
transfus
order
patient
pretransfus
sampl
correct
assign
blood
compon
patient
knowledg
new
nm
allow
design
new
transfus
safeti
indic
backgroundcas
studi
chronic
rbc
transfus
therapi
induc
rbc
alloimmun
patient
sickl
cell
diseas
scd
alloantibodi
format
directli
contribut
morbid
mortal
patient
scd
patient
develop
rbc
alloantibodi
follow
rbc
transfus
despit
factor
contribut
rbc
alloimmun
remain
incomplet
understood
recent
studi
suggest
alloantibodi
respond
possess
inher
distinct
immun
system
directli
contribut
alloantibodi
format
given
differ
gener
immun
function
rbc
alloantigen
respond
patient
may
predict
immun
respons
antigen
encount
vaccin
test
examin
antibodi
titer
patient
vaccin
streptococcu
pneumonia
sp
determin
whether
statu
predict
overal
vaccin
immun
respons
studi
designmethod
chart
review
perform
scd
patient
receiv
pneumovax
part
routin
prevent
care
outpati
sickl
cell
clinic
post
vaccin
sp
igg
titer
sp
serotyp
analyz
via
commerci
avail
elisa
comparison
adequ
respons
defin
mcgml
serotyp
perform
base
alloimmun
statu
statist
signific
determin
compar
mean
subgroup
use
pair
resultsfind
sp
titer
avail
patient
alloimmun
vaccin
titer
avail
patient
alloimmun
patient
chronic
transfus
hydroxyurea
surgic
splenectom
patient
histori
surgic
splenectomi
statu
unknown
patient
previou
histori
previou
year
also
report
previou
histori
sp
conjug
vaccin
within
last
year
baselin
titer
show
differ
alloimmun
patient
group
titer
avail
non
alloimmun
patient
adequ
respons
versu
alloimmun
group
p
ns
vaccin
patient
develop
statist
signific
respons
sp
serotyp
except
serotyp
differ
absolut
titer
chang
titer
serotyp
base
respond
statu
conclus
preliminari
result
demonstr
differ
vaccin
respons
base
respond
statu
howev
immun
respons
antigen
need
evalu
determin
extent
lack
correl
gener
reflect
immun
reactiv
antigen
backgroundcas
studi
blood
transfus
common
procedur
perform
hospit
set
transfus
process
monitor
ensur
regulatori
complianc
safeguard
safeti
efficaci
regulatori
complianc
transfus
servic
activ
benchmark
error
tre
occur
ie
collect
sampl
final
infus
product
goal
ensur
right
productdos
goe
right
patient
right
time
multipl
error
document
process
need
captur
report
tre
within
outsid
blood
bank
bb
present
comprehens
error
manag
program
along
data
five
year
benchmark
tre
larg
academ
medic
center
studi
designmethod
tre
detect
captur
report
sampl
suitabl
test
varianc
biolog
product
deviat
addit
tre
observ
report
provid
clinic
staff
ie
blood
delaysundertransfus
transfus
without
consent
infus
wrong
fluid
report
bb
hospit
qualiti
verita
system
hospit
base
report
system
enabl
report
occurr
potenti
caus
patient
harm
seriou
error
review
daili
summat
tre
discuss
monthli
basi
map
tre
within
perform
review
transfus
medicin
qualiti
record
patient
harm
event
record
within
verita
system
januari
juli
investig
depth
transfus
reaction
exclud
analysi
resultsfind
averag
tre
per
month
per
year
found
five
year
tre
associ
activ
occur
within
bb
event
sampl
collect
handl
repres
total
tre
tre
report
bb
staff
report
staff
patient
harm
analysi
reveal
averag
four
level
near
miss
three
level
known
harm
level
patient
harm
per
month
death
relat
tre
detect
seven
month
januari
juli
period
patient
harm
associ
tre
occur
bb
event
report
extern
bb
staff
conclus
although
tre
detect
phase
patient
harm
associ
event
indic
effici
captur
prior
caus
patient
harm
tre
caus
patient
harm
includ
near
miss
event
mostli
report
extern
occur
entir
bb
phase
result
suggest
signific
opportun
qualiti
improv
may
achiev
two
area
phase
aim
reduct
wast
associ
sampl
collect
handl
bb
phase
aim
improv
tre
detect
decreas
patient
harm
backgroundcas
studi
use
restrict
transfus
threshold
among
otherwis
stabl
patient
key
compon
transfus
practic
sought
assess
degre
adher
threshold
variou
blood
product
academ
medic
center
well
help
character
transfus
practic
amongst
differ
medic
surgic
specialti
studi
designmethod
databas
creat
hospit
informat
use
electron
medic
record
base
physician
blood
product
order
total
x
order
product
evalu
period
aug
dec
order
elig
assess
preced
within
hour
relev
laboratori
result
data
import
tableau
version
tableau
seattl
wa
analyz
proport
adher
order
red
blood
cell
rbc
plasma
platelet
cryo
primari
endpoint
includ
proport
evalu
rbc
transfus
occur
proport
platelet
transfus
occur
proport
plasma
transfus
occur
inr
proport
cryoprecipit
transfus
occur
fibrinogen
resultsfind
period
rbc
occur
hb
plasma
occur
inr
cryo
fibrinogen
platelet
count
conclus
dataset
repres
blood
product
administ
studi
period
found
evalu
order
compli
threshold
rbc
plasma
cryo
transfus
platelet
order
occur
platelet
count
backgroundcas
studi
uncrossmatch
red
blood
cell
rbc
emerg
issu
platelet
plt
plasma
cryoprecipit
cryo
lifesav
bleed
patient
without
valid
type
screen
collect
term
emerg
issu
product
issu
bridg
test
complet
studi
evalu
util
wastag
rate
blood
product
hemorrhag
first
product
issu
emerg
issu
studi
designmethod
list
patient
blood
product
emerg
issu
januari
march
obtain
blood
bank
region
matern
care
hospit
patient
experienc
bleed
eg
postpartum
hemorrhag
bleed
relat
complic
pregnanc
ruptur
ectop
pregnanc
bleed
post
spontan
therapeut
abort
exclud
total
number
product
emerg
issu
plu
crossmatch
issu
product
transfus
return
back
blood
bank
inventori
wast
within
hour
first
emerg
issu
product
enumer
apheresi
plt
unit
multipli
ad
number
individu
whole
blood
plt
apheresi
plasma
unit
multipli
ad
number
whole
blood
plasma
unit
resultsfind
seventi
women
receiv
emerg
issu
blood
product
hemorrhag
identifi
averag
age
year
common
indic
requir
transfus
pph
unspecifi
etiolog
placent
issu
uterin
atoni
rbc
issu
patient
first
hour
first
emerg
issu
product
unit
transfus
unit
return
unit
wast
total
whole
blood
plt
equival
issu
women
equal
approxim
dose
whole
blood
plt
equival
unit
approxim
dose
transfus
unit
approxim
dose
return
unit
approxim
dose
wast
plasma
unit
issu
unit
transfus
unit
return
unit
wast
individu
cryo
unit
dose
transfus
wast
rbc
issu
patient
patient
rbc
issu
receiv
least
one
unit
patient
plt
issu
receiv
least
one
dose
similarli
plasma
patient
plasma
issu
receiv
least
one
unit
patient
cryo
issu
receiv
least
one
dose
hour
period
mean
rbc
plasma
ratio
mean
rbc
plt
ratio
conclus
major
patient
hemorrhag
receiv
least
one
unit
emerg
issu
blood
product
receiv
least
one
unit
product
issu
unit
wast
plt
wastag
higher
product
like
due
room
temperatur
shelf
life
keep
wastag
rate
low
meet
clinic
need
patient
ideal
situat
blood
bank
backgroundcas
studi
platelet
inactiv
allow
increas
infecti
immunolog
safeti
platelet
concentr
pc
transfus
use
pathogen
inactiv
exclud
requir
pc
aim
work
compar
efficaci
safeti
transfus
pathogen
reduc
pc
pc
studi
designmethod
leukoreduc
pc
suspend
donor
plasma
median
pc
collect
target
x
platelet
pc
divid
two
group
pc
first
group
n
dose
gy
pc
second
group
n
treat
intercept
blood
system
platelet
amotosalen
ultraviolet
light
technolog
prpc
total
thrombocytopen
accord
grade
system
grade
patient
men
women
age
year
median
year
receiv
pc
transfus
prophylaxi
treatment
hemorrhag
syndrom
caus
thrombocytopenia
aplast
anemia
acut
leukemia
lymphoma
efficaci
pc
assess
correct
count
increment
cci
platelet
hour
hour
pc
transfus
well
increas
maxim
amplitud
hour
transfus
thromboelastographi
safeti
transfus
assess
incid
complic
within
success
transfus
pc
consid
also
decreas
sever
bleed
therapeut
transfus
assess
resultsfind
total
analyz
transfus
pc
prophylact
therapeut
transfus
patient
blood
platelet
higher
prophylact
therapeut
transfus
vs
signific
differ
frequenc
effect
therapeut
vs
prophylact
vs
transfus
prc
find
signific
differ
prc
prophylact
vs
therapeut
vs
transfus
prophylact
vs
therapeut
vs
transfus
signific
differ
prc
also
prophylact
vs
therapeut
vs
pc
transfus
reduct
sever
bleed
obtain
case
prpc
transfus
case
transfus
signific
differ
frequenc
advers
reaction
group
respect
case
conclus
pc
pi
equal
efficaci
pc
treat
backgroundcas
studi
electron
transfus
manag
process
includ
bedsid
administr
system
develop
implement
larg
academ
center
enabl
safe
administr
blood
compon
patient
bedsid
provid
audit
trail
blood
compon
error
identifi
electron
bedsid
transfus
process
report
nation
hemovigil
scheme
categori
error
relat
inform
technolog
error
incorrect
use
emerg
transfus
process
transfus
standard
process
requir
scan
barcod
patient
wristband
contain
identif
detail
verifi
detail
barcod
compat
label
attach
blood
bag
emerg
transfus
option
intend
use
emerg
group
rhd
neg
blood
unit
unlik
unit
alloc
specif
patient
compat
label
emerg
transfus
option
skip
compat
label
barcod
scan
emerg
unit
transfus
patient
need
urgent
transfus
found
emerg
blood
option
misus
transfus
lead
blood
unit
check
ensur
correct
patient
studi
designmethod
center
work
softwar
supplier
develop
solut
correct
weak
process
revis
process
involv
provid
univers
compat
label
emerg
unit
unit
emerg
requir
scan
compat
label
blood
bag
patient
wristband
bedsid
transfus
use
emerg
process
audit
pre
post
implement
new
process
determin
whether
use
correctli
resultsfind
unit
administ
use
emerg
transfus
process
month
chang
implement
found
unit
unit
administ
incorrectli
without
bedsid
compat
check
follow
implement
chang
instanc
incorrect
administr
unit
next
month
compon
administ
emerg
unit
administ
correctli
user
system
report
revis
process
quicker
safer
unifi
function
devic
conclus
improv
process
administr
blood
emerg
prevent
user
follow
incorrect
procedur
transfus
miss
essenti
final
bedsid
electron
check
report
indic
need
continu
vigil
function
electron
transfus
process
correct
weak
compromis
patient
safeti
backgroundcas
studi
recent
recommend
indic
one
red
blood
cell
rbc
unit
transfus
time
reassess
transfus
determin
need
howev
practic
canadian
transfus
medicin
tm
expert
constitut
reassess
unknown
therefor
conduct
survey
tm
expert
across
canada
gather
inform
practic
criteria
reassess
studi
designmethod
tm
expert
identifi
contact
inform
obtain
canadian
nation
advisori
committe
nac
contact
least
one
tm
expert
per
provinc
respond
assign
uniqu
studi
id
consent
survey
allow
anonym
analysi
survey
contain
demograph
gener
practic
question
question
regard
transfus
stabl
anem
inpati
stabl
anem
inpati
discharg
asymptomat
inpati
resultsfind
identifi
canadian
tm
expert
provid
respons
primari
place
practic
laboratori
set
stabl
anem
inpati
respond
recommend
transfus
one
rbc
unit
reassess
recommend
variabl
outpati
set
gener
recommend
transfus
two
rbc
unit
reassess
recommend
reassess
mainli
function
statussymptom
vital
within
short
time
period
hour
repeat
hemoglobin
hour
later
depend
clinic
scenario
search
underli
caus
anemia
outpati
set
lab
practition
emphas
volum
statu
cardiac
examin
transfus
lower
hemoglobin
threshold
asymptomat
patient
discharg
fewer
respond
chose
transfus
compar
inpati
potenti
symptomat
due
anemia
none
respond
suggest
transfus
asymptomat
patient
hemoglobin
trend
conclus
tm
expert
gener
recommend
transfus
one
unit
time
stabl
inpati
assess
transfus
focu
patient
symptom
pertin
physic
exam
hemoglobin
level
underli
caus
transfus
recommend
recommend
may
help
guid
clinician
research
need
gener
higher
qualiti
evid
around
clinic
benefit
cost
effect
practic
backgroundcas
studi
current
evalu
red
blood
cell
rbc
post
transfus
recoveri
base
ex
vivo
label
store
rbc
radioact
method
sever
limit
includ
risk
associ
radioact
inabl
evalu
multipl
rbc
popul
recipi
rbc
label
overcom
mani
limit
offer
safe
longitudin
track
multipl
transfus
rbc
vivo
purpos
studi
scale
optim
biotinyl
procedur
current
good
manufactur
practic
gmp
environ
studi
designmethod
pack
rbc
unit
divid
two
aliquot
label
select
concentr
cgmp
close
system
averag
hematocrit
optim
label
efficaci
determin
flow
cytometr
analysi
use
streptavidin
sa
approxim
million
rbc
measur
triplic
quantum
simpli
cellular
bead
use
quantifi
fluorochrom
molecul
equival
solubl
fluoresc
mesf
infer
number
biotin
molecul
per
rbc
lower
limit
detect
determin
rbc
label
vari
amount
biotin
product
qualiti
safeti
evalu
endotoxin
steril
test
determin
level
spontan
hemolysi
rbc
biotin
label
resultsfind
investig
differ
fluorochrom
laser
excit
wavelength
laser
power
maxim
signal
nois
ratio
label
unlabel
rbc
reveal
excit
phycoerythrin
pe
high
laser
power
provid
best
separ
two
popul
label
unlabel
rbc
label
biotin
result
mesfrbc
detect
among
unlabel
rbc
lower
limit
detect
lld
ci
rbc
label
biotin
million
biotinyl
associ
increas
level
hemolysi
label
versu
label
bacteri
contamin
conclus
result
manufactur
process
produc
larg
volum
low
risk
contamin
hemolysi
flow
cytometri
assay
detect
unlabel
blood
low
frequenc
plan
use
technolog
studi
impact
donor
characterist
rbc
storag
stabil
surviv
backgroundcas
studi
blood
product
offer
resuscit
benefit
trauma
crystalloidcolloid
volum
expand
provid
hemostat
benefit
oxygen
deliveri
usag
often
hamper
suppli
storag
need
oxygen
carrier
hboc
red
cell
replac
may
supplement
oxygen
deliveri
expand
volum
transport
blood
avail
sinc
hemostasi
critic
resuscit
studi
evalu
bovin
hemoglobin
effect
coagul
paramet
alongsid
plasma
fdp
vitro
model
hemorrhageresuscit
studi
designmethod
whole
blood
wb
collect
healthi
donor
approv
institut
standard
oper
procedur
first
studi
limit
resuscit
sampl
wb
hboc
volum
model
two
unit
adult
fdp
fdp
sampl
simul
autoresuscit
ad
plasmalyt
suscept
lysi
test
tissu
plasminogen
activ
tpa
studi
perform
sever
resuscit
simul
volum
replac
hboc
andor
fdp
without
prior
plasmalyt
dilut
coagul
paramet
obtain
coagul
analyz
thromboelastographi
teg
rbcshemoglobin
measur
hematolog
analyz
thrombin
gener
quantifi
thrombogram
platelet
aggreg
measur
multipl
adhes
collagen
shear
bioflux
viscos
evalu
rheolog
resultsfind
limit
resuscit
model
hboc
andor
fdp
effect
fibrinogen
pt
aptt
ph
hct
hemoglobin
teg
wb
wbhboc
wbhbocfdp
reduc
clot
strength
dilut
tpa
increas
suscept
lysi
wb
wbhboc
autodilut
simul
mean
lysi
vs
p
hboc
fdp
statist
signific
impact
thrombin
gener
effect
platelet
aggreg
observ
signific
differ
within
dilut
v
undilut
group
seen
platelet
adhes
flow
hboc
significantli
chang
viscos
sever
resuscit
simul
increas
ptptt
reduc
clot
strength
particularli
resuscit
howev
even
hboc
volum
replac
produc
clot
accept
teg
paramet
conclus
limit
resuscit
model
signific
vitro
effect
hemostat
paramet
except
increas
suscept
lysi
sever
resuscit
impact
coagul
paramet
prevent
clot
consid
larg
impact
healthi
platelet
coagul
function
vitro
studi
impair
platelet
warrant
alongsid
vivo
studi
hbocplasma
initi
resuscit
hemorrhag
shock
backgroundcas
studi
prothrombin
complex
concentr
pcc
coagul
factor
concentr
prepar
human
plasma
fda
approv
pcc
urgent
revers
vitamin
k
antagonist
therapi
patient
acut
major
bleed
publish
literatur
larg
focus
efficaci
safeti
pcc
actual
usag
practic
less
character
aim
describ
pcc
usag
practic
within
tertiari
care
center
studi
designmethod
conduct
retrospect
review
electron
medic
record
patient
receiv
pcc
addit
institut
formulari
compil
inform
usag
pcc
patient
descript
statist
gener
microsoft
excel
resultsfind
patient
warfarin
pcc
frequent
prescrib
hemorrhag
due
surgeri
pcc
given
warfarin
revers
case
subset
patient
receiv
plasma
within
hour
prior
pcc
hour
pcc
frequent
order
orperiop
servic
conclus
major
pcc
usag
term
prescrib
indic
warfarin
revers
frequent
indic
hemorrhag
due
surgeri
pcc
often
order
orperiop
servic
although
guidelin
recommend
use
pcc
plasma
altern
plasma
administ
within
hour
pcc
notabl
subset
patient
backgroundcas
studi
emerg
situat
patient
life
may
jeopard
delay
transfus
physician
may
decid
transfus
blood
emerg
howev
case
poor
commun
lack
clear
expect
blood
bank
patient
care
area
lead
frustrat
delay
time
provis
blood
product
incid
prompt
apprais
emerg
releas
protocol
erp
reveal
gap
commun
expect
blood
bank
nurs
personnel
thu
imper
standard
er
protocol
clear
commun
blood
bank
nurs
personnel
report
outcom
process
improv
result
improv
commun
expect
turnaround
tat
er
protocol
studi
designmethod
sever
meet
conduct
stakehold
critic
care
unit
icu
emerg
depart
ed
intern
medicin
intervent
radiolog
ir
etc
effort
identifi
process
gap
improv
commun
expect
er
episod
goal
design
process
emerg
blood
product
request
releas
life
threaten
situat
simplifi
expedit
process
improv
commun
expect
decreas
tat
improv
patient
safeti
meet
complianc
order
achiev
goal
seri
activ
conduct
includ
meet
stakehold
ensur
process
improv
meet
need
intend
seri
train
session
nurs
educ
icu
ed
ir
surgeri
manag
conduct
meet
commun
goal
expect
defin
agre
upon
train
session
includ
powerpoint
present
educ
staff
member
perform
dri
run
identifi
weak
strength
process
flow
impact
current
process
analyz
result
led
revis
current
sop
addit
emerg
pack
blood
unit
neg
rbc
implement
electron
emerg
blood
order
set
resultsfind
ten
month
post
implement
improv
standard
er
pack
protocol
total
er
episod
receiv
averag
tat
order
deliveri
bedsid
reduc
minut
compar
minut
previous
complianc
rate
er
order
physician
document
current
wastag
blood
product
conclus
implement
improv
standard
er
protocol
significantli
improv
commun
expect
decreas
tat
delay
transfus
ensur
patient
safeti
complianc
regulatori
requir
backgroundcas
studi
massiv
transfus
mt
trauma
set
extens
studi
yet
literatur
area
especi
oncolog
rather
spars
follow
studi
conduct
understand
background
outcom
mt
cancer
patient
studi
designmethod
singl
center
retrospect
studi
perform
larg
cancer
center
februari
februari
mt
defin
transfus
rbc
unit
period
follow
data
collect
includ
age
gender
primari
diagnosi
surgeri
acut
care
type
amount
type
blood
compon
transfus
whether
massiv
transfus
protocol
mtp
activ
surviv
day
resultsfind
thirti
mt
occur
one
year
period
total
blood
product
transfus
time
period
gender
distribut
male
averag
age
patient
rang
year
age
surgic
patient
account
mt
critic
care
patient
tumor
categori
includ
carcinoma
sarcoma
leukemia
lymphoma
resect
tumor
follow
complex
reconstruct
caus
major
mt
metastat
renal
cancer
common
diseas
seen
follow
sacral
chordoma
mtp
activ
case
surviv
seen
patient
mortal
surgic
case
periton
mesothelioma
remaind
caus
gi
hemorrhag
perisplen
hematoma
overal
ratio
rbc
ffp
entir
group
approxim
rbc
ffp
howev
ratio
rbc
ffp
mortal
group
compar
group
overal
platelet
use
patient
cryoprecipit
patient
conclus
mtp
util
often
institut
surviv
appear
better
surgic
cancer
patient
vs
critic
care
oncolog
patient
receiv
balanc
ratio
rbc
ffp
compar
higher
ratio
rbc
ffp
backgroundcas
studi
plasma
supernat
blood
use
type
screen
crossmatch
analyt
phase
test
plasma
examin
prior
process
plasma
occasion
becom
discolor
interf
crossmatch
procedur
time
identif
etiolog
allow
correct
action
minim
delay
transfus
studi
designmethod
analyt
phase
blood
bank
test
sampl
evalu
crossmatch
identifi
three
sampl
discolor
plasma
present
seri
case
illustr
test
process
resultsfind
woman
diagnos
breast
cancer
present
mastectomi
sentinel
lymph
node
biopsi
preoper
specimen
contain
bright
green
plasma
review
preoper
case
reveal
exposur
intraven
methylen
blue
dye
known
alter
color
urin
tear
blood
known
pharmacolog
effect
altern
caus
green
plasma
includ
dye
use
locat
sentinel
node
oral
contracept
use
although
ideal
sampl
could
use
crossmatch
tube
method
autom
gel
techniqu
specimen
drawn
one
week
later
contain
clear
plasma
woman
diagnos
warm
autoimmun
hemolyt
anemia
refractori
blood
transfus
secondari
alloantibodi
administr
synthet
blood
product
result
dark
maroon
color
plasma
common
caus
dark
red
color
hemolysi
sampl
usual
discard
instanc
hemoglobin
color
due
infus
product
experiment
bovin
pegyl
carboxyhemoglobin
affect
colorimetr
evalu
blood
sampl
mind
sampl
discard
test
complet
tube
method
woman
admit
acut
stroke
treat
thrombolyt
reveal
cloudi
white
plasma
could
use
crossmatch
procedur
common
caus
white
plasma
includ
purul
hypertriglyceridemia
sampl
blood
drawn
proxim
administr
radiopaqu
agent
propofol
although
etiolog
could
identifi
repeat
specimen
drawn
sever
hour
later
clear
conclus
case
highlight
import
appropri
evalu
discolor
plasma
discolor
sampl
identifi
repeat
sampl
requir
confirm
chang
color
first
two
case
discolor
persist
prompt
clinic
investig
etiolog
identifi
need
test
elig
transfus
determin
test
tube
method
could
perform
two
case
third
case
repeat
sampl
reveal
clear
sampl
transfus
process
continu
without
delay
decis
regard
analyt
phase
test
must
includ
reevalu
sampl
identif
etiolog
comprehens
regard
proceed
discolor
persist
backgroundcas
studi
daratumumab
dara
monoclon
antibodi
therapi
specif
target
glycoprotein
highli
express
plasma
cell
success
use
patient
refractori
relaps
multipl
myeloma
dara
interfer
blood
bank
test
bind
express
red
blood
cell
caus
pan
reactiv
dara
interfer
overcom
use
dithiothreitol
dtt
treat
reagent
red
blood
cell
minim
alloimmun
provid
crossmatch
compat
blood
treat
patient
institut
dara
protocol
blood
bank
purpos
retrospect
studi
identifi
outcom
protocol
particular
focu
develop
de
novo
alloantibodi
dara
treatment
institut
studi
designmethod
dara
patient
antibodi
workup
complet
use
dtt
reagent
red
blood
cell
antibodi
screen
neg
k
antigen
neg
rbc
product
provid
antibodi
identifi
k
neg
along
particular
antigen
neg
blood
provid
electron
medic
record
emr
search
patient
receiv
dara
past
eight
month
studi
subject
examin
see
alloantibodi
dara
treatment
whether
form
new
alloantibodi
dara
treatment
age
gender
type
screen
treatment
type
screen
interven
blood
transfus
date
first
dara
treatment
record
resultsfind
overal
subject
identifi
analysi
mean
age
year
male
femal
subject
diagnos
multipl
myeloma
found
alloimmun
rate
prior
administr
dara
patient
transfus
red
blood
cell
rbc
initi
dara
therapi
follow
testingmatch
protocol
none
patient
form
confirm
new
alloantibodi
dara
treatment
patient
underw
least
one
screen
first
rbc
unit
also
found
complic
provid
crossmatch
compat
unit
patient
conclus
knowledg
largest
case
seri
report
result
overcom
dara
interfer
blood
bank
type
screen
test
protocol
implement
laboratori
appear
success
provid
compat
unit
prevent
alloimmun
patient
receiv
dara
therapi
possibl
drug
target
antibodi
form
cell
may
immunosuppress
effect
humor
respons
studi
effect
may
warrant
backgroundcas
studi
transfus
servic
began
stock
liquid
plasma
septemb
use
massiv
transfus
trauma
situat
due
infrequ
occurr
incid
liquid
plasma
would
outdat
use
polici
use
liquid
plasma
situat
unit
near
expir
date
implement
studi
evalu
effect
polici
inr
valu
plasma
recipi
studi
designmethod
retrospect
analysi
develop
compar
effect
fresh
frozen
plasma
ffp
liquid
plasma
lqp
chang
inr
valu
recipi
plasma
unit
transfus
within
facil
septemb
april
identifi
follow
data
obtain
hospit
laboratori
inform
system
unit
recipi
primari
reason
transfus
plasma
number
plasma
unit
transfus
type
plasma
transfus
inr
valu
whether
vitamin
k
administ
patient
divid
group
base
type
plasma
unit
transfus
evalu
base
primari
reason
transfus
number
unit
transfus
administr
vitamin
k
chang
inr
recipi
calcul
along
averag
chang
inr
group
resultsfind
total
unit
plasma
transfus
patient
patient
receiv
ffp
lqp
patient
receiv
ffp
patient
receiv
lqp
chang
inr
avail
patient
inr
decreas
patient
group
see
tabl
averag
decreas
inr
plasma
unit
patient
receiv
ffp
lqp
patient
receiv
ffp
patient
receiv
lqp
patient
receiv
plasma
due
elev
inr
valu
show
greatest
decreas
inr
among
transfus
reason
evalu
patient
receiv
vitamin
k
show
greater
chang
inr
categori
comparison
total
number
plasma
unit
transfus
show
patient
receiv
ffp
greater
chang
inr
valu
receiv
lqp
ffp
lqp
unit
transfus
patient
receiv
unit
plasma
show
greatest
decreas
inr
lqp
transfus
patient
receiv
unit
plasma
show
greatest
chang
inr
receiv
mixtur
ffp
lqp
conclus
attempt
lower
inr
valu
concurr
administr
vitamin
k
show
greater
result
transfus
plasma
alon
transfus
ffp
show
greater
chang
inr
transfus
lqp
result
studi
interpret
caution
due
small
sampl
size
patient
receiv
lqp
chang
inr
valu
avail
backgroundcas
studi
gynaecolog
set
rel
young
anaem
women
iron
defici
due
blood
loss
associ
menstruat
transfus
could
gener
avoid
without
haemodynam
instabl
oral
antifibrinolyt
drug
tranexam
acid
effect
well
toler
treatment
menorrhagia
besid
iron
replac
often
necessari
prolong
period
time
normal
haemoglobin
hb
present
studi
attempt
look
transfus
appropri
use
iron
tranexam
acid
transfus
women
hong
kong
studi
designmethod
anonym
data
gynaeolog
patient
age
retriev
central
databas
public
hospit
includ
age
number
unit
red
cell
transfus
hb
use
iron
andor
tranexam
acid
hospit
upon
discharg
transfus
episod
associ
surgic
oper
admiss
exclud
resultsfind
uniqu
women
receiv
total
unit
red
cell
rc
transfus
episod
identifi
median
age
rang
distribut
transfus
hb
unit
rc
transfus
summar
cohort
hb
absent
transfus
episod
associ
use
unit
rc
result
episod
result
post
transfus
hb
parenter
iron
tranexam
acid
uncommon
hospit
given
women
respect
upon
discharg
women
prescrib
oral
iron
alon
oral
tranexam
acid
alon
respect
howev
neither
given
women
conclus
present
studi
observ
transfus
episod
given
hb
substanti
number
episod
transfus
multipl
unit
result
almost
half
post
transfus
hb
level
iron
replenish
bleed
control
transfus
women
given
iron
tranexam
acid
discharg
result
indic
awar
transfus
appropri
iron
defici
anaemia
manag
improv
recommend
educ
train
provid
better
gynaecolog
patient
blood
manag
backgroundcas
studi
granulocyt
transfus
may
util
boost
immun
respons
patient
neutropenia
neutrophil
dysfunct
evid
bacteri
fungal
infect
howev
granulocyt
rare
administ
due
uncertainti
regard
efficaci
difficulti
collect
increas
propens
advers
reaction
report
case
granulocyt
transfus
therapi
follow
chimer
antigen
receptor
therapi
patient
sever
neutropenia
multipl
infect
context
relaps
acut
lymphoblast
leukemia
studi
designmethod
granulocyt
per
unit
collect
unstimul
donor
region
blood
center
unit
irradi
gy
transfus
hour
within
hour
time
collect
patient
respons
laboratori
data
review
medic
record
resultsfind
patient
femal
diagnos
place
protocol
achiev
complet
remiss
howev
bone
marrow
bm
biopsi
march
reveal
recurr
diseas
prompt
intensifi
therapi
bm
transplant
bmt
sibl
donor
august
experienc
two
addit
relaps
underw
therapi
april
ensu
clinic
cours
complic
continu
sever
neutropenia
serial
infect
includ
dissemin
medic
resist
candidemia
dissemin
infect
ulcer
oral
hsv
mucos
oral
wound
cultur
posit
rothia
mucilaginosa
total
daili
granulocyt
infus
administ
granulocyt
patient
two
hla
antibodi
within
hour
first
transfus
white
blood
cell
wbc
count
increas
oral
cutan
candid
lesion
show
clinic
improv
howev
receiv
margin
benefit
subsequ
transfus
wbc
count
fell
repeat
bm
biopsi
reveal
profound
hypocellular
although
second
bmt
consid
riski
context
activ
candidemia
place
palli
care
expir
day
therapi
conclus
report
case
granulocyt
transfus
clinic
improv
patient
candidiasi
transient
increas
wbc
count
sustain
success
transfus
one
explan
dose
granulocyt
transfus
per
unit
may
suboptim
coordin
provid
crucial
success
granulocyt
transfus
tabl
granulocyt
count
per
unit
wbc
count
backgroundcas
studi
patient
test
class
antibodi
predict
immun
platelet
refractori
institut
platelet
refractori
commonli
identifi
patient
hematolog
malign
determin
factor
associ
hla
alloimmun
lead
cost
effect
test
patient
high
risk
studi
designmethod
patient
undergon
hematopoiet
stem
cell
transplant
test
use
assay
class
antibodi
patient
class
antibodi
group
analyz
diagnosi
abo
blood
group
comparison
patient
hematolog
malign
identifi
hla
antibodi
hm
group
test
use
compar
posit
rate
resultsfind
patient
group
year
patient
hm
group
year
femal
antibodi
vs
hm
p
common
diagnosi
acut
myeloid
leukemia
aml
group
aml
constitut
higher
percentag
group
vs
p
hm
group
patient
aml
abo
blood
group
frequenc
significantli
differ
report
frequenc
gener
popul
unit
state
hm
group
group
group
b
group
ab
aml
group
group
group
b
group
ab
significantli
higher
number
patient
group
b
blood
type
identifi
group
hm
group
higher
rate
group
b
still
seen
consid
subgroup
patient
aml
hm
group
conclus
data
suggest
diagnosi
aml
associ
antibodi
increas
frequenc
blood
group
patient
aml
report
statist
signific
differ
abo
blood
group
frequenc
found
categori
except
patient
hla
antibodi
blood
group
b
signific
associ
hla
alloimmun
studi
patient
report
larg
studi
femal
blood
donor
differ
hla
antibodi
frequenc
observ
base
abo
blood
group
center
use
assay
although
reason
higher
rate
group
b
blood
type
among
patient
antibodi
hematolog
malign
unknown
could
due
variat
immun
event
pregnanc
vs
transfus
immun
dysregul
relat
hematolog
malign
especi
aml
femal
aml
blood
group
b
appear
like
hla
alloimmun
among
patient
hematolog
malign
backgroundcas
studi
patient
misidentif
improp
sampl
label
ongo
risk
safeti
blood
transfus
rate
mistransfus
remain
unchang
year
attempt
made
reduc
mistransfus
includ
barrier
devic
barcod
rfid
within
region
transfus
servic
rt
barcod
rfid
would
requir
standard
admiss
discharg
transfer
inform
system
barrier
method
shown
workaround
step
allow
oper
bypass
barrier
studi
designmethod
develop
plan
reduc
mistransfus
would
work
rt
barrier
devic
dismiss
barcod
rfid
costli
implement
request
second
sampl
collect
differ
color
tube
issu
blood
bank
test
prior
transfus
determin
impract
rural
laboratori
approach
develop
util
transfus
medicin
laboratori
inform
system
li
identifi
patient
histor
blood
group
file
automat
appli
transfus
protocol
would
permit
group
rh
compat
red
cell
issu
manag
sinc
patient
uniqu
identifi
histor
aborh
li
minim
impact
group
inventori
second
sampl
obtain
unit
request
confirm
abo
allow
issu
group
specif
red
cell
neonat
patient
continu
receiv
group
rh
neg
red
cell
increas
demand
group
expect
plasma
compon
exclud
new
transfus
protocol
resultsfind
popul
base
rt
serv
million
process
place
one
year
number
transfus
red
cell
increas
posit
neg
red
cell
unit
per
day
process
subsequ
adapt
request
second
aborh
sampl
first
unit
request
transfus
solut
provid
safeti
patient
perform
two
blood
group
one
sampl
although
process
solv
problem
patient
use
anoth
person
identif
conclus
rt
util
li
ensur
group
rh
compat
red
cell
issu
second
sampl
test
patient
histor
blood
group
file
ensur
mistransfus
risk
reduc
incur
delay
patient
care
prove
cost
effect
effici
way
reduc
abo
mistransfus
due
misidentif
minim
impact
group
inventori
backgroundcas
studi
role
donor
age
sex
hemoglobin
content
suscept
hemolysi
storag
red
blood
cell
rbc
unit
receiv
increas
attent
howev
impact
donor
characterist
efficaci
rbc
transfus
studi
outcom
databas
studi
designmethod
conduct
analysi
use
blood
donor
data
routin
collect
blood
center
transfus
recipi
data
larg
commun
hospit
network
patient
blood
manag
initi
linkag
perform
blood
donor
characterist
hospit
rbc
transfus
recipi
receiv
singl
rbc
unit
studi
exposur
analysi
blood
donor
sex
age
addit
rbc
storag
age
wilcoxon
test
use
examin
chang
hemoglobin
level
follow
rbc
transfus
multivari
logist
analysi
adjust
recipi
sex
age
estim
blood
volum
use
nadler
equat
resultsfind
link
data
hospit
transfus
recipi
receiv
singl
rbc
unit
hospit
blood
donor
demograph
data
median
blood
donor
age
year
iqr
transfus
rbc
unit
male
donor
unit
leukoreduc
median
storag
age
rbc
unit
prior
transfus
day
iqr
median
recipi
age
year
iqr
male
recipi
rbc
male
femal
donor
similar
hemoglobin
level
howev
transfus
recipi
male
donor
rbc
unit
higher
hemoglobin
level
larger
increment
hemoglobin
compar
femal
rbc
unit
vs
vs
femal
recipi
larger
rise
hemoglobin
per
rbc
unit
compar
male
recipi
vs
p
femal
sex
recipi
remain
signific
predictor
chang
hemoglobin
account
recipi
age
estim
circul
blood
volum
multivari
analysi
rbc
storag
age
age
donor
signific
factor
chang
hemoglobin
level
multivari
analysi
respect
conclus
rbc
unit
male
donor
result
larger
rise
hemoglobin
level
compar
femal
donor
chang
appar
femal
recipi
even
account
effect
circul
blood
volum
suggest
dose
hemoglobin
lower
femal
male
rbc
unit
analysi
demonstr
feasibl
use
approach
studi
associ
donor
characterist
rbc
efficaci
hemolysi
interact
backgroundcas
studi
peopl
identifi
jehovah
wit
jw
compris
less
popul
unit
state
howev
group
present
special
challeng
medicin
due
religi
avers
blood
product
base
biblic
read
degre
religi
refus
vari
individu
individu
institut
polici
conserv
approach
warrant
howev
larg
institut
multipl
team
manag
singl
patient
blood
refus
inform
lost
poorli
commun
provid
provid
system
alert
provid
patient
blood
refus
recent
implement
electron
medic
record
larg
institut
studi
designmethod
electron
medic
record
emr
util
studi
institut
modifi
version
epic
ea
best
practic
alert
bpa
design
trigger
time
end
user
attempt
place
order
relat
blood
transfus
lab
test
pharmaci
item
patient
blood
refus
code
histori
problem
list
religion
jehovah
wit
discret
data
field
alert
constitut
order
provid
prompt
either
cancel
trigger
order
acknowledg
blood
refusalreligi
histori
overrid
warn
option
select
reason
overrid
data
trigger
automat
collect
emr
system
gener
report
informat
personnel
resultsfind
avail
data
cover
trigger
two
month
bpa
bpa
trigger
time
total
affect
patient
user
stratifi
locat
major
trigger
occur
periop
area
time
liver
icu
time
minor
occur
regular
hospit
floor
emerg
depart
nurs
attend
resid
pharmacist
nurs
anesthesiologist
user
affect
order
trigger
bpa
includ
type
screen
human
albumin
iv
solut
human
albumin
iv
solut
immun
globulin
human
solut
tabl
action
taken
follow
bpa
trigger
conclus
despit
limit
preliminari
data
user
action
find
seem
indic
bpa
effect
halt
half
contraind
order
product
type
screen
order
given
limit
type
order
bpa
trigger
pattern
suggest
bpa
potenti
alert
previous
unawar
provid
patient
religi
statu
andor
fact
certain
pharmaci
item
therefor
unaccept
mani
jw
patient
despit
posit
initi
find
ongo
studi
track
efficaci
bpa
data
need
collect
better
metric
institut
sensit
patient
blood
refus
backgroundcas
studi
although
introduc
manag
hemophilia
cryoprecipit
primarili
indic
low
fibrinogen
level
institut
transfus
medicin
servic
tm
review
make
recommend
clinician
inappropri
cryoprecipit
order
aim
analyz
effect
intervent
reach
target
fibrinogen
level
order
studi
designmethod
conduct
retrospect
studi
adult
cryoprecipit
order
qualiti
assur
form
refer
rang
fibrinogen
critic
valu
cryoprecipit
order
massiv
transfus
protocol
oper
room
extracorpor
membran
oxygen
review
tm
studi
period
tm
evalu
order
appropri
dose
agreement
estim
requir
dose
fibrinogen
level
due
intervent
compar
hypothes
intervent
level
statist
analysi
perform
use
resultsfind
adult
year
order
review
tm
approv
approv
order
agreement
tm
estim
dose
order
agreement
tm
estim
underestim
overestim
seventeen
order
fibrinogen
level
without
intervent
would
median
deficit
rang
median
excess
rang
fibrinogen
target
median
differ
target
actual
fibrinogen
level
target
significantli
higher
intervent
without
could
target
p
median
differ
target
fibrinogen
level
group
agreement
approv
request
unit
significantli
differ
possibl
differ
without
intervent
vs
median
differ
target
fibrinogen
level
group
approv
request
unit
significantli
differ
possibl
differ
without
intervent
vs
p
seven
order
critic
low
fibrinogen
request
reach
target
fibrinogen
tm
estim
approv
requir
unit
transfus
overal
frequent
order
unit
ie
pool
frequent
order
disagr
group
unit
signific
differ
agreement
disagr
group
base
clinic
servic
order
unit
tabl
conclus
intervent
tm
review
approv
cryoprecipit
order
associ
increas
accuraci
order
achiev
desir
target
fibrinogen
level
studi
need
develop
multidisciplinari
strategi
accur
cryoprecipit
dosag
tabl
backgroundcas
studi
intern
normal
ratio
inr
use
measur
anticoagul
effect
warfarin
plasma
transfus
frequent
use
correct
elev
inr
invas
procedur
studi
shown
inr
unreli
test
bleed
risk
assess
patient
elev
inr
nt
bleed
whether
given
prophylact
plasma
mani
surgicalintervent
societi
guidelin
recommend
correct
inr
prior
invas
procedur
order
reduc
bleed
complic
evalu
plasma
transfus
intervent
radiolog
ir
procedur
inr
correct
studi
designmethod
medic
record
adult
patient
requir
ir
procedur
period
review
retrospect
total
patient
receiv
plasma
inr
correct
met
inclusionexclus
criteria
transfus
unit
plasma
inr
correct
prior
procedur
inr
measur
transfus
patient
characterist
medic
record
vitamin
k
administr
advers
event
collect
tabl
resultsfind
averag
inr
patient
inr
correct
chang
increas
inr
tabl
major
patient
receiv
unit
plasma
mean
plasma
dose
transfus
reaction
report
transfus
associ
circulatori
overload
reaction
requir
admiss
icu
two
patient
experienc
bleed
ir
procedur
tip
develop
hematoma
tunnel
central
line
conclus
median
inr
correct
studi
relationship
number
unit
plasma
transfus
andor
vitamin
k
administ
studi
suggest
may
benefici
may
harm
transfus
plasma
correct
inr
random
trial
need
assess
whether
inr
ration
tool
measur
bleed
risk
whether
prophylact
treatment
plasma
yield
benefit
patient
experienc
bleed
complic
indic
inr
may
consid
safe
lower
risk
procedur
current
practic
may
provid
littl
benefit
substanti
risk
life
threaten
complic
backgroundcas
studi
group
ab
plasma
lack
antibodi
consid
univers
plasma
donor
use
emerg
set
patient
blood
group
avail
approxim
popul
group
ab
limit
avail
inventori
group
ab
plasma
group
ab
popul
plasma
male
donor
consid
suitabl
transfus
sinc
femal
especi
multipar
femal
donor
greater
propens
develop
antibodi
caus
transfus
relat
acut
lung
injuri
trali
make
type
ab
plasma
limit
resourc
hospit
level
one
trauma
center
signific
amount
plasma
transfus
requir
sever
bleed
patient
blood
type
known
group
individu
make
popul
b
antigen
cell
group
second
preval
blood
group
us
popul
b
antigen
cell
group
plasma
compat
group
patient
approxim
patient
popul
patient
blood
type
known
type
red
cell
unit
transfus
plasma
decreas
chanc
hemolysi
conserv
ab
plasma
institut
polici
effect
juli
follow
unit
group
plasma
unit
group
ab
plasma
provid
massiv
transfus
protocol
mtp
along
unit
neg
rbc
patient
blood
type
known
studi
designmethod
prospect
studi
design
monitor
use
group
plasma
mtp
institut
evalu
risk
sever
hemolysi
patient
transfus
incompat
plasma
direct
antiglobulin
test
dat
perform
patient
receiv
incompat
plasma
dat
posit
lactat
dehydrogenas
ldh
haptoglobin
bilirubin
level
obtain
detect
possibl
hemolyt
transfus
reaction
resultsfind
review
mtp
institut
juli
march
twenti
patient
transfus
incompat
group
plasma
group
ab
group
b
patient
five
patient
die
due
sever
injuri
test
patient
could
perform
remain
patient
neg
dat
indic
lack
signific
amount
antibodi
coat
red
cell
could
lead
hemolysi
none
patient
develop
acut
hemolyt
reaction
advers
effect
incompat
plasma
transfus
conclus
studi
add
evid
safeti
group
plasma
transfus
trauma
patient
requir
emerg
massiv
transfus
patient
blood
type
known
base
recent
publish
studi
start
april
institut
provid
group
plasma
emerg
releas
mtp
case
patient
blood
type
known
backgroundcas
studi
bonfil
immunohematolog
refer
lab
irl
sent
approxim
special
platelet
patient
hla
antibodi
hla
platelet
order
increas
dramat
irl
sent
special
platelet
product
purpos
abstract
illumin
method
use
fulfil
increas
client
need
occur
short
period
time
studi
designmethod
bonfil
blood
center
donor
databas
histor
hla
type
howev
approxim
donor
activ
donat
denver
area
one
common
hla
type
donor
type
therefor
fill
hla
platelet
order
request
common
hla
type
donor
system
would
perfect
hla
match
low
number
donor
like
would
platelet
shelf
readi
fill
order
donor
recruit
donat
take
least
two
day
fill
order
less
uncommon
hla
type
like
donor
match
perfectli
case
donor
recruit
fill
order
complic
case
irl
provid
hla
antibodi
list
panel
reactiv
antibodi
test
pra
order
find
product
patient
list
platelet
inventori
correspond
hla
type
print
patient
antibodi
exampl
posit
platelet
cross
list
process
would
continu
manual
platelet
list
one
posit
hla
antigen
patient
antibodi
platelet
pra
match
patient
order
autom
process
report
link
donor
databas
creat
find
pra
platelet
inventori
donor
recruit
blood
center
medic
director
began
suggest
hospit
client
order
pra
patient
platelet
refractori
pra
test
fast
definit
method
discern
hla
antibodi
mediat
refractori
platelet
refractori
due
caus
resultsfind
complic
case
rare
hla
patient
phenotyp
much
easier
find
pra
patient
match
platelet
shelf
hla
match
donor
approxim
special
order
platelet
pra
match
remain
hla
match
donor
recruit
approxim
special
platelet
sent
pra
match
chang
result
fold
increas
find
product
inventori
fill
order
quickli
conclus
develop
system
provid
pra
match
platelet
faster
altern
find
hla
match
platelet
thu
contribut
better
patient
care
backgroundcas
studi
urgent
case
larg
amount
blood
product
need
quickli
maintain
standard
massiv
transfus
protocol
mtp
critic
time
deliveri
product
mtp
pack
ucm
contain
pack
red
blood
cell
prbc
fresh
frozen
plasma
ffp
unit
plateletpheresi
pack
unit
prepool
cryoprecipit
also
given
patient
labor
deliveri
l
one
request
ucm
blood
product
gener
transport
pneumat
tube
system
pt
undertook
review
mtp
issu
practic
effici
pattern
last
three
half
year
studi
designmethod
electron
archiv
blood
bank
laboratori
inform
system
electron
medic
record
institut
queri
patient
mtp
activ
archiv
correl
paper
copi
activ
collect
data
pertain
relev
inform
order
origin
quickli
first
product
sent
mani
product
transfus
resultsfind
august
march
mtp
activ
ucm
order
could
trace
origin
inpati
floor
includ
icu
oper
room
emerg
depart
labor
deliveri
procedur
room
prbc
issu
transfus
util
unit
ffp
issu
transfus
util
platelet
pack
issu
transfus
util
unit
cryoprecipit
issu
transfus
util
sinc
march
time
first
product
issu
initi
mtp
also
track
event
fall
within
time
period
first
product
issu
minut
less
anoth
issu
minut
result
patient
issu
first
blood
product
within
first
minut
event
initi
time
greater
minut
none
greater
minut
conclus
major
activ
current
come
inpati
floor
primarili
icu
institut
anticip
introduct
adult
level
trauma
center
anticip
balanc
shift
addit
data
show
except
cryoprecipit
util
rate
nearli
ident
among
blood
product
sent
mtp
activ
anticip
util
rate
issu
mtp
product
increas
introduct
new
adult
trauma
center
recent
begun
track
time
last
product
issu
mtp
report
variabl
time
overal
data
show
transfus
servic
gener
perform
adequ
issu
first
product
within
minut
mtp
protocol
activ
data
reflect
time
issu
pt
patient
care
area
experi
addit
minut
delay
pt
deliveri
arriv
product
bedsid
must
continu
collabor
clinic
colleagu
collect
accur
data
provid
best
effici
mtp
care
backgroundcas
studi
massiv
bleed
gener
defin
patient
requir
blood
volum
replac
within
hour
andor
receiv
transfus
greater
equal
unit
one
hour
ongo
bleed
mtp
offici
implement
prepar
initi
verif
level
trauma
center
ac
mtp
follow
packag
pack
ratio
rbc
plasma
platelet
subsequ
pack
ratio
mtp
also
includ
prothrombin
time
pt
activ
partial
thromboplastin
time
aptt
fibrinogen
test
pack
transfus
data
use
assess
patient
allow
transfus
servic
clinic
team
identifi
coagulopathi
howev
attempt
supplement
mtp
pack
cryoprecipit
cryo
prothrombin
complex
concentr
pcc
challeng
accomplish
time
manner
studi
designmethod
due
challeng
time
supplement
mtp
packag
cryo
pcc
protocol
modifi
march
add
cryo
pcc
defin
point
mtp
cryo
includ
pack
pcc
pack
order
valid
modif
ad
product
defin
interv
regardless
laboratori
data
decid
review
patient
receiv
rbc
institut
massiv
hemorrhag
patient
would
receiv
pcc
base
current
protocol
review
blood
product
receiv
patient
avail
laboratori
data
resultsfind
patient
receiv
rbc
mtp
activ
patient
patient
receiv
unit
plasma
rbc
unit
transfus
despit
receiv
ratio
blood
product
patient
elev
pt
second
mani
elev
aptt
fibrinogen
level
less
institut
target
tabl
anticip
improv
coagul
paramet
note
cryo
pcc
supplement
conclus
data
massiv
hemorrhag
patient
support
role
supplement
mtp
cryo
pcc
patient
requir
transfus
rbc
current
protocol
addit
cryo
pcc
defin
interv
streamlin
process
improv
time
provis
product
bleed
coagulopath
patient
backgroundcas
studi
red
blood
cell
hemolysi
key
find
diagnosi
passeng
lymphocyt
syndrom
howev
whether
hematopoiet
stem
cell
organ
transplant
recipi
experi
hemolysi
transplant
contain
unintend
passeng
lymphocyt
depend
chanc
recipi
blood
group
phenotyp
live
donor
liver
segment
transplant
result
case
potenti
caus
clinic
signific
hemolyt
event
donor
plasma
contain
absent
recipi
plasma
present
recipi
plasma
although
find
establish
diagnosi
hemolysi
occur
recipi
blood
group
phenotyp
convent
focu
hemolysi
rather
transfer
lymphocyt
divers
primari
pathophysiolog
pl
limit
captur
true
scope
syndrom
studi
designmethod
determin
standard
practic
detect
diagnos
retrospect
pubm
search
journal
articl
conduct
use
key
word
passeng
lymphocyt
syndrom
case
categor
accord
presenc
absenc
hemolysi
whether
routin
antibodi
screen
detect
passeng
blood
group
antibodi
resultsfind
publish
case
report
report
stem
cell
report
organ
transplant
stem
cell
transplant
organ
transplant
associ
hemolysi
reflect
overwhelm
bia
identifi
associ
hemolysi
report
stem
cell
activ
screen
antibodi
immedi
period
report
organ
activ
screen
antibodi
screen
detect
case
stem
cell
hemolysi
becam
appar
case
organ
antibodi
without
hemolysi
infer
current
hemolysi
consist
present
andor
antibodi
screen
perform
routin
conclus
new
categori
recommend
captur
otherwis
undiagnos
case
passeng
lymphocyt
form
blood
group
antibodi
recipi
hemolysi
occur
aforement
case
ensur
includ
full
scope
antibodi
screen
perform
routin
one
week
transplant
repeat
clinic
indic
backgroundcas
studi
mur
antigen
present
individu
southeast
asia
taiwan
part
southeastern
china
rare
elsewher
antibodi
mur
antigen
clinic
signific
henc
mani
countri
asia
routin
screen
countri
includ
us
includ
mur
standard
screen
describ
case
occult
antibodi
caus
anemia
donor
ethnic
distribut
region
blood
center
larg
asian
donor
popul
year
old
hispan
male
chronic
myelomonocyt
leukemia
plasma
cell
dyscrasia
develop
anemia
initi
antibodi
screen
dat
neg
patient
receiv
rbc
unit
everi
week
maintain
hemoglobin
hb
level
patient
remain
stabl
month
hb
level
acut
drop
antibodi
screen
remain
neg
addit
month
becam
posit
donor
ethnic
data
avail
rbc
unit
receiv
unit
asian
donor
unit
transfus
day
prior
hb
drop
caucasianchines
donor
studi
designmethod
review
ethnic
data
donor
blood
center
locat
region
asian
compris
approxim
popul
resultsfind
donor
identifi
chines
vietnames
filipino
southeastern
asian
donor
account
rbc
collect
conclus
identif
patient
trigger
presenc
concurr
alloantibodi
sinc
rbc
suppli
local
blood
center
collect
chines
southeast
asian
donor
chronic
transfus
patient
risk
develop
hemolysi
could
miss
standard
screen
find
rais
possibl
need
blood
bank
locat
region
promin
asian
popul
implement
screen
backgroundcas
studi
antibodi
titrat
test
modal
vital
obstetr
transplant
servic
manual
direct
tube
test
associ
variabl
result
poor
reproducibilityprecis
also
time
resourc
intens
fact
studi
shown
eightfold
differ
antibodi
titer
sampl
use
manual
tube
method
orthovis
autom
analyz
offer
autom
titer
patient
plasma
use
gel
technolog
although
intens
interest
adopt
autom
test
technolog
titer
titer
obtain
manual
gel
test
much
higher
obtain
manualdirect
tube
test
higher
titer
result
lack
clinic
fetal
anemia
outcom
correl
barrier
implement
moreov
despit
increas
sensit
gel
test
prior
studi
found
variabl
result
regard
reproduc
minim
inform
comparison
tube
titer
orthovis
autom
titer
assess
reproduc
autom
method
studi
designmethod
rh
non
rh
minor
rbc
antibodi
titrat
perform
manual
direct
tube
method
clinic
sampl
sampl
analyz
three
differ
ortho
vision
analyz
assess
precis
reproduc
resultsfind
total
sampl
analyz
tabl
rh
antigen
titer
via
autom
test
orthovis
result
mean
titrat
rang
time
higher
averag
fold
chang
rhdce
antibodi
titer
wherea
averag
fold
chang
non
rh
titer
rang
rang
anti
titer
particularli
variabl
wherea
ce
overal
reproducibilityprecis
autom
analyz
correl
increas
titer
observ
class
antibodi
particularli
anti
perform
parallel
test
obstetr
sampl
correl
pregnanc
outcomefet
test
obtain
valu
conclus
autom
titrat
antibodi
use
orthovis
analyz
result
highli
reproduc
result
differ
instrument
use
sampl
howev
autom
analyz
consist
yield
higher
valu
particularli
rh
result
time
higher
manual
tube
test
interestingli
differ
titer
non
rh
antibodi
manual
tube
autom
test
statist
signific
although
n
thu
far
small
order
leverag
effici
reproduc
benefit
autom
titer
need
establish
critic
titer
rang
requir
activ
monitor
fetu
backgroundcas
studi
isoagglutinin
plasma
apheresi
platelet
concern
transfus
high
titer
andor
may
caus
hemolyt
transfus
reaction
htr
recipi
cognat
antigen
apheresi
platelet
collect
usual
reconstitut
donor
plasma
howev
facil
test
high
titer
isoagglutinin
expos
recipi
risk
htr
due
plasma
incompat
given
base
short
outdat
abo
type
facil
test
perform
apheresi
platelet
cutoff
titer
unit
cutoff
mark
high
titer
given
abo
recipi
wash
salin
reduc
plasma
howev
wash
platelet
time
consum
process
result
loss
platelet
platelet
addit
solut
pa
use
altern
collect
storag
solut
replac
approxim
donor
plasma
final
product
goal
studi
determin
affect
pa
isoagglutinin
titer
whether
use
pa
could
lead
revis
one
facil
procedur
manag
group
platelet
transfus
studi
designmethod
isoagglutinin
titer
whole
blood
edta
sampl
compar
final
apheresi
platelet
unit
collect
pa
intersol
freseniu
kabi
lake
zurich
il
use
dilut
step
plasma
test
pool
red
cell
equal
mix
suspens
b
cell
ortho
raritan
nj
gel
matrix
test
mt
buffer
card
ortho
raritan
nj
min
incub
room
temperatur
prior
centrifug
mt
ortho
workstat
fifti
two
donor
group
group
group
b
resultsfind
whole
blood
edta
sampl
test
group
b
exceed
high
titer
threshold
pa
sampl
donor
test
one
group
exceed
threshold
pa
specimen
show
consist
decreas
titer
compar
whole
blood
specimen
nearli
half
group
donor
exceed
titer
whole
blood
specimen
test
conclus
one
sampl
apheresi
platelet
collect
pa
exceed
clinic
appli
titer
threshold
decreas
number
whole
blood
specimen
exceed
threshold
test
platelet
bag
collect
pa
instead
plasma
whole
blood
specimen
would
lower
number
unit
exceed
high
titer
threshold
reduc
product
need
wash
furthermor
facil
collect
platelet
site
without
access
whole
blood
specimen
donor
could
implement
process
describ
screen
platelet
apheresi
collect
potenti
clinic
advers
isoagglutinin
titer
whether
collect
use
pa
backgroundcas
studi
platelet
plt
day
shelf
life
israel
thu
util
rapidli
suscept
expir
compon
major
blood
compon
israel
collect
distribut
magen
david
adom
mda
main
locat
sever
hospit
israel
also
collect
platelet
part
effort
understand
plt
util
nationwid
survey
plt
transfus
expir
conduct
studi
designmethod
data
disposit
plt
unit
acquir
mda
collect
calendar
year
request
hospit
israel
number
plt
distribut
hospit
mda
also
collect
plt
wastag
defin
sum
plt
return
reissu
hospit
blood
bank
plt
expir
blood
bank
shelv
resultsfind
sixteen
hospit
israel
along
mda
particip
survey
list
p
result
present
tabl
along
hospit
distanc
mda
facil
hospit
sum
transfus
wast
plt
slightli
less
number
plt
suppli
mda
like
due
small
number
plt
either
transfus
expir
time
data
collect
period
end
three
largest
hospit
c
b
collect
plt
addit
acquir
unit
mda
hospit
lower
overal
rate
wastag
includ
donat
hospit
collect
plt
hospit
wastag
rate
rang
correl
appar
hospit
distanc
mda
facil
number
bed
plt
wastag
rate
conclus
consider
platelet
wastag
israel
larg
hospit
israel
donat
lowest
overal
wastag
rate
comparison
hospit
factor
known
affect
plt
util
wastag
patient
diagnosi
mix
polici
plt
issu
accept
back
hospit
inventori
plt
inventori
size
time
pool
whole
blood
platelet
rel
time
issu
return
blood
bank
need
investig
optim
order
reduc
wastag
rate
backgroundcas
studi
hemolysi
platelet
rare
report
incid
commonli
case
group
platelet
high
titer
result
clinic
signific
hemolysi
transfus
group
ab
recipi
present
patient
possibl
hemolyt
reaction
follow
transfus
abo
mismatch
platelet
present
set
underli
diseas
associ
hemolysi
studi
designmethod
male
chronic
myelogen
leukemia
blast
crisi
evalu
possibl
transfus
reaction
singl
donor
platelet
sdp
two
hour
post
transfus
develop
chill
rigor
increas
blood
pressur
hg
hg
follow
hematuria
chill
rigor
resolv
blood
pressur
stabil
min
diphenhydramin
solumedrol
acetaminophen
resultsfind
patient
group
posit
platelet
unit
group
posit
cleric
check
show
discrep
associ
transfus
post
transfus
direct
test
dat
neg
identifi
recipi
plasma
specimen
visibl
hemolysi
cultur
unit
transfus
neg
patient
abo
group
rh
type
antibodi
screen
specimen
show
discrep
laboratori
indic
hemolysi
summar
tabl
notabl
total
indirect
bilirubin
increas
hemoglobin
decreas
transfus
test
indetermin
hemolyt
transfus
reaction
abnorm
level
despit
underli
diseas
associ
hemolysi
blood
supplier
unit
contact
investig
possibl
high
titer
donor
reveal
donor
titer
result
igm
igg
donor
defer
futur
platelet
donat
conclus
sampl
visibl
hemolysi
neg
dat
increas
total
indirect
bilirubin
transfus
high
titer
donor
support
immun
mediat
hemolyt
transfus
reaction
key
uniqu
aspect
case
baselin
underli
hemolysi
may
mask
need
investig
donor
high
titer
tabl
backgroundcas
studi
orthotop
liver
transplant
olt
high
complex
procedur
fundament
therapeut
approach
liver
diseas
despit
improv
hemostat
surgic
anaesthet
techniqu
liver
transplant
still
associ
massiv
blood
loss
high
rate
transfus
requir
peri
intraop
transfus
red
blood
cell
rbc
previous
report
major
predictor
post
mortal
identifi
predict
factor
transfus
requir
may
help
optimis
patient
blood
manag
strategi
olt
conduct
singl
center
retrospect
analysi
case
olt
perform
brazil
order
identifi
predict
factor
red
blood
cell
transfus
studi
designmethod
retrospect
analysi
singl
institut
perform
chart
consecut
patient
submit
liver
transplant
review
follow
variabl
collect
patient
gender
race
primari
diagnosi
presenc
hepatocellular
carcinoma
age
bodi
mass
index
correct
model
liver
diseas
meld
durat
warm
cold
ischemia
categor
variabl
analys
use
pearson
test
continu
variabl
analys
use
test
forward
logist
regress
model
use
analys
data
multivari
fashion
identifi
independ
contribut
variabl
previous
found
signific
resultsfind
univari
analysi
femal
patient
absenc
hepatocellular
carcinoma
hcc
primari
diagnosi
correct
meld
warm
ischemia
time
significantli
associ
consumpt
rbc
use
intraop
period
multivari
logist
regress
factor
show
femal
patient
ci
absenc
hcc
cirrhosi
caus
ci
miscellan
diagnosi
metabol
diseas
famili
amyloid
polyneuropathi
vascular
complic
ic
retransplant
due
primari
non
function
graft
ci
p
independ
associ
rbc
transfus
requir
conclus
studi
femal
patient
absenc
hcc
specif
primari
diagnosi
retransplant
due
primari
non
function
graft
significantli
associ
rbc
consumpt
intraop
period
determin
rbc
transfus
predictor
surgeri
might
provid
import
inform
regard
manag
blood
compon
help
optimis
utilis
resourc
blood
conserv
strategi
backgroundcas
studi
platelet
substitut
polici
minor
platelet
donor
plasma
may
contain
antibodi
recipi
red
blood
cell
often
issu
effort
best
util
commun
suppli
howev
rare
report
acut
intravascular
hemolysi
report
transfus
attribut
high
titer
typic
group
donor
one
method
reduc
risk
hemolysi
identifi
high
titer
platelet
unit
prior
transfus
subsequ
intervent
percentag
high
titer
group
platelet
product
present
larg
region
blood
center
collect
month
data
pool
platelet
unit
pspp
apheresi
deriv
platelet
unit
aplt
shown
studi
designmethod
platelet
compon
sampl
collect
edta
sampl
tube
singl
dilut
plasma
prepar
use
hamilton
microlab
seri
dilutor
use
salin
diluent
platelet
compon
sampl
use
standard
transfer
pipett
two
drop
dilut
sampl
transfer
reaction
tube
along
one
drop
b
red
blood
cell
reagent
reaction
tube
centrifug
immedi
serolog
centrifug
second
reaction
read
use
light
agglutin
reader
presenc
macroscop
agglutin
weak
greater
either
cell
b
cell
record
posit
reaction
indic
high
titer
retest
sampl
perform
confirm
high
titer
resultsfind
tabl
conclus
result
indic
titer
use
approxim
group
apheresi
platelet
high
titer
commonli
less
half
percent
pspp
unit
high
titer
test
unit
titer
help
chang
abo
platelet
substitut
polici
exampl
bloodwork
transfus
servic
abl
chang
polici
volum
reduc
group
apheresi
platelet
issu
group
ab
patient
give
high
titer
product
group
patient
subsequ
decreas
episod
volum
reduct
help
improv
overal
avail
apheresi
platelet
maintain
day
outdat
month
test
pspp
unit
verifi
product
rare
high
titer
blood
center
stop
perform
test
pspp
unit
backgroundcas
studi
passeng
lymphocyt
syndrom
pl
refer
hemolysi
trigger
antibodi
produc
donor
b
lymphocyt
primari
secondari
immun
respons
recipi
red
blood
cell
rbc
antigen
usual
associ
solid
organ
hematopoiet
progenitor
cell
hpc
transplant
pl
list
categori
iii
indic
rbc
exchang
american
societi
apheresi
guidelin
base
patient
case
seri
studi
designmethod
old
man
relaps
pre
acut
lymphoblast
leukemia
day
post
minor
peripher
blood
hpc
transplant
patient
rh
donor
rh
start
complain
worsen
back
pain
two
half
hour
receiv
one
unit
rbc
drop
hematocrit
previou
day
hematocrit
increas
ensu
hour
becam
anur
jaundic
cleric
check
confirm
forward
type
posit
also
type
rbc
unit
transfus
reveal
titer
plasma
furthermor
direct
antiglobulin
test
dat
posit
blood
sampl
detect
plasma
collect
three
day
earlier
howev
although
plasma
color
amber
sign
intravascular
hemolysi
undetect
haptoglobin
increas
lactat
dehydrogenas
ldh
total
indirect
bilirubin
resultsfind
posit
dat
sampl
point
ongo
hemolysi
prior
transfus
rbc
unit
set
recent
transplant
pictur
consist
hemolysi
newli
form
prolifer
donor
lymphocyt
pl
perform
emerg
rbc
exchang
use
rbc
goal
hematocrit
reduc
number
rbc
circul
approxim
pain
improv
rapidli
thereaft
complet
recoveri
renal
function
conclus
pl
differenti
diagnosi
suspectinginvestig
clinic
signific
hemolysi
hpc
transplant
recipi
especi
hpc
sourc
peripher
blood
patient
usual
take
day
antibodi
develop
week
due
sever
manifest
perform
emerg
rbc
exchang
success
furthermor
patient
event
expos
vulner
system
issu
proper
blood
type
transplant
recipi
sinc
remedi
electron
tabl
paramet
transfus
well
rbc
exchang
backgroundcas
studi
group
rhd
neg
oneg
red
blood
cell
rbc
preciou
resourc
conserv
oneg
inventori
minim
risk
rhd
alloimmun
oneg
femal
childbear
age
transfus
servic
may
automat
provid
group
rhd
posit
opo
rbc
rhd
neg
male
andor
rhd
neg
femal
bleed
emerg
despit
conserv
strategi
shortag
oneg
rbc
occur
goal
studi
determin
util
oneg
rbc
optim
use
opo
switch
routin
transfus
oneg
patient
studi
designmethod
recipi
age
aborhd
group
obtain
allogen
rbc
transfus
calendar
year
hospit
addit
hospit
provid
data
rbc
transfus
patient
year
age
patient
whose
age
andor
abo
group
unknown
exclud
analysi
aborhd
group
rbc
unit
compar
recipi
determin
number
oneg
rbc
transfus
patient
number
rbc
transfus
oneg
patient
number
oneg
rbc
transfus
oneg
patient
number
oneg
rbc
transfus
specif
oneg
patient
year
also
determin
resultsfind
see
tabl
fraction
transfus
rbc
oneg
rang
row
f
percentag
oneg
rbc
transfus
oneg
patient
rang
row
g
thu
patient
receiv
oneg
unit
transfus
row
h
hospit
differ
wide
practic
issu
oneg
rbc
oneg
patient
row
overal
use
oneg
rbc
could
reduc
opo
unit
given
oneg
patient
year
old
row
j
conclus
time
oneg
shortag
age
base
opo
switch
rule
may
appli
routin
transfus
would
help
ensur
avail
oneg
rbc
unit
oneg
femal
childbear
age
backgroundcas
studi
sensit
transfus
red
cell
may
complic
transfus
make
increasingli
difficult
find
compat
blood
compon
patient
splenectomi
shown
increas
human
leucocyt
antigen
immun
aim
studi
evalu
effect
splenectomi
occurr
red
cell
alloimmun
human
studi
designmethod
studi
conduct
multitransfus
patient
receiv
blood
transfus
chronic
central
blood
center
thalassemia
patient
patient
one
patient
thalassemia
sickl
cell
anemia
patient
immun
hemolyt
anemia
patient
auto
immun
hemolyt
anemia
patient
one
paroxysm
nocturn
hemoglobinemia
patient
one
immun
thrombocytopen
purpra
patient
oncolog
patient
chronic
diseas
patient
histori
demograph
data
document
patient
receiv
blood
examin
presenc
spleenour
patient
subject
direct
revers
blood
group
abo
rh
test
alloantibodi
screen
detect
resultsfind
statist
studi
done
determin
effect
splenectomi
increas
rate
red
cell
sensit
chronic
transfus
hemolyt
patient
studi
reveal
alloimmun
patient
non
alloimun
patient
p
statist
analysi
show
high
statist
signific
differ
patient
perform
splectomi
perform
splenectomi
regard
form
conclus
patient
splenectomi
higher
alloimmun
rate
remov
spleen
recommend
patient
period
need
blood
blood
compon
backgroundcas
studi
recent
recommend
indic
one
red
blood
cell
rbc
unit
transfus
time
reassess
transfus
determin
need
howev
recommend
may
extrapol
literatur
demonstr
benefit
restrict
transfus
trigger
rather
specif
evid
therefor
two
systemat
review
rbc
transfus
guidelin
review
articl
determin
singl
multipl
unit
transfus
strategi
recommend
b
identifi
studi
compar
strategi
perform
studi
designmethod
method
medlin
embas
cinahl
web
scienc
nation
guidelin
clearinghous
trip
databas
search
incept
june
screen
data
abstract
done
independ
two
assessor
review
proport
articl
recommend
articl
recommend
singl
unit
strategi
assess
stratifi
guidelin
systemat
review
review
articl
review
b
primari
outcom
rbc
util
secondari
outcom
includ
proport
unit
transfus
use
singl
unit
strategi
length
stay
mortal
done
use
mantel
haenszel
random
effect
model
resultsfind
review
identifi
articl
data
abstract
articl
transfus
guidelin
guidelin
made
recommend
singl
unit
multipl
unit
transfus
strategi
tabl
review
b
identifi
retrospect
cohort
studi
elig
data
abstract
perform
util
polici
encourag
singl
unit
transfus
strategi
compar
period
period
could
perform
secondari
outcom
proport
unit
transfus
use
singl
unit
strategi
higher
polici
intervent
ci
although
heterogen
high
conclus
systemat
review
demonstr
lack
recommend
amongst
guidelin
pertain
transfus
singl
unit
rbc
retrospect
cohort
studi
support
benefit
use
singl
unit
transfus
strategi
addit
high
qualiti
studi
need
identifi
benefit
singl
unit
transfus
strategi
use
guidelin
group
review
research
area
determin
recommend
made
backgroundcas
studi
platelet
made
platelet
addit
solut
c
pa
c
treat
pathogen
reduct
pr
shown
decreas
post
transfus
platelet
count
platelet
store
plasma
advent
multipl
type
platelet
evalu
whether
mix
platelet
inventori
effect
compon
use
literatur
europ
shown
platelet
red
cell
use
increas
pr
pa
product
use
evalu
rbc
use
institut
shown
chang
number
product
transfus
per
patient
per
month
evalu
whether
mix
inventori
led
platelet
transfus
studi
designmethod
look
occas
patient
receiv
platelet
transfus
singl
day
abl
exclud
refractori
patient
analysi
inform
obtain
routin
qualiti
manag
audit
transfus
decemb
februari
use
analysi
inform
includ
order
servic
product
releas
time
product
code
pre
post
count
statist
analysi
perform
use
minitab
resultsfind
month
unit
platelet
transfus
recipi
month
median
unit
given
patient
rang
overal
distribut
product
use
plasma
pr
pa
f
pa
c
thirti
percent
patient
receiv
product
singl
day
singl
unit
given
patient
receiv
unit
respect
distribut
product
type
plasma
pr
pa
c
pa
f
percentag
present
singl
multipl
product
statist
significantli
differ
overal
distribut
product
given
month
period
p
distribut
servic
differ
group
receiv
multipl
unit
singl
unit
distribut
hematolog
malign
infus
clinic
no
solid
tumor
medicin
surgeri
pediatr
receiv
multipl
unit
distribut
surgeri
solid
tumor
hematolog
infus
no
test
associ
show
increas
multipl
unit
surgic
patient
signific
p
valu
conclus
distribut
type
platelet
given
singl
event
transfus
significantli
differ
overal
distribut
platelet
given
month
period
patient
clinic
servic
better
predictor
use
multipl
product
type
product
given
suggest
surgic
loss
need
higher
platelet
count
procedur
lead
factor
use
multipl
product
transfus
scenario
backgroundcas
studi
anemia
inflamm
ai
high
preval
critic
ill
patient
ai
iron
metabol
alter
high
level
hepcidin
reduc
amount
iron
avail
erythropoiesi
ai
treat
red
blood
cell
rbc
transfus
known
rbc
transfus
increas
iron
level
neonat
thalassemia
patient
effect
rbc
transfus
iron
metabol
inflammatori
process
unknown
sinc
one
unit
rbc
contain
iron
rbc
clear
macrophag
within
hour
follow
transfus
rbc
transfus
could
increas
iron
level
iron
avail
erythropoiesi
investig
effect
rbc
transfus
iron
metabol
icu
patient
addit
compar
effect
septic
patient
patient
studi
designmethod
prospect
cohort
studi
icu
patient
receiv
one
rbc
transfus
differ
iron
paramet
measur
hour
transfus
determin
effect
rbc
transfus
period
time
next
impact
rbc
transfus
plasma
iron
paramet
septic
patient
compar
patient
analyz
plasma
iron
concentr
transferrin
satur
ferritin
haptoglobin
hepcidin
level
determin
resultsfind
cohort
serum
iron
level
low
chang
follow
transfus
vs
also
transfus
effect
transferrin
satur
vs
ferritin
vs
level
vs
pgml
hepcidin
level
increas
icu
patient
rbc
transfus
vs
ngml
septic
patient
rbc
transfus
induc
decreas
haptoglobin
level
compar
baselin
occur
patient
vs
chang
iron
paramet
differ
septic
patient
conclus
transfus
one
unit
rbc
increas
iron
level
icu
patient
increas
hepcidin
suggest
rbc
transfus
induc
upregul
hepcidin
despit
absenc
signific
increas
plasma
iron
level
increas
hepcidin
level
transfus
potenti
hamper
iron
avail
erythropoiesi
sepsi
rbc
transfus
decreas
haptoglobin
level
suggest
hemolysi
conclus
rbc
transfus
might
neg
effect
erythropoiesi
due
increas
hepcidin
level
observ
transfus
backgroundcas
studi
anticip
releas
fda
guidanc
bacteri
risk
control
strategi
blood
collect
establish
transfus
servic
enhanc
safeti
avail
platelet
transfus
use
pathogen
reduc
platelet
pr
often
produc
product
made
platelet
addit
solut
pa
may
becom
common
institut
transfus
platelet
made
addit
solut
sinc
pathogen
reduc
platelet
avail
sinc
data
valid
pa
pr
post
count
transfus
pr
product
statist
lower
platelet
plasma
pp
pa
f
product
studi
look
whether
differ
led
correspond
increas
number
unit
platelet
transfus
studi
designmethod
data
obtain
routin
qualiti
report
produc
blood
util
committe
facil
time
pa
c
pa
f
pr
went
platelet
product
given
recipi
oncolog
diagnosi
data
collect
includ
servic
unit
number
product
code
number
uniqu
recipi
determin
monthli
data
convert
pltmonthrecipi
analysi
statist
analysi
perform
use
two
sampl
resultsfind
data
normal
pltrecipientmonth
patient
receiv
averag
unitsrecipientmonth
averag
unitsrecipientmonth
interven
data
point
respect
year
averag
slope
graph
point
two
sampl
show
pltrecipientmonth
statist
differ
p
valu
conclus
implement
pa
pr
platelet
oncolog
environ
increas
number
platelet
transfus
given
addit
analysi
red
cell
use
decreas
data
shown
interpret
indic
patient
increas
episod
bleed
although
post
platelet
count
paspr
platelet
may
lower
evid
platelet
transfus
data
lead
clinic
outcom
necessit
addit
product
given
backgroundcas
studi
report
incid
alloimmun
aml
patient
unrel
number
transfus
patient
receiv
patient
hla
antibodi
exhibit
platelet
refractori
mani
case
also
found
antibodi
detect
standard
laboratori
test
recent
data
leukemia
hematopoiet
stem
cell
hsct
recipi
transfus
exclus
leukoreduc
product
show
develop
alloimmun
platelet
refractori
object
determin
improv
platelet
count
match
grade
andor
abo
blood
group
hla
match
platelet
highli
alloimmun
patient
concomit
caus
platelet
destruct
studi
designmethod
clinic
document
platelet
refractori
patient
receiv
hla
match
irradi
sda
platelet
hla
type
hla
antibodi
identif
review
two
strategi
util
hla
strategi
match
recipi
donor
type
antibodi
specif
predict
patient
provid
platelet
donor
lack
hla
patient
antibodi
strategi
statist
analysi
one
sampl
test
use
minitab
statist
softwar
perform
compar
mean
platelet
increment
hypothet
differ
least
analysi
reveal
mean
percent
lower
bound
confid
interv
platelet
increment
p
resultsfind
median
rang
hla
match
irradi
sda
platelet
transfus
patient
median
age
year
rang
patient
show
broad
alloimmun
hla
class
iclass
ii
antigen
patient
antibodi
gp
iibiiia
gp
iibiiia
gp
iaiia
major
diagnosi
hematolog
malign
amlmdsmpncmmlmm
femal
patient
prior
exposur
via
pregnanc
histori
hsct
platelet
abo
increment
median
rang
abo
compat
platelet
increment
median
rang
abo
incompat
platelet
increment
median
rang
platelet
count
perform
within
hour
transfus
hla
match
grade
transfus
platelet
follow
grade
platelet
increment
median
rang
grade
platelet
increment
median
rang
grade
platelet
count
increment
median
rang
conclus
found
platelet
increment
higher
patient
receiv
hla
match
grade
b
b
match
grade
platelet
irrespect
abo
compat
compar
hla
match
grade
c
figur
find
confirm
larger
cohort
patient
use
massiv
transfus
protocol
mtp
commun
hospit
backgroundcas
studi
establish
use
massiv
transfus
protocol
mtp
becom
common
practic
especi
trauma
center
tertiari
hospit
due
signific
number
patient
massiv
bleed
howev
well
establish
use
mtp
also
valu
small
hospit
commun
hospit
mtp
use
set
indic
mtp
blood
product
use
outcom
patient
studi
designmethod
retrospect
review
transfus
data
commun
hospit
bed
size
year
perform
patient
mtp
request
includ
studi
resultsfind
pleas
see
tabl
summari
data
notabl
patient
gi
bleed
ob
bleed
two
common
indic
mtp
patient
surviv
support
mtp
one
case
blood
product
use
conclus
establish
readi
mtp
import
support
patient
experi
massiv
bleed
small
hospit
commun
hospit
set
mtp
commonli
use
patient
massiv
gi
bleed
ob
bleed
transfus
manag
sickl
cell
anemia
u
variant
patient
alloantibodi
backgroundcas
studi
provid
compat
red
blood
cell
rbc
chronic
transfus
patient
sickl
cell
diseas
scd
common
challeng
patient
develop
antibodi
high
incid
antigen
find
compat
unit
may
becom
imposs
includ
mn
system
resid
glycophorin
b
gpb
u
antigen
absent
less
black
popul
alter
form
gpb
known
u
variant
produc
divers
group
antibodi
capabl
caus
mild
sever
hemolyt
transfus
reaction
hemolyt
diseas
fetu
newborn
hdfn
case
illustr
balanc
need
transfus
avoid
complic
thereof
ghanaian
woman
scd
histori
chronic
transfus
present
diffus
pain
hemoglobin
valu
baselin
known
e
c
k
fya
jkb
neg
u
variant
c
u
antibodi
elig
famili
donor
nationwid
search
compat
blood
yield
four
crossmatch
compat
u
variant
unit
decis
transfus
made
patient
chang
symptom
vital
sign
transfus
hemoglobin
transfus
reaction
order
serum
sampl
neg
hemolysi
new
antibodi
identifi
dat
weakli
posit
complement
laboratori
data
reveal
decreas
total
bilirubin
two
addit
u
variant
crossmatch
compat
unit
transfus
next
two
day
restor
hemoglobin
patient
discharg
home
stabl
condit
hemoglobin
level
continu
rise
back
baselin
studi
designmethod
molecular
genotyp
use
donor
unit
select
prior
compat
test
transfus
servic
convent
method
use
monitor
patient
condit
pre
resultsfind
donor
unit
came
differ
donor
gpb
genotyp
patient
patient
experi
acut
delay
hemolyt
transfus
reaction
genotyp
match
success
facilit
donor
unit
select
case
conclus
transfus
u
variant
red
cell
u
variant
patient
undertaken
great
caution
due
epitop
antibodi
heterogen
case
highlight
import
genotyp
compat
select
donor
unit
chronic
transfus
scd
patient
sound
transfus
manag
patient
requir
plan
good
commun
part
clinician
laboratori
staff
backgroundcas
studi
patient
decompens
waiha
may
requir
transfus
red
blood
cell
rbc
product
incompat
due
free
autoantibodi
feasibl
blood
transfus
waiha
patient
controversi
difficulti
increas
risk
transfus
reaction
sinc
transfus
rbc
may
destroy
rapidli
patient
activ
hemolysi
studi
actual
vs
theoret
risk
increas
hemolysi
waiha
patient
investig
hematocrit
hct
chang
waiha
patient
transfus
compat
rbc
compar
receiv
li
blood
hypothes
hct
would
invers
relat
degre
incompat
studi
designmethod
review
transfus
patient
hospit
histori
waiha
octob
march
patient
hct
order
prescrib
physician
clinic
purpos
transfus
episod
defin
unit
releas
interv
cbc
crossmatch
tube
test
salin
per
clinic
procedur
transfus
medicin
physician
determin
releas
unit
statist
test
perform
statcalc
epiinfo
cdc
http
wwwsocscistatisticscom
resultsfind
rbc
product
transfus
waiha
patient
patient
receiv
least
incompat
unit
mean
age
year
rang
yr
women
ethnic
composit
caucasian
patient
mixedoth
ethnic
one
hundr
fourteen
product
releas
li
product
compat
li
product
transfus
hct
chang
wherea
compat
product
transfus
result
hct
chang
exact
method
mean
hct
increas
compat
group
per
unit
vs
slightli
lesser
increas
li
group
within
li
group
differ
hct
chang
accord
strength
incompat
tabl
strength
ahg
incompat
avail
unit
unit
incompat
lower
mean
hct
rise
compar
li
unit
vs
howev
differ
statist
signific
conclus
hct
chang
transfus
li
unit
patient
waiha
less
expect
per
unit
frequent
waiha
patient
receiv
compat
product
vs
howev
like
due
small
sampl
size
mean
differ
statist
signific
interestingli
differ
hct
accord
differ
strength
incompat
sampl
although
mean
increas
li
product
less
li
product
combin
increas
unexpectedli
low
unit
studi
futur
work
includ
consider
inpati
vs
outpati
clinic
statu
effect
alloantibodi
comorbid
medic
tabl
backgroundcas
studi
critic
bleed
cb
result
massiv
transfus
mt
occur
mani
differ
clinic
set
often
unexpect
opportun
benchmark
outcom
inform
practic
improv
rel
limit
due
divers
complex
across
clinic
area
set
australian
new
zealand
massiv
transfus
registri
collect
comprehens
clinic
demograph
data
patient
receiv
mt
defin
red
blood
cell
unit
rbc
within
period
aim
studi
compar
mt
patient
characterist
transfus
practic
mortal
accord
treat
hospit
type
studi
designmethod
patient
receiv
mt
particip
hospit
includ
patient
characterist
transfus
manag
summaris
individu
hospit
type
total
case
mortal
adjust
age
sex
comorbid
bleed
context
number
rbc
first
mt
onset
calcul
control
limit
indic
potenti
outlier
data
analyz
use
statist
softwar
stata
resultsfind
mt
case
hospit
smallermedium
size
specialist
women
number
mt
case
per
hospit
rang
patient
median
age
year
iqr
male
requir
admiss
intens
care
common
clinic
group
cardiac
surgeri
case
trauma
gastrointestin
hemorrhag
howev
mark
variat
hospit
ratio
transfus
product
analyz
accord
bleed
context
vari
hospit
type
pool
averag
adjust
mortal
hospit
rang
within
control
limit
cb
requir
rbc
within
mt
onset
occur
case
comparison
transfus
manag
subset
mt
case
show
patient
treat
smallermedium
size
less
like
receiv
cryoprecipit
patient
treat
hospit
versu
conclus
patient
characterist
transfus
practic
vari
hospit
hospit
type
howev
mortal
outcom
compar
result
made
avail
particip
hospit
initi
discuss
practic
review
examin
complianc
nation
standard
patient
blood
manag
guidelin
highlight
area
investig
data
also
avail
review
govern
polici
bodi
state
nation
level
support
practic
improv
activ
highlight
prioriti
area
futur
research
backgroundcas
studi
hospit
medic
center
case
big
trauma
often
intraoss
entranc
via
bone
needl
combin
fast
flow
fluid
warmer
infus
fluid
includ
blood
product
administ
pressur
done
vein
trauma
patient
often
suitabl
infus
fluid
supplier
pump
needl
describ
possibl
transfus
blood
product
mainli
limit
plasma
erythrocyt
inform
avail
concern
transfus
platelet
pressur
via
bone
needl
aim
studi
investig
effect
warm
administr
platelet
concentr
pc
pressur
via
bone
needl
vitro
qualiti
platelet
studi
designmethod
pool
bc
platelet
addit
solut
iii
pasiii
use
produc
pc
pc
store
agit
cyclesmin
cabinet
day
mimic
hospit
condit
pc
warm
use
blood
warmer
transfus
via
bone
needl
transfer
bag
pc
pressur
hg
appli
use
clamp
flow
veloc
realiz
platelet
qualiti
pressur
simul
transfus
determin
mean
variou
vitro
paramet
resultsfind
due
prime
transfus
dispos
salin
pc
dilut
result
significantli
increas
pc
volum
decreas
platelet
concentr
simul
transfus
loss
platelet
dispos
set
also
total
number
platelet
decreas
simul
transfus
simul
transfus
pc
still
fulfil
requir
platelet
concentr
number
simul
transfus
effect
percentag
annexin
v
posit
cell
indic
activ
induct
apoptosi
ph
influenc
simul
transfus
due
dilut
effect
glucos
lactat
concentr
slightli
lower
simul
transfus
conclus
warm
simul
transfus
pc
high
pressur
via
bone
needl
neg
effect
vitro
qualiti
paramet
platelet
transfus
warm
pc
via
intraoss
entranc
via
bone
needl
expect
neg
effect
vivo
function
platelet
recommend
studi
vivo
effect
limit
clinic
studi
backgroundcas
studi
low
titer
plasma
safe
use
substitut
ab
plasma
trauma
patient
low
inventori
ab
plasma
caus
delay
life
save
therapeut
plasma
exchang
tpe
procedur
ab
patient
need
plasma
replac
ab
patient
present
safe
receiv
ab
low
titer
plasma
tpe
one
ab
patient
receiv
ab
plasma
use
control
compar
hemolysi
laboratori
data
tpe
cours
studi
designmethod
retrospect
review
tpe
procedur
patient
conduct
medic
record
number
procedur
volum
replac
total
number
plasma
unit
number
plasma
unit
quantiti
plasma
hemolysi
laboratori
data
record
averag
quantiti
ml
plasma
plasma
total
volum
plasma
use
calcul
plasma
unit
low
titer
unit
laboratori
plasma
dilut
prepar
test
reagent
b
cell
agglutin
observ
unit
label
low
titer
hemolysi
laboratori
data
trace
linear
graph
trend
compar
patient
control
resultsfind
patient
ab
blood
type
patient
year
old
femal
recurr
defici
ttp
receiv
cours
tpe
total
tpe
procedur
relaps
exacerb
ten
procedur
perform
ab
plasma
averag
plasma
total
plasma
volum
tpe
procedur
patient
year
old
femal
thrombocytopenia
schistocyt
presum
ttp
receiv
total
tpe
procedur
four
procedur
perform
ab
plasma
averag
plasma
total
plasma
volum
tpe
procedur
patient
year
old
femal
defici
ttp
serv
control
receiv
total
procedur
ab
plasma
haptoglobin
ldh
hemoglobin
total
bilirubin
graph
compar
patient
trend
hemolysi
laboratori
data
patient
compar
patient
patient
neg
dat
patient
receiv
rbc
transfus
patient
favor
clinic
outcom
tpe
treatment
adequ
platelet
recoveri
conclus
studi
tpe
effect
perform
without
evid
increas
hemolysi
use
low
titer
plasma
approach
reduc
strain
limit
suppli
ab
plasma
provid
vital
treatment
altern
ab
patient
undergo
tpe
requir
plasma
replac
backgroundcas
studi
refractori
platelet
plt
transfus
caus
antibodi
ab
human
leukocyt
antigen
hla
class
antigen
ag
less
frequent
plt
specif
ag
psa
glycoprotein
iv
one
identifi
plt
surfac
ag
defici
rare
found
asian
african
also
peopl
mediterranean
descent
two
type
defici
describ
type
defici
complet
lack
plt
wherea
type
defici
lack
plt
variabl
express
transfus
plt
patient
defici
challeng
given
rariti
neg
phenotyp
risk
immun
give
ag
platelet
studi
designmethod
patient
neg
phenotyp
receiv
multipl
plt
unit
review
electron
medic
record
resultsfind
year
old
man
develop
aplast
anemia
follow
liver
injuri
possibl
due
supplement
bodi
build
requir
multipl
plt
rbc
transfus
receiv
unit
apheresi
plt
unit
week
period
without
signific
increas
plt
count
compat
plt
unit
found
unit
hla
match
unit
tri
without
success
point
ab
identifi
serum
patient
type
defici
confirm
flow
cytometri
hla
class
panel
reactiv
ab
pra
due
multipl
plt
transfus
although
ab
low
level
patient
initi
receiv
prednison
thymocyt
immun
globulin
infus
without
signific
improv
plt
increas
follow
three
dose
ivig
receiv
neg
blood
type
differ
hla
unmatch
plt
unit
rel
slight
increas
plt
count
howev
start
respond
apheresi
plt
receiv
fourth
ivig
two
rituximab
infus
sinc
receiv
ivig
everi
week
medic
includ
filgrastim
eltrombopag
cyclosporin
treatment
aplast
anemia
mean
correct
count
increment
cci
plt
count
avail
shown
tabl
desensit
therapi
antibodi
posit
reactiv
serial
dilut
reduc
dilut
hla
class
pra
decreas
current
receiv
apheresi
plt
unit
twice
week
rbc
unit
period
bone
marrow
bm
slowli
recov
evidenc
increas
wbc
count
zero
slow
increas
reticulocyt
count
current
plan
rbcplt
transfus
support
bm
recov
transplant
bm
recoveri
fail
conclus
report
case
ab
receiv
multipl
plt
transfus
case
demonstr
decreas
ab
level
immunomodul
altern
option
success
plt
transfus
compat
plt
avail
patient
rare
multipl
ab
plt
tabl
mean
avail
cci
plt
transfus
backgroundcas
studi
blood
center
locat
area
consid
moder
endem
babesia
microti
implement
univers
screen
red
cell
collect
minnesota
wisconsin
investig
new
drug
ind
studi
oct
util
immunet
investig
immunoassay
elisa
perform
creativ
test
solut
ct
test
select
approach
univers
screen
blood
donor
oppos
investig
ifapcr
test
combin
studi
designmethod
perform
retrospect
analysi
screen
test
result
deferr
rate
evalu
season
donor
abo
bia
deferr
rate
outcom
lookback
investig
sinc
research
test
origin
offer
report
donor
rate
resultsfind
jan
dec
blood
donat
screen
b
microti
immunet
elisa
posit
percent
posit
donat
evalu
monthli
reveal
variabl
reaction
rate
patient
babesia
transmiss
report
sinc
implement
test
document
babesia
ttd
case
donor
previous
test
neg
demonstr
increas
seroconvers
rate
summer
month
consist
histor
season
variat
correspond
tick
season
minnesota
wisconsin
test
perform
characterist
analyz
abo
group
demonstr
differ
posit
rate
rate
donor
chose
test
significantli
decreas
time
reflect
increas
accept
test
posit
test
result
lookback
investig
initi
repres
posit
donat
lookback
perform
donat
within
month
new
posit
screen
test
accord
ind
protocol
confirmatori
test
perform
per
ind
protocol
donor
counsel
true
posit
rate
unknown
prior
ind
trial
unlik
transmit
infect
region
ie
pcr
blood
smear
neg
although
small
number
antibodi
posit
pcr
neg
donor
may
activ
infect
babesia
infect
identifi
lookback
investig
notif
blood
donor
posit
screen
result
also
perform
inform
provid
healthcar
provid
overal
donor
deferr
repres
loss
elig
donor
period
defer
donor
invit
particip
research
collect
requir
volunt
donor
elig
conclus
test
b
microti
may
help
improv
blood
safeti
particularli
endem
region
although
donor
posit
reaction
repres
signific
loss
elig
donor
time
unlik
transmit
infect
direct
test
capabl
detect
babesia
individu
low
level
organ
without
need
concurr
antibodi
test
would
ideal
reinstat
protocol
donor
test
posit
also
consid
nonetheless
current
method
screen
inexpens
compar
method
backgroundcas
studi
human
anellovirus
smallest
particl
size
smallest
genom
size
least
complex
genet
organ
human
pathogen
establish
chronic
persist
infect
infanc
earli
childhood
produc
constantli
detect
load
plasma
thereaft
studi
suggest
ubiquit
present
human
popul
immun
surveil
requir
control
level
viru
load
studi
designmethod
develop
quantit
dna
pcr
assay
conserv
region
anelloviru
genom
detect
known
genotyp
viru
use
assay
examin
viral
load
plasma
us
blood
donor
transplant
recipi
three
month
resultsfind
blood
donor
posit
averag
load
copiesml
plasma
median
valu
copiesml
plasma
rang
copiesml
viral
load
similar
transplant
candid
posit
averag
copiesml
plasma
median
valu
copiesml
plasma
rang
copiesml
viral
load
remark
differ
transplant
recipi
posit
averag
copiesml
plasma
median
valu
copiesml
plasma
rang
conclus
result
valid
pcr
assay
develop
confirm
detect
viral
load
around
copi
present
blood
donor
survey
addit
effect
immunosuppress
therapi
caus
increas
viral
load
least
order
magnitud
individu
backgroundcas
studi
screen
blood
donor
travel
return
endemicepidem
area
highlight
import
multiplex
diagnost
approach
simultan
analysi
variou
pathogen
furthermor
context
similar
clinic
sign
differenti
diagnosi
arbovirus
acut
infect
essenti
discrimin
caus
agent
patient
manag
epidemiolog
surveil
develop
flexibl
diagnost
approach
key
challeng
face
continu
emerg
arbovirus
belong
flaviviru
alphaviru
dengu
viru
denv
west
nile
viru
wnv
zika
viru
zikv
yellow
fever
viru
yfv
usutu
viru
usuv
chikungunya
viru
chikv
studi
designmethod
innov
diagnost
approach
combin
gener
amplif
identif
low
cost
microarray
develop
patent
origin
polythiol
probe
graft
micropl
robust
sensit
specif
detect
viral
genom
analyt
perform
test
evalu
viral
standard
clinic
sampl
denv
wnv
zikv
chikv
forti
human
plasma
blood
donor
histori
contact
arbovirus
use
neg
control
design
two
set
degener
primer
gener
amplif
flavivirus
chikv
biotinyl
amplicon
captur
complementari
graft
polythiol
probe
micropl
addit
label
molecular
hybrid
event
detect
fluoresc
use
micropl
reader
resultsfind
one
origin
gener
probe
denv
specif
probe
design
four
denv
serotyp
wnv
two
zikv
lineag
chikv
valid
use
methodolog
combin
amplif
viral
genom
identif
use
polythiol
probe
show
specif
fals
posit
result
control
sampl
cross
reaction
use
viral
refer
standard
observ
sensit
chikv
zikv
final
first
result
obtain
denv
zikv
chikv
clinic
sampl
show
correl
respect
approach
commerci
hous
real
time
method
conclus
innov
strategi
allow
develop
flexibl
highli
sensit
easi
handl
platform
dedic
multiplex
screen
identif
emerg
virus
methodolog
adapt
easi
inclus
addit
molecular
target
improv
surveil
prevent
arbovir
infect
backgroundcas
studi
blood
donat
screen
babesia
microti
intraerythrocyt
parasit
endem
northeast
upper
midwest
us
perform
investig
studi
use
nucleic
acid
immunofluoresc
assay
ifa
howev
ifa
time
consum
labor
intens
procedur
possibl
fda
licens
screen
assay
near
futur
investig
b
microti
test
ifa
pool
plasma
serum
could
feasibl
screen
approach
studi
designmethod
test
increas
amount
plasma
serum
interfer
background
fluoresc
pool
prepar
plasma
serum
sampl
determin
b
individu
ifa
screen
pool
test
ifa
without
block
step
use
bovin
serum
albumin
bsa
goat
serum
minim
background
fluoresc
potenti
interfer
multipl
pool
plasma
serum
sampl
endpoint
titer
posit
sampl
investig
includ
posit
sampl
endpoint
titer
dilut
pool
resultsfind
fluoresc
visibl
pool
higher
elimin
addit
block
step
pool
sampl
show
signific
increas
background
differ
test
pool
serum
plasma
sampl
one
singl
posit
sampl
includ
pool
sampl
pool
test
posit
final
titer
posit
sampl
test
individu
two
posit
sampl
includ
pool
final
titer
pool
equal
sampl
highest
titer
conclus
studi
repres
proof
concept
serolog
test
b
microti
ifa
pool
plasma
serum
sampl
increas
fals
posit
maintain
sensit
test
backgroundcas
studi
rapid
detect
bacteri
contamin
platelet
key
reduc
risk
infect
transfus
blood
compon
bactalert
virtuo
advanc
next
gener
system
improv
autom
connect
data
manag
system
virtuo
new
algorithm
significantli
reduc
time
detect
ttd
microorgan
qualiti
control
test
platelet
prepar
use
bactalert
bta
bpa
aerob
bpn
anaerob
bottl
plasma
known
bactericid
studi
complet
evalu
plasma
susceptibilityresist
organ
consid
virtuo
studi
studi
designmethod
human
plasma
thaw
pool
salin
control
seed
cfuml
organ
associ
platelet
contamin
incub
room
temperatur
hour
coloni
count
perform
initi
incub
plasma
resist
determin
coloni
count
seed
plasma
equival
higher
log
coloni
count
seed
salin
incub
resultsfind
serial
dilut
strain
strain
except
p
aeruginosa
nctc
determin
plasma
resist
p
aeruginosa
suscept
antimicrobi
effect
human
plasma
spike
leukocyt
reduc
apheresi
platelet
lrap
inocul
bta
bpa
bottl
load
bta
virtuo
organ
recov
tabl
determin
plasma
resist
cfu
count
incub
conclus
result
confirm
previous
test
organ
addit
strain
plasma
resist
except
p
aeruginosa
nctc
howev
bpa
bottl
still
recov
p
aeruginosa
presenc
lrap
bpabpn
bottl
inocul
select
organ
panel
presenc
lrap
demonstr
recoveri
load
onto
virtuo
tabl
studi
may
requir
determin
higher
test
volum
lrap
could
affect
recoveri
plasma
sensit
strain
virtuo
fda
clear
platelet
test
backgroundcas
studi
ross
river
viru
rrv
rna
arboviru
belong
togavirida
famili
within
genu
alphaviru
rrv
endem
australia
enzoot
transmiss
cycl
involv
aed
culex
mosquito
vector
kangaroo
wallabi
mammalian
reservoir
viru
mosquito
speci
compet
vector
includ
aegypti
albopictu
frequent
associ
zika
viru
chikungunya
viru
chikv
transmiss
notoscriptu
identifi
major
urban
vector
rrv
also
capabl
transmit
dengu
viru
recent
found
lo
angel
illustr
expans
rang
grow
geograph
distribut
aed
speci
mosquito
potenti
rrv
enter
local
transmiss
cycl
outsid
australia
signific
probabl
tt
confirm
caus
rrv
infect
australia
valid
realiti
rrv
tt
occur
rrv
morbid
lead
clinic
manifest
similar
chikv
infect
vari
degre
arthralgia
becom
debilit
variou
asymptomat
symptomat
infect
ratio
report
increas
risk
addit
tt
endem
area
could
mask
spread
diseas
global
studi
designmethod
platelet
concentr
pc
prepar
pa
inocul
rrv
amotosalen
ad
final
concentr
unit
treat
uva
light
illumin
sampl
collect
titrat
rbc
unit
contamin
rrv
mix
process
solutionglutathion
gsh
treat
amustalin
final
concentr
sampl
remov
prior
amustalin
treatment
amustalin
addit
respect
titrat
plaqu
assay
cell
log
reduct
calcul
differ
mean
infecti
titer
vs
sampl
resultsfind
inactiv
rrv
achiev
limit
detect
pc
rbc
pc
rrv
achiev
rrv
inactiv
rbc
conclus
studi
illustr
amotosalenuva
amustalinegsh
treatment
effect
inactiv
rrv
pc
rbc
respect
data
corrobor
previou
result
achiev
alphavirus
includ
chikv
mayaro
viru
inactiv
high
titer
pc
rbc
demonstr
abil
system
mitig
tt
potenti
maintain
safe
blood
compon
avail
endem
area
data
submit
fda
review
intercept
red
blood
cell
approv
commerci
use
backgroundcas
studi
blood
system
platelet
design
inactiv
pathogen
contamin
leukocyt
photochem
treatment
process
util
amotosalen
low
energi
ultraviolet
uva
light
current
avail
set
includ
small
volum
sv
larg
volum
lv
dual
storag
contain
ds
design
treat
platelet
dose
new
tripl
storag
ts
set
design
expand
dose
rang
maximum
volum
gener
either
dose
pathogen
reduc
platelet
compon
pc
object
studi
evalu
effect
system
perform
log
reduct
assay
use
repres
gram
posit
neg
bacteria
envelop
virus
platelet
suspend
pa
plasma
use
ts
set
studi
designmethod
experi
platelet
pool
prepar
either
pa
plasma
final
volum
dose
platelet
condit
repres
inactiv
use
lowest
amotosalen
concentr
highest
concentr
platelet
platelet
unit
inocul
high
titer
virus
bacteria
treat
control
test
sampl
serial
dilut
cultur
plate
suitabl
media
use
bacteria
wherea
viral
titer
determin
use
plaqu
assay
log
reduct
calcul
differ
titer
control
test
sampl
resultsfind
inactiv
repres
virus
bacteria
tabl
conclus
high
level
viral
bacteri
reduct
achiev
platelet
concentr
treat
intercept
tripl
storag
setwhich
similar
valu
obtain
singl
dose
kit
tripl
storag
set
yet
licens
fda
intercept
platelet
backgroundcas
studi
middl
east
respiratori
syndrom
coronaviru
mer
cov
zoonot
pathogen
endem
arabian
peninsula
countri
middl
east
region
first
detect
caus
sever
respiratori
ill
human
mortal
rate
dromedari
camel
identifi
reservoir
mer
cov
transmiss
human
occur
direct
indirect
contact
mer
cov
detect
high
genom
titer
log
respiratori
secret
mer
patient
lower
genom
titer
log
blood
presenc
viral
particl
blood
acut
patient
give
rise
concern
especi
endem
area
high
mortal
rate
especi
critic
ill
patient
often
requir
blood
transfus
rais
need
method
safe
exclud
mer
cov
contamin
blood
product
pathogen
reduct
amotosalenuva
technolog
wide
establish
technolog
broad
rang
data
support
clinic
efficaci
safeti
amotosalenuva
treat
blood
product
aim
studi
assess
mer
cov
inactiv
efficaci
human
plasma
amotosalenuva
pathogen
inactiv
technolog
safe
exclud
presenc
infecti
viru
human
plasma
unit
studi
designmethod
four
therapeut
human
plasma
unit
spike
fulli
character
mer
cov
clinic
isol
follow
pathogen
inactiv
amotosalenuva
intercept
blood
system
ceru
corpor
four
differ
day
pathogen
reduc
sampl
taken
reduct
variou
process
step
assess
infecti
titer
plaqu
assay
titrat
genom
titer
sampl
post
pathogen
reduct
passag
time
day
assess
infecti
titer
genom
titer
everi
exclud
presenc
infecti
particl
resultsfind
viral
particl
plasma
unit
complet
inactiv
averag
efficaci
log
infecti
titer
viral
replic
observ
day
passag
post
inactiv
genom
titer
slightli
affect
pathogen
inactiv
design
target
infecti
titer
physic
titer
conclus
amotosalen
alon
slight
effect
infecti
titer
amotosalenuva
effect
inactiv
infecti
mer
cov
viral
particl
plasma
unit
inactiv
efficaci
log
infecti
titer
give
evid
improv
blood
safeti
amotosalenuva
treat
plasma
mer
cov
endem
region
backgroundcas
studi
world
health
organ
set
goal
elimin
hcv
epidemiolog
indic
gener
nation
blood
servic
use
monitor
effect
studi
aim
evalu
preval
incid
hcv
infect
taiwan
studi
designmethod
taiwan
sinc
triplex
nucleic
acid
test
hcv
hbv
hiv
sinc
use
routin
blood
screen
preval
hcv
rna
estim
donor
respect
preval
confid
interv
ci
calcul
adjust
world
standard
popul
incid
studi
donor
donat
blood
two
time
without
histori
posit
period
includ
incid
confid
interv
estim
number
new
hcv
rna
posit
case
divid
resultsfind
crude
preval
donor
dramat
decreas
per
donor
ci
per
ci
preval
also
decreas
per
donor
ci
per
ci
preval
gener
higher
femal
donor
significantli
higher
male
donor
total
hcv
rna
posit
case
neg
identifi
donor
crude
preval
hcv
rna
per
ci
per
ci
respect
crude
preval
hcv
rna
significantli
higher
femal
donor
p
valu
signific
differ
found
age
standard
p
preval
hcv
rna
increas
age
p
trend
incid
studi
total
new
hcv
rna
posit
case
neg
found
donor
follow
incid
hcv
rna
per
ci
signific
differ
observ
gender
age
group
p
trend
conclus
preval
hcv
infect
dramat
decreas
becom
significantli
higher
male
donor
need
monitor
futur
incid
hcv
rna
low
repeat
blood
donor
need
identifi
incid
case
observ
epidemiolog
characterist
backgroundcas
studi
blood
safeti
challeng
egypt
high
preval
hcv
hbv
nucleic
acid
amplif
test
nat
technolog
potenti
detect
viremia
earlier
current
screen
method
base
seroconvers
primari
benefit
nat
abil
reduc
residu
risk
infecti
wp
donat
estim
reduct
wp
util
nat
hcv
day
hiv
day
hbv
day
studi
designmethod
cross
section
studi
conduct
nation
blood
transfus
center
giza
egypt
total
number
donor
sampl
screen
age
donor
rang
year
sex
f
screen
nat
ulterio
assay
grifol
diagnost
formerli
novarti
diagnost
done
parallel
eia
test
hbsag
hiv
ag
ab
use
individu
donat
nat
multiplex
nat
yield
sampl
test
use
discriminatori
assay
order
ascertain
viral
nucleic
acid
present
donor
sampl
statist
analysi
test
use
measur
associ
two
qualit
variabl
resultsfind
nat
screen
detect
total
nat
yield
donat
among
seroneg
donor
among
nat
yield
case
reactiv
hbv
reactiv
hcv
reactiv
stratifi
age
donor
group
group
year
group
b
year
group
c
year
preval
nat
yield
three
virus
significantli
higher
either
group
b
c
compar
group
p
confid
interv
ci
p
ci
respect
preval
hbv
significantli
higher
age
group
b
compar
group
p
ci
hand
statist
signific
differ
group
c
group
b
c
compar
group
b
c
combin
group
found
significantli
higher
preval
hbv
former
p
ci
differ
significantli
three
group
p
ci
group
b
p
ci
group
c
p
ci
group
b
c
also
differ
significantli
three
group
p
ci
group
b
p
ci
group
b
c
either
group
c
detect
nat
yield
three
virus
significantli
higher
male
femal
p
ci
nat
hbv
significantli
higher
male
p
ci
preval
either
hcv
hiv
differ
significantli
male
femal
p
ci
p
ci
respect
conclus
studi
nat
yield
assum
signific
one
consid
fact
singl
donat
use
gener
compon
use
recipi
henc
effect
nat
yield
becom
time
save
recipi
tti
inde
signific
backgroundcas
studi
babesia
tick
born
parasit
babesia
respons
transfus
transmit
babesiosi
ttb
donor
deferr
base
health
histori
adequ
mitig
issu
current
fda
approv
blood
screen
test
babesia
howev
two
platform
avail
screen
ind
studi
designmethod
may
donor
screen
investig
enzym
immunoassay
eia
combin
igg
igm
antibodi
babesia
microti
immunet
inc
boston
sampl
test
creativ
test
solut
ct
phoenix
az
may
donor
screen
enzym
immunoassay
combin
igg
igm
antibodi
babesia
microti
us
fda
investig
new
drug
program
ind
serum
sampl
collect
blood
donor
perform
test
signalcut
valu
sco
consid
posit
sampl
defin
least
two
three
reactiv
result
donor
repeat
reactiv
result
indefinit
defer
blood
donat
lookback
perform
previou
collect
previou
year
resultsfind
donor
test
donor
center
repeat
reactiv
season
pattern
preval
observ
highest
number
donor
posit
summer
progress
declin
fall
winter
month
increas
spring
singl
case
transfus
transmit
babesiosi
report
center
period
patient
transfus
two
unit
pack
red
blood
cell
rbc
two
donor
begin
juli
present
august
transfus
found
parasitemia
peripher
blood
smear
subsequ
diagnos
babesiosi
donor
call
back
howev
one
could
track
sampl
sent
state
test
immunofluores
assay
perform
combin
igg
igm
iga
test
posit
titer
screen
elia
sco
donor
donor
indefinit
defer
blood
donor
conclus
data
confirm
decreas
risk
transfus
transmiss
use
screen
assay
prior
implement
screen
transfus
transmit
babesia
case
per
year
tabl
month
implement
babesia
screen
one
break
case
transfus
transmit
babesia
observ
donor
test
thu
babesia
eia
screen
test
effect
prevent
ttb
howev
substanti
loss
donor
due
screen
posit
tabl
tabl
backgroundcas
studi
transfus
transmit
diseas
challeng
transfus
medicin
specialist
patient
care
provid
around
globe
blood
safeti
formid
task
especi
high
popul
countri
like
india
newer
technolog
like
equip
us
screen
prevent
transfus
transmit
viral
infect
prevent
transmiss
improv
sensit
specif
convent
method
studi
aim
examin
effect
addit
test
safeti
blood
suppli
studi
designmethod
retrospect
observ
studi
conduct
analyz
data
year
addit
nat
test
blood
bank
dmch
ludhiana
septemb
decemb
resultsfind
result
unit
initi
nat
reactiv
unit
test
discrimin
hiv
hcv
hbv
remain
repeat
could
discrimin
overal
nat
yield
rate
one
wherea
nat
yield
rate
one
hiv
one
hcv
one
hbv
one
hbvhcv
coinfect
respect
conclus
screen
blood
donat
institut
past
year
increas
screen
sensit
check
viral
load
prevent
transmiss
probabl
transfus
transmit
viral
infect
assum
compon
prepar
save
transfus
recipi
harm
implement
nat
along
routin
serolog
test
screen
blood
donat
definit
improv
transfus
safeti
mandat
across
transfus
center
backgroundcas
studi
mani
emerg
infecti
pathogen
known
exist
heathi
blood
donat
could
transmit
via
transfus
potenti
hazard
consequ
recipi
conveni
applic
high
put
sequenc
becom
much
easier
investig
uncultur
microbiom
qualifi
blood
donat
therefor
metagenom
analys
use
reveal
emerg
infecti
diseas
healthi
donat
might
potenti
threat
blood
safeti
studi
designmethod
pool
plasma
sampl
collect
voluntari
blood
donor
chongq
china
total
dna
rna
extract
amplifi
random
primer
pcr
respect
order
construct
librari
peform
deep
sequenc
illumina
miseq
read
trim
remov
low
qualiti
base
adapt
sequenc
fulli
overlap
read
pass
qualiti
filter
concaten
use
pear
classifi
final
read
use
kraken
kraken
databas
made
complet
refseq
bacteri
archaeal
viral
genom
along
human
genom
unclassifi
read
kraken
align
ncbi
nt
databas
use
blastn
best
align
hit
use
classifi
read
krona
use
gener
taxonom
distribut
plot
final
potenti
emerg
infecti
pathogen
identifi
classifi
microbiom
experi
resultsfind
gb
raw
data
read
gener
dna
librari
meanwhil
raw
data
read
gener
rna
librari
clean
human
background
read
bacteria
read
virus
read
parasit
identifi
tabl
hazard
virus
identifi
potenti
threat
blood
safeti
except
virus
bacteria
would
limit
hazard
blood
safeti
plenti
parasit
identifi
alreadi
consid
threat
blood
safeti
develop
countri
also
discov
plasmodium
sp
leishmania
infantum
tabl
conclus
investig
reveal
metagenom
qualifi
blood
donat
chongq
china
result
show
discoveri
genom
fragment
microb
might
threat
blood
safeti
display
seriou
result
let
us
think
regul
reason
screen
method
well
donor
recruit
strategi
certain
epidem
area
season
ensur
blood
safeti
howev
contrari
result
consid
cautious
exist
genom
fragment
could
repres
exist
infecti
pathogen
valid
metagenom
hint
suggest
go
epidemiolog
investig
specif
test
laboratori
way
bacteria
viru
cultur
ensur
vital
pathogen
tabl
annot
microb
qualifi
blood
donat
backgroundcas
studi
caribbean
becom
endem
region
sever
emerg
virus
last
decad
chikungunya
outbreak
recent
zika
shown
endem
caribbean
island
curacao
effect
provid
safe
blood
product
endem
region
convent
intern
recommend
donor
exclus
test
seem
viabl
option
could
sever
affect
local
blood
suppli
pathogen
reduct
pr
consid
import
new
approach
potenti
benefit
introduct
experi
use
pr
platelet
dutch
caribbean
period
one
year
present
studi
designmethod
pathogen
reduct
thrombocyt
concentr
use
riboflavin
ultraviolet
treatment
mirasol
prt
terumo
belgium
introduc
thrombocyt
concentr
provid
gener
hospit
dutch
caribbean
island
bonair
sint
maarten
pr
data
collect
period
februari
februari
thrombocyt
concentr
prepar
singl
donat
unit
buffycoat
method
resultsfind
period
platelet
concentr
provid
adult
pediatr
patient
includ
patient
intens
care
neonat
intens
care
depart
advers
event
report
cci
transfus
within
expect
outcom
introduct
pr
minim
impact
logist
thrombocyt
concentr
prepar
avail
furthermor
transfus
relat
bacteri
contamin
report
conclus
pr
platelet
concentr
seem
viabl
safe
use
small
scale
caribbean
set
endem
emerg
virus
like
chikungunya
zika
offer
realist
altern
convent
recommend
donor
exclus
test
therebi
help
maintain
suffici
labil
blood
product
avail
backgroundcas
studi
due
risk
travel
sexual
transmit
zika
infect
food
drug
administr
issu
guidanc
document
februari
recommend
blood
center
puerto
rico
ceas
distribut
local
collect
blood
product
unless
donor
test
product
pathogen
reduc
march
high
incid
zika
viru
zikv
puerto
rico
uncertainti
impact
continent
us
blood
suppli
intens
pressur
implement
donor
screen
test
zikv
project
initi
februari
includ
clinic
trial
requir
client
onboard
laboratori
oper
stakehold
consist
client
manufactur
institut
review
board
irb
inform
technolog
client
lab
base
food
drug
administr
fda
center
diseas
control
cdc
florida
depart
health
clinic
trial
requir
includ
develop
instrument
assay
valid
sop
creation
result
report
assay
clinic
trial
train
deviat
manag
donor
notif
follow
sampl
handl
client
onboard
began
confidenti
agreement
client
sponsor
zika
base
webinar
creat
provid
overview
sponsor
protocol
lab
test
system
client
respons
complex
project
increas
mosquito
born
zika
transmiss
identifi
two
counti
florida
requir
zikv
test
perform
collect
florida
puerto
rico
perform
singlet
unlik
mpx
wnv
assay
run
signific
impact
instrument
capac
despit
obstacl
chang
regulatori
requir
zikv
screen
test
implement
within
six
week
studi
designmethod
one
metric
use
measur
client
servic
level
abil
meet
establish
upload
time
goal
individu
client
percentag
sampl
releas
time
evalu
daili
run
monthli
total
resultsfind
tabl
result
upload
perform
upload
time
goal
neg
impact
juli
septemb
due
unexpect
increas
zikv
test
requir
perform
test
singlet
result
instrument
capac
issu
addit
instrument
sourc
octob
oper
stabil
conclus
februari
project
implement
zikv
ind
test
initi
six
week
later
test
perform
first
batch
sampl
despit
chang
regulatori
requir
time
implement
extrem
success
initi
new
ind
test
within
week
unpreced
requir
except
collabor
particip
stakehold
backgroundcas
studi
plasmodium
falciparum
pf
intraerythrocyt
protozoan
parasit
account
nearli
malaria
mortal
africa
report
million
new
case
worldwid
result
death
malaria
preval
highest
africa
home
infect
account
mortal
incid
preval
malaria
africa
significantli
increas
potenti
tt
littl
screen
product
develop
countri
object
studi
evalu
inactiv
pf
whole
blood
wb
use
system
specif
develop
realiti
develop
world
support
swiss
red
cross
humanitarian
foundat
whole
blood
pathogen
inactiv
africa
inabl
consist
suppli
blood
compon
lead
routin
wb
transfus
diseas
preval
develop
world
establish
robust
wb
pathogen
inactiv
system
desir
approach
use
small
molecul
amustalin
form
coval
adduct
crosslink
within
nucleic
acid
leukocyt
contamin
pathogen
prevent
replic
process
includ
addit
amustalin
glutathion
gsh
room
temperatur
rt
incub
treat
wb
unit
suitabl
storag
day
rt
studi
designmethod
experi
wb
unit
spike
red
blood
cell
irbc
sampl
remov
prior
addit
amustalin
sampl
remov
amustalin
addit
determin
titer
calcul
level
inactiv
sampl
serial
dilut
flask
contain
medium
fresh
rbc
dilut
sampl
use
inocul
flask
quadrupl
monitor
parasitemia
count
irbc
blood
smear
flow
cytometri
cultur
termin
reach
parasitemia
residu
pf
detect
cultur
log
reduct
calcul
differ
mean
titer
sampl
resultsfind
robust
inactiv
pf
wb
achiev
limit
detect
conclus
pf
inactiv
limit
detect
wb
treatment
amustalinegsh
illustr
system
potenti
mitig
risk
pf
transfus
transmiss
endem
region
lack
test
capac
oper
constraint
limit
blood
compon
suppli
reli
wb
transfus
system
wb
approv
commerci
use
backgroundcas
studi
pathway
current
exist
apheresi
platelet
ap
outdat
extens
day
use
fda
clear
rapid
test
rt
februari
hospit
base
transfus
servic
implement
use
rt
day
routin
extend
ap
shelf
life
day
prior
test
ap
rt
day
transfus
day
day
unit
physician
approv
deem
medic
necessari
report
describ
chang
observ
transfus
practic
platelet
inventori
manag
one
year
follow
routin
use
day
platelet
studi
designmethod
data
obtain
two
studi
period
octob
februari
interv
transit
period
intent
exclud
studi
period
determin
total
number
ap
transfus
rt
statu
day
transfus
total
number
rt
perform
expir
ap
unit
ap
obtain
supplier
use
order
also
obtain
hospit
data
includ
inpati
admiss
surgic
volum
averag
length
stay
case
mix
index
resultsfind
data
shown
tabl
number
ap
transfus
increas
compar
increas
inpati
admiss
increas
surgic
volum
hospit
length
stay
case
mix
index
similar
period
averag
number
platelet
transfus
per
patient
statist
differ
pre
post
number
rt
perform
increas
percentag
transfus
unit
test
least
rt
prior
transfus
increas
p
outdat
rate
decreas
p
order
decreas
p
conclus
use
approv
rt
routin
ap
outdat
extens
day
associ
increas
patient
safeti
transfus
unit
underw
secondari
test
prior
transfus
increas
cost
rt
offset
reduc
ap
wast
less
frequent
need
order
tabl
ap
transfus
practic
inventori
manag
hospit
volum
backgroundcas
studi
rate
hepat
b
hbv
hepat
c
viru
hcv
posit
donat
low
per
donat
respect
among
first
time
donor
aim
determin
frequenc
variou
genotyp
hbv
hcv
canadian
blood
donor
confirm
posit
hbv
hcv
studi
designmethod
roch
multiplex
assay
hcvhivhbv
implement
minipool
unit
hcv
nat
place
sinc
use
minipool
first
time
donor
screen
hbv
nat
hbsag
test
use
abbott
prism
assay
confirmatori
test
hbsag
prism
neutral
assay
repeat
reactiv
confirm
hcv
score
line
immunoassay
sinc
march
sampl
test
hbv
nat
posit
confirm
posit
hbsag
hcv
nat
posit
confirm
posit
sampl
consid
posit
sampl
sent
phac
sequenc
sampl
posit
donat
aliquot
frozen
genotyp
carri
sequenc
phylogenet
analysi
hbv
surfac
antigen
code
region
hcv
viral
rna
extract
subject
revers
transcript
pcr
amplif
region
sanger
sequenc
region
repres
approxim
genom
resultsfind
confirm
posit
donat
whole
blood
donat
hbv
posit
donat
test
hbv
nat
posit
genotyp
type
b
e
sampl
hbv
nat
neg
hbsag
posit
reactiv
could
sequenc
one
genotyp
also
reactiv
sampl
consid
hcv
posit
sampl
hcv
nat
posit
genotyp
type
also
sampl
hcv
nat
neg
posit
none
could
sequenc
conclus
first
month
molecular
surveil
show
rang
genotyp
hbv
hcv
sampl
identifi
nat
posit
date
sampl
nat
neg
reactiv
could
sequenc
howev
one
nat
neg
sampl
posit
hbsag
reactiv
hbv
genotyp
surveil
longer
period
requir
gain
complet
pictur
divers
genotyp
canadian
blood
donor
determin
sampl
identifi
combin
screen
nat
hcv
sequenc
method
backgroundcas
studi
bactalert
microbi
detect
system
bta
current
fda
clear
qualiti
control
test
leukocyt
reduc
apheresi
platelet
lrap
bactalert
virtuo
microbi
detect
system
virtuo
st
loui
mo
new
gener
bactalert
instrument
underli
colorimetr
technolog
use
previou
gener
bactalert
use
virtuo
incorpor
new
instrument
architectur
improv
temperatur
stabil
workflow
improv
via
autom
process
current
perform
manual
improv
user
interfac
enhanc
algorithm
shorten
time
detect
object
studi
compar
perform
virtuo
bactalert
bta
instrument
use
bactalert
bpa
aerob
bactalert
bpn
anaerob
bottl
detect
rang
typic
bacteri
contamin
seed
leukocyt
reduc
apheresi
platelet
lrap
studi
designmethod
studi
perform
two
institut
one
us
uk
aliquot
lrap
seed
low
level
cfuml
bacteri
speci
commonli
associ
platelet
contamin
replic
per
instrument
aliquot
per
bottl
inocul
bpa
bpn
bottl
one
set
bottl
load
bta
virtuo
incub
signal
posit
instrument
day
overal
detect
rate
time
detect
bacteri
contamin
instrument
compar
addit
bottl
test
instrument
lrap
organ
evalu
differ
overal
neg
agreement
rate
detect
fals
posit
instrument
serv
steril
control
platelet
prepar
resultsfind
total
bottl
inocul
seed
lrap
virtuo
detect
bta
detect
bpa
bottl
inocul
seed
lrap
virtuo
detect
bta
detect
bpn
bottl
inocul
seed
lrap
seed
bottl
detect
posit
neg
termin
subcultur
posit
repeat
test
differ
recoveri
rate
system
bottl
type
overal
p
virtuo
neg
bta
neg
bpa
bottl
inocul
lrap
organ
virtuo
neg
bta
neg
bpn
bottl
inocul
lrap
organ
differ
neg
agreement
rate
system
bottl
type
overal
p
one
fals
posit
result
one
bpn
bottl
bta
virtuo
faster
bta
detect
bacteria
bpa
bottl
bpn
bottl
overal
overal
mean
virtuo
versu
bta
overal
differ
hour
p
conclus
studi
lrap
seed
typic
platelet
bacteri
contamin
show
compar
detect
rate
virtuo
bta
instrument
bpa
bpn
bottl
type
faster
detect
virtuo
virtuo
platelet
test
backgroundcas
studi
implement
nucleic
acid
test
nat
blood
screen
still
challeng
countri
time
countri
higher
similar
proport
replac
voluntari
blood
donor
recruit
higher
preval
infect
observ
relat
develop
countri
consequ
incid
case
infect
expect
countri
hospit
blood
bank
could
afford
nat
due
high
cost
belong
net
central
nat
refer
blood
center
process
consolid
small
blood
bank
region
blood
center
abl
implement
nat
yet
complet
although
effort
reduc
replac
familiar
blood
donat
progress
goal
complet
achiev
aim
compar
preval
hiv
hcv
hbv
nat
screen
blood
center
recruit
voluntari
blood
donor
preval
center
recruit
replac
voluntari
blood
donor
describ
nat
yield
rate
hiv
hcv
hbv
period
three
half
year
experi
studi
designmethod
region
blood
donor
center
rbdc
central
nat
screen
center
differ
region
countri
due
sinc
august
process
requir
achiev
adequ
laboratori
condit
staff
qualif
develop
softwar
assur
sampl
traceabl
interfac
transmiss
result
window
period
suspect
nat
screen
repeat
plasma
unit
second
sampl
blood
donor
requir
confirm
nat
result
rbdc
also
develop
voluntari
donor
program
sinc
center
countri
achiev
goal
resultsfind
total
donat
studi
august
decemb
rbdc
voluntari
blood
donat
recruit
preval
per
donat
hiv
per
hbv
per
hcv
center
togeth
voluntari
replac
blood
donat
recruit
preval
per
donat
hiv
per
hbv
per
hcv
window
period
infect
detect
center
recruit
voluntari
replac
blood
donat
give
nat
yield
rate
hbv
hiv
hcv
conclus
hiv
hbv
hcv
preval
lower
center
task
sustain
voluntari
blood
donor
program
develop
nat
yield
rate
could
reduc
region
program
could
complet
appli
center
backgroundcas
studi
occult
hepat
b
viru
infect
obi
blood
donor
import
facet
hbv
infect
natur
histori
observ
china
mechan
lead
obi
includ
variou
factor
imperfect
host
immun
respons
viral
variat
factor
studi
determin
viral
load
obi
current
recruit
screen
among
blood
donor
five
blood
servic
zhejiang
provinc
china
studi
designmethod
donat
donor
screen
preclud
hbsag
preliminari
test
posit
alt
level
abnorm
follow
sampl
detect
hbsag
twice
use
differ
elisa
reagent
hbv
dna
use
tma
techniqu
sampl
hbv
dna
posit
elisa
neg
test
viral
load
use
taqman
techniqu
coba
system
hbv
region
also
sequenc
resultsfind
obi
found
donat
viral
load
assay
sampl
neg
sampl
viral
load
lower
mean
viral
load
iuml
sampl
mean
viral
load
hbsaghbv
dna
sampl
iuml
sampl
obi
analyz
hbv
genotyp
b
preval
subtyp
hbv
c
genotyp
compar
sampl
hbsaghbv
dna
found
two
obi
sampl
carri
c
mutat
could
caus
amino
acid
conclus
studi
viral
load
obi
infect
donor
much
low
hbsaghbv
dna
uniqu
variat
identifi
obi
individu
backgroundcas
studi
per
recent
report
india
consid
intermedi
level
endem
hepat
b
viru
hbv
gener
popul
screen
blood
donor
hbv
india
primarili
base
upon
detect
hepat
b
surfac
antigen
hbsag
donor
sera
current
studi
undertaken
determin
preval
occult
hbv
infect
obi
voluntari
blood
donor
analyz
burden
hbv
window
period
donat
studi
designmethod
prospect
observ
studi
perform
nation
accredit
board
hospit
nabh
accredit
apex
blood
bank
locat
maharashtra
state
india
monolisa
hbsag
ultra
franc
sandwich
type
elisa
use
monoclon
polyclon
antibodi
use
hbsag
detect
donor
sera
elisa
sampl
also
test
addit
real
time
multiplex
polymeras
chain
reaction
mpx
test
donor
found
posit
hbv
dna
follow
upat
day
month
month
monolisa
hbsag
ultra
franc
analyz
interv
window
period
delin
window
period
donat
wpd
true
obi
resultsfind
total
sampl
obtain
voluntari
blood
donor
studi
period
januari
march
initi
screen
hbsag
specimen
hbsag
posit
elisa
amongst
hbsag
sampl
sampl
also
test
sampl
found
posit
hbv
dna
give
nucleic
acid
amplif
test
nat
yield
mean
age
distribut
nat
posit
donor
found
year
year
male
femalesof
thehbv
dna
posit
sampl
posit
hbsag
serolog
test
classifi
wpd
donor
test
posit
month
respect
remain
donor
found
neg
hbsag
serolog
test
classifi
true
obi
preval
window
period
donat
true
obi
found
respect
conclus
hbsag
screen
blood
donor
inadequ
limit
recogn
obi
wpd
thu
consid
obscur
menac
question
safeti
blood
transfus
nucleic
acid
amplif
test
play
great
role
circumv
potenti
risk
hbv
transmiss
unravelingth
miss
case
hbv
infect
hbsag
screen
moreov
mantl
blood
transfus
make
nat
crucial
element
modern
transfus
servic
backgroundcas
studi
occult
hepat
b
infect
obi
character
hepat
b
viru
hbv
hbv
surfac
antigen
hbsag
sinc
may
test
apheresi
donor
hbv
nucleic
acid
improv
laboratori
test
reduc
risk
infect
number
apheresi
collect
increas
significantli
year
year
howev
data
hepat
b
viru
marker
rate
among
donor
continu
lack
aim
studi
evalu
epidem
characterist
incid
estim
risk
factor
obi
among
apheresi
donor
region
central
china
studi
designmethod
apheresi
donor
data
may
dec
retrospect
analyz
sampl
test
hbsag
hbv
dna
marker
nucleic
acid
test
nat
perform
roch
coba
platform
use
pool
serolog
neg
sampl
pool
posit
would
undergo
nat
individu
hbsag
neg
hbv
dna
posit
test
hbv
dna
quantit
pcr
antibodi
hepat
b
surfac
antigen
hbsab
antibodi
hepat
b
core
antigen
hbcab
hepat
b
e
antigen
hbeag
antibodi
hepat
b
e
hbeab
resultsfind
evalu
seroneg
donat
screen
nat
total
hbv
donor
detect
hiv
rna
hcv
rna
sampl
detect
complet
serolog
screen
index
donat
indic
major
donor
occult
hbv
infect
major
marri
men
fix
donor
mani
whole
blood
apheresi
donat
age
distribut
age
group
year
old
show
larg
proport
account
report
infect
hbv
dna
case
reach
senior
high
school
educ
averag
hbsag
dna
posit
rate
incid
among
apheresi
donor
period
hbsag
dna
estim
compar
among
repeat
whole
blood
donor
conclus
risk
occult
hepat
b
viru
infect
among
current
apheresi
donor
exist
introduct
nat
reduc
residu
risk
transfus
backgroundcas
studi
cryoprecipit
cryo
enrich
fibrinogen
fb
factor
viii
fviii
xiii
fxiii
von
willebrand
factor
vwf
replenish
fb
level
massiv
hemorrhag
coagulopathi
convent
practic
involv
pool
individu
ffp
cryo
unit
potenti
pathogen
transmiss
limit
post
thaw
hr
develop
pathogen
reduc
pr
cryo
deriv
ffp
day
stabil
studi
designmethod
six
replic
pool
whole
blood
deriv
wbd
apheresi
aph
plasma
split
produc
convent
control
test
compon
test
compon
pr
amotosalen
uva
light
aph
wbd
ffp
produc
freez
plasma
within
hr
wbd
within
hr
cryo
manufactur
accord
site
sop
frozen
test
control
test
control
cryo
thaw
character
immedi
post
thaw
storag
test
fb
fviii
function
thromboelastographi
rotem
thrombin
gener
cat
resultsfind
pr
cryo
retain
suffici
fb
fviii
activ
post
thaw
tabl
hemostat
capac
rotem
extem
show
retent
fibrin
format
angl
clot
qualiti
mcf
tabl
thrombin
gener
robust
demonstr
multipl
paramet
lag
time
peak
thrombin
endogen
total
thrombin
potenti
etp
time
peak
tt
despit
lower
fviii
level
paramet
maintain
storag
conclus
pr
cryo
process
plasma
sourc
includ
store
rt
day
pr
plasma
provid
adequ
level
fb
hemostat
capac
equival
control
demonstr
rotem
cat
use
stabil
day
increas
avail
cryo
reduc
risk
infect
cryo
produc
pr
plasma
approv
use
us
backgroundcas
studi
parasit
trypanosoma
cruzi
cruzi
caus
chaga
diseas
endem
america
infect
million
peopl
order
prevent
transfus
mediat
transmiss
parasit
endem
countri
blood
collect
center
requir
high
throughput
cruzi
assay
good
specif
sensit
countri
select
test
risk
donor
strategi
avoid
temporari
donor
deferr
addit
continu
pressur
laboratori
oper
demand
assay
perform
platform
capabl
increas
walk
away
time
enhanc
autom
area
reagent
manag
retest
option
commoditywast
manag
studi
designmethod
perform
new
autom
chemiluminesc
immunoassay
detect
antibodi
cruzi
evalu
alin
autom
platform
compar
anoth
chemiluminesc
immunoassay
precis
assess
day
use
panel
posit
neg
sampl
sensit
evalu
presum
antibodi
posit
specimen
specif
evalu
random
blood
donor
sampl
resultsfind
precis
cv
less
posit
sampl
day
overal
specif
blood
donor
popul
sensit
presum
antibodi
posit
sampl
conclus
result
indic
new
autom
alin
chaga
assay
provid
good
perform
sensit
specif
compar
current
cruzi
assay
equal
suitabl
use
univers
screen
endem
select
donor
screen
countri
backgroundcas
studi
despit
develop
sensit
nat
method
blood
transfus
mani
part
world
reli
serolog
screen
hepat
b
surfac
antigen
hbsag
prevent
transfus
transmit
hbv
infect
sensit
hbsag
assay
must
capabl
cope
wide
rang
mutant
exhibit
uncompromis
specif
addit
continu
pressur
laboratori
oper
demand
assay
perform
platform
capabl
increas
walk
away
time
enhanc
autom
area
reagent
manag
retest
option
commoditywast
manag
studi
designmethod
perform
new
autom
chemiluminesc
immunoassay
detect
confirm
hbsag
evalu
next
gener
autom
platform
abbott
alin
precis
assess
day
sensit
evalu
use
known
posit
sampl
commerci
avail
seroconvers
panel
standard
hbsag
mutant
hbsag
genotyp
specimen
h
specif
evalu
random
blood
plasmapheresi
donor
resultsfind
precis
less
cv
posit
sampl
day
blood
donor
specif
sensit
presum
posit
sampl
sensit
genotyp
mutant
detect
vs
compar
assay
seroconvers
detect
equival
compar
assay
reactiv
sampl
detect
alin
assay
reactiv
sampl
detect
compar
assay
analyt
sensit
rang
iuml
alin
hbsag
confirmatori
assay
confirm
known
posit
hbsag
specimen
includ
hbsag
mutant
sampl
confirm
compar
hbsag
confirmatori
assay
conclus
new
autom
alin
hbsag
assay
provid
precis
specif
seroconvers
sensit
compar
current
compar
assay
howev
alin
hbsag
assay
demonstr
gain
sensit
compar
assay
detect
confirm
wider
rang
mutant
backgroundcas
studi
blood
donat
commonli
screen
detect
presenc
antibodi
antibodi
antigen
human
immunodefici
viru
type
blood
center
requir
high
throughput
assay
high
specif
sensit
prevent
unnecessari
donor
deferr
maintain
safe
blood
suppli
addit
continu
pressur
laboratori
oper
demand
assay
perform
platform
capabl
increas
walk
away
time
enhanc
autom
area
reagent
manag
retest
option
commoditywast
manag
respons
need
screen
assay
evalu
improv
autom
assay
detect
antibodi
antigen
studi
designmethod
perform
new
chemiluminesc
combin
immunoassay
detect
antibodi
antigen
evalu
abbott
alin
system
precis
assess
day
evalu
posit
sampl
specif
evalu
sampl
obtain
random
blood
donor
plasmapheresi
donor
sensit
evalu
use
presum
posit
sampl
hiv
group
antibodi
antigen
seroconvers
sensit
evalu
commerci
seroconvers
panel
resultsfind
precis
less
cv
posit
sampl
day
blood
donor
specif
sensit
presum
antibodi
posit
sampl
compris
group
n
p
crf
urf
sampl
also
sensit
antigen
posit
viral
isol
sampl
compris
group
n
p
crf
urf
sampl
seroconvers
detect
equival
compar
assay
reactiv
sampl
detect
alin
assay
reactiv
sampl
detect
compar
assay
conclus
result
indic
new
autom
alin
hiv
agab
combo
assay
provid
accept
perform
specif
sensit
precis
provid
similar
seroconvers
sensit
compar
assay
backgroundcas
studi
countri
low
preval
hepat
b
blood
donat
commonli
screen
detect
presenc
antibodi
hepat
b
core
antigen
alongsid
hbsag
hbv
nat
detect
donor
occult
hepat
b
infect
obi
blood
center
requir
assay
high
specif
sensit
prevent
unnecessari
donor
deferr
maintain
safe
blood
suppli
addit
continu
pressur
laboratori
oper
demand
assay
perform
platform
capabl
increas
walk
away
time
enhanc
autom
area
reagent
manag
retest
option
commoditywast
manag
respons
need
screen
assay
develop
improv
autom
assay
detect
alin
system
studi
designmethod
perform
new
chemiluminesc
assay
detect
antibodi
evalu
next
gener
autom
abbott
alin
system
precis
assess
day
evalu
posit
sampl
specif
evalu
sampl
obtain
random
blood
donor
sensit
evalu
use
specimen
character
posit
mean
serolog
method
analyt
sensit
assess
use
intern
standard
seroconvers
sensit
evalu
use
commerci
seroconvers
panel
resultsfind
precis
less
cv
posit
sampl
day
blood
donor
specif
sensit
sampl
presum
posit
analyt
sensit
result
alin
assay
rang
iuml
seroconvers
detect
equival
compar
assay
reactiv
sampl
detect
alin
assay
reactiv
sampl
detect
compar
assay
conclus
result
indic
new
autom
alin
assay
provid
good
perform
specif
sensit
precis
versu
compar
assay
backgroundcas
studi
endem
countri
univers
blood
screen
necessari
prevent
transfus
transmit
htlv
infect
ihtlv
ii
countri
select
test
may
avoid
unnecessari
tempor
deferr
donor
high
risk
return
travel
donor
born
countri
high
htlv
preval
blood
center
requir
high
throughput
ihtlv
ii
assay
high
specif
sensit
prevent
unnecessari
donor
deferr
maintain
safe
blood
suppli
addit
continu
pressur
laboratori
oper
demand
assay
perform
platform
capabl
increas
walk
away
time
enhanc
autom
area
reagent
manag
retest
option
commoditywast
manag
respons
need
assay
high
specif
high
throughput
instrument
develop
new
assay
detect
antibodi
antibodi
alin
system
studi
designmethod
precis
assess
day
use
htlv
htlv
ii
posit
sampl
specif
evalu
use
blood
donor
specimen
europ
diagnost
sampl
obtain
unit
state
sensit
evalu
use
preselect
htlv
htlv
ii
posit
sampl
sensit
specif
sampl
split
across
reagent
lot
test
confirm
repeatedli
reactiv
sampl
done
use
mp
diagnost
htlv
blot
resultsfind
imprecis
less
posit
sampl
day
clinic
sensit
preselect
htlv
htlv
ii
posit
sampl
specif
blood
donor
popul
diagnost
sampl
conclus
result
indic
new
alin
autom
htlv
iii
assay
provid
good
perform
specif
sensit
precis
sensit
specif
compar
compar
assay
backgroundcas
studi
current
hepat
c
viru
hcv
supplement
test
algorithm
blood
donat
colombia
requir
immunoblot
assay
perform
everi
hcv
enzym
immunoassay
eia
sampl
higher
proport
indetermin
ind
result
immunoblot
assay
document
donor
sampl
affect
donor
counsel
eventu
increas
cost
opportun
notif
infect
donor
work
aim
establish
distribut
immunoblot
result
colombian
sampl
well
frequenc
band
detect
posit
indetermin
blot
studi
designmethod
total
donor
sampl
sco
ratio
greater
abbott
architect
underw
supplement
test
immunoblot
either
chiron
riba
hcv
sia
hcv
blot
test
mp
diagnost
neg
neg
indetermin
ind
posit
po
blot
result
group
sco
rang
follow
band
detect
intens
independ
analyz
indetermin
posit
result
resultsfind
immunoblot
result
neg
sampl
indetermin
posit
direct
relationship
observ
posit
immunoblot
increas
sco
proport
ind
result
higher
sco
group
compar
sampl
indetermin
result
frequent
band
detect
contrast
frequent
band
group
posit
result
core
one
sampl
indetermin
group
strong
band
intens
compar
sampl
posit
group
conclus
proport
indetermin
immunoblot
result
sampl
colombian
donor
one
highest
ever
report
twice
much
proport
found
larger
sampl
us
donor
high
proport
ind
result
found
sco
group
suggest
optim
sco
ratio
predict
confirm
result
popul
higher
one
recommend
cdc
us
popul
overal
result
suggest
supplement
test
algorithm
blood
donat
colombia
could
improv
use
high
sco
ratio
altern
immunoblot
also
introduc
hcv
genom
assay
instead
immunoblot
least
sampl
intermedi
sco
ratio
colombian
popul
warrant
investig
backgroundcas
studi
blood
donat
commonli
screen
syphili
order
detect
presenc
antibodi
bacterium
treponema
pallidum
addit
continu
pressur
laboratori
oper
demand
full
panel
ttid
assay
perform
singl
platform
capabl
increas
walk
away
time
enhanc
autom
area
reagent
manag
retest
option
commoditywast
manag
respons
need
evalu
new
autom
immunoassay
detect
antibodi
pallidum
studi
designmethod
perform
new
autom
chemiluminesc
immunoassay
detect
antibodi
treponema
pallidum
evalu
alin
system
precis
assess
day
use
posit
sampl
specif
evalu
sampl
obtain
blood
plasmapheresi
donor
unit
state
europ
diagnost
sampl
obtain
unit
state
sensit
evalu
use
preselect
posit
sampl
sensit
specif
sampl
split
across
reagent
lot
test
confirm
repeatedli
reactiv
sampl
done
use
test
algorithm
confirmatori
assay
syphili
score
mikrogen
recomlin
treponema
igg
igm
blot
resultsfind
imprecis
less
cv
posit
sampl
day
clinic
sensit
preselect
syphili
posit
sampl
specif
blood
donor
specimen
diagnost
sampl
conclus
result
indic
new
autom
alin
syphili
assay
provid
good
perform
precis
specif
sensit
line
data
found
compar
assay
backgroundcas
studi
serolog
screen
antibodi
hepat
c
viru
hcv
often
conjunct
nucleic
acid
test
nat
use
worldwid
prevent
transfus
transmit
hcv
infect
nat
provid
improv
sensit
detect
hcv
window
serolog
test
provid
continu
detect
hcv
infect
individu
individu
resolv
infect
detect
hcv
rna
blood
plasma
center
requir
high
throughput
assay
high
specif
sensit
prevent
unnecessari
donor
deferr
maintain
safeti
blood
plasma
suppli
addit
continu
pressur
laboratori
oper
demand
assay
perform
platform
capabl
increas
walk
away
time
enhanc
autom
area
reagent
manag
retest
option
commoditywast
manag
studi
designmethod
perform
new
autom
chemiluminesc
immunoassay
detect
antibodi
hcv
evalu
alin
system
precis
assess
day
evalu
posit
sampl
sensit
evalu
use
preselect
posit
sampl
seroconvers
panel
specif
evalu
sampl
obtain
blood
plasmapheresi
donor
unit
state
europ
diagnost
sampl
obtain
unit
state
sensit
specif
sampl
split
across
reagent
lot
test
confirm
repeatedli
reactiv
sampl
done
use
test
algorithm
consist
hcv
score
nathcv
discriminatori
nat
assay
resultsfind
imprecis
less
cv
posit
sampl
day
overal
clinic
sensit
preselect
posit
sampl
seroconvers
sensit
better
compar
evidenc
new
assay
identifi
bleed
compar
assay
specif
blood
donor
specimen
test
diagnost
sampl
conclus
result
indic
new
autom
alin
assay
provid
good
perform
precis
specif
sensit
backgroundcas
studi
zika
viru
zikv
outbroken
south
america
unit
state
sinc
middl
declar
public
health
emerg
intern
concern
feb
addit
mosquito
zikv
transmit
via
relationship
sexual
intercours
blood
transfus
potenti
zika
viru
shown
french
polynesia
asymptomat
blood
donor
test
posit
zika
viru
rna
use
nucleic
acid
test
nat
sever
case
report
confirm
zikv
transmit
transfus
shown
among
blood
donor
zikv
infect
asymptomat
ratio
symptomat
asymptomat
patient
observ
micronesia
approxim
thu
zikv
rais
great
challeng
transfus
safeti
measur
taken
prevent
zikv
includ
temporari
deferr
blood
donor
epidem
locat
donor
zikv
symptom
donat
without
quarantin
blood
compon
suppli
blood
collect
area
epidem
region
nat
blood
donat
pathogen
inactiv
blood
product
studi
evalu
zikv
inactiv
plasma
use
methylen
blue
photochem
treatment
mbpt
studi
designmethod
plasma
unit
randomli
select
healthi
donor
collect
spike
zikv
sampl
ad
mb
final
concentr
assay
illumin
visibl
light
side
viral
infect
zikv
rna
load
revers
transcript
pcr
measur
spike
plasma
mbpt
confirm
use
repetit
passag
cell
cultur
control
zikv
spike
plasma
without
photochem
treatment
resultsfind
zikv
titer
control
sampl
log
tissu
cultur
infecti
dose
ml
viral
infect
detect
mb
photochem
inactiv
treatment
loss
infect
demonstr
repetit
passag
cell
cultur
meanwhil
zikv
rna
load
decreas
significantli
initi
treatment
wherebi
jump
control
mbpt
tabl
conclus
show
mb
photochem
treatment
could
effect
inactiv
zikv
plasma
rna
lesion
induc
mbpt
process
nucleic
acid
revers
transcript
amplif
inhibit
mbpt
prove
effici
method
prevent
plasma
zikv
infect
backgroundcas
studi
hepat
e
viru
hev
known
transmiss
part
risk
assess
infect
studi
carri
canadian
blood
donor
subset
donor
sampl
seropreval
howev
donor
sampl
posit
hev
nucleic
acid
test
sinc
studi
suggest
exposur
hev
canada
use
limit
detect
iuml
larger
studi
perform
use
sensit
assay
studi
designmethod
donor
inform
studi
read
materi
link
sampl
approxim
canadian
whole
blood
donor
includ
canadian
blood
servic
cb
hq
collect
clinic
select
ensur
repres
sampl
donor
popul
donat
avail
plasma
sampl
test
individu
donat
nat
american
red
cross
laboratori
gaithersburg
md
use
coba
hev
test
lod
iuml
ci
use
coba
system
test
current
approv
canada
usa
avail
ce
mark
test
donor
question
concern
risk
factor
recent
hev
infect
travel
anim
contact
food
water
exposur
undergo
confirmatori
test
altern
nat
viral
load
genotyp
igmigg
serolog
notifi
letter
defer
donat
month
product
collect
donor
frozen
red
blood
cell
plasma
previou
month
destroy
recipi
trace
event
product
transfus
previou
month
resultsfind
april
cb
hq
test
sampl
valid
result
found
reactiv
donor
confirm
test
date
confirm
pend
donor
donor
quebec
one
nova
scotia
alberta
male
femal
age
rang
year
two
donor
report
symptom
fatigu
term
risk
factor
ate
pork
includ
ate
pork
liver
ate
shellfish
ate
venison
drank
well
water
one
donor
identifi
risk
factor
viral
load
rang
iuml
iuml
igm
posit
igg
posit
index
wantai
assay
conclus
preval
rate
acut
hev
infect
donor
popul
appear
around
data
studi
contribut
ongo
risk
assess
hev
infect
canada
backgroundcas
studi
introduct
infect
donat
blood
malaria
signific
health
problem
face
human
uganda
screen
malaria
parasit
neither
routin
done
blood
bank
stipul
current
uganda
nation
blood
transfus
servic
ubt
guidelin
ministri
health
result
proport
donat
blood
infect
malaria
larg
unknown
malaria
infect
place
half
world
popul
risk
major
tropic
region
world
million
case
million
death
occur
per
year
howev
studi
aim
determin
preval
malaria
parasit
donat
blood
nakasero
blood
bank
kampala
uganda
studi
designmethod
cross
section
studi
carri
nakasero
blood
bank
kampala
uganda
four
hundr
seventi
randomli
select
donor
sampl
blood
bank
june
august
thin
thick
glass
stain
blood
smear
blood
sampl
giemsa
examin
use
microscop
resultsfind
donat
blood
sampl
test
posit
malaria
parasit
p
falciparum
although
signific
differ
occurr
plasmodium
relat
sex
age
blood
group
p
major
blood
donor
test
posit
belong
blood
group
conclus
preval
malaria
parasit
studi
regardless
preval
presenc
malaria
parasit
plasmodium
falciparum
donat
blood
donor
presum
healthi
rais
seriou
concern
safeti
donat
blood
uganda
ministri
health
review
exist
guidelin
screen
malaria
mandatori
univers
blood
donor
screen
polici
malaria
exclus
blood
donor
plasmodia
parasitaemia
use
method
like
pathogen
inactiv
compar
tediou
microscop
procedur
screen
donat
blood
introduc
enhanc
blood
safeti
commun
backgroundcas
studi
blood
system
red
blood
cell
rbc
inactiv
pathogen
leukocyt
rbc
compon
transfus
use
amustalin
form
nucleic
acid
adduct
prevent
replic
broad
rang
contamin
pathogen
leukocyt
banco
de
sangr
de
servicio
mutuo
bssm
provid
intercept
treat
rbc
phase
studi
transfus
safeti
efficaci
intercept
rbc
compar
convent
rbc
puerto
rico
object
studi
qualifi
intercept
process
bssm
studi
designmethod
wb
deriv
rbc
prepar
day
collect
store
test
unit
ml
treat
intercept
process
within
collect
control
c
unit
ml
untreat
c
rbc
store
day
sampl
c
sampl
analysi
vitro
paramet
tabl
resultsfind
post
intercept
volum
hemoglobin
hb
recoveri
less
extracellular
protein
c
day
storag
higher
atp
na
c
lactat
hemolysi
lower
hct
ph
k
glucos
equival
c
hemolysi
c
c
atp
hb
level
atp
associ
effect
rbc
viabil
throughout
storag
tabl
conclus
intercept
blood
system
rbc
success
qualifi
bssm
studi
demonstr
intercept
rbc
unit
met
us
criterion
hemolysi
end
storag
measur
vitro
paramet
intercept
treat
rbc
indic
suitabl
transfus
tabl
vitro
function
day
storag
mean
b
backgroundcas
studi
rapid
detect
bacteri
contamin
platelet
key
reduc
risk
infect
transfus
blood
compon
bactalert
virtuo
virtuo
advanc
next
gener
system
improv
autom
connect
data
manag
system
importantli
virtuo
new
algorithm
significantli
reduc
time
detect
ttd
microorgan
qualiti
control
test
platelet
prepar
use
bactalert
bpa
aerob
bpn
anaerob
bottl
bpa
bpn
bottl
test
virtuo
bactalert
bta
evalu
repeat
detect
growth
seed
leukocyt
reduc
apheresi
platelet
lrap
without
platelet
addit
solut
pa
throughout
platelet
shelf
life
day
collect
studi
designmethod
pool
lrap
seed
low
level
organ
commonli
associ
platelet
contamin
day
post
collect
seed
lrap
inocul
bpa
bpn
bottl
differ
day
consecut
altern
team
peopl
seed
bottl
load
virtuo
bta
incub
declar
posit
neg
day
addit
bpa
bpn
bottl
inocul
unseed
lrap
test
virtuo
bta
bottl
respect
serv
neg
control
steril
control
evalu
risk
fals
posit
caus
lrap
resultsfind
repeat
virtuo
detect
organ
lrap
demonstr
recoveri
rate
seed
bottl
virtuo
bta
virtuo
demonstr
averag
improv
ttd
hour
compar
bta
presenc
lrap
platelet
lrap
caus
fals
posit
addit
age
lrap
unit
within
day
expiri
impact
ttd
seed
organ
tabl
analysi
bpa
bpn
bottl
ttd
platelet
shelf
life
conclus
virtuo
bta
demonstr
repeat
result
regardless
peopl
age
platelet
henc
system
reliabl
depend
detect
contamin
lrap
virtuo
fda
clear
platelet
test
backgroundcas
studi
zika
viru
zikv
emerg
flaviviru
transmit
aed
aegypti
mosquito
sometim
albopictu
mosquito
infect
asymptomat
zikv
nucleic
acid
test
nat
becam
requir
test
blood
donor
per
fda
guidanc
entitl
revis
recommend
reduc
risk
zika
viru
transmiss
blood
blood
compon
base
geograph
locat
implement
test
began
week
guidanc
issu
perform
zikv
nat
donor
whole
blood
blood
compon
investig
new
drug
ind
studi
sponsor
holog
inc
perform
retrospect
analysi
nat
result
potenti
defer
donat
due
fals
posit
screen
result
studi
designmethod
donor
consent
donat
blood
test
zikv
obtain
three
blood
bank
colorado
nebraska
nat
perform
use
procleix
viru
assay
qualit
vitro
nucleic
acid
assay
system
detect
zikv
rna
plasma
specimen
assay
perform
autom
procleix
panther
system
test
perform
accord
manufactur
packag
insert
resultsfind
event
reactiv
result
donor
would
retest
nat
addit
test
igm
antibodi
test
neutral
test
donor
defer
day
bar
continu
zikv
test
nonreact
result
total
donor
screen
zikv
donor
screen
zikv
nonreact
nat
invalid
test
result
obtain
addit
number
fail
test
run
due
instrument
assay
issu
experienc
quit
low
data
indic
assay
instrument
robust
low
frequenc
addit
test
allow
laboratori
publish
time
infecti
diseas
result
blood
bank
custom
conclus
reactiv
rate
data
present
demonstr
lowzero
incid
rate
region
whole
blood
blood
compon
discard
due
reactiv
result
screen
import
continu
ensur
blood
safeti
unit
state
backgroundcas
studi
yellow
fever
viru
yfv
known
caus
explos
outbreak
one
angola
rapidli
increas
number
infect
brazil
hundr
fatal
sinc
decemb
concern
yfv
flaviviru
transmit
aed
mosquito
could
spread
like
zika
viru
part
america
vector
endem
effect
antivir
support
therapi
avail
best
mitig
strategi
vaccin
live
attenu
vaccin
strain
like
strain
yfv
vaccin
consid
effect
safe
vaccin
howev
major
advers
event
report
includ
neurolog
viscer
advers
effect
addit
transfus
transmiss
tt
live
attenu
yfv
report
sever
clinic
outcom
especi
immunosuppress
patient
order
prevent
tt
yfv
vaccin
strain
aabb
recommend
deferr
yfv
vaccin
yfv
outbreak
vaccin
campaign
may
therefor
reduc
blood
avail
pilot
studi
evalu
abil
inactiv
use
amotosalen
uva
light
prt
platelet
compon
pc
studi
designmethod
pc
pa
plasma
spike
high
titer
treat
prt
sampl
taken
illumin
infecti
titer
determin
plaqu
assay
use
cell
extent
inactiv
quantifi
compar
titer
inactiv
resultsfind
infecti
titer
pfuml
pc
plasma
pfuml
pc
plasma
titer
sampl
pfuml
pc
plasma
pfuml
pc
plasma
inactiv
limit
detect
inactiv
pfuml
achiev
pc
plasma
inactiv
limit
detect
inactiv
achiev
pc
plasma
conclus
find
pilot
studi
suggest
similar
flavivirus
includ
west
nile
dengu
zika
viru
prt
effici
inactiv
vaccin
strain
pc
independ
resuspens
medium
potenti
mitig
strategi
maintain
pc
avail
area
affect
larg
yfv
outbreak
widespread
vaccin
campaign
data
pathogen
reduct
zika
yellow
fever
virus
intercept
blood
system
submit
fda
review
backgroundcas
studi
use
biotin
supplement
increas
recent
year
mani
health
care
profession
may
awar
high
dosag
intak
patient
high
dosag
result
increas
preval
individu
expos
biotin
level
much
greater
recommend
daili
dose
consequ
led
inaccur
lab
result
assay
util
free
captur
methodolog
although
abbott
alin
assay
util
free
captur
methodolog
eight
assay
develop
blood
screen
alin
system
evalu
biotin
interfer
ensur
unknown
consequ
high
biotin
level
studi
designmethod
purpos
studi
determin
eight
develop
abbott
alin
assay
would
suscept
biotin
interfer
evalu
perform
presenc
high
concentr
biotin
alin
assay
evalu
hiv
agab
combo
htlv
iii
hcv
chaga
hbsag
syphili
cmv
igg
sampl
spike
concentr
biotin
approxim
ngml
test
control
unspik
sampl
prepar
determin
differ
control
biotin
contain
sampl
two
sampl
one
neg
one
posit
test
assay
except
hiv
htlv
assay
test
two
posit
sampl
antibodi
antigen
antibodi
antibodi
respect
resultsfind
neg
sampl
sampl
cutoff
sco
differ
biotin
spike
control
hcv
hbc
syphili
cmv
igg
chaga
hiv
agab
htlv
iii
hbsag
posit
sampl
mean
sco
differ
biotin
spike
control
antibodi
sampl
antigen
sampl
hiv
agab
combo
htlv
antibodi
sampl
htlv
ii
antibodi
sampl
hcv
chaga
hbsag
syphili
cmv
igg
conclus
eight
abbott
alin
assay
evalu
determin
suscept
biotin
interfer
result
indic
eight
alin
assay
show
suscept
biotin
interfer
approxim
concentr
ngml
backgroundcas
studi
use
biotin
dietari
supplement
increas
significantli
recent
year
mani
health
care
profession
realiz
patient
take
high
dose
increas
result
increas
preval
peopl
expos
biotin
level
much
higher
recommend
daili
dose
consequ
potenti
inaccur
lab
result
assay
util
free
captur
methodolog
purpos
studi
identifi
abbott
prism
assay
may
suscept
biotin
interfer
base
assay
design
evalu
perform
assay
high
concentr
biotin
comprehens
review
abbott
current
market
prism
assay
assay
identifi
util
captur
howev
assay
identifi
subsequ
test
contain
biotin
assay
design
studi
designmethod
prism
assay
hiv
plu
ln
htlv
ihtlv
ii
ln
hcv
ln
neg
posit
control
test
spike
buffer
biotin
buffer
concentr
ngml
biotin
spike
sampl
compar
control
sampl
prepar
buffer
spike
determin
statist
signific
differ
untreat
biotin
contain
specimen
resultsfind
tabl
prism
assay
use
biotin
assay
design
conclus
three
candid
abbott
prism
assay
identifi
potenti
suscept
biotin
interfer
use
test
sampl
contain
increasingli
higher
concentr
biotin
signific
interfer
observ
abbott
prism
assay
biotin
concentr
backgroundcas
studi
bacteri
contamin
platelet
highest
residu
infecti
risk
transfus
despit
current
prevent
strategi
bacteri
contamin
may
affect
blood
compon
ambient
storag
temperatur
condit
platelet
make
like
facilit
bacteri
growth
base
precautionari
measur
final
platelet
concentr
includ
worst
case
limit
viabl
bacteria
number
estim
coloni
form
unit
cfu
bag
ie
cfuml
one
major
differ
virus
bacteria
bacteria
abil
grow
concentr
cfuml
day
product
moreov
larg
divers
strain
found
contamin
platelet
repres
key
challeng
develop
gener
bacteri
test
aim
studi
develop
econom
easi
diagnost
approach
earli
rapid
sensit
gener
detect
bacteria
platelet
concentr
adapt
process
blood
transfus
servic
requir
major
concern
henc
attent
focus
easi
autom
techniqu
abl
deliv
result
day
collect
studi
designmethod
larg
panel
bacteria
involv
transfus
reaction
includ
clinic
isol
refer
strain
establish
use
mous
immun
antibodi
screen
platelet
spike
step
origin
approach
use
produc
select
monoclon
antibodi
direct
bacteria
develop
gener
immunoassay
recommend
hour
day
collect
sampl
volum
spike
platelet
cfuml
test
short
gener
cultur
lysi
captur
bacteria
magnet
microparticl
micropl
format
immunoassay
perform
detect
captur
bacteria
resultsfind
approach
test
panel
bacteri
strain
involv
transfus
reaction
step
captur
bacteria
microparticl
improv
avoid
fals
neg
result
enhanc
sensit
detect
full
test
develop
studi
combin
cultur
step
follow
immunoassay
easi
autom
allow
sensit
detect
cfuml
gram
neg
bacteria
test
cfuml
gram
posit
one
conclus
studi
new
approach
rapid
bacteri
cultur
follow
micropl
immunoassay
develop
gener
sensit
detect
bacteria
platelet
concentr
abl
easili
implement
transfus
servic
deliv
test
platelet
soon
day
collect
origin
approach
could
adapt
bacteri
detect
blood
product
backgroundcas
studi
hepat
b
viru
hbv
infect
import
factor
caus
hepat
liver
cirrhosi
hepatocellular
hbv
infect
million
peopl
worldwid
preval
hbsag
high
chines
popul
occult
hbv
infect
obi
defin
detect
hbv
dna
serum
andor
liver
tissu
individu
hbsag
test
neg
potenti
risk
hbv
transmiss
blood
transfus
hbsag
screen
genet
mutat
one
mechan
result
obi
strain
gener
appear
certain
divers
differ
region
infect
differ
hbv
genotyp
studi
perform
investig
serolog
character
mutat
surfac
protein
basal
core
promoterprecor
bcppc
region
obi
strain
blood
donor
east
china
studi
designmethod
blood
donor
sampl
confirm
hbsag
neg
hbv
dna
posit
collect
region
blood
center
serum
test
immunosorb
assay
elisa
hbv
dna
load
determin
roch
cobasampliprepcoba
taqmanhbvtest
hbv
bcppc
region
amplifi
use
product
clone
ta
clone
kit
sequenc
nucleotid
sequenc
translat
amino
acid
sequenc
accord
frame
dnaman
softwar
hbsag
serolog
subtyp
predict
amino
acid
sequenc
posit
hbv
genotyp
determin
blast
genebank
protein
bcppc
gene
mutat
determin
compar
hbv
sequenc
genbank
databas
resultsfind
total
sampl
confirm
hbsag
neg
hbv
dna
posit
collect
sampl
andor
posit
classifi
obi
seroneg
sampl
classifi
window
period
wp
sampl
posit
weakli
reactiv
hbv
dna
load
obi
sampl
less
lower
wp
sampl
significantli
p
region
amplifi
sampl
includ
obi
sampl
genotyp
b
genotyp
c
wp
sampl
genotyp
b
genotyp
c
obi
adw
subty
adr
subtyp
vari
ayw
subty
unknown
chang
protein
mutat
identifi
obi
sampl
rel
high
incid
genotyp
b
r
genotyp
c
mutat
rate
averag
number
amino
acid
substitut
obi
sampl
higher
hbsag
posit
blood
donor
p
mutat
observ
wp
sampl
bcppc
region
amplifi
sampl
obi
wp
obi
nucleotid
mutat
rel
high
incid
conclus
found
blood
donor
obi
low
hbv
dna
load
east
china
amino
acid
substitut
protein
nucleotid
replac
bcppc
region
may
import
mechan
occurr
obi
carrier
infect
genotyp
b
genotyp
c
hbv
backgroundcas
studi
taiwan
high
endem
area
liver
diseas
hcv
infect
gener
popul
hcv
preval
rate
report
howev
incid
rate
difficult
obtain
mcewan
etal
estim
approach
use
observ
hepatocellular
carcinoma
incid
patient
live
chronic
hcv
infect
taiwan
taiwan
blood
servic
foundat
tbsf
initi
elisa
routin
test
sinc
hcv
rna
nat
routin
test
sinc
everi
donat
preval
incid
hcv
among
taiwanes
could
estim
blood
donor
databas
studi
designmethod
achiev
goal
hcv
erad
taiwan
establish
nation
hepat
c
program
offic
nhcpo
coordin
multidisciplinari
nation
plan
includ
health
educ
screen
prevent
treatment
research
surveil
evalu
mani
stakehold
involv
hcv
erad
program
includ
govern
author
center
diseas
control
prevent
nation
health
insur
health
promot
administr
privat
properti
like
hospit
medic
societi
pharmaceut
vaccin
industri
npo
academia
resultsfind
tbsf
privat
nationwid
singl
blood
servic
program
taiwan
perform
screen
test
nat
confirmatori
test
everi
collect
blood
popul
screen
hcv
taiwan
high
blood
donat
rate
tbsf
confirm
posit
test
result
repeat
blood
donor
identifi
hcv
rna
seroconvers
case
hepat
patient
infect
patient
would
refer
physician
medic
care
defer
perman
tbsf
secur
blood
safeti
interview
case
risk
factor
hcv
patient
studi
help
identifi
elimin
sourc
hcv
infect
tbsf
also
contribut
health
educ
teach
donor
awar
potenti
risk
hcv
infect
keep
monitor
everi
paramet
hcv
epidemiolog
evalu
efficaci
hcv
erad
program
conclus
hcv
erad
program
tbsf
secur
blood
safeti
also
particip
health
educ
diseas
screen
etiolog
find
prevent
surveil
evalu
thu
among
stakehold
tbsf
particularli
import
play
pivot
role
erad
hcv
taiwan
backgroundcas
studi
theraflex
system
macopharma
pathogen
inactiv
system
platelet
concentr
pc
inactiv
effici
shown
broad
rang
virus
bacteria
protozoan
previou
studi
first
set
bacteria
speci
intern
repositori
platelet
transfus
relev
bacteri
refer
strain
reveal
high
inactiv
capac
clinic
relev
bacteria
aim
current
studi
investig
bacteria
inactiv
efficaci
theraflex
system
enterobact
cloaca
pseudomona
fluorescen
staphylococcu
aureu
streptococcu
bovi
recent
ad
intern
repositori
studi
designmethod
pc
produc
buffi
coat
use
addit
solut
ssp
macopharma
residu
plasma
content
inactiv
kinet
pc
spike
bacteria
final
concentr
form
unit
cfu
ml
irradi
increas
dose
full
uvc
dose
achiev
sampl
taken
bacteri
titer
determin
irradi
step
steril
studi
two
pc
pool
inocul
bacteria
final
concentr
approxim
cfuml
bacteria
allow
grow
pc
agit
split
one
pc
remain
untreat
growth
control
one
storag
seven
day
sampl
taken
bag
steril
test
bactalert
biomerieux
determin
bacteri
titer
untreat
control
unit
resultsfind
bacteria
pc
inactiv
manner
treatment
use
theraflex
system
mean
factor
rang
enterobact
cloaca
pseudomona
fluorescen
staphylococcu
aureu
streptococcu
bovi
pc
speci
spike
differ
bacteria
speci
effici
steril
treat
pc
remain
steril
storag
day
bacteria
pc
grew
high
titer
conclus
theraflex
system
effici
inactiv
broad
rang
differ
bacteria
speci
includ
refer
strain
steril
maintain
storag
period
day
result
suggest
pathogen
inactiv
technolog
significantli
improv
bacteri
safeti
platelet
transfus
backgroundcas
studi
blood
compon
life
save
howev
also
associ
life
threaten
hazard
transfus
transmit
infect
tti
hepat
b
viru
hbv
hepat
c
viru
hcv
human
immunodefici
viru
hiv
syphili
seriou
infect
transmit
blood
transfus
seriou
blood
shortag
especi
develop
countri
relianc
unsaf
famili
replac
paid
donor
also
contribut
increas
risk
tti
know
current
preval
tti
among
blood
donor
crucial
donor
program
strategi
develop
cost
effect
altern
strategi
blood
screen
highli
requir
especi
resourc
limit
setup
studi
designmethod
retrospect
analysi
blood
donor
record
cover
period
juli
juli
conduct
data
collect
nation
al
blood
bank
nbb
center
donor
data
base
addit
direct
laboratori
cost
parallel
versu
sequenti
strategi
blood
screen
compar
use
current
price
laboratori
cost
data
first
export
spss
version
softwar
analysi
data
analysi
perform
use
score
odd
ratio
use
softwar
look
associ
depend
independ
variabl
p
valu
less
consid
signific
resultsfind
total
consecut
blood
donor
screen
overal
seropreval
rate
hbv
hiv
hcv
syphili
blood
donor
respect
higher
among
blood
donor
follow
whish
account
significantli
increas
tti
observ
among
famili
replac
donor
factori
worker
daili
labor
age
group
studi
differ
cost
current
use
strategi
parallel
versu
newli
propos
design
sequenti
test
algor
ethiopian
birr
conclus
signific
percentag
blood
donor
harbor
tti
nbb
center
work
voluntari
blood
donor
mobil
develop
cultur
voluntar
direct
laboratori
cost
analysi
use
current
use
strategi
parallel
higher
newli
design
sequenti
test
algorithm
thu
new
strategi
implement
make
screen
tti
cost
effect
nbb
center
backgroundcas
studi
larg
pediatr
hospit
month
old
infant
support
day
extracorpor
membran
oxygen
ecmo
time
blood
product
transfus
day
end
ecmo
support
routin
blood
smear
examin
reveal
inclus
patient
red
cell
patient
also
intermitt
fever
malaria
confirm
pcr
plasmodium
oval
p
oval
patient
risk
infect
suspect
transfus
relat
report
blood
center
suppli
transfus
product
studi
designmethod
investig
began
focus
donor
red
cell
product
sinc
chanc
apheresi
platelet
product
transmit
malaria
rel
small
frozen
product
remot
identifi
donor
red
cell
product
donor
contact
ask
four
question
addit
question
ask
clarif
need
base
donor
respons
risk
activ
malaria
infect
assess
also
consid
area
p
oval
found
donor
identifi
possibl
risk
test
antibodi
parasit
dna
resultsfind
five
donor
ill
common
cold
bronchiti
like
symptom
donor
travel
went
area
three
donor
former
resid
anoth
countri
may
risk
live
malaria
endem
countri
sinc
birth
came
us
adult
discov
one
three
meetal
donor
criteria
donor
fail
disclos
complet
year
stay
us
emigr
cameroon
area
endem
p
oval
travel
anywher
come
unit
state
octob
answer
travel
antibodi
test
donor
posit
p
oval
p
falciparum
pcr
test
neg
anoth
possibl
donor
former
resid
iran
test
pcr
antibodi
neg
third
donor
yet
test
countri
resid
p
oval
malaria
conclus
could
definit
proven
donor
antibodi
p
oval
activ
malaria
time
donat
donor
indefinit
defer
refer
outsid
physician
treatment
backgroundcas
studi
yo
male
patient
admit
emerg
room
sever
acut
gastrointestin
bleed
caus
malform
later
locat
proxim
jejunum
clip
endoscop
admiss
receiv
total
unit
red
blood
cell
approxim
week
later
due
anoth
episod
gi
bleed
manifest
melena
part
routin
evalu
cbc
perform
blood
smear
reveal
presenc
intraerythrocyt
parasit
consist
babesia
sp
studi
designmethod
upon
notif
suspect
case
babesiosi
lookback
donor
involv
prior
transfus
event
initi
resultsfind
confirm
presumpt
diagnosi
babesiosi
pcr
perform
babesia
microti
dna
detect
evalu
patient
risk
factor
reveal
prior
gi
bleed
episod
receiv
transfus
eight
month
earlier
also
transfus
open
heart
surgeri
travel
histori
us
midwest
travel
new
england
two
year
ago
spend
time
outdoor
splenectom
mid
donor
lookback
identifi
donor
live
new
london
counti
connecticut
spent
winter
season
central
florida
blood
donat
doubl
rbc
collect
apheresi
took
place
never
diagnos
babesiosi
particip
regularli
outdoor
activ
connecticut
put
risk
tick
bite
although
never
notic
bitten
show
sign
upon
test
found
neg
b
microti
pcr
well
igm
antibodi
igg
antibodi
titer
recipi
rbc
unit
collect
donat
deceas
within
hour
transfus
follow
could
perform
phone
interview
none
remain
donor
risk
factor
babesiosi
four
test
found
serolog
neg
conclus
transmiss
babesiosi
zoonot
rout
confin
region
appropri
host
vector
coexist
peopl
area
endem
may
establish
temporari
resid
donat
blood
locat
facilit
transmiss
transfus
illustr
case
licens
assay
babesia
microti
becom
avail
test
scheme
formul
polici
take
issu
consider
backgroundcas
studi
bacteri
infect
ttbi
rare
seriou
complic
blood
product
transfus
fatal
report
fda
attribut
bacteri
contamin
red
cell
unit
rare
implic
sever
fatal
ttbi
present
contamin
often
rod
gnr
bacteria
psychrophil
properti
present
case
sickl
cell
patient
develop
definit
sepsi
receiv
red
cell
unit
contamin
stenotrophomona
maltophilia
maltophilia
studi
designmethod
femal
sickl
cell
diseas
admit
hospit
possibl
pain
crise
blood
urin
cultur
collect
day
hospit
show
growth
five
day
day
patient
requir
blood
transfus
issu
irradi
crossmatch
red
cell
unit
unit
aliquot
via
steril
connect
devic
day
prior
pediatr
patient
pediatr
aliquot
transfus
without
advers
effect
patient
temperatur
within
minut
start
transfus
patient
temperatur
increas
subsequ
reach
maximum
transfus
stop
blood
bank
notifi
immedi
gram
stain
remaind
transfus
compon
reveal
gnr
bacteria
blood
collect
patient
cultur
antibiot
treatment
initi
resultsfind
initi
transfus
reaction
reveal
evid
cleric
error
neg
antibodi
screen
direct
antiglobulin
test
blood
cultur
patient
implic
red
cell
unit
grew
gnr
bacteria
identifi
maltophilia
microbi
test
reveal
cultur
pathogen
abl
prolifer
find
characterist
observ
maltophilia
conclus
first
definit
case
ttbi
maltophilia
bacterium
global
emerg
gnr
wide
spread
environ
caus
nosocomi
infect
immunocompromis
debilit
patient
contamin
unlik
due
asymptomat
donor
laboratori
evid
pathogen
transfus
recipi
transfus
compon
patient
infect
pathogen
prior
transfus
potenti
exposur
could
identifi
patient
recov
follow
appropri
antibiot
treatment
endur
prolong
hospit
transfus
reaction
classifi
definit
sever
tti
definit
imput
backgroundcas
studi
plasma
fraction
test
plasma
product
pool
hbsag
hiv
antibodi
qualit
limit
test
control
impur
safeguard
error
donat
test
pool
european
medicin
agenc
ema
publish
guidelin
valid
immunoassay
detect
hbsag
hiv
antibodi
product
pool
aim
valid
commerci
immunoassay
test
product
pool
hbsag
hiv
antibodi
util
ema
guidelin
studi
designmethod
lower
calcul
cutoff
valu
abbott
prism
hbsag
hiv
plu
assay
determin
calcul
mean
ratio
sco
plu
standard
deviat
four
differ
type
plasma
product
pool
sampl
calcul
cutoff
valu
util
rest
valid
detect
limit
determin
test
triplic
serial
dilut
hbsag
hiv
antibodi
standard
dilut
plasma
normal
detect
limit
calcul
hbsag
assay
use
product
pool
contain
low
typic
high
titer
variabl
determin
test
minimum
determin
low
posit
control
run
variabl
determin
test
least
repres
neg
product
pool
sampl
least
low
posit
sampl
titrat
seri
standard
spike
plasma
product
sampl
run
perform
six
separ
day
use
two
differ
instrument
two
differ
lot
assay
reagent
resultsfind
lower
calcul
cutoff
valu
hbsag
assay
manufactur
cutoff
respect
hbsag
assay
detect
limit
iuml
sourc
plasma
iuml
recov
plasma
sampl
normal
detect
limit
studi
demonstr
one
half
hour
maximum
amount
time
pool
sampl
could
sit
sampl
still
reactiv
hbsag
lowest
posit
dilut
replic
vari
depend
subtyp
group
cv
sco
valu
replic
variabl
valid
less
assay
cv
sco
valu
panel
sampl
variabl
valid
less
conclus
lower
calcul
cutoff
valu
could
determin
commerci
avail
immunoassay
hbsag
immunoassay
could
meetal
recommend
ema
valid
guidelin
abbott
prism
hbsag
hiv
plu
assay
util
test
product
pool
sampl
zika
viru
univers
donor
year
experi
backgroundcas
studi
due
hawaii
geograph
locat
presenc
aed
mosquito
recent
outbreak
dengu
viru
denv
began
univers
individu
donor
test
zikv
august
find
repres
first
month
test
studi
designmethod
procleix
zikv
tma
holog
inc
investig
new
drug
protocol
perform
creativ
test
solut
temp
az
initi
reactiv
sampl
repeat
duplic
supplement
test
includ
zikv
plasma
red
cell
zikv
igm
elisa
zikv
igg
elisa
denv
igg
elisa
perform
blood
system
research
institut
san
francisco
ca
zikv
antibodi
test
posit
report
viral
particl
neutral
test
perform
trioplex
serum
urin
zikv
igm
elisa
perform
hawaii
state
depart
health
doh
donor
reactiv
donat
inform
result
assess
risk
factor
medic
director
donor
reactiv
zikv
nat
result
invit
particip
follow
studi
addit
sampl
drawn
approxim
one
week
interv
lookback
perform
per
fda
recommend
resultsfind
ten
initi
reactiv
donat
identifi
donat
initi
reactiv
rate
per
donat
test
repeat
supplement
test
neg
donat
donor
risk
factor
zikv
infect
follow
test
perform
donor
day
index
donat
donor
follow
studi
test
doh
donor
test
doh
particip
follow
studi
follow
test
neg
donor
denv
antibodi
neg
donat
equivoc
initi
reactiv
rate
higher
report
date
procleix
zikv
tma
per
p
williamson
etal
transfus
press
conclus
univers
test
ind
success
implement
incorpor
blood
center
oper
note
initi
reactiv
rate
per
reason
higher
initi
reactiv
rate
unclear
appear
relat
prior
infect
denv
tabl
fals
posit
donat
backgroundcas
studi
cytomegaloviru
cmv
herpesviru
usual
produc
mild
symptom
healthi
peopl
caus
sever
neurolog
effect
unborn
infant
immunocompromis
patient
although
leukoreduct
wide
accept
equival
seroneg
mani
hospit
still
order
cmv
seroneg
red
blood
cell
platelet
unit
highest
risk
popul
cmv
seroposit
associ
age
ethnic
educ
level
incom
level
young
children
household
high
risk
job
healthcar
worker
daycar
worker
studi
report
higher
educ
incom
level
associ
lower
cmv
seroposit
rate
need
maintain
inventori
cmv
seroneg
rbc
plt
center
investig
use
donor
zip
code
surrog
marker
incom
educ
level
predict
cmv
seroconvers
studi
designmethod
retrospect
data
collect
period
april
march
inform
collect
includ
total
number
number
posit
cmv
antibodi
test
stratifi
zip
code
donor
resid
median
incom
resid
colleg
degre
obtain
zip
code
censu
data
year
cmv
antibodi
assay
passiv
particl
agglutin
igg
igm
beckman
coulter
resultsfind
zip
code
censu
data
median
incom
resid
colleg
degre
includ
analysi
addit
zip
code
test
year
period
includ
total
zip
code
includ
analysi
median
household
incom
rang
per
year
per
zip
code
resid
colleg
degre
rang
per
zip
code
cmv
seroconvers
rate
rang
per
zip
code
statist
analysi
show
correl
coeffici
median
household
incom
cmv
seroconvers
correl
coeffici
resid
colleg
degre
cmv
seroconvers
conclus
donor
zip
code
use
surrog
marker
incom
level
educ
level
order
predict
cmv
seroconvers
rate
demograph
analyz
potenti
use
predict
cmv
seroconvers
rate
includ
gender
age
race
ethnic
combin
backgroundcas
studi
grow
geograph
footprint
prioriti
organ
sinc
four
year
period
organ
doubl
number
blood
center
continu
growth
expect
current
challeng
blood
industri
audit
program
need
flexibl
maxim
effici
capac
util
without
increas
complianc
risk
intern
audit
function
central
late
program
consist
type
audit
oper
complianc
audit
support
system
complianc
audit
type
perform
twice
per
year
main
center
model
longer
serv
chang
organ
studi
designmethod
lean
six
sigma
concept
appli
project
survey
result
brainstorm
aid
captur
strength
current
program
opportun
improv
idea
redesign
program
inform
primari
input
swot
analysi
strength
weak
opportun
threat
purpos
understand
perform
current
program
well
element
could
impact
futur
design
potenti
solut
place
pugh
matrix
use
facilit
disciplin
process
concept
gener
select
potenti
solut
compar
criteria
evalu
select
best
solut
resultsfind
program
perform
intern
audit
annual
singl
comprehens
audit
remot
audit
incorpor
requir
less
time
less
disrupt
improv
auditor
worklif
balanc
cost
save
formula
creat
determin
audit
time
includ
adjust
risk
factor
audit
report
process
also
autom
simplif
effici
meet
stakehold
need
approach
leverag
auditor
strength
foster
learn
environ
increas
detect
concern
conclus
comprehens
approach
program
improv
effect
respond
organiz
growth
without
sacrif
qualiti
increas
complianc
risk
extern
inspect
perform
achiev
record
perform
level
past
year
divers
auditor
skill
led
stronger
skill
presenc
consist
appli
across
system
audit
effici
effect
stronger
collabor
among
audit
team
member
provid
stronger
object
fair
consist
across
system
auditor
audite
increas
knowledg
intern
qualiti
audit
program
improv
backgroundcas
studi
mani
place
blood
bank
use
system
perform
fraction
differ
blood
compon
red
blood
cell
platelet
plasma
banc
de
sang
teixit
bst
adopt
fulli
autom
reveo
system
terumo
bct
inc
lakewood
co
year
ago
manufactur
blood
compon
june
bst
start
valid
new
blood
bag
manufactur
terumo
bct
differ
variabl
platelet
volum
process
kit
perform
platelet
pool
new
filter
studi
designmethod
perform
valid
blood
donat
use
differ
condit
see
tabl
current
filter
evalu
platelet
pool
haemonet
corpor
compar
new
filter
terumo
bct
inc
new
blood
bag
manufactur
use
new
vinyl
supplier
portion
process
blood
compon
red
blood
cell
platelet
plasma
use
differ
qualiti
control
qc
test
routin
qc
perform
bst
follow
european
director
qualiti
medicin
healthcar
cytokin
analysi
platelet
recoveri
filter
resultsfind
result
similar
bag
current
new
one
well
filter
analysi
done
evalu
qualiti
blood
compon
similar
condit
also
shown
better
perform
platelet
pool
came
bag
centrifug
plasma
vs
plasma
addit
solut
tabl
conclus
new
bag
filter
shown
similar
behavior
use
manufactur
blood
donat
reveo
system
blood
bank
regard
new
platelet
pool
kit
better
manipul
oper
observ
although
tube
shorter
meant
difficult
manipul
pool
issu
found
implement
routin
use
plan
start
implement
year
larger
result
order
proper
procedur
qualif
backgroundcas
studi
fda
draft
guidanc
industri
titl
bacteri
risk
control
strategi
blood
collect
establish
transfus
servic
enhanc
safeti
avail
platelet
transfus
final
would
requir
secondari
test
day
day
platelet
purpos
studi
assess
cost
implement
platelet
bacteri
risk
control
strategi
across
healthcar
system
platelet
yet
avail
region
blood
supplier
implement
secondari
test
model
implement
platelet
pan
genera
detect
test
verax
biomed
marlborough
massachusett
studi
designmethod
anticip
volum
platelet
need
test
extrapol
retrospect
data
cost
includ
pdg
kit
valid
daili
qualiti
control
qc
profici
test
pt
train
reagent
personnel
addit
steril
connect
devic
heat
sealer
courier
cost
transport
test
platelet
hospit
personnel
cost
consid
test
perform
result
entri
inventori
manag
platelet
pack
cost
separ
cost
associ
implement
equip
valid
train
recur
cost
routin
test
daili
qc
pt
annual
compet
addit
staff
fte
three
differ
test
model
assess
complet
central
test
highest
transfus
volum
hospit
manag
platelet
inventori
perform
pdg
test
healthcar
system
region
test
three
test
distribut
hub
local
test
hospit
supplier
platelet
avail
assum
remain
compar
current
inventori
resultsfind
platelet
inventori
usag
data
reveal
approxim
day
day
platelet
would
need
test
per
year
cost
pgd
kit
alon
estim
addit
per
year
model
independ
system
cost
repeat
duplic
test
discard
platelet
tabl
show
total
cost
exclus
repeat
test
platelet
discard
tabl
conclus
current
condit
limit
avail
product
test
option
implement
platelet
bacteri
detect
test
healthcar
system
regardless
strategi
use
would
associ
yearli
cost
exceed
half
million
dollar
model
like
underestim
true
financi
impact
reduc
platelet
avail
associ
patient
manag
consequ
consid
backgroundcas
studi
american
rare
donor
program
nation
databas
donor
identifi
qualifi
regist
rare
donor
frequenc
less
donor
ardp
facil
donor
found
neg
high
preval
antigen
compris
approxim
total
regist
rare
donor
end
activ
donor
ardp
approxim
lack
red
cell
antigen
high
preval
perspect
obtain
unit
requir
request
seem
challeng
fill
studi
focus
interrog
data
number
unit
request
number
unit
obtain
authent
observ
studi
designmethod
ardp
softwar
program
contain
donor
databas
well
request
ardp
member
request
receiv
locat
high
preval
antigen
neg
unit
tabul
data
gather
includ
number
request
type
system
number
unit
obtain
resultsfind
request
ardp
rare
unit
ship
total
request
unit
lack
high
preval
antigen
request
categor
request
antigen
neg
specif
shown
tabl
data
tabl
focus
high
preval
antigen
neg
type
request
frequent
patient
also
antibodi
common
low
preval
antigen
complic
request
type
unit
avail
ship
ardp
member
facil
cr
en
rhnull
sc
we
total
combin
request
request
make
request
type
unit
obtain
tabl
contain
data
type
interest
tabl
conclus
patient
requir
rare
blood
product
rare
lack
high
preval
antigen
challeng
obtain
antigen
neg
blood
clear
request
exquisit
rare
type
abl
fill
current
donor
molecular
test
larg
number
donor
like
help
identifi
rare
donor
recent
year
recogn
commerci
platform
includ
mani
make
rare
type
even
challeng
find
consider
given
test
donor
ethnic
identifi
rare
donor
backgroundcas
studi
part
requir
qualiti
program
assay
valid
must
perform
ldt
perform
characterist
relat
analyt
valid
establish
use
test
system
lab
environ
ldt
detect
red
blood
cell
rbc
igg
develop
becton
dickinson
facscaliburtm
facscantm
san
jose
ca
assay
valid
includ
optim
work
dilut
fluoresc
antibodi
develop
normal
rang
prior
studi
test
normal
rang
determin
new
lot
igg
reagent
calcul
mean
standard
deviat
sd
igg
level
donor
similar
approach
clinic
instrument
optim
dilut
normal
rang
instrument
establish
studi
designmethod
residu
aliquot
blood
donor
util
institut
review
board
approv
group
donor
pool
creat
donor
aliquot
made
separ
aliquot
coat
tannic
acid
treatment
iga
igg
igm
untreat
pool
ig
coat
cell
evalu
flow
cytometri
fc
fluorescein
isothiocyan
fitc
igg
lot
jackson
immunoresearch
lab
west
grove
pa
dilut
dulbecco
pb
contain
bsa
optim
dilut
chosen
donor
sampl
evalu
instrument
batch
separ
day
test
becton
dickinson
facscaliburtm
facscantm
san
jose
ca
fc
analyz
rbc
sampl
test
run
control
react
expect
resultsfind
optim
dilut
chosen
calcul
percent
differ
igg
coat
rbc
iga
igm
coat
rbc
minim
dilut
highest
percent
differ
facscaliburtm
facscantm
fc
detect
igg
report
percent
rbc
bound
igg
mean
valu
donor
test
facscaliburtm
igg
sd
minimum
valu
maximum
valu
calcul
normal
rang
facscantm
mean
valu
donor
igg
sd
minimum
valu
maximum
valu
calcul
normal
rang
conclus
calcul
normal
rang
donor
sampl
test
minut
apart
yield
optim
antibodi
dilut
igg
normal
rang
facscantm
greater
compar
facscaliburtm
data
suggest
import
perform
assay
valid
instrument
separ
reagent
qualif
normal
rang
data
also
support
clia
requir
method
comparison
perform
like
instrument
use
test
method
backgroundcas
studi
march
aabb
publish
associ
bulletin
updat
strategi
limit
prevent
iron
defici
blood
donor
associ
bulletin
recommend
follow
limit
prevent
iron
defici
updat
educ
materi
implement
one
follow
strategi
donor
iron
supplement
ferritin
test
lengthen
interdon
intervalsdecreas
number
donat
per
year
addit
aabb
ask
blood
collect
facil
focu
follow
risk
group
young
donor
premenopaus
femal
frequent
donor
donor
near
hemoglobin
cut
valu
studi
designmethod
order
determin
potenti
impact
aabb
bulletin
bec
data
donor
collect
april
april
use
analysi
follow
data
analyz
gender
number
donat
hematocrit
age
resultsfind
order
evalu
potenti
impact
data
pull
donor
risk
iron
defici
tabl
data
risk
group
year
period
tabl
b
addit
categori
frequent
donor
recommend
updat
donor
educ
materi
provid
comprehens
inform
risk
iron
defici
recommend
iron
supplement
updat
educ
materi
like
minor
impact
recommend
implement
strategi
iron
supplement
ferritin
test
increas
interdon
interv
donor
group
risk
iron
defici
initi
implement
would
like
either
iron
supplement
ferritin
test
risk
group
implement
either
one
strategi
would
potenti
affect
donor
recommend
limit
number
donat
would
substanti
impact
analysi
focu
year
old
premenopaus
women
age
donor
averag
year
old
donat
time
year
premenopaus
women
donat
time
year
group
limit
donat
year
total
donat
year
old
donat
premenopaus
donor
would
collect
conclus
analyz
impact
aabb
associ
bulletin
bulletin
signific
impact
donor
local
blood
suppli
half
donor
would
receiv
either
ferritin
test
iron
supplement
measur
employ
limit
number
time
donor
could
donat
year
old
premenopaus
women
recommend
would
substanti
impact
abil
provid
blood
product
local
hospit
refer
associ
bulletin
updat
strategi
limit
prevent
iron
defici
blood
donor
bethesda
md
aabb
avail
http
backgroundcas
studi
transfus
medicin
knowledg
deficit
appar
among
medic
student
resid
practic
physician
defici
may
due
frequenc
type
educ
major
medic
student
unit
state
receiv
four
fewer
hour
transfus
medicin
educ
transfus
medicin
academ
award
group
publish
educ
content
guidelin
medic
school
resid
fellowship
howev
frequenc
educ
method
remain
poorli
evalu
littl
guidanc
investig
effect
differ
educ
techniqu
transfus
medicin
knowledg
acquisit
novic
learner
studi
designmethod
three
educ
pathway
develop
teach
principl
transfus
medicin
allow
learner
recogn
problem
develop
solut
transfus
medicin
complic
simul
group
receiv
educ
activ
within
hour
live
session
hybrid
group
receiv
educ
compon
onlin
also
attend
simul
session
onlin
group
receiv
educ
materi
onlin
includ
simul
session
learner
second
year
medic
student
enrol
one
institut
faculti
member
taught
live
session
develop
onlin
materi
ensur
content
creat
address
blood
group
blood
donat
blood
test
blood
compon
indic
transfus
complic
educ
session
evalu
likert
scale
survey
rang
zero
poorunsatisfactori
five
outstand
resultsfind
simul
group
student
improv
score
averag
likert
scale
rate
good
hybrid
group
student
improv
score
averag
likert
scale
rate
good
onlin
student
improv
score
averag
likert
scale
rate
good
averag
chang
score
statist
signific
within
train
group
p
valu
addit
simul
group
larger
increas
averag
score
compar
onlin
group
p
hybrid
group
p
conclus
studi
demonstr
faculti
taught
transfus
medicin
simul
curriculum
consist
didact
session
simul
session
second
year
medic
student
produc
greater
knowledg
acquisit
compar
onlin
hybrid
curriculum
simul
curriculum
also
prefer
onlin
educ
indic
likert
survey
result
backgroundcas
studi
diagnost
manag
team
dmt
innov
way
bridg
commun
gap
laboratori
clinic
servic
therebi
facilit
deliveri
improv
patient
care
dmt
employ
multidisciplinari
approach
integr
clinic
laboratori
data
succinct
interpret
recommend
interpret
must
moder
high
complex
order
clinic
valuabl
recommend
made
regard
futur
test
time
test
prior
blood
compon
need
pertin
concern
allow
improv
coordin
patient
care
timeli
dmt
report
vital
patient
manag
inher
design
dmt
also
provid
educ
opportun
traine
academ
center
studi
designmethod
transfus
medicin
servic
larg
academ
medic
center
implement
dmt
case
involv
complex
antibodi
identif
workup
transfus
reaction
deviat
standard
oper
procedur
consult
blood
compon
util
massiv
transfus
protocol
juli
januari
evalu
transfus
medicin
resid
electron
medic
record
emr
patient
also
review
determin
relev
clinic
histori
signific
find
present
transfus
medicin
dmt
confer
dmt
compris
physician
transfus
medicin
hematologyoncolog
anesthesiolog
transfus
servic
technic
staff
well
visit
clinic
staff
surgeri
obstetr
gynecolog
transplant
servic
pediatr
dmt
integr
clinic
laboratori
data
formul
relev
interpret
recommend
final
dmt
report
place
emr
access
health
care
provid
financi
benefit
transfus
medicin
dmt
also
evalu
resultsfind
period
case
complex
antibodi
identif
workup
transfus
reaction
consult
blood
compon
util
deviat
standard
oper
procedur
massiv
transfus
protocol
present
transfus
medicin
dmt
confer
placement
dmt
narr
emr
progress
note
laboratori
report
provid
inform
time
commun
resid
particip
dmt
demonstr
improv
clinic
laboratori
correl
skill
result
resid
compet
transfus
medicin
enhanc
revenu
gener
util
standard
profession
compon
cpt
code
conclus
dmt
encompass
multipl
aspect
transfus
medicin
improv
patient
care
enhanc
commun
laboratori
clinic
servic
addit
benefit
dmt
program
includ
resid
clinician
technic
staff
educ
gener
revenu
institut
backgroundcas
studi
inventori
manag
major
challeng
integr
part
hospit
transfus
servic
ht
blood
center
bc
oper
current
process
institut
involv
shipment
bc
ht
shipment
predic
upon
current
stock
level
ht
manual
obtain
inventori
level
product
manual
determin
also
aim
enhanc
inventori
manag
oper
develop
informat
solut
streamlin
order
process
accur
reflect
inventori
statu
transfus
practic
valuabl
ht
tech
time
studi
designmethod
ht
gener
inventori
account
product
categori
broken
compon
blood
type
irradi
statu
statu
therefor
sought
establish
electron
method
reliabl
infer
gener
inventori
level
sinc
raw
electron
inventori
report
compris
gener
inventori
physic
sequest
unit
eg
special
antigen
unit
unit
calibr
period
perform
linear
regress
electron
manual
count
imput
electron
censu
number
unit
product
categori
gener
inventori
reliabl
electron
method
determin
inventori
level
implement
pilot
period
analyz
variou
metric
pre
post
pilot
implement
ensur
electron
system
ratio
unit
transfus
per
week
number
stock
number
product
order
stat
number
expir
product
creat
program
visual
basic
applic
microsoft
redmond
wa
calibr
pilot
period
line
code
written
program
includ
class
modul
distinct
subroutin
resultsfind
pilot
period
investig
system
averag
weekli
ratio
cryoprecipit
plasma
rbc
respect
pilot
period
compar
pilot
period
differ
reach
statist
signific
also
monitor
number
stat
order
product
pilot
period
stat
unit
per
week
respect
lastli
also
monitor
number
monthli
wast
product
due
expir
indic
inventori
mismanag
pilot
period
unit
respect
p
estim
hour
per
week
technologist
time
realloc
task
electron
censu
adopt
translat
fte
per
year
save
labor
cost
per
year
perman
adopt
conclus
creat
electron
order
system
enhanc
inform
fidel
technologist
time
standard
order
system
show
manual
system
chang
number
stat
order
ratio
increas
number
expir
product
achiev
free
hour
staff
time
per
year
futur
direct
includ
full
autom
involv
ht
informat
depart
backgroundcas
studi
provinci
region
blood
coordin
network
prbcn
held
qualiti
focu
day
qfd
explor
transfus
qualiti
indic
includ
provinc
wide
qualiti
improv
plan
qip
plan
main
goal
reduc
patient
harm
improv
transfus
practic
hospit
reduct
inappropri
use
follow
recommend
made
select
blood
compon
hospit
could
monitordisplay
progress
public
forum
hospit
could
compar
peersstrik
transfus
qip
committe
guid
develop
plan
support
resourc
ongo
improv
initi
studi
designmethod
provinci
transfus
qualiti
improv
plan
ptqip
committe
form
includ
broad
represent
provinci
patient
blood
manag
coordin
physician
technologist
nurs
administr
clinician
qualityrisk
manag
region
provinc
provinci
blood
advisori
committe
blood
supplier
patient
collabor
organ
provinci
health
qualiti
divis
choos
wise
canada
local
health
integr
network
lhin
canadian
societi
transfus
medicin
healthcar
insur
reciproc
canada
resultsfind
ptqip
launch
april
toolkit
format
conjunct
choos
wise
canada
toolkit
contain
narr
templat
base
provinci
health
qualiti
divis
model
hospit
adapt
needsclin
practic
recommend
blood
compon
adult
inpatientstransfus
order
set
templatechoos
wise
canada
screensaversop
algorithm
train
aid
technologist
prospect
blood
order
screen
launch
inform
survey
indic
provinc
hospit
interest
alreadi
adopt
portion
ptqip
assist
hospit
advanc
qip
technologist
prospect
screen
educ
modul
develop
addit
electron
track
tool
hospit
enter
baselin
data
subsequ
audit
data
track
success
hospit
provinci
report
gener
track
tool
formal
survey
conduct
indic
plan
implement
alreadi
implement
ptqip
respond
alreadi
put
prospect
order
screen
technologist
place
conclus
help
hospit
develop
standard
templat
instruct
educ
tool
transfus
qualiti
improv
increas
abil
hospit
uptak
qualiti
improv
initi
take
standard
approach
across
provinc
allow
aggreg
hospit
data
comparison
analys
backgroundcas
studi
militari
civilian
studi
demonstr
advantag
transfus
blood
product
prior
patient
hospit
arriv
process
known
transfus
pht
helicopt
emerg
medic
servic
hem
worldwid
implement
protocol
great
success
despit
current
lack
guidanc
advisori
public
need
literatur
address
regulatori
requir
logist
challeng
associ
develop
pht
program
herein
report
experi
larg
hospit
system
embark
develop
pht
servic
studi
designmethod
octob
work
group
form
establish
pht
servic
hem
provid
care
thirti
region
hospit
compos
flight
care
staff
emerg
physician
transfus
medicin
specialist
group
identifi
major
task
address
federalst
regul
inventori
structuremanag
product
storagetest
trackingtrac
emerg
releas
protocol
staff
train
specif
regul
govern
pht
regul
pertain
blood
product
storag
valid
monitor
appli
fda
aabb
state
agenc
consult
ensur
complianc
direct
resultsfind
largest
hospit
within
system
alreadi
act
refer
site
design
perform
confirmatori
test
product
suppli
hem
similarli
hospit
task
remot
monitor
blood
refriger
helipad
site
system
fda
licens
blood
supplier
deem
respons
product
consign
transport
four
hem
site
blood
inventori
site
design
contain
group
posit
rbc
group
low
titer
liquid
plasma
prothrombin
complex
concentr
medic
record
system
use
transfer
transfus
inform
hospit
need
valid
cooler
protocol
product
emerg
releas
inventori
track
system
schedul
also
requisit
plan
staff
compet
regard
emerg
releas
guidelin
transfus
reaction
handlingstorag
product
maintain
hem
medic
director
addit
oversight
provid
transfus
medicin
physician
conclus
work
group
success
identifi
challeng
associ
pht
helicopt
base
servic
span
blood
product
manag
adapt
exist
transfus
procedur
oper
polici
licens
requir
personnel
train
pht
servic
go
live
publish
experi
may
benefit
futur
site
launch
similar
pht
initi
backgroundcas
studi
million
peopl
affect
humanitarian
emerg
eastern
mediterranean
region
world
health
organ
affect
countri
world
locat
countri
health
system
weaken
destroy
health
worker
provid
health
servic
difficult
circumst
humanitarian
emerg
increas
demand
blood
transfus
make
deliveri
challeng
complex
despit
obviou
need
across
region
lack
inform
emerg
prepared
respons
capac
blood
transfus
challeng
countri
health
respond
face
meet
need
patient
emerg
studi
designmethod
search
pubm
index
medicu
eastern
mediterranean
region
data
avail
safeti
blood
transfus
humanitarian
emerg
conduct
structur
survey
blood
transfus
servic
bt
countri
region
identifi
follow
type
humanitarian
emerg
current
strategi
ensur
avail
safeti
blood
transfus
emerg
coordin
collabor
countri
gap
challeng
addit
inform
collect
region
consult
eastern
mediterranean
region
held
may
tunisia
resultsfind
found
public
disast
five
countri
region
public
disast
prepared
blood
transfus
casualti
sever
trauma
outsid
region
howev
none
dealt
question
avail
safeti
blood
transfus
emerg
twelv
countri
respond
survey
arm
conflict
terror
commonest
type
emerg
estim
injur
requir
blood
transfus
nine
countri
emerg
prepared
respons
plan
bt
potenti
blood
donor
mobil
public
call
besid
direct
appeal
regular
replac
donor
seven
respond
countri
keep
emerg
blood
stock
collabor
differ
stakehold
exist
seven
countri
lack
adequ
compet
human
resourc
transport
cold
chain
deficit
shortag
suppli
consum
mainten
equip
lack
reliabl
power
suppli
shortag
financ
gap
identifi
conclus
need
integr
bt
overal
nation
emerg
prepared
respons
collect
dissemin
updat
inform
factor
affect
provis
blood
transfus
humanitarian
emerg
provid
technic
financi
assist
affect
countri
strengthen
mechan
coordin
collabor
among
differ
parti
develop
region
emerg
blood
servic
system
manag
expertis
backgroundcas
studi
polycythemia
frequent
develop
individu
testosteron
replac
therapi
trt
given
risk
factor
develop
cardiovascular
diseas
physician
frequent
request
therapeut
phlebotomi
keep
hemoglobin
studi
designmethod
review
therapeut
phlebotomi
request
donor
trt
blood
center
year
period
well
total
number
therapeut
phlebotomi
collect
resultsfind
total
number
therapeut
collect
respect
total
number
trt
collect
period
time
respect
number
repres
total
therapeut
collect
year
total
number
trt
donor
increas
proportion
year
number
collect
per
regist
trt
donor
vari
significantli
rang
therapeut
drawsdonor
per
year
exclud
nt
present
therapeut
blood
collect
averag
number
trt
collectionsdonor
per
year
decreas
conclus
blood
center
experienc
increas
number
therapeut
phlebotomi
well
individu
trt
refer
therapeut
phlebotomi
due
elev
hemoglobin
valu
clear
inform
provid
order
physician
whether
intend
temporari
measur
decreas
hemoglobin
patient
trt
whether
dose
adjust
discontinu
due
known
risk
factor
cardiovascular
diseas
patient
polycythemia
howev
averag
number
donat
per
trt
donor
decreas
timefram
percentag
men
testosteron
present
regular
blood
donor
blood
center
known
sinc
hormon
reason
deferr
find
rais
concern
howev
regular
phlebotomi
necessari
reduc
risk
polycythemia
popul
duti
provid
safe
adequ
blood
suppli
blood
center
also
concern
perpetu
mispercept
repeat
phlebotomi
particularli
requir
frequent
day
suffici
mitig
risk
testosteron
therapi
henc
made
decis
discontinu
offer
phlebotomi
servic
popul
donor
testosteron
meetal
donor
elig
requir
backgroundcas
studi
venipunctur
critic
step
blood
collect
locat
suitabl
vein
procedur
challeng
unaccept
vein
select
incorrect
needl
placement
lead
incomplet
collect
infiltr
blood
donor
center
primari
select
vein
done
palpat
within
antecubit
area
prior
needl
insert
skin
site
must
prepar
contact
avoid
needl
place
vein
illumin
vi
devic
avail
aid
visual
display
potenti
suitabl
vein
devic
made
avail
staff
march
initi
test
instruct
period
vi
sinc
use
staff
object
studi
discov
reason
staff
use
vi
identifi
potenti
suitabl
vein
studi
designmethod
staff
survey
develop
distribut
staff
march
inquir
usag
vi
obtain
feedback
devic
time
survey
sent
devic
avail
sever
year
survey
includ
question
involv
frequenc
use
adequaci
train
comfort
use
devic
knowledg
devic
storag
locat
willing
tri
devic
gener
feedback
resultsfind
survey
respons
rate
never
rare
util
vi
reason
low
util
focus
two
domin
theme
first
devic
need
second
nt
accur
show
vein
respond
awar
vi
store
access
locat
share
devic
identifi
although
respond
provid
train
use
vi
group
mix
regard
comfort
level
use
devic
independ
group
will
tri
vi
conclus
infiltr
incomplet
collect
account
approxim
unitsyear
qualifi
blood
donor
yet
vi
appear
viabl
solut
blood
donor
program
seem
opportun
challeng
vi
implement
opportun
creat
critic
awar
problem
vein
cannul
challeng
identifi
devic
effect
visual
deeper
vein
necessari
blood
donat
backgroundcas
studi
apheresi
red
cell
arc
repres
total
red
cell
collect
center
hae
mc
util
collect
arc
due
age
instrument
challeng
collect
mobil
well
need
increas
collect
right
type
product
decis
made
chang
technolog
studi
designmethod
freseniu
kabi
demonstr
fenwal
alyx
technolog
well
busi
case
primari
stakehold
implic
depart
involv
initi
impact
assess
kick
meet
held
project
team
form
due
product
demand
decis
made
valid
arc
plasma
apheresi
primari
depart
affect
blood
collect
product
freseniu
kabi
provid
sampl
valid
plan
sop
train
train
materi
use
four
purchas
easi
transport
alyx
feet
instal
mobil
buse
lead
trainer
bc
technic
administr
travel
affili
blood
center
observ
alyx
program
identifi
best
practic
team
blood
collect
trainer
preceptor
initi
group
train
valid
perform
team
also
serv
subject
matter
expert
field
preceptor
freseniu
kabi
return
advanc
alyx
oper
train
train
plan
target
previou
mc
oper
first
oper
new
apheresi
train
goal
mobil
staff
valid
alyx
began
took
approxim
day
complet
time
freseniu
kabi
conduct
alyx
educ
apheresi
recruit
train
collect
recruit
staff
mc
machin
remov
servic
alyx
occur
addit
oper
train
continu
septemb
resultsfind
due
eas
mobil
use
alyx
reduc
procedur
time
compar
mc
donor
convers
train
increas
compon
collect
alyx
dispos
kit
includ
solut
contain
reduc
ancillari
item
requir
pack
carri
mobil
decreas
kit
cost
provid
estim
annual
save
conclus
multipl
alyx
donat
type
abl
increas
collect
right
type
procedur
approxim
decreas
kit
cost
alyx
collect
plasma
mobil
blood
drive
possibl
due
eas
use
oper
embrac
technolog
consist
met
monthli
collect
goal
octob
backgroundcas
studi
high
frequenc
donat
risk
factor
iron
defici
femal
iron
store
gener
lower
male
start
donat
career
femal
donat
frequent
particularli
high
risk
minimum
hemoglobin
hb
long
male
femal
male
fall
normal
limit
first
step
mitig
iron
defici
criteria
whole
blood
donor
modifi
male
minimum
hb
increas
femal
minimum
interdon
interv
increas
day
longer
interdon
interv
femal
gradual
implement
start
donor
messag
octob
chang
rebook
donat
appoint
decemb
culmin
eprogesa
criteria
chang
march
chang
expect
initi
result
donat
loss
may
partli
counteract
decreas
hb
deferr
rate
femal
donor
aim
assess
impact
chang
hb
deferr
rate
studi
designmethod
percentag
hb
deferr
calcul
number
donat
attempt
result
hb
deferr
divid
number
success
donat
plu
hb
deferr
multipli
percentag
calcul
male
femal
donor
chang
made
resultsfind
percentag
hb
deferr
increas
male
donor
week
implement
week
chang
hb
criterion
hb
deferr
rate
femal
donor
septemb
octobernovemb
decemb
march
conclus
hb
deferr
frequent
male
donor
minimum
hb
increas
gradual
implement
increas
interdon
interv
femal
result
reduct
deferr
thu
initi
donat
loss
associ
chang
may
partli
offset
time
decreas
hb
deferr
longer
observ
period
necessari
confirm
find
assess
impact
phenotyp
blood
donor
retent
backgroundcas
studi
research
investig
perform
vitro
studi
involv
human
blood
need
reliabl
sourc
blood
compon
deriv
screen
donor
minim
risk
potenti
infect
tti
resourc
may
difficult
costli
obtain
protocol
develop
collect
blood
compon
vitro
research
use
healthi
volunt
donor
blood
bank
object
describ
success
oper
protocol
studi
designmethod
subject
recruit
enrol
protocol
donat
blood
apheresi
compon
research
prior
initi
donat
donor
elig
determin
includ
donor
histori
questionnair
tti
test
donor
screen
perform
time
donat
blood
product
collect
accord
standard
phlebotomi
apheresi
techniqu
donor
compens
particip
research
blood
compon
prior
distribut
track
alloc
issu
blood
compon
investig
perform
aid
electron
databas
system
resultsfind
year
donor
enrol
research
blood
donor
program
f
ratio
averag
age
year
caucasian
donor
activ
research
program
last
year
repres
activ
blood
donor
center
donor
recruit
commun
allogen
blood
donor
pool
temporari
indefinit
deferr
donor
hereditari
hemochromatosi
contribut
research
whole
blood
donat
past
year
blood
product
deriv
procedur
distribut
differ
investig
laboratori
whole
blood
common
product
follow
unmanipul
mononuclear
cell
collect
elutri
monocyt
lymphocyt
less
common
request
includ
platelet
plasma
granulocyt
advers
donor
reaction
infrequ
procedur
conclus
report
feasibl
program
collect
distribut
blood
investig
obtain
blood
compon
vitro
research
use
util
staff
resourc
blood
bank
research
blood
donat
essenti
support
laboratori
research
maintain
posit
relationship
donor
defer
allogen
transfus
backgroundcas
studi
safeti
platelet
product
continu
improv
due
test
despit
continu
emerg
microbi
threat
recent
fda
approv
platelet
pathogen
reduct
technolog
protect
transfus
recipi
regardless
new
microbi
danger
order
platelet
product
use
pathogen
reduct
technolog
volum
platelet
yield
dose
concentr
must
collect
within
tight
specif
object
studi
determin
optim
collect
set
enabl
collect
pathogen
reduc
platelet
limit
loss
product
studi
designmethod
collect
instrument
evalu
studi
fda
approv
platelet
suspend
plasma
correspond
pathogen
reduct
system
use
studi
kit
differ
collect
specif
apheresi
collect
occur
fix
site
count
perform
hematolog
analyz
yield
scale
factor
establish
correl
hematolog
analyz
apheresi
collect
devic
order
determin
optim
collect
target
apheresi
collect
instrument
varieti
multipl
yield
volum
establish
collect
staff
instruct
collect
highest
avail
yield
per
donor
collect
volum
platelet
yield
concentr
data
obtain
data
use
determin
product
met
specif
one
avail
kit
actual
platelet
yield
higher
thu
meet
criteria
doubl
product
resultsfind
higher
platelet
concentr
product
ideal
produc
doubl
product
target
product
platelet
concentr
greater
x
like
outsid
specif
pathogen
reduct
kit
platelet
concentr
target
x
result
discard
product
quickli
remov
instrument
set
collect
platelet
yield
low
platelet
concentr
like
produc
product
within
specif
pathogen
reduct
kit
conclus
loss
tripl
platelet
product
lower
platelet
recoveri
requir
collect
platelet
far
precis
goal
platelet
collect
shift
simpli
maxim
platelet
collect
approach
consid
optim
collect
within
limit
kit
specif
final
collect
instrument
configur
platelet
yield
volum
ml
platelet
yield
volum
ml
backgroundcas
studi
devic
use
bonfil
blood
center
determin
donor
hemoglobin
donor
elig
reach
end
life
bbc
need
defin
path
forward
reliabl
replac
devic
studi
designmethod
bbc
evalu
devic
follow
criteria
mind
devic
dispos
cost
reagentscontrolsqu
control
object
hgbhct
measur
portabl
durabl
mobil
environ
eas
use
donor
experi
batteri
life
valid
requir
plan
blood
center
suitabl
abil
link
bec
multipl
depart
includ
donor
care
equip
manag
valid
qualiti
regulatori
affair
involv
evalu
product
select
bbc
test
donor
per
devic
fix
mobil
site
bbc
also
consid
donor
feedback
choic
replac
technolog
project
start
februari
target
implement
date
juli
creat
necessari
sop
adopt
exist
sop
bbc
success
complet
valid
devic
chose
compolab
technolog
freseniu
kabi
new
devic
bbc
blood
bank
resultsfind
compolab
select
met
project
scope
select
criteria
import
bbc
reduc
paperwork
daili
task
compolab
elimin
daili
qc
reduc
paperwork
time
improv
error
manag
convert
new
technolog
bbc
donor
deferr
rate
increas
approxim
consequ
increas
bbc
conduct
remind
train
bbc
staff
ensur
proper
sampl
techniqu
higher
sampl
qualiti
time
bbc
deferr
rate
stabil
time
period
bbc
also
success
recruit
new
blood
donor
bbc
program
may
contribut
increas
deferr
rate
deferr
rate
increas
probabl
due
part
fda
final
rule
requir
blood
blood
compon
intend
transfus
manufactur
use
went
effect
may
conclus
evalu
new
equip
bbc
learn
critic
understand
equip
life
cycl
effect
equip
aspect
busi
comprehens
evalu
multipl
donor
elig
screen
platform
compolab
devic
select
bbc
facil
met
major
aspect
project
scope
qualifi
criteria
bbc
also
learn
continu
refresh
train
staff
ensur
optim
devic
perform
extern
factor
chang
regulatori
environ
may
impact
deferr
rate
backgroundcas
studi
vasovag
reaction
vvr
known
common
advers
reaction
blood
collect
effect
measur
prevent
vvr
yet
develop
effect
time
intervent
apheresi
donat
particular
hold
key
predict
vvr
research
done
topic
studi
designmethod
studi
investig
potenti
predict
vvr
fluctuat
peripher
blood
flow
measur
laser
doppler
flowmetri
platelet
apheresi
donor
popul
highli
like
experi
vvr
data
collect
individu
donat
platelet
period
februari
august
data
donor
experienc
vvr
analyz
calcul
level
issu
vvr
alert
percent
decreas
blood
flow
dbf
percent
decreas
heart
rate
dhr
calcul
time
alert
vvr
estim
three
dbf
level
detect
perform
alert
level
calcul
resultsfind
eight
men
women
experienc
vvr
one
donor
experi
vvr
blood
collect
delay
reaction
rest
afterward
mean
maximum
dbf
donor
vvr
group
significantli
higher
group
maximum
dbf
threshold
sensit
discrimin
vvr
donor
accuraci
dbf
use
alert
level
alert
issu
donor
includ
vvr
group
therefor
sensit
predict
vvr
specif
mean
time
alert
diagnosi
vvr
group
minut
accuraci
alert
vvr
could
predict
even
valu
maximum
dbf
exceed
reason
suppos
differ
donor
suscept
dbf
conclus
investig
whether
vvr
platelet
apheresi
donor
prevent
predict
found
possibl
predict
vvr
earli
enough
onset
interven
monitor
dbf
real
time
blood
collect
use
laser
doppler
flowmetri
futur
research
must
also
investig
whether
incid
vvr
actual
reduc
intervent
adjust
extracorpor
circul
backgroundcas
studi
red
blood
cell
rbc
transfus
often
lifesav
measur
patient
sickl
cell
diseas
scd
critic
manag
scd
complic
splenic
sequestr
stroke
priapism
iron
overload
acut
chest
syndrom
complic
chronic
transfus
scd
patient
alloimmun
rbc
antigen
prevent
alloimmun
transfus
rbc
neg
c
e
k
antigen
advoc
led
report
reduct
rate
alloimmun
decreas
hemolyt
transfus
reaction
report
summari
three
year
experi
prophylact
transfus
rbc
unit
neg
c
e
k
antigen
scd
patient
red
blood
cell
exchang
transfus
rbcx
studi
designmethod
retrospect
review
scd
patient
histori
stroke
refractori
sickl
pain
crisi
priapism
done
rbcx
perform
everi
week
decemb
march
blood
bank
use
mt
gel
method
antibodi
screen
identif
base
donor
center
proactiv
work
hospit
blood
bank
prepar
unit
time
manner
resultsfind
total
patient
femal
male
underw
total
rbcx
octob
march
use
averag
number
rbc
unit
per
rbcx
rbc
unit
neg
c
e
k
antigen
use
rbcx
patient
two
patient
posit
c
antigen
underw
rbcx
use
e
k
antigen
neg
rbc
unit
review
antibodi
screen
test
result
perform
prior
rce
show
new
clinic
signific
alloantibodi
form
exposur
multipl
rbc
unit
conclus
although
consist
standard
care
transfus
practic
relat
extent
antigen
match
scd
patient
studi
suggest
standard
care
transfus
patient
scd
provid
rbc
neg
c
e
k
antigen
abil
find
rare
unit
also
affect
characterist
one
institut
blood
supplier
advantag
hospit
base
donor
center
work
proactiv
collabor
provid
rare
unit
approach
institut
transfus
rbc
unit
neg
c
e
k
combin
base
scd
patient
phenotyp
show
new
clinic
signific
alloantibodi
detect
past
year
possibl
random
clinic
trial
futur
may
help
elucid
signific
transfus
c
e
k
neg
rbc
unit
scd
patient
reduc
prevent
alloimmun
backgroundcas
studi
investig
tempor
variat
recoveri
blood
immunolog
indic
blood
donat
healthi
fix
volunt
studi
designmethod
venou
blood
specimen
healthi
volunt
collect
blood
donat
blood
donat
immedi
day
week
week
week
among
men
week
among
women
immunoglobulin
g
igg
immunoglobulin
igm
immunoglobulin
iga
complement
compon
red
blood
cell
rbc
white
blood
cell
count
wbc
hemoglobin
hb
hematocrit
hct
serum
iron
fe
measur
monitor
dynam
chang
biomark
blood
qualiti
resultsfind
level
igg
slightli
decreas
blood
donat
immedi
iga
decreas
significantli
still
within
normal
rang
igm
chang
blood
donat
level
iga
significantli
decreas
week
among
men
week
among
women
significantli
increas
time
period
igg
rbc
hb
hct
fe
start
recov
week
blood
donat
reach
level
blood
donat
within
week
among
men
week
among
women
conclus
biomark
mutual
chang
cours
week
among
men
week
among
women
donat
blood
significantli
affect
overal
blood
qualiti
backgroundcas
studi
increas
platelet
demand
opportun
export
product
set
initi
increas
platelet
product
collect
form
exist
donor
base
also
face
challeng
manag
multipl
collect
site
multipl
state
decis
made
implement
amicu
dxt
relay
data
manag
solut
provid
us
insight
procedur
detail
make
data
driven
decis
day
day
variabl
previous
dip
low
split
forc
reactiv
plan
studi
designmethod
incorpor
dxt
strateg
plan
day
day
oper
dxt
report
monitor
manag
freseniu
kabi
team
product
site
phlebotomist
devic
report
measur
target
vs
actual
yield
donor
paramet
procedur
event
perform
donat
opportun
analysi
allow
us
adjust
configur
set
appropri
improv
accuraci
yield
predict
report
phlebotomist
util
train
optim
donor
gift
donat
addit
platelet
plasma
product
increas
procedur
success
rate
resultsfind
monthli
dxt
report
analysi
result
devic
configur
improv
phlebotomist
center
manag
account
effect
train
donat
optim
increas
overal
platelet
split
rate
percent
increas
concurr
plasma
collect
percent
util
dxt
report
abl
take
proactiv
approach
allow
us
predict
product
avail
day
day
variabl
drop
lower
percent
split
phlebotomist
qn
rate
easili
monitor
regularli
daili
weekli
monthli
result
decreas
overal
qn
rate
consist
percent
conclus
dxt
easi
implement
user
friendli
continu
help
improv
platelet
collect
process
improv
donor
center
dxt
provid
invalu
tool
oper
supervisor
monitor
staff
improv
product
multipl
site
next
step
develop
plan
implement
paperless
document
dxt
abil
immedi
review
data
directli
amicu
key
product
improv
realiz
backgroundcas
studi
blood
blood
product
limit
expens
resourc
prescrib
handl
store
transfus
accord
hospit
guidelin
establish
ensur
best
practic
standard
maintain
patient
safeti
prerequisit
regist
nurs
rn
involv
blood
blood
product
administr
possess
fundament
knowledg
transfus
practic
aim
aim
studi
evalu
impact
transfus
practic
train
program
among
regist
nurs
administr
questionnair
implement
program
result
gather
would
identifi
gap
assimil
knowledg
suggest
improv
design
implement
specif
content
transfus
train
programm
studi
designmethod
rn
variou
unit
depart
invit
particip
blood
transfus
knowledg
questionnair
octob
formal
transfus
practic
train
programm
introduc
consist
onlin
learn
platform
train
session
questionnair
administ
rn
one
year
later
septemb
programm
evalu
individu
item
score
proport
nurs
perfect
score
compar
resultsfind
total
number
rn
rn
complet
questionnair
give
respons
rate
respect
overal
mean
score
point
rang
mean
score
point
rang
percentag
rn
perfect
score
increas
tabl
show
result
question
item
tabl
number
correct
answer
conclus
implement
transfus
practic
train
programm
led
encourag
improv
blood
transfus
knowledg
amongst
rn
train
may
need
prepar
blood
set
manag
fever
backgroundcas
studi
clinic
use
blood
shown
least
develop
part
transfus
chain
global
survey
therefor
carri
order
investig
level
awar
access
util
learn
qualiti
blood
use
among
blood
prescrib
clinician
nurs
studi
designmethod
descript
facto
survey
design
use
purpos
select
blood
prescrib
clinician
nurs
hospit
countri
human
develop
index
hdi
group
low
medium
high
high
particip
three
research
question
answer
seven
null
hypothes
test
level
signific
descript
statist
tool
frequenc
count
percentag
use
analyz
demograph
background
inferenti
statist
pearson
correl
coeffici
ppmc
analysi
varianc
anova
use
analys
hypothes
resultsfind
qualiti
clinic
use
blood
posit
significantli
correl
level
awar
r
access
learn
among
blood
prescrib
cliniciansnurs
signific
differ
level
awar
f
p
access
f
p
util
f
p
learn
among
blood
prescrib
cliniciansnurs
base
hdi
group
particularli
high
low
hdi
signific
differ
level
access
f
p
util
f
p
learn
among
blood
prescrib
clinician
base
clinic
specialtydepart
signific
differ
qualiti
clinic
blood
use
base
clinic
specialtydepart
f
p
conclus
today
learn
becom
conditio
sine
qua
non
effect
qualiti
clinic
use
blood
higher
hdi
level
better
awar
access
util
continu
educ
convent
program
better
awar
among
clinician
routin
prescrib
blood
compar
other
involv
incident
blood
transfus
access
depend
highli
presenc
sustain
societ
infrastructur
less
guarante
low
medium
hdi
countri
reliabl
power
suppli
mainten
hardwar
tool
updat
softwar
program
togeth
necessari
knowledg
skill
promin
factor
result
use
polici
strategi
recommend
improv
knowledg
clinic
practic
continu
program
eg
start
undergradu
medic
nurs
school
continu
postgradu
vocat
medic
special
institut
principl
clinic
transfus
practic
comprehens
includ
appropri
time
curricula
creation
technic
climat
guarante
access
cours
materi
stimul
nation
intern
exchang
program
focus
continu
educ
creation
mentor
network
profession
societi
associ
educ
institut
backgroundcas
studi
transfus
medicin
tm
didact
teach
materi
patholog
resid
wide
avail
share
among
resid
train
program
advanc
blood
knowledg
abo
leader
project
novel
approach
wherein
educ
materi
creat
collabor
commun
practic
cop
educ
theorist
etienn
wenger
defin
cop
group
peopl
share
concern
passion
someth
learn
better
interact
regularli
studi
designmethod
pilot
project
junior
faculti
west
coast
institut
month
creat
minut
powerpoint
present
fundament
tm
topic
member
month
review
edit
therefor
member
creat
review
present
three
total
step
step
member
wrote
question
particular
topic
end
topic
would
quiz
question
assess
learn
complet
peer
review
present
would
avail
member
use
teach
patholog
resid
three
method
plan
measur
effect
materi
pre
abo
leader
exam
use
question
made
topic
assess
learn
pre
question
valid
examin
best
collabor
assess
learn
resid
examin
trend
specif
tm
resultsfind
six
present
develop
abo
leader
member
continu
particip
cop
tm
educ
abo
leader
best
result
shown
tabl
abo
leader
data
could
obtain
institut
b
traine
declin
particip
examin
institut
challeng
experienc
cop
includ
heterogen
resid
schedul
balanc
time
dedic
group
given
busi
schedul
difficulti
give
present
defin
teach
period
result
includ
assess
complet
conclus
despit
logist
organiz
challeng
feasibl
creat
multicent
cop
tm
educ
impact
group
resid
learn
assess
plan
growth
evalu
tabl
abo
leader
result
institut
tabl
best
result
institut
backgroundcas
studi
tradit
educ
curriculum
patholog
resid
program
primarili
base
didact
lectur
present
discuss
case
use
dramat
vignett
proven
effect
educ
tool
illustr
complex
multidisciplinari
topic
medicin
goal
use
evalu
relev
approach
resid
educ
studi
designmethod
clinic
vignett
base
placenta
accreta
case
written
patholog
resid
transfus
medicin
rotat
laboratori
manag
cours
resid
prepar
dramat
vignett
perform
focu
transfus
medicin
laboratori
manag
topic
resid
complet
question
topic
relat
vignett
sever
meet
review
adapt
script
topic
discuss
rehears
held
sever
commonli
encount
problem
deviat
standard
oper
procedur
resid
audienc
ask
identifi
prior
perform
skit
resid
present
least
one
major
transfus
manag
teach
point
resultsfind
educ
activ
includ
minut
vignett
perform
minut
discuss
complet
focu
commun
oper
room
blood
bank
surgeri
maximum
surgic
blood
order
schedul
test
transfus
safeti
inform
consent
massiv
transfus
protocol
emerg
releas
blood
product
thromboelastometri
interpret
patient
safeti
advers
event
root
caus
analysi
perform
significantli
improv
score
mean
compar
score
mean
ttest
p
vignett
discuss
resid
togeth
identifi
intend
answer
relat
question
resid
audienc
activ
particip
post
skit
discuss
report
satisfactori
learn
experi
conclus
dramat
clinic
vignett
illustr
multidisciplinari
complex
interact
pivot
import
daili
activ
profession
develop
patholog
resid
specif
structur
goal
clinic
dramat
vignett
use
complementari
educ
tool
illustr
challeng
topic
integr
way
enjoy
easi
understand
rememb
skit
perform
benefit
activ
prepar
extens
studi
topic
deliv
multifacet
coher
present
emphasi
integr
role
laboratori
transfus
medicin
patient
care
backgroundcas
studi
finnish
red
cross
blood
servic
frcb
nationwid
blood
servic
provid
finland
respons
collect
test
process
distribut
blood
product
hospit
health
care
provid
frcb
serv
nation
blood
group
refer
laboratori
provid
wide
rang
laboratori
servic
eg
test
hemostasi
tissu
type
possibl
donor
well
patient
wait
organ
stem
cell
transplant
frcb
also
perform
antenat
blood
group
rbc
antibodi
test
cover
whole
countri
sole
nation
oper
provid
educ
servic
ensur
safe
use
blood
product
well
accur
use
laboratori
servic
studi
designmethod
perform
custom
survey
healthcar
profession
assembl
need
educ
base
result
continu
feedback
frcb
provid
hospit
custom
blood
bank
clinic
follow
addit
servic
regular
educ
applic
transfus
medicin
handbook
blood
product
web
site
report
hospit
use
blood
product
annual
nation
blood
safeti
report
regular
element
educ
program
practic
problem
solv
cours
blood
bank
person
safe
transfus
train
day
clinician
everi
educ
collect
numer
feedback
follow
educ
respond
expect
util
knowledg
practic
also
inquir
like
would
recommend
train
colleg
indic
net
promot
score
np
resultsfind
healthcar
profession
particip
train
day
frcb
annual
addit
expert
give
ten
lectur
hospit
across
finland
feedback
educ
good
vari
rang
np
vari
accord
custom
survey
frcb
provid
appropri
educ
healthcar
profession
score
increas
conclus
feedback
np
score
survey
ensur
educ
train
program
frcb
respons
custom
need
hospit
util
annual
cours
frcb
initi
program
togeth
clinic
contact
person
hospit
aim
ensur
patient
blood
manag
pbm
optim
use
blood
product
also
plan
increas
applic
cours
transfus
medicin
nurs
medic
student
backgroundcas
studi
hemovigil
program
monitor
advers
event
transfus
depend
clinician
abil
recogn
report
reaction
blood
center
apheresi
platelet
donat
implic
septic
transfus
reaction
str
could
underestim
risk
difficulti
recogn
delay
mild
reaction
larg
blood
center
design
educ
outreach
program
increas
awar
str
assess
effect
rate
str
report
nation
hemovigil
program
studi
designmethod
dec
larg
blood
center
develop
web
base
cours
str
cmeceu
credit
letter
sent
hospit
custom
recogn
report
str
alert
avail
cours
blood
center
physician
staff
sale
market
also
engag
hospit
custom
directli
discuss
recogn
report
str
use
onlin
educ
content
physician
track
interact
blood
center
nation
hemovigil
program
compar
number
str
report
month
launch
educ
outreach
resultsfind
web
base
cours
complet
particip
physician
base
review
evalu
cours
highli
valu
particip
rate
excel
good
blood
center
physician
gave
present
hospit
custom
report
suspect
str
increas
compar
prior
year
increas
report
came
specif
region
total
number
str
met
hemovigil
definit
definit
probabl
str
nationwid
system
increas
chang
significantli
compar
previou
year
conclus
educ
initi
design
deliv
consist
messag
risk
recognit
report
str
number
report
suspect
str
two
region
increas
meaning
chang
overal
report
suspect
confirm
str
across
nation
blood
system
find
could
reflect
hospit
alreadi
recogn
report
medic
signific
reaction
target
audienc
laboratori
personnel
physician
transfus
medicin
clinician
closest
patient
care
bedsid
target
educ
effort
provid
personnel
interfac
hospit
could
use
address
identifi
profession
practic
gap
transfus
medicin
backgroundcas
studi
previou
cgmp
cours
develop
requir
minut
learner
complet
feedback
posit
manufactur
area
struggl
schedul
time
staff
complet
cours
within
assign
schedul
time
shift
design
trend
suggest
learn
effect
thalheim
util
minut
modul
deliv
regular
interv
chang
learn
process
singular
event
regular
interact
reinforc
learn
keep
content
top
learner
mind
studi
designmethod
began
develop
cgmp
select
first
five
seri
topic
equip
personnel
label
sop
record
first
topic
equip
divid
modul
select
valid
calibr
qualiti
control
mainten
modul
equip
seri
develop
assign
employe
job
use
learn
manag
system
assign
employe
june
new
equip
modul
assign
month
follow
five
month
seri
conclud
decemb
resultsfind
use
survey
assess
incid
report
evalu
train
effect
use
three
four
kirkpatrick
level
level
reaction
previou
cgmp
cours
receiv
good
rate
learner
equip
seri
receiv
highest
rate
scale
employe
complet
version
cgmp
cours
major
prefer
equip
seri
previou
cours
combin
comment
clearli
demonstr
learner
prefer
short
subscript
format
previou
cours
posit
neg
comment
level
learn
averag
score
user
increas
greatest
improv
note
score
laboratori
employe
determin
result
statist
signific
valu
valu
level
result
error
decreas
train
enough
data
demonstr
statist
signific
conclus
level
evalu
data
valid
subscript
approach
effect
knowledg
increas
learner
report
appreci
shorter
train
complet
modul
without
special
schedul
requir
result
continu
develop
remain
seri
backgroundcas
studi
interdisciplinari
natur
transfus
medicin
requir
collabor
multipl
work
unit
effici
patient
care
department
silo
imped
collabor
care
team
hypothes
regular
educ
meet
would
improv
knowledg
awar
depart
role
octob
multidisciplinari
educ
meet
call
friday
blood
confer
fbc
began
collabor
interprofession
forum
involv
frontlin
staff
transfus
practic
monthli
meet
also
broadcast
onlin
unabl
attend
person
present
differ
work
unit
share
background
inform
patient
case
open
floor
construct
discuss
studi
designmethod
survey
sent
fbc
particip
retrospect
captur
effect
fbc
interdepartment
collabor
survey
structur
obtain
form
feedback
use
publish
interprofession
collabor
practic
compet
icpc
guid
core
compet
target
maintain
climat
mutual
respect
commun
within
depart
foster
teamwork
understand
everyon
role
patient
care
resultsfind
survey
respons
rate
endors
fbc
creat
climat
respect
within
transfus
practic
believ
improv
commun
work
unit
feel
fbc
lead
increas
understand
interdepartment
process
notabl
laboratori
scientist
transfus
nurs
highest
attend
rate
furthermor
attend
via
onlin
broadcast
report
lowest
satisfact
respond
posit
main
reason
individu
attend
fbc
increas
knowledg
transfus
medicin
interact
learn
depart
hear
patient
case
studi
understand
big
pictur
one
role
patient
care
suggest
improv
includ
prepar
question
help
initi
discuss
increas
represent
area
broader
perspect
interdepartment
dialogu
post
record
fbc
later
view
conclus
applic
icpc
transfus
medicin
effect
len
assess
valu
interprofession
collabor
although
room
improv
result
support
fbc
contribut
better
commun
care
team
increas
understand
interdepartment
process
within
transfus
practic
backgroundcas
studi
transfus
medicin
essenti
element
educ
requir
futur
physician
variou
disciplin
like
surgeri
intern
medicin
anesthesiologist
work
effect
blood
bank
personnel
transfus
carri
consider
advantag
well
risk
consequ
educ
initi
requir
identifi
particular
knowledg
deficit
transfus
medicin
subsequ
bridg
gap
challeng
updat
undergradu
medic
curriculum
reflect
latest
enhanc
transfus
medicin
studi
designmethod
student
undergradu
semest
student
semest
particip
studi
learn
resourc
combin
modul
interact
instruct
implement
tbl
cours
design
five
educ
modul
focus
qualiti
manag
blood
collect
transfus
reaction
precis
util
blood
product
innov
compon
safeti
design
student
student
reaction
tbl
transfus
medicin
evalu
use
qualit
quantit
assess
tool
analyz
knowledg
attain
critic
think
develop
along
team
continu
particip
first
assess
readi
assur
test
rat
guarante
understood
concept
applic
follow
case
studi
base
test
question
resultsfind
student
reaction
tbl
primarili
posit
student
give
posit
feedback
evalu
readi
assur
test
rat
illustr
improv
team
knowledg
acquisit
implement
effect
qualiti
manag
system
knowledg
acquir
individu
studi
student
grasp
conceptu
knowledg
principl
transfus
medicin
achiev
confid
deal
complic
anecdot
student
significantli
attain
percept
blood
compon
prepar
storag
optim
util
along
develop
safeti
techniqu
blood
donat
conclus
studi
suggest
reform
medic
curricula
undergradu
medic
student
specif
educ
modul
design
focu
blood
bank
blood
transfus
principl
latest
advanc
transfus
medicin
much
requir
interest
patient
care
safeti
futur
physician
tbl
interest
effici
way
deliv
key
aspect
transfus
medicin
student
backgroundcas
studi
despit
interact
countless
hospit
employe
depart
blood
bank
bb
natur
facil
presenc
irradi
requisit
associ
secur
measur
make
bb
even
unwelcom
place
attempt
make
hospit
commun
familiar
bb
transfus
medicin
hospit
commun
welcom
seri
bb
open
hous
studi
designmethod
bb
open
hous
advertis
hospit
intranet
webpag
blood
donor
hospit
blood
donor
center
invit
via
email
bb
open
hous
surgeri
anesthesia
depart
invit
via
email
second
third
bb
open
hous
clinic
laboratori
staff
invit
via
email
bb
open
hous
third
bb
open
hous
occur
conjunct
medic
laboratori
profession
week
resultsfind
open
hous
attende
given
tour
bb
led
bb
attend
bb
resid
bb
supervisor
bb
qualiti
coordin
patient
blood
manag
nurs
also
attend
answer
attende
question
educ
patient
blood
manag
light
refresh
offer
attende
bb
break
room
first
bb
open
hous
held
wednesday
attende
includ
medic
student
four
regular
blood
donor
hospit
blood
donor
center
also
employe
facil
manag
univers
offic
admiss
respect
hospit
senior
six
apheresi
nurs
two
clinic
laboratori
staff
two
medic
laboratori
scienc
student
one
addit
staff
member
univers
offic
admiss
second
bb
open
hous
held
thursday
attende
includ
regular
blood
donor
also
employe
offic
intern
affair
suppli
chain
respect
hematologyoncolog
fellow
surgic
resid
third
bb
open
hous
held
thursday
attende
includ
regular
blood
donor
also
employe
risk
manag
wound
care
univers
administr
cancer
center
clinic
researchclin
trial
perform
improv
electron
medic
record
respect
addit
wound
care
nurs
technologist
microbiologyimmunolog
two
addit
individu
clinic
researchclin
trial
two
minor
children
particip
take
child
work
day
conclus
bb
open
hous
allow
individu
differ
depart
background
familiar
bb
transfus
medicin
bb
open
hous
facilit
collabor
foster
relationship
hospit
depart
improv
understand
goe
behind
close
door
bb
backgroundcas
studi
simpl
partial
exchang
transfus
routin
perform
patient
diseas
scd
goal
increas
oxygen
carri
capac
blood
reduc
rel
percentag
sickl
cell
essenti
clinician
abl
rapidli
estim
effect
avail
therapeut
modal
use
clinic
inform
minim
risk
red
blood
cell
exposur
given
formula
calcul
complic
develop
valid
onlin
calcul
assist
physician
task
studi
designmethod
web
applic
gener
http
wwwphamcalcscom
perform
simpl
transfus
partial
manual
exchang
calcul
valid
compar
predict
clinic
data
perform
autom
deplet
rbcx
calcul
valid
use
terumo
bct
lakewood
co
calcul
fraction
cell
remain
fcr
patient
fcr
may
benefit
delay
procedur
perform
futur
valid
process
includ
deme
regress
global
assess
predict
vs
actual
result
individu
comparison
wherein
valid
conting
result
expect
result
demonstr
valid
perform
hematocrit
hct
hemoglobin
hgb
level
simpl
partial
manual
exchang
volum
replac
fluid
autom
deplet
rbc
exchang
resultsfind
see
tabl
valid
result
conclus
http
phamcalcscom
allow
perform
complic
calcul
wifi
access
locat
formula
rigor
valid
formula
autom
deplet
rbcx
perform
well
compar
expect
result
deme
regress
detect
small
degre
bia
volum
red
blood
cell
calcul
autom
exchang
replac
deplet
rbcx
howev
deviat
minut
formula
partial
simpl
transfus
demonstr
detect
bia
via
deme
regress
howev
result
valid
anticip
result
calcul
slightli
underestim
post
therapeut
hct
hgb
potenti
sourc
error
includ
variabl
hct
transfus
unit
inaccur
patient
weight
paramet
backgroundcas
studi
focu
new
technolog
modern
medicin
requir
expens
despit
increas
target
impact
patient
still
risk
advers
reaction
medic
treatment
issu
current
discuss
use
standard
person
approach
doctor
multidisciplinari
narrow
special
integr
new
technolog
need
train
result
knowledg
defici
russia
develop
insur
medicin
creat
demand
intens
treatment
program
multidisciplinari
approach
pbm
optim
transfus
practic
reduc
risk
advers
effect
improv
financi
perform
health
care
institut
howev
prosper
implement
pbm
also
requir
supplement
medic
compet
provid
harmon
dialogu
logist
administr
clinician
transfusiologist
studi
designmethod
medic
simul
centr
hospit
uniqu
opportun
launch
educ
program
medic
specialist
practic
blood
compon
transfus
main
innov
featur
train
cours
interdisciplinari
approach
intens
learn
perform
comprehens
learn
method
day
academ
hour
traine
attend
lectur
discuss
method
materi
particip
seminar
interact
clinic
discuss
master
class
game
present
model
work
process
sinc
initi
project
june
group
capac
peopl
number
medic
specialist
attend
train
nearli
resultsfind
medic
compet
gain
knowledg
modern
recommend
use
blood
componentsth
abil
interpretal
paramet
haemogram
coagulogram
tromboelastogramth
abil
unveil
indic
contraind
urgent
schedul
blood
compon
transfusionperson
blood
transfus
risksus
person
approach
select
type
dose
transfus
habitatpredict
efficaci
transfusionth
correct
anemia
hemostasi
system
malfunct
use
medicin
treatmentperform
macroscop
assess
blood
compon
transfus
procedureperform
differenti
diagnost
abil
prescrib
advers
effect
treatment
carri
auditori
check
health
card
conclus
launch
program
guidanc
safe
effect
blood
use
adult
patient
hospit
aim
meet
educ
profession
need
medic
specialist
develop
algorithm
think
rang
use
motiv
case
patient
blood
manag
reach
complianc
practic
backgroundcas
studi
teamwork
composur
essenti
technologist
deal
emerg
situat
larg
blood
bank
multipl
situat
occur
simultan
effort
reduc
error
improv
emerg
respons
group
form
evalu
effect
emerg
situat
drill
esd
esd
base
common
emerg
situat
encount
lab
run
per
month
per
shift
main
goal
esd
improv
teamwork
comfort
level
real
emerg
situat
therefor
reduc
amount
unplan
standard
oper
procedur
sop
deviat
studi
designmethod
prior
esd
implement
survey
sent
technologist
determin
baselin
comfort
level
associ
variou
emerg
situat
one
year
post
esd
implement
survey
sent
technologist
reassess
comfort
level
situat
survey
ask
employe
rate
satisfact
comfort
level
grade
scale
least
satisfiedcomfort
satisfiedcomfort
pre
post
survey
result
evalu
calcul
lab
averag
comfort
level
per
situat
survey
addit
unplan
sop
deviat
relat
emerg
situat
count
one
year
one
year
esd
implement
resultsfind
total
technologist
technologist
took
pre
esd
survey
technologist
took
one
year
post
esd
implement
survey
tabl
show
lab
averag
pre
post
survey
well
percent
differ
employe
respond
post
survey
answer
true
statement
esd
improv
comfort
level
emerg
situat
year
prior
esd
implement
unplan
sop
deviat
year
esd
implement
deviat
tabl
averag
esd
survey
result
lab
staff
comfort
level
conclus
one
area
increas
comfort
level
post
esd
implement
also
technologist
agre
esd
help
improv
overal
comfort
level
emerg
situat
goal
implement
esd
met
base
unplan
sop
deviat
decreas
technologist
satisfact
increas
therefor
esd
deem
effect
monthli
esd
continu
run
hope
continu
improv
teamwork
comfort
level
deviat
level
backgroundcas
studi
categori
indic
red
blood
cell
exchang
rbc
exchang
children
sickl
cell
diseas
includ
follow
acut
stroke
stroke
prophylaxi
well
iron
overload
prevent
describ
first
instal
seri
therapeut
plasma
exchang
tpe
challeng
access
volum
manag
instrument
persist
along
need
address
psycholog
emot
well
popul
rbc
exchang
complic
procedur
explain
adult
becom
even
intimid
task
translat
languag
childhood
nevertheless
educ
shown
decreas
anxieti
associ
medic
care
provid
age
appropri
specif
treatment
inform
pediatr
patient
decreas
neg
behavior
reduc
stress
promot
faster
recoveri
previou
project
explain
tpe
pediatr
popul
reveal
lack
age
specif
literatur
apheresi
procedur
gener
includ
tpe
rbc
exchang
studi
designmethod
collabor
child
life
specialist
explan
rbc
exchang
procedur
adapt
previous
implement
project
relat
tpe
artwork
produc
aid
medic
illustr
complement
resultsfind
stori
board
address
rbc
exchang
perform
step
involv
prepar
perform
procedur
strategi
cope
procedur
idea
therapi
also
briefli
address
prepar
children
concept
ongo
therapi
booklet
product
concert
hospit
medic
illustr
avail
hospit
websit
patient
use
conclus
use
previous
illustr
stori
guid
explan
red
cell
exchang
creat
provid
educ
reduc
anxieti
second
instal
continu
pediatr
seri
help
explain
apheresi
procedur
pediatr
popul
hope
reduc
patient
stress
promot
age
appropri
cope
strategi
backgroundcas
studi
report
royal
commiss
inquiri
blood
system
canada
releas
novemb
result
role
transfus
safeti
offic
tso
establish
enhanc
safeti
qualiti
blood
transfus
canada
tso
fundament
role
improv
patient
safeti
aspect
transfus
practic
posit
come
sever
respons
encompass
follow
area
technic
clinic
util
manag
qualiti
risk
profession
educ
research
guid
assist
healthcar
profession
transit
role
tso
advantag
howev
limit
resourc
date
studi
designmethod
clinic
project
safeti
nurs
provinci
blood
coordin
network
visit
variou
larg
healthcar
institut
inform
collect
observ
discuss
tso
daili
activ
respons
tso
institut
identifi
minim
guidanc
limit
resourc
assist
transit
role
acknowledg
tso
might
come
divers
background
healthcar
could
contribut
limit
understand
clinic
technic
terminolog
gap
commun
experienc
tso
six
larg
provinci
healthcar
institut
close
involv
develop
resourc
resultsfind
resourc
manual
deliv
detail
inform
regard
role
respons
tso
expect
time
commit
resourc
provid
inform
follow
tso
job
descriptionabbrevi
glossari
termscommitte
organizationsus
linksinvestig
report
transfus
reactionsrecallswithdrawalsproduct
administr
guidelin
monograph
equip
use
infus
blood
conclus
resourc
manual
develop
refer
guid
medic
laboratori
technologist
regist
nurs
healthcar
profession
appoint
tso
role
also
intend
util
hospit
formal
tso
posit
deleg
respons
staff
resourc
provid
help
inform
assist
educ
transfus
safeti
advers
event
investig
report
product
administr
guidelin
monograph
link
inform
equip
use
infus
blood
resourc
manual
serv
use
refer
tool
assist
healthcar
profession
transit
tso
role
backgroundcas
studi
critic
aspect
implement
new
method
manufactur
blood
product
develop
train
plan
adequ
prepar
staff
nt
interfer
product
caus
delay
patient
care
implement
pathogen
reduct
technolog
prt
use
blood
system
platelet
understood
would
need
collect
make
loss
product
specif
tripl
collect
institut
collect
major
blood
product
supplement
inventori
major
blood
collect
center
crucial
compon
laboratori
maintain
daili
process
level
learn
new
method
order
sustain
optim
platelet
inventori
level
without
reli
purchas
addit
platelet
extern
vendor
approach
introduc
prt
apheresi
platelet
flip
switch
process
product
new
method
rather
step
wise
roll
dual
inventori
studi
designmethod
essenti
priorit
would
train
first
collect
occur
monday
friday
first
group
train
would
perform
train
two
person
team
product
valid
train
ceru
deploy
team
second
group
would
process
platelet
weekend
even
hour
without
direct
manag
support
last
group
technologist
would
work
normal
hour
direct
manag
support
prt
process
platelet
plasma
broken
two
day
day
platelet
treat
amotosalen
place
compound
adsorpt
devic
remov
residu
amotosalen
hour
day
product
remov
cad
modifi
final
product
code
label
technologist
train
one
one
one
week
period
trainer
altern
train
process
day
day
day
week
follow
train
import
technologist
rotat
back
thru
prt
process
maintain
profici
resultsfind
employe
train
two
month
time
period
prior
flip
switch
daili
averag
product
collect
two
month
train
period
daili
averag
rose
conclus
flip
switch
train
plan
implement
prt
platelet
plasma
highli
success
laboratori
train
implement
new
technolog
creat
process
imper
priorit
would
train
first
insur
complet
coverag
hour
shift
technologist
abl
becom
profici
new
process
maintain
daili
process
expect
sustain
optim
platelet
inventori
backgroundcas
studi
massiv
transfus
protocol
mtp
implement
wide
indic
trauma
rapid
consist
respons
transfus
servic
ts
staff
mtp
order
essenti
use
combin
simul
involv
icu
ts
staff
simpl
drill
improv
mtp
train
effect
improv
ts
respons
mtp
activ
studi
designmethod
ts
staff
train
mtp
sop
checklist
prior
studi
period
mock
code
simul
incorpor
mtp
scenario
perform
icu
nurs
physician
drill
consist
gener
mtp
order
test
patient
ts
technologist
particip
least
one
drill
technologist
awar
gener
timefram
plan
drill
actual
start
time
simul
unit
prepar
photocopi
actual
product
order
issu
time
record
part
real
drill
procedur
uncrossmatch
rbc
product
plt
issu
manual
icu
simul
photocopi
unit
deliv
pneumat
tube
time
minut
measur
initi
mtp
order
issu
first
rbc
unit
first
unit
plasma
platelet
goal
time
min
rbc
plt
min
ffp
deviat
sop
identifi
staff
coach
part
debrief
resultsfind
ts
without
icu
staff
conduct
drillssimul
measur
perform
actual
mtp
jan
dec
total
mtp
baselin
ts
met
goal
time
issu
product
mtp
activ
drill
rbc
ffp
plt
follow
ts
met
goal
issu
time
activ
rbc
ffp
time
plt
rbc
median
time
order
receipt
issu
improv
rang
min
baselin
rang
min
follow
median
issu
time
plt
improv
min
baselin
min
follow
median
time
issu
ffp
chang
baselin
follow
rang
issu
time
smaller
median
issu
time
min
baselin
rang
min
min
follow
rang
min
tabl
mtp
activ
meet
goal
order
issu
time
product
type
conclus
audit
ts
mtp
perform
time
activ
issu
first
product
show
improv
need
icu
simul
mtp
drill
improv
ts
respons
time
rbc
plt
issu
improv
consist
perform
mtp
situat
improv
ffp
issu
time
may
possibl
unless
polici
maintain
thaw
plasma
mtp
implement
simpl
mtp
drill
incorpor
ts
train
compet
assess
backgroundcas
studi
million
jehovah
wit
jw
present
throughout
world
nearli
million
resid
within
unit
state
due
belief
patient
abstain
receiv
major
blood
fraction
mabf
minor
blood
fraction
mibf
may
accept
depend
individu
conscienc
due
uniqu
medic
challeng
import
caretak
understand
belief
order
provid
optim
care
describ
process
identifi
jw
hospit
commun
treatment
need
staff
studi
designmethod
proper
treatment
jw
requir
abil
identifi
patient
hisher
need
jw
admit
hospit
electron
medic
record
emr
trigger
sever
process
base
patient
list
religion
one
process
creat
order
remind
caretak
complet
declin
blood
consent
dbc
patient
dbc
contain
languag
declin
mabf
review
mibf
patient
identifi
would
accept
emr
order
regard
dbc
provid
educ
link
includ
bloodless
polici
instruct
obtain
dbc
inform
altern
transfus
second
emr
process
trigger
prevent
complet
mabf
order
mibf
order
product
patient
declin
third
enrol
patient
minim
blood
volum
lab
protocol
use
microtain
vacutain
blood
reservoir
set
reduc
blood
loss
draw
addit
registr
bloodless
packet
ad
patient
paper
chart
packet
contain
dbc
glossari
dbc
term
bloodless
sign
place
patient
bed
bloodless
wristband
worn
patient
two
bloodless
chart
sticker
ad
outsid
chart
step
remind
caretak
patient
special
request
final
patient
blood
manag
pbm
depart
receiv
emr
develop
report
identifi
jw
present
hospit
patient
follow
pbm
nurs
medic
director
durat
care
treatment
plan
optim
hemoglobin
oxygen
carri
capac
hemostasi
discuss
bedsid
caretak
implement
need
resultsfind
nearli
jw
enter
hospit
dbc
complet
result
increas
educ
medic
staff
addit
patient
report
better
commun
caretak
lead
invit
environ
patient
conclus
hospit
found
success
use
approach
involv
emr
pbm
caretak
care
jw
patient
approach
set
foundat
treat
bloodless
medicin
patient
backgroundcas
studi
transfus
servic
provid
safe
blood
compon
vein
vein
donor
act
supplier
patient
final
custom
process
involv
activ
critic
materi
human
resourc
facil
highli
coordin
process
cost
manag
great
impact
technic
process
guid
decis
upon
suppli
technic
staff
cost
abc
method
determin
cost
driver
within
activ
determin
process
product
final
cost
allow
manag
take
precis
decis
demonstr
effect
abc
approach
result
financi
save
without
compromis
process
qualiti
transfus
servic
studi
designmethod
materi
cost
repres
far
activ
central
storag
suppli
satellit
storag
depart
replac
done
independ
residu
stock
purchas
perform
demand
end
perform
suppli
inventori
depart
plan
futur
purchas
control
residu
stock
implement
annual
purchas
satellit
storag
suppli
replenish
program
stock
cost
driver
defin
upon
activ
standard
oper
procedur
sop
result
cost
estim
technic
staff
involv
cost
driver
calcul
indic
possibl
chang
sop
supplier
deliveri
minim
season
fluctuat
compar
last
quarter
last
quarter
work
present
activ
data
blood
collect
illustr
abc
method
resultsfind
blood
bag
use
compar
demonstr
activ
price
negoti
result
readjust
indic
estim
cost
possibl
impact
us
identifi
real
cost
repres
overal
us
r
save
conclus
economi
deterior
countri
higher
inflat
exchang
rate
variat
directli
impact
import
materi
critic
even
advers
economi
abc
show
effect
tool
allow
cost
decreas
without
signific
chang
critic
materi
process
cost
driver
calcul
demand
review
sop
supplier
technic
staff
result
optim
activ
also
staff
involv
reduc
discharg
materi
sinc
cost
area
supervisor
satellit
stock
review
briefli
titl
autom
verif
immunohematolog
result
impact
donor
test
backgroundcas
studi
staf
challeng
today
blood
bank
requir
instrument
minim
oper
intervent
technolog
advanc
develop
everi
immunohematolog
result
necessarili
requir
oper
visual
review
studi
evalu
impact
autom
result
verif
immunohematolog
system
data
manag
system
dm
donor
process
laboratori
studi
designmethod
studi
perform
donor
sampl
shown
tabl
evalu
two
commonli
use
gel
card
avail
us
workflow
data
analyz
use
process
modellar
app
ipad
studi
focus
step
result
verif
evalu
without
autom
result
verif
determin
impact
qualiti
oper
touchpoint
visual
result
review
occurr
result
accuraci
speed
time
result
interpret
li
data
transfer
oper
touchpoint
phase
requir
visual
result
verif
softwar
defin
speed
metric
analyz
use
minitab
statist
signific
access
use
pair
p
valu
consid
signific
resultsfind
use
automat
result
verif
option
sampl
evalu
aborh
test
would
requir
visual
verif
oper
would
result
reduct
oper
touchpoint
test
phase
p
labor
save
minut
hh
mm
aborh
test
pool
antibodi
screen
ab
autom
verif
result
would
result
reduct
oper
touchpoint
test
phase
p
labor
save
minut
hh
mm
aborh
ab
misinterpret
occur
result
automat
verifi
tabl
conclus
studi
demonstr
option
dm
result
signific
reduct
amount
oper
time
touchpoint
routin
pool
ab
aborh
test
impact
accuraci
result
donor
environ
backgroundcas
studi
ongo
challeng
recruit
qualifi
medic
technologist
transfus
medicin
often
stretch
capac
transfus
servic
tsv
meet
patient
care
need
expect
clinician
autom
tsv
posit
impact
counterbal
challeng
previou
gener
autom
instrument
impact
allevi
certain
amount
workload
labor
intens
studi
evalu
potenti
impact
newer
instrument
ortho
vs
compar
current
state
instrument
immucor
ec
autom
test
done
current
type
screen
ts
averag
ts
per
day
stat
ts
may
may
autom
depend
instrument
statu
test
profil
complet
manual
tube
studi
designmethod
studi
conduct
phase
use
current
state
cs
futur
state
fs
approach
direct
observ
process
employ
time
studi
use
compar
workflow
util
instrument
evalu
consist
achiev
use
least
observ
process
result
averag
metric
evalu
cycl
time
ct
min
sec
manual
labor
instrument
time
turnaround
time
tat
consum
wast
resultsfind
cs
time
test
follow
manual
stat
ts
abid
patient
aborh
neonat
type
cord
blood
cb
titrat
tt
major
measur
time
manual
test
labor
vigil
time
requir
technologist
presenc
attent
wast
gener
ec
equat
solid
phase
strip
test
avoid
wast
hold
sampl
process
observ
case
result
longer
tat
often
stat
ts
direct
manual
workbench
avoid
issu
fs
vs
autom
process
ts
aborh
abid
cb
tt
laboratori
achiev
improv
labor
time
improv
ct
ct
ts
abid
patient
aborh
cb
tt
total
tat
ts
often
shorter
vs
sampl
held
ec
test
avoid
wast
averag
stat
ts
vs
result
improv
tat
stat
tat
complianc
respect
autom
abid
test
provid
labor
improv
minut
walkaway
time
manual
abid
allow
focu
critic
tsv
activ
autom
cb
tt
deliv
addit
labor
reduct
overal
labor
hour
recov
move
fs
conclus
base
gain
labor
reduct
deliv
vision
tsv
modifi
cs
workflow
process
util
echo
system
deliv
improv
tat
adequ
staff
time
resourc
challeng
backgroundcas
studi
california
seismic
law
recent
necessit
build
new
hospit
replac
one
two
exist
facil
longer
met
current
earthquak
standard
august
outdat
facil
merg
onto
site
hospit
form
singl
larger
campu
new
electron
health
record
ehr
system
activ
day
new
campu
design
maintain
store
paper
record
prepar
bridg
cultur
two
separ
facil
train
staff
new
work
environ
use
new
ehr
began
studi
examin
impact
transfus
servic
staff
prepar
variou
workflow
chang
associ
implement
new
ehr
integr
patient
workflow
new
locat
studi
designmethod
order
ensur
effect
transit
implement
transfus
servic
develop
train
modul
tailor
use
new
blood
order
modul
bom
within
ehr
bom
requir
order
one
testingproduct
transfus
order
repres
new
workflow
affect
nurs
physician
transfus
team
collabor
multipl
user
group
educ
regard
new
process
gap
analysi
perform
determin
optim
deliveri
process
blood
product
key
stakehold
invit
review
option
use
pneumat
tube
system
deliv
blood
throughout
entir
campu
investig
determin
whether
would
viabl
option
given
expand
size
new
campu
resultsfind
user
group
request
addit
train
session
question
aros
regard
use
ehr
blood
order
pneumat
tube
system
would
heavili
use
due
concern
blood
product
could
becom
lost
decid
would
best
rout
deliveri
blood
depart
educ
request
support
creat
job
aid
specif
workflow
chang
impact
depart
order
rh
immun
globulin
cord
blood
workup
etc
conclus
leadership
challeng
provid
stabl
posit
environ
complex
set
chang
simultan
hospit
movemerg
implement
new
ehr
constitut
arduou
task
would
possibl
substanti
prepar
initi
year
advanc
train
essenti
success
scope
chang
big
minim
train
thorough
prior
move
gap
nonetheless
discov
follow
move
backgroundcas
studi
million
live
save
year
blood
transfus
global
howev
develop
countri
includ
ethiopia
peopl
still
die
due
inadequ
suppli
blood
product
sinc
year
govern
usa
grant
call
cdc
blood
safeti
project
sole
develop
partner
organ
support
bt
ethiopia
assess
impact
partner
support
govern
commit
level
toward
establish
sustain
safe
blood
servic
program
major
input
continu
health
care
deliveri
ethiopia
studi
designmethod
retrospect
analysi
us
govern
cdc
blood
safeti
grant
award
project
period
review
ethiopian
govern
gm
nation
blood
donor
databas
record
cover
review
new
blood
servic
strategi
implement
statu
also
made
understand
impact
grant
govern
commit
level
resultsfind
grant
project
period
cover
analysi
reveal
first
project
period
found
challeng
govern
underutil
poor
gm
delay
grant
budget
releas
review
second
project
period
highlight
grant
level
increas
usd
usd
per
annum
follow
good
perform
proper
fund
util
rate
govern
review
new
strategi
implement
statu
indic
increas
govern
commit
level
initi
develop
new
strategi
full
revers
blood
servic
administr
red
cross
societi
govern
health
care
system
made
fund
agent
support
focus
govern
new
strategi
implement
identifi
impact
nation
blood
servic
establish
nation
coordin
bt
independ
govern
budget
institut
initi
year
budgetalloc
million
usd
construct
new
standard
non
hospit
base
blood
bank
center
furnish
standard
equip
train
man
power
procur
new
mini
collect
van
enabl
increas
mobil
blood
collect
team
mobil
site
number
hospit
util
safe
blood
year
round
awar
creation
effort
total
annual
blood
donat
trend
analysi
also
show
increas
donat
increas
proport
voluntari
donat
respect
conclus
strateg
develop
partner
fund
support
base
newli
develop
govern
strategi
blood
servic
commit
govern
brought
posit
impact
establish
sustain
safe
nation
blood
servic
program
ethiopia
even
though
identifi
posit
impact
mention
achiev
bt
remain
multipl
challeng
need
continu
fund
partner
support
govern
commit
backgroundcas
studi
nation
blood
servic
zimbabw
nbsz
introduc
first
perform
manag
system
pm
nbsz
strateg
plan
note
current
pm
lack
objectiviteti
relationship
perfom
remuner
order
revis
pm
nbsz
set
three
member
committe
execut
manag
level
spearhead
revamp
nbsz
pm
aim
new
pm
achiev
share
vision
purpos
object
organ
help
staff
member
understand
recogn
contribut
strateg
plan
paper
share
nbsz
revamp
implement
new
hybrid
pm
deriv
input
establish
pmss
nbsz
monitor
evalu
e
process
link
togeth
department
result
one
quarter
share
demonstr
system
work
studi
designmethod
pm
committe
develop
share
execut
manag
pm
conceptu
implement
framework
consult
includ
field
visit
done
three
establish
pm
assess
suitabl
nbsz
adopt
hybrid
pm
adopt
nbsz
pilot
applic
one
quarter
select
depart
done
review
polici
procedur
includ
hybrid
pm
templat
form
done
pm
committe
train
staff
implement
integr
scorecard
conduct
apprais
develop
scorecard
measur
perform
use
new
pm
weight
perform
reward
system
base
layer
perform
bonu
payment
work
use
standardis
tool
throughout
process
risk
assess
done
resultsfind
nbsz
hybrid
pm
base
five
level
plan
name
strateg
department
branch
section
individu
traffic
light
report
system
central
uniformli
assess
perform
level
level
account
properli
defin
level
plan
weight
overal
integr
individu
scorecard
ii
determin
base
individu
four
level
bonu
calcul
base
ii
follow
categori
ii
categori
b
ii
categori
c
ii
categori
ii
pilot
implement
individu
score
staff
rang
ii
number
staff
bonu
categori
categori
categori
b
conclus
new
hybrid
pm
gener
accept
staff
easili
implement
variou
staff
level
provid
basi
full
implement
new
pm
simplifi
pm
easili
adapt
similar
set
ensur
staff
contribut
suffici
object
realis
organis
strateg
vision
backgroundcas
studi
rare
donor
defin
blood
type
occur
less
peopl
given
popul
donor
discov
test
new
donor
random
target
way
requir
test
mani
donor
find
one
rare
donor
found
facil
member
american
rare
donor
program
aabb
accredit
american
red
cross
accredit
irl
donor
regist
ardp
databas
rare
donor
activ
rare
donor
ardp
mobil
popul
usa
import
donor
reloc
recogn
rare
donor
donat
unit
identifi
use
patient
rare
blood
need
addit
recruit
need
patient
need
correct
contact
inform
donor
requir
studi
designmethod
ardp
procedur
ardp
member
requir
donor
contact
everi
six
month
ensur
ardp
facil
latest
contact
inform
time
determin
postal
servic
time
limit
six
month
forward
mail
new
address
contact
ensur
recruit
requir
obtain
blood
patient
rare
blood
need
donor
contact
collect
center
donat
contact
achiev
ardp
send
contact
card
postal
mail
twice
yearli
donor
ardp
address
demograph
resultsfind
ardp
report
inform
obtain
contact
card
return
ardp
annual
activ
report
ardp
member
aabb
annual
meet
total
activ
donor
return
contact
card
alert
ardp
chang
calendar
year
donor
move
one
ardp
facil
anoth
donor
longer
elig
donat
addit
address
chang
chang
reactiv
donor
donor
notifi
deceas
want
list
ardp
new
rare
donor
submit
ardp
registr
number
donor
could
potenti
lost
would
new
donor
submit
conclus
nearli
respons
rate
donor
receiv
mail
contact
card
clear
rare
donor
famili
respons
ardp
contact
card
inform
ardp
address
chang
chang
health
statu
affect
abil
donat
evid
import
card
ensur
correct
donor
contact
inform
donor
chang
address
often
known
collect
facil
donor
donat
move
ardp
contact
card
effect
retain
relationship
ardp
regist
donor
keep
address
inform
rare
donor
current
backgroundcas
studi
workflow
studi
becom
popular
analyz
choic
capabl
vari
market
purpos
studi
evalu
provu
ortho
clinic
diagnost
laboratori
inc
larg
volum
transfus
servic
use
lean
process
flow
studi
designmethod
run
one
six
sampl
per
run
observ
two
ortho
provu
altern
test
larg
transfus
servic
perform
type
screen
type
screen
annual
workflow
pattern
observ
repeat
compar
process
map
detail
direct
observ
use
process
modellar
app
ipad
evalu
start
sampl
centrifug
complet
end
result
sent
analyz
li
lab
inform
system
evalu
qualiti
test
process
step
biohazard
exposur
episod
mainten
task
speed
operatoranalyz
time
cost
testingmainten
personnel
hour
recaptur
time
studi
analyz
use
minitab
statist
signific
assess
use
pair
p
valu
consid
signific
resultsfind
detail
process
step
biohazard
exposur
episod
publish
analyz
mainten
task
evaluatedcompar
tabl
part
time
studi
focus
oper
test
time
analyz
time
oper
mainten
time
tabl
part
b
regardless
qualiti
speed
metric
evalu
demonstr
signific
reduct
improv
process
step
associ
time
compar
ortho
provu
p
process
step
time
studi
address
tabl
account
reagent
storag
capac
realiti
improv
would
greater
display
oper
evalu
total
number
mainten
task
requir
annual
well
time
associ
mainten
perform
signific
reduct
reduct
differ
hoursyear
conclus
studi
verifi
provid
signific
effici
cost
avoid
ortho
provu
larg
volum
transfus
servic
tabl
result
backgroundcas
studi
workflow
studi
perform
high
volum
high
throughput
blood
bank
analyz
larg
volum
test
facil
purpos
studi
evalu
neo
immucor
laboratori
inc
use
lean
process
flow
studi
designmethod
total
separ
test
run
sampl
per
run
observ
three
day
period
galileo
neo
refer
laboratori
annual
perform
approxim
type
screen
workflow
pattern
observ
repeat
compar
process
map
detail
direct
observ
use
process
modellar
app
ipad
evalu
start
sampl
centrifug
complet
test
area
end
result
sent
analyz
li
lab
inform
system
evalu
qualiti
process
step
biohazard
exposur
speed
operatoranalyz
time
cost
testingmainten
personnel
hour
recaptur
time
studi
analyz
use
minitab
statist
signific
assess
use
pair
p
valu
consid
signific
resultsfind
detail
process
step
biohazard
exposur
publish
analyz
mainten
task
evaluatedcompar
tabl
part
time
studi
focus
oper
time
analyz
time
mainten
time
tabl
part
b
regardless
qualiti
speed
metric
evalu
demonstr
signific
reduct
improv
process
step
associ
time
compar
galileo
neo
p
evalu
total
number
mainten
task
requir
annual
well
time
associ
mainten
perform
downtim
significantli
reduc
differ
hoursyear
conclus
studi
verifi
provid
signific
effici
cost
avoid
galileo
neo
high
volumehigh
throughput
test
facil
tabl
result
backgroundcas
studi
immunohematolog
facil
face
mani
challeng
includ
standard
process
control
product
staf
patient
safeti
allevi
challeng
instrument
complementari
data
manag
system
dm
design
provid
lean
autom
enhanc
blood
test
facil
workflow
purpos
studi
focu
lean
function
autom
result
verif
dm
determin
impact
workflow
studi
designmethod
intern
extern
studi
use
dm
perform
patient
donor
sampl
assay
includ
aborh
blood
group
antibodi
screen
ab
shown
tabl
workflow
data
analyz
use
process
modellar
app
ipad
evalu
focus
step
result
verif
evalu
without
autom
result
verif
determin
impact
qualiti
oper
touchpoint
visual
result
review
occurr
result
accuraci
speed
time
result
interpret
li
data
transfer
oper
touchpoint
phase
requir
visual
result
verif
softwar
defin
speed
metric
analyz
use
minitab
statist
signific
assess
use
pair
p
valu
consid
signific
tabl
resultsfind
use
autom
result
verif
sampl
evalu
aborh
test
would
requir
visual
verif
result
reduct
oper
touchpoint
p
labor
save
minut
hh
mm
aborh
test
antibodi
screen
automat
valid
result
would
result
reduct
oper
touchpoint
p
labor
save
minut
hh
mm
fals
posit
fals
neg
type
result
fals
neg
screen
occur
result
conclus
studi
demonstr
lean
oper
workflow
improv
achiev
dm
featur
employ
option
result
signific
reduct
oper
touchpoint
oper
time
risk
patient
safeti
backgroundcas
studi
demand
rh
neg
neg
red
blood
cell
rbc
remain
fact
proport
increas
blood
usag
notabl
declin
era
patient
blood
manag
past
year
steadi
increas
demand
neg
rbc
compar
blood
type
observ
blood
center
util
metric
hospit
custom
monitor
monthli
overal
trend
forecast
data
share
regular
visit
despit
heighten
awar
percent
neg
rbc
sale
continu
rise
annual
peak
mid
better
understand
increas
demand
survey
conduct
gather
insight
improv
util
specul
survey
observ
effect
chang
staff
behavior
would
result
reduct
neg
rbc
sale
studi
designmethod
tie
tag
design
survey
tool
attach
neg
rbc
distribut
hospit
custom
period
late
hospit
transfus
servic
staff
ask
record
final
disposit
neg
rbc
transfus
wast
return
tie
tag
inform
survey
object
instruct
tie
tag
complet
commun
via
custom
meet
email
remind
sent
blood
center
driver
complet
tag
return
blood
center
custom
allow
return
rbc
unit
greater
day
shelf
life
remain
unit
tie
tag
attach
hospit
inventori
month
due
shelf
life
rbc
return
rate
percent
net
sale
gross
sale
minu
return
aborh
type
track
monthli
survey
resultsfind
particip
hospit
survey
mean
percent
neg
rbc
gross
sale
month
period
survey
respect
mean
percent
neg
net
sale
survey
fell
compar
averag
month
prior
survey
period
neg
rbc
monthli
return
rate
increas
averag
compar
averag
month
prior
month
survey
averag
neg
rbc
return
rate
increas
mean
percent
neg
rbc
net
sale
trend
slightli
upward
custom
hospit
queri
whether
process
chang
occur
major
chang
polici
inventori
level
report
conclus
survey
percent
neg
rbc
gross
sale
fairli
constant
indic
target
inventori
level
transfus
servic
staff
order
practic
remain
unchang
howev
period
increas
neg
rbc
return
rate
correspond
declin
percent
net
sale
suggest
improv
neg
rbc
util
increas
awar
particip
survey
staff
know
observ
like
play
role
lower
percent
neg
rbc
net
sale
track
monthli
metric
provid
ongo
review
determin
effect
transient
sustain
identifi
opportun
improv
neg
rbc
util
backgroundcas
studi
platelet
activ
unwant
side
effect
procedur
current
use
blood
bank
prepar
platelet
concentr
transfus
partli
activ
platelet
could
inde
increas
risk
advers
transfus
reaction
aim
evalu
effect
innov
fraction
devic
carri
qualit
function
vivo
analysi
isol
human
platelet
studi
designmethod
whole
blood
obtain
donor
fraction
use
devic
platelet
recoveri
puriti
determin
quantifi
blood
cell
subpopul
microchannel
outlet
sampl
qualiti
isol
platelet
evalu
use
surfac
express
two
activ
marker
use
flow
cytometr
method
procoagul
abil
investig
use
vivo
experiment
platelet
isol
use
protocol
use
inactiv
control
resultsfind
fraction
use
devic
led
red
blood
cell
clearanc
ratio
whole
blood
greater
p
puriti
platelet
close
find
differ
term
qualiti
function
platelet
donor
isol
use
acoust
devic
versu
protocol
conclus
blood
process
method
led
excel
preserv
platelet
qualiti
function
provid
novel
promis
techniqu
whole
blood
fraction
clinic
set
backgroundcas
studi
nowaday
blood
bank
requir
new
strategi
manufactur
blood
compon
due
increas
product
banc
de
sang
teixit
bst
implement
last
year
autom
manufactur
includ
lean
manag
method
abl
process
need
blood
donat
area
million
peopl
studi
designmethod
autom
blood
donat
process
bst
done
differ
chang
equip
orbisac
terumo
bct
equip
obtain
buffi
coat
product
got
platelet
concentr
move
equip
atreu
terumo
bct
get
red
blood
cell
buffi
coat
fresh
frozen
plasma
updat
atreu
chang
atreu
terumo
bct
final
move
reveo
system
terumo
bct
sinc
chang
blood
compon
red
cell
concentr
plasma
platelet
leukocyt
residu
chang
process
equip
ad
also
autom
registr
donat
id
weight
temperatur
label
step
implement
two
homemad
robot
final
get
better
result
efficaci
product
bst
incorpor
engin
introduc
lean
manufactur
method
method
base
identif
analysi
problem
chose
activ
add
valu
procedur
resultsfind
chang
updat
evalu
qualiti
blood
compon
red
cell
platelet
also
number
donat
miss
work
hour
necessari
process
blood
donat
evalu
done
process
conclus
result
obviou
autom
blood
bank
make
effici
manufactur
blood
compon
get
better
qualiti
also
cheaper
way
encourag
maintain
lean
philosophi
order
keep
improv
method
identifi
activ
add
valu
process
get
rid
one
necessari
global
industri
world
everyth
chang
fast
improv
necessari
top
field
state
art
blood
bank
backgroundcas
studi
improv
suppli
chain
effici
cost
contain
requir
initi
review
establish
practic
manag
blood
suppli
freseniu
kabi
compotrac
rfid
enabl
inventori
manag
system
implement
assist
manag
blood
compon
inventori
two
hospit
blood
bank
bb
addit
manag
compon
inventori
hospit
use
compotrac
order
modul
commun
daili
replenish
need
replac
establish
practic
order
via
phone
start
june
juli
began
two
hospit
studi
identifi
opportun
improv
effici
blood
compon
suppli
chain
studi
designmethod
compotrac
system
compon
includ
rfid
tag
comput
kiosk
rfid
reader
barcod
scanner
blood
center
bc
distribut
team
appli
rfid
tag
blood
compon
record
inventori
compotrac
use
rfid
reader
barcod
scanner
hospit
order
receiv
hospit
bb
use
compotrac
rfid
reader
receiv
blood
compon
inventori
hospit
also
use
rfid
reader
record
chang
blood
compon
inventori
statu
issu
unit
return
unit
bb
inventori
dispos
unit
return
unit
bc
hospit
studi
continu
use
bb
system
critic
decis
make
track
blood
compon
meditech
hcll
bb
staff
use
compotrac
order
daili
commun
replenish
need
standard
time
stat
order
resultsfind
visibl
frequenc
blood
compon
movement
hospit
bb
provid
great
insight
opportun
cost
issu
compon
compar
target
inventori
level
provid
opportun
discuss
inventori
order
result
reduct
miscommun
inventori
need
hospit
bb
ad
process
effici
size
equip
barrier
use
studi
site
hospit
rbc
lrbc
day
inventori
hand
dioh
hospit
b
lrbc
dioh
conclus
compotrac
data
assist
identifi
opportun
inventori
optim
deliveri
technician
found
system
easi
use
appli
rfid
tag
problemat
continu
partner
hospit
monitor
par
level
best
practic
backgroundcas
studi
laboratori
envis
autom
blood
product
deliveri
system
extend
blood
access
bedsid
use
remot
blood
alloc
devic
smart
blood
refriger
improv
patient
safeti
provid
time
access
blood
product
potenti
reduc
laboratori
workload
part
initi
bloodtrack
haemobank
hb
haemonet
braintre
instal
interfac
exist
safetrac
tx
haemonet
braintre
laboratori
inform
system
one
hb
instal
methodist
hospit
rmh
campu
includ
busi
outpati
infus
therapi
center
itc
studi
designmethod
assess
current
blood
suppli
chain
reveal
improv
opportun
nurs
blood
bank
staff
frequent
daili
trip
blood
bank
take
nurs
away
patient
besid
creat
congest
blood
bank
window
peak
time
itc
daili
outpati
volum
patient
averag
travel
time
approxim
even
small
delay
wait
line
blood
bank
window
would
produc
profound
rippl
effect
itc
nurs
face
addit
challeng
maintain
ratio
provid
time
patient
care
patient
itc
transfus
order
ad
blood
bank
workload
creat
unpredict
workflow
often
patient
itc
nurs
repeat
vital
sign
much
time
elaps
gather
vital
obtain
blood
ineffici
result
longer
patient
wait
time
ultim
longer
stay
itc
resultsfind
hb
devic
allow
nurs
staff
access
red
blood
cell
rbc
major
patient
point
care
sinc
implement
novemb
hb
significantli
improv
turnaround
time
rbc
issu
less
help
maintain
nurs
patient
ratio
reduc
traffic
blood
bank
issu
window
prior
hb
implement
blood
bank
staff
rmh
issu
approxim
rbc
per
month
window
patient
reduc
approxim
rbc
per
month
averag
monthli
reduct
conclus
hb
locat
itc
help
expedit
care
patient
easili
manag
blood
product
patient
order
use
hb
devic
result
reduct
blood
bank
fte
rather
shift
workload
issu
product
monitor
inventori
restock
backgroundcas
studi
rescu
squadron
unit
california
air
nation
guard
rescu
wing
establish
consist
regist
paramed
pararescu
specialist
helicopt
personnel
combat
squadron
conduct
personnel
recoveri
oper
rescu
down
airmen
station
us
mitig
state
emerg
perform
aeromed
evacu
support
civilian
medic
emerg
patient
need
transfus
field
procur
blood
product
distant
air
forc
base
adjac
medic
facil
debrief
member
rescu
squadron
rq
decid
find
local
civilian
blood
supplier
master
sergeant
contact
blood
center
set
contract
blood
suppli
studi
designmethod
blood
center
repres
met
rq
master
sergeant
januari
ask
rq
order
deliveri
expect
said
sporad
use
blood
order
would
rbc
wrote
procedur
consign
packag
use
standard
blood
transport
box
develop
commun
templat
staff
anticip
rq
need
staff
train
base
data
januari
meet
contact
rq
septemb
perform
trial
run
time
learn
master
sergeant
ship
militari
theater
invit
replac
blood
center
pararescu
senior
airman
return
syria
assign
civilian
duti
prior
knowledg
rq
associ
civilian
blood
center
base
field
experi
chang
blood
order
rbc
introduc
blood
transport
contain
use
militari
oper
say
easier
carri
water
land
pararescu
mission
rewrot
procedur
incorpor
transport
contain
made
pictori
job
aid
assist
staff
packag
blood
use
contain
blood
center
rq
perform
mock
run
octob
felt
prepar
futur
event
resultsfind
novemb
rq
deploy
civilian
aeromed
evacu
anticip
rbc
order
actual
order
rbc
ffp
staff
prepar
frozen
ffp
ship
norm
fill
hospit
order
realiz
could
thaw
plasma
flight
contact
rq
offer
liquid
plasma
instead
accept
product
consign
pick
rq
patient
transfus
field
taken
nearbi
hospit
joint
debrief
novemb
establish
maximum
blood
order
rbc
liquid
plasma
note
futur
order
may
request
fewer
product
yet
meet
prefer
rbc
plasma
transfus
ratio
conclus
militari
personnel
adapt
instantli
adjust
ever
chang
environ
regul
blood
center
adapt
clear
comprehens
commun
anticip
blood
center
part
suppli
civilian
blood
product
air
nation
guard
backgroundcas
studi
minimum
potenc
requir
singl
unit
cryoprecipit
ahf
cryoprecipit
unit
aabb
technic
manual
recommend
estim
fibrinogen
fib
concentr
unit
calcul
cryoprecipit
dosag
howev
fib
level
shown
variabl
cryoprecipit
intent
studi
determin
extent
variabl
fib
concentr
impact
manufactur
process
fib
concentr
differ
blood
center
studi
designmethod
fib
level
measur
blood
center
laboratori
januari
januari
cross
section
survey
gather
data
blood
center
manufactur
process
june
decemb
survey
sent
site
resultsfind
overal
studi
mean
fib
concentr
unit
tabl
highest
mean
fib
concentr
unit
lowest
mean
fib
concentr
unit
site
mean
fib
concentr
least
unit
fda
minimum
requir
unit
fifteen
blood
center
complet
manufactur
process
survey
one
use
leukocyt
reduct
filter
ahf
destin
plasma
blood
center
manufactur
singl
donor
cryoprecipit
manufactur
pool
donor
cryoprecipit
froze
plasma
colder
blood
bank
freezer
one
froze
plasma
use
dri
ice
one
use
blast
freezer
two
blood
center
method
thaw
frozen
plasma
took
longer
hour
conclus
blood
center
consist
met
overal
fib
minimum
requir
mean
unit
doubl
fda
requir
howev
variabl
fib
level
amongst
blood
center
gener
manufactur
process
similar
except
blood
center
inform
hospit
custom
averag
fib
level
cryoprecipit
order
appropri
care
patient
receiv
product
tabl
fibrinogen
concentr
ahf
unit
blood
center
site
backgroundcas
studi
healthcar
industri
particularli
blood
bank
industri
continu
experi
tremend
pressur
ensur
patient
safeti
qualiti
daili
manag
maintain
effici
oper
cost
competit
structur
applic
basic
industri
engin
tool
coupl
sigma
techniqu
time
studi
analysi
bottleneck
elimin
process
standard
reduc
variat
transform
applic
short
app
util
determin
process
staf
optim
provid
flexibl
dynam
natur
chang
need
blood
bank
studi
designmethod
time
studi
analysi
offer
valuabl
data
process
requir
baselin
establish
translat
data
app
would
enabl
eas
practic
use
facilit
busi
well
effect
manag
daili
oper
import
concept
product
system
bottleneck
elimin
balanc
togeth
basic
develop
app
use
ms
excel
softwar
demonstr
resultsfind
success
rollout
implement
staffingschedul
calcul
app
across
pilot
facil
onto
facil
nationwid
yield
improv
product
togeth
sustain
complianc
scorecard
app
approach
program
via
commonli
use
softwar
ms
excel
use
analyz
optim
staf
requir
togeth
ie
match
incom
volumework
content
staf
avail
staffingschedul
calcul
app
util
execut
evalu
scenario
sensit
analysi
well
plan
toolkit
proactiv
manag
chang
demand
blood
bank
conclus
besid
provid
key
mechan
increas
product
sustain
complianc
top
prioriti
blood
bank
staffingschedul
calcul
app
highlight
continu
improv
opportun
accept
standard
staffingschedul
calcul
applic
app
backgroundcas
studi
transfus
servic
typic
valid
cooler
blood
storag
red
blood
cell
rbc
unit
bottom
ice
top
howev
cooler
often
return
oper
room
rbc
unit
top
ice
unit
wast
studi
determin
maximum
time
rbc
unit
maintain
temperatur
oc
ice
place
bottom
cooler
unit
top
studi
designmethod
five
differ
brand
size
cooler
larg
red
igloo
larg
blue
igloo
larg
rubbermaid
medium
rubbermaid
small
blue
igloo
test
rbc
unit
larg
cooler
unit
medium
cooler
unit
small
cooler
cooler
prepar
refriger
two
scoop
wet
ice
two
ice
pack
place
bottom
largemedium
small
cooler
respect
rbc
unit
top
ice
thermomet
place
top
rbc
unit
control
thermomet
place
interfac
ice
rbc
unit
one
larg
one
medium
cooler
start
temperatur
record
temperatur
record
everi
minut
hour
period
temperatur
exceed
resultsfind
temperatur
record
thermomet
top
unit
five
cooler
reach
minut
shown
tabl
control
thermomet
record
temperatur
maintain
entir
hour
observ
period
larg
medium
cooler
tabl
conclus
unit
place
top
ice
cooler
temperatur
reliabl
maintain
minut
data
support
polici
wast
unit
return
blood
bank
rbc
unit
top
ice
backgroundcas
studi
fda
draft
guidanc
highlight
need
reduc
risk
bacteri
contamin
platelet
compon
pc
via
pathogen
reduct
pr
secondari
rapid
test
rt
hospit
must
understand
cost
implic
may
result
object
creat
interact
model
analyz
budget
impact
differ
pc
type
across
rang
exist
us
hospit
studi
designmethod
excel
model
built
popul
base
case
cost
probabl
identifi
literatur
search
well
survey
administ
us
hospit
transfus
servic
director
model
review
refin
panel
seven
transfus
medicin
physician
model
allow
assumpt
overwritten
valu
specif
institut
three
scenario
gener
compar
annual
cost
plt
acquisit
test
wastag
dispens
transfus
advers
event
ae
reimburs
hospit
purchas
pc
convent
mix
model
assumpt
apheresi
plt
unit
purchasedyear
gamma
irradi
pr
replac
irradi
cmv
test
bacteri
detect
bd
unit
cost
purchas
irradi
purchas
purchas
pc
transfus
outpati
reimburs
resultsfind
tabl
annual
cost
outpati
reimburs
conclus
model
predict
modest
cost
increas
compar
depend
degre
pr
convers
take
account
cost
offset
elimin
bd
irradi
decreas
wast
due
increas
outpati
reimburs
effect
pc
potenti
increas
pr
due
elimin
bd
depend
nat
turnaround
time
benefit
captur
model
includ
infecti
risk
mitig
emerg
pathogen
may
impact
costbenefit
analys
futur
iter
model
also
enabl
hospit
consid
scenario
rt
use
model
serv
import
tool
hospit
consid
pr
adopt
backgroundcas
studi
attempt
increas
number
donat
rare
donor
new
process
donor
notif
implement
januari
report
creat
identifi
donor
previous
classifi
rare
accord
american
rare
donor
program
ardp
criteria
donor
classifi
rare
meet
one
follow
antigen
neg
multipl
common
antigen
neg
iga
defici
new
process
util
report
involv
send
letter
donor
notifi
rare
donor
statu
encourag
continu
donat
databas
creat
track
letter
sent
rare
donor
august
inventori
reduct
effort
implement
gradual
decreas
number
allogen
red
blood
cell
rbc
collect
minim
unit
age
transfus
inventori
reduct
occur
phase
complet
januari
studi
perform
determin
impact
inventori
reduct
number
rare
donor
donat
studi
designmethod
total
number
allogen
rbc
donat
rare
donor
donat
number
rare
donor
letter
sent
analyz
see
tabl
percentag
rare
donor
donat
per
year
calcul
resultsfind
number
allogen
rbc
donat
unit
compar
unit
inventori
reduct
unit
seven
year
donor
letter
implement
total
letter
sent
rare
donor
includ
rare
donor
donat
number
rare
donor
donat
increas
donat
inventori
reduct
measur
implement
yet
number
rare
donor
donat
decreas
donat
sinc
percentag
rare
donor
donat
compar
total
number
donat
per
year
maintain
averag
conclus
despit
inventori
reduct
effort
maintain
number
rare
donor
donat
one
possibl
explan
letter
educ
donor
rare
statu
decreas
number
letter
sent
maintain
consist
percentag
rare
donat
indic
mani
rare
donor
repeat
donor
tabl
donat
per
year
backgroundcas
studi
blood
center
client
often
carri
low
inventori
blood
blood
compon
laboratori
perform
donor
screen
therefor
limit
time
determin
presenc
absenc
infecti
diseas
within
product
order
measur
ensur
expedit
donor
screen
implement
daili
perform
metric
consist
upload
time
goal
releas
result
client
nat
test
implement
travel
deferr
donor
juli
follow
univers
individu
donor
screen
septemb
novemb
respons
fda
recommend
reduc
risk
zkv
transmiss
blood
blood
compon
per
fda
guidanc
implement
mandatori
zkv
test
client
proxim
area
local
acquir
case
zkv
within
week
sept
phase
nationwid
within
week
nov
phase
zkv
test
perform
individu
sampl
unlik
nat
test
perform
therefor
zkv
test
disproportion
impact
turnaround
time
test
analyz
studi
studi
designmethod
within
two
region
test
lab
particip
clinic
trial
lab
lab
client
requir
univers
zkv
test
evalu
test
result
upload
perform
period
determin
impact
zkv
test
implement
resultsfind
lab
upload
time
perform
rang
januari
juli
upload
time
perform
fell
august
novemb
return
perform
decemb
lab
upload
time
perform
rang
januari
august
perform
fell
septemb
decemb
lab
experienc
low
upload
time
perform
phase
rapid
implement
client
requir
zkv
nat
improv
perform
observ
phase
increas
zkv
client
lab
phase
experienc
modest
declin
upload
perform
rang
client
implement
zkv
nat
perform
phase
addit
client
implement
zkv
test
conclus
unpreced
rapid
implement
zkv
test
laboratori
experienc
short
period
reduc
abil
maintain
upload
time
perform
metric
backgroundcas
studi
respons
two
septic
transfus
reaction
draft
fda
guidanc
releas
march
regard
bacteri
risk
control
strategi
transfus
servic
system
implement
verax
pgd
enhanc
platelet
bacteri
screen
test
hospit
transfus
servic
site
implement
test
arrang
fresh
platelet
rotat
blood
supplier
site
implement
verax
pgd
test
perform
test
day
day
platelet
issu
transfus
abstract
summar
data
collect
first
week
test
studi
designmethod
platelet
bacteri
test
log
review
entir
time
period
studi
platelet
test
day
day
test
twice
inventori
report
review
platelet
issu
day
day
requir
test
total
number
platelet
issu
time
period
studi
resultsfind
month
februari
week
perform
test
platelet
issu
particip
transfus
servic
day
day
platelet
march
number
drop
expect
number
level
percentag
data
collect
februari
platelet
test
twice
prior
final
issu
transfus
servic
march
platelet
test
twice
look
platelet
test
day
februari
test
twice
march
test
twice
repres
ad
suppli
cost
transfus
servic
februari
march
final
februari
total
issu
platelet
test
least
march
total
issu
platelet
test
least
conclus
percent
platelet
issu
fresh
day
day
like
level
number
due
inventori
manag
blood
supplier
individu
transfus
servic
test
platelet
twice
undesir
ideal
platelet
would
test
twice
repres
high
cost
test
reagent
well
staff
time
complet
test
addit
site
perform
test
level
trauma
center
need
test
platelet
avail
time
requir
amount
doubl
test
goal
number
low
possibl
percent
test
vs
issu
platelet
exceed
transfus
servic
staff
becom
comfort
judg
inventori
level
perform
test
expect
amount
doubl
test
decreas
backgroundcas
studi
order
make
defici
apheresi
platelet
clinic
applic
also
improv
comprehens
util
blood
investig
feasibl
prepar
pool
platelet
concentr
pc
provid
reliabl
sourc
clinic
applic
speed
storag
research
pool
pc
china
evalu
chang
platelet
function
filter
leukocyt
leukocyt
filter
pc
qualiti
chang
storag
blood
bag
studi
designmethod
pc
prepar
viru
free
whole
blood
plasma
prp
method
five
six
bag
pc
pool
filter
leukocyt
filter
pc
swirl
phenomenon
ph
automat
blood
count
platelet
aggreg
hypoton
shock
respons
hsr
extent
shape
chang
esc
express
atp
level
platelet
glucos
lactat
concentr
detect
filter
storag
respect
resultsfind
platelet
recoveri
ratio
therapeut
dose
pool
platelet
concentr
filter
leukocyt
rel
chang
rate
hsr
residu
leukocyt
ph
hsr
express
pool
platelet
concentr
filter
vs
vs
vs
signific
chang
wbc
filter
p
storag
blood
bag
biochem
paramet
pool
platelet
concentr
chang
increas
storag
time
shown
tabl
tabl
result
mean
sd
pool
platelet
concentr
store
bag
conclus
storag
blood
bag
five
day
qualiti
pool
pc
met
requir
chines
standard
gb
complementari
sourc
apheresi
platelet
supplement
china
backgroundcas
studi
current
method
use
obtain
sampl
blood
compon
tube
segment
cumbersom
present
signific
risk
exposur
biohazard
sharp
injuri
cross
contamin
itl
biomed
develop
segment
sampler
ss
devic
obtain
measur
sampl
seal
tube
segment
less
cumbersom
offer
improv
safeti
elimin
need
manual
cut
squeez
tube
segment
ss
evalu
goal
reduc
number
step
requir
obtain
measur
sampl
reduc
biohazard
sharp
exposur
studi
designmethod
ss
obtain
fluid
sampl
seal
tube
segment
needleless
syring
consist
two
chamber
recess
intern
needl
locat
top
devic
femal
port
locat
bottom
devic
needleless
syring
attach
femal
port
seal
tube
end
align
ss
chamber
gentli
push
onto
needl
pierc
end
segment
sampl
segment
withdrawn
syring
studi
perform
rhode
island
blood
center
provid
ri
use
tube
segment
three
bag
manufactur
demonstr
eas
use
follow
process
segment
align
needl
pierc
abil
draw
sampl
syring
abil
expel
air
bubbl
syring
fluid
leak
eas
transfer
sampl
syring
tube
collect
user
feedback
two
length
tube
segment
fill
contain
sampl
volum
two
user
evalu
ss
tube
segment
type
sampl
total
data
point
sampl
collect
attach
syring
measur
sampl
transfer
syring
test
tube
tube
result
tabul
pass
fail
resultsfind
total
ss
evalu
two
user
sampl
success
collect
transfer
tube
insert
segment
edg
requir
observ
ensur
placement
onto
needl
air
bubbl
collect
syring
could
easili
move
top
flick
syring
express
back
segment
result
summar
tabl
tabl
conclus
segment
sampler
provid
easier
effici
method
obtain
measur
volum
sampl
tube
segment
improv
safeti
reduc
potenti
exposur
biohazard
sharp
backgroundcas
studi
manag
platelet
inventori
crucial
due
number
factor
includ
day
product
outdat
alloc
staff
due
lengthi
donat
process
increasingli
small
donor
pool
high
cost
product
eg
platelet
collect
kit
test
product
process
use
platelet
inventori
manag
tool
potenti
enhanc
understand
unit
transfus
optim
inventori
increas
effici
reduc
wast
object
assess
deciph
platelet
inventori
manag
tool
reduc
amount
outdat
platelet
product
total
cost
platelet
product
full
time
equival
fte
alloc
studi
designmethod
januari
platelet
inventori
manag
process
implement
use
spreadsheet
base
tool
predict
amount
platelet
collect
procedur
need
schedul
day
tool
use
daili
histor
transfus
data
last
five
week
addit
calcul
includ
account
deferr
show
incomplet
collect
product
split
rate
number
gener
calcul
correl
mani
platelet
collect
procedur
schedul
specif
day
week
consid
test
releas
histor
daili
transfus
trend
effect
tool
verifi
compar
platelet
collect
platelet
product
outdat
fte
inform
one
year
period
prior
implement
platelet
inventori
manag
one
year
period
follow
implement
resultsfind
implement
platelet
inventori
manag
tool
collect
lower
shift
accommod
transfus
need
staf
adjust
target
collect
lower
fte
outdat
cost
platelet
outdat
rate
drop
implement
platelet
inventori
tool
unit
unit
decreas
fte
abl
monitor
close
donor
schedul
lower
yearli
averag
fte
fte
lower
fte
conclus
consid
histor
transfus
data
potenti
platelet
demand
posit
impact
schedul
platelet
collect
staf
requir
outdat
product
decreas
sinc
implement
platelet
manag
spreadsheet
tool
lead
less
wast
term
staf
platelet
given
posit
result
begin
develop
similar
tool
whole
blood
collect
backgroundcas
studi
abil
track
inventori
blood
compon
real
time
challeng
hospit
transfus
servic
ts
blood
center
bc
use
current
blood
bank
inform
system
bbi
addit
determin
establish
par
level
individu
compon
meet
exceed
daili
transfus
need
difficult
ascertain
pilot
design
track
monitor
blood
compon
distribut
bc
issu
hospit
ts
use
freseniu
kabi
compotrac
radio
frequenc
id
rfid
enabl
inventori
manag
system
object
determin
feasibl
compotrac
system
analyz
compotrac
data
usag
optim
inventori
level
studi
designmethod
month
pilot
conduct
pediatr
hospit
bc
use
bbi
compotrac
system
track
blood
compon
staff
train
use
compotrac
system
upon
receipt
order
pilot
hospit
bc
staff
appli
rfid
tag
compon
bag
scan
compon
compotrac
system
compon
transport
deliv
ts
follow
establish
procedur
upon
receipt
hospit
compon
scan
inventori
use
ts
bbi
compotrac
system
dual
scan
compon
occur
upon
issu
return
floor
compon
modif
return
bc
product
emerg
use
time
high
demand
priori
pilot
would
stop
compotrac
system
hamper
current
workflow
compon
issu
delay
ts
error
increas
inventori
chang
made
pilot
resultsfind
data
compotrac
system
provid
actual
usag
blood
compon
includ
compon
dispos
shipment
bc
averag
daili
rbc
inventori
level
usag
select
blood
type
shown
tabl
lesson
learn
relat
equip
workflow
use
smaller
irradi
canist
may
damag
rfid
tag
resolv
reloc
tag
ts
workflow
stat
order
challeng
consist
use
dual
process
track
compon
statu
howev
increas
ts
error
delay
issu
compon
occur
conclus
use
rfid
track
blood
compon
bc
final
disposit
feasibl
data
compotrac
system
identifi
optim
inventori
level
rbc
pilot
ts
use
rfid
track
inventori
adjust
target
level
base
actual
daili
usag
time
may
reveal
season
influenc
affect
target
inventori
backgroundcas
studi
demonstr
electron
crossmatch
exm
improv
effici
transfus
servic
decreas
technologist
time
shown
c
ratio
lower
cost
reduc
red
blood
cell
rbc
inventori
studi
designmethod
retrospect
studi
involv
data
review
red
blood
cell
inventori
januari
june
differ
categori
inform
captur
due
chang
polici
transfus
servic
demonstr
tabl
number
rbc
crossmatch
dispens
transfus
wast
enter
microsoft
excel
c
ratio
c
ratio
cost
calcul
red
blood
cell
inventori
level
track
start
may
total
red
cell
unit
avail
crossmatch
enter
microsoft
excel
spreadsheet
daili
daili
averag
calcul
time
period
seen
tabl
resultsfind
mean
standard
deviat
level
signific
perform
determin
statist
signific
decreas
c
ratio
c
ratio
time
period
c
ratio
mean
standard
deviat
c
ratio
mean
standard
deviat
conclus
studi
show
implement
exm
help
transfus
servic
becom
effici
lower
inventori
level
littl
impact
physician
order
practic
lower
level
blood
held
patient
transfus
servic
decreas
total
stock
level
rbc
reduc
wastag
thu
lower
blood
cost
hospit
red
cell
cost
per
unit
tabl
red
cell
inventori
activ
c
c
ratio
time
period
major
chang
made
blood
manag
umc
transfus
servic
backgroundcas
studi
physician
expect
blood
avail
time
follow
nation
appeal
juli
donor
base
predict
summer
shortag
high
likelihood
extend
fall
transfus
servic
ts
recogn
potenti
dire
situat
given
institut
patient
acuiti
ts
support
full
rang
servic
level
trauma
servic
stem
cell
solid
organ
transplant
servic
brisk
cardiothorac
surgic
program
high
risk
obstetr
servic
high
acuiti
medicalsurg
servic
region
donor
center
suppli
blood
product
insur
appropri
respons
patient
need
ts
creat
manag
plan
input
multipl
stakehold
assist
product
manag
time
extrem
shortag
approach
describ
herein
studi
designmethod
direct
transfus
committe
tc
ts
director
present
concern
impend
shortag
hospit
qualiti
director
qd
committe
qd
committe
consist
clinician
train
health
care
qualityregulatori
affair
respons
institut
health
care
qualiti
hcq
activ
qd
recommend
creation
multidisciplinari
team
blood
shortag
task
forc
bstf
analog
exist
task
forc
start
manag
drug
shortag
resultsfind
hcq
tc
support
ts
creat
bstf
blood
shortag
manag
algorithm
bsma
stand
member
bstf
includ
ts
medic
director
chair
senior
vice
presid
svp
hcq
svp
clinic
servic
director
regulatori
affair
legal
counsel
repres
ethic
social
work
pharmaci
patient
referr
commun
ad
hoc
member
includ
whose
patient
would
impact
specif
shortag
bsma
design
bstf
provid
framework
ts
conduct
oper
therapeut
assess
potenti
impact
defin
criteria
conven
bstf
trigger
criteria
includ
mark
ts
concern
essenti
product
high
likelihood
inventori
deplet
broad
patient
impact
conven
bstf
respons
situat
assess
formul
manag
plan
goal
maintain
qualiti
patient
care
conclus
face
potenti
limit
blood
suppli
ts
reach
beyond
laboratori
engag
tc
member
hcq
assembl
robust
multidisciplinari
task
forc
result
inclus
plan
activ
time
address
shortag
assist
manag
impact
patient
backgroundcas
studi
larg
midwest
bed
hospit
activ
level
trauma
center
struggl
get
blood
transfus
servic
ts
patient
emerg
situat
multipl
process
evalu
lean
emerg
releas
er
process
well
massiv
transfus
protocol
mtp
autom
blood
dispens
evalu
due
high
cost
incomplet
interfac
laboratori
inform
system
li
solut
abandon
manual
track
process
creat
ensur
blood
track
correct
patient
studi
designmethod
process
requir
review
complet
discuss
oper
room
nurs
staff
help
determin
need
respons
train
two
set
neg
red
blood
cell
rbc
packag
togeth
transfus
administr
record
tar
remot
blood
record
rbr
form
indic
date
time
blood
receiv
staff
place
refriger
unit
remov
design
staff
rbr
complet
indic
patient
demograph
patient
label
date
time
rbc
util
individu
remov
unit
refriger
return
rbr
ts
indic
replac
unit
need
audit
process
includ
complet
rbr
well
complet
tar
program
start
data
evalu
end
march
resultsfind
event
blood
util
differ
patient
seven
event
involv
patient
take
unit
rather
set
doe
patient
involv
event
determin
time
receiv
inform
complet
rbr
time
blood
use
inform
incomplet
event
patient
identif
record
rbr
follow
requir
event
find
identif
either
tar
copi
medic
record
conclus
ts
uncomfort
rbc
unit
complet
ts
control
hesit
allow
area
blood
store
remot
due
continu
demand
caus
high
number
trauma
event
concern
set
asid
ts
staff
continu
work
togeth
identifi
issu
basi
process
review
addit
train
complet
soon
possibl
program
expand
emerg
depart
ed
februari
due
high
number
trauma
need
blood
part
patient
resuscit
evalu
process
show
blood
need
faster
ts
send
although
struggl
document
type
process
need
accommod
patient
surgeon
hope
save
live
backgroundcas
studi
cryoprecipit
short
cryo
play
critic
role
clot
control
hemorrhag
often
use
treatment
massiv
trauma
major
diseas
includ
metastas
cancer
cardiac
diseas
hepat
failur
organ
transplant
collect
process
cryo
particularli
challeng
due
fact
process
cryo
unit
collect
whole
blood
ship
product
facil
process
within
collect
tight
time
constraint
collect
product
satisfi
precis
collect
plan
extra
courier
servic
make
collect
cryo
unit
costli
product
studi
designmethod
american
red
cross
arc
partnership
research
georgia
institut
technolog
gt
develop
blood
collect
model
increas
amount
whole
blood
process
cryoprecipit
review
blood
collect
process
schedul
collect
locat
factor
subject
matter
expert
togeth
gt
research
abl
analyz
problem
structur
sever
analyticdynam
program
properti
develop
near
optim
solut
algorithm
mathemat
model
resultsfind
facilit
implement
decis
support
tool
dst
develop
systemat
select
collect
site
determin
mobil
collect
site
collect
blood
cryo
product
schedul
courier
servic
collect
target
met
total
collect
cost
minim
implement
dst
led
increas
number
whole
blood
unit
satisfi
tight
complet
time
constraint
cryo
product
capac
expans
particular
blood
process
region
abl
process
cryo
unitsmonth
increas
slightli
lower
collect
cost
cost
avoid
result
approxim
reduct
per
unit
collect
cost
cryo
conclus
util
oper
research
toolkit
mathemat
model
algorithm
could
develop
optim
cryoprecipit
collect
process
ensur
time
constraint
product
consist
level
achiev
interdisciplinari
improv
cryoprecipit
collect
collabor
project
select
finalist
franz
edelman
award
recogn
outstand
achiev
practic
oper
research
backgroundcas
studi
shelf
life
apheresi
platelet
ap
unit
store
plasma
may
extend
day
usa
use
fda
clear
rapid
test
rt
august
hospit
base
transfus
servic
began
use
rt
day
routin
extend
ap
shelf
life
day
report
describ
chang
platelet
inventori
manag
transfus
practic
six
month
follow
routin
use
ap
studi
designmethod
data
obtain
two
studi
period
septemb
septemb
studi
period
intent
made
span
month
year
due
season
variabl
platelet
transfus
rate
region
transit
period
ap
inventori
exclud
follow
data
collect
studi
period
total
number
ap
transfus
recipi
ap
unit
transfus
expir
ap
unit
ap
unit
order
supplier
inpati
admiss
surgic
volum
averag
length
stay
resultsfind
data
shown
tabl
number
ap
transfus
decreas
inpati
admiss
surgic
volum
increas
respect
hospit
length
stay
similar
period
ap
inventori
decreas
outdat
rate
decreas
p
order
statist
differ
studi
period
averag
number
ap
transfus
per
patient
period
statist
differ
respect
conclus
use
platelet
decreas
wast
help
reduc
stand
order
volum
approxim
one
third
ap
unit
underw
secondari
bacteri
test
prior
transfus
thu
increas
patient
safeti
tabl
backgroundcas
studi
fda
state
guidanc
industri
leukocyt
reduct
whole
blood
blood
compon
intend
transfus
test
residu
wbc
rwbc
count
within
hour
collect
per
manufactur
direct
cell
count
methodolog
bd
bioscienc
state
packag
insert
prepar
run
sampl
within
hour
follow
leucoreduct
follow
event
requir
excess
number
rwbc
confirm
test
hypothes
test
sampl
use
bd
leucocounttm
kit
would
produc
valid
result
test
time
exceed
requir
hour
follow
leukocyt
reduct
studi
designmethod
total
red
blood
cell
unit
test
within
hour
leukocyt
reduct
use
bd
leucocounttm
kit
within
qualiti
control
depart
bonfil
blood
center
unit
exceed
allow
rwbc
count
million
stay
within
upper
linear
limit
test
assay
wbcmcl
result
averag
wbc
count
unit
properli
store
total
day
follow
leukocyt
reduct
consecut
day
sampl
remov
unit
test
use
bd
leucocounttm
kit
result
consecut
day
compar
origin
result
test
within
requir
hour
follow
leukocyt
reduct
resultsfind
unit
test
demonstr
decreas
rwbc
test
day
compar
result
test
within
hour
follow
leukocyt
reduct
review
result
obtain
note
unit
test
day
demonstr
decreas
rwbc
less
averag
differ
rang
conclus
studi
conclud
complet
rwbc
test
use
bd
leucocounttm
kit
would
yield
reliabl
result
test
day
extenu
circumst
extend
allow
timefram
perform
rwbc
test
beyond
may
provid
blood
center
realist
window
assess
leukocyt
reduct
statu
larg
number
otherwis
transfus
red
blood
cell
backgroundcas
studi
lipaemia
natur
occur
phenomenon
may
caus
appear
blood
product
milki
studi
identifi
triglycerid
tg
lipid
associ
lactesc
sampl
lipaemia
affect
safeti
product
might
interfer
abil
perform
viral
marker
test
kuwait
central
blood
bank
kcbb
facil
kuwait
respons
blood
collect
test
process
distribut
object
studi
evalu
current
polici
deal
lipaem
donat
improv
perform
kcbb
studi
designmethod
retrospect
studi
done
includ
statist
analysi
number
test
discard
unit
due
lipaemia
kcbb
period
time
unit
discard
either
due
gross
lipaemia
moder
turbid
case
due
tg
level
dl
deriv
piccolo
xpress
chemistri
analyz
insert
instruct
furthermor
new
reject
threshold
lipaem
product
implement
threshold
repres
tg
concentr
viral
marker
test
donor
screen
affect
kcbb
abbott
prism
assay
use
hbsag
ab
ab
resultsfind
use
data
manag
system
file
record
kcbb
regard
discard
blood
compon
due
lipaemia
last
five
year
demonstr
number
discard
rbc
due
lipaemia
whole
period
unit
number
discard
differ
plasma
platelet
cryoprecipit
compon
last
two
year
due
lipaemia
unit
respect
mean
number
discard
rbc
unit
five
year
studi
exce
test
one
literatur
guidelin
manag
lipaem
donat
review
order
minim
donat
loss
establish
accur
reject
threshold
lipaem
donat
review
sampl
requir
viral
marker
test
kcbb
accept
level
tg
blood
sampl
reject
threshold
lipaemia
level
equal
conclus
mani
blood
product
unit
discard
needlessli
kcbb
due
lipaemia
last
five
year
includ
rbc
plasma
product
apheresi
platelet
unit
effort
reduc
wast
potenti
lifesav
product
reject
threshold
lipaem
product
recommend
chang
affect
blood
safeti
follow
studi
recommend
appli
new
threshold
evalu
new
polici
backgroundcas
studi
approv
fda
provid
opportun
improv
safeti
platelet
inventori
across
patient
demograph
outlin
approach
address
issu
face
first
month
avail
studi
designmethod
nurs
educ
team
provid
present
nurs
clinic
unit
support
staff
trainer
staf
session
eveningnight
shift
clinic
ward
present
physician
made
blood
bank
medic
staff
inform
technolog
personnel
creat
new
product
type
blood
bank
comput
system
test
aborh
truth
tabl
ensur
bill
code
place
necess
transient
support
dual
inventori
convent
platelet
led
consult
ethic
committe
risk
manag
confirm
convent
platelet
test
bacteria
safeti
measur
test
could
consid
hospit
standard
care
chose
gamma
irradi
unit
consist
packag
insert
resultsfind
ethic
committe
risk
manag
confirm
inform
consent
need
transfus
avail
blood
supplier
increment
monthli
first
four
month
avail
transfus
hospit
total
platelet
transfus
month
approxim
inventori
question
receiv
nurs
medic
confer
relat
risk
bacteri
contamin
vs
toxicolog
pr
process
scan
label
electron
medic
record
need
irradi
use
safeti
measur
address
concern
bacteri
contamin
publish
toxicolog
data
compar
content
psoralen
food
product
grapefruit
per
content
ng
per
ml
address
toxicolog
concern
nursingit
allay
concern
scan
issu
simpl
demonstr
final
ensur
parti
awar
fda
requir
irradi
present
medic
confer
also
use
opportun
provid
diseas
train
inform
platelet
util
compani
personnel
present
medic
nurs
confer
per
institut
polici
complaint
receiv
follow
despit
presenc
dual
inventori
conclus
use
inclus
approach
staff
train
seamlessli
ad
blood
bank
inventori
backgroundcas
studi
ensur
platelet
suppli
capabl
repres
challeng
term
donor
recruit
inventori
manag
oper
septemb
apheresi
collect
process
acp
complet
revis
increas
number
product
per
donat
maxim
rate
donat
dpd
process
review
led
sever
chang
includ
substitut
platelet
plt
count
measur
donat
type
alloc
favor
use
donor
past
donat
record
multipl
process
step
elimin
evalu
plt
concentr
function
time
deduc
complet
blood
count
cbc
measur
allow
central
analysi
qc
depart
final
introduc
concept
donat
led
increas
proport
dpd
studi
designmethod
donat
center
whole
blood
wb
donor
collect
tube
plt
concentr
determin
qc
depart
use
coulter
act
diff
hematolog
analyz
beckman
coulter
sampl
tube
store
measur
hour
singl
platelet
donat
spd
dpd
collect
use
trima
accel
unit
pool
split
elp
extend
life
platelet
terumo
bct
storag
bag
mimic
spd
dpd
unit
plt
pool
store
mild
agit
seven
day
except
dpd
split
two
bag
sampl
taken
day
ph
hypoton
shock
respons
hsr
extent
shape
chang
esc
express
atp
content
lactat
glucos
concentr
use
vitroqu
marker
resultsfind
plt
concentr
function
time
determin
wb
cbc
measur
show
signific
differ
dpd
store
collect
bag
donat
without
signific
impact
plt
qualiti
marker
plt
concentr
within
manufactur
accept
limit
split
day
lactat
concentr
increas
dpd
howev
valu
normal
control
unit
expir
day
conclus
project
approv
health
canada
implement
organ
march
numer
oper
cost
benefit
process
optim
initi
without
signific
impact
safeti
qualiti
effici
data
compar
target
increas
target
number
plt
unit
per
donat
ratio
backgroundcas
studi
pathogen
reduc
platelet
prp
provid
improv
safeti
compar
convent
apheresi
platelet
collect
manufactur
complex
earli
evid
show
doubl
platelet
collect
meet
requir
pathogen
reduct
blood
center
need
hospit
implement
prp
start
manufactur
hospit
may
wish
use
prp
provid
product
patient
scale
manufactur
blood
center
phase
prp
across
patient
popul
meet
parti
need
evalu
strategi
univers
health
system
transfus
volum
apheresi
platelet
annual
includ
two
hospit
inpati
bed
outpati
cancer
center
studi
designmethod
initi
approv
fund
obtain
hospit
qualiti
council
administr
stakehold
group
hematologyoncolog
educ
consensu
gain
live
train
provid
nurs
outpati
cancer
center
week
bone
marrow
transplant
bmt
ward
week
commun
explain
chang
physician
nurs
phase
implement
prp
outpati
cancer
center
patient
immunocompromis
access
immedi
advanc
critic
care
inpati
environ
septic
reaction
occur
phase
expand
usag
includ
inpati
bmt
ward
phase
lift
restrict
prp
could
use
throughout
health
system
goal
reach
prp
within
month
resultsfind
phase
week
request
prp
product
weekli
base
typic
usag
outpati
cancer
center
blood
supplier
provid
averag
prp
weekli
rang
prp
constitut
platelet
transfus
cancer
center
week
excess
prp
inventori
requir
use
prp
inpati
bmt
ward
ahead
schedul
practic
continu
throughout
phase
phase
week
formal
expand
issu
prp
includ
inpati
bmt
ward
request
prp
product
weekli
blood
supplier
provid
averag
prp
weekli
rang
prp
constitut
platelet
transfus
area
phase
week
began
issu
prp
throughout
health
system
supplier
provid
averag
prp
weekli
rang
prp
constitut
platelet
transfus
ongo
conclus
phase
implement
prp
patient
group
priorit
patient
stand
benefit
product
allow
time
blood
center
scale
manufactur
flexibl
use
prp
differ
area
need
accommod
variat
number
transfus
physician
nurs
staff
recept
chang
complaint
receiv
refer
aabb
america
blood
center
american
red
cross
comment
regard
docket
april
backgroundcas
studi
maintain
adequ
inventori
platelet
without
signific
outdat
wast
product
constant
challeng
mani
institut
especi
smaller
commun
hospit
health
system
compris
hospit
includ
smaller
commun
hospit
sch
larger
tertiari
care
medic
center
tcmc
sever
year
use
limit
intern
process
platelet
share
institut
success
reduc
platelet
wastag
encourag
us
analyz
platelet
usag
throughout
health
system
devis
expand
novel
concept
platelet
distribut
partnership
blood
supplier
would
allow
us
maintain
inventori
apheresi
platelet
ap
unit
smaller
commun
hospit
without
significantli
increas
platelet
wast
associ
cost
studi
designmethod
round
robin
rr
transport
system
platelet
deliveri
pick
strateg
develop
region
blood
center
align
routin
deliveri
red
blood
cell
rbc
stand
order
effici
deliveri
system
implement
region
blood
center
would
realiz
reduc
supplement
emerg
deliveri
blood
compon
hospit
platelet
transfer
time
rbc
stand
order
deliveri
base
predetermin
rout
schedul
day
ap
deliv
sch
previou
day
platelet
retriev
transfus
pack
blood
center
transport
box
pick
blood
center
driver
platelet
typic
hour
shelf
life
remain
process
occur
next
sch
rout
retriev
platelet
sch
deliv
tcmc
last
stop
rout
thu
sch
adequ
number
unit
avail
regular
transfus
massiv
transfus
protocol
resultsfind
review
rr
process
reveal
signific
benefit
smaller
commun
hospit
abl
routin
maintain
ap
inventori
patient
requir
urgent
platelet
transfus
addit
benefit
decreas
ap
wast
tabl
result
cost
save
addit
cost
save
approxim
note
due
decreas
cost
emerg
platelet
transport
conclus
novel
rr
process
platelet
distribut
result
improv
platelet
avail
smaller
commun
hospit
maintain
reduc
level
ap
wast
health
system
previou
platelet
share
process
anticip
addit
decreas
ap
wast
streamlin
process
trend
merg
health
deliveri
system
predict
health
system
adopt
similar
process
improv
platelet
avail
reduc
wast
backgroundcas
studi
implement
pathogen
reduct
apheresi
platelet
use
intercept
system
apheresi
platelet
substanti
endeavor
encompass
mani
differ
area
process
chang
adjust
modif
occur
along
way
implement
pathogen
reduct
technolog
prt
apheresi
platelet
made
two
addit
adjust
sampl
process
ensur
accur
labelingcategorizationbrand
final
product
studi
designmethod
prt
valid
consist
apheresi
platelet
product
product
test
white
blood
cell
wbc
content
platelet
yield
along
post
process
platelet
yield
data
use
calcul
yield
volum
retent
process
anticip
product
preprocess
yield
may
end
final
storag
bag
would
need
sampl
ensur
product
met
criteria
platelet
resultsfind
valid
discov
one
collect
leukoreduc
two
collect
start
yield
end
yield
two
discoveri
led
adjust
prt
platelet
process
wbc
failur
review
wbc
count
sysmex
preprocess
report
see
would
alert
us
potenti
wbc
failur
review
discov
result
except
wbc
failur
count
monitor
wbc
count
discov
result
test
adam
wbc
count
determin
leukoreduc
decid
sysmex
wbc
result
sysmex
report
would
review
prior
process
wbc
result
test
adam
confirm
leukoreduc
product
also
discov
preprocess
yield
product
end
post
process
yield
decid
increas
yield
requir
post
process
sampl
includ
conclus
continu
sampl
collect
post
process
yield
confid
releas
product
inventori
yield
platelet
enough
data
accur
determin
volum
yield
loss
process
backgroundcas
studi
univers
kentucki
medic
center
ukmc
larg
academ
hospit
level
trauma
center
suppli
blood
product
kentucki
blood
center
kbc
consign
contract
ukmc
kbc
largest
consum
blood
product
platelet
usag
vari
wide
day
day
platelet
usag
project
provid
kbc
ukmc
blood
bank
therebi
allow
kbc
act
accordingli
given
day
stock
ie
import
vs
export
daili
platelet
project
base
phone
call
ask
clinician
work
locat
estim
need
process
easili
confound
multipl
factor
undergon
multipl
adjust
improv
accuraci
studi
designmethod
daili
platelet
project
form
retrospect
review
compar
actual
usag
data
time
predict
system
use
ukmc
bb
time
estim
clinic
need
evalu
effect
base
total
number
day
number
day
larg
averag
number
unit
averag
differ
predict
usag
predict
system
subsequ
chang
base
data
revis
predict
method
estim
clinic
need
evalu
retrospect
use
data
sourc
cover
compar
prior
method
resultsfind
averag
number
platelet
transfus
ud
standard
deviat
ud
predict
amount
ud
differ
predict
amount
number
unit
use
ud
day
averag
ud
day
u
averag
u
max
u
averag
number
platelet
use
ud
standard
deviat
ud
predict
amount
ud
differ
predict
unit
use
ud
day
averag
ud
one
day
period
u
u
conclus
review
clinic
platelet
usag
time
identifi
rel
stabl
averag
daili
clinic
demand
adjust
predict
system
ensur
possibl
day
project
less
averag
markedli
reduc
catastroph
shortag
reduc
number
day
decreas
discrep
day
u
u
improv
estim
usag
allow
increas
abil
handl
unpredict
event
without
suddenli
strain
kbc
suppli
flexibl
sever
limit
ukmc
clinic
set
backgroundcas
studi
fda
issu
guidanc
document
reduc
risk
zkv
transmiss
blood
blood
compon
respons
plan
implement
mandatori
zkv
test
client
local
acquir
case
zkv
within
week
nationwid
week
organ
perform
test
client
blood
center
hospit
across
countri
report
manufactur
sponsor
provid
investig
new
drug
ind
protocol
singl
project
manag
pmo
system
use
control
requir
process
studi
designmethod
project
focu
includ
clinic
trial
requir
client
onboard
lab
oper
lab
object
implement
zkv
test
client
within
week
addit
client
within
week
minim
impact
lab
stagger
implement
use
trackedstreamlin
commun
stakehold
vendor
institut
review
board
irb
client
lab
base
client
servic
lab
resultsfind
clinic
trial
requir
increas
complex
implement
unlicens
test
document
includ
donor
notif
inform
consent
protocol
train
staff
certif
deviat
manag
result
report
multipl
irb
document
requir
ensur
accuraci
ind
commit
principl
investig
assign
lab
client
deliver
multipl
includ
client
requir
vendor
respons
lab
client
onboard
includ
confidenti
agreement
client
sponsor
immedi
zkv
base
webinar
provid
materi
understand
sponsor
protocol
lab
test
system
clientdonor
base
respons
facilit
ensur
effect
commun
twice
weekli
confer
call
held
client
sent
question
facilit
lab
direct
sponsor
specif
client
irb
document
updatesvalid
zkv
test
order
result
receipt
lab
multifacet
vendor
instrument
assay
materi
packag
insert
staff
train
assess
includ
zkv
sampl
volum
throughput
instrument
capabilitycapac
work
requir
includ
vendor
instal
equip
assay
reagent
qualif
staff
train
compet
assess
result
report
client
provid
zkv
test
within
requir
timefram
conclus
success
meet
rapid
implement
zkv
test
larg
due
central
pmo
system
provid
control
process
sponsor
client
vendor
lab
within
lesson
learn
strength
found
onboard
process
weak
understand
instrument
test
volum
capac
throughput
exceed
period
overcom
cycl
backgroundcas
studi
ill
children
like
receiv
red
blood
cell
rbc
transfus
patient
age
group
rbc
compon
often
transfus
neonat
period
small
volum
aliquot
use
limit
donor
exposur
prevent
circul
overload
decreas
donor
relat
risk
traceabl
abil
trace
individu
unit
donor
recipi
dispos
blood
compon
fulli
traceabl
collect
final
disposit
kuwait
central
blood
bank
kcbb
prepar
babi
unit
distribut
hospit
countri
kcbb
accredit
american
associ
blood
bank
aabb
follow
aabb
regul
trace
everi
compon
studi
designmethod
retrospect
studi
assess
final
deposit
percentag
discard
prepar
pack
rbc
babi
unit
kcbb
five
hospit
blood
bank
hbb
also
assess
level
traceabl
reflect
improv
effici
use
blood
product
method
total
rbc
babi
unit
randomli
chosen
trace
final
deposit
year
till
half
unit
trace
kcbb
tabl
show
number
chosen
unit
distribut
five
government
hbb
unit
year
studi
period
resultsfind
preliminari
result
show
trace
rbc
babi
unit
kcbb
effici
result
hospit
process
statist
analysi
traceabl
done
soon
data
collect
studi
analyz
usag
babi
unit
differ
depart
percentag
discard
unit
conclus
traceabl
rbc
babi
unit
kcbb
excel
due
good
manag
train
work
staff
use
electron
system
registr
issu
kuwait
government
hospit
use
electron
system
traceabl
recommend
level
percentag
discard
babi
unit
hospit
high
may
due
practic
use
fresh
blood
day
donat
reserv
babi
unit
donor
babi
reduc
hazard
multipl
donor
exposur
creation
nation
polici
use
rbc
babi
unit
highli
recommend
reduc
discard
unit
backgroundcas
studi
hospit
percent
rbc
purchas
much
higher
supplier
custom
averag
hospit
level
trauma
center
serv
divers
predomin
popul
histor
stock
trauma
blood
bank
monitor
refriger
rbc
trauma
request
stock
addit
rbc
abl
initi
mtp
multipl
patient
time
believ
trauma
patient
male
elderli
agre
add
type
rbc
stock
rule
determin
unit
use
establish
rbc
given
adult
male
women
age
wncba
rbc
use
yet
restock
rbc
given
women
childbear
age
wcba
children
patient
aborh
type
determin
sought
assess
impact
chang
usag
purchas
rbc
studi
designmethod
patient
issu
emerg
releas
trauma
rbc
follow
addit
rbc
assess
adher
rule
judg
overal
rbc
purchas
analyz
compar
histor
monthli
purchas
resultsfind
patient
receiv
least
rang
rbc
trauma
refriger
mtp
activ
patient
receiv
mean
rbc
rang
plasma
rang
sdp
rang
first
hour
patient
patient
male
wcba
mean
age
rang
year
given
trauma
patient
emerg
medicin
patient
patient
definit
requir
emerg
trauma
rbc
patient
receiv
given
rbc
rbc
appropri
given
wncba
rbc
given
although
patient
met
criteria
receiv
rbc
wcba
rbc
use
inappropri
quarterli
rbc
purchas
averag
unit
purchas
fewer
rbc
without
advers
impact
daili
inventori
par
level
conclus
stock
rbc
save
rbc
patient
requir
enabl
lab
purchas
fewer
type
rbc
march
trauma
rbc
issu
accord
rule
unit
would
need
addit
rbc
trauma
refriger
enabl
us
markedli
reduc
purchas
rbc
backgroundcas
studi
rural
blood
center
serv
hospit
divers
patient
popul
includ
acut
trauma
vari
need
platelet
product
vari
per
day
investig
use
verax
test
better
manag
valuabl
inventori
studi
designmethod
verax
test
implement
septemb
test
follow
manufactur
direct
product
test
expir
day
total
product
test
day
day
tabul
along
number
product
expir
transfus
also
calcul
number
fals
posit
result
studi
trace
product
resultsfind
total
product
test
fifteen
unit
fals
posit
result
could
life
span
extend
fifteen
reactiv
unit
two
repeat
donor
identifi
chart
mark
test
subsequ
donat
antibodi
identifi
vendor
none
true
posit
unit
success
test
test
day
use
day
platelet
transfus
expir
day
cost
test
product
includ
control
calcul
cost
produc
product
would
need
import
product
meet
need
cost
would
roughli
without
ship
cost
estim
averag
expir
platelet
product
per
month
rang
verax
test
rang
implement
conclus
use
verax
test
save
platelet
product
discard
cost
save
import
produc
replac
product
averag
discard
rate
per
month
went
verax
implement
extend
platelet
shelf
life
day
paid
cost
test
ensur
product
avail
patient
need
backgroundcas
studi
secur
text
messag
hospit
set
allow
quick
easi
hipaa
compliant
commun
member
patient
care
team
work
mobil
phone
comput
provid
confirm
temporari
record
team
commun
secur
text
potenti
use
manag
tool
transfus
medicin
reduc
blood
product
wastag
exampl
provid
rel
mean
busi
clinician
provid
feedback
transfus
servic
scenario
potenti
wastag
inform
use
identifi
area
manag
strategi
could
develop
also
allow
person
educ
opportun
clinician
blood
bank
usag
guidelin
reduc
futur
wastag
goal
studi
use
secur
text
investig
wastag
evalu
respons
clinician
evalu
potenti
effect
reduc
wastag
hope
result
identifi
secur
text
use
manag
tool
transfus
medicin
studi
designmethod
wastag
record
investig
without
assist
secur
text
juli
decemb
review
identifi
common
scenario
prevent
blood
product
wastag
wastag
record
januari
april
review
wast
product
consid
prevent
investig
use
secur
text
commun
order
physician
resultsfind
data
unit
investig
without
use
secur
text
unit
identifi
prevent
wastag
wast
unit
consid
beyond
control
clinician
categori
prevent
wastag
defin
follow
product
releas
procedur
patient
stabil
product
return
outsid
appropri
temperatur
rang
clinician
unawar
product
assign
thu
far
wastag
record
identifi
unit
prevent
wastag
secur
text
use
transfus
servic
physician
investig
twelv
respons
provid
use
feedback
futur
manag
strategi
respons
thank
transfus
servic
inform
instanc
messag
read
repli
conclus
secur
text
messag
potenti
improv
commun
transfus
medicin
easi
use
hipaa
compliant
help
identifi
strategi
reduc
wastag
improv
commun
allow
person
educ
opportun
order
physician
transfus
servic
backgroundcas
studi
dimethyl
sulfoxid
dmso
human
serum
albumin
hsa
wide
use
prepar
cryopreserv
freez
solut
use
autolog
plasma
instead
hsa
studi
identifi
choic
reagent
optim
sequenc
ad
reagent
make
freez
solut
studi
designmethod
materi
dmso
hsa
autolog
plasma
extract
contain
transfer
pack
bag
polystyren
tube
freez
solut
recip
use
studi
volum
ratio
dmso
hsa
kept
room
temperatur
rt
refriger
plasma
rt
simul
temperatur
dmso
rt
due
high
freez
point
differ
combin
reagent
choic
storag
temperatur
ad
sequenc
test
photo
taken
total
test
least
minut
cool
dmso
ad
next
reagent
resultsfind
see
tabl
directli
ad
dmso
alon
bag
bag
turn
transpar
white
dmso
add
first
tube
autolog
plasma
first
dmso
next
precipit
tube
dmso
first
hsa
next
precipit
instantli
layer
appear
tube
first
hsa
dmso
last
precipit
form
rt
hsa
combin
form
thicker
precipit
kept
tube
hsa
first
dmso
next
precipit
form
heavili
sculptur
shape
precipit
group
slightli
milderslow
rt
group
hsa
ad
first
trace
hsa
mix
bag
tube
ad
first
dmso
small
fragment
precipit
form
dmso
add
last
tube
first
rt
dmso
either
plasma
hsa
clear
conclus
ideal
sequenc
add
first
dmso
cool
suffici
add
hsa
plasma
last
backgroundcas
studi
maintain
robust
blood
product
suppli
essenti
requir
guarante
optim
patient
care
major
hospit
howev
daili
blood
product
use
difficult
anticip
platelet
product
variabl
daili
usag
short
shelf
live
also
one
expens
product
produc
test
store
due
combin
absolut
need
uncertain
daili
demand
short
platelet
product
also
frequent
wast
due
expir
sophist
data
analysi
potenti
accur
predict
hospit
wide
platelet
need
therefor
reduc
wastag
studi
designmethod
investig
platelet
usag
pattern
institut
specif
interrog
relationship
platelet
usag
aggreg
patient
data
recent
consecut
period
use
convex
statist
formul
found
platelet
usag
highli
depend
sever
factor
includ
day
week
number
abnorm
cbc
hospit
censu
data
less
import
factor
exploit
relationship
develop
mathemat
model
guid
collect
order
strategi
resultsfind
model
minim
wast
due
expir
never
allow
shortag
number
remain
platelet
unit
end
day
never
drop
model
compar
histor
expir
rate
period
model
reduc
expir
rate
annual
platelet
usag
approxim
unit
reduct
equat
approxim
unit
save
expir
annual
depend
platelet
price
differ
region
account
annual
save
per
institut
conclus
knowledg
research
first
use
hospit
wide
data
inform
donor
recruit
strategi
base
anticip
patient
demand
backgroundcas
studi
plasma
ffp
store
outdat
hour
thaw
collect
function
close
system
may
relabel
thaw
plasma
tp
extend
expir
day
thaw
date
although
coagul
factor
level
decreas
period
remain
hemostat
level
tp
safe
use
vast
major
patient
requir
coagul
support
implement
use
tp
tertiari
care
system
aim
decreas
cost
minim
wastag
studi
designmethod
massiv
transfus
protocol
instiut
alreadi
allow
use
group
ab
tp
follow
review
literatur
practic
larg
center
transfus
committe
extend
approv
tp
patient
neonat
month
patient
undergo
plasmapheresi
factor
defici
disord
concentr
avail
continu
support
thaw
ffp
design
deploy
dynam
blood
product
inventori
dashboard
monitor
facilit
easi
inventori
look
identifi
plasma
unit
near
expir
assist
rotat
thaw
inventori
differ
transfus
servic
hospit
site
minim
wastag
data
number
plasma
unit
transfus
tr
outdat
od
obtain
li
report
disposit
unit
resultsfind
plasma
disposit
month
prior
month
implement
tp
review
tabl
implement
tp
thaw
plasma
unit
wast
decreas
implement
reduct
likelihood
unit
wast
mean
number
plasma
unit
wastedmonth
decreas
monthli
save
blood
procur
cost
also
note
signific
decreas
quantifi
technologist
time
effort
less
time
expend
follow
thaw
unit
print
inventori
report
discard
unit
conclus
mani
larg
facil
provid
frequent
order
plasma
unit
ultim
transfus
lead
high
plasma
wastag
rate
due
limit
hr
tp
extend
use
interchang
ffp
patient
implement
tp
tertiari
health
care
system
result
sustain
decreas
plasma
wastag
save
thousand
dollar
help
conserv
preciou
resourc
tabl
plasma
disposit
statist
tp
implement
backgroundcas
studi
immunohematolog
refer
lab
irl
must
maintain
divers
inventori
antisera
aid
antibodi
identif
antigen
type
rbc
unit
meet
regulatori
requir
current
organ
establish
two
irl
site
independ
inventori
manag
system
although
purpos
maintain
antisera
inventori
organ
storag
access
instruct
use
ifu
irl
develop
synergist
method
organ
store
antisera
coupl
design
custom
excel
spreadsheet
organ
search
antisera
view
ifu
studi
designmethod
list
similar
differ
construct
best
practic
method
identifi
determin
antisera
could
broadli
classifiedorgan
two
main
categori
rare
bulk
screen
sequenti
lab
assign
number
given
antiserum
categori
rare
sera
b
bulk
sera
dynamicstat
freezer
box
storag
system
static
dynam
determin
best
option
combin
two
inventori
conserv
element
allow
librari
growth
antisera
assign
box
remain
box
may
move
within
box
box
may
move
among
freezer
track
box
locat
movement
within
box
custom
excel
spreadsheet
creat
locat
track
featur
allow
two
differ
storag
method
function
one
spreadsheet
spreadsheet
tab
b
antisera
categori
abo
group
desir
unwant
antibodi
filter
allow
quick
search
appropri
antisera
spreadsheetalso
hyperlink
scan
ifu
resultsfind
sequenti
lab
b
number
assign
new
addit
use
dynamicstat
storag
system
excel
spreadsheet
scan
ifu
hyperlink
use
system
took
averag
minut
choos
antiserum
obtain
appropri
ifu
system
reduc
averag
minut
tabl
conclus
merg
two
irl
antisera
inventori
result
need
innov
creat
inventori
manag
system
advanc
search
function
hyperlink
ifu
process
save
valuabl
technologist
time
organ
antisera
effici
backgroundcas
studi
although
data
analyt
tool
greatli
aid
blood
inventori
manag
laboratori
may
lack
resourc
access
technolog
use
skill
design
deploy
fulli
autom
dynam
transfus
servic
ts
electron
dashboard
studi
designmethod
dashboard
use
hyper
text
markup
languag
html
cascad
style
sheet
css
hypertext
preprocessor
php
data
extract
sunquest
laboratori
inform
system
databas
intersystem
cach
webpag
deliv
data
client
distribut
via
microsoft
group
polici
shortcut
webserv
host
intern
center
data
secur
rest
transit
client
workstat
secur
socket
layer
certif
resultsfind
laboratori
informat
ts
collabor
build
dashboard
week
prototyp
test
technologist
feedback
help
make
tool
integr
seamlessli
workflow
dashboard
data
valid
dashboard
access
via
desktop
shortcut
also
display
larg
monitor
lab
data
refresh
automat
everi
min
webpag
complet
customiz
afford
flexibl
updat
page
fli
well
capabl
run
test
environ
five
differ
tab
provid
inform
product
inventori
tab
display
follow
variabl
rbc
unit
aborh
cmv
statu
unit
await
abo
retyp
children
hospit
dashboard
provid
detail
rbc
age
day
divid
unit
expir
time
wash
unit
page
also
display
unit
requir
replenish
inventori
color
code
scheme
alert
staff
platelet
aborh
cmv
statu
shown
plasma
cryoprecipit
abo
type
display
unit
avail
tab
display
unit
number
compon
type
aborh
expir
date
time
differ
color
display
unit
expir
hour
hour
hour
flash
display
alert
staff
unit
expir
hour
expir
unit
continu
flash
remov
shelf
statu
updat
databas
unit
alloc
tab
includ
truncat
patient
name
protect
privaci
unit
number
compon
type
alloc
expir
datetim
time
sinc
alloc
flash
alert
unit
expir
hour
xmhla
platelet
tab
provid
patient
name
statu
unit
alloc
trxnxmplat
tab
list
pend
transfus
reaction
platelet
cross
match
report
dashboard
elimin
print
sever
timesshift
lengthi
report
simplifi
thaw
plasma
inventori
manag
help
decreas
plasma
wastag
conclus
use
talent
minim
capit
expenditur
design
implement
dynam
dashboard
manag
blood
product
inventori
across
transfus
servic
dashboard
stabl
customiz
requir
littl
mainten
initi
built
optim
inventori
display
thaw
plasma
implement
dashboard
expand
includ
allogen
blood
product
past
year
tool
replac
manual
process
monitor
rotat
inventori
directli
help
decreas
plasma
wastag
backgroundcas
studi
region
blood
shortag
document
across
unit
state
winter
holiday
timefram
deglycerol
red
blood
cell
drbc
shown
effect
altern
though
expens
manufactur
studi
look
fiscal
inventori
efficaci
use
drbc
meet
need
transfus
servic
time
blood
shortag
studi
designmethod
three
separ
occas
medium
size
dod
donor
center
use
frozen
blood
inventori
produc
type
drbc
meet
need
two
region
transfus
servic
frozen
red
cell
manufactur
offsit
facil
haemonet
use
low
glycerol
freez
method
frozen
within
six
day
collect
thaw
occur
water
bath
follow
order
posit
neg
januari
posit
neg
februari
neg
februari
deglycerol
occur
site
use
unit
pass
intern
qc
requir
drbc
ship
day
hospit
transfus
servic
allow
day
shelf
life
prior
expir
resultsfind
three
event
support
transfus
servic
blood
center
minimum
inventori
requir
standard
type
red
blood
cell
rbc
posit
rbc
avail
nbe
limit
arriv
next
busi
day
collect
process
time
liquid
rbc
take
approxim
two
day
includ
donor
screen
phlebotomi
compon
process
test
label
drbc
cost
dod
averag
per
unit
produc
distribut
drbc
shorter
shelf
life
day
versu
day
rbc
wash
deglycerol
thu
produc
fewer
transfus
reaction
one
tech
oper
four
deglycerol
four
unit
time
januari
februari
took
one
tech
four
hour
per
iter
eight
unit
includ
thaw
label
pack
shipment
conclus
readili
avail
tradit
rbc
drbc
effect
product
bridg
inventori
gap
small
number
unit
need
due
reduc
inventori
collect
process
whole
blood
compon
take
approxim
two
day
produc
greater
number
unit
timefram
base
drbc
readi
faster
freshli
collect
unit
blood
increas
cost
associ
manufactur
frbc
compens
longer
avail
shelf
life
year
small
conting
suppli
frozen
red
cell
deglycerol
equip
effect
three
occas
ensur
avail
type
red
blood
cell
hospit
transfus
servic
backgroundcas
studi
plasma
fraction
requir
quantit
test
perform
plasma
sampl
collect
individu
donor
plasma
product
pool
test
serv
qualiti
control
test
help
estim
antibodi
potenc
product
bind
site
human
toxoid
immunoglobulin
liquid
reagent
kit
use
turbidimetr
analyz
aim
optim
valid
human
toxoid
immunoglobulin
liquid
reagent
kit
use
photometr
analyz
studi
designmethod
experi
perform
order
determin
optim
amount
requir
reagent
buffer
latex
reagent
toxoid
immunoglobulin
kit
util
abbott
instrument
precis
new
assay
paramet
determin
test
replic
panel
sampl
three
concentr
tetanu
antibodi
singl
test
run
panel
sampl
creat
spike
appropri
amount
tetanu
antibodi
standard
sodium
citrat
plasma
accuraci
determin
test
seri
sampl
rang
iuml
iuml
tetanu
antibodi
sampl
accuraci
studi
creat
dilut
appropri
amount
tetanu
antibodi
standard
sampl
diluent
reagent
kit
linear
regress
determin
use
accuraci
studi
valu
within
rang
iuml
stabil
sampl
determin
test
sampl
store
triplic
variou
time
interv
resultsfind
cv
optim
assay
antibodi
level
determin
precis
studi
vari
precis
accept
sinc
cv
sampl
test
mean
valu
sampl
test
accuraci
studi
expect
valu
much
lower
accept
criteria
expect
valu
linear
assay
accept
linear
studi
establish
known
tetanu
concentr
statist
signific
predictor
observ
concentr
sampl
stabil
studi
demonstr
abil
quantit
tetanu
antibodi
concentr
sampl
store
day
month
conclus
data
present
show
success
optim
human
immunoglobulin
reagent
kit
use
photometr
analyz
valid
studi
optim
assay
demonstr
excel
accuraci
precis
linear
use
sampl
store
day
store
one
month
backgroundcas
studi
intraven
immunoglobulin
ivig
gener
safe
effect
therapi
immun
thrombocytopenia
itp
suggest
scenario
rapid
increas
platelet
count
desir
first
line
therapi
steroid
contraind
due
concern
regard
advers
effect
cost
resourc
avail
ivig
request
form
implement
jurisdict
track
util
appropri
recent
audit
request
form
four
academ
institut
found
lack
complianc
form
requir
inadequ
document
efficaci
led
author
conclud
use
ivig
broadli
inappropri
shih
etal
aim
conduct
extens
chart
review
patient
receiv
ivig
itp
institut
assess
appropri
use
studi
designmethod
conduct
retrospect
chart
review
patient
itp
receiv
ivig
institut
april
march
local
research
ethic
board
approv
obtain
resultsfind
patient
receiv
ivig
itp
smh
studi
period
total
uniqu
ivig
infus
common
indic
ivig
within
current
accept
guidelin
activ
bleed
antepartum
care
platelet
count
less
contraind
corticosteroid
addit
indic
still
fell
within
accept
guidelin
recommend
includ
patient
arterialven
thromboembol
risk
thereof
requir
initi
antithrombot
therapi
patient
requir
myelosuppress
chemotherapi
indic
fell
outsid
guidelin
includ
use
ivig
diagnost
challeng
etiolog
thrombocytopenia
unclear
use
prior
intern
travel
patient
chronic
itp
despit
platelet
count
x
patient
receiv
ivig
like
diagnosi
itp
investig
altern
explan
thrombocytopenia
three
patient
refractori
therapi
itp
depend
regular
ivig
infus
infus
consist
day
remaind
infus
consist
receiv
patient
evid
partial
remiss
first
dose
ivig
gener
well
toler
infus
reaction
mitig
use
corticosteroid
antipyret
andor
antihistamin
conclus
found
institut
use
ivig
itp
gener
appropri
care
consid
even
case
meet
current
guidelin
recommend
believ
ivig
remain
import
treatment
itp
particularli
age
popul
preval
condit
complic
bleed
risk
increas
detail
util
knowledg
data
inquiri
requir
develop
tool
polici
enhanc
appropri
ivig
use
multipl
set
believ
opportun
promot
administr
singl
dose
minim
unnecessari
util
ivig
amongst
hematologist
manag
itp
backgroundcas
studi
mission
institut
reduc
risk
injuri
accordingli
year
ergonom
survey
undertaken
compon
gener
depart
laboratori
medicin
patholog
safeti
audit
survey
identifi
potenti
musculoskelet
risk
suggest
redesign
crossmatch
bench
studi
designmethod
seven
item
ergonom
survey
work
environ
sent
staff
member
earli
februari
technologist
respond
respons
rate
tabl
report
survey
item
respons
resultsfind
problemat
area
avail
workspac
respond
indic
workspac
size
insuffici
chair
fix
height
bench
problemat
problem
note
difficulti
climb
chair
back
chair
hold
chosen
height
laboratori
lean
team
oper
support
group
task
aid
bench
redesign
choos
product
improv
workspac
goal
design
layout
streamlin
test
workflow
better
util
lab
space
includ
plasma
thaw
sink
space
elimin
dead
space
configur
new
workspac
guid
survey
find
adjust
height
workstat
recommend
replac
fix
height
bench
work
facil
design
contactor
purchas
adjust
bench
plan
cabinet
shop
work
bench
assembl
site
allow
bench
top
layout
determin
instal
cabinet
shop
drawer
suppli
pull
breadboard
write
surfac
opportun
assembl
site
streamlin
process
instal
result
minim
disrupt
test
conclus
survey
effect
identifi
work
area
improv
employe
comment
posit
new
workstat
effect
assess
follow
use
origin
survey
assess
success
project
tabl
crossmatch
bench
ergonom
survey
backgroundcas
studi
type
screen
test
often
order
patient
present
emerg
depart
ed
patient
histor
type
second
sampl
drawn
addit
phlebotomi
type
confirm
patient
need
transfus
red
blood
cell
rbc
test
second
phlebotomi
ineffici
use
resourc
time
studi
designmethod
part
perform
improv
initi
transfus
medicin
perform
retrospect
studi
order
initi
ed
determin
test
subsequ
follow
transfus
blood
product
patient
stratifi
ed
depart
time
draw
tsd
transfus
hour
hour
hour
second
sampl
requir
resultsfind
total
order
initi
ed
time
period
patient
subsequ
transfus
type
blood
product
within
hour
tsd
patient
subsequ
transfus
type
blood
product
within
hour
tsd
total
patient
requir
second
sampl
patient
requir
second
sampl
subsequ
transfus
type
blood
product
within
hour
tsd
subsequ
transfus
type
blood
product
within
hour
tsd
conclus
routin
order
test
effici
use
resourc
time
mani
patient
subsequ
transfus
ultim
unnecessari
second
sampl
collect
test
patient
subsequ
transfus
within
hour
tsd
amount
estim
unnecessari
patient
charg
approxim
nurs
hour
phlebotomi
six
month
period
backgroundcas
studi
institut
healthcar
improv
tripl
aim
incorpor
enhanc
patient
satisfact
provid
high
qualiti
safe
care
toward
goal
bbtm
charg
commun
obstetr
physician
ob
patient
antibodi
specif
associ
hemolyt
diseas
fetusnewborn
risk
thu
detect
femal
childbear
age
critic
determin
whether
repres
rh
immun
globulin
rhig
alloimmun
review
patient
electron
health
record
ehr
help
quickli
identifi
rhig
administr
document
miss
easi
assum
presenc
rhd
alloimmun
impact
mom
fetu
newborn
futur
pregnanc
therefor
without
nation
comprehens
health
inform
exchang
hie
system
imper
investig
beyond
ehr
whether
patient
receiv
rhig
outsid
hospit
oh
report
irb
approv
exempt
case
seri
detect
work
reveal
rhig
administr
oh
studi
designmethod
two
month
time
period
identifi
four
pregnant
women
review
ehr
reveal
histori
rhig
administr
subsequ
direct
commun
obstetrician
ob
reveal
histori
rhig
base
patient
home
address
bbtm
nearbi
oh
contact
primari
care
physician
list
ehr
resultsfind
investig
beyond
ehr
ob
reveal
four
patient
receiv
discontinu
prenat
care
present
multipl
site
phone
call
bbtm
oh
histori
one
rhig
administr
within
preced
three
month
found
patient
bbtm
record
ehr
amend
reflect
presenc
passiv
due
rhig
rather
chang
also
directli
commun
ob
care
patient
conclus
new
identifi
pregnant
femal
investig
requir
determin
whether
passiv
rhig
versu
neither
ehr
patient
histori
ob
reveal
rhig
histori
remain
patient
best
interest
investig
phone
call
oh
reveal
histori
rhig
administr
four
patient
find
commun
critic
inform
help
enhanc
qualiti
safeti
patient
ensur
subsequ
rhig
administr
indic
institut
futur
strategi
avoid
similar
situat
includ
expand
nation
hie
critic
inform
bbtm
histori
allergi
histori
expand
use
patient
identif
card
rhig
alloantibodi
histori
backgroundcas
studi
larg
midwest
hospit
system
level
trauma
site
evalu
audit
massiv
transfus
protocol
mtp
possibl
real
time
audit
impract
due
unpredict
event
search
internet
found
exampl
new
zealand
post
process
evalu
share
team
start
point
adjust
system
specif
prioriti
start
audit
initi
mtp
need
determin
event
often
start
verbal
request
follow
either
downtim
comput
order
studi
designmethod
transfus
servic
ts
determin
sourc
truth
mtp
event
track
sheet
creat
captur
patient
demograph
start
stop
time
number
type
product
issu
wastag
pass
onto
nurs
qualiti
staff
use
track
form
patient
chart
enter
event
error
manag
data
base
focus
event
focus
event
built
includ
patient
demograph
inform
track
form
well
event
call
surgeri
emerg
ed
labor
deliveri
l
etc
type
event
use
tranexam
acid
txa
calcium
chlorid
cacl
temperatur
monitor
pre
post
lab
result
trial
start
month
data
evalu
contain
event
resultsfind
equal
number
event
initi
ed
male
patient
involv
time
time
patient
expir
trauma
type
major
caus
case
involv
gi
bleed
obstetr
case
see
chart
lowest
hemoglobin
hgb
found
averag
post
hgb
averag
ratio
red
blood
cell
rbc
plasma
well
rbc
platelet
plt
cryoprecipit
cryo
also
determin
target
found
rbc
plasma
rbc
plt
rbc
cryo
use
txa
cacl
util
case
conclus
although
data
short
period
time
point
sever
opportun
improv
use
mtp
gi
case
previous
understood
open
new
group
peopl
educ
understand
mtp
process
need
low
use
txa
need
evalu
alreadi
start
convers
drug
store
access
mtp
process
product
ratio
number
suspect
data
avail
much
easier
speak
issu
look
improv
process
expand
level
ii
trauma
site
system
routin
evalu
share
site
backgroundcas
studi
clinic
signific
antibodi
promptli
clearli
commun
patient
healthcar
team
avoid
potenti
transfus
delay
blood
avail
complic
incompat
transfus
institut
newli
identifi
clinic
signific
antibodi
immedi
result
electron
medic
record
emr
interpret
comment
also
enter
transfus
medicin
servic
tm
physician
antibodi
review
may
week
antibodi
identifi
comment
describ
antibodi
i
identifi
indic
need
crossmatch
compat
blood
alert
clinician
possibl
delay
provid
crossmatch
unit
sinc
clinician
may
alway
review
result
tm
physician
also
simultan
add
allergi
red
blood
cell
alert
patient
emr
time
interpret
comment
enter
studi
designmethod
juli
implement
autom
report
reduc
turnaround
time
tat
entri
allergi
alert
report
contain
detect
red
cell
antibodi
prior
hour
provid
tm
physician
daili
morn
round
monday
friday
manual
entri
allergi
alert
studi
describ
three
month
comparison
autom
report
intervent
evalu
tat
allergi
alert
entri
emr
resultsfind
august
novemb
newli
identifi
clinic
signific
antibodi
result
patient
compar
patient
month
august
novemb
tat
allergi
alert
entri
period
shown
tabl
observ
allergi
comment
perform
within
hour
period
versu
use
new
process
nearli
alert
enter
emr
within
hour
antibodi
result
none
entri
miss
conclus
signific
improv
tat
allergi
comment
entri
follow
implement
autom
report
project
illustr
inform
technolog
leverag
facilit
time
commun
antibodi
identif
tabl
comparison
tat
allergi
comment
entri
process
improv
backgroundcas
studi
institut
tertiari
care
facil
perform
cardiovascular
surgeri
cv
increas
healthcar
system
cv
integr
transfus
support
patient
includ
preoper
prepar
prbc
accord
maximum
surgic
blood
order
schedul
addit
blood
compon
issu
order
place
decemb
addit
written
order
submit
blood
bank
via
pneumat
tube
system
without
commun
report
event
result
delay
blood
transfus
examin
process
close
identifi
opportun
improv
collabor
cv
blood
bank
implement
new
workflow
process
enhanc
commun
cv
team
reduc
turnaround
time
improv
patient
safeti
studi
designmethod
open
discuss
collabor
blood
bank
cv
nurs
teamsmap
process
use
flowchart
addit
blood
order
cvsidentifi
bottleneck
brainstorm
solutionsa
verbal
cv
order
process
form
implement
improv
commun
cv
blood
bank
solidifi
commun
includ
time
order
patient
identifi
caller
identif
order
prescrib
staff
receiv
order
quantiti
kind
product
order
mode
order
deliveri
anticip
futur
order
read
back
also
document
verif
orderth
blood
bank
staff
immedi
process
order
wait
written
order
arriv
upon
receipt
written
order
blood
issu
orfollow
transfus
safeti
offic
review
order
follow
paramet
numbertyp
product
turn
around
time
tat
wastagereturn
product
overal
efficaci
sinc
implement
process
resultsfind
signific
improv
note
commun
tat
implement
process
describ
period
blood
bank
receiv
verbal
order
vari
product
combin
tabl
repres
averag
time
issu
blood
product
tabl
mean
tat
blood
product
issu
conclus
introduct
verbal
order
tool
cv
streamlin
blood
order
process
lead
increas
effici
lower
tat
effect
commun
team
transfus
servic
key
time
provis
blood
product
critic
patient
backgroundcas
studi
report
midwestern
univers
transfus
servic
challeng
obtain
correct
blood
type
rbc
exchang
sickl
cell
diseas
scd
patient
test
primari
test
method
red
cell
adher
analyz
echo
immucor
norcross
ga
echo
oper
manual
chapter
appendix
state
warn
galileo
echo
reliabl
detect
hemagglutin
reaction
grade
less
tube
methodolog
galileo
echo
gener
interpret
reaction
interpret
posit
neg
equivoc
report
challeng
analyz
limit
impact
assign
correct
blood
type
multipli
transfus
scd
patient
studi
designmethod
two
scd
initi
test
echo
neg
howev
patient
histor
posit
patient
receiv
rbc
exchang
transfus
neg
red
blood
cell
day
previous
repeat
test
sampl
complet
vision
ortho
clinic
diagnost
raritan
nj
neo
immucor
norcross
ga
standard
aborh
manual
test
seri
seri
cell
b
cell
immucor
norcross
ga
repeat
test
compar
verifi
patient
aborh
type
result
enter
comput
system
allow
assign
patient
aborh
type
electron
crossmatch
resultsfind
tabl
summar
initi
repeat
test
two
patient
sampl
although
echo
fail
interpret
flag
blood
type
method
identifi
transfus
neg
blood
detect
type
fail
interpret
aborh
type
determin
ntd
vision
manual
aborh
type
yield
easiest
interpret
macroscop
conclus
result
agre
find
summer
etal
transfus
report
challeng
detect
use
echo
compar
improv
detect
autom
gel
column
agglutin
sampl
test
multipl
autom
manual
aborh
method
expect
detect
failur
echo
detect
acknowledg
manufactur
risk
facil
may
mistyp
aborh
histor
aborh
compar
avoid
risk
may
appropri
first
time
scd
patient
method
rather
echo
avoid
challeng
consist
summer
etal
consist
may
observ
vision
manual
aborh
test
tabl
initi
repeat
test
histor
posit
patient
backgroundcas
studi
safe
transfus
order
requir
knowledg
patient
transfus
reaction
histori
multipl
health
care
provid
involv
patient
care
inform
hand
crucial
patient
safeti
repeat
exposur
transfus
increas
risk
transfus
advers
event
warrant
effect
tool
commun
transfus
safeti
offic
tso
facilit
accredit
council
graduat
medic
educ
acgm
requir
transit
care
resid
involv
studi
designmethod
april
decemb
transfus
reaction
report
nation
health
safeti
network
nhsn
hemovigil
recurr
allerg
reaction
evalu
document
gap
electron
medic
record
emr
evalu
tso
implement
measur
ensur
report
transfus
reaction
transfus
medicin
team
direct
care
provid
util
electron
medic
record
emr
frequenc
care
provid
updat
emr
versu
tso
evalu
june
decemb
plan
studi
act
pdsa
methodolog
use
incorpor
systemat
hand
resid
day
transfus
medicin
team
transfus
safeti
offic
tso
focu
creation
implement
revis
standard
templat
intranet
drop
box
util
complianc
assess
resultsfind
total
compon
issu
patient
transfus
reaction
rate
per
compon
april
decemb
allerg
transfus
reaction
account
patient
experienc
repeat
reaction
requir
premed
escal
three
patient
requir
volum
reduct
requir
wash
product
one
patient
experienc
repeat
reaction
associ
lack
frequenc
tso
versu
direct
provid
updat
emr
shown
tabl
resid
report
intranet
drop
box
increas
month
time
span
conclus
safe
transfus
order
requir
team
approach
ensur
right
inform
avail
order
provid
right
time
safe
order
prevent
recurr
allerg
reaction
patient
popul
tso
play
pivot
role
ensur
full
circl
commun
occur
process
integr
patholog
resid
improv
pdsa
cycl
impact
qualiti
timeli
hand
final
data
provid
resid
enabl
effici
particip
hemovigil
backgroundcas
studi
track
except
laboratori
defin
instanc
result
test
whole
blood
donor
sampl
sent
client
within
contractu
hour
turnaround
time
failur
releas
test
result
within
contractu
turnaround
time
affect
avail
client
blood
product
avail
possibl
neg
affect
patient
aim
significantli
decreas
number
except
laboratori
baselin
level
except
except
per
day
defect
per
million
opportun
dpmo
lean
six
sigma
approach
process
improv
util
identifi
root
caus
develop
countermeasur
order
decreas
except
lab
studi
designmethod
daili
except
count
track
graph
thru
whi
perform
determin
root
caus
except
gemba
walk
perform
lab
test
process
help
identifi
area
improv
process
improv
team
met
frontlin
staff
develop
new
process
need
countermeasur
gener
implement
student
util
determin
statist
signific
number
except
observ
counter
measur
compar
number
except
seen
counter
measur
resultsfind
main
root
caus
determin
standard
work
process
sop
follow
standard
work
process
includ
detail
test
follow
effici
work
flow
counter
measur
implement
includ
implement
standard
work
process
visual
cue
ad
work
process
sampl
await
test
report
creat
batch
releas
depart
specif
locat
identifi
within
work
cell
lab
place
sampl
base
phasestag
test
counter
measur
implement
number
except
decreas
per
day
dpmo
per
day
dpmo
statist
signific
differ
sinc
calcul
conclus
lean
six
sigma
approach
process
improv
util
identifi
root
caus
develop
countermeasur
order
decreas
number
except
relat
test
whole
blood
sampl
laboratori
approach
counter
measur
statist
significantli
decreas
number
except
seen
whole
blood
test
process
backgroundcas
studi
maintain
suffici
red
blood
cell
rbc
inventori
key
role
hospit
blood
bank
balanc
ensur
shortag
affect
patient
care
excess
stockingexpiri
previou
approach
focus
shortag
bsr
outdat
rate
odr
account
region
distribut
mani
larg
hospit
act
region
hub
redistribut
may
appear
optim
inventori
base
odr
bsr
hypothes
crude
key
perform
indic
kpi
requir
redevelop
studi
designmethod
kpi
redevelop
occur
larg
tertiari
care
hospit
blood
bank
canada
respons
transfus
region
provinc
respect
rbc
suppli
inventori
disposit
data
retrospect
assess
februari
baselin
period
inventori
plan
polici
ddip
institut
assess
implement
optim
rbc
reorder
quantiti
base
differ
histor
maximum
minimum
rbc
inventori
weekday
would
lead
blood
shortag
inventori
sli
chosen
main
surrog
marker
assess
effici
suppli
chain
process
calcul
differ
age
blood
transfus
abt
receiv
abr
iter
simul
model
r
statist
softwar
perform
optim
sli
period
june
resultsfind
model
predict
observ
rbc
disposit
simul
optim
sli
found
occur
optim
set
kpi
abo
blood
group
tabl
led
reduct
observ
overal
sli
day
vs
day
p
odr
vs
bsr
significantli
increas
period
conclus
optim
use
simul
model
multipl
factor
bsr
odr
led
effici
gain
larg
tertiari
care
hospit
blood
bank
hospit
blood
bank
use
integr
approach
set
kpi
optim
suppli
chain
approach
requir
valid
blood
bank
jurisdict
tabl
comparison
key
perform
indic
optim
blood
group
backgroundcas
studi
hospit
transfus
unit
blood
potenti
hiv
hcv
infecti
cm
condit
particip
cfr
b
requir
hospit
make
reason
attempt
notifi
patient
patient
physician
counsel
patient
offer
test
hospit
must
maintain
record
lookback
notif
part
patient
medic
record
paper
record
lookback
notif
less
access
electron
record
greater
risk
damag
lost
facilit
lookback
process
reduc
paper
document
sought
use
electron
medic
record
emr
perform
document
notif
studi
designmethod
repres
transfus
medicin
tm
inform
technolog
work
togeth
defin
minimum
optim
emr
solut
minim
complet
paper
packet
could
scan
emr
solut
advantag
term
eas
use
process
control
transpar
desir
optim
function
includ
abil
send
letter
emr
document
control
origin
commun
may
alter
opportun
patient
physician
electron
sign
return
respons
letter
form
templat
individu
abil
track
notif
sent
receiv
emr
system
institut
epic
epic
system
corp
verona
wi
function
call
letter
capac
task
seri
five
templat
develop
hiv
hcv
letter
physician
respons
form
physician
return
transfus
servic
blank
letter
templat
use
special
tailor
letter
templat
open
within
patient
emr
demograph
inform
automat
popul
epic
elimin
mani
possibl
cleric
error
blood
product
transfus
eg
rbc
plasma
select
menu
date
transfus
manual
enter
sender
complet
letter
rout
patient
physician
show
automat
instantli
electron
basket
well
patient
emr
physician
may
electron
complet
return
respons
form
within
epic
print
return
form
fax
resultsfind
januari
decemb
notif
sent
physician
use
epic
letter
fourteen
respond
epic
notif
five
use
provid
electron
respons
form
case
time
mail
paper
notif
avoid
remain
case
requir
paper
notif
electron
letter
remain
perman
easili
access
document
transfus
servic
first
notifi
physician
conclus
lookback
notif
within
emr
make
complianc
govern
requir
transpar
record
access
caregiv
patient
assessor
secondarili
effici
may
improv
reduc
need
print
maildeliv
letter
backgroundcas
studi
blood
product
wastag
issu
mani
hospit
aim
address
identifi
highest
rate
wastag
within
hospit
studi
assess
appropri
product
order
util
understand
impact
wastag
studi
designmethod
data
product
order
issu
return
two
month
analyz
hospit
cpoe
product
requisit
form
use
collect
data
surgic
procedur
number
order
unit
compar
hospit
maximum
surgic
blood
order
schedul
msbo
trend
inappropri
order
product
physician
evalu
resultsfind
total
order
review
approxim
product
issu
found
physician
order
within
guidelin
msbo
case
issu
product
return
blood
bank
case
observ
percentag
product
order
use
compar
product
order
return
cardiac
surgeri
nearli
equal
addit
product
order
use
albeit
order
frequenc
significantli
lower
cardiac
case
conclus
data
analyz
demonstr
major
surgeon
adher
institut
msbo
guidelin
note
surgeon
request
product
issu
invas
procedur
rapid
exsanguin
possibl
analysi
reveal
hospit
msbo
allow
excess
blood
order
surgic
procedur
msbo
updat
reduc
suggest
maximum
product
order
gener
data
impli
blood
product
wastag
due
order
practic
surgeon
larger
period
surgic
blood
order
practic
analyz
detect
blood
product
order
util
wastag
trend
subspecialti
backgroundcas
studi
max
ortho
diagnost
raritan
new
jersey
gel
autom
immunohematolog
analyz
market
small
medium
type
screen
per
day
blood
respect
laboratori
serv
larg
multispecialti
academ
hospit
receiv
specimen
per
day
need
replac
three
provu
analyz
prior
avail
max
implement
three
analyz
work
exist
immucor
inc
norcross
georgia
recent
multicent
field
applic
trial
report
mean
turnaround
time
tat
abo
rh
type
aborh
respect
object
studi
determin
tat
routin
daili
practic
studi
designmethod
one
oper
period
phase
two
addit
analyz
brought
servic
phase
ii
tat
defin
time
order
receiv
instrument
test
complet
avail
review
screen
aborh
tat
number
antibodi
panel
collect
period
tat
screen
use
tat
screen
rate
determin
step
test
perform
use
analyz
routin
patient
sampl
train
technologist
sampl
deliber
batch
place
analyz
base
volum
flow
work
time
resultsfind
high
volum
condit
laboratori
three
analyz
mean
tat
longer
larger
standard
deviat
sd
publish
trial
result
phase
perform
panel
phase
ii
perform
panel
tabl
tat
mean
sd
minut
mean
sampl
per
day
phase
ii
conclus
analyz
use
high
volum
condit
suitabl
max
balanc
test
menu
includ
abil
perform
select
cell
panel
tat
use
three
analyz
satisfactori
larg
standard
deviat
indic
opportun
remain
improv
tat
workflow
improv
refer
fda
clear
ortho
vision
r
max
analyz
transfus
medicin
lab
oct
retriev
apr
http
aysola
wheeler
l
etal
laboratori
medicin
feb
backgroundcas
studi
emerg
zikv
unit
state
import
assess
fda
respons
time
provid
guidanc
ensur
safeti
avail
blood
product
face
newli
emerg
infecti
diseas
research
compar
respons
fda
west
nile
viru
wnv
zika
viru
zikv
outbreak
evalu
current
prepared
studi
designmethod
literatur
review
conduct
analyz
fda
respons
time
wnv
crisi
determin
effect
effici
research
survey
perform
determin
donor
histori
questionnair
dhq
adequ
screen
donor
zikv
sole
prevent
method
per
februari
guidanc
industri
recommend
donor
screen
deferr
product
manag
reduc
risk
zika
viru
determin
current
regulatori
practic
includ
august
guidanc
industri
revis
recommend
reduc
risk
zika
viru
transmiss
blood
blood
compon
perceiv
effect
effici
face
current
zikv
outbreak
survey
monkey
use
particip
anonym
email
sent
member
aabb
scabb
seabb
person
network
target
respons
rate
particip
deselect
base
inclus
exclus
criteria
list
consent
letter
resultsfind
literatur
review
reveal
fda
respons
slow
wnv
outbreak
zikv
respons
effici
thu
far
total
particip
respond
survey
respons
rate
statist
particip
agreement
fda
decis
perform
test
df
null
hypothesi
vs
altern
true
mean
overal
particip
favor
opinion
fda
decis
statist
whether
particip
differ
level
demograph
variabl
region
profess
year
experi
answer
significantli
differ
one
way
anova
model
use
question
respons
continu
null
hypothesi
level
explanatori
variabl
mean
respons
variabl
signific
differ
year
experi
profess
variabl
particip
region
determin
unreli
due
undefin
state
region
list
conclus
research
reveal
industri
expert
conclud
current
system
dhq
fda
guidanc
document
issu
time
adequ
tabl
ct
breakdown
min
sec
backgroundcas
studi
evalu
new
instrument
solut
test
import
consid
oper
impact
system
lab
varieti
oper
perform
system
metric
evalu
determin
impact
includ
test
workflow
hand
time
autom
time
studi
designmethod
studi
involv
current
state
futur
state
comparison
test
process
instrument
ortho
pv
manual
test
vs
instrument
ortho
ov
data
collect
method
includ
direct
observ
time
studi
interview
pv
bench
perform
type
screen
ts
pv
manual
abidselect
cell
panel
gel
test
test
cord
blood
cb
dat
unit
confirm
uc
patient
type
confirm
pc
crossmatch
xm
etc
done
manual
tube
futur
state
incorpor
ov
ts
abid
uc
evalu
state
cycl
time
ct
averag
base
run
cycl
ct
compris
metric
instrument
time
standbi
time
st
labor
time
lt
st
may
compris
compon
time
could
util
walkaway
time
vigil
time
vt
requir
oper
presenc
oper
action
autom
instrument
vt
cycl
measur
instrument
access
unavail
instrument
daili
mainten
dm
ct
evalu
well
similarli
time
manual
tube
test
process
use
metric
repetit
activ
within
process
uc
xm
time
per
individu
process
captur
multipli
per
unit
resultsfind
tabl
provid
detail
metric
current
state
futur
state
process
tube
base
test
time
follow
pc
xm
cb
dat
implement
futur
state
averag
min
lt
vt
save
sampl
load
ts
equat
labor
reduct
current
state
improv
tat
ts
achiev
futur
state
move
manual
abid
autom
process
result
lt
reduct
averag
min
continu
time
achiev
autom
abid
uc
less
impact
labor
time
minim
differ
howev
allow
focu
consist
qualiti
metric
conclus
base
metric
evalu
compar
current
state
futur
state
ov
demonstr
improv
lab
oper
labor
requir
result
tat
deliveri
opportun
exist
autom
workflow
test
still
manual
perform
backgroundcas
studi
high
throughput
effici
autom
serolog
test
crucial
workflow
blood
bank
test
type
screen
sampl
per
day
grifol
walkaway
analyz
util
gel
card
pretransfus
test
blood
bank
valid
implement
use
abod
type
antibodi
screen
identif
patient
sampl
replac
solid
phase
test
platform
blood
bank
also
valid
autom
donor
unit
retyp
instrument
bidirect
interfac
blood
bank
lab
inform
system
li
hclltm
hemocar
life
line
mediwar
instrument
valid
implement
done
conjunct
softwar
version
upgrad
hclltm
interfac
system
chang
maestrotm
studi
designmethod
correl
test
result
manual
tube
test
peg
iat
refer
method
perform
patient
sampl
abod
type
antibodi
screen
least
posit
antibodi
screen
known
antibodi
specif
rbc
unit
also
test
abod
confirm
calcul
concord
sensit
specif
perform
precis
studi
also
done
interfac
test
hcll
hospit
inform
system
use
maestrotminterfac
system
perform
valid
resultsfind
concord
result
method
obtain
patient
donor
sampl
test
concord
sampl
posit
antibodi
screen
obtain
method
clinic
signific
antibodi
detect
system
gave
sensit
specif
precis
studi
show
method
gave
type
screen
result
sampl
differ
test
event
valid
li
upgrad
interfac
system
chang
bidirect
interfac
hclltmwa
establish
instrument
oper
lab
month
conclus
found
reliabl
accur
handl
high
workload
lab
user
found
instrument
easi
use
henc
train
profici
compet
user
achiev
manag
valid
instrument
straightforward
major
challeng
delay
implement
experienc
blood
bank
attribut
concurr
occur
li
upgrad
migrat
data
integr
system
workflow
assess
would
ideal
perform
ensur
instrument
use
full
potenti
backgroundcas
studi
suffici
number
blood
compon
avail
meet
routin
emerg
hospit
need
must
assur
minim
outdat
scarc
expens
blood
compon
inher
challeng
platelet
unit
short
report
result
qualiti
improv
project
implement
custom
computer
platelet
inventori
report
design
mitig
common
caus
platelet
wastag
institut
high
platelet
outdat
rate
report
includ
blood
type
product
code
unit
number
respect
product
attribut
supplier
avail
statu
platelet
unit
hospit
locat
system
blood
bank
receiv
morn
fax
report
facilit
transfer
unit
prior
expir
adjust
readili
made
product
order
supplier
studi
designmethod
studi
conduct
blood
bank
base
avail
platelet
inventori
wastag
qualiti
data
report
went
live
octob
qualiti
data
review
august
decemb
collect
data
analyz
use
descript
statist
method
resultsfind
data
indic
platelet
wastag
compris
total
receiv
platelet
wast
platelet
unit
due
expir
reason
includ
fail
visual
inspect
blood
dispens
use
wast
floor
potenti
tube
station
problem
unit
transfer
blood
bank
anoth
facil
mean
monthli
wast
platelet
unit
month
report
unit
compar
unit
month
unit
month
wastag
rate
improv
wast
yearli
plateletstot
receiv
yearli
platelet
unit
year
report
implement
rate
see
tabl
importantli
occur
despit
greater
increas
platelet
inventori
result
cost
save
period
conclus
studi
limit
includ
restrict
data
collect
one
campu
option
transfer
expir
platelet
unit
anoth
blood
bank
avail
particip
sister
hospit
would
interest
see
effect
report
hospit
lower
transfus
rate
differ
order
practic
asid
lower
platelet
wastag
within
year
implement
addit
benefit
report
includ
facilit
order
blood
supplier
cornerston
success
inventori
manag
plan
includ
daili
inventori
monitor
ideal
coordin
effort
share
platelet
unit
shown
achiev
end
facilit
custom
daili
platelet
inventori
report
efficaci
easili
adapt
tool
demonstr
gain
backgroundcas
studi
transfus
emerg
depart
level
trauma
center
order
use
handwritten
order
form
transfus
lab
tl
manag
team
medic
director
met
emerg
depart
ed
leadership
resourc
defin
need
success
electron
blood
transfus
system
handwritten
order
form
sever
potenti
error
sourc
could
lead
delay
fill
order
pend
correct
best
circumst
could
lead
transfus
wrong
patient
wrong
product
error
detect
potenti
error
sourc
includ
cleric
error
involv
patient
name
medic
record
number
mrn
write
two
differ
name
order
form
two
locat
record
patient
name
two
product
type
order
one
form
requir
one
product
type
per
order
prioriti
indic
stat
routin
includ
prescrib
inform
number
ed
report
transfus
relat
event
events
transfus
studi
designmethod
electron
order
ed
implement
march
transfus
order
gener
ed
electron
unless
case
electron
downtim
system
electron
fill
patient
name
mrn
control
type
blood
product
order
requir
order
prioriti
provid
servic
contact
inform
design
accommod
transfus
order
need
adult
pediatr
patient
pediatr
patient
pediatr
order
three
critic
field
identifi
requir
order
process
includ
patient
weight
product
volum
infus
rate
electron
system
design
order
submit
unless
critic
field
complet
resultsfind
electron
order
system
place
year
april
march
time
instanc
blood
order
unintend
patient
previou
patient
medic
record
access
rather
intend
patient
medic
record
instanc
cleric
error
name
misspel
mrn
transposit
etc
miss
servic
contact
inform
miss
order
prioriti
inform
one
product
type
order
singl
order
two
patient
name
one
order
electron
order
also
provid
place
transfusionist
chart
lead
increas
transfus
document
complianc
prior
electron
order
implement
unit
transfus
ed
chart
patient
medic
record
transfus
chart
howev
first
full
year
electron
transfus
order
capabl
transfus
chart
patient
medic
record
conclus
electron
order
ed
essenti
elimin
order
error
area
result
less
rework
technologist
physician
allow
order
process
quickli
tl
result
faster
turnaround
time
improv
overal
qualiti
transfus
order
electron
order
reduc
influenc
human
factor
order
placement
provid
ad
benefit
specif
order
chart
backgroundcas
studi
blood
bank
receiv
numer
phone
call
daili
basi
call
occupi
valuabl
time
also
made
line
unavail
real
emerg
occur
hospit
categor
level
trauma
center
inpati
bed
oper
room
propos
implement
blood
bank
autom
attend
recommend
decreas
phone
call
minim
error
due
distract
phone
call
free
team
member
perform
duti
direct
line
design
request
trauma
cooler
massiv
transfus
protocol
mtp
emerg
releas
blood
product
studi
designmethod
first
step
categor
type
phone
call
receiv
blood
bank
creat
phone
log
data
collect
analyz
four
week
blood
bank
collabor
nurs
hospit
administr
staff
telecommun
team
evalu
possibl
implement
autom
attend
minim
phone
call
import
maintain
patient
safeti
qualiti
servic
time
autom
attend
consist
option
urgent
trauma
emerg
releas
mtp
obstetr
hemorrhag
emerg
releas
option
verbal
verbal
order
cooler
set
option
staff
speak
staff
member
instruct
also
given
specimen
inquiri
product
avail
hospit
inform
system
resultsfind
data
tabl
show
incom
call
fall
three
categori
specimen
inquiri
product
order
inquiri
inquiri
call
nurs
staff
inquir
length
wait
time
blood
product
specimen
avail
overal
decreas
phone
call
implement
autom
attend
tabl
autom
attend
implement
data
conclus
implement
autom
attend
blood
bank
team
abl
identifi
respond
accordingli
effici
urgent
request
verbal
phone
order
decreas
phone
call
freed
team
member
perform
critic
task
depart
backgroundcas
studi
organ
use
blood
bank
identif
bbid
band
system
test
detect
wrong
blood
tube
error
wbit
addit
type
screen
result
compar
patient
histor
record
specimen
retyp
second
technologist
histor
result
avail
bbid
band
prone
cleric
error
excess
specimen
reject
believ
miss
wbit
error
blood
bank
account
reject
clinic
laboratori
sampl
yet
compris
total
laboratori
volum
reject
blood
bank
sampl
due
bbid
band
issu
wbit
error
rate
detect
system
studi
designmethod
multidisciplinari
workgroup
form
review
data
best
practic
decis
made
discontinu
bbid
band
implement
verif
process
keep
standard
new
laboratori
test
order
creat
emr
system
embed
exist
order
provid
prompt
order
abo
verif
test
previou
aborh
type
result
found
educ
provid
clinic
staff
form
email
annual
compet
complet
electron
new
process
went
live
septemb
resultsfind
five
month
follow
implement
four
wbit
error
detect
second
sampl
may
miss
use
bbid
band
system
improv
detect
reveal
wbit
error
rate
three
time
nation
averag
new
system
reject
blood
bank
sampl
decreas
averag
reject
laboratori
sampl
decreas
implement
new
process
produc
net
save
conclus
replac
bbid
band
system
verif
success
improv
abil
detect
wbit
error
among
patient
lack
histor
blood
bank
result
addit
discontinu
bbid
system
decreas
incid
cleric
error
unnecessari
specimen
reject
also
save
money
organ
next
step
blood
bank
laboratori
qualiti
leader
partner
nurs
leadership
drive
wbit
error
incid
backgroundcas
studi
cultur
residu
blood
product
occur
clinic
suspicion
septic
transfus
reaction
str
final
cultur
result
typic
avail
within
day
laboratori
inform
system
li
result
cross
associ
patient
electron
medic
record
emr
phone
notif
occur
cultur
posit
emr
document
product
cultur
result
occur
transfus
medicin
physician
manual
enter
result
addendum
transfus
reaction
clinic
note
effort
improv
turnaround
time
tat
cultur
result
document
collabor
li
staff
develop
autom
email
alert
notifi
blood
bank
medic
director
transfus
safeti
offic
final
cultur
result
avail
purpos
project
determin
whether
intervent
decreas
tat
emr
document
cultur
result
studi
designmethod
implement
autom
email
alert
august
manual
review
transfus
reaction
clinic
note
cultur
residu
product
februari
august
period
august
februari
period
measur
number
day
origin
transfus
reaction
note
entri
addendum
final
cultur
result
use
student
test
determin
whether
statist
signific
differ
mean
tat
result
addendum
entri
period
compar
period
resultsfind
period
cultur
residu
product
suspect
str
tat
final
cultur
result
entri
patient
emr
day
mean
day
sd
period
cultur
residu
product
suspect
str
tat
final
cultur
result
entri
patient
emr
day
mean
day
sd
posit
cultur
either
studi
period
conclus
studi
demonstr
tat
document
improv
use
inform
technolog
notifi
transfus
medicin
physician
result
avail
document
patient
emr
backgroundcas
studi
primari
test
perform
blood
bank
regard
test
type
screen
ty
current
target
institut
blood
bank
minut
turnaround
time
tat
april
blood
bank
forc
move
temporari
locat
due
build
construct
necessit
switch
autom
solid
phase
methodolog
manual
gel
method
averag
number
outlier
increas
tat
analysi
repres
one
week
sampl
per
month
show
increas
outlier
per
month
per
month
averag
monthli
ty
sampl
perform
number
improv
even
upon
return
origin
facil
studi
designmethod
two
ortho
clinic
diagnost
analyz
raritan
nj
purchas
blood
bank
instrument
set
interfac
allow
sampl
continu
load
without
manual
order
test
batch
test
elimin
allow
sampl
run
receiv
result
auto
interpret
transmit
laboratori
inform
system
li
base
predetermin
rule
result
need
manual
review
interpret
held
back
final
verif
result
perform
technologist
within
li
reagent
need
consum
could
preload
instrument
elimin
need
repeatedli
load
consum
sampl
run
key
qualiti
indic
includ
tat
continu
monitor
throughout
implement
data
monitor
signific
chang
improv
patient
care
date
resultsfind
averag
number
outlier
decreas
per
month
benefit
includ
reduct
number
technologist
need
perform
ty
test
addit
reduc
wast
due
better
util
suppli
instrument
along
less
repeat
test
result
project
cost
save
fiscal
year
conclus
use
gel
technolog
combin
two
way
interfac
continu
load
instrument
result
signific
decreas
tat
manual
gel
method
repres
one
week
random
sampl
outlier
per
month
color
tabl
view
http
wileyonlinelibrarycom
backgroundcas
studi
certain
transfus
reaction
requir
cultur
return
blood
product
perform
cultur
report
cerner
oper
system
result
cross
patient
emr
final
product
cultur
result
enter
patient
emr
addendum
transfus
reaction
clinic
note
review
transfus
reaction
databas
reveal
occas
final
product
cultur
result
enter
patient
emr
time
manner
import
patient
care
transfus
medicin
servic
patient
primari
provid
know
transfus
reaction
relat
contamin
product
patient
gener
overal
health
inform
also
crucial
supplier
product
determin
other
receiv
compon
affect
unit
possibl
determin
qualiti
control
issu
donor
facil
studi
designmethod
review
specif
month
period
reveal
timefram
final
product
cultur
result
enter
patient
emr
rang
day
mean
day
determin
interest
improv
patient
care
collabor
laboratori
inform
servic
report
creat
product
cultur
result
final
email
would
gener
notifi
medic
director
transfus
safeti
offic
result
avail
resultsfind
data
collect
month
follow
implement
report
note
timeli
final
product
cultur
result
enter
patient
emr
improv
rang
day
mean
day
conclus
improv
patient
care
requir
dilig
time
report
final
cultur
report
determin
potenti
caus
transfus
reaction
process
made
easier
correct
tool
use
backgroundcas
studi
transfus
blood
patient
hematolog
malign
receiv
cytotox
chemotherapi
result
graft
versu
host
diseas
gvhd
note
sever
instanc
blood
transfus
patient
requir
irradi
blood
design
qualiti
improv
project
educ
session
involv
oncolog
unit
blood
bank
studi
designmethod
project
separ
three
part
first
part
data
transfus
practic
retrospect
collect
four
month
period
oncolog
unit
variabl
collect
includ
date
time
transfus
transfus
hemoglobin
patient
diagnos
whether
blood
order
irradi
whether
irradi
blood
issu
blood
bank
patient
hematolog
malign
patient
receiv
cytotox
chemotherapi
candid
irradi
blood
second
part
project
educ
intervent
resid
oncolog
floor
nurs
blood
bank
staff
given
lectur
import
transfus
irradi
blood
oncolog
floor
resid
also
instruct
order
irradi
blood
patient
oncolog
unit
third
part
project
repeat
data
collect
two
month
period
assess
whether
intervent
success
resultsfind
unit
transfus
oncolog
floor
unit
requir
irradi
unit
order
irradi
sinc
blood
bank
occasion
issu
irradi
blood
without
specif
order
addit
irradi
unit
issu
unit
transfus
oncolog
floor
unit
requir
irradi
unit
order
irradi
specif
prevent
gvhd
eight
addit
irradi
unit
order
requir
irradi
thu
total
unit
order
irradi
addit
irradi
unit
issu
without
specif
order
blood
bank
result
summar
accompani
tabl
tabl
conclus
qualiti
improv
project
demonstr
educ
intervent
succeed
chang
clinic
practic
continu
monitor
order
practic
ensur
complianc
continu
plan
expand
qualiti
improv
project
set
includ
emerg
depart
surgic
floor
expect
adher
transfus
guidelin
patient
popul
reduc
incid
advers
event
backgroundcas
studi
blood
center
apheresi
platelet
red
cell
collect
trima
accel
doubl
red
cell
haemonet
addit
routin
qualiti
control
qc
qc
perform
instrument
flag
collect
instrument
qualiti
control
apheresi
platelet
includ
volum
varianc
rwbc
qualiti
control
apheresi
red
cell
includ
product
volum
volum
varianc
hemoglobin
red
blood
cell
mass
studi
designmethod
period
januari
april
total
collect
flag
addit
qc
trima
accel
haemonet
instrument
qualiti
control
center
track
qualiti
control
softwar
manag
system
hematerra
hemacompli
allow
abil
track
retriev
inform
resultsfind
trima
accel
flag
unit
addit
trima
apheresi
platelet
procedur
trima
red
cell
procedur
haemonet
flag
doubl
red
cell
procedur
total
procedur
addit
qc
trima
apheresi
platelet
procedur
addit
qc
failur
total
unit
flag
trima
apheresi
rbc
procedur
addit
qc
failur
unit
flag
haemonet
procedur
addit
qc
failur
unit
flag
conclus
major
product
flag
instrument
qc
pass
releas
distribut
small
percentag
howev
fail
qc
lead
loss
product
qualiti
control
data
retriev
monitor
trend
use
qualiti
control
softwar
manag
system
backgroundcas
studi
center
medicar
medicaid
servic
cm
roll
plan
implement
iqcp
individu
qualiti
control
plan
new
qualiti
control
option
base
risk
manag
plan
clia
laboratori
perform
test
plan
meant
clia
approv
test
serv
good
tool
lab
perform
tradit
test
sampl
studi
designmethod
clia
clinic
laboratori
either
follow
tradit
clinic
clia
qc
requir
accord
regul
implement
iqcp
perfrom
tradit
qc
assess
test
perfrom
cellular
product
decid
implement
iqcp
program
within
qualiti
control
laboratori
follow
iqcp
process
assess
qc
test
use
assess
safeti
puriti
potenc
cell
base
product
one
test
particular
appli
tool
review
qc
steril
test
method
found
use
improv
overal
process
tool
walk
three
process
requir
risk
assess
qualiti
control
plan
qualiti
assess
analyt
post
analyt
phase
test
resultsfind
risk
assess
result
conclus
integr
iqcp
qualiti
control
laboratori
determin
success
iqcp
tool
success
identifi
gap
within
steril
test
process
tool
use
addit
qualiti
control
test
manufactur
process
implement
iqcp
program
ensur
regulatori
qc
requir
appropri
test
perform
abl
revis
procedur
reeduc
involv
process
hope
minim
potenti
sourc
error
backgroundcas
studi
hemorrhag
lead
caus
mortal
trauma
patient
morbid
patient
use
balanc
transfus
ratio
tr
massiv
resuscit
recommend
base
trauma
data
object
perform
massiv
transfus
protocol
mtp
activ
poorli
studi
may
differ
base
site
medic
servic
mtp
initi
impend
releas
unifi
redesign
exsanguin
protocol
exp
institut
establish
baselin
perform
characterist
exist
mtp
obstetr
massiv
transfus
protocol
obp
studi
designmethod
follow
institut
review
board
approv
perform
retrospect
studi
blood
product
util
outcom
mtp
obp
activ
juli
data
manual
collect
transfus
servic
paper
record
electron
safetrac
record
autom
data
report
electron
medic
record
epic
resultsfind
studi
period
obp
mtp
activ
rbc
plasma
platelet
apheresi
cryoprecipit
transfus
ratio
tr
obp
mtp
among
mtp
case
trauma
case
tr
tr
trauma
case
mtp
activ
emerg
depart
oper
room
icu
mortal
day
mean
length
stay
lo
hospit
list
tabl
tabl
conclus
observ
consider
variabl
transfus
practic
acut
hemorrhag
depend
servic
locat
activ
trauma
activ
demonstr
sharpest
deficit
platelet
transfus
wherea
group
lag
somewhat
transfus
plasma
rel
pack
red
blood
cell
lo
mortal
vari
among
group
like
reflect
underli
medic
condit
indic
massiv
transfus
identifi
opportun
improv
mtp
transfus
ratio
observ
trauma
case
specif
environ
ratio
deriv
impact
blood
resuscit
efficaci
backgroundcas
studi
blood
bank
bb
process
approxim
specimen
per
year
bb
specimen
unaccept
unlabel
unsign
miss
necessari
document
case
new
specimen
request
drawn
per
protocol
investig
unaccept
specimen
previous
includ
gener
report
blood
bank
staff
subsequ
submit
bb
supervisor
complet
follow
complet
report
sent
nurs
manag
patient
care
unit
pcu
investig
staff
member
involv
process
cumbersom
take
day
staff
member
pcu
alert
deviat
protocol
time
resid
float
staff
involv
difficult
identifi
often
challeng
track
staff
necessari
investig
studi
designmethod
june
patient
identif
improv
strategi
implement
jointli
depart
nurs
bb
address
mislabel
unlabel
unsign
specimen
part
patient
safeti
initi
current
follow
strategi
unaccept
specimen
receiv
nurs
manag
nm
pcu
immedi
notifi
bb
staff
nm
promptli
initi
debrief
process
staff
involv
draw
specimen
debrief
form
tool
creat
guid
discuss
process
follow
nm
also
engag
avail
staff
huddl
review
incid
reinforc
polici
debrief
form
submit
hospit
qa
bb
prevent
action
includ
believ
use
cultur
model
help
us
understand
reason
staff
label
specimen
accord
polici
cultur
help
promot
share
account
ensur
proper
system
process
place
deliv
high
qualiti
care
resultsfind
tabl
repres
percentag
unaccept
specimen
identifi
bb
sinc
second
quarter
tabl
bb
unaccept
specimen
implement
new
process
led
decreas
number
unaccept
specimen
quarterli
follow
implement
opportun
direct
intervent
nm
staff
involv
risen
due
immedi
debrief
process
conclus
patient
identif
improv
strategi
allow
real
time
engag
bb
pcu
staff
promptli
investig
institut
correctiveprevent
action
deviat
polici
relat
specimen
collect
heighten
awar
correct
patient
specimen
label
error
improv
patient
safeti
patient
experi
backgroundcas
studi
despit
advanc
adult
platelet
transfus
ptx
literatur
question
persist
regard
pediatr
transfus
threshold
dosag
respons
therefor
ptx
commonli
guid
local
institut
recommend
ir
aim
studi
determin
degre
adher
ptx
practic
ir
pediatr
tertiari
institut
studi
designmethod
retrospect
review
ptx
practic
includ
transfus
threshold
respons
dosag
collect
platelet
count
within
hour
pre
post
transfus
evalu
patient
year
receiv
prophylact
ptx
juli
decemb
admit
oncolog
acut
care
unit
diagnosi
leukemia
lymphoma
includ
prevent
volum
overload
ir
ptx
patient
one
apheresi
unit
au
patient
therefor
patient
separ
group
resultsfind
signific
proport
order
meet
patient
platelet
threshold
criteria
p
conclus
ptx
threshold
ir
group
common
reason
ir
threshold
invas
procedur
low
molecular
weight
heparin
therapi
greater
ptx
dosag
group
ir
howev
platelet
respons
increas
significantli
p
higher
dose
vs
ir
dose
studi
demonstr
still
consider
deviat
ir
ptx
practic
among
pediatr
oncolog
patient
addit
fals
assumpt
higher
dose
yield
better
respons
put
patient
increas
risk
transfus
relat
advers
event
institut
conduct
qualiti
assur
review
determin
ptx
practic
backgroundcas
studi
institut
provid
option
sampl
pss
drawn
day
prior
surgeri
long
patient
report
transfus
blood
blood
compon
contain
allogen
red
cell
pregnant
preced
month
date
pss
collect
pss
patient
return
surgeri
patient
servic
requir
ask
patient
transfus
pregnanc
histori
determin
new
opportun
allogen
red
cell
exposur
howev
process
captur
inform
patient
report
time
pss
draw
day
surgeryposs
transfus
studi
designmethod
electron
fix
design
appli
surgic
intak
process
new
set
question
ad
admit
questionnair
must
complet
prior
patient
surgic
procedur
question
ask
patient
pregnant
transfus
preced
three
month
answer
affirm
comput
system
run
blaze
rule
caus
alert
blood
bank
blood
bank
tech
review
alert
inactiv
patient
pss
base
new
transfusionpregnani
inform
one
year
electron
fix
transfus
lab
perform
retrospect
review
pss
alert
gener
period
resultsfind
result
review
analyz
display
tabl
determin
patient
pss
alert
activ
sampl
requir
inactiv
tabl
conclus
implement
electron
solut
requir
document
pss
elig
upon
return
surgeri
result
estim
pss
alert
blood
bank
year
alert
estim
approxim
patient
per
year
identifi
longer
elig
pss
statu
retrospect
review
perform
share
project
stakehold
determin
electron
questionnair
could
tailor
patient
base
age
gender
pss
statu
benefit
fewer
fals
posit
pss
alert
recogn
ideal
futur
state
compat
institut
current
project
implement
new
electron
medic
record
emr
system
safeti
enhanc
provid
current
electron
fix
remain
improv
suggest
share
team
creat
paramet
new
emr
intent
target
patient
activ
pss
blood
bank
rather
surgic
patient
backgroundcas
studi
blood
order
complex
process
multipl
step
potenti
error
delay
risk
associ
process
order
requir
evalu
strategi
mitig
given
complex
natur
blood
order
proactiv
risk
assess
pra
blood
product
order
use
fmea
methodolog
conduct
goal
project
proactiv
assess
effect
redesign
electron
order
set
qualiti
safeti
blood
order
studi
designmethod
evalu
electron
blood
order
redesign
process
pra
complet
use
fmea
methodolog
team
identifi
step
electron
blood
order
process
failur
mode
caus
score
sever
occurr
detect
determin
risk
prioriti
number
rpn
rpn
score
threshold
review
rescor
base
mitig
strategi
design
address
failur
mode
resultsfind
group
score
identifi
failur
mode
categori
use
root
caus
analys
electron
blood
order
process
intern
logic
alert
improv
commun
reduc
risk
score
sever
mitig
strategi
reduc
risk
identifi
failur
mode
includ
type
screen
statu
within
rbc
order
streamlin
alert
order
meet
laboratori
threshold
nurs
task
list
transfus
chang
pickup
process
link
product
readi
statu
laboratori
inform
system
transfus
histori
avail
provid
order
blood
product
reduc
commun
risk
categori
failur
mode
includ
clinic
commun
equip
peopl
process
system
averag
overal
failur
mode
rpn
reduc
commun
categori
averag
rpn
greatest
reduct
conclus
fmea
electron
blood
order
process
proactiv
improv
qualiti
patient
safeti
prevent
transfus
delay
error
blood
product
administr
accur
time
inform
blood
order
process
potenti
reduc
risk
associ
order
prepar
dispens
blood
backgroundcas
studi
expediti
time
tat
blood
bank
critic
provid
fulli
test
crossmatch
compat
blood
time
manner
blood
bank
rhode
island
hospit
level
trauma
center
teach
hospit
associ
brown
univers
origin
design
accommod
tube
test
technologist
origin
setup
lab
split
three
section
allow
prepar
issu
unit
first
section
bench
test
second
receipt
compon
third
technolog
chang
blood
bank
adopt
first
manual
gel
station
autom
gel
system
ortho
adapt
space
second
section
blood
bank
contain
manual
subsequ
autom
gel
station
chang
process
sampl
receipt
complet
test
issu
unit
remain
segment
ineffici
averag
tat
type
screen
minut
studi
designmethod
blood
bank
design
remodel
make
open
concept
allow
collabor
amongst
technologist
well
best
use
space
technolog
first
section
tabl
remov
replac
center
consol
allow
movement
entir
front
laboratori
wall
construct
separ
main
work
flow
autom
gel
test
issu
unit
area
complic
workup
inventori
receipt
third
section
remain
repurpos
teach
medic
technolog
student
resid
addit
remodel
blood
bank
retir
ortho
ortho
consid
true
continu
feed
machin
although
tat
significantli
differ
minut
built
schedul
effect
handl
system
process
sampl
effici
also
equip
two
centrifug
process
sampl
reduc
tat
multipl
sampl
onboard
interfac
design
allow
test
order
type
screen
go
test
result
go
directli
li
without
need
manual
order
test
transmit
result
data
tat
collect
analyz
use
independ
test
chi
squar
resultsfind
mean
tat
reconfigur
implement
ortho
fraction
sampl
tat
minut
shown
tabl
tabl
result
show
reduct
tat
minut
reduct
tat
greater
minut
conclus
combin
new
technolog
space
remodel
lead
signific
reduct
tat
test
blood
bank
backgroundcas
studi
type
screen
fundament
laboratori
test
allow
blood
bank
provid
compat
blood
patient
despit
erron
blood
product
administr
may
occur
much
blood
transfus
prevent
error
adequ
specimen
lack
hemolysi
proper
specimen
label
necessari
otherwis
specimen
reject
lead
second
blood
draw
delay
medicalsurg
manag
hemolysi
rate
specimen
report
high
prior
intervent
may
potenti
reduc
littl
howev
littl
publish
data
type
screen
reject
initi
undertaken
reduc
reject
rate
blood
bank
sustain
rate
particular
emphasi
form
reject
studi
designmethod
root
caus
analysi
rca
perform
preced
month
obtain
baselin
understand
error
involv
submiss
facil
involv
standard
complet
specimen
label
plu
complet
uniqu
wit
form
confirm
ident
patient
specimen
collect
specimen
wit
form
must
submit
simultan
specimen
reject
record
patient
name
medic
record
number
reason
reject
follow
rca
intervent
creat
resolv
common
issu
document
result
reject
approv
intervent
grant
depart
chair
transfus
committe
form
committe
medic
execut
committe
implement
prospect
data
collect
sever
month
manner
determin
effect
intervent
resultsfind
studi
period
reject
rate
averag
reason
specimen
reject
divid
group
hemolysi
blood
bank
wit
collect
form
error
quantiti
suffici
duplic
sampl
specimen
tube
label
error
highest
percentag
reject
due
wit
form
tabl
multipl
form
redesign
approv
appropri
committe
new
form
implement
preliminari
data
collect
thu
far
demonstr
reject
rate
reject
relat
wit
form
error
conclus
reject
specimen
impedi
safe
clinic
care
may
delay
medicalsurg
manag
reject
rate
could
reduc
simplif
blood
bank
specimen
collect
form
care
provid
multipl
task
need
perform
short
amount
time
therefor
simplif
often
time
necessari
reduc
human
error
futur
qualiti
initi
aim
simplifi
complex
healthcar
process
without
compromis
patient
care
tabl
type
screen
reject
rca
period
backgroundcas
studi
part
qualiti
control
program
track
number
technician
relat
fail
run
observ
roch
coba
system
system
use
test
whole
blood
donor
sampl
human
immunodefici
viru
hiv
rna
hepat
c
viru
hcv
rna
hepat
b
viru
hbv
dna
west
nile
viru
wnv
rna
technician
relat
fail
test
run
caus
laboratori
report
result
outsid
contractu
hour
turnaround
time
fail
run
also
caus
retest
increas
reagent
util
system
current
whole
blood
donor
test
turnaround
time
delay
due
issu
fail
run
system
technician
relat
failur
per
week
lean
six
sigma
approach
process
improv
util
identifi
root
caus
develop
countermeasur
order
decreas
number
technician
relat
failur
system
studi
designmethod
number
technician
relat
fail
run
system
track
thru
pareto
chart
use
determin
technician
relat
error
largest
control
factor
caus
run
failur
whi
perform
determin
root
caus
technician
relat
fail
run
gemba
walk
perform
lab
test
process
help
identifi
area
improv
process
improv
team
talk
met
observ
work
directli
staff
oper
system
roch
also
contact
provid
guidanc
help
decreas
technician
relat
failur
resultsfind
main
root
caus
determin
current
process
flow
map
whole
blood
donor
test
use
system
counter
measur
implement
includ
creat
two
phase
process
map
one
phase
relat
process
relat
system
second
phase
relat
process
involv
process
sampl
roch
provid
job
aid
technician
provid
clear
step
technician
take
handl
clean
crash
fail
run
system
counter
measur
implement
number
technician
relat
fail
run
decreas
failur
per
week
decreas
conclus
lean
six
sigma
approach
process
improv
util
identifi
root
caus
develop
countermeasur
order
decreas
number
technician
relat
fail
run
coba
system
lean
six
sigma
approach
counter
measur
significantli
decreas
number
technician
relat
fail
run
backgroundcas
studi
blood
bank
process
approxim
specimen
per
month
sinc
requir
second
blood
type
record
met
util
histor
blood
type
current
specimen
orhav
second
type
perform
specimen
differ
technologist
andeach
type
screen
specimen
sign
staff
one
licens
practition
attest
identif
patient
done
accur
bedsid
compli
aabb
standard
edit
decis
made
chang
practic
consid
challeng
encount
hospit
collabor
nurs
creat
streamlin
safe
process
april
second
specimen
procedur
implement
address
follow
prevent
draw
specimen
timeelimin
need
rn
track
provid
order
aborhminim
draw
unnecessari
second
specimensavoid
delay
provid
blood
emerg
situat
studi
designmethod
condit
order
creat
valid
order
appear
electron
medic
record
emr
patient
type
screen
order
histor
result
step
new
process
provid
enter
order
emrcondit
aborh
order
appear
along
previou
histori
patient
care
staff
collect
st
arriv
bbblood
order
arriv
bbbb
determin
second
specimen
requir
ye
bb
call
rn
activ
condit
orderb
aborh
specimen
drawnin
order
elimin
delay
emerg
room
patient
specimen
hand
deliv
staff
told
point
drop
second
specimen
need
ii
extens
educ
provid
involv
process
prior
implement
includ
learn
modul
prepar
blood
bank
nurs
collabor
resultsfind
minor
adjust
period
phone
call
made
blood
bank
explain
processther
minim
impact
turn
around
time
releas
componentsaborh
retyp
workload
decreas
volum
per
monthunnecessari
blood
draw
minim
improv
patient
experienceno
emerg
releas
request
due
absenc
second
specimen
conclus
second
specimen
process
condit
order
benefici
blood
bank
well
patient
care
servic
overal
feedback
staff
process
posit
workload
decreas
result
cost
save
increas
effici
allow
us
devot
resourc
grow
servic
institut
backgroundcas
studi
hazard
transfus
well
recogn
certain
case
restrict
transfus
strategi
compar
liber
transfus
strategi
may
associ
better
clinic
outcom
mind
aabb
other
publish
guidelin
transfus
even
guidelin
place
rate
inappropri
blood
transfus
report
high
computer
provid
order
entri
cpoe
process
electron
medic
order
entri
medic
practition
instruct
guidelin
treatment
object
studi
determin
transfus
practic
qualiti
thorough
chart
electron
medic
record
review
measur
place
avoid
inappropri
transfus
addit
factor
associ
inappropri
transfus
examin
studi
designmethod
bed
hospit
retrospect
chart
review
perform
hospit
intern
medicin
patient
cpoe
hospit
guidelin
rbc
transfus
place
transfus
threshold
differ
clinic
set
determin
thorough
literatur
review
studi
analyz
restrict
transfus
strategi
transfus
guidelin
variou
medic
societi
chart
patient
transfus
hgb
result
hgb
review
demograph
medic
histori
provid
ident
indic
transfus
complic
abstract
compil
individu
volunt
intern
medicin
resid
group
discuss
case
ensu
determin
transfus
appropri
occur
princip
investigatorattend
physician
made
final
determin
appropri
rbc
transfus
resultsfind
patient
chart
review
exclud
bleed
cardiovascular
instabl
determin
transfus
inappropri
differ
appropri
transfus
respect
age
sex
patient
solid
tumor
vs
anemia
chronic
diseas
vs
like
inappropri
transfus
patient
higher
hemoglobin
like
inappropri
transfus
median
hgb
vs
p
inappropri
transfus
patient
also
higher
median
hemoglobin
vs
p
moreov
lab
evalut
reveal
associ
lower
folat
level
median
nmoll
vs
nmoll
patient
inappropri
transfus
least
part
receiv
one
unit
without
interv
hemoglobin
check
provid
respons
inappropri
transfus
patient
experienc
fnhtr
death
unrel
transfus
occur
appropri
inappropri
group
conclus
physician
train
interest
promulg
optim
rbc
transfus
practic
studi
identifi
patient
factor
solid
tumor
anemia
chronic
diseas
correl
higher
likelihood
receiv
inappropri
transfus
beyond
cpoe
educ
intervent
individu
level
design
specif
provid
respons
inappropri
transfus
backgroundcas
studi
import
tool
compli
gmp
qualiti
standard
effect
use
blood
bank
inform
system
bi
valid
implement
bi
describ
central
larg
blood
bank
literatur
guidelin
lack
small
scale
blood
bank
environ
blood
bank
face
specif
challeng
computer
relat
economi
scale
exist
process
requir
special
attent
introduct
bi
blood
bank
dutch
caribbean
island
specif
procedur
design
base
exist
guidelin
adapt
local
set
studi
designmethod
red
cross
blood
bank
foundat
sole
provid
labil
blood
compon
dutch
caribbean
island
bonair
sint
maarten
select
bi
provid
implement
isbt
bcsh
guidelin
valid
inform
system
blood
establish
care
analyz
prepar
design
local
procedur
procedur
meant
evalu
valid
featur
bi
hemasoft
america
miami
usa
introduct
outcom
approach
enter
worksheet
evalu
implement
team
manag
implement
plan
design
implement
extern
auditor
sanquin
consult
servic
amsterdam
netherland
invit
evalu
implement
valid
plan
practic
implement
evalu
perform
accord
risk
assess
critic
process
step
resultsfind
base
isbt
bcsh
guidelin
process
flow
chart
describ
relev
phase
critic
step
introduct
valid
bi
design
comparison
current
process
procedur
compar
bi
characterist
make
use
worksheet
worksheet
exist
gap
bi
procedur
care
describ
gap
appropri
procedur
chang
bi
blood
bank
effectu
worksheet
also
provid
basi
staff
train
separ
train
environ
bi
introduct
earli
valid
phase
procedur
process
audit
extern
auditor
feedback
expert
sever
improv
ad
valid
subsequ
implement
process
conclus
use
exist
intern
guidelin
valid
implement
plan
design
prepar
success
introduct
bi
small
scale
caribbean
blood
bank
program
design
seem
well
suit
small
scale
blood
bank
contempl
introduct
bi
backgroundcas
studi
rapid
deliveri
emerg
releas
group
red
blood
cell
rbc
vital
patient
care
commerci
remot
blood
fridg
packag
avail
larg
upfront
mainten
cost
implement
remot
blood
fridg
directli
emerg
depart
ed
use
counter
fridg
requir
id
access
io
applic
scan
track
alert
transfus
servic
ts
product
use
dispens
prior
ed
fridg
implement
rbc
unit
verbal
request
ed
blood
runner
would
pick
return
cooler
given
ed
locat
separ
build
ts
meant
minut
may
requir
transit
unit
often
releas
less
minut
net
effect
provid
would
routin
order
product
ensur
bedsid
patient
arriv
precaut
return
requir
implement
blood
fridg
bedsid
result
predict
outcom
deliv
emerg
releas
rbc
quickli
observ
benefit
decreas
wast
staff
time
studi
designmethod
remot
blood
fridg
implement
juli
data
rbc
request
cooler
rbc
return
rbc
transfus
ed
collect
compar
baselin
data
includ
januari
june
post
chang
includ
august
decemb
juli
data
exclud
includ
pre
post
process
resultsfind
baselin
data
show
ed
request
averag
rbcmonth
cooler
post
chang
drop
rbcmonth
thu
less
blood
request
transfus
servic
cooler
unit
use
fridg
baselin
data
also
show
averag
rbcmonth
return
post
chang
averag
rbcmonth
return
repres
absolut
reduct
number
return
product
rbc
dispens
return
take
approxim
minut
complet
paperwork
transport
therefor
chang
save
averag
minut
per
month
also
note
averag
rbcmonth
transfus
baselin
post
chang
confirm
decreas
request
return
due
decreas
patient
volum
sever
fridg
also
success
decreas
deliveri
time
blood
patient
bedsid
baselin
deliveri
time
minut
estim
reduc
minut
conclus
implement
remot
blood
fridg
move
blood
access
closer
patient
bedsid
ensur
faster
deliveri
blood
patient
chang
addit
benefit
decreas
wast
time
henc
cost
decreas
unnecessari
product
request
return
implement
blood
fridg
also
done
reduc
cost
homegrown
process
backgroundcas
studi
internet
thing
iot
technolog
enabl
autom
increas
number
medic
nurs
procedur
modern
intraven
blood
plasma
etc
transfus
everyday
procedur
file
relat
transfus
medicin
relat
transfus
alarm
last
year
employ
numer
technic
set
aim
support
autom
supervis
mention
action
aim
contribut
present
develop
individu
intraven
monitor
system
base
internet
thing
studi
designmethod
design
system
base
commerci
avail
ptz
camera
employ
inch
color
cmo
sensor
provid
effect
mp
len
daynight
minimum
illumin
view
angl
camera
focus
droplet
act
visir
detector
hz
softwar
support
droplet
caus
acoust
necessari
eg
clot
blood
suspens
deplet
etc
enabl
necessari
video
set
provid
compress
video
frame
rate
fp
refresh
rate
hz
audio
input
bidirect
microphon
acquir
connect
mode
wireless
network
interfac
support
protocol
includ
dhcp
tcpip
upnp
http
smtp
provid
typic
size
weigh
client
softwar
requir
ir
rang
filter
remot
access
dual
stream
motion
detect
daynight
ir
night
vision
distanc
offer
provid
well
tf
record
storag
gb
movement
perform
system
facilit
need
also
patient
posit
monitor
read
monitor
display
nibp
ecg
present
resultsfind
system
present
test
laboratori
environ
simul
virtual
patient
phantom
combin
neg
pressur
viscos
resist
regul
conclus
system
measur
deviat
lower
develop
take
advantag
exist
hospit
network
environ
offer
solut
allow
even
io
android
window
connect
particip
exampl
nurs
physician
etc
backgroundcas
studi
bpa
bpn
cultur
bottl
use
bactalert
microbi
detect
system
rapid
screen
detect
microbi
contamin
leukocyt
reduc
apheresi
platelet
lrap
recent
chang
clia
qualiti
control
guidelin
aabb
accredit
program
requir
addit
qualiti
control
manufactur
media
lot
specif
shipment
specif
ensur
recoveri
bacteri
growth
studi
conduct
use
commerci
prepar
organ
evalu
comprehens
organ
panel
well
streamlin
method
util
two
organ
panel
studi
designmethod
gener
protocol
consist
three
replic
organ
inocul
two
lot
bpa
bpn
two
differ
analyst
studi
two
part
aspergillu
brasiliensi
candida
albican
bacillu
subtili
subsp
spizizenii
pseudomona
aeruginosa
escherichia
coli
clostridium
sporogen
staphylococcu
aureu
streptococcu
pyogen
prepar
biobal
singleshot
cfu
multishot
cfu
highdos
organ
prepar
low
level
cfu
evalu
day
prepar
method
valid
second
part
studi
util
escherichia
coli
staphylococcu
aureu
prepar
frozen
higher
level
evalut
day
studi
stream
line
approach
routin
qualiti
control
test
bactalert
cultur
bottl
inocul
prepar
enumer
duplic
confirm
level
inocul
time
point
inocul
bpa
bpn
bottl
load
bactalert
microbi
detect
system
automat
monitor
growth
neg
bpa
bpn
bottl
includ
duplic
day
test
resultsfind
escherichia
coli
staphylococcu
aureu
streptoococcu
pyogen
bacillu
subtili
subsp
spizizenii
posit
bpa
bpn
cultur
bottl
aerob
aspergillu
brasiliensi
candida
albican
pseudomona
aeruginosa
grew
report
posit
bpa
aerob
cultur
bottl
expect
oblig
anaerob
clostridium
sporogen
posit
anaerob
bpn
cultur
bottl
bacteri
cultur
posit
bactalert
bpa
bpn
bottl
day
fungal
organ
day
overal
agreement
bottl
test
signific
differ
observ
time
detect
differ
lot
differ
analyst
conclus
biobal
prepar
organ
demonstr
reproduc
method
comprehens
streamlin
approach
qualiti
control
bactalert
bpa
bpn
cultur
media
method
simpl
requir
addit
microbi
prepar
storag
live
organ
laboratori
backgroundcas
studi
anticip
implement
new
addit
aabb
standard
concern
confirm
patient
abo
blood
type
type
screen
crossmatch
specimen
perform
prior
issu
crossmatch
blood
product
laboratori
organiz
leadership
evalu
practic
applic
electron
patient
identif
system
label
blood
bank
specimen
collect
versu
tradit
use
blood
bank
armband
continu
use
armband
would
requir
second
sampl
abo
confirm
patient
histor
blood
type
file
concern
rais
regard
amount
increas
workload
staff
delay
result
avail
base
number
increas
specimen
would
gener
well
potenti
increas
iatrogen
blood
loss
patient
dissatisfact
moreov
sampl
collect
alon
would
improv
rate
mislabel
specimen
observ
supplementari
concern
studi
designmethod
current
organ
employ
electron
patient
identif
system
label
laboratori
specimen
collect
made
feasibl
appli
technolog
blood
bank
well
evalu
includ
failur
mode
effect
analysi
fmea
span
sever
day
complet
ensur
use
electron
system
would
produc
compar
superior
safeti
result
armband
counterpart
altern
process
specimen
label
abo
confirm
would
satisfi
new
standard
establish
support
care
area
capabl
use
electron
system
extens
educ
provid
staff
physician
advanc
practic
provid
phlebotomist
nurs
ensur
comprehens
well
ration
new
process
alert
congruent
built
electron
health
record
ehr
supplement
inform
regard
crossmatch
test
expir
may
readili
avail
elimin
armband
use
resultsfind
within
day
implement
new
process
septemb
notic
reduct
amount
mislabel
blood
bank
specimen
receiv
total
month
post
implement
compar
month
prior
addit
vast
major
specimen
receiv
blood
bank
henceforth
collect
label
use
electron
system
thu
reduc
amount
potenti
specimen
collect
need
abo
confirm
conclus
use
electron
patient
identif
system
label
blood
bank
specimen
collect
lieu
tradit
blood
bank
armband
proven
improv
patient
safeti
depart
effici
substanti
reduc
occurr
mislabel
specimen
negat
need
specimen
collect
reduc
potenti
iatrogen
blood
loss
improv
patient
satisfact
backgroundcas
studi
base
small
randomis
control
trial
rct
perform
late
earli
intraven
immunoglobulin
ivig
use
suggest
potenti
treatment
avoid
exchang
transfus
et
rh
hemolyt
diseas
newborn
hdn
treatment
modal
routin
use
extend
hdn
caus
abo
incompat
red
blood
cell
antibodi
howev
larger
rct
perform
sinc
shown
prophylact
ivig
reduc
need
et
durat
hyperbilirubinemia
maximum
bilirubin
level
need
red
blood
cell
transfus
primari
object
studi
describ
usag
ivig
hdn
tertiari
academ
referr
hospit
studi
designmethod
retrospect
chart
review
perform
neonat
receiv
ivig
hdn
neonat
intens
care
unit
nicu
januari
june
data
collect
includ
patient
demograph
featur
diagnosi
indic
ivig
neonat
laboratori
result
treatment
detail
advers
event
patient
outcom
resultsfind
neonat
receiv
ivig
studi
period
femal
less
week
gestat
age
none
defici
pyruv
kinas
defici
spherocytosi
neonat
receiv
phototherapi
prior
ivig
treatment
indic
ivig
antibodi
often
implic
sixteen
infant
receiv
intrauterin
transfus
mean
cumul
dose
ivig
rang
neonat
receiv
one
four
ivig
administr
tabl
show
number
patient
receiv
ivig
two
time
period
three
advers
reaction
note
ivig
administr
cutan
rash
hypotens
fever
neonat
requir
et
patient
need
transfus
hospitalis
three
month
age
mean
number
transfus
three
conclus
although
initi
describ
one
frequent
indic
ivig
neonat
optim
use
ivig
need
better
character
studi
show
wide
variat
ivig
dose
signific
proport
neonat
requir
transfus
research
requir
evalu
whether
anemia
might
exacerb
hemolysi
ivig
isohemagglutinin
tabl
use
ivig
backgroundcas
studi
background
one
seriou
advers
reaction
transfus
develop
graft
versu
host
diseas
symptom
includ
develop
characterist
cutan
rash
enter
often
result
wateri
diarrhea
elev
liver
function
test
ultim
pancytopenia
clinic
cours
rapid
case
fatal
rate
patient
popul
risk
reason
includ
patient
immunocompromis
due
diseas
process
therapi
fetu
low
neonat
recipi
cellular
blood
product
recipi
cellular
blood
product
donat
blood
rel
basic
etiolog
inabl
transfus
recipi
mount
effect
immun
respons
donor
treatment
option
ineffect
make
imper
cellular
blood
compon
irradi
prior
transfus
virtual
elimin
risk
complic
studi
designmethod
transfus
servic
inform
system
mechan
alert
transfus
servic
staff
patient
previous
identifi
need
irradi
blood
compon
howev
patient
identifi
transfus
servic
time
initi
hospit
visit
time
qualifi
diagnosi
patient
erron
receiv
blood
compon
follow
situat
hospit
inform
depart
develop
program
minim
risk
transfus
servic
notifi
patient
newli
requir
irradi
blood
compon
resultsfind
blood
product
order
system
redesign
includ
specif
queri
identifi
patient
requir
irradi
cellular
blood
product
first
physician
notifi
includ
need
blood
product
irradi
patient
problem
list
includ
list
transfus
servic
notifi
need
irradi
subsequ
transfus
order
problem
list
modifi
clinic
staff
second
irradi
blood
compon
ever
request
patient
alert
gener
order
physician
even
requir
irradi
product
includ
problem
list
final
system
automat
default
request
irradi
cellular
product
order
children
less
month
age
compli
local
irradi
polici
conclus
believ
approach
enhanc
includ
list
specif
diagnos
typic
requir
blood
product
irradi
within
comput
algorithm
believ
list
provid
addit
level
safeti
insur
patient
receiv
irradi
blood
compon
appropri
backgroundcas
studi
transfus
servic
routin
issu
blood
product
valid
cooler
high
acuiti
area
or
icu
etc
cooler
also
use
emerg
releas
massiv
transfus
protocol
ship
product
differ
hospit
site
robot
hold
one
cooler
deliv
product
locat
serv
pneumat
tube
averag
cooler
issu
everi
day
cooler
process
transfus
servic
staff
track
cooler
locat
elaps
notifi
clinic
team
returnrecharg
cooler
avoid
product
wastag
develop
lab
inform
system
li
solut
manag
cooler
label
track
effici
studi
designmethod
nine
cooler
test
batteri
built
batteri
rbc
plasma
platelet
cryoprecipit
ident
wherea
final
batteri
design
cooler
deliv
robot
contain
plasma
rbc
variabl
expir
time
slightli
differ
second
batteri
pair
built
avoid
duplic
test
cancel
li
second
cooler
compon
type
set
patient
batteri
consist
test
captur
follow
inform
cooler
locat
cooler
id
number
unit
issu
expir
custom
barcod
repres
test
batteri
differ
locat
scan
list
avoid
need
manual
entri
cooler
return
final
entri
made
test
batteri
updat
li
dynam
cooler
track
dashboard
li
display
data
captur
test
batteri
elaps
time
start
cooler
ident
time
cooler
batteri
order
li
captur
automat
color
code
alert
user
cooler
less
hour
expir
flash
alert
pop
cooler
expir
resultsfind
replac
manual
process
patient
inform
expir
time
separ
tag
affix
one
tag
cooler
retain
second
one
track
cooler
locat
expir
novel
label
track
system
time
cooler
set
test
batteri
order
result
li
scan
relat
custom
barcod
singl
label
print
attach
cooler
cooler
expir
default
hour
per
current
cooler
valid
time
test
batteri
order
cooler
set
tech
pay
attent
expir
product
place
cooler
individu
product
outdat
cooler
expir
time
inform
enter
test
batteri
get
display
dashboard
cooler
expir
time
distinct
countdown
visual
display
alert
greatli
simplifi
cooler
monitor
elimin
manual
step
improv
staff
satisfact
conclus
use
li
cooler
deploy
link
dynam
dashboard
display
cooler
locat
expir
time
make
cooler
manag
effici
tool
reduc
manual
step
decreas
likelihood
wastag
aid
cooler
track
backgroundcas
studi
midwestern
transfus
servic
ts
evalu
appropri
autom
platform
vision
ortho
clinic
diagnost
raritan
nj
prenat
titrat
studi
establish
previou
public
assay
vision
base
may
lead
higher
titer
result
compar
standard
tube
titrat
studi
sought
evalu
transit
manual
autom
titer
studi
sensit
well
cost
perspect
studi
designmethod
prenat
retent
plasma
sampl
test
part
evalu
titrat
studi
vision
sampl
manual
test
standard
serial
dilut
titer
report
last
tube
demonstr
reaction
macroscop
observ
titer
studi
repeat
use
vision
result
manual
autom
process
compar
categor
grade
grade
differ
endpoint
analysi
similar
accept
rang
use
evalu
colleg
american
pathologist
cap
profici
survey
challeng
cost
analysi
complet
base
direct
indirect
cost
method
exclud
cost
analyz
resultsfind
tabl
demonstr
summari
sampl
test
manual
titer
studi
vision
titrat
method
vision
titer
result
mean
median
mode
higher
manual
tube
titer
result
less
half
sampl
titer
result
higher
major
titer
result
differ
cost
analysi
summar
tabl
indirect
cost
labor
significantli
lower
use
vision
reduct
technic
time
manual
prepar
titrat
elimin
vision
complet
titrat
part
profil
titer
studi
analyz
conclus
estim
decreas
cost
vision
titer
compar
manual
tube
method
chang
practic
would
clearli
cost
effici
measur
blood
bank
howev
vision
demonstr
expect
increas
titer
result
compar
manual
tube
titer
result
would
impact
critic
valu
current
util
impact
assess
clinic
staff
would
necessari
adequ
implement
chang
method
consider
must
given
chang
comput
logic
critic
valu
titer
studi
train
physician
nurs
obstetr
practition
chang
critic
valu
addit
part
chang
vision
implement
period
necessari
ensur
manual
titer
compar
previou
manual
titer
vision
titer
result
would
higher
may
interpret
signific
chang
clinic
care
patient
tabl
comparison
manual
tube
vs
vision
titer
result
tabl
cost
analysi
result
estim
due
includ
price
instrument
backgroundcas
studi
want
discov
best
routin
qualiti
control
practic
test
residu
white
blood
cell
blood
compon
aim
valid
adam
devic
count
thne
number
residu
white
blood
cell
wbc
leucocyt
deplet
deplet
blood
compon
bc
compar
standard
count
method
microscopi
fuch
rosenth
chamber
frc
use
ghc
flow
cytometri
fc
studi
designmethod
sampl
red
blood
cell
rbc
platelet
plt
fresh
frozen
plasma
ffp
leucocyt
deplet
top
top
tt
bag
deplet
top
bottom
tb
bag
stain
propidium
iodid
pi
adam
rwbc
devic
messur
fluoresc
imag
stain
wbc
nucleu
data
analis
imag
analysi
softwar
later
compar
result
test
sampl
frc
microscopi
fc
sampl
bc
microscop
test
frc
depart
laboratori
medicin
ghc
anoth
sampl
measur
fc
ucc
maribor
resultsfind
sampl
rbc
plt
leucocyt
deplet
deplet
ffp
test
triplic
adam
frc
coeffici
variat
kv
sampl
measur
adam
leucocyt
deplet
bc
vari
rbc
plt
ffp
deplet
ffp
tabl
sampl
rbc
plt
ffp
leucocyt
deplet
deplet
ffp
test
triplic
adam
fc
kv
sampl
measur
adam
leucocyt
deplet
bc
vari
rbc
plt
ffp
deplet
ffp
tabl
high
percentag
kv
notic
sampl
low
number
wbc
leucocyt
deplet
bc
low
percentag
kv
deplet
ffp
higher
amount
wbc
observ
conclus
sampl
test
adam
met
expect
criteria
wbc
bc
european
union
less
leucocyt
deplet
deplet
compar
test
fc
correl
microscopi
frc
wors
use
dispos
risk
exposur
potenti
hazard
blood
sampl
grate
reduc
method
precis
time
consum
januari
chang
protocol
test
residu
wbc
bc
adam
devic
advis
best
practic
monthli
routin
qualiti
control
